Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemia

ABSTRACT

This disclosure relates to mRNA therapy for the treatment of propionic acidemia (PA). mRNAs for use in the invention, when administered in vivo, encode human propionyl-CoA carboxylase alpha (PCCA) and/or human propionyl-CoA carboxylase beta (PCCB), and isoforms thereof, functional fragments thereof, and fusion proteins comprising PCCA and/or PCCB. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of propionyl-CoA carboxylase (PCC) expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of disease-associated toxic metabolites associated with deficient PCCA or PCCB activity, in subjects.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Provisional Appl. No.62/590,199, filed Nov. 22, 2017, U.S. Provisional Appl. No. 62/614,787,filed Jan. 8, 2018, U.S. Provisional Appl. No. 62/663,024, filed Apr.26, 2018, U.S. Provisional Appl. No. 62/693,552, filed Jul. 3, 2018, andU.S. Provisional Appl. No. 62/747,356, filed Oct. 18, 2018. The contentof the prior applications are incorporated by reference herein in theirentirety.

BACKGROUND

Propionic acidemia (PA), or propionic aciduria, is a rare, autosomalrecessive metabolic disorder with significant morbidity and mortalitythat is caused by a deficiency in propionyl-CoA carboxylase (PCC) thatprevents the enzyme from catalyzing the carboxylation of propionyl-CoAto methylmalonyl-CoA. Wongkittichote et al., Mol. Genet. Metab., Epubahead of print. (2017). Disruption of PCC function causes propionyl-CoAand metabolites of propionate metabolism (breakdown of certain aminoacids and fats) to accumulate in the blood, urine and other fluids andtissues/cells, which can lead to metabolic acidosis and hyperammonemia.Propionylcarnitine (C3), the levocarnitine ester of propionyl-CoA,2-methylcitirc acid (2-MC), 3-hydroxypropionic acid (30HPA),propionylglycine, glycine, lactate and ammonia are also elevated inindividuals with PA, and can serve as biomarkers for the disorder.Classical PA, caused by a complete loss of PCC function, usuallypresents in neonates in the first few hours or days after birth, withsymptoms resulting from metabolic decompensation, including poorfeeding, vomiting, hyper- or hypotonia, temperature instability,irritability, and lethargy. In rarer cases, late onset PA can occurafter infancy, triggered by physical stress, such as infection.Mistreatment of acute metabolic discompensation, or lack of treatment,can lead to coma or death. The risk of mortality in this disorder issignificant, as each acute metabolic decompensation is life-threateningand can lead to irreversible sequelae. Long-term complications of PAinclude neurodevelopmental sequelae, including significant cognitivedeficits and developmental delays in motor and language skills,cardiomyopathy, arrhythmia, and pancreatitis. PA has an estimatedincidence of 1:105,000 to 1:130,000 in the United States, but is higherin parts of the Middle East. Shchelochkov et al., GeneReviews (2016).

PCC (E.C. 6.4.1.3) is a heterodecamer composed of six propionyl-CoAcarboxylase alpha subunits, encoded by PCCA (OMIM 232000), and 6propionyl-CoA beta subunits, encoded by PCCB (OMIM 232050). The PCCenzyme is expressed in several tissues, and localizes to mitochondriawhere it engages with its necessary co-factor, biotin. There are threePCCA isoforms. The first isoform (NM_000282.3) encodes a protein (NP000273.2) that is 728 amino acids in length, while isoform 2(NM_001127692.2) encodes a protein (NP 001121164.1) that is 702 aminoacids long, and isoform 3 (NM_001178004.1) encodes a protein(NP_001171475.1) that is 681 amino acids long. PCCA null variants, suchas R288X and S537X, result in severe phenotypes, while splice typevariants can result in milder disease. PCCB isoform 1 (NM_000532.4encodes a protein (NP_000523.2) that is 539 amino acids in length, whileisoform 2 (NM_001178014.1) encodes a protein (NP_001171485.1) that is559 amino acids long. PCCB requires PCCA for stability, and can beabsent in individuals lacking functional PCCA. Some PCCB gene variantsdisturb the interaction between PCCA and PCCB.

Elevated levels of intermediaries such as C3, 2-MC, 3-OHPA, and/orammonia can be used as diagnostic markers for PA. Prenatal testing of2-MC levels in amniotic fluids and newborn screening for elevated levelsof C3 in dried blood spot can be used to diagnose PA prior to clinicalpresentation of the disease postpartum. There are no approved therapiesfor PA in the U.S., and management of the disorder is limited generallyto the strict dietary restriction of amino acids and odd-chain fattyacids, the precursors of propionic acid, while ensuring sufficientessential amino acids and nutrients to the diet, camitinesupplementation, antibiotics to decrease propionate production from gutbacteria, and vigilant medical monitoring. Acutely hyperammonemicindividuals may require detoxification using ammonia scavengers such asCarbaglu® (which is approved in Europe for the treatment ofhyperammonemia due to PA) and/or sodium benzoate. In severe cases, anindividual could receive a liver transplant.

In view of the significant problems associated with existing PAtreatments, there is an unmet need for an improved treatment for PA

SUMMARY

The present invention provides messenger RNA (mRNA) therapeutics for thetreatment of propionic acidemia (PA). The mRNA therapeutics of theinvention are particularly well-suited for the treatment of PA as thetechnology provides for the intracellular delivery of mRNA encoding PCCAand/or PCCB followed by de novo synthesis of functional PCCA and/or PCCBprotein within target cells. The instant invention features theincorporation of modified nucleotides within therapeutic mRNAs to (1)minimize unwanted immune activation (e.g., the innate immune responseassociated with the in vivo introduction of foreign nucleic acids) and(2) optimize the translation efficiency of mRNA to protein. Exemplaryaspects of the invention feature a combination of nucleotidemodification to reduce the innate immune response and sequenceoptimization, in particular, within the open reading frame (ORF) oftherapeutic mRNAs encoding PCCA or PCCB to enhance protein expression.

In further embodiments, the mRNA therapeutic technology of the instantinvention also features delivery of mRNA encoding PCCA and/or PCCB via alipid nanoparticle (LNP) delivery system. The instant invention featuresionizable lipid-based LNPs, which have improved properties when combinedwith mRNA encoding PCCA and/or PCCB and administered in vivo, forexample, cellular uptake, intracellular transport and/or endosomalrelease or endosomal escape. The LNP formulations of the invention alsodemonstrate reduced immunogenicity associated with the in vivoadministration of LNPs.

In certain aspects, the invention relates to compositions and deliveryformulations comprising a polynucleotide, e.g., a ribonucleic acid(RNA), e.g., a mRNA, encoding PCCA or PCCB and methods for treating PAin a human subject in need thereof by administering the same.

The present disclosure provides a pharmaceutical composition comprisinga lipid nanoparticle encapsulated mRNA that comprises an open readingframe (ORF) encoding a PCCA or PCCB polypeptide, wherein the compositionis suitable for administration to a human subject in need of treatmentfor PA.

The present disclosure further provides a pharmaceutical compositioncomprising: (a) a mRNA that comprises (i) an open reading frame (ORF)encoding a PCCA or PCCB polypeptide, wherein the ORF comprises at leastone chemically modified nucleobase, sugar, backbone, or any combinationthereof and (ii) an untranslated region (UTR) comprising a microRNA(miRNA) binding site; and (b) a delivery agent, wherein thepharmaceutical composition is suitable for administration to a humansubject in need of treatment for PA. In some cases, the pharmaceuticalcomposition comprises (a) an mRNA that comprises an ORF encoding PCCA,and an mRNA that comprises an ORF encoding PCCB, wherein each ORFcomprises at least one chemically modified nucleobase, sugar, backbone,or any combination thereof, and an untranslated region (UTR) comprisinga microRNA (miRNA) binding site; and (b) a delivery agent.

In one aspect, the disclosure features a pharmaceutical compositioncomprising an mRNA comprising an open reading frame (ORF) encoding apropionyl-CoA carboxylase alpha (PCCA) polypeptide, wherein thecomposition when administered as a single intravenous dose to a humansubject in need thereof is sufficient to:

(i) increase the level of PCC activity in liver tissue to within atleast 2%, at least 5%, at least 10%, at least 20%, at least 30%, atleast 40%, at least 50%, at least 60%, at least 70%, at least 80%, atleast 90%, or at least 100% of normal PCC activity level for at least 12hours, at least 24 hours, at least 48 hours, at least 72 hours, at least96 hours, at least 120 hours, at least 1 week, at least 2 weeks, atleast 3 weeks, at least 4 weeks, at least 8 weeks, or at least 12 weekspost-administration;

(ii) increase the level of PCC activity in liver tissue at least1.5-fold, at least 2-fold, at least 3-fold, at least 4-fold, at least5-fold, at least 10-fold, at least 20-fold, or at least 50-fold comparedto the subject's baseline PCC activity level or a reference PCC activitylevel in a human subject having propionic academia (PA) for at least 12hours, at least 24 hours, at least 48 hours, at least 72 hours, at least96 hours, at least 120 hours, at least 1 week, at least 2 weeks, atleast 3 weeks, at least 4 weeks, at least 8 weeks, or at least 12 weekspost-administration;

(iii) reduce plasma, serum, whole blood (including dried blood spot),urine, and/or liver levels of propionic acid at least 30%, at least 40%,at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, orat least 100% compared to the subject's baseline plasma, serum, wholeblood, urine, and/or liver levels of propionic acid or a referenceplasma, serum, whole blood (including dried blood spot), urine, and/orliver levels of propionic acid in a human subject having propionicacidemia (PA) for at least 12 hours, at least 24 hours, at least 48hours, at least 72 hours, at least 96 hours, at least 120 hours, atleast 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, atleast 8 weeks, or at least 12 weeks post-administration;

(iv) reduce plasma, serum, whole blood, and/or urine levels ofpropionyl-L-carnitine (C3), 2-methylcitric acid (2-MC),3-hydroxypropionic acid, (30HPA), propionylglycine, glycine, lactateand/or ammonia at least 30%, at least 40%, at least 50%, at least 60%,at least 70%, at least 80%, at least 90%, or at least 100% compared tothe subject's baseline plasma, serum, or urine level or a referenceplasma, serum, or urine C3, 2-MC, 30HPA, propionylglycine, glycine,lactate and/or ammonia level in a human subject having PA for at least12 hours, at least 24 hours, at least 48 hours, at least 72 hours, atleast 96 hours, at least 120 hours, at least 1 week, at least 2 weeks,at least 3 weeks, at least 4 weeks, at least 8 weeks, or at least 12weeks post-administration;

(v) reduce plasma, serum, whole blood, urine, and/or liver levels ofpropionic acid at least 1.5-fold, at least 2-fold, at least 5-fold, atleast 10-fold, at least 20-fold, or at least 50-fold as compared to thesubject's baseline plasma, serum, whole blood, urine, and/or liverpropionic acid level or a reference plasma, serum, whole blood, urine,and/or liver propionic acid level in a patient with PA for at least 12hours, at least 24 hours, at least 48 hours, at least 72 hours, at least96 hours, at least 120 hours, at least 1 week, at least 2 weeks, atleast 3 weeks, at least 4 weeks, at least 8 weeks, or at least 12 weekspost-administration; and/or

(vi) reduce plasma, serum, and/or urine level of C3, 2-MC, 30HPA,propionylglycine, glycine, lactate and/or ammonia at least 1.5-fold, atleast 2-fold at least 5-fold, at least 10-fold, at least 20-fold or atleast 50-fold as compared to the subject's baseline plasma, serum,and/or urine C3, 2-MC, 30HPA, propionylglycine, glycine, lactate and/orammonia level or a reference plasma, serum, and/or urine C3, 2-MC,30HPA, propionylglycine, glycine, lactate and/or ammonia level in apatient with PA for at least 12 hours, at least 24 hours, at least 48hours, at least 72 hours, at least 96 hours, at least 120 hours, atleast 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, atleast 8 weeks, or at least 12 weeks post-administration.

In another aspect, the disclosure features a pharmaceutical compositioncomprising an mRNA comprising an open reading frame (ORF) encoding apropionyl-CoA carboxylase beta (PCCB) polypeptide, wherein thecomposition when administered as a single intravenous dose to a humansubject in need thereof is sufficient to:

(i) increase the level of PCC activity in liver tissue to within atleast 2%, at least 5%, at least 10%, at least 20%, at least 30%, atleast 40%, at least 50%, at least 60%, at least 70%, at least 80%, atleast 90%, or at least 100% of normal PCC activity level for at least 12hours, at least 24 hours, at least 48 hours, at least 72 hours, at least96 hours, at least 120 hours, at least 1 week, at least 2 weeks, atleast 3 weeks, at least 4 weeks, at least 8 weeks, or at least 12 weekspost-administration;

(ii) increase the level of PCC activity in liver tissue at least1.5-fold, at least 2-fold, at least 3-fold, at least 4-fold, at least5-fold, at least 10-fold, at least 20-fold, or at least 50-fold comparedto the subject's baseline PCC activity level or a reference PCC activitylevel in a human subject having propionic academia (PA) for at least 12hours, at least 24 hours, at least 48 hours, at least 72 hours, at least96 hours, at least 120 hours, at least 1 week, at least 2 weeks, atleast 3 weeks, at least 4 weeks, at least 8 weeks, or at least 12 weekspost-administration;

(iii) reduce plasma, serum, whole blood, urine, and/or liver levels ofpropionic acid at least 30%, at least 40%, at least 50%, at least 60%,at least 70%, at least 80%, at least 90%, or at least 100% compared tothe subject's baseline plasma, serum, whole blood, urine, and/or liverpropionic acid level or a reference plasma, serum, whole blood, urine,and/or liver propionic acid level in a human subject having PA for atleast 12 hours, at least 24 hours, at least 48 hours, at least 72 hours,at least 96 hours, at least 120 hours, at least 1 week, at least 2weeks, at least 3 weeks, at least 4 weeks, at least 8 weeks, or at least12 weeks post-administration;

(iv) reduce plasma, serum, whole blood, and/or urine levels ofpropionyl-L-carnitine (C3), 2-methylcitric acid (2-MC),3-hydroxypropionic acid, (30HPA), propionylglycine, glycine, lactateand/or ammonia at least 30%, at least 40%, at least 50%, at least 60%,at least 70%, at least 80%, at least 90%, or at least 100% compared tothe subject's baseline plasma, serum, or urine level or a referenceplasma, serum, or urine C3, 2-MC, 30HPA, propionylglycine, glycine,lactate and/or ammonia level in a human subject having PA for at least12 hours, at least 24 hours, at least 48 hours, at least 72 hours, atleast 96 hours, at least 120 hours, at least 1 week, at least 2 weeks,at least 3 weeks, at least 4 weeks, at least 8 weeks, or at least 12weeks post-administration;

(v) reduce plasma, serum, whole blood, urine, and/or liver levels ofpropionic acid at least 1.5-fold, at least 2-fold, at least 5-fold, atleast 10-fold, at least 20-fold, or at least 50-fold as compared to thesubject's baseline plasma, serum, whole blood, urine, and/or liverpropionic acid level or a reference plasma, serum, whole blood, urine,and/or liver propionic acid level in a patient with PA for at least 12hours, at least 24 hours, at least 48 hours, at least 72 hours, at least96 hours, at least 120 hours, at least 1 week, at least 2 weeks, atleast 3 weeks, at least 4 weeks, at least 8 weeks, or at least 12 weekspost-administration; and/or

(vi) reduce plasma, serum, and/or urine level of C3, 2-MC, 30HPA,propionylglycine, glycine, lactate and/or ammonia at least 1.5-fold, atleast 2-fold at least 5-fold, at least 10-fold, at least 20-fold or atleast 50-fold as compared to the subject's baseline plasma, serum,and/or urine C3, 2-MC, 30HPA, propionylglycine, glycine, lactate and/orammonia level or a reference plasma, serum, and/or urine C3, 2-MC,30HPA, propionylglycine, glycine, lactate and/or ammonia level in apatient with PA for at least 12 hours, at least 24 hours, at least 48hours, at least 72 hours, at least 96 hours, at least 120 hours, atleast 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, atleast 8 weeks, or at least 12 weeks post-administration.

In another aspect, the disclosure features a pharmaceutical compositioncomprising an mRNA comprising an open reading frame (ORF) encoding apropionyl-CoA carboxylase alpha (PCCA) polypeptide and an mRNAcomprising an open reading frame (ORF) encoding a propionyl-CoAcarboxylase beta (PCCB) polypeptide, wherein the composition whenadministered as a single intravenous dose to a human subject in needthereof is sufficient to:

(i) increase the level of PCC activity in liver tissue to within atleast 2%, at least 5%, at least 10%, at least 20%, at least 30%, atleast 40%, at least 50%, at least 60%, at least 70%, at least 80%, atleast 90%, or at least 100% of normal PCC activity level for at least 12hours, at least 24 hours, at least 48 hours, at least 72 hours, at least96 hours, at least 120 hours, at least 1 week, at least 2 weeks, atleast 3 weeks, at least 4 weeks, at least 8 weeks, or at least 12 weekspost-administration;

(ii) increase the level of PCC activity in liver tissue at least1.5-fold, at least 2-fold, at least 3-fold, at least 4-fold, at least5-fold, at least 10-fold, at least 20-fold, or at least 50-fold comparedto the subject's baseline PCC activity level or a reference PCC activitylevel in a human subject having propionic academia (PA) for at least 12hours, at least 24 hours, at least 48 hours, at least 72 hours, at least96 hours, at least 120 hours, at least 1 week, at least 2 weeks, atleast 3 weeks, at least 4 weeks, at least 8 weeks, or at least 12 weekspost-administration;

(iii) reduce plasma, serum, whole blood, urine, and/or liver levels ofpropionic acid at least 30%, at least 40%, at least 50%, at least 60%,at least 70%, at least 80%, at least 90%, or at least 100% compared tothe subject's baseline plasma, serum, whole blood, urine, and/or liverpropionic acid level or a reference plasma, serum, whole blood, urine,and/or liver propionic acid level in a human subject having PA for atleast 12 hours, at least 24 hours, at least 48 hours, at least 72 hours,at least 96 hours, at least 120 hours, at least 1 week, at least 2weeks, at least 3 weeks, at least 4 weeks, at least 8 weeks, or at least12 weeks post-administration;

(iv) reduce plasma, serum, whole blood, and/or urine levels ofpropionyl-L-carnitine (C3), 2-methylcitric acid (2-MC),3-hydroxypropionic acid, (30HPA), propionylglycine, glycine, lactateand/or ammonia at least 30%, at least 40%, at least 50%, at least 60%,at least 70%, at least 80%, at least 90%, or at least 100% compared tothe subject's baseline plasma, serum, or urine level or a referenceplasma, serum, or urine C3, 2-MC, 30HPA, propionylglycine, glycine,lactate and/or ammonia level in a human subject having PA for at least12 hours, at least 24 hours, at least 48 hours, at least 72 hours, atleast 96 hours, at least 120 hours, at least 1 week, at least 2 weeks,at least 3 weeks, at least 4 weeks, at least 8 weeks, or at least 12weeks post-administration;

(v) reduce plasma, serum, whole blood, urine, and/or liver levels ofpropionic acid at least 1.5-fold, at least 2-fold, at least 5-fold, atleast 10-fold, at least 20-fold, or at least 50-fold as compared to thesubject's baseline plasma, serum, whole blood, urine, and/or liverpropionic acid level or a reference plasma, serum, whole blood, urine,and/or liver propionic acid level in a patient with PA for at least 12hours, at least 24 hours, at least 48 hours, at least 72 hours, at least96 hours, at least 120 hours, at least 1 week, at least 2 weeks, atleast 3 weeks, at least 4 weeks, at least 8 weeks, or at least 12 weekspost-administration; and/or

(vi) reduce plasma, serum, and/or urine level of C3, 2-MC, 30HPA,propionylglycine, glycine, lactate and/or ammonia at least 1.5-fold, atleast 2-fold at least 5-fold, at least 10-fold, at least 20-fold or atleast 50-fold as compared to the subject's baseline plasma, serum,and/or urine C3, 2-MC, 30HPA, propionylglycine, glycine, lactate and/orammonia level or a reference plasma, serum, and/or urine C3, 2-MC,30HPA, propionylglycine, glycine, lactate and/or ammonia level in apatient with PA for at least 12 hours, at least 24 hours, at least 48hours, at least 72 hours, at least 96 hours, at least 120 hours, atleast 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, atleast 8 weeks, or at least 12 weeks post-administration.

In some embodiments of the aspects, the pharmaceutical compositionfurther comprises a delivery agent. In some embodiments, the deliveryagent comprises a lipid nanoparticle comprising: (i) Compound II, (ii)Cholesterol, and (iii) PEG-DMG or Compound I; (i) Compound VI, (ii)Cholesterol, and (iii) PEG-DMG or Compound I; (i) Compound II, (ii) DSPCor DOPE, (iii) Cholesterol, and (iv) PEG-DMG or Compound I; (i) CompoundVI, (ii) DSPC or DOPE, (iii) Cholesterol, and (iv) PEG-DMG or CompoundI; (i) Compound II, (ii) Cholesterol, and (iii) Compound I; or (i)Compound II, (ii) DSPC or DOPE, (iii) Cholesterol, and (iv) Compound I.

In some embodiments of the aspects, the pharmaceutical compositionfurther comprises a delivery agent. In some embodiments, the deliveryagent comprises a lipid nanoparticle comprising (i) Compound II, (ii)Cholesterol, and (iii) Compound I.

In some embodiments of the aspects, the pharmaceutical compositionfurther comprises a delivery agent. In some embodiments, the deliveryagent comprises a lipid nanoparticle comprising (i) Compound II, (ii)DSPC or DOPE, (iii) Cholesterol, and (iv) Compound I.

In some embodiments, the PCCA polypeptide comprises the amino acidsequence set forth in SEQ ID NO:1 and the PCCB polypeptide comprises theamino acid sequence set forth in SEQ ID NO: 15.

In some embodiments, the ORF has at least 79%, at least 80%, at least85%, at least 90%, at least 91%, at least 92%, at least 93%, at least94%, at least 95%, at least 96%, at least 97%, at least 98%, at least99%, or 100% sequence identity to a nucleic acid sequence selected fromthe group consisting of SEQ ID NOs: 2, 5-14, 16-27, 196, 197, and 198.

In some embodiments, the mRNA comprises a microRNA (miR) binding site.In certain instances, the microRNA is expressed in an immune cell ofhematopoietic lineage or a cell that expresses TLR7 and/or TLR8 andsecretes pro-inflammatory cytokines and/or chemokines. In someinstances, the microRNA binding site is for a microRNA selected from thegroup consisting of miR-126, miR-142, miR-144, miR-146, miR-150,miR-155, miR-16, miR-21, miR-223, miR-24, miR-27, miR-26a, or anycombination thereof. In some instances, the microRNA binding site is fora microRNA selected from the group consisting of miR126-3p, miR-142-3p,miR-142-5p, miR-155, or any combination thereof. In some instances, themicroRNA binding site is a miR-142-3p binding site. In some instances,the microRNA binding site is located in the 3′ UTR of the mRNA.

In some embodiments, the mRNA comprises a 3′ UTR comprising a nucleicacid sequence at least about 90%, at least about 95%, at least about96%, at least about 97%, at least about 98%, at least about 99%, or 100%identical to a 3′ UTR sequence of SEQ ID NO:4, SEQ ID NO: 112, or SEQ IDNO:178.

In some embodiments, the mRNA comprises a 3′ UTR comprising a nucleicacid sequence at least about 90%, at least about 95%, at least about96%, at least about 97%, at least about 98%, at least about 99%, or 100%identical to a 3′ UTR sequence of SEQ ID NO:4, SEQ ID NO:111, SEQ IDNO:150, SEQ ID NO:175, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:207, orSEQ ID NO:208.

In some embodiments, the mRNA comprises a 5′ UTR comprising a nucleicacid sequence at least 90%, at least about 95%, at least about 96%, atleast about 97%, at least about 98%, at least about 99%, or 100%identical to a 5′ UTR sequence of SEQ ID NO:3, SEQ ID NO:64, or SEQ IDNO:199.

In some embodiments, the mRNA comprises a 5′ UTR comprising a nucleicacid sequence at least 90%, at least about 95%, at least about 96%, atleast about 97%, at least about 98%, at least about 99%, or 100%identical to a 5′ UTR sequence of SEQ ID NO:3, SEQ ID NO:191, SEQ IDNO:199, or SEQ ID NO:206.

In some embodiments, the mRNA comprises a 5′ terminal cap. In someinstances, the 5′ terminal cap comprises a Cap0, Cap1, ARCA, inosine,N1-methyl-guanosine, 2′-fluoro-guanosine, 7-deaza-guanosine,8-oxo-guanosine, 2-amino-guanosine, LNA-guanosine, 2-azidoguanosine,Cap2, Cap4, 5′ methylG cap, or an analog thereof.

In some embodiments, the mRNA comprises a poly-A region. In someinstances, the poly-A region is at least about 10, at least about 20, atleast about 30, at least about 40, at least about 50, at least about 60,at least about 70, at least about 80, at least about 90 nucleotides inlength, or at least about 100 nucleotides in length. In some instances,the poly-A region has about 10 to about 200, about 20 to about 180,about 50 to about 160, about 70 to about 140, or about 80 to about 120nucleotides in length.

In some embodiments, the mRNA comprises at least one chemically modifiednucleobase, sugar, backbone, or any combination thereof. In someinstances, the at least one chemically modified nucleobase is selectedfrom the group consisting of pseudouracil (ψ), N1 methylpseudouracil(m1ψ), 1-ethylpseudouracil, 2-thiouracil (s2U), 4′-thiouracil,5-methylcytosine, 5-methyluracil, 5-methoxyuracil, and any combinationthereof. In some instances, at least about 25%, at least about 30%, atleast about 40%, at least about 50%, at least about 60%, at least about70%, at least about 80%, at least about 90%, at least about 95%, atleast about 99%, or 100% of the uracils are chemically modified toN1-methylpseudouracils. In some instances, at least about 25%, at leastabout 30%, at least about 40%, at least about 50%, at least about 60%,at least about 70%, at least about 80%, at least about 90%, at leastabout 95%, at least about 99%, or 100% of the guanines are chemicallymodified. In some instances, at least about 25%, at least about 30%, atleast about 40%, at least about 50%, at least about 60%, at least about70%, at least about 80%, at least about 90%, at least about 95%, atleast about 99%, or 100% of the cytosines are chemically modified. Insome instances, at least about 25%, at least about 30%, at least about40%, at least about 50%, at least about 60%, at least about 70%, atleast about 80%, at least about 90%, at least about 95%, at least about99%, or 100% of the adenines are chemically modified.

In some embodiments, the human subject has propionic acidemia (PA).

In some embodiments, the human subject is on a protein restricted diet.In some embodiments, the human subject is not on a protein restricteddiet.

In one aspect, the disclosure features a polynucleotide comprising anmRNA comprising: (i) a 5′ UTR; (ii) an open reading frame (ORF) encodinga human PCCA polypeptide, wherein the ORF has at least 79%, at least80%, at least 85%, at least 90%, at least 91%, at least 92%, at least93%, at least 94%, at least 95%, at least 96%, at least 97%, at least98%, at least 99%, or 100% sequence identity to a nucleic acid sequenceselected from the group consisting of SEQ ID NOs:2 and 5-14; and (iii) a3′ UTR.

In one aspect, the disclosure features a polynucleotide comprising anmRNA comprising: (i) a 5′ UTR; (ii) an open reading frame (ORF) encodinga human PCCA polypeptide, wherein the ORF has at least 79%, at least80%, at least 85%, at least 90%, at least 91%, at least 92%, at least93%, at least 94%, at least 95%, at least 96%, at least 97%, at least98%, at least 99%, or 100% sequence identity to SEQ ID NO:11; and (iii)a 3′ UTR. In some embodiments, the PCCA polypeptide consists of theamino acid sequence of SEQ ID NO:1.

In one aspect, the disclosure features a polynucleotide comprising anmRNA comprising: (i) a 5′ UTR; (ii) an open reading frame (ORF) encodinga human PCCA polypeptide, wherein the ORF has at least 80% sequenceidentity to SEQ ID NO:11; and (iii) a 3′ UTR. In some embodiments, thePCCA polypeptide consists of the amino acid sequence of SEQ ID NO:1.

In one aspect, the disclosure features a polynucleotide comprising anmRNA comprising: (i) a 5′ UTR; (ii) an open reading frame (ORF) encodinga human PCCA polypeptide, wherein the ORF has at least 85% sequenceidentity to SEQ ID NO:11; and (iii) a 3′ UTR. In some embodiments, thePCCA polypeptide consists of the amino acid sequence of SEQ ID NO:1.

In one aspect, the disclosure features a polynucleotide comprising anmRNA comprising: (i) a 5′ UTR; (ii) an open reading frame (ORF) encodinga human PCCA polypeptide, wherein the ORF has at least 90% sequenceidentity to SEQ ID NO:11; and (iii) a 3′ UTR. In some embodiments, thePCCA polypeptide consists of the amino acid sequence of SEQ ID NO:1.

In one aspect, the disclosure features a polynucleotide comprising anmRNA comprising: (i) a 5′ UTR; (ii) an open reading frame (ORF) encodinga human PCCA polypeptide, wherein the ORF has at least 95% sequenceidentity to SEQ ID NO:11; and (iii) a 3′ UTR. In some embodiments, thePCCA polypeptide consists of the amino acid sequence of SEQ ID NO:1.

In one aspect, the disclosure features a polynucleotide comprising anmRNA comprising: (i) a 5′ UTR; (ii) an open reading frame (ORF) encodinga human PCCA polypeptide, wherein the ORF has at least 98% sequenceidentity to SEQ ID NO:11; and (iii) a 3′ UTR. In some embodiments, thePCCA polypeptide consists of the amino acid sequence of SEQ ID NO:1.

In one aspect, the disclosure features a polynucleotide comprising anmRNA comprising: (i) a 5′ UTR; (ii) an open reading frame (ORF) encodinga human PCCA polypeptide, wherein the ORF comprises a nucleic acidsequence selected from the group consisting of SEQ ID NOs:2 and 5-14;and (iii) a 3′ UTR.

In one aspect, the disclosure features a polynucleotide comprising anmRNA comprising: (i) a 5′ UTR; (ii) an open reading frame (ORF) encodinga human PCCB polypeptide, wherein the ORF has at least 79%, at least80%, at least 85%, at least 90%, at least 91%, at least 92%, at least93%, at least 94%, at least 95%, at least 96%, at least 97%, at least98%, at least 99%, or 100% sequence identity to a nucleic acid sequenceselected from the group consisting of SEQ ID NOs: 16-27, 196, 197, and198; and (iii) a 3′ UTR. In some embodiments, the PCCB polypeptideconsists of the amino acid sequence of SEQ ID NO:15.

In one aspect, the disclosure features a polynucleotide comprising anmRNA comprising: (i) a 5′ UTR; (ii) an open reading frame (ORF) encodinga human PCCB polypeptide, wherein the ORF has at least 94% sequenceidentity to SEQ ID NO:23; and (iii) a 3′ UTR. In some embodiments, thePCCB polypeptide consists of the amino acid sequence of SEQ ID NO:15.

In one aspect, the disclosure features a polynucleotide comprising anmRNA comprising: (i) a 5′ UTR; (ii) an open reading frame (ORF) encodinga human PCCB polypeptide, wherein the ORF has at least 95% sequenceidentity to SEQ ID NO:23; and (iii) a 3′ UTR. In some embodiments, thePCCB polypeptide consists of the amino acid sequence of SEQ ID NO:15.

In one aspect, the disclosure features a polynucleotide comprising anmRNA comprising: (i) a 5′ UTR; (ii) an open reading frame (ORF) encodinga human PCCB polypeptide, wherein the ORF has at least 96% sequenceidentity to SEQ ID NO:23; and (iii) a 3′ UTR. In some embodiments, thePCCB polypeptide consists of the amino acid sequence of SEQ ID NO:15.

In one aspect, the disclosure features a polynucleotide comprising anmRNA comprising: (i) a 5′ UTR; (ii) an open reading frame (ORF) encodinga human PCCB polypeptide, wherein the ORF has at least 97% sequenceidentity to SEQ ID NO:23; and (iii) a 3′ UTR. In some embodiments, thePCCB polypeptide consists of the amino acid sequence of SEQ ID NO:15.

In one aspect, the disclosure features a polynucleotide comprising anmRNA comprising: (i) a 5′ UTR; (ii) an open reading frame (ORF) encodinga human PCCB polypeptide, wherein the ORF has at least 98% sequenceidentity to SEQ ID NO:23; and (iii) a 3′ UTR. In some embodiments, thePCCB polypeptide consists of the amino acid sequence of SEQ ID NO:15.

In one aspect, the disclosure features a polynucleotide comprising anmRNA comprising: (i) a 5′ UTR; (ii) an open reading frame (ORF) encodinga human PCCB polypeptide, wherein the ORF has at least 99% sequenceidentity to SEQ ID NO:23; and (iii) a 3′ UTR. In some embodiments, thePCCB polypeptide consists of the amino acid sequence of SEQ ID NO:15.

In one aspect, the disclosure features a polynucleotide comprising anmRNA comprising: (i) a 5′ UTR; (ii) an open reading frame (ORF) encodinga human PCCB polypeptide, wherein the ORF has at least 94% sequenceidentity to SEQ ID NO:25; and (iii) a 3′ UTR. In some embodiments, thePCCB polypeptide consists of the amino acid sequence of SEQ ID NO:15.

In one aspect, the disclosure features a polynucleotide comprising anmRNA comprising: (i) a 5′ UTR; (ii) an open reading frame (ORF) encodinga human PCCB polypeptide, wherein the ORF has at least 95% sequenceidentity to SEQ ID NO:25; and (iii) a 3′ UTR. In some embodiments, thePCCB polypeptide consists of the amino acid sequence of SEQ ID NO:15.

In one aspect, the disclosure features a polynucleotide comprising anmRNA comprising: (i) a 5′ UTR; (ii) an open reading frame (ORF) encodinga human PCCB polypeptide, wherein the ORF has at least 96% sequenceidentity to SEQ ID NO:25; and (iii) a 3′ UTR. In some embodiments, thePCCB polypeptide consists of the amino acid sequence of SEQ ID NO:15.

In one aspect, the disclosure features a polynucleotide comprising anmRNA comprising: (i) a 5′ UTR; (ii) an open reading frame (ORF) encodinga human PCCB polypeptide, wherein the ORF has at least 97% sequenceidentity to SEQ ID NO:25; and (iii) a 3′ UTR. In some embodiments, thePCCB polypeptide consists of the amino acid sequence of SEQ ID NO:15.

In one aspect, the disclosure features a polynucleotide comprising anmRNA comprising: (i) a 5′ UTR; (ii) an open reading frame (ORF) encodinga human PCCB polypeptide, wherein the ORF has at least 98% sequenceidentity to SEQ ID NO:25; and (iii) a 3′ UTR. In some embodiments, thePCCB polypeptide consists of the amino acid sequence of SEQ ID NO:15.

In one aspect, the disclosure features a polynucleotide comprising anmRNA comprising: (i) a 5′ UTR; (ii) an open reading frame (ORF) encodinga human PCCB polypeptide, wherein the ORF has at least 99% sequenceidentity to SEQ ID NO:25; and (iii) a 3′ UTR. In some embodiments, thePCCB polypeptide consists of the amino acid sequence of SEQ ID NO:15.

In one aspect, the disclosure features a polynucleotide comprising anmRNA comprising: (i) a 5′ UTR; (ii) an open reading frame (ORF) encodinga human PCCB polypeptide, wherein the ORF comprises a nucleic acidsequence selected from the group consisting of SEQ ID NOs:16-27, 196,197, and 198; and (iii) a 3′ UTR.

In some embodiments of the aspects, the mRNA comprises a microRNA (miR)binding site. In some instances, the microRNA is expressed in an immunecell of hematopoietic lineage or a cell that expresses TLR7 and/or TLR8and secretes pro-inflammatory cytokines and/or chemokines. In someinstances, the microRNA binding site is for a microRNA selected from thegroup consisting of miR-126, miR-142, miR-144, miR-146, miR-150,miR-155, miR-16, miR-21, miR-223, miR-24, miR-27, miR-26a, or anycombination thereof. In some instances, the microRNA binding site is fora microRNA selected from the group consisting of miR126-3p, miR-142-3p,miR-142-5p, miR-155, or any combination thereof. In some instances, themicroRNA binding site is a miR-142-3p binding site.

In some embodiments, the microRNA binding site is located in the 3′ UTRof the mRNA. In some instances, the 3′ UTR comprises a nucleic acidsequence at least about 90%, at least about 95%, at least about 96%, atleast about 97%, at least about 98%, at least about 99%, or 100%identical to a 3′ UTR of SEQ ID NO:4, SEQ ID NO: 112, or SEQ ID NO:178.

In some embodiments, the microRNA binding site is located in the 3′ UTRof the mRNA. In some instances, the 3′ UTR comprises a nucleic acidsequence at least about 90%, at least about 95%, at least about 96%, atleast about 97%, at least about 98%, at least about 99%, or 100%identical to a 3′ UTR of SEQ ID NO:4, SEQ ID NO:111, SEQ ID NO:150, SEQID NO:175, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:207, or SEQ IDNO:208. In some embodiments, the 5′ UTR comprises a nucleic acidsequence at least 90%, at least about 95%, at least about 96%, at leastabout 97%, at least about 98%, at least about 99%, or 100% identical toa 5′ UTR sequence of SEQ ID NO:3, SEQ ID NO:64, or SEQ ID NO:199.

In some embodiments, the 5′ UTR comprises a nucleic acid sequence atleast 90%, at least about 95%, at least about 96%, at least about 97%,at least about 98%, at least about 99%, or 100% identical to a 5′ UTRsequence of SEQ ID NO:3, SEQ ID NO:191, SEQ ID NO:199, or SEQ ID NO:206.In some embodiments, the mRNA comprises a 5′ terminal cap. In someinstances, the 5′ terminal cap comprises a Cap0, Cap1, ARCA, inosine,N1-methyl-guanosine, 2′-fluoro-guanosine, 7-deaza-guanosine,8-oxo-guanosine, 2-amino-guanosine, LNA-guanosine, 2-azidoguanosine,Cap2, Cap4, 5′ methylG cap, or an analog thereof.

In some embodiments, the mRNA comprises a poly-A region. In someinstances, the poly-A region is at least about 10, at least about 20, atleast about 30, at least about 40, at least about 50, at least about 60,at least about 70, at least about 80, at least about 90 nucleotides inlength, or at least about 100 nucleotides in length. In some instances,the poly-A region has about 10 to about 200, about 20 to about 180,about 50 to about 160, about 70 to about 140, or about 80 to about 120nucleotides in length.

In some embodiments, the mRNA comprises at least one chemically modifiednucleobase, sugar, backbone, or any combination thereof. In someinstances, the at least one chemically modified nucleobase is selectedfrom the group consisting of pseudouracil (ψ), N1-methylpseudouracil(m1ψ), 1-ethylpseudouracil, 2-thiouracil (s2U), 4′-thiouracil,5-methylcytosine, 5-methyluracil, 5-methoxyuracil, and any combinationthereof. In some instances, at least about 25%, at least about 30%, atleast about 40%, at least about 50%, at least about 60%, at least about70%, at least about 80%, at least about 90%, at least about 95%, atleast about 99%, or 100% of the uracils are chemically modified toN1-methylpseudouracils.

In some embodiments, the polynucleotide comprises a nucleic acidsequence selected from the group consisting of SEQ ID NOs: 28-38, 63,65, and 203. In some embodiments, the polynucleotide comprises a nucleicacid sequence selected from the group consisting of SEQ ID NOs: 39-50,66, 67, 200-202, 204, and 205.

In one aspect, the disclosure features a polynucleotide comprising anmRNA comprising: (i) a 5′-terminal cap; (ii) a 5′ UTR comprising thenucleic acid sequence of SEQ ID NO:3, SEQ ID NO:64, or SEQ ID NO:199;(iii) an open reading frame (ORF) encoding a human PCCA polypeptide,wherein the ORF comprises a sequence selected from the group consistingof SEQ ID NOs:2 and 5-14; (iv) a 3′ UTR comprising the nucleic acidsequence of SEQ ID NO:4, SEQ ID NO: 112, or SEQ ID NO:178; and (v) apoly-A-region.

In one aspect, the disclosure features a polynucleotide comprising anmRNA comprising: (i) a 5′-terminal cap; (ii) a 5′ UTR comprising thenucleic acid sequence of SEQ ID NO: 3, SEQ ID NO:64, or SEQ ID NO:199;(iii) an open reading frame (ORF) encoding a human PCCB polypeptide,wherein the ORF comprises a sequence selected from the group consistingof SEQ ID NOs: 16-27, 196, 197, and 198; (iv) a 3′ UTR comprising thenucleic acid sequence of SEQ ID NO:4, SEQ ID NO: 112, or SEQ ID NO:178;and (v) a poly-A-region.

In one aspect, the disclosure features a polynucleotide comprising anmRNA comprising: (i) a 5′-terminal cap; (ii) a 5′ UTR comprising thenucleic acid sequence of SEQ ID NO:3, SEQ ID NO:191, SEQ ID NO:199, orSEQ ID NO:206; (iii) an open reading frame (ORF) encoding a human PCCApolypeptide, wherein the ORF comprises a sequence selected from thegroup consisting of SEQ ID NOs:2 and 5-14; (iv) a 3′ UTR comprising thenucleic acid sequence of SEQ ID NO:4, SEQ ID NO:111, SEQ ID NO:150, SEQID NO:175, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:207, or SEQ IDNO:208; and (v) a poly-A-region.

In one aspect, the disclosure features a polynucleotide comprising anmRNA comprising: (i) a 5′-terminal cap; (ii) a 5′ UTR comprising thenucleic acid sequence of SEQ ID NO:3, SEQ ID NO:191, SEQ ID NO:199, orSEQ ID NO:206; (iii) an open reading frame (ORF) encoding a human PCCBpolypeptide, wherein the ORF comprises a sequence selected from thegroup consisting of SEQ ID NOs: 16-27, 196, 197, and 198; (iv) a 3′ UTRcomprising the nucleic acid sequence of SEQ ID NO:4, SEQ ID NO:111, SEQID NO:150, SEQ ID NO:175, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:207,or SEQ ID NO:208; and (v) a poly-A-region.

In some embodiments, the 5′ terminal cap comprises a Cap0, Cap1, ARCA,inosine, N1-methyl-guanosine, 2′-fluoro-guanosine, 7-deaza-guanosine,8-oxo-guanosine, 2-amino-guanosine, LNA-guanosine, 2-azidoguanosine,Cap2, Cap4, 5′ methylG cap, or an analog thereof.

In some embodiments, the poly-A region is at least about 10, at leastabout 20, at least about 30, at least about 40, at least about 50, atleast about 60, at least about 70, at least about 80, or at least about90 nucleotides in length. In some instances, the poly-A region has about10 to about 200, about 20 to about 180, about 50 to about 160, about 70to about 140, or about 80 to about 120 nucleotides in length.

In some embodiments, the mRNA comprises at least one chemically modifiednucleobase, sugar, backbone, or any combination thereof. In someembodiments, the at least one chemically modified nucleobase is selectedfrom the group consisting of pseudouracil (ψ), N1-methylpseudouracil(m1ψ), 1-ethylpseudouracil, 2-thiouracil (s2U), 4′-thiouracil,5-methylcytosine, 5-methyluracil, 5-methoxyuracil, and any combinationthereof.

In some embodiments, the polynucleotide comprises a nucleic acidsequence selected from the group consisting of SEQ ID NOs: 28-38, 63,65, and 203. In some embodiments, the polynucleotide comprises a nucleicacid sequence selected from the group consisting of SEQ ID NOs: 39-50,66, 67, 200-202, 204, and 205. In some of these embodiments, the 5′terminal cap comprises Cap1 and all of the uracils of the polynucleotideare N1-methylpseudouracils. In some of these embodiments, thepoly-A-region is 100 nucleotides in length.

In some embodiments, the pharmaceutical composition comprises apolynucleotide described herein, and a delivery agent.

In one aspect, the disclosure features a pharmaceutical compositioncomprising two polynucleotides, wherein the first polynucleotidecomprises an open reading frame (ORF) described herein encoding a humanPCCA polypeptide and the second polynucleotide comprises an open readingframe (ORF) described herein encoding a human PCCB polypeptide, and adelivery agent.

In some embodiments of the pharmaceutical composition, the firstpolynucleotide comprises an mRNA comprising: (i) a 5′ UTR; (ii) an openreading frame (ORF) encoding a human PCCA polypeptide (e.g., SEQ IDNO:1), wherein the ORF has at least 80% sequence identity to SEQ ID NO:11; and (iii) a 3′ UTR, and the second polynucleotide comprises an mRNAcomprising: (i) a 5′ UTR; (ii) an open reading frame (ORF) encoding ahuman PCCB polypeptide (e.g., SEQ ID NO:15), wherein the ORF has atleast 80% sequence identity to SEQ ID NO:23; and (iii) a 3′ UTR.

In some embodiments of the pharmaceutical composition, the firstpolynucleotide comprises an mRNA comprising: (i) a 5′ UTR; (ii) an openreading frame (ORF) encoding a human PCCA polypeptide (e.g., SEQ IDNO:1), wherein the ORF has at least 85% sequence identity to SEQ ID NO:11; and (iii) a 3′ UTR, and the second polynucleotide comprises an mRNAcomprising: (i) a 5′ UTR; (ii) an open reading frame (ORF) encoding ahuman PCCB polypeptide (e.g., SEQ ID NO:15), wherein the ORF has atleast 85% sequence identity to SEQ ID NO:23; and (iii) a 3′ UTR.

In some embodiments of the pharmaceutical composition, the firstpolynucleotide comprises an mRNA comprising: (i) a 5′ UTR; (ii) an openreading frame (ORF) encoding a human PCCA polypeptide (e.g., SEQ IDNO:1), wherein the ORF has at least 90% sequence identity to SEQ IDNO:11; and (iii) a 3′ UTR, and the second polynucleotide comprises anmRNA comprising: (i) a 5′ UTR; (ii) an open reading frame (ORF) encodinga human PCCB polypeptide (e.g., SEQ ID NO:15), wherein the ORF has atleast 90% sequence identity to SEQ ID NO:23; and (iii) a 3′ UTR.

In some embodiments of the pharmaceutical composition, the firstpolynucleotide comprises an mRNA comprising: (i) a 5′ UTR; (ii) an openreading frame (ORF) encoding a human PCCA polypeptide (e.g., SEQ IDNO:1), wherein the ORF has at least 95% sequence identity to SEQ ID NO:11; and (iii) a 3′ UTR, and the second polynucleotide comprises an mRNAcomprising: (i) a 5′ UTR; (ii) an open reading frame (ORF) encoding ahuman PCCB polypeptide (e.g., SEQ ID NO:15), wherein the ORF has atleast 95% sequence identity to SEQ ID NO:23; and (iii) a 3′ UTR.

In some embodiments of the pharmaceutical composition, the firstpolynucleotide comprises an mRNA comprising: (i) a 5′ UTR; (ii) an openreading frame (ORF) encoding a human PCCA polypeptide (e.g., SEQ IDNO:1), wherein the ORF has at least 98% sequence identity to SEQ ID NO:11; and (iii) a 3′ UTR, and the second polynucleotide comprises an mRNAcomprising: (i) a 5′ UTR; (ii) an open reading frame (ORF) encoding ahuman PCCB polypeptide (e.g., SEQ ID NO:15), wherein the ORF has atleast 98% sequence identity to SEQ ID NO:23; and (iii) a 3′ UTR.

In some embodiments of the pharmaceutical composition, the firstpolynucleotide comprises an mRNA comprising: (i) a 5′ UTR; (ii) an openreading frame (ORF) encoding a human PCCA polypeptide (e.g., SEQ IDNO:1), wherein the ORF comprises SEQ ID NO: 11; and (iii) a 3′ UTR, andthe second polynucleotide comprises an mRNA comprising: (i) a 5′ UTR;(ii) an open reading frame (ORF) encoding a human PCCB polypeptide(e.g., SEQ ID NO: 15), wherein the ORF comprises SEQ ID NO:23; and (iii)a 3′ UTR.

In some embodiments of the pharmaceutical composition, the firstpolynucleotide comprises an mRNA comprising: (i) a 5′ UTR; (ii) an openreading frame (ORF) encoding a human PCCA polypeptide (e.g., SEQ IDNO:1), wherein the ORF has at least 80% sequence identity to SEQ ID NO:11; and (iii) a 3′ UTR, and the second polynucleotide comprises an mRNAcomprising: (i) a 5′ UTR; (ii) an open reading frame (ORF) encoding ahuman PCCB polypeptide (e.g., SEQ ID NO:15), wherein the ORF has atleast 80% sequence identity to SEQ ID NO:25; and (iii) a 3′ UTR.

In some embodiments of the pharmaceutical composition, the firstpolynucleotide comprises an mRNA comprising: (i) a 5′ UTR; (ii) an openreading frame (ORF) encoding a human PCCA polypeptide (e.g., SEQ IDNO:1), wherein the ORF has at least 85% sequence identity to SEQ ID NO:11; and (iii) a 3′ UTR, and the second polynucleotide comprises an mRNAcomprising: (i) a 5′ UTR; (ii) an open reading frame (ORF) encoding ahuman PCCB polypeptide (e.g., SEQ ID NO:15), wherein the ORF has atleast 85% sequence identity to SEQ ID NO:25; and (iii) a 3′ UTR.

In some embodiments of the pharmaceutical composition, the firstpolynucleotide comprises an mRNA comprising: (i) a 5′ UTR; (ii) an openreading frame (ORF) encoding a human PCCA polypeptide (e.g., SEQ IDNO:1), wherein the ORF has at least 90% sequence identity to SEQ IDNO:11; and (iii) a 3′ UTR, and the second polynucleotide comprises anmRNA comprising: (i) a 5′ UTR; (ii) an open reading frame (ORF) encodinga human PCCB polypeptide (e.g., SEQ ID NO:15), wherein the ORF has atleast 90% sequence identity to SEQ ID NO:25; and (iii) a 3′ UTR.

In some embodiments of the pharmaceutical composition, the firstpolynucleotide comprises an mRNA comprising: (i) a 5′ UTR; (ii) an openreading frame (ORF) encoding a human PCCA polypeptide (e.g., SEQ IDNO:1), wherein the ORF has at least 95% sequence identity to SEQ ID NO:11; and (iii) a 3′ UTR, and the second polynucleotide comprises an mRNAcomprising: (i) a 5′ UTR; (ii) an open reading frame (ORF) encoding ahuman PCCB polypeptide (e.g., SEQ ID NO:15), wherein the ORF has atleast 95% sequence identity to SEQ ID NO:25; and (iii) a 3′ UTR.

In some embodiments of the pharmaceutical composition, the firstpolynucleotide comprises an mRNA comprising: (i) a 5′ UTR; (ii) an openreading frame (ORF) encoding a human PCCA polypeptide (e.g., SEQ IDNO:1), wherein the ORF has at least 98% sequence identity to SEQ ID NO:11; and (iii) a 3′ UTR, and the second polynucleotide comprises an mRNAcomprising: (i) a 5′ UTR; (ii) an open reading frame (ORF) encoding ahuman PCCB polypeptide (e.g., SEQ ID NO:15), wherein the ORF has atleast 98% sequence identity to SEQ ID NO:25; and (iii) a 3′ UTR.

In some embodiments of the pharmaceutical composition, the firstpolynucleotide comprises an mRNA comprising: (i) a 5′ UTR; (ii) an openreading frame (ORF) encoding a human PCCA polypeptide (e.g., SEQ IDNO:1), wherein the ORF comprises SEQ ID NO: 11; and (iii) a 3′ UTR, andthe second polynucleotide comprises an mRNA comprising: (i) a 5′ UTR;(ii) an open reading frame (ORF) encoding a human PCCB polypeptide(e.g., SEQ ID NO: 15), wherein the ORF comprises SEQ ID NO:25; and (iii)a 3′ UTR.

In some embodiments, the delivery agent comprises a lipid nanoparticlecomprising: (i) Compound II, (ii) Cholesterol, and (iii) PEG-DMG orCompound I; (i) Compound VI, (ii) Cholesterol, and (iii) PEG-DMG orCompound I; (i) Compound II, (ii) DSPC or DOPE, (iii) Cholesterol, and(iv) PEG-DMG or Compound I; (i) Compound VI, (ii) DSPC or DOPE, (iii)Cholesterol, and (iv) PEG-DMG or Compound I; (i) Compound II, (ii)Cholesterol, and (iii) Compound I; or (i) Compound II, (ii) DSPC orDOPE, (iii) Cholesterol, and (iv) Compound I.

In one aspect, the disclosure features a method of expressing apropionyl-CoA carboxylase alpha (PCCA) polypeptide in a human subject inneed thereof, comprising administering to the subject an effectiveamount or a pharmaceutical composition or a polynucleotide describedherein.

In one aspect, the disclosure features a method of expressing apropionyl-CoA carboxylase beta (PCCB) polypeptide in a human subject inneed thereof, comprising administering to the subject an effectiveamount of a pharmaceutical composition or a polynucleotide describedherein.

In one aspect, the disclosure features a method of expressing apropionyl-CoA carboxylase alpha (PCCA) polypeptide and a propionyl-CoAcarboxylase beta (PCCB) polypeptide in a human subject in need thereof,comprising administering to the subject an effective amount of at leastone of the pharmaceutical compositions described herein or twopolynucleotides described herein, wherein the first polynucleotidecomprises an open reading frame (ORF) encoding a human PCCA polypeptideand the second polynucleotide comprises an open reading frame (ORF)encoding a human PCCB polypeptide.

In some embodiments, pharmaceutical composition comprises a firstpolynucleotide comprising an open reading frame (ORF) described hereinencoding a human PCCA polypeptide and a second polynucleotide comprisingan open reading frame (ORF) described herein encoding a human PCCBpolypeptide.

In some embodiments, the method comprises administering a firstpharmaceutical composition and a second pharmaceutical composition,wherein the first pharmaceutical composition comprises a firstpolynucleotide comprising an open reading frame (ORF) described hereinencoding a human PCCA polypeptide, and wherein the second pharmaceuticalcomposition comprises a second polynucleotide comprising an open readingframe (ORF) described herein encoding a human PCCB polypeptide.

In one aspect, the disclosure features a method of treating, preventing,or delaying the onset and/or progression of propionic academia (PA) in ahuman subject in need thereof, comprising administering to the subjectan effective amount of a pharmaceutical composition or a polynucleotidedescribed herein.

In one aspect, the disclosure features a method of treating, preventing,or delaying the onset and/or progression of propionic academia (PA) in ahuman subject in need thereof, comprising administering to the subjectan effective amount of a pharmaceutical composition or a polynucleotidedescribed herein.

In one aspect, the disclosure features a method of treating, preventing,or delaying the onset and/or progression of propionic academia (PA) in ahuman subject in need thereof, comprising administering to the subjectan effective amount of at least one of the pharmaceutical compositionsdescribed herein or two polynucleotides described herein, wherein thefirst polynucleotide comprises an open reading frame (ORF) encoding ahuman PCCA polypeptide and the second polynucleotide comprises an openreading frame (ORF) encoding a human PCCB polypeptide.

In some embodiments, the method comprises administering a pharmaceuticalcomposition comprising a first polynucleotide comprising an open readingframe (ORF) described herein encoding a human PCCA polypeptide and asecond polynucleotide comprising an open reading frame (ORF) describedherein encoding a human PCCB polypeptide.

In some embodiments, the method comprises administering a firstpharmaceutical composition and a second pharmaceutical composition,wherein the first pharmaceutical composition comprises a firstpolynucleotide comprising an open reading frame (ORF) described hereinencoding a human PCCA polypeptide, and wherein the second pharmaceuticalcomposition comprises a second polynucleotide comprising an open readingframe (ORF) described herein encoding a human PCCB polypeptide.

In one aspect, the disclosure features a method of reducing propionicacid blood level in a human subject in need thereof, comprisingadministering to the subject an effective amount of a pharmaceuticalcomposition or a polynucleotide described herein.

In one aspect, the disclosure features a method of reducing propionicacid blood level in a human subject in need thereof, comprisingadministering to the subject an effective amount of a pharmaceuticalcomposition or a polynucleotide described herein.

In one aspect, the discourse features a method of reducing propionicacid blood level in a human subject in need thereof, comprisingadministering to the subject an effective amount of at least one of thepharmaceutical compositions described herein or two polynucleotidesdescribed herein, wherein the first polynucleotide comprises an openreading frame (ORF) encoding a human PCCA polypeptide and the secondpolynucleotide comprises an open reading frame (ORF) encoding a humanPCCB polypeptide.

In some embodiments, the method comprises administering a pharmaceuticalcomposition comprising a first polynucleotide comprising an open readingframe (ORF) described herein encoding a human PCCA polypeptide and asecond polynucleotide comprising an open reading frame (ORF) describedherein encoding a human PCCB polypeptide.

In some embodiments, the method comprises administering a firstpharmaceutical composition and a second pharmaceutical composition,wherein the first pharmaceutical composition comprises a firstpolynucleotide comprising an open reading frame (ORF) described hereinencoding a human PCCA polypeptide, and wherein the second pharmaceuticalcomposition comprises a second polynucleotide comprising an open readingframe (ORF) described herein encoding a human PCCB polypeptide.

In one aspect, the disclosure features a method of reducing C3, 2-MC,30HPA, propionylglycine, glycine, lactate and/or ammonia plasma, serum,whole blood, urine, and/or liver level in a human subject in needthereof, comprising administering to the subject an effective amount ofa pharmaceutical composition or a polynucleotide described herein.

In one aspect, the disclosure features a method of reducing C3, 2-MC,30HPA, propionylglycine, glycine, lactate and/or ammonia plasma, serum,whole blood, urine, and/or liver level in a human subject in needthereof, comprising administering to the subject an effective amount ofat least one of the pharmaceutical compositions described herein or twopolynucleotides described herein, wherein the first polynucleotidecomprises an open reading frame (ORF) encoding a human PCCA polypeptideand the second polynucleotide comprises an open reading frame (ORF)encoding a human PCCB polypeptide.

In some embodiments, the method comprises administering a pharmaceuticalcomposition comprising a first polynucleotide comprising an open readingframe (ORF) described herein encoding a human PCCA polypeptide and asecond polynucleotide comprising an open reading frame (ORF) describedherein encoding a human PCCB polypeptide.

In some embodiments, the method comprises administering a firstpharmaceutical composition and a second pharmaceutical composition,wherein the first pharmaceutical composition comprises a firstpolynucleotide comprising an open reading frame (ORF) encoding a humanPCCA polypeptide, and wherein the second pharmaceutical compositioncomprises a second polynucleotide comprising an open reading frame (ORF)encoding a human PCCB polypeptide.

In some embodiments of the above methods:

(i) the propionic acid blood and/or liver level is reduced at least 20%,at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, atleast 80%, at least 90%, or at least 100% as compared to the humansubject's baseline propionic acid blood and/or liver level or areference propionic acid blood and/or liver level in a patient with PA,for at least 24 hours, at least 48 hours, at least 72 hours, at least 96hours, at least 120 hours, 6 days, 1 week, 8 days, 9 days, 10 days, 11days, 12 days, 14 days, 18 days, or 21 days after a singleadministration;

(ii) the propionic acid plasma, serum, and/or urine level is reduced atleast 20%, at least 30%, at least 40%, at least 30%, at least 40%, atleast 50%, at least 60%, at least 70%, at least 80%, at least 90%, or atleast 100% as compared to the human subject's baseline propionic acidplasma, serum, and/or urine level or a reference propionic acid plasma,serum, and/or urine level in a patient with PA, for at least 24 hours,at least 48 hours, at least 72 hours, at least 96 hours, at least 120hours, 6 days, 1 week, 8 days, 9 days, 10 days, 11 days, 12 days, 14days, 18 days, or 21 days after a single administration;

(iii) the propionic acid blood and/or liver level is reduced to at leastwithin 10-fold, at least within 5-fold, at least within 2-fold, or atleast within 1.5-fold as compared to a normal propionic acid bloodand/or liver level within at least 24 hours, at least 48 hours, at least72 hours, at least 96 hours, at least 120 hours, 6 days, 1 week, 8 days,9 days, 10 days, 11 days, 12 days, 14 days, 18 days, or 21 days after asingle administration;

(iv) the propionic acid plasma, serum, and/or urine level is reduced toat least within 10-fold, at least within 5-fold, at least within 2-fold,or at least within 1.5-fold, as compared to a normal propionic acidplasma, serum, and/or urine level, for at least 24 hours, at least 48hours, at least 72 hours, at least 96 hours, at least 120 hours, 6 days,1 week, 8 days, 9 days, 10 days, 11 days, 12 days, 14 days, 18 days, or21 days after a single administration;

(v) the C3, 2-MC, 30HPA, propionylglycine, glycine, lactate and/orammonia plasma, serum, whole blood, urine, and/or liver level is reducedat least 20%, at least 30%, at least 40%, at least 50%, at least 60%, atleast 70%, at least 80%, at least 90%, or at least 100% as compared tothe human subject's baseline plasma, serum, whole blood, urine, and/orliver C3, 2-MC, 30HPA, propionylglycine, glycine, lactate and/or ammoniaor a reference C3, 2-MC, 30HPA, propionylglycine, glycine, lactateand/or ammonia plasma, serum, whole blood, urine, and/or liver level ina patient with PA, for at least 24 hours, at least 48 hours, at least 72hours, at least 96 hours, at least 120 hours, 6 days, 1 week, 8 days, 9days, 10 days, 11 days, 12 days, 14 days, 18 days, or 21 days after asingle administration; and/or

(vi) the C3, 2-MC, 30HPA, propionylglycine, glycine, lactate and/orammonia plasma, serum, whole blood, urine, and/or liver level is reducedto at least within 10-fold, at least within 5-fold, at least within2-fold, or at least within 1.5-fold as compared to a normal C3, 2-MC,30HPA, propionylglycine, glycine, lactate and/or ammonia plasma, serum,whole blood, urine, and/or liver level within at least 24 hours, atleast 48 hours, at least 72 hours, at least 96 hours, at least 120hours, 6 days, 1 week, 8 days, 9 days, 10 days, 11 days, 12 days, 14days, 18 days, or 21 days after a single administration.

In one aspect, the disclosure features a method of increasing PCCactivity in a human subject in need thereof, comprising administering tothe subject an effective amount of a pharmaceutical compositiondescribed herein or a polynucleotide described herein.

In one aspect, the disclosure features a method of increasing PCCactivity in a human subject in need thereof, comprising administering tothe subject an effective amount of at least one of the pharmaceuticalcompositions described herein or two polynucleotides described herein,wherein the first polynucleotide comprises an open reading frame (ORF)encoding a human PCCA polypeptide and the second polynucleotidecomprises an open reading frame (ORF) encoding a human PCCB polypeptide.

In some embodiments, the disclosure features a method comprisingadministering a pharmaceutical composition comprising a firstpolynucleotide comprising an open reading frame (ORF) encoding a humanPCCA polypeptide and a second polynucleotide comprising an open readingframe (ORF) encoding a human PCCB polypeptide.

In some embodiments, the method comprises administering a firstpharmaceutical composition and a second pharmaceutical composition,wherein the first pharmaceutical composition comprises a firstpolynucleotide comprising an open reading frame (ORF) encoding a humanPCCA polypeptide, and wherein the second pharmaceutical compositioncomprises a second polynucleotide comprising an open reading frame (ORF)encoding a human PCCB polypeptide.

In certain embodiments of the above methods:

(i) the level of PCC activity in the human subject is increased at least1.5-fold, at least 2-fold, at least 5-fold, at least 10-fold, at least20-fold, or at least 50-fold as compared to a reference PCC activitylevel in a human subject having PA for at least 24 hours, at least 48hours, at least 72 hours, at least 96 hours, or at least 120 hours aftera single administration; and/or

(ii) 12 hours after a single administration of the pharmaceuticalcomposition or polynucleotide is administered to the human subject, thePCC activity in the human subject is increased at least 20%, at least30%, at least 40%, at least 50%, at least 60%, at least 70%, at least80%, at least 90%, at least 100%, at least 150%, at least 200%, at least300%, at least 400%, at least 500%, or at least 600% compared to thesubject's baseline PCC activity.

In some embodiments of the above methods, the PCC activity is increasedin the liver or blood of the human subject.

In some embodiments of the above methods, the administration to thehuman subject is about once a week, about once every two weeks, aboutonce a month, about once every six weeks, or about once every twomonths.

In certain embodiments, the pharmaceutical composition or polynucleotideis administered intravenously. In some instances, the pharmaceuticalcomposition or polynucleotide is administered at a dose of 0.1 mg/kg to2.0 mg/kg. In some instances, the pharmaceutical composition orpolynucleotide is administered at a dose of 0.1 mg/kg to 1.5 mg/kg. Insome instances, the pharmaceutical composition or polynucleotide isadministered at a dose of 0.1 mg/kg to 1.0 mg/kg. In some instances, thepharmaceutical composition or polynucleotide is administered at a doseof 0.1 mg/kg to 0.5 mg/kg.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A shows the percent change inpropionyl-L-carnitine/acetyl-L-carnitine (C3/C2) levels measured inPcca^(−/−) (A138T) mice at 2, 7, 14, 21, and 24 days followingintravenous injection of modified human PCCA mRNA constructs or eGFPmRNA control.

FIG. 1B shows the percent change in 2-methylcitric acid (2-MC) levelsmeasured in Pcca^(−/−) (A138T) mice at mice at 2, 7, 14, 21, and 24 daysfollowing intravenous injection of modified human PCCA mRNA constructsor eGFP mRNA control.

FIG. 2A is a graph showing the levels of plasma ammonia (μmol/L) inPcca^(−/−) (A138T) mice at 21 days following single intravenousinjection of modified human PCCA mRNA or control mRNA.

FIG. 2B is a bar graph showing plasma ammonia levels (μmol/L) inPcca^(−/−) (A138T) mice at 3 weeks and 4 weeks following singleintravenous injection of modified human PCCA and PCCB mRNAs or controlmRNA.

FIG. 3 is a bar graph showing PCC activity (MicroBeta readout/μgprotein) in wild-type CD-1 mice at 24, 40, 48, 72, or 96 hours followingsingle intravenous injection of a modified human PCCA mRNA or controlmRNA.

FIG. 4 is a bar graph showing PCC activity (MicroBeta readout/μgprotein) in wild-type FVB mice at 72 hours following single intravenousinjection of modified human PCCA mRNAs or control mRNA.

FIG. 5 is a bar graph showing PCCA expression levels (Western blotsassessed with capillary electrophoresis, normalized to actin levels) inwild-type FVB mice at 72 hours following single intravenous injection ofmodified human PCCA mRNAs or control mRNA.

FIG. 6 is a bar graph showing PCC activity (MicroBeta readout/μgprotein) in GM371 PCCA-deficient patient fibroblasts transfected with amodified human PCCA mRNA or control mRNA at 24- or 48-hourspost-transfection.

FIG. 7A is a bar graph showing PCC activity (MicroBeta readout/μgprotein) in GM371 PCCA-deficient patient fibroblasts transfected withmodified human PCCA mRNAs or control mRNA at 40-hours post-transfection.

FIG. 7B shows the PCC activity levels produced by each PCCA mRNAconstruct of FIG. 7A relative to the PCC activity level produced by thecontrol mRNA (ratio to GFP).

FIG. 8A is a bar graph showing PCCA expression levels (Western blotsassessed with capillary electrophoresis, normalized to actin levels) inGM371 PCCA-deficient patient fibroblasts transfected with modified humanPCCA mRNAs or control mRNA.

FIG. 8B is a bar graph showing PCCB expression levels (Western blotsassessed with capillary electrophoresis, normalized to actin levels) inGM371 PCCA-deficient patient fibroblasts transfected with modified humanPCCA mRNAs or control mRNA.

FIG. 9 is a bar graph showing PCC activity (MicroBeta readout/μgprotein) in GM1298 PCCB-deficient patient fibroblasts transfected with amodified human PCCB mRNA or control mRNA at 24- or 48-hourspost-transfection.

FIG. 10 is a bar graph showing PCC activity (MicroBeta readout/μgprotein) in GM1298 PCCB-deficient patient fibroblasts transfected withmodified human PCCB mRNAs or control mRNA at 24-hours post-transfection.

FIG. 11A is a bar graph showing PCCB expression levels (Western blotsassessed with capillary electrophoresis, normalized to actin levels) inGM1298 PCCB-deficient patient fibroblasts transfected with modifiedhuman PCCB mRNAs or control mRNA.

FIG. 11B is a bar graph showing PCCA expression levels (Western blotsassessed with capillary electrophoresis, normalized to actin levels) inGM1298 PCCB-deficient patient fibroblasts transfected with modifiedhuman PCCB mRNAs or control mRNA.

FIG. 11C shows the capillary electrophoresis images of Western blotassays to detect PCCA and PCCB expression levels in GM1298PCCB-deficient patient fibroblasts transfected with modified human PCCBmRNAs or control mRNA.

FIG. 12A is a bar graph showing PCC activity (MicroBeta readout/μgprotein) in GM371 PCCA-deficient patient fibroblasts transfected withdifferent ratios of a modified human PCCA mRNA and a modified human PCCBmRNA at 24- or 40-hours post-transfection.

FIG. 12B is a bar graph showing PCC activity (MicroBeta readout/μgprotein) in GM1298 PCCB-deficient patient fibroblasts transfected withdifferent ratios of a modified human PCCA mRNA and a modified human PCCBmRNA at 24-hours post-transfection.

FIG. 13A is a bar graph showing PCC activity (MicroBeta readout/μgprotein) in PCCA-deficient and PCCB-deficient patient fibroblaststransfected with 0.5 μg or 1 μg of modified human PCCA mRNA, modifiedhuman PCCB mRNA, both modified human PCCA and PCCB mRNAs, or 1 μg ofcontrol (eGFP) mRNA at 24-hours post-transfection.

FIG. 13B is a bar graph showing PCC activity (MicroBeta readout/μgprotein) in PCCA-deficient and PCCB-deficient patient fibroblaststransfected with different amounts (0.03125-2 μg) of modified human PCCAand PCCB mRNAs, or a control (eGFP) mRNA at 24-hours post-transfection.

FIG. 14 is a bar graph showing PCC activity (MicroBeta readout/μgprotein) in Hep1-6 liver cells transfected with different ratios of amodified human PCCA mRNA and a modified human PCCB mRNA at 24- or40-hours post-transfection.

FIG. 15 is a bar graph showing PCC activity (MicroBeta readout/μgprotein) in Hep1-6 liver cells transfected with a modified human PCCAmRNA or control mRNA at 24-, 48-, or 72-hours post-transfection.

FIG. 16A is a bar graph showing PCC activity (MicroBeta readout/μgprotein) in Hep1-6 liver cells transfected with 2 μg of modified humanPCCA mRNAs or control mRNA at 48-hours post-transfection.

FIG. 16B shows the PCC activity levels produced by each PCCA mRNAconstruct of FIG. 16A relative to the PCC activity level produced by thecontrol mRNA (ratio to GFP).

FIG. 17A is a bar graph showing PCCA expression levels (Western blotsassessed with capillary electrophoresis, normalized to actin levels) inHep1-6 liver cells transfected with modified human PCCA mRNAs or controlmRNA.

FIG. 17B is a bar graph showing PCCB expression levels (Western blotsassessed with capillary electrophoresis, normalized to actin levels) inHep1-6 liver cells transfected with modified human PCCA mRNAs or controlmRNA.

FIG. 18 is a bar graph showing PCC activity (MicroBeta readout/μgprotein) in Hep1-6 liver cells transfected with a modified human PCCBmRNA or control mRNA at 24-hours post-transfection.

FIG. 19 is a bar graph showing PCC activity (MicroBeta readout/μgprotein) in Hep1-6 liver cells transfected with modified human PCCBmRNAs or control mRNA at 24- or 48-hours post-transfection.

FIG. 20A is a bar graph showing PCC activity in Pcca^(−/−) (A138T) miceat 2 days following a single intravenous injection of modified humanPCCA mRNA and PCCB mRNA, or control mRNA.

FIGS. 20B and 20C are bar graphs showing PCCA and PCCB protein levels(Western blots assessed with capillary electrophoresis), respectively,in Pcca^(−/−) (A138T) mice at 2 days following a single intravenousinjection of modified human PCCA mRNA and PCCB mRNA, or control mRNA.

FIG. 20D is a bar graph showing the change in plasma 2-methylcitric acid(2-MC) levels measured in Pcca^(−/−) (A138T) mice at 2 days followingintravenous injection of modified human PCCA mRNA and PCCB mRNA, orcontrol mRNA, relative to pre-bleed 2-MC levels.

FIG. 20E is a bar graph showing the change in dried blood spot (DBS)propionyl-L-carnitine (C3) levels (normalized to acetyl-L-carnitine (C2)levels) measured in Pcca^(−/−) (A138T) mice at 2 days followingintravenous injection of modified human PCCA mRNA and PCCB mRNA, orcontrol mRNA, relative to pre-bleed C3/C2 levels.

FIG. 21A is a graph showing propionyl-L-carnitine/acetyl-L-carnitine(C3/C2) levels measured in plasma collected from Pcca^(−/−) (A138T) micefollowing 6 intravenous injections (at a dose of 0.5 mg/kg or 1 mg/kg ofmRNAs per injection) of modified human PCCA mRNA and PCCB mRNA, or 1mg/kg control mRNA in a 6-month pharmacology study.

FIG. 21B is a graph showing 2-methylcitric acid (2-MC) levels measuredin plasma collected from Pcca^(−/−) (A138T) mice following 6 intravenousinjections (at a dose of 0.5 mg/kg or 1 mg/kg of mRNAs per injection) ofmodified human PCCA mRNA and PCCB mRNA, or 1 mg/kg control mRNA in a6-month pharmacology study.

FIG. 21C is a graph showing 3-hydroxypropionic acid (3-HP) levelsmeasured in plasma collected from Pcca^(−/−) (A138T) mice following 6intravenous injections (at a dose of 0.5 mg/kg or 1 mg/kg of mRNAs perinjection) of modified human PCCA mRNA and PCCB mRNA, or 1 mg/kg ofcontrol mRNA in a 6-month pharmacology study.

FIG. 22A is a bar graph showing plasma ammonia levels (μmol/L) measuredin Pcca^(−/−) (A138T) mice following 6 intravenous injections (at a doseof 0.5 mg/kg or 1 mg/kg of mRNAs per injection) of modified human PCCAmRNA and PCCB mRNA, or 1 mg/kg of control mRNA. The shaded bar indicatesthe minimum and maximum plasma ammonia levels observed in wild-typemice.

FIG. 22B is a bar graph showing body weight gain measured in Pcca^(−/−)(A138T) mice following 6 intravenous injections (at a dose of 0.5 mg/kgor 1 mg/kg of mRNAs per injection) of modified human PCCA mRNA and PCCBmRNA, or 1 mg/kg of control mRNA.

FIG. 22C is a bar graph showing heart weight (normalized to body weight)measured in Pcca^(−/−) (A138T) mice following 6 intravenous injections(at a dose of 0.5 mg/kg or 1 mg/kg of mRNAs per injection) of modifiedhuman PCCA mRNA and PCCB mRNA, or 1 mg/kg of control mRNA. The shadedbar indicates the minimum and maximum heart weights (normalized to bodyweights) observed in wild-type mice

FIG. 23A is a bar graph showing the levels of human wild-type PCCAprotein and human PCCB protein quantified by LC-MS/MS withhuman-specific peptides in Pcca^(−/−) (A138T) mice at 6 hours and at 1,2, 7, 14, 21, and 28 days following a single intravenous injection of 1mg/kg modified human PCCA mRNA and PCCB mRNA, or control mRNA.

FIG. 23B is a bar graph showing PCC activity in Pcca^(−/−) (A138T) miceat 6 hours and at 1, 2, 7, 14, 21, and 28 days following a singleintravenous injection with 1 mg/kg modified human PCCA mRNA and PCCBmRNA, or control mRNA. The baseline shaded bar represents the range(minimum and maximum values) observed in Pcca^(−/−) (A138T) miceinjected with luciferase control mRNA.

FIG. 23C is a bar graph showing plasma 2-methylcitric acid (2-MC) levelsmeasured in Pcca^(−/−) (A138T) mice at 6 hours and at 1, 2, 7, 14, 21,and 28 days following a single intravenous injection of 1 mg/kg modifiedhuman PCCA mRNA and PCCB mRNA, or control mRNA.

FIG. 23D is a bar graph showing plasmapropionyl-L-carnitine/acetyl-L-carnitine (C3/C2) levels measured inPcca^(−/−) (A138T) mice at 6 hours and at 1, 2, 7, 14, 21, and 28 daysfollowing a single intravenous injection of 1 mg/kg modified human PCCAmRNA and PCCB mRNA, or control mRNA.

FIG. 23E is a bar graph showing plasma 3-hydroxypropionic (3-HP) levelsmeasured in Pcca^(−/−) (A138T) mice at 6 hours and at 1, 2, 7, 14, 21,and 28 days following a single intravenous injection of 1 mg/kg modifiedhuman PCCA mRNA and PCCB mRNA, or control mRNA.

FIGS. 23F, 23G, and 23H are bar graphs showing the 2-methylcitric acid(2-MC) levels measured in the livers, hearts, and brains, respectively,of Pcca^(−/−) (A138T) mice at 6 hours and at 1, 2, 7, 14, 21, and 28days (at only 1, 2, 7, and 14 days in heart) following a singleintravenous injection of 1 mg/kg modified human PCCA mRNA and PCCB mRNA,or control mRNA.

FIG. 24A shows immunofluorescence images showing the subcellularco-localization of human PCCA and human PCCB in mitochondria in GM371PCCA-deficient patient fibroblasts transfected with 1 μg of modifiedhuman PCCA and PCCB mRNAs or control luciferase mRNA at 24-hourspost-transfection.

FIG. 24B is a bar graph showing marked luciferase expression in negativecontrol cells that were transfected with mRNA encoding luciferase.

FIG. 25A is a graph showing plasma 2-MC levels measured over the courseof 30 days in Pcca^(−/−) (A138T) mice injected with two doses ofmodified human PCCA and PCCB mRNAs formulated in either CompoundII/Compound I LNPs or Compound II/PEG-DMG LNPs, or tris-sucrose buffercontrol, at day 0 and day 28.

FIG. 25B is a graph showing plasma C3/C2 levels measured over the courseof 30 days in Pcca^(−/−) (A138T) mice injected with two doses ofmodified human PCCA and PCCB mRNAs formulated in either CompoundII/Compound I LNPs or Compound II/PEG-DMG LNPs, or tris-sucrose buffercontrol, at day 0 and day 28.

FIG. 25C is a graph showing plasma 3-HP levels measured over the courseof 30 days in Pcca^(−/−) (A138T) mice injected with two doses ofmodified human PCCA and PCCB mRNAs formulated in either CompoundII/Compound I LNPs or Compound II/PEG-DMG LNPs, or tris-sucrose buffercontrol, at day 0 and day 28.

FIG. 25D is a bar graph showing PCC activity levels at day 30, measuredin Pcca^(−/−) (A138T) mice injected with two doses of modified humanPCCA and PCCB mRNAs formulated in either Compound II/Compound I LNPs orCompound II/PEG-DMG LNPs, or tris-sucrose buffer control, at day 0 andday 28. PCC activity levels in wild-type mice 30 days after injectionwith tris-sucrose buffer control is also shown.

DETAILED DESCRIPTION

The present invention provides mRNA therapeutics for the treatment ofpropionic acidemia (PA). PA is an autosomal recessive metabolic disorderaffecting the ability to catalyze carboxylation of propionyl-CoA tomethylmalonyl-CoA. As a result, propionyl-CoA and metabolites ofpropionate metabolism can accumulate in the blood, urine and otherfluids, as well as tissues, which can result in metabolic acidosis andhyperammonemia. PA is caused by loss-of-function mutations in the PCCAor PCCB genes, which code for the alpha and beta subunits ofpropionyl-CoA carboxylase (PCC). mRNA therapeutics are particularlywell-suited for the treatment of PA, as the technology provides for theintracellular delivery of mRNA encoding PCCA and/or PCCB, followed by denovo synthesis of functional PCCA and/or PCCB protein capable ofassembling into PCC within target cells with the proper subcellularlocalization. After delivery of mRNA to the target cells, the desiredPCCA and/or PCCB protein is expressed by the cells' own translationalmachinery, and hence, fully functional PCCA and/or PCCB protein replacesthe defective or missing protein.

One challenge associated with delivering nucleic acid-based therapeutics(e.g., mRNA therapeutics) in vivo stems from the innate immune responsewhich can occur when the body's immune system encounters foreign nucleicacids. Foreign mRNAs can activate the immune system via recognitionthrough toll-like receptors (TLRs), in particular TLR7/8, which isactivated by single-stranded RNA (ssRNA). In nonimmune cells, therecognition of foreign mRNA can occur through the retinoicacid-inducible gene I (RIG-I). Immune recognition of foreign mRNAs canresult in unwanted cytokine effects including interleukin-1β (IL-1β)production, tumor necrosis factor-α (TNF-α) distribution and a strongtype I interferon (type I IFN) response. This disclosure features theincorporation of different modified nucleotides within therapeutic mRNAsto minimize the immune activation and optimize the translationefficiency of mRNA to protein. Particular aspects feature a combinationof nucleotide modification to reduce the innate immune response andsequence optimization, in particular, within the open reading frame(ORF) of therapeutic mRNAs encoding PCCA or PCCB to enhance proteinexpression.

Certain embodiments of the mRNA therapeutic technology of the instantdisclosure also feature delivery of mRNA encoding PCCA and/or PCCB via alipid nanoparticle (LNP) delivery system. Lipid nanoparticles (LNPs) arean ideal platform for the safe and effective delivery of mRNAs to targetcells. LNPs have the unique ability to deliver nucleic acids by amechanism involving cellular uptake, intracellular transport andendosomal release or endosomal escape. The instant invention featuresionizable lipid-based LNPs combined with mRNA encoding PCCA and/or PCCB,which have improved properties when administered in vivo. Without beingbound in theory, it is believed that the ionizable lipid-based LNPformulations of the invention have improved properties, for example,cellular uptake, intracellular transport and/or endosomal release orendosomal escape. LNPs administered by systemic route (e.g., intravenous(IV) administration), for example, in a first administration, canaccelerate the clearance of subsequently injected LNPs, for example, infurther administrations. This phenomenon is known as accelerated bloodclearance (ABC) and is a key challenge, in particular, when replacingdeficient enzymes (e.g., PCC) in a therapeutic context. This is becauserepeat administration of mRNA therapeutics is in most instancesessential to maintain necessary levels of enzyme in target tissues inhuman subjects (e.g., human subjects suffering from PA.) Repeat dosingchallenges can be addressed on multiple levels. mRNA engineering and/orefficient delivery by LNPs can result in increased levels and orenhanced duration of protein (e.g., PCCA or PCCB) being expressedfollowing a first dose of administration, which in turn, can lengthenthe time between first dose and subsequent dosing. It is known that theABC phenomenon is, at least in part, transient in nature, with theimmune responses underlying ABC resolving after sufficient timefollowing systemic administration. As such, increasing the duration ofprotein expression and/or activity following systemic delivery of anmRNA therapeutic of the disclosure in one aspect, combats the ABCphenomenon. Moreover, LNPs can be engineered to avoid immune sensingand/or recognition and can thus further avoid ABC upon subsequent orrepeat dosing. An exemplary aspect of the disclosure features LNPs whichhave been engineered to have reduced ABC.

1. Propionyl-CoA Carboxylase (PCC)

Propionyl-CoA carboxylase (PCC; EC 6.4.1.3) catalyzes the carboxylationof propionyl-CoA with bicarbonate, producing methylmalonyl-CoA.Methylmalonyl-CoA is then converted to succinyl-CoA, which is anintermediate in the tricarboxylic acid cycle (TCA). In the cell, PCCexists as a heterododecamer composed of six propionyl-CoA carboxylasealpha subunits, encoded by PCCA (OMIM 232000), and 6 propionyl-CoA betasubunits, encoded by PCCB (OMIM 232050).

Propionic Acidemia (PA; OMIM 606054), also known as propionic aciduria,is an autosomal recessive metabolic disorder associated with PCCfunction. PA results when bi-allelic variants eliminate or reduce thefunction of the PCCA or PCCB subunits of PCC. Propionyl-CoA accumulatesintracellularly in human subjects with PA, which has many metaboliceffects, including, e.g., the inhibition of mitochondrial respiratoryfunction and reduced synthesis of citrate, GTP and ATP. A variety ofvariant PCCA and PCCB proteins have different levels of activity, withthe severity of PA being correlated with the severity of the enzymes'mutations. For example, PCCA null mutations, such as R288X and S537X,result in severe phenotypes, while certain splice site variants canresult in milder disease. Generally, variations in the PCCA N and Cterminal regions can cause PA because regions are necessary for PCC'sholocarboxylase synthase interaction. PCCB mutations, e.g., A497V,R512C, L519P, and W531X, often affect the interaction between PCCA andPCCB, thereby disturbing PCC stability and function.

The wild type PCCA canonical mRNA sequence, corresponding to isoform 1,is described at the NCBI Reference Sequence database (RefSeq) underaccession number NM_000282.3 (“Homo sapiens propionyl-CoA carboxylasealpha subunit (PCCA), transcript variant 1, mRNA”). The wild type PCCAcanonical protein sequence, corresponding to isoform 1, is described atthe RefSeq database under accession number NP_000273.2 (“propionyl-CoAcarboxylase alpha chain, mitochondrial isoform a precursor [Homosapiens]”). The PCCA isoform 1 protein is 728 amino acids long. Thespecific nucleic acid sequences encoding the reference protein sequencein the Ref Seq sequences are the coding sequence (CDS) as indicated inthe respective RefSeq database entry.

PCCA isoform 2 is produced by alternative splicing. The RefSeq proteinand mRNA sequences for isoform 2 of PCCA are NP_001121164.1 andNM_001127692.2, respectively. Isoform 2 PCCA is encoded by the CDSdisclosed in each one of the above mentioned mRNA RefSeq entries. Theisoform 2 polynucleotide is shorter than PCCA isoform 1. The PCCAisoform 2 protein is 702 amino acids long, and lacks amino acids 36-61of isoform 1.

PCCA isoform 3 is produced by alternative splicing. The RefSeq proteinand mRNA sequences for isoform 3 of PCCA are NP_001171475.1 andNM_001178004.1, respectively. Isoform 3 of PCCA is encoded by the CDSdisclosed in each one of the above mentioned mRNA RefSeq entries. Theisoform 3 polynucleotide is shorter than PCCA isoforms 1 and 2. The PCCAisoform 3 protein is 681 amino acids long, and lacks amino acids 634-680of isoform 1.

The CDS for wild type PCCB canonical mRNA sequence, corresponding toisoform 1, is described at the NCBI Reference Sequence database (RefSeq)under accession number NM_000532.4 (“Homo sapiens propionyl-CoAcarboxylase beta subunit (PCCB), transcript variant 1, mRNA”). The wildtype PCCB canonical protein sequence, corresponding to isoform 1, isdescribed at the RefSeq database under accession number NP_000523.2(“propionyl-CoA carboxylase beta chain, mitochondrial isoform 1precursor [Homo sapiens]”). The PCCB isoform 1 protein is 539 aminoacids long. It is noted that the specific nucleic acid sequencesencoding the reference protein sequence in the Ref Seq sequences are theCDS as indicated in the respective RefSeq database entry.

PCCB isoform 2 is produced by alternative splicing. The RefSeq proteinand mRNA sequences for isoform 2 of PCCB are NP_001171485.1 andNM_001178014.1, respectively. Isoform 2 of PCCB is encoded by the CDSdisclosed in each one of the above mentioned mRNA RefSeq entries. Theisoform 2 polynucleotide is longer than PCCB isoform 1. The PCCB isoform2 protein is 559 amino acids long, and has an additional 20 amino acidsover isoform 1 (amino acids QQIIGWAQWLPLVISALWEAE in place of a Q atposition 124 of isoform 1).

The amino acid sequence of wild-type isoform 1 of human PCCA is providedin SEQ ID NO: 1. The amino acid sequence of wild-type isoform 1 of humanPCCB is provided in SEQ ID NO:15.

In certain aspects, the invention provides a polynucleotide (e.g., aribonucleic acid (RNA), e.g., a mRNA) comprising a nucleotide sequence(e.g., an open reading frame (ORF)) encoding a PCCA or PCCB polypeptide.In some embodiments, the PCCA polypeptide of the invention is a wildtype human PCCA isoform 1, 2 or 3 protein. In some embodiments, the PCCBpolypeptide of the invention is a wild type human PCCB isoform 1 or 2protein. In some embodiments, the PCCA polypeptide or PCCB polypeptideof the invention is a variant, a peptide or a polypeptide containing asubstitution, and insertion and/or an addition, a deletion and/or acovalent modification with respect to a wild-type PCCA isoform 1, 2 or 3sequence or wild-type PCCB isoform 1 or 2 sequence, respectively. Insome embodiments, sequence tags or amino acids, can be added to thesequences encoded by the polynucleotides of the invention (e.g., at theN-terminal or C-terminal ends), e.g., for localization. In someembodiments, amino acid residues located at the carboxy, amino terminal,or internal regions of a polypeptide of the invention can optionally bedeleted providing for fragments.

In some embodiments, the polynucleotide (e.g., a RNA, e.g., an mRNA)comprising a nucleotide sequence (e.g., an ORF) of the invention encodesa substitutional variant of a human PCCA isoform 1, 2 or 3 sequence, ora human PCCB isoform 1 or 2 sequence, which can comprise one, two, threeor more than three substitutions. In some embodiments, thesubstitutional variant can comprise one or more conservative amino acidssubstitutions. In other embodiments, the variant is an insertionalvariant. In other embodiments, the variant is a deletional variant.

PCCA or PCCB protein fragments, functional protein domains, variants,and homologous proteins (orthologs) are also within the scope of thePCCA and PCCB polypeptides of the invention. Nonlimiting examples ofpolypeptides encoded by the polynucleotides of the invention are shownin SEQ ID NO:1 and SEQ ID NO:15.

Certain compositions and methods presented in this disclosure refer tothe protein or polynucleotide sequences of PCCA isoform 1 and/or PCCBisoform 1. Such disclosures are equally applicable to any other isoformsof PCCA and/or PCCB.

2. Polynucleotides and Open Reading Frames (ORFs)

The instant invention features mRNAs for use in treating or preventingpropionic academia (PA). The mRNAs featured for use in the invention areadministered to human subjects and encode human priopionyl-CoAcarboxylase alpha (PCCA) protein or human priopionyl-CoA carboxylasebeta (PCCB) protein in vivo. PCCA and PCCB bind to form propionyl-CoAcarboxylase (PCC). Accordingly, the invention relates topolynucleotides, e.g., mRNA, comprising an open reading frame of linkednucleosides encoding human PCCA (SEQ ID NO:1) or PCCB (SEQ ID NO:15),isoforms thereof, functional fragments thereof, and fusion proteinscomprising PCCA or PCCB. In some embodiments, the open reading frame issequence-optimized. In particular embodiments, the invention providessequence-optimized polynucleotides comprising nucleotides encoding thepolypeptide sequence of human PCCA or human PCCB, or sequence havinghigh sequence identity with those sequence optimized polynucleotides.

In certain aspects, the invention provides polynucleotides (e.g., a RNAsuch as an mRNA) that comprise a nucleotide sequence (e.g., an ORF)encoding one or more PCCA and/or PCCB polypeptides. In some embodiments,the encoded PCCA or PCCB polypeptide of the invention can be selectedfrom:

-   -   (i) a full length PCCA or PCCB polypeptide (e.g., having the        same or essentially the same length as wild-type PCCA isoform 1,        2 or 3, or wild-type PCCB isoform 1 or 2);    -   (ii) a functional fragment of PCCA or PCCB described herein        (e.g., a truncated (e.g., deletion of carboxy, amino terminal,        or internal regions) sequence shorter than wild-type PCCA or        PCCB; but still retaining PCC enzymatic activity);    -   (iii) a variant thereof (e.g., full length or truncated PCCA or        PCCB proteins in which one or more amino acids have been        replaced, e.g., variants that retain all or most of the PCCA or        PCCB activity of the polypeptide with respect to a reference        isoform (such as any natural or artificial variants known in the        art); or    -   (iv) a fusion protein comprising (i) a full length PCCA (SEQ ID        NO:1) or PCCB (SEQ ID NO:15) protein, a functional fragment or a        variant thereof, and (ii) a heterologous protein.

In certain embodiments, the encoded PCCA polypeptide is a mammalian PCCApolypeptide, such as a human PCCA polypeptide, a functional fragment ora variant thereof. In certain embodiments, the encoded PCCB polypeptideis a mammalian PCCB polypeptide, such as a human PCCB polypeptide, afunctional fragment or a variant thereof.

In some embodiments, the polynucleotide (e.g., a RNA, e.g., an mRNA) ofthe invention increases PCCA or PCCB protein expression levels and/ordetectable PCC enzymatic activity levels in cells when introduced inthose cells, e.g., by at least 2%, by at least 5%, by at least 10%, atleast 15%, at least 20%, at least 25%, at least 30%, at least 35%, atleast 40%, at least 45%, at least 50%, at least 55%, at least 60%, atleast 65%, at least 70%, at least 75%, at least 80%, at least 85%, atleast 90%, at least 95%, or at least 100%, compared to PCCA or PCCBprotein expression levels and/or detectable PCC enzymatic activitylevels in the cells prior to the administration of the polynucleotide ofthe invention. PCCA and PCCB protein expression levels and/or PCCenzymatic activity can be measured according to methods know in the art.In some embodiments, the polynucleotide is introduced to the cells invitro. In some embodiments, the polynucleotide is introduced to thecells in vivo.

In some embodiments, the polynucleotides (e.g., a RNA, e.g., an mRNA) ofthe invention comprise a nucleotide sequence (e.g., an ORF) that encodesa wild-type human PCCA, e.g., wild-type isoform 1 of human PCCA (SEQ IDNO: 1). In some embodiments, the polynucleotides (e.g., a RNA, e.g., anmRNA) of the invention comprise a nucleotide sequence (e.g., an ORF)that encodes a wild-type human PCCB, e.g., wild-type isoform 1 of humanPCCB (SEQ ID NO: 15).

In some embodiments, the polynucleotide (e.g., a RNA, e.g., an mRNA) ofthe invention comprises a codon optimized nucleic acid sequence, whereinthe open reading frame (ORF) of the codon optimized nucleic acidsequence is derived from a wild-type PCCA or PCCB sequence (e.g.,wild-type human PCCA or wild-type human PCCB). For example, forpolynucleotides of invention comprising a sequence optimized ORFencoding PCCA or PCCB, the corresponding wild type sequence is thenative PCCA or PCCB. Similarly, for a sequence optimized mRNA encoding afunctional fragment of human PCCA or PCCB, the corresponding wild typesequence is the corresponding fragment from human PCCA or PCCB.

In some embodiments, the polynucleotides (e.g., a RNA, e.g., an mRNA) ofthe invention comprise a nucleotide sequence encoding PCCA isoform 1having the full length sequence of human PCCA isoform 1 (i.e., includingthe initiator methionine; amino acids 1-728). In some embodiments, thepolynucleotides (e.g., a RNA, e.g., an mRNA) of the invention comprise anucleotide sequence encoding PCCB isoform 1 having the full lengthsequence of human PCCB isoform 1 (i.e., including the initiatormethionine; amino acids 1-539). In some embodiments, the polynucleotide(e.g., a RNA, e.g., an mRNA) of the invention comprising a nucleotidesequence encoding PCCA or PCCB having the full length or mature sequenceof human PCCA or PCCB is sequence optimized.

In some embodiments, the polynucleotides (e.g., a RNA, e.g., an mRNA) ofthe invention comprise a nucleotide sequence (e.g., an ORF) encoding amutant PCCA or PCCB polypeptide. In some embodiments, thepolynucleotides of the invention comprise an ORF encoding a PCCA or PCCBpolypeptide that comprises at least one point mutation in the PCCA orPCCB sequence and retains PCC enzymatic activity. In some embodiments,the mutant PCCA or PCCB polypeptide causes a PCC activity which is atleast 10%, at least 15%, at least 20%, at least 25%, at least 30%, atleast 35%, at least 40%, at least 45%, at least 50%, at least 55%, atleast 60%, at least 65%, at least 70%, at least 75%, at least 80%, atleast 85%, at least 90%, at least 95%, or at least 100% of the PCCactivity resulting from the corresponding wild-type PCCA or PCCB (i.e.,the same PCCA or PCCB isoform but without the mutation(s)). In someembodiments, the polynucleotide (e.g., a RNA, e.g., an mRNA) of theinvention comprising an ORF encoding a mutant PCCA or PCCB polypeptideis sequence optimized.

In some embodiments, the polynucleotide (e.g., a RNA, e.g., an mRNA) ofthe invention comprises a nucleotide sequence (e.g., an ORF) thatencodes a PCCA or PCCB polypeptide with mutations that do not alter PCCenzymatic activity. Such mutant PCCA or PCCB polypeptides can bereferred to as function-neutral. In some embodiments, the polynucleotidecomprises an ORF that encodes a mutant PCCA or PCCB polypeptidecomprising one or more function-neutral point mutations.

In some embodiments, the mutant PCCA or PCCB polypeptide leads to higherPCC enzymatic activity than the corresponding wild-type PCCA or PCCB. Insome embodiments, the mutant PCCA or PCCB polypeptide causes a PCCactivity that is at least 10%, at least 15%, at least 20%, at least 25%,at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, atleast 55%, at least 60%, at least 65%, at least 70%, at least 75%, atleast 80%, at least 85%, at least 90%, at least 95%, or at least 100%higher than the activity of the corresponding wild-type PCCA or PCCB(i.e., the same PCCA or PCCB isoform but without the mutation(s)).

In some embodiments, the polynucleotides (e.g., a RNA, e.g., an mRNA) ofthe invention comprise a nucleotide sequence (e.g., an ORF) encoding afunctional PCCA or PCCB fragment, e.g., where one or more fragmentscorrespond to a polypeptide subsequence of a wild type PCCA or PCCBpolypeptide and retain PCC enzymatic activity. In some embodiments, thePCCA or PCCB fragment causes a PCC activity which is at least 10%, atleast 15%, at least 20%, at least 25%, at least 30%, at least 35%, atleast 40%, at least 45%, at least 50%, at least 55%, at least 60%, atleast 65%, at least 70%, at least 75%, at least 80%, at least 85%, atleast 90%, at least 95%, or at least 100% of the PCC activity of thecorresponding full length PCCA or PCCB. In some embodiments, thepolynucleotides (e.g., a RNA, e.g., an mRNA) of the invention comprisingan ORF encoding a functional PCCA or PCCB fragment is sequenceoptimized.

In some embodiments, the polynucleotide (e.g., a RNA, e.g., an mRNA) ofthe invention comprises a nucleotide sequence (e.g., an ORF) encoding aPCCA or PCCB fragment that causes higher PCC enzymatic activity than thecorresponding full length PCCA or PCCB. Thus, in some embodiments thePCCA or PCCB fragment causes a PCC activity which is at least 10%, atleast 15%, at least 20%, at least 25%, at least 30%, at least 35%, atleast 40%, at least 45%, at least 50%, at least 55%, at least 60%, atleast 65%, at least 70%, at least 75%, at least 80%, at least 85%, atleast 90%, at least 95%, or at least 100% higher than the PCC activityof the corresponding full length PCCA or PCCB.

In some embodiments, the polynucleotide (e.g., a RNA, e.g., an mRNA) ofthe invention comprises a nucleotide sequence (e.g., an ORF) encoding aPCCA fragment that is at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%,11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24% or25% shorter than wild-type PCCA isoform 1. In some embodiments, thepolynucleotide (e.g., a RNA, e.g., an mRNA) of the invention comprises anucleotide sequence (e.g., an ORF) encoding a PCCB fragment that is atleast 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 3%1, 4%1, 5%1,6%1, 7%1, 8%1, 19%, 20%, 21%, 22%, 23%, 24% or 25% shorter thanwild-type PCCB isoform 1.

In some embodiments, the polynucleotide (e.g., a RNA, e.g., an mRNA) ofthe invention comprises a nucleotide sequence (e.g., an ORF) encoding aPCCA polypeptide (e.g., the wild-type sequence, functional fragment, orvariant thereof), wherein the nucleotide sequence has at least 70%, atleast 71%, at least 72%, at least 73%, at least 74%, at least 75%, atleast 76%, at least 77%, at least 78%, at least 79%, at least 80%, atleast 81%, at least 82%, at least 83%, at least 84%, at least 85%, atleast 86%, at least 87%, at least 88%, at least 89%, at least 90%, atleast 91%, at least 92%, at least 93%, at least 94%, at least 95%, atleast 96%, at least 97%, at least 98%, at least 99%, or 100% sequenceidentity to a sequence selected from the group consisting of SEQ ID NOs:2 and 5-14. In some embodiments, the polynucleotide (e.g., a RNA, e.g.,an mRNA) of the invention comprises a nucleotide sequence (e.g., an ORF)encoding a PCCB polypeptide (e.g., the wild-type sequence, functionalfragment, or variant thereof), wherein the nucleotide sequence has atleast 70%, at least 71%, at least 72%, at least 73%, at least 74%, atleast 75%, at least 76%, at least 77%, at least 78%, at least 79%, atleast 80%, at least 81%, at least 82%, at least 83%, at least 84%, atleast 85%, at least 86%, at least 87%, at least 88%, at least 89%, atleast 90%, at least 91%, at least 92%, at least 93%, at least 94%, atleast 95%, at least 96%, at least 97%, at least 98%, at least 99%, or100% sequence identity to a sequence selected from the group consistingof SEQ ID NOs: 16-27, 196, 197, and 198.

In some embodiments, the polynucleotide (e.g., a RNA, e.g., an mRNA) ofthe invention comprises an ORF encoding a PCCA polypeptide (e.g., thewild-type sequence, functional fragment, or variant thereof), whereinthe polynucleotide comprises a nucleic acid sequence having 70% to 100%,75% to 100%, 80% to 100%, 85% to 100%, 70% to 95%, 80% to 95%, 70% to85%, 75% to 90%, 80% to 95%, 70% to 75%, 75% to 80%, 80% to 85%, 85% to90%, 90% to 95%, or 95% to 100%, sequence identity to a sequenceselected from the group consisting of SEQ ID NOs: 2 and 5-14 In someembodiments, the polynucleotide (e.g., a RNA, e.g., an mRNA) of theinvention comprises an ORF encoding a PCCB polypeptide (e.g., thewild-type sequence, functional fragment, or variant thereof), whereinthe polynucleotide comprises a nucleic acid sequence having 70% to 100%,75% to 100%, 80% to 100%, 85% to 100%, 70% to 95%, 80% to 95%, 70% to85%, 75% to 90%, 80% to 95%, 70% to 75%, 75% to 80%, 80% to 85%, 85% to90%, 90% to 95%, or 95% to 100%, sequence identity to a sequenceselected from the group consisting of SEQ ID NOs: 16-27, 196, 197, and198.

In some embodiments the polynucleotide (e.g., a RNA, e.g., an mRNA) ofthe invention comprises a nucleotide sequence (e.g., an ORF) encoding aPCCA polypeptide (e.g., the wild-type sequence, functional fragment, orvariant thereof), wherein the nucleotide sequence is between 70% and 90%identical; between 75% and 85% identical; between 76% and 84% identical;between 77% and 83% identical, between 77% and 82% identical, or between78% and 81% identical to a sequence selected from the group consistingof SEQ ID NO: 2 or 5-14. In some embodiments the polynucleotide (e.g., aRNA, e.g., an mRNA) of the invention comprises a nucleotide sequence(e.g., an ORF) encoding a PCCB polypeptide (e.g., the wild-typesequence, functional fragment, or variant thereof), wherein thenucleotide sequence is between 70% and 90% identical; between 75% and85% identical; between 76% and 84% identical; between 77% and 83%identical, between 77% and 82% identical, or between 78% and 81%identical to a sequence selected from the group consisting of SEQ ID NO:16-27, 196, 197, and 198.

In some embodiments, the polynucleotide (e.g., a RNA, e.g., an mRNA) ofthe invention comprises from about 900 to about 100,000 nucleotides(e.g., from 900 to 1,000, from 900 to 1,100, from 900 to 1,200, from 900to 1,300, from 900 to 1,400, from 900 to 1,500, from 1,000 to 1,100,from 1,000 to 1,100, from 1,000 to 1,200, from 1,000 to 1,300, from1,000 to 1,400, from 1,000 to 1,500, from 1,187 to 1,200, from 1,187 to1,400, from 1,187 to 1,600, from 1,187 to 1,800, from 1,187 to 2,000,from 1,187 to 3,000, from 1,187 to 5,000, from 1,187 to 7,000, from1,187 to 10,000, from 1,187 to 25,000, from 1,187 to 50,000, from 1,187to 70,000, or from 1,187 to 100,000).

In some embodiments, the polynucleotide of the invention (e.g., a RNA,e.g., an mRNA) comprises a nucleotide sequence (e.g., an ORF) encoding aPCCA or PCCB polypeptide (e.g., the wild-type sequence, functionalfragment, or variant thereof), wherein the length of the nucleotidesequence (e.g., an ORF) is at least 500 nucleotides in length (e.g., atleast or greater than about 500, 600, 700, 80, 900, 1,000, 1,050, 1,100,1,187, 1,200, 1,300, 1,400, 1,500, 1,600, 1,700, 1,800, 1,900, 2,000,2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 2,700, 2,800, 2,900, 3,000,3,100, 3,200, 3,300, 3,400, 3,500, 3,600, 3,700, 3,800, 3,900, 4,000,4,100, 4,200, 4,300, 4,400, 4,500, 4,600, 4,700, 4,800, 4,900, 5,000,5,100, 5,200, 5,300, 5,400, 5,500, 5,600, 5,700, 5,800, 5,900, 6,000,7,000, 8,000, 9,000, 10,000, 20,000, 30,000, 40,000, 50,000, 60,000,70,000, 80,000, 90,000 or up to and including 100,000 nucleotides).

In some embodiments, the polynucleotide of the invention (e.g., a RNA,e.g., an mRNA) comprises a nucleotide sequence (e.g., an ORF) encoding aPCCA or PCCB polypeptide (e.g., the wild-type sequence, functionalfragment, or variant thereof) further comprises at least one nucleicacid sequence that is noncoding, e.g., a microRNA binding site. In someembodiments, the polynucleotide (e.g., a RNA, e.g., an mRNA) of theinvention further comprises a 5′-UTR (e.g., selected from the sequencesof SEQ ID NOs: 3, 64, 88-102, 165-167, or 199 or selected from thesequences of SEQ ID NO:3, SEQ ID NO:191, SEQ ID NO:199, or SEQ IDNO:206) and a 3′UTR (e.g., selected from the sequences of SEQ ID NOs: 4,104-112, 150, or 178 or selected from the sequences of SEQ ID NO:4, SEQID NO:111, SEQ ID NO:150, SEQ ID NO:175, SEQ ID NO:177, SEQ ID NO:178,SEQ ID NO:207, or SEQ ID NO:208). In some embodiments, thepolynucleotide (e.g., a RNA, e.g., an mRNA) of the invention comprises asequence selected from the group consisting of SEQ ID NOs: 2, 5-14,16-27, 196, 197, and 198. In a further embodiment, the polynucleotide(e.g., a RNA, e.g., an mRNA) comprises a 5′ terminal cap (e.g., Cap0,Cap1, ARCA, inosine, N1-methyl-guanosine, 2′-fluoro-guanosine,7-deaza-guanosine, 8-oxo-guanosine, 2-amino-guanosine, LNA-guanosine,2-azidoguanosine, Cap2, Cap4, 5′ methylG cap, or an analog thereof) anda poly-A-tail region (e.g., about 100 nucleotides in length). In afurther embodiment, the polynucleotide (e.g., a RNA, e.g., an mRNA) acomprises a 3′ UTR comprising a nucleic acid sequence selected from thegroup consisting of SEQ ID NOs: 4, 111, 112, or 178 or any combinationthereof. In a further embodiment, the polynucleotide (e.g., a RNA, e.g.,an mRNA) a comprises a 3′ UTR comprising a nucleic acid sequenceselected from the group consisting of SEQ ID NO:4, SEQ ID NO:111, SEQ IDNO:150, SEQ ID NO:175, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:207, orSEQ ID NO:208 or any combination thereof. In some embodiments, the mRNAcomprises a 3′ UTR comprising a nucleic acid sequence of SEQ ID NO: 111.In some embodiments, the mRNA comprises a 3′ UTR comprising a nucleicacid sequence of SEQ ID NO: 4. In some embodiments, the mRNA comprises a3′ UTR comprising a nucleic acid sequence of SEQ ID NO: 112. In someembodiments, the mRNA comprises a 3′ UTR comprising a nucleic acidsequence of SEQ ID NO: 178. In some embodiments, the mRNA comprises a 3′UTR comprising a nucleic acid sequence of SEQ ID NO:150. In someembodiments, the mRNA comprises a 3′ UTR comprising a nucleic acidsequence of SEQ ID NO:175. In some embodiments, the mRNA comprises a 3′UTR comprising a nucleic acid sequence of SEQ ID NO:207. In someembodiments, the mRNA comprises a 3′ UTR comprising a nucleic acidsequence of SEQ ID NO:208. In some embodiments, the mRNA comprises a 3′UTR comprising a nucleic acid sequence of SEQ ID NO:177.

In some embodiments, the mRNA comprises a polyA tail. In some instances,the poly A tail is 50-150, 75-150, 85-150, 90-150, 90-120, 90-130, or90-150 nucleotides in length. In some instances, the poly A tail is 100nucleotides in length.

In some embodiments, the polynucleotide of the invention (e.g., a RNA,e.g., an mRNA) comprises a nucleotide sequence (e.g., an ORF) encoding aPCCA or PCCB polypeptide is single stranded or double stranded.

In some embodiments, the polynucleotide of the invention comprising anucleotide sequence (e.g., an ORF) encoding a PCCA or PCCB polypeptide(e.g., the wild-type sequence, functional fragment, or variant thereof)is DNA or RNA. In some embodiments, the polynucleotide of the inventionis RNA. In some embodiments, the polynucleotide of the invention is, orfunctions as, a mRNA. In some embodiments, the mRNA comprises anucleotide sequence (e.g., an ORF) that encodes at least one PCCA orPCCB polypeptide, and is capable of being translated to produce theencoded PCCA or PCCB polypeptide in vitro, in vivo, in situ or ex vivo.

In some embodiments, the polynucleotide of the invention (e.g., a RNA,e.g., an mRNA) comprises a sequence-optimized nucleotide sequence (e.g.,an ORF) encoding a PCCA or PCCB polypeptide (e.g., the wild-typesequence, functional fragment, or variant thereof, see e.g., SEQ IDNOs.; 2, 5-14, 16-27, 196, 197, and 198), wherein the polynucleotidecomprises at least one chemically modified nucleobase, e.g.,N1-methylpseudouracil or 5-methoxyuracil. In certain embodiments, alluracils in the polynucleotide are N1-methylpseudouracils. In otherembodiments, all uracils in the polynucleotide are 5-methoxyuracils. Insome embodiments, the polynucleotide further comprises a miRNA bindingsite, e.g., a miRNA binding site that binds to miR-142 and/or a miRNAbinding site that binds to miR-126.

In some embodiments, the polynucleotide (e.g., a RNA, e.g., a mRNA)disclosed herein is formulated with a delivery agent comprising, e.g., acompound having the Formula (I), e.g., any of Compounds 1-232, e.g.,Compound II; a compound having the Formula (III), (IV), (V), or (VI),e.g., any of Compounds 233-342, e.g., Compound VI; or a compound havingthe Formula (VIII), e.g., any of Compounds 419-428, e.g., Compound I, orany combination thereof. In some embodiments, the delivery agentcomprises Compound II, DSPC, Cholesterol, and Compound I or PEG-DMG,e.g., with a mole ratio of about 50:10:38.5:1.5. In some embodiments,the delivery agent comprises Compound VI, DSPC, Cholesterol, andCompound I or PEG-DMG, e.g., with a mole ratio in the range of about 30to about 60 mol % Compound II or VI (or related suitable amino lipid)(e.g., 30-40, 40-45, 45-50, 50-55 or 55-60 mol % Compound II or VI (orrelated suitable amino lipid)), about 5 to about 20 mol % phospholipid(or related suitable phospholipid or “helper lipid”) (e.g., 5-10, 10-15,or 15-20 mol % phospholipid (or related suitable phospholipid or “helperlipid”)), about 20 to about 50 mol % cholesterol (or related sterol or“non-cationic” lipid) (e.g., about 20-30, 30-35, 35-40, 40-45, or 45-50mol % cholesterol (or related sterol or “non-cationic” lipid)) and about0.05 to about 10 mol % PEG lipid (or other suitable PEG lipid) (e.g.,0.05-1, 1-2, 2-3, 3-4, 4-5, 5-7, or 7-10 mol % PEG lipid (or othersuitable PEG lipid)). An exemplary delivery agent can comprise moleratios of, for example, 47.5:10.5:39.0:3.0 or 50:10:38.5:1.5. In certaininstances, an exemplary delivery agent can comprise mole ratios of, forexample, 47.5:10.5:39.0:3; 47.5:10:39.5:3; 47.5:11:39.5:2;47.5:10.5:39.5:2.5; 47.5:11:39:2.5; 48.5:10:38.5:3; 48.5:10.5:39:2;48.5:10.5:38.5:2.5; 48.5:10.5:39.5:1.5; 48.5:10.5:38.0:3;47:10.5:39.5:3; 47:10:40.5:2.5; 47:11:40:2; 47:10.5:39.5:3;48:10.5:38.5:3; 48:10:39.5:2.5; 48:11:39:2; or 48:10.5:38.5:3. In someembodiments, the delivery agent comprises Compound II or VI, DSPC,Cholesterol, and Compound I or PEG-DMG, e.g., with a mole ratio of about47.5:10.5:39.0:3.0. In some embodiments, the delivery agent comprisesCompound II or VI, DSPC, Cholesterol, and Compound I or PEG-DMG, e.g.,with a mole ratio of about 50:10:38.5:1.5.

In some embodiments, the polynucleotide of the disclosure is an mRNAthat comprises a 5′-terminal cap (e.g., Cap 1), a 5′UTR (e.g., SEQ IDNO:3, SEQ ID NO:64, or SEQ ID NO:199), a ORF sequence selected from thegroup consisting of SEQ ID NOs.: 2, 5-14, 16-27, 196, 197, and 198, a3′UTR (e.g., SEQ ID NO:4, SEQ ID NO: 112, or SEQ ID NO:178), and a polyA tail (e.g., about 100 nt in length), wherein all uracils in thepolynucleotide are N1-methylpseudouracils. In some embodiments, thedelivery agent comprises Compound II or Compound VI as the ionizablelipid and PEG-DMG or Compound I as the PEG lipid.

In some embodiments, the polynucleotide of the disclosure is an mRNAthat comprises a 5′-terminal cap (e.g., Cap 1), a 5′UTR (e.g., SEQ IDNO:3, SEQ ID NO:191, SEQ ID NO:199, or SEQ ID NO:206), a ORF sequenceselected from the group consisting of SEQ ID NOs.: 2, 5-14, 16-27, 196,197, and 198, a 3′UTR (e.g., SEQ ID NO:4, SEQ ID NO:111, SEQ ID NO:150,SEQ ID NO:175, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:207, or SEQ IDNO:208), and a poly A tail (e.g., about 100 nt in length), wherein alluracils in the polynucleotide are N1 methylpseudouracils. In someembodiments, the delivery agent comprises Compound II or Compound VI asthe ionizable lipid and PEG-DMG or Compound I as the PEG lipid.

3. Signal Sequences

The polynucleotides (e.g., a RNA, e.g., an mRNA) of the invention canalso comprise nucleotide sequences that encode additional features thatfacilitate trafficking of the encoded polypeptides to therapeuticallyrelevant sites. One such feature that aids in protein trafficking is thesignal sequence, or targeting sequence. The peptides encoded by thesesignal sequences are known by a variety of names, including targetingpeptides, transit peptides, and signal peptides. In some embodiments,the polynucleotide (e.g., a RNA, e.g., an mRNA) comprises a nucleotidesequence (e.g., an ORF) that encodes a signal peptide operably linked toa nucleotide sequence that encodes a PCCA or PCCB polypeptide describedherein.

In some embodiments, the “signal sequence” or “signal peptide” is apolynucleotide or polypeptide, respectively, which is from about 30-210,e.g., about 45-80 or 15-60 nucleotides (e.g., about 20, 30, 40, 50, 60,or 70 amino acids) in length that, optionally, is incorporated at the 5′(or N-terminus) of the coding region or the polypeptide, respectively.Addition of these sequences results in trafficking the encodedpolypeptide to a desired site, such as the endoplasmic reticulum or themitochondria through one or more targeting pathways. Some signalpeptides are cleaved from the protein, for example by a signal peptidaseafter the proteins are transported to the desired site.

[In some embodiments, the polynucleotide of the invention comprises anucleotide sequence encoding a PCCA or PCCB polypeptide, wherein thenucleotide sequence further comprises a 5′ nucleic acid sequenceencoding a heterologous signal peptide.

4. Fusion Proteins

In some embodiments, the polynucleotide of the invention (e.g., a RNA,e.g., an mRNA) can comprise more than one nucleic acid sequence (e.g.,an ORF) encoding a polypeptide of interest. In some embodiments,polynucleotides of the invention comprise a single ORF encoding a PCCAor PCCB polypeptide, a functional fragment, or a variant thereof.However, in some embodiments, the polynucleotide of the invention cancomprise more than one ORF, for example, a first ORF encoding a PCCA orPCCB polypeptide (a first polypeptide of interest), a functionalfragment, or a variant thereof, and a second ORF expressing a secondpolypeptide of interest. In some embodiments, two or more polypeptidesof interest can be genetically fused, i.e., two or more polypeptides canbe encoded by the same ORF. In some embodiments, the polynucleotide cancomprise a nucleic acid sequence encoding a linker (e.g., a G4S (SEQ IDNO: 86) peptide linker or another linker known in the art) between twoor more polypeptides of interest.

In some embodiments, a polynucleotide of the invention (e.g., a RNA,e.g., an mRNA) can comprise two, three, four, or more ORFs, eachexpressing a polypeptide of interest.

In some embodiments, the polynucleotide of the invention (e.g., a RNA,e.g., an mRNA) can comprise a first nucleic acid sequence (e.g., a firstORF) encoding a PCCA or PCCB polypeptide and a second nucleic acidsequence (e.g., a second ORF) encoding a second polypeptide of interest.

Linkers and Cleavable Peptides

In certain embodiments, the mRNAs of the disclosure encode more than onePCCA OR PCCB domain (e.g., PCCA OR PCCB catalytic domain, PCCA OR PCCBtetramerization domain) or a heterologous domain, referred to herein asmultimer constructs. In certain embodiments of the multimer constructs,the mRNA further encodes a linker located between each domain. Thelinker can be, for example, a cleavable linker or protease-sensitivelinker. In certain embodiments, the linker is selected from the groupconsisting of F2A linker, P2A linker, T2A linker, E2A linker, andcombinations thereof. This family of self-cleaving peptide linkers,referred to as 2A peptides, has been described in the art (see forexample, Kim, J. H. et al. (2011) PLoS ONE 6:e18556). In certainembodiments, the linker is an F2A linker. In certain embodiments, thelinker is a GGGS (SEQ ID NO: 86) linker. In certain embodiments, thelinker is a (GGGS)n (SEQ ID NO: 190) linker, wherein n=2, 3,4, or 5. Incertain embodiments, the multimer construct contains three domains withintervening linkers, having the structure:domain-linker-domain-linker-domain e.g., PCCA OR PCCB domain-linker-PCCAOR PCCB domain-linker-PCCA OR PCCB domain.

In one embodiment, the cleavable linker is an F2A linker (e.g., havingthe amino acid sequence GSGVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO:186)). Inother embodiments, the cleavable linker is a T2A linker (e.g., havingthe amino acid sequence GSGEGRGSLLTCGDVEENPGP (SEQ ID NO:187)), a P2Alinker (e.g., having the amino acid sequence GSGATNFSLLKQAGDVEENPGP (SEQID NO:188)) or an E2A linker (e.g., having the amino acid sequenceGSGQCTNYALLKLAGDVESNPGP (SEQ ID NO:189)). The skilled artisan willappreciate that other art-recognized linkers may be suitable for use inthe constructs of the invention (e.g., encoded by the polynucleotides ofthe invention). The skilled artisan will likewise appreciate that othermulticistronic constructs may be suitable for use in the invention. Inexemplary embodiments, the construct design yields approximatelyequimolar amounts of intrabody and/or domain thereof encoded by theconstructs of the invention.

In one embodiment, the self-cleaving peptide may be, but is not limitedto, a 2A peptide. A variety of 2A peptides are known and available inthe art and may be used, including e.g., the foot and mouth diseasevirus (FMDV) 2A peptide, the equine rhinitis A virus 2A peptide, theThosea asigna virus 2A peptide, and the porcine teschovirus-1 2Apeptide. 2A peptides are used by several viruses to generate twoproteins from one transcript by ribosome-skipping, such that a normalpeptide bond is impaired at the 2A peptide sequence, resulting in twodiscontinuous proteins being produced from one translation event. As anon-limiting example, the 2A peptide may have the protein sequence ofSEQ ID NO:188, fragments or variants thereof. In one embodiment, the 2Apeptide cleaves between the last glycine and last proline. As anothernon-limiting example, the polynucleotides of the present invention mayinclude a polynucleotide sequence encoding the 2A peptide having theprotein sequence of fragments or variants of SEQ ID NO:188. One exampleof a polynucleotide sequence encoding the 2A peptide is:GGAAGCGGAGCUACUAACUUCAGCCUGCUGAAGCAGGCUGGAGACGU GGAGGAGAACCCUGGACCU (SEQID NO:209). In one illustrative embodiment, a 2A peptide is encoded bythe following sequence:5′-UCCGGACUCAGAUCCGGGGAUCUCAAAAUUGUCGCUCCUGUCAAACAAACUCUUAACUUUGAUUUACUCAAACUGGCTGGGGAUGUAGAAAGCAAU CCAGGTCCACUC-3′(SEQ IDNO:210). The polynucleotide sequence of the 2A peptide may be modifiedor codon optimized by the methods described herein and/or are known inthe art.

In one embodiment, this sequence may be used to separate the codingregions of two or more polypeptides of interest. As a non-limitingexample, the sequence encoding the F2A peptide may be between a firstcoding region A and a second coding region B (A-F2Apep-B). The presenceof the F2A peptide results in the cleavage of the one long proteinbetween the glycine and the proline at the end of the F2A peptidesequence (NPGP is cleaved to result in NPG and P) thus creating separateprotein A (with 21 amino acids of the F2A peptide attached, ending withNPG) and separate protein B (with 1 amino acid, P, of the F2A peptideattached). Likewise, for other 2A peptides (P2A, T2A and E2A), thepresence of the peptide in a long protein results in cleavage betweenthe glycine and proline at the end of the 2A peptide sequence (NPGP iscleaved to result in NPG and P). Protein A and protein B may be the sameor different peptides or polypeptides of interest (e.g., a PCCA OR PCCBpolypeptide such as full length human PCCA OR PCCB or a truncatedversion thereof comprising the catalytic and tetramerization domain ofPCCA OR PCCB). In particular embodiments, protein A and protein B are aPCCA OR PCCB catalytic domain, and a PCCA OR PCCB tetramerizationdomain, in either order. In certain embodiments, the first coding regionand the second coding region encode a PCCA OR PCCB catalytic domain anda PCCA OR PCCB tetramerization domain, in either order.

5. Sequence Optimization of Nucleotide Sequence Encoding a PCCA or PCCBPolypeptide

In some embodiments, the polynucleotide (e.g., a RNA, e.g., an mRNA) ofthe invention is sequence optimized. In some embodiments, thepolynucleotide (e.g., a RNA, e.g., an mRNA) of the invention comprises anucleotide sequence (e.g., an ORF) encoding a PCCA or PCCB polypeptide,optionally, a nucleotide sequence (e.g., an ORF) encoding anotherpolypeptide of interest, a 5′-UTR, a 3′-UTR, the 5′ UTR or 3′ UTRoptionally comprising at least one microRNA binding site, optionally anucleotide sequence encoding a linker, a polyA tail, or any combinationthereof), in which the ORF(s) are sequence optimized.

A sequence-optimized nucleotide sequence, e.g., a codon-optimized mRNAsequence encoding a PCCA or PCCB polypeptide, is a sequence comprisingat least one synonymous nucleobase substitution with respect to areference sequence (e.g., a wild type nucleotide sequence encoding aPCCA or PCCB polypeptide).

A sequence-optimized nucleotide sequence can be partially or completelydifferent in sequence from the reference sequence. For example, areference sequence encoding polyserine uniformly encoded by UCU codonscan be sequence-optimized by having 100% of its nucleobases substituted(for each codon, U in position 1 replaced by A, C in position 2 replacedby G, and U in position 3 replaced by C) to yield a sequence encodingpolyserine which would be uniformly encoded by AGC codons. Thepercentage of sequence identity obtained from a global pairwisealignment between the reference polyserine nucleic acid sequence and thesequence-optimized polyserine nucleic acid sequence would be 0%.However, the protein products from both sequences would be 100%identical.

Some sequence optimization (also sometimes referred to codonoptimization) methods are known in the art (and discussed in more detailbelow) and can be useful to achieve one or more desired results. Theseresults can include, e.g., matching codon frequencies in certain tissuetargets and/or host organisms to ensure proper folding; biasing G/Ccontent to increase mRNA stability or reduce secondary structures;minimizing tandem repeat codons or base runs that can impair geneconstruction or expression; customizing transcriptional andtranslational control regions; inserting or removing protein traffickingsequences; removing/adding post translation modification sites in anencoded protein (e.g., glycosylation sites); adding, removing orshuffling protein domains; inserting or deleting restriction sites;modifying ribosome binding sites and mRNA degradation sites; adjustingtranslational rates to allow the various domains of the protein to foldproperly; and/or reducing or eliminating problem secondary structureswithin the polynucleotide. Sequence optimization tools, algorithms andservices are known in the art, non-limiting examples include servicesfrom GeneArt (Life Technologies), DNA2.0 (Menlo Park Calif.) and/orproprietary methods.

Codon options for each amino acid are given in TABLE 1.

TABLE 1 Codon Options Single Letter Amino Acid Code Codon OptionsIsoleucine I AUU, AUC, AUA Leucine L CUU, CUC, CUA, CUG, UUA, UUG ValineV GUU, GUC, GUA, GUG Phenylalanine F UUU, UUC Methionine M AUG CysteineC UGU, UGC Alanine A GCU, GCC, GCA, GCG Glycine G GGU, GGC, GGA, GGGProline P CCU, CCC, CCA, CCG Threonine T ACU, ACC, ACA, ACG Serine SUCU, UCC, UCA, UCG, AGU, AGC Tyrosine Y UAU, UAC Tryptophan W UGGGlutamine Q CAA, CAG Asparagine N AAU, AAC Histidine H CAU, CAC Glutamicacid E GAA, GAG Aspartic acid D GAU, GAC Lysine K AAA, AAG Arginine RCGU, CGC, CGA, CGG, AGA, AGG Selenocysteine Sec UGA in mRNA in presenceof Selenocysteine insertion element (SECIS) Stop codons Stop UAA, UAG,UGA

In some embodiments, a polynucleotide (e.g., a RNA, e.g., an mRNA) ofthe invention comprises a sequence-optimized nucleotide sequence (e.g.,an ORF) encoding a PCCA or PCCB polypeptide, a functional fragment, or avariant thereof, wherein the PCCA or PCCB polypeptide, functionalfragment, or a variant thereof encoded by the sequence-optimizednucleotide sequence has improved properties (e.g., compared to a PCCA orPCCB polypeptide, functional fragment, or a variant thereof encoded by areference nucleotide sequence that is not sequence optimized), e.g.,improved properties related to expression efficacy after administrationin vivo. Such properties include, but are not limited to, improvingnucleic acid stability (e.g., mRNA stability), increasing translationefficacy in the target tissue, reducing the number of truncated proteinsexpressed, improving the folding or prevent misfolding of the expressedproteins, reducing toxicity of the expressed products, reducing celldeath caused by the expressed products, increasing and/or decreasingprotein aggregation.

In some embodiments, the sequence-optimized nucleotide sequence (e.g.,an ORF) is codon optimized for expression in human subjects, havingstructural and/or chemical features that avoid one or more of theproblems in the art, for example, features which are useful foroptimizing formulation and delivery of nucleic acid-based therapeuticswhile retaining structural and functional integrity; overcoming athreshold of expression; improving expression rates; half-life and/orprotein concentrations; optimizing protein localization; and avoidingdeleterious bio-responses such as the immune response and/or degradationpathways.

In some embodiments, the polynucleotides of the invention comprise anucleotide sequence (e.g., a nucleotide sequence (e.g., an ORF) encodinga PCCA or PCCB polypeptide, a nucleotide sequence (e.g., an ORF)encoding another polypeptide of interest, a 5′-UTR, a 3′-UTR, a microRNAbinding site, a nucleic acid sequence encoding a linker, or anycombination thereof) that is sequence-optimized according to a methodcomprising:

-   -   (i) substituting at least one codon in a reference nucleotide        sequence (e.g., an ORF encoding a PCCA or PCCB polypeptide) with        an alternative codon to increase or decrease uridine content to        generate a uridine-modified sequence;    -   (ii) substituting at least one codon in a reference nucleotide        sequence (e.g., an ORF encoding a PCCA or PCCB polypeptide) with        an alternative codon having a higher codon frequency in the        synonymous codon set;    -   (iii) substituting at least one codon in a reference nucleotide        sequence (e.g., an ORF encoding a PCCA or PCCB polypeptide) with        an alternative codon to increase G/C content; or    -   (iv) a combination thereof.

In some embodiments, the sequence-optimized nucleotide sequence (e.g.,an ORF encoding a PCCA or PCCB polypeptide) has at least one improvedproperty with respect to the reference nucleotide sequence.

In some embodiments, the sequence optimization method is multiparametricand comprises one, two, three, four, or more methods disclosed hereinand/or other optimization methods known in the art.

Features, which can be considered beneficial in some embodiments of theinvention, can be encoded by or within regions of the polynucleotide andsuch regions can be upstream (5′) to, downstream (3′) to, or within theregion that encodes the PCCA or PCCB polypeptide. These regions can beincorporated into the polynucleotide before and/or aftersequence-optimization of the protein encoding region or open readingframe (ORF). Examples of such features include, but are not limited to,untranslated regions (UTRs), microRNA sequences, Kozak sequences,oligo(dT) sequences, poly-A tail, and detectable tags and can includemultiple cloning sites that can have XbaI recognition.

In some embodiments, the polynucleotide of the invention comprises a 5′UTR, a 3′ UTR and/or a microRNA binding site. In some embodiments, thepolynucleotide comprises two or more 5′ UTRs and/or 3′ UTRs, which canbe the same or different sequences. In some embodiments, thepolynucleotide comprises two or more microRNA binding sites, which canbe the same or different sequences. Any portion of the 5′ UTR, 3′ UTR,and/or microRNA binding site, including none, can be sequence-optimizedand can independently contain one or more different structural orchemical modifications, before and/or after sequence optimization.

In some embodiments, after optimization, the polynucleotide isreconstituted and transformed into a vector such as, but not limited to,plasmids, viruses, cosmids, and artificial chromosomes. For example, theoptimized polynucleotide can be reconstituted and transformed intochemically competent E. coli, yeast, neurospora, maize, drosophila, etc.where high copy plasmid-like or chromosome structures occur by methodsdescribed herein.

6. Sequence-Optimized Nucleotide Sequences Encoding PCCA or PCCBPolypeptides

In some embodiments, the polynucleotide of the invention comprises asequence-optimized nucleotide sequence encoding a PCCA or PCCBpolypeptide disclosed herein. In some embodiments, the polynucleotide ofthe invention comprises an open reading frame (ORF) encoding a PCCA orPCCB polypeptide, wherein the ORF has been sequence optimized.

Exemplary sequence-optimized nucleotide sequences encoding human PCCAare set forth as SEQ ID NOs: 2 and 5-14 (PCCA_11, PCCA_12, PCCA_13,PCCA_14, PCCA 15, PCCA 16, PCCA 17, PCCA 18, PCCA 19, PCCA 20, PCCA_21,PCCA 22, PCCA-01-014.2, and SE_PCCA_018). Exemplary sequence-optimizednucleotide sequences encoding human PCCB are set forth as SEQ ID NOs:16-27, 196, 197, and 198 (PCCB_11, PCCB_12, PCCB_13, PCCB_14, PCCB_15,PCCB_16, PCCB_17, PCCB_18, PCCB_19, PCCB_20, PCCB_21, PCCB_22,PCCB-01-014, SE_PCCB_026, SE_PCCB_027, SE_PCCB_028, and SE_PCCB_020). Insome embodiments, the sequence optimized PCCA or PCCB sequences,fragments, and variants thereof are used to practice the methodsdisclosed herein.

In some embodiments, a polynucleotide of the present disclosure, forexample a polynucleotide comprising an mRNA nucleotide sequence encodinga PCCA or PCCB polypeptide, comprises from 5′ to 3′ end:

-   -   (i) a 5′ cap provided herein, for example, Cap1;    -   (ii) a 5′ UTR, such as the sequences provided herein, for        example, SEQ ID NO:3, SEQ ID NO:64, or SEQ ID NO:199;    -   (iii) an open reading frame encoding a PCCA or PCCB polypeptide,        e.g., a sequence optimized nucleic acid sequence encoding PCCA        or PCCB set forth as SEQ ID NOs: 2, 5-14, 16-27, 196, 197, and        198;    -   (iv) at least one stop codon (if not present at 5′ terminus of        3′UTR);    -   (v) a 3′ UTR, such as the sequences provided herein, for        example, SEQ ID NO:4, SEQ ID NO:112, or SEQ ID NO:178; and    -   (vi) a poly-A tail provided above.

In some embodiments, a polynucleotide of the present disclosure, forexample a polynucleotide comprising an mRNA nucleotide sequence encodinga PCCA or PCCB polypeptide, comprises from 5′ to 3′ end:

-   -   (i) a 5′ cap provided herein, for example, Cap1;    -   (ii) a 5′ UTR, such as the sequences provided herein, for        example, SEQ ID NO:3, SEQ ID NO:191, SEQ ID NO:199, or SEQ ID        NO:206;    -   (iii) an open reading frame encoding a PCCA or PCCB polypeptide,        e.g., a sequence optimized nucleic acid sequence encoding PCCA        or PCCB set forth as SEQ ID NOs: 2, 5-14, 16-27, 196, 197, and        198;    -   (iv) at least one stop codon (if not present at 5′ terminus of        3′UTR);    -   (v) a 3′ UTR, such as the sequences provided herein, for        example, SEQ ID NO:4, SEQ ID NO:111, SEQ ID NO:150, SEQ ID        NO:175, SEQ ID NO:177, SEQ ID NO: 178, SEQ ID NO:207, or SEQ ID        NO:208; and    -   (vi) a poly-A tail provided above.

In certain embodiments, all uracils in the polynucleotide areN1-methylpseudouracil (G5). In certain embodiments, all uracils in thepolynucleotide are 5-methoxyuracil (G6).

The sequence-optimized nucleotide sequences disclosed herein aredistinct from the corresponding wild type nucleotide acid sequences andfrom other known sequence-optimized nucleotide sequences, e.g., thesesequence-optimized nucleic acids have unique compositionalcharacteristics.

In some embodiments, the percentage of uracil or thymine nucleobases ina sequence-optimized nucleotide sequence (e.g., encoding a PCCA or PCCBpolypeptide, a functional fragment, or a variant thereof) is modified(e.g., reduced) with respect to the percentage of uracil or thyminenucleobases in the reference wild-type nucleotide sequence. Such asequence is referred to as a uracil-modified or thymine-modifiedsequence. The percentage of uracil or thymine content in a nucleotidesequence can be determined by dividing the number of uracils or thyminesin a sequence by the total number of nucleotides and multiplying by 100.In some embodiments, the sequence-optimized nucleotide sequence has alower uracil or thymine content than the uracil or thymine content inthe reference wild-type sequence. In some embodiments, the uracil orthymine content in a sequence-optimized nucleotide sequence of theinvention is greater than the uracil or thymine content in the referencewild-type sequence and still maintain beneficial effects, e.g.,increased expression and/or reduced Toll-Like Receptor (TLR) responsewhen compared to the reference wild-type sequence.

Methods for optimizing codon usage are known in the art. For example, anORF of any one or more of the sequences provided herein may be codonoptimized. Codon optimization, in some embodiments, may be used to matchcodon frequencies in target and host organisms to ensure proper folding;bias GC content to increase mRNA stability or reduce secondarystructures; minimize tandem repeat codons or base runs that may impairgene construction or expression; customize transcriptional andtranslational control regions; insert or remove protein traffickingsequences; remove/add post translation modification sites in encodedprotein (e.g., glycosylation sites); add, remove or shuffle proteindomains; insert or delete restriction sites; modify ribosome bindingsites and mRNA degradation sites; adjust translational rates to allowthe various domains of the protein to fold properly; or reduce oreliminate problem secondary structures within the polynucleotide. Codonoptimization tools, algorithms and services are known in theart—non-limiting examples include services from GeneArt (LifeTechnologies), DNA2.0 (Menlo Park Calif.) and/or proprietary methods. Insome embodiments, the open reading frame (ORF) sequence is optimizedusing optimization algorithms.

7. Characterization of Sequence Optimized Nucleic Acids

In some embodiments of the invention, the polynucleotide (e.g., a RNA,e.g., an mRNA) comprising a sequence optimized nucleic acid disclosedherein encoding a PCCA or PCCB polypeptide can be tested to determinewhether at least one nucleic acid sequence property (e.g., stabilitywhen exposed to nucleases) or expression property has been improved withrespect to the non-sequence optimized nucleic acid.

As used herein, “expression property” refers to a property of a nucleicacid sequence either in vivo (e.g., translation efficacy of a syntheticmRNA after administration to a human subject in need thereof) or invitro (e.g., translation efficacy of a synthetic mRNA tested in an invitro model system). Expression properties include but are not limitedto the amount of protein produced by an mRNA encoding a PCCA or PCCBpolypeptide after administration, and the amount of soluble or otherwisefunctional protein produced. In some embodiments, sequence optimizednucleic acids disclosed herein can be evaluated according to theviability of the cells expressing a protein encoded by a sequenceoptimized nucleic acid sequence (e.g., a RNA, e.g., an mRNA) encoding aPCCA or PCCB polypeptide disclosed herein.

In a particular embodiment, a plurality of sequence optimized nucleicacids disclosed herein (e.g., a RNA, e.g., an mRNA) containing codonsubstitutions with respect to the non-optimized reference nucleic acidsequence can be characterized functionally to measure a property ofinterest, for example an expression property in an in vitro modelsystem, or in vivo in a target tissue or cell.

a. Optimization of Nucleic Acid Sequence Intrinsic Properties

In some embodiments of the invention, the desired property of thepolynucleotide is an intrinsic property of the nucleic acid sequence.For example, the nucleotide sequence (e.g., a RNA, e.g., an mRNA) can besequence optimized for in vivo or in vitro stability. In someembodiments, the nucleotide sequence can be sequence optimized forexpression in a particular target tissue or cell. In some embodiments,the nucleic acid sequence is sequence optimized to increase its plasmahalf-life by preventing its degradation by endo and exonucleases.

In other embodiments, the nucleic acid sequence is sequence optimized toincrease its resistance to hydrolysis in solution, for example, tolengthen the time that the sequence optimized nucleic acid or apharmaceutical composition comprising the sequence optimized nucleicacid can be stored under aqueous conditions with minimal degradation.

In other embodiments, the sequence optimized nucleic acid can beoptimized to increase its resistance to hydrolysis in dry storageconditions, for example, to lengthen the time that the sequenceoptimized nucleic acid can be stored after lyophilization with minimaldegradation.

b. Nucleic Acids Sequence Optimized for Protein Expression

In some embodiments of the invention, the desired property of thepolynucleotide is the level of expression of a PCCA or PCCB polypeptideencoded by a sequence optimized sequence disclosed herein. Proteinexpression levels can be measured using one or more expression systems.In some embodiments, expression can be measured in cell culture systems,e.g., CHO cells, HEK293 cells, Hepa1-6 cells, primary fibroblasts. Insome embodiments, expression can be measured using in vitro expressionsystems prepared from extracts of living cells, e.g., rabbitreticulocyte lysates, or in vitro expression systems prepared byassembly of purified individual components. In other embodiments, theprotein expression is measured in an in vivo system, e.g., mouse,rabbit, monkey, etc.

In some embodiments, protein expression in solution form can bedesirable. Accordingly, in some embodiments, a reference sequence can besequence optimized to yield a sequence optimized nucleic acid sequencehaving optimized levels of expressed proteins in soluble form. Levels ofprotein expression and other properties such as solubility, levels ofaggregation, and the presence of truncation products (i.e., fragmentsdue to proteolysis, hydrolysis, or defective translation) can bemeasured according to methods known in the art, for example, usingelectrophoresis (e.g., native or SDS-PAGE) or chromatographic methods(e.g., HPLC, size exclusion chromatography, etc.).

c. Optimization of Target Tissue or Target Cell Viability

In some embodiments, the expression of heterologous therapeutic proteinsencoded by a nucleic acid sequence can have deleterious effects in thetarget tissue or cell, reducing protein yield, or reducing the qualityof the expressed product (e.g., due to the presence of protein fragmentsor precipitation of the expressed protein in inclusion bodies), orcausing toxicity.

Accordingly, in some embodiments of the invention, the sequenceoptimization of a nucleic acid sequence disclosed herein, e.g., anucleic acid sequence encoding a PCCA or PCCB polypeptide, can be usedto increase the viability of target cells expressing the protein encodedby the sequence optimized nucleic acid.

Heterologous protein expression can also be deleterious to cellstransfected with a nucleic acid sequence for autologous or heterologoustransplantation. Accordingly, in some embodiments of the presentdisclosure the sequence optimization of a nucleic acid sequencedisclosed herein can be used to increase the viability of target cellsexpressing the protein encoded by the sequence optimized nucleic acidsequence. Changes in cell or tissue viability, toxicity, and otherphysiological reaction can be measured according to methods known in theart.

d. Reduction of Immune and/or Inflammatory Response

In some cases, the administration of a sequence optimized nucleic acidencoding PCCA or PCCB polypeptide or a functional fragment thereof cantrigger an immune response, which could be caused by (i) the therapeuticagent (e.g., an mRNA encoding a PCCA or PCCB polypeptide), or (ii) theexpression product of such therapeutic agent (e.g., the PCCA or PCCBpolypeptide encoded by the mRNA), or (iv) a combination thereof.Accordingly, in some embodiments of the present disclosure the sequenceoptimization of nucleic acid sequence (e.g., an mRNA) disclosed hereincan be used to decrease an immune or inflammatory response triggered bythe administration of a nucleic acid encoding a PCCA or PCCB polypeptideor by the expression product of PCCA or PCCB encoded by such nucleicacid.

In some aspects, an inflammatory response can be measured by detectingincreased levels of one or more inflammatory cytokines using methodsknown in the art, e.g., ELISA. The term “inflammatory cytokine” refersto cytokines that are elevated in an inflammatory response. Examples ofinflammatory cytokines include interleukin-6 (IL-6), CXCL1 (chemokine(C—X—C motif) ligand 1; also known as GROα, interferon-γ (IFNγ), tumornecrosis factor α (TNFα), interferon γ-induced protein 10 (IP-10), orgranulocyte-colony stimulating factor (G-CSF). The term inflammatorycytokines includes also other cytokines associated with inflammatoryresponses known in the art, e.g., interleukin-1 (IL-1), interleukin-8(IL-8), interleukin-12 (IL-12), interleukin-13 (II-13), interferon α(IFN-α), etc. 8. Modified Nucleotide Sequences Encoding PCCA or PCCBPolypeptides

In some embodiments, the polynucleotide (e.g., a RNA, e.g., an mRNA) ofthe invention comprises a chemically modified nucleobase, for example, achemically modified uracil, e.g., pseudouracil, N1-methylpseudouracil,5-methoxyuracil, or the like. In some embodiments, the mRNA is auracil-modified sequence comprising an ORF encoding a PCCA or PCCBpolypeptide, wherein the mRNA comprises a chemically modifiednucleobase, for example, a chemically modified uracil, e.g.,pseudouracil, N1-methylpseudouracil, or 5-methoxyuracil.

In certain aspects of the invention, when the modified uracil base isconnected to a ribose sugar, as it is in polynucleotides, the resultingmodified nucleoside or nucleotide is referred to as modified uridine. Insome embodiments, uracil in the polynucleotide is at least about 25%, atleast about 30%, at least about 40%, at least about 50%, at least about60%, at least about 70%, at least about 80%, at least 90%, at least 95%,at least 99%, or about 100% modified uracil. In one embodiment, uracilin the polynucleotide is at least 95% modified uracil. In anotherembodiment, uracil in the polynucleotide is 100% modified uracil.

In embodiments where uracil in the polynucleotide is at least 95%modified uracil overall uracil content can be adjusted such that an mRNAprovides suitable protein expression levels while inducing little to noimmune response. In some embodiments, the uracil content of the ORF isbetween about 100% and about 150%, between about 100% and about 110%,between about 105% and about 115%, between about 110% and about 120%,between about 115% and about 125%, between about 120% and about 130%,between about 125% and about 135%, between about 130% and about 140%,between about 135% and about 145%, between about 140% and about 150% ofthe theoretical minimum uracil content in the corresponding wild-typeORF (% U_(TM)). In other embodiments, the uracil content of the ORF isbetween about 121% and about 136% or between 123% and 134% of the %U_(TM). In some embodiments, the uracil content of the ORF encoding aPCCA or PCCB polypeptide is about 115%, about 120%, about 125%, about130%, about 135%, about 140%, about 145%, or about 150% of the % U_(TM).In this context, the term “uracil” can refer to modified uracil and/ornaturally occurring uracil.

In some embodiments, the uracil content in the ORF of the mRNA encodinga PCCA or PCCB polypeptide of the invention is less than about 30%,about 25%, about 20%, about 15%, or about 10% of the total nucleobasecontent in the ORF. In some embodiments, the uracil content in the ORFis between about 10% and about 20% of the total nucleobase content inthe ORF. In other embodiments, the uracil content in the ORF is betweenabout 10% and about 25% of the total nucleobase content in the ORF. Inone embodiment, the uracil content in the ORF of the mRNA encoding aPCCA or PCCB polypeptide is less than about 20% of the total nucleobasecontent in the open reading frame. In this context, the term “uracil”can refer to modified uracil and/or naturally occurring uracil.

In further embodiments, the ORF of the mRNA encoding a PCCA or PCCBpolypeptide having modified uracil and adjusted uracil content hasincreased Cytosine (C), Guanine (G), or Guanine/Cytosine (G/C) content(absolute or relative). In some embodiments, the overall increase in C,G, or G/C content (absolute or relative) of the ORF is at least about2%, at least about 3%, at least about 4%, at least about 5%, at leastabout 6%, at least about 7%, at least about 10%, at least about 15%, atleast about 20%, at least about 40%, at least about 50%, at least about60%, at least about 70%, at least about 80%, at least about 90%, atleast about 95%, or at least about 100% relative to the G/C content(absolute or relative) of the wild-type ORF. In some embodiments, the G,the C, or the G/C content in the ORF is less than about 100%, less thanabout 90%, less than about 85%, or less than about 80% of thetheoretical maximum G, C, or G/C content of the corresponding wild typenucleotide sequence encoding the PCCA or PCCB polypeptide (% G_(TMX); %C_(TMX), or % G/C_(TMX)). In some embodiments, the increases in G and/orC content (absolute or relative) described herein can be conducted byreplacing synonymous codons with low G, C, or G/C content withsynonymous codons having higher G, C, or G/C content. In otherembodiments, the increase in G and/or C content (absolute or relative)is conducted by replacing a codon ending with U with a synonymous codonending with G or C.

In further embodiments, the ORF of the mRNA encoding a PCCA or PCCBpolypeptide of the invention comprises modified uracil and has anadjusted uracil content containing less uracil pairs (UU) and/or uraciltriplets (UUU) and/or uracil quadruplets (UUUU) than the correspondingwild-type nucleotide sequence encoding the PCCA or PCCB polypeptide. Insome embodiments, the ORF of the mRNA encoding a PCCA or PCCBpolypeptide of the invention contains no uracil pairs and/or uraciltriplets and/or uracil quadruplets. In some embodiments, uracil pairsand/or uracil triplets and/or uracil quadruplets are reduced below acertain threshold, e.g., no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,12, 13, 14, 15, 16, 17, 18, 19, or 20 occurrences in the ORF of the mRNAencoding the PCCA or PCCB polypeptide. In a particular embodiment, theORF of the mRNA encoding the PCCA or PCCB polypeptide of the inventioncontains less than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7,6, 5, 4, 3, 2, or 1 non-phenylalanine uracil pairs and/or triplets. Inanother embodiment, the ORF of the mRNA encoding the PCCA or PCCBpolypeptide contains no non-phenylalanine uracil pairs and/or triplets.

In further embodiments, the ORF of the mRNA encoding a PCCA or PCCBpolypeptide of the invention comprises modified uracil and has anadjusted uracil content containing less uracil-rich clusters than thecorresponding wild-type nucleotide sequence encoding the PCCA or PCCBpolypeptide. In some embodiments, the ORF of the mRNA encoding the PCCAor PCCB polypeptide of the invention contains uracil-rich clusters thatare shorter in length than corresponding uracil-rich clusters in thecorresponding wild-type nucleotide sequence encoding the PCCA or PCCBpolypeptide.

In further embodiments, alternative lower frequency codons are employed.At least about 5%, at least about 10%, at least about 15%, at leastabout 20%, at least about 25%, at least about 30%, at least about 35%,at least about 40%, at least about 45%, at least about 50%, at leastabout 55%, at least about 60%, at least about 65%, at least about 70%,at least about 75%, at least about 80%, at least about 85%, at leastabout 90%, at least about 95%, at least about 99%, or 100% of the codonsin the PCCA or PCCB polypeptide-encoding ORF of the modifieduracil-comprising mRNA are substituted with alternative codons, eachalternative codon having a codon frequency lower than the codonfrequency of the substituted codon in the synonymous codon set. The ORFalso has adjusted uracil content, as described above. In someembodiments, at least one codon in the ORF of the mRNA encoding the PCCAor PCCB polypeptide is substituted with an alternative codon having acodon frequency lower than the codon frequency of the substituted codonin the synonymous codon set.

In some embodiments, the adjusted uracil content, PCCA or PCCBpolypeptide-encoding ORF of the modified uracil-comprising mRNA exhibitsexpression levels of PCCA or PCCB when administered to a mammalian cellthat are higher than expression levels of PCCA or PCCB from thecorresponding wild-type mRNA. In some embodiments, the mammalian cell isa mouse cell, a rat cell, or a rabbit cell. In other embodiments, themammalian cell is a monkey cell or a human cell. In some embodiments,the human cell is a HeLa cell, a BJ fibroblast cell, or a peripheralblood mononuclear cell (PBMC). In some embodiments, PCCA or PCCB isexpressed a level higher than expression levels of PCCA or PCCB from thecorresponding wild-type mRNA when the mRNA is administered to amammalian cell in vivo. In some embodiments, the mRNA is administered tomice, rabbits, rats, monkeys, or humans. In one embodiment, mice arenull mice. In some embodiments, the mRNA is administered to mice in anamount of about 0.01 mg/kg, about 0.05 mg/kg, about 0.1 mg/kg, or 0.2mg/kg or about 0.5 mg/kg. In some embodiments, the mRNA is administeredintravenously or intramuscularly. In other embodiments, the PCCA or PCCBpolypeptide is expressed when the mRNA is administered to a mammaliancell in vitro. In some embodiments, the expression is increased by atleast about 2-fold, at least about 5-fold, at least about 10-fold, atleast about 50-fold, at least about 500-fold, at least about 1500-fold,or at least about 3000-fold. In other embodiments, the expression isincreased by at least about 10%, about 20%, about 30%, about 40%, about50%, 60%, about 70%, about 80%, about 90%, or about 100%.

In some embodiments, adjusted uracil content, PCCA or PCCBpolypeptide-encoding ORF of the modified uracil-comprising mRNA exhibitsincreased stability. In some embodiments, the mRNA exhibits increasedstability in a cell relative to the stability of a correspondingwild-type mRNA under the same conditions. In some embodiments, the mRNAexhibits increased stability including resistance to nucleases, thermalstability, and/or increased stabilization of secondary structure. Insome embodiments, increased stability exhibited by the mRNA is measuredby determining the half-life of the mRNA (e.g., in a plasma, serum,cell, or tissue sample) and/or determining the area under the curve(AUC) of the protein expression by the mRNA over time (e.g., in vitro orin vivo). An mRNA is identified as having increased stability if thehalf-life and/or the AUC is greater than the half-life and/or the AUC ofa corresponding wild-type mRNA under the same conditions.

In some embodiments, the mRNA of the present invention induces adetectably lower immune response (e.g., innate or acquired) relative tothe immune response induced by a corresponding wild-type mRNA under thesame conditions. In other embodiments, the mRNA of the presentdisclosure induces a detectably lower immune response (e.g., innate oracquired) relative to the immune response induced by an mRNA thatencodes for a PCCA or PCCB polypeptide but does not comprise modifieduracil under the same conditions, or relative to the immune responseinduced by an mRNA that encodes for a PCCA or PCCB polypeptide and thatcomprises modified uracil but that does not have adjusted uracil contentunder the same conditions. The innate immune response can be manifestedby increased expression of pro-inflammatory cytokines, activation ofintracellular PRRs (RIG-I, MDA5, etc.), cell death, and/or terminationor reduction in protein translation. In some embodiments, a reduction inthe innate immune response can be measured by expression or activitylevel of Type 1 interferons (e.g., IFN-α, IFN-β, IFN-κ, IFN-δ, IFN-ε,IFN-τ, IFN-ω, and IFN-ζ) or the expression of interferon-regulated genessuch as the toll-like receptors (e.g., TLR7 and TLR8), and/or bydecreased cell death following one or more administrations of the mRNAof the invention into a cell.

In some embodiments, the expression of Type-1 interferons by a mammaliancell in response to the mRNA of the present disclosure is reduced by atleast 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.9%, orgreater than 99.9% relative to a corresponding wild-type mRNA, to anmRNA that encodes a PCCA or PCCB polypeptide but does not comprisemodified uracil, or to an mRNA that encodes a PCCA or PCCB polypeptideand that comprises modified uracil but that does not have adjusteduracil content. In some embodiments, the interferon is IFN-β. In someembodiments, cell death frequency caused by administration of mRNA ofthe present disclosure to a mammalian cell is 10%, 25%, 50%, 75%, 85%,90%, 95%, or over 95% less than the cell death frequency observed with acorresponding wild-type mRNA, an mRNA that encodes for a PCCA or PCCBpolypeptide but does not comprise modified uracil, or an mRNA thatencodes for a PCCA or PCCB polypeptide and that comprises modifieduracil but that does not have adjusted uracil content. In someembodiments, the mammalian cell is a BJ fibroblast cell. In otherembodiments, the mammalian cell is a splenocyte. In some embodiments,the mammalian cell is that of a mouse or a rat. In other embodiments,the mammalian cell is that of a human. In one embodiment, the mRNA ofthe present disclosure does not substantially induce an innate immuneresponse of a mammalian cell into which the mRNA is introduced.

9. Methods for Modifying Polynucleotides

The disclosure includes modified polynucleotides comprising apolynucleotide described herein (e.g., a polynucleotide, e.g. mRNA,comprising a nucleotide sequence encoding a PCCA or PCCB polypeptide).The modified polynucleotides can be chemically modified and/orstructurally modified. When the polynucleotides of the present inventionare chemically and/or structurally modified the polynucleotides can bereferred to as “modified polynucleotides.”

The present disclosure provides for modified nucleosides and nucleotidesof a polynucleotide (e.g., RNA polynucleotides, such as mRNApolynucleotides) encoding a PCCA or PCCB polypeptide. A “nucleoside”refers to a compound containing a sugar molecule (e.g., a pentose orribose) or a derivative thereof in combination with an organic base(e.g., a purine or pyrimidine) or a derivative thereof (also referred toherein as “nucleobase”). A “nucleotide” refers to a nucleoside includinga phosphate group. Modified nucleotides can be synthesized by any usefulmethod, such as, for example, chemically, enzymatically, orrecombinantly, to include one or more modified or non-naturalnucleosides. Polynucleotides can comprise a region or regions of linkednucleosides. Such regions can have variable backbone linkages. Thelinkages can be standard phosphodiester linkages, in which case thepolynucleotides would comprise regions of nucleotides.

The modified polynucleotides disclosed herein can comprise variousdistinct modifications. In some embodiments, the modifiedpolynucleotides contain one, two, or more (optionally different)nucleoside or nucleotide modifications. In some embodiments, a modifiedpolynucleotide, introduced to a cell can exhibit one or more desirableproperties, e.g., improved protein expression, reduced immunogenicity,or reduced degradation in the cell, as compared to an unmodifiedpolynucleotide.

In some embodiments, a polynucleotide of the present invention (e.g., apolynucleotide comprising a nucleotide sequence encoding a PCCA or PCCBpolypeptide) is structurally modified. As used herein, a “structural”modification is one in which two or more linked nucleosides areinserted, deleted, duplicated, inverted or randomized in apolynucleotide without significant chemical modification to thenucleotides themselves. Because chemical bonds will necessarily bebroken and reformed to effect a structural modification, structuralmodifications are of a chemical nature and hence are chemicalmodifications. However, structural modifications will result in adifferent sequence of nucleotides. For example, the polynucleotide“ATCG” can be chemically modified to “AT-5meC-G”. The samepolynucleotide can be structurally modified from “ATCG” to “ATCCCG”.Here, the dinucleotide “CC” has been inserted, resulting in a structuralmodification to the polynucleotide.

Therapeutic compositions of the present disclosure comprise, in someembodiments, at least one nucleic acid (e.g., RNA) having an openreading frame encoding PCCA or PCCB (e.g., SEQ ID NOs: 2, 5-14, 16-27,196, 197, and 198), wherein the nucleic acid comprises nucleotidesand/or nucleosides that can be standard (unmodified) or modified as isknown in the art. In some embodiments, nucleotides and nucleosides ofthe present disclosure comprise modified nucleotides or nucleosides.Such modified nucleotides and nucleosides can be naturally-occurringmodified nucleotides and nucleosides or non-naturally occurring modifiednucleotides and nucleosides. Such modifications can include those at thesugar, backbone, or nucleobase portion of the nucleotide and/ornucleoside as are recognized in the art.

In some embodiments, a naturally-occurring modified nucleotide ornucleotide of the disclosure is one as is generally known or recognizedin the art. Non-limiting examples of such naturally occurring modifiednucleotides and nucleotides can be found, inter alia, in the widelyrecognized MODOMICS database.

In some embodiments, a non-naturally occurring modified nucleotide ornucleoside of the disclosure is one as is generally known or recognizedin the art. Non-limiting examples of such non-naturally occurringmodified nucleotides and nucleosides can be found, inter alia, inpublished US application Nos. PCT/US2012/058519; PCT/US2013/075177;PCT/US2014/058897; PCT/US2014/058891; PCT/US2014/070413;PCT/US2015/36773; PCT/US2015/36759; PCT/US2015/36771; orPCT/IB2017/051367 all of which are incorporated by reference herein.

In some embodiments, at least one RNA (e.g., mRNA) of the presentdisclosure is not chemically modified and comprises the standardribonucleotides consisting of adenosine, guanosine, cytosine anduridine. In some embodiments, nucleotides and nucleosides of the presentdisclosure comprise standard nucleoside residues such as those presentin transcribed RNA (e.g. A, G, C, or U). In some embodiments,nucleotides and nucleosides of the present disclosure comprise standarddeoxyribonucleosides such as those present in DNA (e.g. dA, dG, dC, ordT).

Hence, nucleic acids of the disclosure (e.g., DNA nucleic acids and RNAnucleic acids, such as mRNA nucleic acids) can comprise standardnucleotides and nucleosides, naturally-occurring nucleotides andnucleosides, non-naturally-occurring nucleotides and nucleosides, or anycombination thereof.

Nucleic acids of the disclosure (e.g., DNA nucleic acids and RNA nucleicacids, such as mRNA nucleic acids), in some embodiments, comprisevarious (more than one) different types of standard and/or modifiednucleotides and nucleosides. In some embodiments, a particular region ofa nucleic acid contains one, two or more (optionally different) types ofstandard and/or modified nucleotides and nucleosides.

In some embodiments, a modified RNA nucleic acid (e.g., a modified mRNAnucleic acid), introduced to a cell or organism, exhibits reduceddegradation in the cell or organism, respectively, relative to anunmodified nucleic acid comprising standard nucleotides and nucleosides.

In some embodiments, a modified RNA nucleic acid (e.g., a modified mRNAnucleic acid), introduced into a cell or organism, may exhibit reducedimmunogenicity in the cell or organism, respectively (e.g., a reducedinnate response) relative to an unmodified nucleic acid comprisingstandard nucleotides and nucleosides.

Nucleic acids (e.g., RNA nucleic acids, such as mRNA nucleic acids), insome embodiments, comprise non-natural modified nucleotides that areintroduced during synthesis or post-synthesis of the nucleic acids toachieve desired functions or properties. The modifications may bepresent on internucleotide linkages, purine or pyrimidine bases, orsugars. The modification may be introduced with chemical synthesis orwith a polymerase enzyme at the terminal of a chain or anywhere else inthe chain. Any of the regions of a nucleic acid may be chemicallymodified.

The present disclosure provides for modified nucleosides and nucleotidesof a nucleic acid (e.g., RNA nucleic acids, such as mRNA nucleic acids).A “nucleoside” refers to a compound containing a sugar molecule (e.g., apentose or ribose) or a derivative thereof in combination with anorganic base (e.g., a purine or pyrimidine) or a derivative thereof(also referred to herein as “nucleobase”). A “nucleotide” refers to anucleoside, including a phosphate group. Modified nucleotides may bysynthesized by any useful method, such as, for example, chemically,enzymatically, or recombinantly, to include one or more modified ornon-natural nucleosides. Nucleic acids can comprise a region or regionsof linked nucleosides. Such regions may have variable backbone linkages.The linkages can be standard phosphodiester linkages, in which case thenucleic acids would comprise regions of nucleotides.

Modified nucleotide base pairing encompasses not only the standardadenosine-thymine, adenosine-uracil, or guanosine-cytosine base pairs,but also base pairs formed between nucleotides and/or modifiednucleotides comprising non-standard or modified bases, wherein thearrangement of hydrogen bond donors and hydrogen bond acceptors permitshydrogen bonding between a non-standard base and a standard base orbetween two complementary non-standard base structures, such as, forexample, in those nucleic acids having at least one chemicalmodification. One example of such non-standard base pairing is the basepairing between the modified nucleotide inosine and adenine, cytosine oruracil. Any combination of base/sugar or linker may be incorporated intonucleic acids of the present disclosure.

In some embodiments, modified nucleobases in nucleic acids (e.g., RNAnucleic acids, such as mRNA nucleic acids) compriseN1-methyl-pseudouridine (m1ψ), 1-ethyl-pseudouridine (e1ψ),5-methoxy-uridine (mo5U), 5-methyl-cytidine (m5C), and/or pseudouridine(ψ). In some embodiments, modified nucleobases in nucleic acids (e.g.,RNA nucleic acids, such as mRNA nucleic acids) comprise 5-methoxymethyluridine, 5-methylthio uridine, 1-methoxymethyl pseudouridine, 5-methylcytidine, and/or 5-methoxy cytidine. In some embodiments, thepolyribonucleotide includes a combination of at least two (e.g., 2, 3, 4or more) of any of the aforementioned modified nucleobases, includingbut not limited to chemical modifications.

In some embodiments, a RNA nucleic acid of the disclosure comprisesN1-methyl-pseudouridine (m1ψ) substitutions at one or more or alluridine positions of the nucleic acid.

In some embodiments, a RNA nucleic acid of the disclosure comprisesN1-methyl-pseudouridine (m1ψ) substitutions at one or more or alluridine positions of the nucleic acid and 5-methyl cytidinesubstitutions at one or more or all cytidine positions of the nucleicacid.

In some embodiments, a RNA nucleic acid of the disclosure comprisespseudouridine (ψ) substitutions at one or more or all uridine positionsof the nucleic acid.

In some embodiments, a RNA nucleic acid of the disclosure comprisespseudouridine (ψ) substitutions at one or more or all uridine positionsof the nucleic acid and 5-methyl cytidine substitutions at one or moreor all cytidine positions of the nucleic acid.

In some embodiments, a RNA nucleic acid of the disclosure comprisesuridine at one or more or all uridine positions of the nucleic acid.

In some embodiments, nucleic acids (e.g., RNA nucleic acids, such asmRNA nucleic acids) are uniformly modified (e.g., fully modified,modified throughout the entire sequence) for a particular modification.For example, a nucleic acid can be uniformly modified withN1-methyl-pseudouridine, meaning that all uridine residues in the mRNAsequence are replaced with N1-methyl-pseudouridine. Similarly, a nucleicacid can be uniformly modified for any type of nucleoside residuepresent in the sequence by replacement with a modified residue such asthose set forth above.

The nucleic acids of the present disclosure may be partially or fullymodified along the entire length of the molecule. For example, one ormore or all or a given type of nucleotide (e.g., purine or pyrimidine,or any one or more or all of A, G, U, C) may be uniformly modified in anucleic acid of the disclosure, or in a predetermined sequence regionthereof (e.g., in the mRNA including or excluding the polyA tail). Insome embodiments, all nucleotides X in a nucleic acid of the presentdisclosure (or in a sequence region thereof) are modified nucleotides,wherein X may be any one of nucleotides A, G, U, C, or any one of thecombinations A+G, A+U, A+C, G+U, G+C, U+C, A+G+U, A+G+C, G+U+C or A+G+C.

The nucleic acid may contain from about 1% to about 100% modifiednucleotides (either in relation to overall nucleotide content, or inrelation to one or more types of nucleotide, i.e., any one or more of A,G, U or C) or any intervening percentage (e.g., from 1% to 20%, from 1%to 25%, from 1% to 50%, from 1% to 60%, from 1% to 70%, from 1% to 80%,from 1% to 90%, from 1% to 95%, from 10% to 20%, from 10% to 25%, from10% to 50%, from 10% to 60%, from 10% to 70%, from 10% to 80%, from 10%to 90%, from 10% to 95%, from 10% to 100%, from 20% to 25%, from 20% to50%, from 20% to 60%, from 20% to 70%, from 20% to 80%, from 20% to 90%,from 20% to 95%, from 20% to 100%, from 50% to 60%, from 50% to 70%,from 50% to 80%, from 50% to 90%, from 50% to 95%, from 50% to 100%,from 70% to 80%, from 70% to 90%, from 70% to 95%, from 70% to 100%,from 80% to 90%, from 80% to 95%, from 80% to 100%, from 90% to 95%,from 90% to 100%, and from 95% to 100%). It will be understood that anyremaining percentage is accounted for by the presence of unmodified A,G, U, or C.

The nucleic acids may contain at a minimum 1% and at maximum 100%modified nucleotides, or any intervening percentage, such as at least 5%modified nucleotides, at least 10% modified nucleotides, at least 25%modified nucleotides, at least 50% modified nucleotides, at least 80%modified nucleotides, or at least 90% modified nucleotides. For example,the nucleic acids may contain a modified pyrimidine such as a modifieduracil or cytosine. In some embodiments, at least 5%, at least 10%, atleast 25%, at least 50%, at least 80%, at least 90% or 100% of theuracil in the nucleic acid is replaced with a modified uracil (e.g., a5-substituted uracil). The modified uracil can be replaced by a compoundhaving a single unique structure, or can be replaced by a plurality ofcompounds having different structures (e.g., 2, 3, 4 or more uniquestructures). In some embodiments, at least 5%, at least 10%, at least25%, at least 50%, at least 80%, at least 90% or 100% of the cytosine inthe nucleic acid is replaced with a modified cytosine (e.g., a5-substituted cytosine). The modified cytosine can be replaced by acompound having a single unique structure, or can be replaced by aplurality of compounds having different structures (e.g., 2, 3, 4 ormore unique structures).

10. Untranslated Regions (UTRs)

Translation of a polynucleotide comprising an open reading frameencoding a polypeptide can be controlled and regulated by a variety ofmechanisms that are provided by various cis-acting nucleic acidstructures. For example, naturally-occurring, cis-acting RNA elementsthat form hairpins or other higher-order (e.g., pseudoknot)intramolecular mRNA secondary structures can provide a translationalregulatory activity to a polynucleotide, wherein the RNA elementinfluences or modulates the initiation of polynucleotide translation,particularly when the RNA element is positioned in the 5′ UTR close tothe 5′-cap structure (Pelletier and Sonenberg (1985) Cell 40(3):515-526;Kozak (1986) Proc Natl Acad Sci 83:2850-2854).

Untranslated regions (UTRs) are nucleic acid sections of apolynucleotide before a start codon (5′ UTR) and after a stop codon (3′UTR) that are not translated. In some embodiments, a polynucleotide(e.g., a ribonucleic acid (RNA), e.g., a messenger RNA (mRNA)) of theinvention comprising an open reading frame (ORF) encoding a PCCA or PCCBpolypeptide further comprises UTR (e.g., a 5′ UTR or functional fragmentthereof, a 3′ UTR or functional fragment thereof, or a combinationthereof).

Cis-acting RNA elements can also affect translation elongation, beinginvolved in numerous frameshifting events (Namy et al., (2004) Mol Cell13(2):157-168). Internal ribosome entry sequences (IRES) representanother type of cis-acting RNA element that are typically located in 5′UTRs, but have also been reported to be found within the coding regionof naturally-occurring mRNAs (Holcik et al. (2000) Trends Genet16(10):469-473). In cellular mRNAs, IRES often coexist with the 5′-capstructure and provide mRNAs with the functional capacity to betranslated under conditions in which cap-dependent translation iscompromised (Gebauer et al., (2012) Cold Spring Harb Perspect Biol4(7):a012245). Another type of naturally-occurring cis-acting RNAelement comprises upstream open reading frames (uORFs).Naturally-occurring uORFs occur singularly or multiply within the 5′UTRs of numerous mRNAs and influence the translation of the downstreammajor ORF, usually negatively (with the notable exception of GCN4 mRNAin yeast and ATF4 mRNA in mammals, where uORFs serve to promote thetranslation of the downstream major ORF under conditions of increasedeIF2 phosphorylation (Hinnebusch (2005) Annu Rev Microbiol 59:407-450)).Additional exemplary translational regulatory activities provided bycomponents, structures, elements, motifs, and/or specific sequencescomprising polynucleotides (e.g., mRNA) include, but are not limited to,mRNA stabilization or destabilization (Baker & Parker (2004) Curr OpinCell Biol 16(3):293-299), translational activation (Villalba et al.,(2011) Curr Opin Genet Dev 21(4):452-457), and translational repression(Blumer et al., (2002) Mech Dev 110(1-2):97-112). Studies have shownthat naturally-occurring, cis-acting RNA elements can confer theirrespective functions when used to modify, by incorporation into,heterologous polynucleotides (Goldberg-Cohen et al., (2002) J Biol Chem277(16):13635-13640).

Modified Polynucleotides Comprising Functional RNA Elements

The present disclosure provides synthetic polynucleotides comprising amodification (e.g., an RNA element), wherein the modification provides adesired translational regulatory activity. In some embodiments, thedisclosure provides a polynucleotide comprising a 5′ untranslated region(UTR), an initiation codon, a full open reading frame encoding apolypeptide, a 3′ UTR, and at least one modification, wherein the atleast one modification provides a desired translational regulatoryactivity, for example, a modification that promotes and/or enhances thetranslational fidelity of mRNA translation. In some embodiments, thedesired translational regulatory activity is a cis-acting regulatoryactivity. In some embodiments, the desired translational regulatoryactivity is an increase in the residence time of the 43S pre-initiationcomplex (PIC) or ribosome at, or proximal to, the initiation codon. Insome embodiments, the desired translational regulatory activity is anincrease in the initiation of polypeptide synthesis at or from theinitiation codon. In some embodiments, the desired translationalregulatory activity is an increase in the amount of polypeptidetranslated from the full open reading frame. In some embodiments, thedesired translational regulatory activity is an increase in the fidelityof initiation codon decoding by the PIC or ribosome. In someembodiments, the desired translational regulatory activity is inhibitionor reduction of leaky scanning by the PIC or ribosome. In someembodiments, the desired translational regulatory activity is a decreasein the rate of decoding the initiation codon by the PIC or ribosome. Insome embodiments, the desired translational regulatory activity isinhibition or reduction in the initiation of polypeptide synthesis atany codon within the mRNA other than the initiation codon. In someembodiments, the desired translational regulatory activity is inhibitionor reduction of the amount of polypeptide translated from any openreading frame within the mRNA other than the full open reading frame. Insome embodiments, the desired translational regulatory activity isinhibition or reduction in the production of aberrant translationproducts. In some embodiments, the desired translational regulatoryactivity is a combination of one or more of the foregoing translationalregulatory activities.

Accordingly, the present disclosure provides a polynucleotide, e.g., anmRNA, comprising an RNA element that comprises a sequence and/or an RNAsecondary structure(s) that provides a desired translational regulatoryactivity as described herein. In some aspects, the mRNA comprises an RNAelement that comprises a sequence and/or an RNA secondary structure(s)that promotes and/or enhances the translational fidelity of mRNAtranslation. In some aspects, the mRNA comprises an RNA element thatcomprises a sequence and/or an RNA secondary structure(s) that providesa desired translational regulatory activity, such as inhibiting and/orreducing leaky scanning. In some aspects, the disclosure provides anmRNA that comprises an RNA element that comprises a sequence and/or anRNA secondary structure(s) that inhibits and/or reduces leaky scanningthereby promoting the translational fidelity of the mRNA.

In some embodiments, the RNA element comprises natural and/or modifiednucleotides. In some embodiments, the RNA element comprises of asequence of linked nucleotides, or derivatives or analogs thereof, thatprovides a desired translational regulatory activity as describedherein. In some embodiments, the RNA element comprises a sequence oflinked nucleotides, or derivatives or analogs thereof, that forms orfolds into a stable RNA secondary structure, wherein the RNA secondarystructure provides a desired translational regulatory activity asdescribed herein. RNA elements can be identified and/or characterizedbased on the primary sequence of the element (e.g., GC-rich element), byRNA secondary structure formed by the element (e.g. stem-loop), by thelocation of the element within the RNA molecule (e.g., located withinthe 5′ UTR of an mRNA), by the biological function and/or activity ofthe element (e.g., “translational enhancer element”), and anycombination thereof.

In some aspects, the disclosure provides an mRNA having one or morestructural modifications that inhibits leaky scanning and/or promotesthe translational fidelity of mRNA translation, wherein at least one ofthe structural modifications is a GC-rich RNA element. In some aspects,the disclosure provides a modified mRNA comprising at least onemodification, wherein at least one modification is a GC-rich RNA elementcomprising a sequence of linked nucleotides, or derivatives or analogsthereof, preceding a Kozak consensus sequence in a 5′ UTR of the mRNA.In one embodiment, the GC-rich RNA element is located about 30, about25, about 20, about 15, about 10, about 5, about 4, about 3, about 2, orabout 1 nucleotide(s) upstream of a Kozak consensus sequence in the 5′UTR of the mRNA. In another embodiment, the GC-rich RNA element islocated 15-30, 15-20, 15-25, 10-15, or 5-10 nucleotides upstream of aKozak consensus sequence. In another embodiment, the GC-rich RNA elementis located immediately adjacent to a Kozak consensus sequence in the 5′UTR of the mRNA.

In any of the foregoing or related aspects, the disclosure provides aGC-rich RNA element which comprises a sequence of 3-30, 5-25, 10-20,15-20, about 20, about 15, about 12, about 10, about 7, about 6 or about3 nucleotides, derivatives or analogs thereof, linked in any order,wherein the sequence composition is 70-80% cytosine, 60-70% cytosine,50%-60% cytosine, 40-50% cytosine, 30-40% cytosine bases. In any of theforegoing or related aspects, the disclosure provides a GC-rich RNAelement which comprises a sequence of 3-30, 5-25, 10-20, 15-20, about20, about 15, about 12, about 10, about 7, about 6 or about 3nucleotides, derivatives or analogs thereof, linked in any order,wherein the sequence composition is about 80% cytosine, about 70%cytosine, about 60% cytosine, about 50% cytosine, about 40% cytosine, orabout 30% cytosine.

In any of the foregoing or related aspects, the disclosure provides aGC-rich RNA element which comprises a sequence of 20, 19, 18, 17, 16,15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, or 3 nucleotides, orderivatives or analogs thereof, linked in any order, wherein thesequence composition is 70-80% cytosine, 60-70% cytosine, 50%-60%cytosine, 40-50% cytosine, or 30-40% cytosine. In any of the foregoingor related aspects, the disclosure provides a GC-rich RNA element whichcomprises a sequence of 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9,8, 7, 6, 5, 4, or 3 nucleotides, or derivatives or analogs thereof,linked in any order, wherein the sequence composition is about 80%cytosine, about 70% cytosine, about 60% cytosine, about 50% cytosine,about 40% cytosine, or about 30% cytosine.

In some embodiments, the disclosure provides a modified mRNA comprisingat least one modification, wherein at least one modification is aGC-rich RNA element comprising a sequence of linked nucleotides, orderivatives or analogs thereof, preceding a Kozak consensus sequence ina 5′ UTR of the mRNA, wherein the GC-rich RNA element is located about30, about 25, about 20, about 15, about 10, about 5, about 4, about 3,about 2, or about 1 nucleotide(s) upstream of a Kozak consensus sequencein the 5′ UTR of the mRNA, and wherein the GC-rich RNA element comprisesa sequence of 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,19, or 20 nucleotides, or derivatives or analogs thereof, linked in anyorder, wherein the sequence composition is >50% cytosine. In someembodiments, the sequence composition is >55% cytosine, >60%cytosine, >65% cytosine, >70% cytosine, >75% cytosine, >80%cytosine, >85% cytosine, or >90% cytosine.

In other aspects, the disclosure provides a modified mRNA comprising atleast one modification, wherein at least one modification is a GC-richRNA element comprising a sequence of linked nucleotides, or derivativesor analogs thereof, preceding a Kozak consensus sequence in a 5′ UTR ofthe mRNA, wherein the GC-rich RNA element is located about 30, about 25,about 20, about 15, about 10, about 5, about 4, about 3, about 2, orabout 1 nucleotide(s) upstream of a Kozak consensus sequence in the 5′UTR of the mRNA, and wherein the GC-rich RNA element comprises asequence of about 3-30, 5-25, 10-20, 15-20 or about 20, about 15, about12, about 10, about 6 or about 3 nucleotides, or derivatives oranalogues thereof, wherein the sequence comprises a repeating GC-motif,wherein the repeating GC-motif is [CCG]n, wherein n=1 to 10, n=2 to 8,n=3 to 6, or n=4 to 5. In some embodiments, the sequence comprises arepeating GC-motif [CCG]n, wherein n=1, 2, 3, 4 or 5. In someembodiments, the sequence comprises a repeating GC-motif [CCG]n, whereinn=1, 2, or 3. In some embodiments, the sequence comprises a repeatingGC-motif [CCG]n, wherein n=1. In some embodiments, the sequencecomprises a repeating GC-motif [CCG]n, wherein n=2. In some embodiments,the sequence comprises a repeating GC-motif [CCG]n, wherein n=3. In someembodiments, the sequence comprises a repeating GC-motif [CCG]n, whereinn=4. In some embodiments, the sequence comprises a repeating GC-motif[CCG]n, wherein n=5.

In another aspect, the disclosure provides a modified mRNA comprising atleast one modification, wherein at least one modification is a GC-richRNA element comprising a sequence of linked nucleotides, or derivativesor analogs thereof, preceding a Kozak consensus sequence in a 5′ UTR ofthe mRNA, wherein the GC-rich RNA element comprises any one of thesequences set forth in Table 2. In one embodiment, the GC-rich RNAelement is located about 30, about 25, about 20, about 15, about 10,about 5, about 4, about 3, about 2, or about 1 nucleotide(s) upstream ofa Kozak consensus sequence in the 5′ UTR of the mRNA. In anotherembodiment, the GC-rich RNA element is located about 15-30, 15-20,15-25, 10-15, or 5-10 nucleotides upstream of a Kozak consensussequence. In another embodiment, the GC-rich RNA element is locatedimmediately adjacent to a Kozak consensus sequence in the 5′ UTR of themRNA.

In other aspects, the disclosure provides a modified mRNA comprising atleast one modification, wherein at least one modification is a GC-richRNA element comprising the sequence V1 [CCCCGGCGCC (SEQ ID NO:194)] asset forth in Table 2, or derivatives or analogs thereof, preceding aKozak consensus sequence in the 5′ UTR of the mRNA. In some embodiments,the GC-rich element comprises the sequence V1 as set forth in Table 2located immediately adjacent to and upstream of the Kozak consensussequence in the 5′ UTR of the mRNA. In some embodiments, the GC-richelement comprises the sequence V1 as set forth in Table 2 located 1, 2,3, 4, 5, 6, 7, 8, 9 or 10 bases upstream of the Kozak consensus sequencein the 5′ UTR of the mRNA. In other embodiments, the GC-rich elementcomprises the sequence V1 as set forth in Table 2 located 1-3, 3-5, 5-7,7-9, 9-12, or 12-15 bases upstream of the Kozak consensus sequence inthe 5′ UTR of the mRNA.

In other aspects, the disclosure provides a modified mRNA comprising atleast one modification, wherein at least one modification is a GC-richRNA element comprising the sequence V2 [CCCCGGC (SEQ ID NO: 195)] as setforth in Table 2, or derivatives or analogs thereof, preceding a Kozakconsensus sequence in the 5′ UTR of the mRNA. In some embodiments, theGC-rich element comprises the sequence V2 as set forth in Table 2located immediately adjacent to and upstream of the Kozak consensussequence in the 5′ UTR of the mRNA. In some embodiments, the GC-richelement comprises the sequence V2 as set forth in Table 2 located 1, 2,3, 4, 5, 6, 7, 8, 9 or 10 bases upstream of the Kozak consensus sequencein the 5′ UTR of the mRNA. In other embodiments, the GC-rich elementcomprises the sequence V2 as set forth in Table 2 located 1-3, 3-5, 5-7,7-9, 9-12, or 12-15 bases upstream of the Kozak consensus sequence inthe 5′ UTR of the mRNA.

In other aspects, the disclosure provides a modified mRNA comprising atleast one modification, wherein at least one modification is a GC-richRNA element comprising the sequence EK [GCCGCC (SEQ ID NO:193)] as setforth in Table 2, or derivatives or analogs thereof, preceding a Kozakconsensus sequence in the 5′ UTR of the mRNA. In some embodiments, theGC-rich element comprises the sequence EK as set forth in Table 2located immediately adjacent to and upstream of the Kozak consensussequence in the 5′ UTR of the mRNA. In some embodiments, the GC-richelement comprises the sequence EK as set forth in Table 2 located 1, 2,3, 4, 5, 6, 7, 8, 9 or 10 bases upstream of the Kozak consensus sequencein the 5′ UTR of the mRNA. In other embodiments, the GC-rich elementcomprises the sequence EK as set forth in Table 2 located 1-3, 3-5, 5-7,7-9, 9-12, or 12-15 bases upstream of the Kozak consensus sequence inthe 5′ UTR of the mRNA.

In yet other aspects, the disclosure provides a modified mRNA comprisingat least one modification, wherein at least one modification is aGC-rich RNA element comprising the sequence V1 [CCCCGGCGCC (SEQ IDNO:194)] as set forth in Table 2, or derivatives or analogs thereof,preceding a Kozak consensus sequence in the 5′ UTR of the mRNA, whereinthe 5′ UTR comprises the following sequence shown in Table 2:

GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGA (SEQ ID NO:211). The skilledartisan will of course recognize that all Us in the RNA sequencesdescribed herein will be Ts in a corresponding template DNA sequence,for example, in DNA templates or constructs from which mRNAs of thedisclosure are transcribed, e.g., via IVT.

In some embodiments, the GC-rich element comprises the sequence V1 asset forth in Table 2 located immediately adjacent to and upstream of theKozak consensus sequence in the 5′ UTR sequence shown in Table 2. Insome embodiments, the GC-rich element comprises the sequence V1 as setforth in Table 2 located 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 bases upstreamof the Kozak consensus sequence in the 5′ UTR of the mRNA, wherein the5′ UTR comprises the following sequence shown in Table 2:

GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGA (SEQ ID NO:211).

In other embodiments, the GC-rich element comprises the sequence V1 asset forth in Table 2 located 1-3, 3-5, 5-7, 7-9, 9-12, or 12-15 basesupstream of the Kozak consensus sequence in the 5′ UTR of the mRNA,wherein the 5′ UTR comprises the following sequence shown in Table 2:

(SEQ ID NO: 211) GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGA.

In some embodiments, the 5′ UTR comprises the following sequence setforth in Table 2:

(SEQ ID NO: 191) GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGACCCCGGCGCCGCCACC

TABLE 2 5′ UTRs 5′ UTR Sequence Standard GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACC (SEQ ID NO: 3) V1-UTR GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGACCCCGGCGCCGCCACC (SEQ ID NO: 191) V2-UTRGGGAAAUAAGAGAGAAAAGAAGAGUAAGAAG AAAUAUAAGACCCCGGCGCCACC (SEQ ID NO: 190)GC-Rich RNA Elements Sequence K0 (Traditional Kozak consensus)[GCCA/GCC] (SEQ ID NO: 192) EK [GCCGCC] (SEQ ID NO: 193) V1[CCCCGGCGCC] (SEQ ID NO: 194) V2 [CCCCGGC] (SEQ ID NO: 195)(CCG)_(n), where n = 1-10 [CCG]_(n) (GCC)_(n), where n = 1-10 [GCC]_(n)

In another aspect, the disclosure provides a modified mRNA comprising atleast one modification, wherein at least one modification is a GC-richRNA element comprising a stable RNA secondary structure comprising asequence of nucleotides, or derivatives or analogs thereof, linked in anorder which forms a hairpin or a stem-loop. In one embodiment, thestable RNA secondary structure is upstream of the Kozak consensussequence. In another embodiment, the stable RNA secondary structure islocated about 30, about 25, about 20, about 15, about 10, or about 5nucleotides upstream of the Kozak consensus sequence. In anotherembodiment, the stable RNA secondary structure is located about 20,about 15, about 10 or about 5 nucleotides upstream of the Kozakconsensus sequence. In another embodiment, the stable RNA secondarystructure is located about 5, about 4, about 3, about 2, about 1nucleotides upstream of the Kozak consensus sequence. In anotherembodiment, the stable RNA secondary structure is located about 15-30,about 15-20, about 15-25, about 10-15, or about 5-10 nucleotidesupstream of the Kozak consensus sequence. In another embodiment, thestable RNA secondary structure is located 12-15 nucleotides upstream ofthe Kozak consensus sequence. In another embodiment, the stable RNAsecondary structure has a deltaG of about −30 kcal/mol, about −20 to −30kcal/mol, about −20 kcal/mol, about −10 to −20 kcal/mol, about −10kcal/mol, about −5 to −10 kcal/mol.

In another embodiment, the modification is operably linked to an openreading frame encoding a polypeptide and wherein the modification andthe open reading frame are heterologous.

In another embodiment, the sequence of the GC-rich RNA element iscomprised exclusively of guanine (G) and cytosine (C) nucleobases.

RNA elements that provide a desired translational regulatory activity asdescribed herein can be identified and characterized using knowntechniques, such as ribosome profiling. Ribosome profiling is atechnique that allows the determination of the positions of PICs and/orribosomes bound to mRNAs (see e.g., Ingolia et al., (2009) Science324(5924):218-23, incorporated herein by reference). The technique isbased on protecting a region or segment of mRNA, by the PIC and/orribosome, from nuclease digestion. Protection results in the generationof a 30-bp fragment of RNA termed a ‘footprint’. The sequence andfrequency of RNA footprints can be analyzed by methods known in the art(e.g., RNA-seq). The footprint is roughly centered on the A-site of theribosome. If the PIC or ribosome dwells at a particular position orlocation along an mRNA, footprints generated at these position would berelatively common. Studies have shown that more footprints are generatedat positions where the PIC and/or ribosome exhibits decreasedprocessivity and fewer footprints where the PIC and/or ribosome exhibitsincreased processivity (Gardin et al., (2014) eLife 3:e03735). In someembodiments, residence time or the time of occupancy of the PIC orribosome at a discrete position or location along an polynucleotidecomprising any one or more of the RNA elements described herein isdetermined by ribosome profiling.

A UTR can be homologous or heterologous to the coding region in apolynucleotide. In some embodiments, the UTR is homologous to the ORFencoding the PCCA or PCCB polypeptide. In some embodiments, the UTR isheterologous to the ORF encoding the PCCA or PCCB polypeptide. In someembodiments, the polynucleotide comprises two or more 5′ UTRs orfunctional fragments thereof, each of which has the same or differentnucleotide sequences. In some embodiments, the polynucleotide comprisestwo or more 3′ UTRs or functional fragments thereof, each of which hasthe same or different nucleotide sequences.

In some embodiments, the 5′ UTR or functional fragment thereof, 3′ UTRor functional fragment thereof, or any combination thereof is sequenceoptimized.

In some embodiments, the 5′UTR or functional fragment thereof, 3′ UTR orfunctional fragment thereof, or any combination thereof comprises atleast one chemically modified nucleobase, e.g., N1-methylpseudouracil or5-methoxyuracil.

UTRs can have features that provide a regulatory role, e.g., increasedor decreased stability, localization and/or translation efficiency. Apolynucleotide comprising a UTR can be administered to a cell, tissue,or organism, and one or more regulatory features can be measured usingroutine methods. In some embodiments, a functional fragment of a 5′ UTRor 3′ UTR comprises one or more regulatory features of a full length 5′or 3′ UTR, respectively.

Natural 5′UTRs bear features that play roles in translation initiation.They harbor signatures like Kozak sequences that are commonly known tobe involved in the process by which the ribosome initiates translationof many genes. Kozak sequences have the consensus CCR(A/G)CCAUGG (SEQ IDNO:87), where R is a purine (adenine or guanine) three bases upstream ofthe start codon (AUG), which is followed by another ‘G’. 5′ UTRs alsohave been known to form secondary structures that are involved inelongation factor binding.

By engineering the features typically found in abundantly expressedgenes of specific target organs, one can enhance the stability andprotein production of a polynucleotide. For example, introduction of 5′UTR of liver-expressed mRNA, such as albumin, serum amyloid A,Apolipoprotein A/B/E, transferrin, alpha fetoprotein, erythropoietin, orFactor VIII, can enhance expression of polynucleotides in hepatic celllines or liver. Likewise, use of 5′UTR from other tissue-specific mRNAto improve expression in that tissue is possible for muscle (e.g., MyoD,Myosin, Myoglobin, Myogenin, Herculin), for endothelial cells (e.g.,Tie-1, CD36), for myeloid cells (e.g., C/EBP, AML1, G-CSF, GM-CSF,CD11b, MSR, Fr-1, i-NOS), for leukocytes (e.g., CD45, CD18), for adiposetissue (e.g., CD36, GLUT4, ACRP30, adiponectin) and for lung epithelialcells (e.g., SP-A/B/C/D).

In some embodiments, UTRs are selected from a family of transcriptswhose proteins share a common function, structure, feature or property.For example, an encoded polypeptide can belong to a family of proteins(i.e., that share at least one function, structure, feature,localization, origin, or expression pattern), which are expressed in aparticular cell, tissue or at some time during development. The UTRsfrom any of the genes or mRNA can be swapped for any other UTR of thesame or different family of proteins to create a new polynucleotide.

In some embodiments, the 5′ UTR and the 3′ UTR can be heterologous. Insome embodiments, the 5′ UTR can be derived from a different speciesthan the 3′ UTR. In some embodiments, the 3′ UTR can be derived from adifferent species than the 5′ UTR.

Co-owned International Patent Application No. PCT/US2014/021522 (Publ.No. WO/2014/164253, incorporated herein by reference in its entirety)provides a listing of exemplary UTRs that can be utilized in thepolynucleotide of the present invention as flanking regions to an ORF.

Exemplary UTRs of the application include, but are not limited to, oneor more 5′UTR and/or 3′UTR derived from the nucleic acid sequence of: aglobin, such as an α- or β-globin (e.g., a Xenopus, mouse, rabbit, orhuman globin); a strong Kozak translational initiation signal; a CYBA(e.g., human cytochrome b-245 α polypeptide); an albumin (e.g., humanalbumin7); a HSD17B4 (hydroxysteroid (17-0) dehydrogenase); a virus(e.g., a tobacco etch virus (TEV), a Venezuelan equine encephalitisvirus (VEEV), a Dengue virus, a cytomegalovirus (CMV) (e.g., CMVimmediate early 1 (IE1)), a hepatitis virus (e.g., hepatitis B virus), asindbis virus, or a PAV barley yellow dwarf virus); a heat shock protein(e.g., hsp70); a translation initiation factor (e.g., elF4G); a glucosetransporter (e.g., hGLUT1 (human glucose transporter 1)); an actin(e.g., human a or R actin); a GAPDH; a tubulin; a histone; a citric acidcycle enzyme; a topoisomerase (e.g., a 5′UTR of a TOP gene lacking the5′ TOP motif (the oligopyrimidine tract)); a ribosomal protein Large 32(L32); a ribosomal protein (e.g., human or mouse ribosomal protein, suchas, for example, rps9); an ATP synthase (e.g., ATP5A1 or the R subunitof mitochondrial H+-ATP synthase); a growth hormone e (e.g., bovine(bGH) or human (hGH)); an elongation factor (e.g., elongation factor 1al (EEF1A1)); a manganese superoxide dismutase (MnSOD); a myocyteenhancer factor 2A (MEF2A); a 13-F1-ATPase, a creatine kinase, amyoglobin, a granulocyte-colony stimulating factor (G-CSF); a collagen(e.g., collagen type I, alpha 2 (Col1A2), collagen type I, alpha 1(Col1A1), collagen type VI, alpha 2 (Col6A2), collagen type VI, alpha 1(Col6A1)); a ribophorin (e.g., ribophorin I (RPNI)); a low densitylipoprotein receptor-related protein (e.g., LRP1); a cardiotrophin-likecytokine factor (e.g., Nnt1); calreticulin (Calr); a procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 (Plod1); and a nucleobindin (e.g.,Nucbl).

In some embodiments, the 5′ UTR is selected from the group consisting ofa β-globin 5′ UTR; a 5′UTR containing a strong Kozak translationalinitiation signal; a cytochrome b-245 α polypeptide (CYBA) 5′ UTR; ahydroxysteroid (17-β) dehydrogenase (HSD17B4) 5′ UTR; a Tobacco etchvirus (TEV) 5′ UTR; a Venezuelen equine encephalitis virus (TEEV) 5′UTR; a 5′ proximal open reading frame of rubella virus (RV) RNA encodingnonstructural proteins; a Dengue virus (DEN) 5′ UTR; a heat shockprotein 70 (Hsp70) 5′ UTR; a eIF4G 5′ UTR; a GLUT1 5′ UTR; functionalfragments thereof and any combination thereof.

In some embodiments, the 3′ UTR is selected from the group consisting ofa β-globin 3′ UTR; a CYBA 3′ UTR; an albumin 3′ UTR; a growth hormone(GH) 3′ UTR; a VEEV 3′ UTR; a hepatitis B virus (HBV) 3′ UTR; α-globin3′UTR; a DEN 3′ UTR; a PAV barley yellow dwarf virus (BYDV-PAV) 3′ UTR;an elongation factor 1 al (EEF1A1) 3′ UTR; a manganese superoxidedismutase (MnSOD) 3′ UTR; a R subunit of mitochondrial H(+)-ATP synthase(0-mRNA) 3′ UTR; a GLUT1 3′ UTR; a MEF2A 3′ UTR; a β-F1-ATPase 3′ UTR;functional fragments thereof and combinations thereof.

Wild-type UTRs derived from any gene or mRNA can be incorporated intothe polynucleotides of the invention. In some embodiments, a UTR can bealtered relative to a wild type or native UTR to produce a variant UTR,e.g., by changing the orientation or location of the UTR relative to theORF; or by inclusion of additional nucleotides, deletion of nucleotides,swapping or transposition of nucleotides. In some embodiments, variantsof 5′ or 3′ UTRs can be utilized, for example, mutants of wild typeUTRs, or variants wherein one or more nucleotides are added to orremoved from a terminus of the UTR.

Additionally, one or more synthetic UTRs can be used in combination withone or more non-synthetic UTRs. See, e.g., Mandal and Rossi, Nat.Protoc. 2013 8(3):568-82, the contents of which are incorporated hereinby reference in their entirety.

UTRs or portions thereof can be placed in the same orientation as in thetranscript from which they were selected or can be altered inorientation or location. Hence, a 5′ and/or 3′ UTR can be inverted,shortened, lengthened, or combined with one or more other 5′ UTRs or 3′UTRs.

In some embodiments, the polynucleotide comprises multiple UTRs, e.g., adouble, a triple or a quadruple 5′ UTR or 3′ UTR. For example, a doubleUTR comprises two copies of the same UTR either in series orsubstantially in series. For example, a double beta-globin 3′UTR can beused (see US2010/0129877, the contents of which are incorporated hereinby reference in its entirety).

In certain embodiments, the polynucleotides of the invention comprise a5′ UTR and/or a 3′ UTR selected from any of the UTRs disclosed herein.In some embodiments, the 5′ UTR comprises:

5′ UTR-001 (Upstream UTR) (SEQ ID NO: 3)(GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACC);5′ UTR-002 (Upstream UTR) (SEQ ID NO: 89)(GGGAGAUCAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACC);5′ UTR-003 (Upstream UTR) (See WO2016/100812) 5′ UTR-004 (Upstream UTR)(SEQ ID NO: 90) (GGGAGACAAGCUUGGCAUUCCGGUACUGUUGGUAAAGCCACC);5′ UTR-005 (Upstream UTR) (SEQ ID NO: 89)(GGGAGAUCAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACC);5′ UTR-006 (Upstream UTR) (See WO2016/100812) 5′ UTR-007 (Upstream UTR)(SEQ ID NO: 90) (GGGAGACAAGCUUGGCAUUCCGGUACUGUUGGUAAAGCCACC);5′ UTR-008 (Upstream UTR) (SEQ ID NO: 93)(GGGAAUUAACAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACC);5′ UTR-009 (Upstream UTR) (SEQ ID NO: 94)(GGGAAAUUAGACAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACC); 5′ UTR-010, Upstream(SEQ ID NO: 95) (GGGAAAUAAGAGAGUAAAGAACAGUAAGAAGAAAUAUAAGAGCCACC);5′ UTR-011 (Upstream UTR) (SEQ ID NO: 96)(GGGAAAAAAGAGAGAAAAGAAGACUAAGAAGAAAUAUAAGAGCCACC);5′ UTR-012 (Upstream UTR) (SEQ ID NO: 97)(GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAUAUAUAAGAGCCACC);5′ UTR-013 (Upstream UTR) (SEQ ID NO: 98)(GGGAAAUAAGAGACAAAACAAGAGUAAGAAGAAAUAUAAGAGCCACC);5′ UTR-014 (Upstream UTR) (SEQ ID NO: 99)(GGGAAAUUAGAGAGUAAAGAACAGUAAGUAGAAUUAAAAGAGCCACC);5′ UTR-015 (Upstream UTR) (SEQ ID NO: 100)(GGGAAAUAAGAGAGAAUAGAAGAGUAAGAAGAAAUAUAAGAGCCACC);5′ UTR-016 (Upstream UTR) (SEQ ID NO: 101)(GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAAUUAAGAGCCACC);5′ UTR-017 (Upstream UTR); (SEQ ID NO: 102)(GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUUUAAGAGCCACC); or5′ UTR-018 (Upstream UTR) 5′ UTR (SEQ ID NO: 88)(UCAAGCUUUUGGACCCUCGUACAGAAGCUAAUACGACUCACUAUAGGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACC). 5′ UTR-019 (SEQ ID NO: 64)(GGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAATATAAGAGCCACC) 5′ UTR v1 A Start(SEQ ID NO: 199) (AGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACC)

In some embodiments, the 3′ UTR comprises:

142-3p 3′ UTR (UTR including miR142-3p binding site) (SEQ ID NO: 104)(UGAUAAUAGUCCAUAAAGUAGGAAACACUACAGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC);142-3p 3′ UTR (UTR including miR142-3p binding site) (SEQ ID NO: 105)(UGAUAAUAGGCUGGAGCCUCGGUGGCUCCAUAAAGUAGGAAACACUACACAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC); or142-3p 3′ UTR (UTR including miR142-3p binding site) (SEQ ID NO: 106)(UGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUCCAUAAAGUAGGAAACACUACAUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC);142-3p 3′ UTR (UTR including miR142-3p binding site) (SEQ ID NO: 107)(UGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGUCCAUAAAGUAGGAAACACUACACCCCUCCUCCCCUUCCUGCACCCGUACCCCCGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC);142-3p 3′ UTR (UTR including miR142-3p binding site) (SEQ ID NO: 108)(UGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCUCCAUAAAGUAGGAAACACUACACUGCACCCGUACCCCCGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC);142-3p 3′ UTR (UTR including miR142-3p binding site) (SEQ ID NO: 109)(UGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCUCCAUAAAGUAGGAAACACUACAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC).142-3p 3′ UTR (UTR including miR142-3p binding site) (SEQ ID NO: 110)(UGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCGUGGUCUUUGAAUAAAGUUCCAUAAAGUAGGAAACACUACACUGAGUGGGCGGC); 3′ UTR-018;(See SEQ ID NO: 150) 3′ UTR (miR142 and miR126 binding sites variant 1)(SEQ ID NO: 111) (UGAUAAUAGUCCAUAAAGUAGGAAACACUACAGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCGCAUUAUUACUCACGGUACGAGUGGUCUUUGAAU AAAGUCUGAGUGGGCGGC)3′ UTR (miR142 and miR126 binding sites variant 2) (SEQ ID NO: 112)(UGAUAAUAGUCCAUAAAGUAGGAAACACUACAGCUGGAGCCUCGGUGGCCUAGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCGCAUUAUUACUCACGGUACGAGUGGUCUUUGAAU AAAGUCUGAGUGGGCGGC);or 3′UTR (miR142-3p binding site variant 3) (SEQ ID NO: 4)UGAUAAUAGGCUGGAGCCUCGGUGGCCUAGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCUCCAUAAAGUAGGAAACACUACAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC.

In certain embodiments, the 5′ UTR and/or 3′ UTR sequence of theinvention comprises a nucleotide sequence at least about 60%, at leastabout 70%, at least about 80%, at least about 90%, at least about 95%,at least about 96%, at least about 97%, at least about 98%, at leastabout 99%, or about 100% identical to a sequence selected from the groupconsisting of 5′ UTR sequences comprising any of SEQ ID NOs: 3, 64,88-102, 165-167, or 199 and/or 3′ UTR sequences comprises any of SEQ IDNOs:4, 104-112, 150, or 178, and any combination thereof.

In certain embodiments, the 5′ UTR and/or 3′ UTR sequence of theinvention comprises a nucleotide sequence at least about 60%, at leastabout 70%, at least about 80%, at least about 90%, at least about 95%,at least about 96%, at least about 97%, at least about 98%, at leastabout 99%, or about 100% identical to a sequence selected from the groupconsisting of 5′ UTR sequences comprising any of SEQ ID NO:3, SEQ IDNO:191, SEQ ID NO:199, or SEQ ID NO:206 and/or 3′ UTR sequencescomprises any of SEQ ID NO:4, SEQ ID NO:111, SEQ ID NO:150, SEQ IDNO:175, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:207, or SEQ ID NO:208,and any combination thereof.

In some embodiments, the 5′ UTR comprises an amino acid sequence setforth in Table 4B (SEQ ID NO:3, SEQ ID NO:191, SEQ ID NO:199, or SEQ IDNO:206). In some embodiments, the 3′ UTR comprises an amino acidsequence set forth in Table 4B (SEQ ID NO:4, SEQ ID NO:111, SEQ IDNO:150, SEQ ID NO:175, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:207, orSEQ ID NO:208). In some embodiments, the 5′ UTR comprises an amino acidsequence set forth in Table 4B (SEQ ID NO:3, SEQ ID NO:191, SEQ IDNO:199, or SEQ ID NO:206) and the 3′ UTR comprises an amino acidsequence set forth in Table 4B (SEQ ID NO:4, SEQ ID NO:111, SEQ IDNO:150, SEQ ID NO:175, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:207, orSEQ ID NO:208).

The polynucleotides of the invention can comprise combinations offeatures. For example, the ORF can be flanked by a 5′UTR that comprisesa strong Kozak translational initiation signal and/or a 3′UTR comprisingan oligo(dT) sequence for templated addition of a poly-A tail. A 5′UTRcan comprise a first polynucleotide fragment and a second polynucleotidefragment from the same and/or different UTRs (see, e.g., US2010/0293625,herein incorporated by reference in its entirety).

Other non-UTR sequences can be used as regions or subregions within thepolynucleotides of the invention. For example, introns or portions ofintron sequences can be incorporated into the polynucleotides of theinvention. Incorporation of intronic sequences can increase proteinproduction as well as polynucleotide expression levels. In someembodiments, the polynucleotide of the invention comprises an internalribosome entry site (IRES) instead of or in addition to a UTR (see,e.g., Yakubov et al., Biochem. Biophys. Res. Commun. 2010394(1):189-193, the contents of which are incorporated herein byreference in their entirety). In some embodiments, the polynucleotidecomprises an IRES instead of a 5′ UTR sequence. In some embodiments, thepolynucleotide comprises an ORF and a viral capsid sequence. In someembodiments, the polynucleotide comprises a synthetic 5′ UTR incombination with a non-synthetic 3′ UTR.

In some embodiments, the UTR can also include at least one translationenhancer polynucleotide, translation enhancer element, or translationalenhancer elements (collectively, “TEE,” which refers to nucleic acidsequences that increase the amount of polypeptide or protein producedfrom a polynucleotide. As a non-limiting example, the TEE can be locatedbetween the transcription promoter and the start codon. In someembodiments, the 5′ UTR comprises a TEE.

In one aspect, a TEE is a conserved element in a UTR that can promotetranslational activity of a nucleic acid such as, but not limited to,cap-dependent or cap-independent translation.

11. MicroRNA (miRNA) Binding Sites

Polynucleotides of the invention can include regulatory elements, forexample, microRNA (miRNA) binding sites, transcription factor bindingsites, structured mRNA sequences and/or motifs, artificial binding sitesengineered to act as pseudo-receptors for endogenous nucleic acidbinding molecules, and combinations thereof. In some embodiments,polynucleotides including such regulatory elements are referred to asincluding “sensor sequences”.

In some embodiments, a polynucleotide (e.g., a ribonucleic acid (RNA),e.g., a messenger RNA (mRNA)) of the invention comprises an open readingframe (ORF) encoding a polypeptide of interest and further comprises oneor more miRNA binding site(s). Inclusion or incorporation of miRNAbinding site(s) provides for regulation of polynucleotides of theinvention, and in turn, of the polypeptides encoded therefrom, based ontissue-specific and/or cell-type specific expression ofnaturally-occurring miRNAs.

The present invention also provides pharmaceutical compositions andformulations that comprise any of the polynucleotides described above.In some embodiments, the composition or formulation further comprises adelivery agent.

In some embodiments, the composition or formulation can contain apolynucleotide comprising a sequence optimized nucleic acid sequencedisclosed herein which encodes a polypeptide. In some embodiments, thecomposition or formulation can contain a polynucleotide (e.g., a RNA,e.g., an mRNA) comprising a polynucleotide (e.g., an ORF) havingsignificant sequence identity to a sequence optimized nucleic acidsequence disclosed herein which encodes a polypeptide. In someembodiments, the polynucleotide further comprises a miRNA binding site,e.g., a miRNA binding site that binds

A miRNA, e.g., a natural-occurring miRNA, is a 19-25 nucleotide longnoncoding RNA that binds to a polynucleotide and down-regulates geneexpression either by reducing stability or by inhibiting translation ofthe polynucleotide. A miRNA sequence comprises a “seed” region, i.e., asequence in the region of positions 2-8 of the mature miRNA. A miRNAseed can comprise positions 2-8 or 2-7 of the mature miRNA.

microRNAs derive enzymatically from regions of RNA transcripts that foldback on themselves to form short hairpin structures often termed apre-miRNA (precursor-miRNA). A pre-miRNA typically has a two-nucleotideoverhang at its 3′ end, and has 3′ hydroxyl and 5′ phosphate groups.This precursor-mRNA is processed in the nucleus and subsequentlytransported to the cytoplasm where it is further processed by DICER (aRNase III enzyme), to form a mature microRNA of approximately 22nucleotides. The mature microRNA is then incorporated into a ribonuclearparticle to form the RNA-induced silencing complex, RISC, which mediatesgene silencing. Art-recognized nomenclature for mature miRNAs typicallydesignates the arm of the pre-miRNA from which the mature miRNA derives;“5p” means the microRNA is from the 5 prime arm of the pre-miRNA hairpinand “3p” means the microRNA is from the 3 prime end of the pre-miRNAhairpin. A miR referred to by number herein can refer to either of thetwo mature microRNAs originating from opposite arms of the samepre-miRNA (e.g., either the 3p or 5p microRNA). All miRs referred toherein are intended to include both the 3p and 5p arms/sequences, unlessparticularly specified by the 3p or 5p designation.

As used herein, the term “microRNA (miRNA or miR) binding site” refersto a sequence within a polynucleotide, e.g., within a DNA or within anRNA transcript, including in the 5′UTR and/or 3′UTR, that has sufficientcomplementarity to all or a region of a miRNA to interact with,associate with or bind to the miRNA. In some embodiments, apolynucleotide of the invention comprising an ORF encoding a polypeptideof interest and further comprises one or more miRNA binding site(s). Inexemplary embodiments, a 5′ UTR and/or 3′ UTR of the polynucleotide(e.g., a ribonucleic acid (RNA), e.g., a messenger RNA (mRNA)) comprisesthe one or more miRNA binding site(s).

A miRNA binding site having sufficient complementarity to a miRNA refersto a degree of complementarity sufficient to facilitate miRNA-mediatedregulation of a polynucleotide, e.g., miRNA-mediated translationalrepression or degradation of the polynucleotide. In exemplary aspects ofthe invention, a miRNA binding site having sufficient complementarity tothe miRNA refers to a degree of complementarity sufficient to facilitatemiRNA-mediated degradation of the polynucleotide, e.g., miRNA-guidedRNA-induced silencing complex (RISC)-mediated cleavage of mRNA. ThemiRNA binding site can have complementarity to, for example, a 19-25nucleotide long miRNA sequence, to a 19-23 nucleotide long miRNAsequence, or to a 22 nucleotide long miRNA sequence. A miRNA bindingsite can be complementary to only a portion of a miRNA, e.g., to aportion less than 1, 2, 3, or 4 nucleotides of the full length of anaturally-occurring miRNA sequence, or to a portion less than 1, 2, 3,or 4 nucleotides shorter than a naturally-occurring miRNA sequence. Fullor complete complementarity (e.g., full complementarity or completecomplementarity over all or a significant portion of the length of anaturally-occurring miRNA) is preferred when the desired regulation ismRNA degradation.

In some embodiments, a miRNA binding site includes a sequence that hascomplementarity (e.g., partial or complete complementarity) with anmiRNA seed sequence. In some embodiments, the miRNA binding siteincludes a sequence that has complete complementarity with a miRNA seedsequence. In some embodiments, a miRNA binding site includes a sequencethat has complementarity (e.g., partial or complete complementarity)with an miRNA sequence. In some embodiments, the miRNA binding siteincludes a sequence that has complete complementarity with a miRNAsequence. In some embodiments, a miRNA binding site has completecomplementarity with a miRNA sequence but for 1, 2, or 3 nucleotidesubstitutions, terminal additions, and/or truncations.

In some embodiments, the miRNA binding site is the same length as thecorresponding miRNA. In other embodiments, the miRNA binding site isone, two, three, four, five, six, seven, eight, nine, ten, eleven ortwelve nucleotide(s) shorter than the corresponding miRNA at the 5′terminus, the 3′ terminus, or both. In still other embodiments, themicroRNA binding site is two nucleotides shorter than the correspondingmicroRNA at the 5′ terminus, the 3′ terminus, or both. The miRNA bindingsites that are shorter than the corresponding miRNAs are still capableof degrading the mRNA incorporating one or more of the miRNA bindingsites or preventing the mRNA from translation.

In some embodiments, the miRNA binding site binds the correspondingmature miRNA that is part of an active RISC containing Dicer. In anotherembodiment, binding of the miRNA binding site to the corresponding miRNAin RISC degrades the mRNA containing the miRNA binding site or preventsthe mRNA from being translated. In some embodiments, the miRNA bindingsite has sufficient complementarity to miRNA so that a RISC complexcomprising the miRNA cleaves the polynucleotide comprising the miRNAbinding site. In other embodiments, the miRNA binding site has imperfectcomplementarity so that a RISC complex comprising the miRNA inducesinstability in the polynucleotide comprising the miRNA binding site. Inanother embodiment, the miRNA binding site has imperfect complementarityso that a RISC complex comprising the miRNA represses transcription ofthe polynucleotide comprising the miRNA binding site.

In some embodiments, the miRNA binding site has one, two, three, four,five, six, seven, eight, nine, ten, eleven or twelve mismatch(es) fromthe corresponding miRNA.

In some embodiments, the miRNA binding site has at least about ten, atleast about eleven, at least about twelve, at least about thirteen, atleast about fourteen, at least about fifteen, at least about sixteen, atleast about seventeen, at least about eighteen, at least about nineteen,at least about twenty, or at least about twenty-one contiguousnucleotides complementary to at least about ten, at least about eleven,at least about twelve, at least about thirteen, at least about fourteen,at least about fifteen, at least about sixteen, at least aboutseventeen, at least about eighteen, at least about nineteen, at leastabout twenty, or at least about twenty-one, respectively, contiguousnucleotides of the corresponding miRNA.

By engineering one or more miRNA binding sites into a polynucleotide ofthe invention, the polynucleotide can be targeted for degradation orreduced translation, provided the miRNA in question is available. Thiscan reduce off-target effects upon delivery of the polynucleotide. Forexample, if a polynucleotide of the invention is not intended to bedelivered to a tissue or cell but ends up is said tissue or cell, then amiRNA abundant in the tissue or cell can inhibit the expression of thegene of interest if one or multiple binding sites of the miRNA areengineered into the 5′ UTR and/or 3′ UTR of the polynucleotide. Thus, insome embodiments, incorporation of one or more miRNA binding sites intoan mRNA of the disclosure may reduce the hazard of off-target effectsupon nucleic acid molecule delivery and/or enable tissue-specificregulation of expression of a polypeptide encoded by the mRNA. In yetother embodiments, incorporation of one or more miRNA binding sites intoan mRNA of the disclosure can modulate immune responses upon nucleicacid delivery in vivo. In further embodiments, incorporation of one ormore miRNA binding sites into an mRNA of the disclosure can modulateaccelerated blood clearance (ABC) of lipid-comprising compounds andcompositions described herein.

Conversely, miRNA binding sites can be removed from polynucleotidesequences in which they naturally occur in order to increase proteinexpression in specific tissues. For example, a binding site for aspecific miRNA can be removed from a polynucleotide to improve proteinexpression in tissues or cells containing the miRNA.

Regulation of expression in multiple tissues can be accomplished throughintroduction or removal of one or more miRNA binding sites, e.g., one ormore distinct miRNA binding sites. The decision whether to remove orinsert a miRNA binding site can be made based on miRNA expressionpatterns and/or their profilings in tissues and/or cells in developmentand/or disease. Identification of miRNAs, miRNA binding sites, and theirexpression patterns and role in biology have been reported (e.g.,Bonauer et al., Curr Drug Targets 2010 11:943-949; Anand and ChereshCurr Opin Hematol 2011 18:171-176; Contreras and Rao Leukemia 201226:404-413 (2011 Dec. 20. doi: 10.1038/leu.2011.356); Bartel Cell 2009136:215-233; Landgraf et al, Cell, 2007 129:1401-1414; Gentner andNaldini, Tissue Antigens. 2012 80:393-403 and all references therein;each of which is incorporated herein by reference in its entirety).

Examples of tissues where miRNA are known to regulate mRNA, and therebyprotein expression, include, but are not limited to, liver (miR-122),muscle (miR-133, miR-206, miR-208), endothelial cells (miR-17-92,miR-126), myeloid cells (miR-142-3p, miR-142-5p, miR-16, miR-21,miR-223, miR-24, miR-27), adipose tissue (let-7, miR-30c), heart(miR-1d, miR-149), kidney (miR-192, miR-194, miR-204), and lungepithelial cells (let-7, miR-133, miR-126).

Specifically, miRNAs are known to be differentially expressed in immunecells (also called hematopoietic cells), such as antigen presentingcells (APCs) (e.g., dendritic cells and macrophages), macrophages,monocytes, B lymphocytes, T lymphocytes, granulocytes, natural killercells, etc. Immune cell specific miRNAs are involved in immunogenicity,autoimmunity, the immune-response to infection, inflammation, as well asunwanted immune response after gene therapy and tissue/organtransplantation. Immune cells specific miRNAs also regulate many aspectsof development, proliferation, differentiation and apoptosis ofhematopoietic cells (immune cells). For example, miR-142 and miR-146 areexclusively expressed in immune cells, particularly abundant in myeloiddendritic cells. It has been demonstrated that the immune response to apolynucleotide can be shut-off by adding miR-142 binding sites to the3′-UTR of the polynucleotide, enabling more stable gene transfer intissues and cells. miR-142 efficiently degrades exogenouspolynucleotides in antigen presenting cells and suppresses cytotoxicelimination of transduced cells (e.g., Annoni A et al., blood, 2009,114, 5152-5161; Brown B D, et al., Nat med. 2006, 12(5), 585-591; BrownB D, et al., blood, 2007, 110(13): 4144-4152, each of which isincorporated herein by reference in its entirety).

An antigen-mediated immune response can refer to an immune responsetriggered by foreign antigens, which, when entering an organism, areprocessed by the antigen presenting cells and displayed on the surfaceof the antigen presenting cells. T cells can recognize the presentedantigen and induce a cytotoxic elimination of cells that express theantigen.

Introducing a miR-142 binding site into the 5′ UTR and/or 3′UTR of apolynucleotide of the invention can selectively repress gene expressionin antigen presenting cells through miR-142 mediated degradation,limiting antigen presentation in antigen presenting cells (e.g.,dendritic cells) and thereby preventing antigen-mediated immune responseafter the delivery of the polynucleotide. The polynucleotide is thenstably expressed in target tissues or cells without triggering cytotoxicelimination.

In one embodiment, binding sites for miRNAs that are known to beexpressed in immune cells, in particular, antigen presenting cells, canbe engineered into a polynucleotide of the invention to suppress theexpression of the polynucleotide in antigen presenting cells throughmiRNA mediated RNA degradation, subduing the antigen-mediated immuneresponse. Expression of the polynucleotide is maintained in non-immunecells where the immune cell specific miRNAs are not expressed. Forexample, in some embodiments, to prevent an immunogenic reaction againsta liver specific protein, any miR-122 binding site can be removed and amiR-142 (and/or mirR-146) binding site can be engineered into the 5′ UTRand/or 3′ UTR of a polynucleotide of the invention.

To further drive the selective degradation and suppression in APCs andmacrophage, a polynucleotide of the invention can include a furthernegative regulatory element in the 5′ UTR and/or 3′ UTR, either alone orin combination with miR-142 and/or miR-146 binding sites. As anon-limiting example, the further negative regulatory element is aConstitutive Decay Element (CDE).

Immune cell specific miRNAs include, but are not limited to,hsa-let-7a-2-3p, hsa-let-7a-3p, hsa-7a-5p, hsa-let-7c, hsa-let-7e-3p,hsa-let-7e-5p, hsa-let-7g-3p, hsa-let-7g-5p, hsa-let-7i-3p,hsa-let-7i-5p, miR-10a-3p, miR-10a-5p, miR-1184, hsa-let-7f-1--3p,hsa-let-7f-2--5p, hsa-let-7f-5p, miR-125b-1-3p, miR-125b-2-3p,miR-125b-5p, miR-1279, miR-130a-3p, miR-130a-5p, miR-132-3p, miR-132-5p,miR-142-3p, miR-142-5p, miR-143-3p, miR-143-5p, miR-146a-3p,miR-146a-5p, miR-146b-3p, miR-146b-5p, miR-147a, miR-147b, miR-148a-5p,miR-148a-3p, miR-150-3p, miR-150-5p, miR-151b, miR-155-3p, miR-155-5p,miR-15a-3p, miR-15a-5p, miR-15b-5p, miR-15b-3p, miR-16-1-3p,miR-16-2-3p, miR-16-5p, miR-17-5p, miR-181a-3p, miR-181a-5p,miR-181a-2-3p, miR-182-3p, miR-182-5p, miR-197-3p, miR-197-5p,miR-21-5p, miR-21-3p, miR-214-3p, miR-214-5p, miR-223-3p, miR-223-5p,miR-221-3p, miR-221-5p, miR-23b-3p, miR-23b-5p, miR-24-1-5p,miR-24-2-5p, miR-24-3p, miR-26a-1-3p, miR-26a-2-3p, miR-26a-5p,miR-26b-3p, miR-26b-5p, miR-27a-3p, miR-27a-5p, miR-27b-3p, miR-27b-5p,miR-28-3p, miR-28-5p, miR-2909, miR-29a-3p, miR-29a-5p, miR-29b-1-5p,miR-29b-2-5p, miR-29c-3p, miR-29c-5p, miR-30e-3p, miR-30e-5p,miR-331-5p, miR-339-3p, miR-339-5p, miR-345-3p, miR-345-5p, miR-346,miR-34a-3p, miR-34a-5p, miR-363-3p, miR-363-5p, miR-372, miR-377-3p,miR-377-5p, miR-493-3p, miR-493-5p, miR-542, miR-548b-5p, miR548c-5p,miR-548i, miR-548j, miR-548n, miR-574-3p, miR-598, miR-718, miR-935,miR-99a-3p, miR-99a-5p, miR-99b-3p, and miR-99b-5p. Furthermore, novelmiRNAs can be identified in immune cell through micro-arrayhybridization and microtome analysis (e.g., Jima D D et al, Blood, 2010,116:e118-e127; Vaz C et al., BMC Genomics, 2010, 11,288, the content ofeach of which is incorporated herein by reference in its entirety.)

miRNAs that are known to be expressed in the liver include, but are notlimited to, miR-107, miR-122-3p, miR-122-5p, miR-1228-3p, miR-1228-5p,miR-1249, miR-129-5p, miR-1303, miR-151a-3p, miR-151a-5p, miR-152,miR-194-3p, miR-194-5p, miR-199a-3p, miR-199a-5p, miR-199b-3p,miR-199b-5p, miR-296-5p, miR-557, miR-581, miR-939-3p, and miR-939-5p.miRNA binding sites from any liver specific miRNA can be introduced toor removed from a polynucleotide of the invention to regulate expressionof the polynucleotide in the liver. Liver specific miRNA binding sitescan be engineered alone or further in combination with immune cell(e.g., APC) miRNA binding sites in a polynucleotide of the invention.

miRNAs that are known to be expressed in the lung include, but are notlimited to, let-7a-2-3p, let-7a-3p, let-7a-5p, miR-126-3p, miR-126-5p,miR-127-3p, miR-127-5p, miR-130a-3p, miR-130a-5p, miR-130b-3p,miR-130b-5p, miR-133a, miR-133b, miR-134, miR-18a-3p, miR-18a-5p,miR-18b-3p, miR-18b-5p, miR-24-1-5p, miR-24-2-5p, miR-24-3p, miR-296-3p,miR-296-5p, miR-32-3p, miR-337-3p, miR-337-5p, miR-381-3p, andmiR-381-5p. miRNA binding sites from any lung specific miRNA can beintroduced to or removed from a polynucleotide of the invention toregulate expression of the polynucleotide in the lung. Lung specificmiRNA binding sites can be engineered alone or further in combinationwith immune cell (e.g., APC) miRNA binding sites in a polynucleotide ofthe invention.

miRNAs that are known to be expressed in the heart include, but are notlimited to, miR-1, miR-133a, miR-133b, miR-149-3p, miR-149-5p,miR-186-3p, miR-186-5p, miR-208a, miR-208b, miR-210, miR-296-3p,miR-320, miR-451a, miR-451b, miR-499a-3p, miR-499a-5p, miR-499b-3p,miR-499b-5p, miR-744-3p, miR-744-5p, miR-92b-3p, and miR-92b-5p. miRNAbinding sites from any heart specific microRNA can be introduced to orremoved from a polynucleotide of the invention to regulate expression ofthe polynucleotide in the heart. Heart specific miRNA binding sites canbe engineered alone or further in combination with immune cell (e.g.,APC) miRNA binding sites in a polynucleotide of the invention.

miRNAs that are known to be expressed in the nervous system include, butare not limited to, miR-124-5p, miR-125a-3p, miR-125a-5p, miR-125b-1-3p,miR-125b-2-3p, miR-125b-5p, miR-1271-3p, miR-1271-5p, miR-128,miR-132-5p, miR-135a-3p, miR-135a-5p, miR-135b-3p, miR-135b-5p, miR-137,miR-139-5p, miR-139-3p, miR-149-3p, miR-149-5p, miR-153, miR-181c-3p,miR-181c-5p, miR-183-3p, miR-183-5p, miR-190a, miR-190b, miR-212-3p,miR-212-5p, miR-219-1-3p, miR-219-2-3p, miR-23a-3p, miR-23a-5p,miR-30a-5p, miR-30b-3p, miR-30b-5p, miR-30c-1-3p, miR-30c-2-3p,miR-30c-5p, miR-30d-3p, miR-30d-5p, miR-329, miR-342-3p, miR-3665,miR-3666, miR-380-3p, miR-380-5p, miR-383, miR-410, miR-425-3p,miR-425-5p, miR-454-3p, miR-454-5p, miR-483, miR-510, miR-516a-3p,miR-548b-5p, miR-548c-5p, miR-571, miR-7-1-3p, miR-7-2-3p, miR-7-5p,miR-802, miR-922, miR-9-3p, and miR-9-5p. miRNAs enriched in the nervoussystem further include those specifically expressed in neurons,including, but not limited to, miR-132-3p, miR-132-3p, miR-148b-3p,miR-148b-5p, miR-151a-3p, miR-151a-5p, miR-212-3p, miR-212-5p, miR-320b,miR-320e, miR-323a-3p, miR-323a-5p, miR-324-5p, miR-325, miR-326,miR-328, miR-922 and those specifically expressed in glial cells,including, but not limited to, miR-1250, miR-219-1-3p, miR-219-2-3p,miR-219-5p, miR-23a-3p, miR-23a-5p, miR-3065-3p, miR-3065-5p,miR-30e-3p, miR-30e-5p, miR-32-5p, miR-338-5p, and miR-657. miRNAbinding sites from any CNS specific miRNA can be introduced to orremoved from a polynucleotide of the invention to regulate expression ofthe polynucleotide in the nervous system. Nervous system specific miRNAbinding sites can be engineered alone or further in combination withimmune cell (e.g., APC) miRNA binding sites in a polynucleotide of theinvention.

miRNAs that are known to be expressed in the pancreas include, but arenot limited to, miR-105-3p, miR-105-5p, miR-184, miR-195-3p, miR-195-5p,miR-196a-3p, miR-196a-5p, miR-214-3p, miR-214-5p, miR-216a-3p,miR-216a-5p, miR-30a-3p, miR-33a-3p, miR-33a-5p, miR-375, miR-7-1-3p,miR-7-2-3p, miR-493-3p, miR-493-5p, and miR-944. miRNA binding sitesfrom any pancreas specific miRNA can be introduced to or removed from apolynucleotide of the invention to regulate expression of thepolynucleotide in the pancreas. Pancreas specific miRNA binding sitescan be engineered alone or further in combination with immune cell (e.g.APC) miRNA binding sites in a polynucleotide of the invention.

miRNAs that are known to be expressed in the kidney include, but are notlimited to, miR-122-3p, miR-145-5p, miR-17-5p, miR-192-3p, miR-192-5p,miR-194-3p, miR-194-5p, miR-20a-3p, miR-20a-5p, miR-204-3p, miR-204-5p,miR-210, miR-216a-3p, miR-216a-5p, miR-296-3p, miR-30a-3p, miR-30a-5p,miR-30b-3p, miR-30b-5p, miR-30c-1-3p, miR-30c-2-3p, miR30c-5p,miR-324-3p, miR-335-3p, miR-335-5p, miR-363-3p, miR-363-5p, and miR-562.miRNA binding sites from any kidney specific miRNA can be introduced toor removed from a polynucleotide of the invention to regulate expressionof the polynucleotide in the kidney. Kidney specific miRNA binding sitescan be engineered alone or further in combination with immune cell(e.g., APC) miRNA binding sites in a polynucleotide of the invention.

miRNAs that are known to be expressed in the muscle include, but are notlimited to, let-7g-3p, let-7g-5p, miR-1, miR-1286, miR-133a, miR-133b,miR-140-3p, miR-143-3p, miR-143-5p, miR-145-3p, miR-145-5p, miR-188-3p,miR-188-5p, miR-206, miR-208a, miR-208b, miR-25-3p, and miR-25-5p. MiRNAbinding sites from any muscle specific miRNA can be introduced to orremoved from a polynucleotide of the invention to regulate expression ofthe polynucleotide in the muscle. Muscle specific miRNA binding sitescan be engineered alone or further in combination with immune cell(e.g., APC) miRNA binding sites in a polynucleotide of the invention.

miRNAs are also differentially expressed in different types of cells,such as, but not limited to, endothelial cells, epithelial cells, andadipocytes.

miRNAs that are known to be expressed in endothelial cells include, butare not limited to, let-7b-3p, let-7b-5p, miR-100-3p, miR-100-5p,miR-101-3p, miR-101-5p, miR-126-3p, miR-126-5p, miR-1236-3p,miR-1236-5p, miR-130a-3p, miR-130a-5p, miR-17-5p, miR-17-3p, miR-18a-3p,miR-18a-5p, miR-19a-3p, miR-19a-5p, miR-19b-1-5p, miR-19b-2-5p,miR-19b-3p, miR-20a-3p, miR-20a-5p, miR-217, miR-210, miR-21-3p,miR-21-5p, miR-221-3p, miR-221-5p, miR-222-3p, miR-222-5p, miR-23a-3p,miR-23a-5p, miR-296-5p, miR-361-3p, miR-361-5p, miR-421, miR-424-3p,miR-424-5p, miR-513a-5p, miR-92a-1-5p, miR-92a-2-5p, miR-92a-3p,miR-92b-3p, and miR-92b-5p. Many novel miRNAs are discovered inendothelial cells from deep-sequencing analysis (e.g., Voellenkle C etal., RNA, 2012, 18, 472-484, herein incorporated by reference in itsentirety). miRNA binding sites from any endothelial cell specific miRNAcan be introduced to or removed from a polynucleotide of the inventionto regulate expression of the polynucleotide in the endothelial cells.

miRNAs that are known to be expressed in epithelial cells include, butare not limited to, let-7b-3p, let-7b-5p, miR-1246, miR-200a-3p,miR-200a-5p, miR-200b-3p, miR-200b-5p, miR-200c-3p, miR-200c-5p,miR-338-3p, miR-429, miR-451a, miR-451b, miR-494, miR-802 and miR-34a,miR-34b-5p, miR-34c-5p, miR-449a, miR-449b-3p, miR-449b-5p specific inrespiratory ciliated epithelial cells, let-7 family, miR-133a, miR-133b,miR-126 specific in lung epithelial cells, miR-382-3p, miR-382-5pspecific in renal epithelial cells, and miR-762 specific in cornealepithelial cells. miRNA binding sites from any epithelial cell specificmiRNA can be introduced to or removed from a polynucleotide of theinvention to regulate expression of the polynucleotide in the epithelialcells.

In addition, a large group of miRNAs are enriched in embryonic stemcells, controlling stem cell self-renewal as well as the developmentand/or differentiation of various cell lineages, such as neural cells,cardiac, hematopoietic cells, skin cells, osteogenic cells and musclecells (e.g., Kuppusamy K T et al., Curr. Mol Med, 2013, 13(5), 757-764;Vidigal J A and Ventura A, Semin Cancer Biol. 2012, 22(5-6), 428-436;Goff L A et al., PLoS One, 2009, 4:e7192; Morin R D et al., Genome Res,2008, 18, 610-621; Yoo J K et al., Stem Cells Dev. 2012, 21(11),2049-2057, each of which is herein incorporated by reference in itsentirety). miRNAs abundant in embryonic stem cells include, but are notlimited to, let-7a-2-3p, let-a-3p, let-7a-5p, let7d-3p, let-7d-5p,miR-103a-2-3p, miR-103a-5p, miR-106b-3p, miR-106b-5p, miR-1246,miR-1275, miR-138-1-3p, miR-138-2-3p, miR-138-5p, miR-154-3p,miR-154-5p, miR-200c-3p, miR-200c-5p, miR-290, miR-301a-3p, miR-301a-5p,miR-302a-3p, miR-302a-5p, miR-302b-3p, miR-302b-5p, miR-302c-3p,miR-302c-5p, miR-302d-3p, miR-302d-5p, miR-302e, miR-367-3p, miR-367-5p,miR-369-3p, miR-369-5p, miR-370, miR-371, miR-373, miR-380-5p,miR-423-3p, miR-423-5p, miR-486-5p, miR-520c-3p, miR-548e, miR-548f,miR-548g-3p, miR-548g-5p, miR-548i, miR-548k, miR-548l, miR-548m,miR-548n, miR-548o-3p, miR-548o-5p, miR-548p, miR-664a-3p, miR-664a-5p,miR-664b-3p, miR-664b-5p, miR-766-3p, miR-766-5p, miR-885-3p,miR-885-5p, miR-93-3p, miR-93-5p, miR-941,miR-96-3p, miR-96-5p,miR-99b-3p and miR-99b-5p. Many predicted novel miRNAs are discovered bydeep sequencing in human embryonic stem cells (e.g., Morin R D et al.,Genome Res, 2008,18, 610-621; Goff L A et al., PLoS One, 2009, 4:e7192;Bar M et al., Stem cells, 2008, 26, 2496-2505, the content of each ofwhich is incorporated herein by reference in its entirety).

In some embodiments, miRNAs are selected based on expression andabundance in immune cells of the hematopoietic lineage, such as B cells,T cells, macrophages, dendritic cells, and cells that are known toexpress TLR7/TLR8 and/or able to secrete cytokines such as endothelialcells and platelets. In some embodiments, the miRNA set thus includesmiRs that may be responsible in part for the immunogenicity of thesecells, and such that a corresponding miR-site incorporation inpolynucleotides of the present invention (e.g., mRNAs) could lead todestabilization of the mRNA and/or suppression of translation from thesemRNAs in the specific cell type. Non-limiting representative examplesinclude miR-142, miR-144, miR-150, miR-155 and miR-223, which arespecific for many of the hematopoietic cells; miR-142, miR150, miR-16and miR-223, which are expressed in B cells; miR-223, miR-451, miR-26a,miR-16, which are expressed in progenitor hematopoietic cells; andmiR-126, which is expressed in plasmacytoid dendritic cells, plateletsand endothelial cells. For further discussion of tissue expression ofmiRs see e.g., Teruel-Montoya, R. et al. (2014) PLoS One 9:e102259;Landgraf, P. et al. (2007) Cell 129:1401-1414; Bissels, U. et al. (2009)RNA 15:2375-2384. Any one miR-site incorporation in the 3′ UTR and/or 5′UTR may mediate such effects in multiple cell types of interest (e.g.,miR-142 is abundant in both B cells and dendritic cells).

In some embodiments, it may be beneficial to target the same cell typewith multiple miRs and to incorporate binding sites to each of the 3pand 5p arm if both are abundant (e.g., both miR-142-3p and miR142-5p areabundant in hematopoietic stem cells). Thus, in certain embodiments,polynucleotides of the invention contain two or more (e.g., two, three,four or more) miR bindings sites from: (i) the group consisting ofmiR-142, miR-144, miR-150, miR-155 and miR-223 (which are expressed inmany hematopoietic cells); or (ii) the group consisting of miR-142,miR150, miR-16 and miR-223 (which are expressed in B cells); or thegroup consisting of miR-223, miR-451, miR-26a, miR-16 (which areexpressed in progenitor hematopoietic cells).

In some embodiments, it may also be beneficial to combine various miRssuch that multiple cell types of interest are targeted at the same time(e.g., miR-142 and miR-126 to target many cells of the hematopoieticlineage and endothelial cells). Thus, for example, in certainembodiments, polynucleotides of the invention comprise two or more(e.g., two, three, four or more) miRNA bindings sites, wherein: (i) atleast one of the miRs targets cells of the hematopoietic lineage (e.g.,miR-142, miR-144, miR-150, miR-155 or miR-223) and at least one of themiRs targets plasmacytoid dendritic cells, platelets or endothelialcells (e.g., miR-126); or (ii) at least one of the miRs targets B cells(e.g., miR-142, miR150, miR-16 or miR-223) and at least one of the miRstargets plasmacytoid dendritic cells, platelets or endothelial cells(e.g., miR-126); or (iii) at least one of the miRs targets progenitorhematopoietic cells (e.g., miR-223, miR-451, miR-26a or miR-16) and atleast one of the miRs targets plasmacytoid dendritic cells, platelets orendothelial cells (e.g., miR-126); or (iv) at least one of the miRstargets cells of the hematopoietic lineage (e.g., miR-142, miR-144,miR-150, miR-155 or miR-223), at least one of the miRs targets B cells(e.g., miR-142, miR150, miR-16 or miR-223) and at least one of the miRstargets plasmacytoid dendritic cells, platelets or endothelial cells(e.g., miR-126); or any other possible combination of the foregoing fourclasses of miR binding sites (i.e., those targeting the hematopoieticlineage, those targeting B cells, those targeting progenitorhematopoietic cells and/or those targeting plasmacytoid dendriticcells/platelets/endothelial cells).

In one embodiment, to modulate immune responses, polynucleotides of thepresent invention can comprise one or more miRNA binding sequences thatbind to one or more miRs that are expressed in conventional immune cellsor any cell that expresses TLR7 and/or TLR8 and secrete pro-inflammatorycytokines and/or chemokines (e.g., in immune cells of peripherallymphoid organs and/or splenocytes and/or endothelial cells). It has nowbeen discovered that incorporation into an mRNA of one or more miRs thatare expressed in conventional immune cells or any cell that expressesTLR7 and/or TLR8 and secrete pro-inflammatory cytokines and/orchemokines (e.g., in immune cells of peripheral lymphoid organs and/orsplenocytes and/or endothelial cells) reduces or inhibits immune cellactivation (e.g., B cell activation, as measured by frequency ofactivated B cells) and/or cytokine production (e.g., production of IL-6,IFN-γ and/or TNFα). Furthermore, it has now been discovered thatincorporation into an mRNA of one or more miRs that are expressed inconventional immune cells or any cell that expresses TLR7 and/or TLR8and secrete pro-inflammatory cytokines and/or chemokines (e.g., inimmune cells of peripheral lymphoid organs and/or splenocytes and/orendothelial cells) can reduce or inhibit an anti-drug antibody (ADA)response against a protein of interest encoded by the mRNA.

In another embodiment, to modulate accelerated blood clearance of apolynucleotide delivered in a lipid-comprising compound or composition,polynucleotides of the invention can comprise one or more miR bindingsequences that bind to one or more miRNAs expressed in conventionalimmune cells or any cell that expresses TLR7 and/or TLR8 and secretepro-inflammatory cytokines and/or chemokines (e.g., in immune cells ofperipheral lymphoid organs and/or splenocytes and/or endothelial cells).It has now been discovered that incorporation into an mRNA of one ormore miR binding sites reduces or inhibits accelerated blood clearance(ABC) of the lipid-comprising compound or composition for use indelivering the mRNA. Furthermore, it has now been discovered thatincorporation of one or more miR binding sites into an mRNA reducesserum levels of anti-PEG anti-IgM (e.g., reduces or inhibits the acuteproduction of IgMs that recognize polyethylene glycol (PEG) by B cells)and/or reduces or inhibits proliferation and/or activation ofplasmacytoid dendritic cells following administration of alipid-comprising compound or composition comprising the mRNA.

In some embodiments, miR sequences may correspond to any known microRNAexpressed in immune cells, including but not limited to those taught inUS Publication US2005/0261218 and US Publication US2005/0059005, thecontents of which are incorporated herein by reference in theirentirety. Non-limiting examples of miRs expressed in immune cellsinclude those expressed in spleen cells, myeloid cells, dendritic cells,plasmacytoid dendritic cells, B cells, T cells and/or macrophages. Forexample, miR-142-3p, miR-142-5p, miR-16, miR-21, miR-223, miR-24 andmiR-27 are expressed in myeloid cells, miR-155 is expressed in dendriticcells, B cells and T cells, miR-146 is upregulated in macrophages uponTLR stimulation and miR-126 is expressed in plasmacytoid dendriticcells. In certain embodiments, the miR(s) is expressed abundantly orpreferentially in immune cells. For example, miR-142 (miR-142-3p and/ormiR-142-5p), miR-126 (miR-126-3p and/or miR-126-5p), miR-146 (miR-146-3pand/or miR-146-5p) and miR-155 (miR-155-3p and/or miR155-5p) areexpressed abundantly in immune cells. These microRNA sequences are knownin the art and, thus, one of ordinary skill in the art can readilydesign binding sequences or target sequences to which these microRNAswill bind based upon Watson-Crick complementarity.

Accordingly, in various embodiments, polynucleotides of the presentinvention comprise at least one microRNA binding site for a miR selectedfrom the group consisting of miR-142, miR-146, miR-155, miR-126, miR-16,miR-21, miR-223, miR-24 and miR-27. In another embodiment, the mRNAcomprises at least two miR binding sites for microRNAs expressed inimmune cells. In various embodiments, the polynucleotide of theinvention comprises 1-4, one, two, three or four miR binding sites formicroRNAs expressed in immune cells. In another embodiment, thepolynucleotide of the invention comprises three miR binding sites. ThesemiR binding sites can be for microRNAs selected from the groupconsisting of miR-142, miR-146, miR-155, miR-126, miR-16, miR-21,miR-223, miR-24, miR-27, and combinations thereof. In one embodiment,the polynucleotide of the invention comprises two or more (e.g., two,three, four) copies of the same miR binding site expressed in immunecells, e.g., two or more copies of a miR binding site selected from thegroup of miRs consisting of miR-142, miR-146, miR-155, miR-126, miR-16,miR-21, miR-223, miR-24, miR-27.

In one embodiment, the polynucleotide of the invention comprises threecopies of the same miRNA binding site. In certain embodiments, use ofthree copies of the same miR binding site can exhibit beneficialproperties as compared to use of a single miRNA binding site.Non-limiting examples of sequences for 3′ UTRs containing three miRNAbindings sites are shown in SEQ ID NO: 155 (three miR-142-3p bindingsites) and SEQ ID NO: 157 (three miR-142-5p binding sites).

In another embodiment, the polynucleotide of the invention comprises twoor more (e.g., two, three, four) copies of at least two different miRbinding sites expressed in immune cells. Non-limiting examples ofsequences of 3′ UTRs containing two or more different miR binding sitesare shown in SEQ ID NO: 111 (one miR-142-3p binding site and onemiR-126-3p binding site), SEQ ID NO: 158 (two miR-142-5p binding sitesand one miR-142-3p binding sites), and SEQ ID NO: 161 (two miR-155-5pbinding sites and one miR-142-3p binding sites).

In another embodiment, the polynucleotide of the invention comprises atleast two miR binding sites for microRNAs expressed in immune cells,wherein one of the miR binding sites is for miR-142-3p. In variousembodiments, the polynucleotide of the invention comprises binding sitesfor miR-142-3p and miR-155 (miR-155-3p or miR-155-5p), miR-142-3p andmiR-146 (miR-146-3 or miR-146-5p), or miR-142-3p and miR-126 (miR-126-3por miR-126-5p).

In another embodiment, the polynucleotide of the invention comprises atleast two miR binding sites for microRNAs expressed in immune cells,wherein one of the miR binding sites is for miR-126-3p. In variousembodiments, the polynucleotide of the invention comprises binding sitesfor miR-126-3p and miR-155 (miR-155-3p or miR-155-5p), miR-126-3p andmiR-146 (miR-146-3p or miR-146-5p), or miR-126-3p and miR-142(miR-142-3p or miR-142-5p).

In another embodiment, the polynucleotide of the invention comprises atleast two miR binding sites for microRNAs expressed in immune cells,wherein one of the miR binding sites is for miR-142-5p. In variousembodiments, the polynucleotide of the invention comprises binding sitesfor miR-142-5p and miR-155 (miR-155-3p or miR-155-5p), miR-142-5p andmiR-146 (miR-146-3 or miR-146-5p), or miR-142-5p and miR-126 (miR-126-3por miR-126-5p).

In yet another embodiment, the polynucleotide of the invention comprisesat least two miR binding sites for microRNAs expressed in immune cells,wherein one of the miR binding sites is for miR-155-5p. In variousembodiments, the polynucleotide of the invention comprises binding sitesfor miR-155-5p and miR-142 (miR-142-3p or miR-142-5p), miR-155-5p andmiR-146 (miR-146-3 or miR-146-5p), or miR-155-5p and miR-126 (miR-126-3por miR-126-5p).

miRNA can also regulate complex biological processes such asangiogenesis (e.g., miR-132) (Anand and Cheresh Curr Opin Hematol 201118:171-176). In the polynucleotides of the invention, miRNA bindingsites that are involved in such processes can be removed or introduced,in order to tailor the expression of the polynucleotides to biologicallyrelevant cell types or relevant biological processes. In this context,the polynucleotides of the invention are defined as auxotrophicpolynucleotides.

In some embodiments, a polynucleotide of the invention comprises a miRNAbinding site, wherein the miRNA binding site comprises one or morenucleotide sequences selected from Table 3, including one or more copiesof any one or more of the miRNA binding site sequences. In someembodiments, a polynucleotide of the invention further comprises atleast one, two, three, four, five, six, seven, eight, nine, ten, or moreof the same or different miRNA binding sites selected from Table 3,including any combination thereof.

In some embodiments, the miRNA binding site binds to miR-142 or iscomplementary to miR-142. In some embodiments, the miR-142 comprises SEQID NO:114. In some embodiments, the miRNA binding site binds tomiR-142-3p or miR-142-5p. In some embodiments, the miR-142-3p bindingsite comprises SEQ ID NO:116. In some embodiments, the miR-142-5pbinding site comprises SEQ ID NO:118. In some embodiments, the miRNAbinding site comprises a nucleotide sequence at least 80%, at least 85%,at least 90%, at least 95%, or 100% identical to SEQ ID NO:116 or SEQ IDNO:118.

In some embodiments, the miRNA binding site binds to miR-126 or iscomplementary to miR-126. In some embodiments, the miR-126 comprises SEQID NO: 119. In some embodiments, the miRNA binding site binds tomiR-126-3p or miR-126-5p. In some embodiments, the miR-126-3p bindingsite comprises SEQ ID NO: 121. In some embodiments, the miR-126-5pbinding site comprises SEQ ID NO: 123. In some embodiments, the miRNAbinding site comprises a nucleotide sequence at least 80%, at least 85%,at least 90%, at least 95%, or 100% identical to SEQ ID NO: 121 or SEQID NO: 123.

In one embodiment, the 3′ UTR comprises two miRNA binding sites, whereina first miRNA binding site binds to miR-142 and a second miRNA bindingsite binds to miR-126. In a specific embodiment, the 3′ UTR binding tomiR-142 and miR-126 comprises, consists, or consists essentially of thesequence of SEQ ID NO:98 or 105.

TABLE 3 miR-142, miR-126, and miR-142 and miR-126 binding sitesSEQ ID NO. Description Sequence 114 miR-142GACAGUGCAGUCACCCAUAAAGUAGAAAGCACUACUAACAGCACUGGAGGGUGUAGUGUUUCCUACUUUAUGGAUG AGUGUACUGUG 115 miR-142-3pUGUAGUGUUUCCUACUUUAUGGA 116 miR-142-3p binding siteUCCAUAAAGUAGGAAACACUACA 117 miR-142-5p CAUAAAGUAGAAAGCACUACU 118miR-142-5p binding site AGUAGUGCUUUCUACUUUAUG 119 miR-126CGCUGGCGACGGGACAUUAUUACUUUUGGUACGCGCUGUGACACUUCAAACUCGUACCGUGAGUAAUAAUGCGCCG UCCACGGCA 120 miR-126-3pUCGUACCGUGAGUAAUAAUGCG 121 miR-126-3p binding siteCGCAUUAUUACUCACGGUACGA 122 miR-126-5p CAUUAUUACUUUUGGUACGCG 123miR-126-5p binding site CGCGUACCAAAAGUAAUAAUG

In some embodiments, a miRNA binding site is inserted in thepolynucleotide of the invention in any position of the polynucleotide(e.g., the 5′ UTR and/or 3′ UTR). In some embodiments, the 5′ UTRcomprises a miRNA binding site. In some embodiments, the 3′ UTRcomprises a miRNA binding site. In some embodiments, the 5′ UTR and the3′ UTR comprise a miRNA binding site. The insertion site in thepolynucleotide can be anywhere in the polynucleotide as long as theinsertion of the miRNA binding site in the polynucleotide does notinterfere with the translation of a functional polypeptide in theabsence of the corresponding miRNA; and in the presence of the miRNA,the insertion of the miRNA binding site in the polynucleotide and thebinding of the miRNA binding site to the corresponding miRNA are capableof degrading the polynucleotide or preventing the translation of thepolynucleotide.

In some embodiments, a miRNA binding site is inserted in at least about30 nucleotides downstream from the stop codon of an ORF in apolynucleotide of the invention comprising the ORF. In some embodiments,a miRNA binding site is inserted in at least about 10 nucleotides, atleast about 15 nucleotides, at least about 20 nucleotides, at leastabout 25 nucleotides, at least about 30 nucleotides, at least about 35nucleotides, at least about 40 nucleotides, at least about 45nucleotides, at least about 50 nucleotides, at least about 55nucleotides, at least about 60 nucleotides, at least about 65nucleotides, at least about 70 nucleotides, at least about 75nucleotides, at least about 80 nucleotides, at least about 85nucleotides, at least about 90 nucleotides, at least about 95nucleotides, or at least about 100 nucleotides downstream from the stopcodon of an ORF in a polynucleotide of the invention. In someembodiments, a miRNA binding site is inserted in about 10 nucleotides toabout 100 nucleotides, about 20 nucleotides to about 90 nucleotides,about 30 nucleotides to about 80 nucleotides, about 40 nucleotides toabout 70 nucleotides, about 50 nucleotides to about 60 nucleotides,about 45 nucleotides to about 65 nucleotides downstream from the stopcodon of an ORF in a polynucleotide of the invention.

In some embodiments, a miRNA binding site is inserted within the 3′ UTRimmediately following the stop codon of the coding region within thepolynucleotide of the invention, e.g., mRNA. In some embodiments, ifthere are multiple copies of a stop codon in the construct, a miRNAbinding site is inserted immediately following the final stop codon. Insome embodiments, a miRNA binding site is inserted further downstream ofthe stop codon, in which case there are 3′ UTR bases between the stopcodon and the miR binding site(s). In some embodiments, threenon-limiting examples of possible insertion sites for a miR in a 3′ UTRare shown in SEQ ID NOs: 104, 105, and 164, which show a 3′ UTR sequencewith a miR-142-3p site inserted in one of three different possibleinsertion sites, respectively, within the 3′ UTR.

In some embodiments, one or more miRNA binding sites can be positionedwithin the 5′ UTR at one or more possible insertion sites. For example,three non-limiting examples of possible insertion sites for a miR in a5′ UTR are shown in SEQ ID NOs: 165, 166, or 167, which show a 5′ UTRsequence with a miR-142-3p site inserted into one of three differentpossible insertion sites, respectively, within the 5′ UTR.

In one embodiment, a codon optimized open reading frame encoding apolypeptide of interest comprises a stop codon and the at least onemicroRNA binding site is located within the 3′ UTR 1-100 nucleotidesafter the stop codon. In one embodiment, the codon optimized openreading frame encoding the polypeptide of interest comprises a stopcodon and the at least one microRNA binding site for a miR expressed inimmune cells is located within the 3′ UTR 30-50 nucleotides after thestop codon. In another embodiment, the codon optimized open readingframe encoding the polypeptide of interest comprises a stop codon andthe at least one microRNA binding site for a miR expressed in immunecells is located within the 3′ UTR at least 50 nucleotides after thestop codon. In other embodiments, the codon optimized open reading frameencoding the polypeptide of interest comprises a stop codon and the atleast one microRNA binding site for a miR expressed in immune cells islocated within the 3′ UTR immediately after the stop codon, or withinthe 3′ UTR 15-20 nucleotides after the stop codon or within the 3′ UTR70-80 nucleotides after the stop codon. In other embodiments, the 3′ UTRcomprises more than one miRNA binding site (e.g., 2-4 miRNA bindingsites), wherein there can be a spacer region (e.g., of 10-100, 20-70 or30-50 nucleotides in length) between each miRNA binding site. In anotherembodiment, the 3′ UTR comprises a spacer region between the end of themiRNA binding site(s) and the poly A tail nucleotides. For example, aspacer region of 10-100, 20-70 or 30-50 nucleotides in length can besituated between the end of the miRNA binding site(s) and the beginningof the poly A tail.

In one embodiment, a codon optimized open reading frame encoding apolypeptide of interest comprises a start codon and the at least onemicroRNA binding site is located within the 5′ UTR 1-100 nucleotidesbefore (upstream of) the start codon. In one embodiment, the codonoptimized open reading frame encoding the polypeptide of interestcomprises a start codon and the at least one microRNA binding site for amiR expressed in immune cells is located within the 5′ UTR 10-50nucleotides before (upstream of) the start codon. In another embodiment,the codon optimized open reading frame encoding the polypeptide ofinterest comprises a start codon and the at least one microRNA bindingsite for a miR expressed in immune cells is located within the 5′ UTR atleast 25 nucleotides before (upstream of) the start codon. In otherembodiments, the codon optimized open reading frame encoding thepolypeptide of interest comprises a start codon and the at least onemicroRNA binding site for a miR expressed in immune cells is locatedwithin the 5′ UTR immediately before the start codon, or within the 5′UTR 15-20 nucleotides before the start codon or within the 5′ UTR 70-80nucleotides before the start codon. In other embodiments, the 5′ UTRcomprises more than one miRNA binding site (e.g., 2-4 miRNA bindingsites), wherein there can be a spacer region (e.g., of 10-100, 20-70 or30-50 nucleotides in length) between each miRNA binding site.

In one embodiment, the 3′ UTR comprises more than one stop codon,wherein at least one miRNA binding site is positioned downstream of thestop codons. For example, a 3′ UTR can comprise 1, 2 or 3 stop codons.Non-limiting examples of triple stop codons that can be used include:UGAUAAUAG (SEQ ID NO:124), UGAUAGUAA (SEQ ID NO:125), UAAUGAUAG (SEQ IDNO:126), UGAUAAUAA (SEQ ID NO:127), UGAUAGUAG (SEQ ID NO:128), UAAUGAUGA(SEQ ID NO:129), UAAUAGUAG (SEQ ID NO:130), UGAUGAUGA (SEQ ID NO:131),UAAUAAUAA (SEQ ID NO:132), and UAGUAGUAG (SEQ ID NO:133). Within a 3′UTR, for example, 1, 2, 3 or 4 miRNA binding sites, e.g., miR-142-3pbinding sites, can be positioned immediately adjacent to the stopcodon(s) or at any number of nucleotides downstream of the final stopcodon. When the 3′ UTR comprises multiple miRNA binding sites, thesebinding sites can be positioned directly next to each other in theconstruct (i.e., one after the other) or, alternatively, spacernucleotides can be positioned between each binding site.

In one embodiment, the 3′ UTR comprises three stop codons with a singlemiR-142-3p binding site located downstream of the 3rd stop codon.Non-limiting examples of sequences of 3′ UTR having three stop codonsand a single miR-142-3p binding site located at different positionsdownstream of the final stop codon are shown in SEQ ID NOs: 109, 104,105, and 164.

TABLE 4A 5′ UTRs, 3′UTRs, miR sequences, and miR binding sitesSEQ ID NO: Sequence 134GCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCUCCAUAAAGUAGGAAACACUACAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC (3′ UTR with miR 142-3p binding site) 116UCCAUAAAGUAGGAAACACUACA (miR 142-3p binding site) 115UGUAGUGUUUCCUACUUUAUGGA (miR 142-3p sequence) 117 CAUAAAGUAGAAAGCACUACU(miR 142-5p sequence) 135 CCUCUGAAAUUCAGUUCUUCAG (miR 146-3p sequence)136 UGAGAACUGAAUUCCAUGGGUU (miR 146-5p sequence) 137CUCCUACAUAUUAGCAUUAACA (miR 155-3p sequence) 138 UUAAUGCUAAUCGUGAUAGGGGU(miR 155-5p sequence) 120 UCGUACCGUGAGUAAUAAUGCG (miR 126-3p sequence)122 CAUUAUUACUUUUGGUACGCG (miR 126-5p sequence) 139CCAGUAUUAACUGUGCUGCUGA (miR 16-3p sequence) 140 UAGCAGCACGUAAAUAUUGGCG(miR 16-5p sequence) 141 CAACACCAGUCGAUGGGCUGU (miR 21-3p sequence) 142UAGCUUAUCAGACUGAUGUUGA (miR 21-5p sequence) 143 UGUCAGUUUGUCAAAUACCCCA(miR 223-3p sequence) 144 CGUGUAUUUGACAAGCUGAGUU (miR 223-5p sequence)145 UGGCUCAGUUCAGCAGGAACAG (miR 24-3p sequence) 146UGCCUACUGAGCUGAUAUCAGU (miR 24-5p sequence) 147 UUCACAGUGGCUAAGUUCCGC(miR 27-3p sequence) 148 AGGGCUUAGCUGCUUGUGAGCA (miR 27-5p sequence) 121CGCAUUAUUACUCACGGUACGA (miR 126-3p binding site) 149UGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCC

GUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC (3′ UTR with miR 126-3p binding site)150 UGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCGUGGUCUUUGAAUAAA GUCUGAGUGGGCGGC(3′ UTR, no miR binding sites) 109UGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCUCCAUAAAGUAGGAAACACUACAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC(3′ UTR with miR 142-3p binding site) 111 UGAUAAUAGUCCAUAAAGUAGGAAACACUACAGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCG UACCCCC

GUGGUCUUUGAAUAAAGUCUGAG UGGGCGGC(3′ UTR with miR 142-3p and miR 126-3p binding sites variant 1) 153UUAAUGCUAAUUGUGAUAGGGGU (miR 155-5p sequence) 154ACCCCUAUCACAAUUAGCAUUAA (miR 155-5p binding site) 155 UGAUAAUAGUCCAUAAAGUAGGAAACACUACAGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCAUAAAGUAGGAAACACUACAUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCUCCAUAAAGUAGGAAACACUACAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC(3′ UTR with 3 miR 142-3p binding sites) 156UGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCC

GUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC (3′ UTR with miR 142-5p binding site)157 UGAUAAUAG

GCUGGAGCCUCGGUGGCCAUGC UUCUUGCCCCUUGGGCC

UCCCCCCAGCCCCU CCUCCCCUUCCUGCACCCGUACCCCC

GUGGU CUUUGAAUAAAGUCUGAGUGGGCGGC(3′ UTR with 3 miR 142-5p binding sites) 158 UGAUAAUAG

GCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCAUAAAGUAGGAAACACUACAUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCC

GUG GUCUUUGAAUAAAGUCUGAGUGGGCGGC(3′ UTR with 2 miR 142-5p binding sites and 1 miR 142-3p binding site)159 UGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCACCCCUAUCACAAUUAGCAUUAAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC(3′ UTR with miR 155-5p binding site) 160 UGAUAAUAGACCCCUAUCACAAUUAGCAUUAAGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCACCCCUAUCACAAUUAGCAUUAAUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCACCCCUAUCACAAUUAGCAUUAAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC(3′ UTR with 3 miR 155-5p binding sites) 161 UGAUAAUAGACCCCUAUCACAAUUAGCAUUAAGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCAUAAAGUAGGAAACACUACAUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCACCCCUAUCACAAUUAGCAUUAAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC(3′ UTR with 2 miR 155-5p binding sites and 1 miR 142-3p binding site)104 UGAUAAUAG UCCAUAAAGUAGGAAACACUACAGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC(3′ UTR with miR 142-3p binding site, P1 insertion) 105UGAUAAUAGGCUGGAGCCUCGGUGGCUCCAUAAAGUAGGAAACACUACACAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC(3′ UTR with miR 142-3p binding site, P2 insertion) 164UGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCAUAAAGUAGGAAACACUACAUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC(3′ UTR with miR 142-3p binding site, P3 insertion) 118AGUAGUGCUUUCUACUUUAUG (miR-142-5p binding site) 114GACAGUGCAGUCACCCAUAAAGUAGAAAGCACUACUAACAGCACUGGAGGGUGUAGUGUUUCCUACUUUAUGGAUGAGUGUACUGUG (miR-142)   3GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACC (5′ UTR) 165GGGAAAUAAGAGUCCAUAAAGUAGGAAACACUACAAGAAAAGAAGAGUAAGA AGAAAUAUAAGAGCCACC(5′ UTR with miR142-3p binding site at position p1) 166GGGAAAUAAGAGAGAAAAGAAGAGUAAUCCAUAAAGUAGGAAACACUACAGA AGAAAUAUAAGAGCCACC(5′ UTR with miR142-3p binding site at position p2) 167GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAUCCAUAAAGUAGG AAACACUACAGAGCCACC(5′ UTR with miR142-3p binding site at position p3) 169 UGAUAAUAG

GCUGGAGCCUCGGUGGCCAUGC UUCUUGCCCCUUGGGCC

UCCCCCCAGCCCCU CUCCCCUUCCUGCACCCGUACCCCC

GUGGUC UUUGAAUAAAGUCUGAGUGGGCGGC(3′ UTR with 3 miR 142-5p binding sites) 106UGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUCCAUAAAGUAGGAAACACUACAUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC(3′UTR including miR142-3p binding site) 107UGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGUCCAUAAAGUAGGAAACACUACACCCCUCCUCCCCUUCCUGCACCCGUACCCCCGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC(3′UTR including miR142-3p binding site) 108UGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCUCCAUAAAGUAGGAAACACUACACUGCACCCGUACCCCCGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC(3′UTR including including miR142-3p binding site) 110UGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCGUGGUCUUUGAAUAAAGUUCCAUAAAGUAGGAAACACUACACUGAGUGGGCGGC(3′UTR including including miR142-3p binding site) 112 UGAUAAUAGUCCAUAAAGUAGGAAACACUACAGCUGGAGCCUCGGUGGCCUAGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCG UACCCCC

GUGGUCUUUGAAUAAAGUCUGAG UGGGCGGC(3′ UTR with miR 142-3p and miR 126-3p binding sites variant 2) 175UGAUAAUAGGCUGGAGCCUCGGUGGCCUAGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCGUGGUCUUUGAAUAAA GUCUGAGUGGGCGGC(3′ UTR, no miR binding sites variant 2)   4UGAUAAUAGGCUGGAGCCUCGGUGGCCUAGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCUCCAUAAAGUAGGAAACACUACAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC(3′ UTR with miR 142-3p binding site variant 3) 177UGAUAAUAGGCUGGAGCCUCGGUGGCCUAGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCC

GUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC(3′ UTR with miR 126-3p binding site variant 3) 178 UGAUAAUAGUCCAUAAAGUAGGAAACACUACAGCUGGAGCCUCGGUGGCCUAGCUUCUUGCCCCUUGGGCCUCCAUAAAGUAGGAAACACUACAUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCUCCAUAAAGUAGGAAACACUACAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC(3′ UTR with 3 miR 142-3p binding sites variant 2) 179 UGAUAAUAGUCCAUAAAGUAGGAAACACUACAGCUGGAGCCUCGGUGGCCUAGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC(3′UTR with miR 142-3p binding site, P1 insertion variant 2) 180UGAUAAUAGGCUGGAGCCUCGGUGGCUCCAUAAAGUAGGAAACACUACACUAGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC(3′UTR with miR 142-3p binding site, P2 insertion variant 2) 181UGAUAAUAGGCUGGAGCCUCGGUGGCCUAGCUUCUUGCCCCUUGGGCCUCCAUAAAGUAGGAAACACUACAUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC(3′UTR with miR 142-3p binding site, P3 insertion variant 2) 182UGAUAAUAGGCUGGAGCCUCGGUGGCCUAGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCACCCCUAUCACAAUUAGCAUUAAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC(3′UTR with miR 155-5p binding site variant 2) 183 UGAUAAUAGACCCCUAUCACAAUUAGCAUUAAGCUGGAGCCUCGGUGGCCUAGCUUCUUGCCCCUUGGGCCACCCCUAUCACAAUUAGCAUUAAUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCACCCCUAUCACAAUUAGCAUUAAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC(3′ UTR with 3 miR 155-5p binding sites variant 2) 184 UGAUAAUAGACCCCUAUCACAAUUAGCAUUAGCUGGAGCCUCGGUGGCCUAGCUUCUUGCCCCUUGGGCCUCCAUAAAGUAGGAAACACUACAUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCACCCCUAUCACAAUUAGCAUUAAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC(3′UTR with 2 miR 155-5p binding sites and 1 miR 142-3p binding sitevariant 2) Stop codon = bold miR 142-3p binding site = underline miR126-3p binding site = bold underline miR 155-5p binding site = doubleunderline miR 142-5p binding site = bold double underline

TABLE 4B Exemplary Preferred UTRs SEQ ID NO: Sequence 5′ UTR (v1)GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACC (SEQ ID NO: 3)5′UTR (v1 A) AGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACC(SEQ ID NO: 199) 5′ UTR (v1.1)GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGACCCCGGC (SEQ ID NO: 191)GCCGCCACC 5′ UTR (v1.1 A)AGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGACCCCGGC (SEQ ID NO: 206)GCCGCCACC 3′ UTR (v1) UGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCC(SEQ ID NO: 150) UCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC 3′ UTR (v1.1)UGAUAAUAGGCUGGAGCCUCGGUGGCCUAGCUUCUUGCCCCUUGGGCC (SEQ ID NO: 175)UCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCGUGGUCUU UGAAUAAAGUCUGAGUGGGCGGC3′ UTR (miR122) UGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCC(SEQ ID NO: 207) UCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCAAACACCAUUGUCACACUCCAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC 3′ UTR (v1.1 miR122) AGAUAAUAGGCUGGAGCCUCGGUGGCCUAGCUUCUUGCCCCUUGGGCC (SEQ ID NO: 208)UCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCAAACACCAUUGUCACACUCCAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC 3′ UTR (v1.1 mir142- UGAUAAUAGGCUGGAGCCUCGGUGGCCUAGCUUCUUGCCCCUUGGGCC 3P)UCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCUCCAUAAA (SEQ ID NO: 4)GUAGGAAACACUACAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC 3′ UTR (v1.1 mir 126-UGAUAAUAGGCUGGAGCCUCGGUGGCCUAGCUUCUUGCCCCUUGGGCC 3P)UCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCGCAUUAU (SEQ ID NO:177)UACUCACGGUACGAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC 3′ UTR (mir-126,UGAUAAUAGUCCAUAAAGUAGGAAACACUACAGCUGGAGCCUCGGUGG miR-142-3p)CCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCC (SEQ ID NO: 111)UGCACCCGUACCCCCCGCAUUAUUACUCACGGUACGAGUGGUCUUUGA AUAAAGUCUGAGUGGGCGGC3′ UTR (v.1.1 3x UGAUAAUAGUCCAUAAAGUAGGAAACACUACAGCUGGAGCCUCGGUGGmiR142-3p) CCUAGCUUCUUGCCCCUUGGGCCUCCAUAAAGUAGGAAACACUACAUC(SEQ ID NO: 178) CCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCUCCAUAAAGUAGGAAACACUACAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC

In one embodiment, the polynucleotide of the invention comprises a 5′UTR, a codon optimized open reading frame encoding a polypeptide ofinterest, a 3′ UTR comprising the at least one miRNA binding site for amiR expressed in immune cells, and a 3′ tailing region of linkednucleosides. In various embodiments, the 3′ UTR comprises 1-4, at leasttwo, one, two, three or four miRNA binding sites for miRs expressed inimmune cells, preferably abundantly or preferentially expressed inimmune cells.

In one embodiment, the at least one miRNA expressed in immune cells is amiR-142-3p microRNA binding site. In one embodiment, the miR-142-3pmicroRNA binding site comprises the sequence shown in SEQ ID NO: 116. Inone embodiment, the 3′ UTR of the mRNA comprising the miR-142-3pmicroRNA binding site comprises the sequence shown in SEQ ID NO: 134.

In one embodiment, the at least one miRNA expressed in immune cells is amiR-126 microRNA binding site. In one embodiment, the miR-126 bindingsite is a miR-126-3p binding site. In one embodiment, the miR-126-3pmicroRNA binding site comprises the sequence shown in SEQ ID NO: 121. Inone embodiment, the 3′ UTR of the mRNA of the invention comprising themiR-126-3p microRNA binding site comprises the sequence shown in SEQ IDNO: 149.

Non-limiting exemplary sequences for miRs to which a microRNA bindingsite(s) of the disclosure can bind include the following: miR-142-3p(SEQ ID NO: 115), miR-142-5p (SEQ ID NO: 117), miR-146-3p (SEQ ID NO:135), miR-146-5p (SEQ ID NO: 136), miR-155-3p (SEQ ID NO: 137),miR-155-5p (SEQ ID NO: 138), miR-126-3p (SEQ ID NO: 120), miR-126-5p(SEQ ID NO: 122), miR-16-3p (SEQ ID NO: 139), miR-16-5p (SEQ ID NO:140), miR-21-3p (SEQ ID NO: 141), miR-21-5p (SEQ ID NO: 142), miR-223-3p(SEQ ID NO: 143), miR-223-5p (SEQ ID NO: 144), miR-24-3p (SEQ ID NO:145), miR-24-5p (SEQ ID NO: 146), miR-27-3p (SEQ ID NO: 147) andmiR-27-5p (SEQ ID NO: 148). Other suitable miR sequences expressed inimmune cells (e.g., abundantly or preferentially expressed in immunecells) are known and available in the art, for example at the Universityof Manchester's microRNA database, miRBase. Sites that bind any of theaforementioned miRs can be designed based on Watson-Crickcomplementarity to the miR, typically 100% complementarity to the miR,and inserted into an mRNA construct of the disclosure as describedherein.

In another embodiment, a polynucleotide of the present invention (e.g.,and mRNA, e.g., the 3′ UTR thereof) can comprise at least one miRNAbinding site to thereby reduce or inhibit accelerated blood clearance,for example by reducing or inhibiting production of IgMs, e.g., againstPEG, by B cells and/or reducing or inhibiting proliferation and/oractivation of pDCs, and can comprise at least one miRNA binding site formodulating tissue expression of an encoded protein of interest.

miRNA gene regulation can be influenced by the sequence surrounding themiRNA such as, but not limited to, the species of the surroundingsequence, the type of sequence (e.g., heterologous, homologous,exogenous, endogenous, or artificial), regulatory elements in thesurrounding sequence and/or structural elements in the surroundingsequence. The miRNA can be influenced by the 5′UTR and/or 3′UTR. As anon-limiting example, a non-human 3′UTR can increase the regulatoryeffect of the miRNA sequence on the expression of a polypeptide ofinterest compared to a human 3′ UTR of the same sequence type.

In one embodiment, other regulatory elements and/or structural elementsof the 5′ UTR can influence miRNA mediated gene regulation. One exampleof a regulatory element and/or structural element is a structured IRES(Internal Ribosome Entry Site) in the 5′ UTR, which is necessary for thebinding of translational elongation factors to initiate proteintranslation. EIF4A2 binding to this secondarily structured element inthe 5′-UTR is necessary for miRNA mediated gene expression (Meijer H Aet al., Science, 2013, 340, 82-85, herein incorporated by reference inits entirety). The polynucleotides of the invention can further includethis structured 5′ UTR in order to enhance microRNA mediated generegulation.

At least one miRNA binding site can be engineered into the 3′ UTR of apolynucleotide of the invention. In this context, at least two, at leastthree, at least four, at least five, at least six, at least seven, atleast eight, at least nine, at least ten, or more miRNA binding sitescan be engineered into a 3′ UTR of a polynucleotide of the invention.For example, 1 to 10, 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1to 3, 2, or 1 miRNA binding sites can be engineered into the 3′UTR of apolynucleotide of the invention. In one embodiment, miRNA binding sitesincorporated into a polynucleotide of the invention can be the same orcan be different miRNA sites. A combination of different miRNA bindingsites incorporated into a polynucleotide of the invention can includecombinations in which more than one copy of any of the different miRNAsites are incorporated. In another embodiment, miRNA binding sitesincorporated into a polynucleotide of the invention can target the sameor different tissues in the body. As a non-limiting example, through theintroduction of tissue-, cell-type-, or disease-specific miRNA bindingsites in the 3′-UTR of a polynucleotide of the invention, the degree ofexpression in specific cell types (e.g., myeloid cells, endothelialcells, etc.) can be reduced.

In one embodiment, a miRNA binding site can be engineered near the 5′terminus of the 3′UTR, about halfway between the 5′ terminus and 3′terminus of the 3′UTR and/or near the 3′ terminus of the 3′ UTR in apolynucleotide of the invention. As a non-limiting example, a miRNAbinding site can be engineered near the 5′ terminus of the 3′UTR andabout halfway between the 5′ terminus and 3′ terminus of the 3′UTR. Asanother non-limiting example, a miRNA binding site can be engineerednear the 3′ terminus of the 3′UTR and about halfway between the 5′terminus and 3′ terminus of the 3′ UTR. As yet another non-limitingexample, a miRNA binding site can be engineered near the 5′ terminus ofthe 3′ UTR and near the 3′ terminus of the 3′ UTR.

In another embodiment, a 3′UTR can comprise 1, 2, 3, 4, 5, 6, 7, 8, 9,or 10 miRNA binding sites. The miRNA binding sites can be complementaryto a miRNA, miRNA seed sequence, and/or miRNA sequences flanking theseed sequence.

In some embodiments, the expression of a polynucleotide of the inventioncan be controlled by incorporating at least one sensor sequence in thepolynucleotide and formulating the polynucleotide for administration. Asa non-limiting example, a polynucleotide of the invention can betargeted to a tissue or cell by incorporating a miRNA binding site andformulating the polynucleotide in a lipid nanoparticle comprising aionizable lipid, including any of the lipids described herein.

A polynucleotide of the invention can be engineered for more targetedexpression in specific tissues, cell types, or biological conditionsbased on the expression patterns of miRNAs in the different tissues,cell types, or biological conditions. Through introduction oftissue-specific miRNA binding sites, a polynucleotide of the inventioncan be designed for optimal protein expression in a tissue or cell, orin the context of a biological condition.

In some embodiments, a polynucleotide of the invention can be designedto incorporate miRNA binding sites that either have 100% identity toknown miRNA seed sequences or have less than 100% identity to miRNA seedsequences. In some embodiments, a polynucleotide of the invention can bedesigned to incorporate miRNA binding sites that have at least: 60%,65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity toknown miRNA seed sequences. The miRNA seed sequence can be partiallymutated to decrease miRNA binding affinity and as such result in reduceddownmodulation of the polynucleotide. In essence, the degree of match ormis-match between the miRNA binding site and the miRNA seed can act as arheostat to more finely tune the ability of the miRNA to modulateprotein expression. In addition, mutation in the non-seed region of amiRNA binding site can also impact the ability of a miRNA to modulateprotein expression.

In one embodiment, a miRNA sequence can be incorporated into the loop ofa stem loop.

In another embodiment, a miRNA seed sequence can be incorporated in theloop of a stem loop and a miRNA binding site can be incorporated intothe 5′ or 3′ stem of the stem loop.

In one embodiment the miRNA sequence in the 5′ UTR can be used tostabilize a polynucleotide of the invention described herein.

In another embodiment, a miRNA sequence in the 5′ UTR of apolynucleotide of the invention can be used to decrease theaccessibility of the site of translation initiation such as, but notlimited to a start codon. See, e.g., Matsuda et al., PLoS One. 201011(5):e15057; incorporated herein by reference in its entirety, whichused antisense locked nucleic acid (LNA) oligonucleotides andexon-junction complexes (EJCs) around a start codon (−4 to +37 where theA of the AUG codons is +1) in order to decrease the accessibility to thefirst start codon (AUG). Matsuda showed that altering the sequencearound the start codon with an LNA or EJC affected the efficiency,length and structural stability of a polynucleotide. A polynucleotide ofthe invention can comprise a miRNA sequence, instead of the LNA or EJCsequence described by Matsuda et al, near the site of translationinitiation in order to decrease the accessibility to the site oftranslation initiation. The site of translation initiation can be priorto, after or within the miRNA sequence. As a non-limiting example, thesite of translation initiation can be located within a miRNA sequencesuch as a seed sequence or binding site.

In some embodiments, a polynucleotide of the invention can include atleast one miRNA in order to dampen the antigen presentation by antigenpresenting cells. The miRNA can be the complete miRNA sequence, themiRNA seed sequence, the miRNA sequence without the seed, or acombination thereof. As a non-limiting example, a miRNA incorporatedinto a polynucleotide of the invention can be specific to thehematopoietic system. As another non-limiting example, a miRNAincorporated into a polynucleotide of the invention to dampen antigenpresentation is miR-142-3p.

In some embodiments, a polynucleotide of the invention can include atleast one miRNA in order to dampen expression of the encoded polypeptidein a tissue or cell of interest. As a non-limiting example apolynucleotide of the invention can include at least one miR-142-3pbinding site, miR-142-3p seed sequence, miR-142-3p binding site withoutthe seed, miR-142-5p binding site, miR-142-5p seed sequence, miR-142-5pbinding site without the seed, miR-146 binding site, miR-146 seedsequence and/or miR-146 binding site without the seed sequence.

In some embodiments, a polynucleotide of the invention can comprise atleast one miRNA binding site in the 3′UTR in order to selectivelydegrade mRNA therapeutics in the immune cells to subdue unwantedimmunogenic reactions caused by therapeutic delivery. As a non-limitingexample, the miRNA binding site can make a polynucleotide of theinvention more unstable in antigen presenting cells. Non-limitingexamples of these miRNAs include miR-142-5p, miR-142-3p, miR-146a-5p,and miR-146-3p.

In one embodiment, a polynucleotide of the invention comprises at leastone miRNA sequence in a region of the polynucleotide that can interactwith a RNA binding protein.

In some embodiments, the polynucleotide of the invention (e.g., a RNA,e.g., an mRNA) comprising (i) a sequence-optimized nucleotide sequence(e.g., an ORF) encoding a PCCA or PCCB polypeptide (e.g., the wild-typesequence, functional fragment, or variant thereof) and (ii) a miRNAbinding site (e.g., a miRNA binding site that binds to miR-142) and/or amiRNA binding site that binds to miR-126.

12. 3′ UTRs

In certain embodiments, a polynucleotide of the present invention (e.g.,a polynucleotide comprising a nucleotide sequence encoding a PCCA orPCCB polypeptide of the invention) further comprises a 3′ UTR.

3′-UTR is the section of mRNA that immediately follows the translationtermination codon and often contains regulatory regions thatpost-transcriptionally influence gene expression. Regulatory regionswithin the 3′-UTR can influence polyadenylation, translation efficiency,localization, and stability of the mRNA. In one embodiment, the 3′-UTRuseful for the invention comprises a binding site for regulatoryproteins or microRNAs.

In certain embodiments, the 3′ UTR useful for the polynucleotides of theinvention comprises a 3′ UTR selected from the group consisting of SEQID NO: 4, 104 to 113, and 178, or any combination thereof. In someembodiments, the 3′ UTR comprises a nucleic acid sequence selected fromthe group consisting of SEQ ID NOs: 111, 112, or 113 or any combinationthereof. In certain embodiments, the 3′ UTR comprises a 3′ UTR selectedfrom the group consisting of SEQ ID NO:4, SEQ ID NO:111, SEQ ID NO:150,SEQ ID NO:175, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:207, or SEQ IDNO:208, or any combination thereof. In some embodiments, the 3′ UTRcomprises a nucleic acid sequence of SEQ ID NO: 111. In someembodiments, the 3′ UTR comprises a nucleic acid sequence of SEQ ID NO:112. In some embodiments, the 3′ UTR comprises a nucleic acid sequencesof SEQ ID NO: 113. In some embodiments, the 3′ UTR comprises a nucleicacid sequence of SEQ ID NO: 150. In some embodiments, the 3′ UTRcomprises a nucleic acid sequence of SEQ ID NO: 175. In someembodiments, the 3′ UTR comprises a nucleic acid sequences of SEQ ID NO:207. In some embodiments, the 3′ UTR comprises a nucleic acid sequenceof SEQ ID NO: 208. In some embodiments, the 3′ UTR comprises a nucleicacid sequence of SEQ ID NO: 4. In some embodiments, the 3′ UTR comprisesa nucleic acid sequences of SEQ ID NO: 177. In some embodiments, the 3′UTR comprises a nucleic acid sequence of SEQ ID NO: 178.

In certain embodiments, the 3′ UTR sequence useful for the inventioncomprises a nucleotide sequence at least about 60%, at least about 70%,at least about 80%, at least about 90%, at least about 95%, at leastabout 96%, at least about 97%, at least about 98%, at least about 99%,or about 100% identical to a sequence selected from the group consistingof 3′ UTR sequences selected from the group consisting of SEQ ID NOs: 4,104 to 113, and 178, or any combination thereof.

In certain embodiments, the 3′ UTR sequence useful for the inventioncomprises a nucleotide sequence at least about 60%, at least about 70%,at least about 80%, at least about 90%, at least about 95%, at leastabout 96%, at least about 97%, at least about 98%, at least about 99%,or about 100% identical to a sequence selected from the group consistingof 3′ UTR sequences selected from the group consisting of SEQ ID NO:4,SEQ ID NO:111, SEQ ID NO:150, SEQ ID NO:175, SEQ ID NO:177, SEQ IDNO:178, SEQ ID NO:207, or SEQ ID NO:208, or any combination thereof.

13. Regions Having a 5′ Cap

The disclosure also includes a polynucleotide that comprises both a 5′Cap and a polynucleotide of the present invention (e.g., apolynucleotide comprising a nucleotide sequence encoding a PCCA or PCCBpolypeptide).

The 5′ cap structure of a natural mRNA is involved in nuclear export,increasing mRNA stability and binds the mRNA Cap Binding Protein (CBP),which is responsible for mRNA stability in the cell and translationcompetency through the association of CBP with poly(A) binding proteinto form the mature cyclic mRNA species. The cap further assists theremoval of 5′ proximal introns during mRNA splicing.

Endogenous mRNA molecules can be 5′-end capped generating a5′-ppp-5′-triphosphate linkage between a terminal guanosine cap residueand the 5′-terminal transcribed sense nucleotide of the mRNA molecule.This 5′-guanylate cap can then be methylated to generate anN7-methyl-guanylate residue. The ribose sugars of the terminal and/oranteterminal transcribed nucleotides of the 5′ end of the mRNA canoptionally also be 2′-O-methylated. 5′-decapping through hydrolysis andcleavage of the guanylate cap structure can target a nucleic acidmolecule, such as an mRNA molecule, for degradation.

In some embodiments, the polynucleotides of the present invention (e.g.,a polynucleotide comprising a nucleotide sequence encoding a PCCA orPCCB polypeptide) incorporate a cap moiety.

In some embodiments, polynucleotides of the present invention (e.g., apolynucleotide comprising a nucleotide sequence encoding a PCCA or PCCBpolypeptide) comprise a non-hydrolyzable cap structure preventingdecapping and thus increasing mRNA half-life. Because cap structurehydrolysis requires cleavage of 5′-ppp-5′ phosphorodiester linkages,modified nucleotides can be used during the capping reaction. Forexample, a Vaccinia Capping Enzyme from New England Biolabs (Ipswich,Mass.) can be used with u-thio-guanosine nucleotides according to themanufacturer's instructions to create a phosphorothioate linkage in the5′-ppp-5′ cap. Additional modified guanosine nucleotides can be usedsuch as a-methyl-phosphonate and seleno-phosphate nucleotides.

Additional modifications include, but are not limited to,2′-O-methylation of the ribose sugars of 5′-terminal and/or5′-anteterminal nucleotides of the polynucleotide (as mentioned above)on the 2′-hydroxyl group of the sugar ring. Multiple distinct 5′-capstructures can be used to generate the 5′-cap of a nucleic acidmolecule, such as a polynucleotide that functions as an mRNA molecule.Cap analogs, which herein are also referred to as synthetic cap analogs,chemical caps, chemical cap analogs, or structural or functional capanalogs, differ from natural (i.e., endogenous, wild-type orphysiological) 5′-caps in their chemical structure, while retaining capfunction. Cap analogs can be chemically (i.e., non-enzymatically) orenzymatically synthesized and/or linked to the polynucleotides of theinvention.

For example, the Anti-Reverse Cap Analog (ARCA) cap contains twoguanines linked by a 5′-5′-triphosphate group, wherein one guaninecontains an N7 methyl group as well as a 3′-O-methyl group (i.e.,N7,3′-O-dimethyl-guanosine-5′-triphosphate-5′-guanosine (m7G-3′mppp-G;which can equivalently be designated 3′ O-Me-m7G(5′)ppp(5′)G). The 3′-0atom of the other, unmodified, guanine becomes linked to the 5′-terminalnucleotide of the capped polynucleotide. The N7- and 3′-O-methylatedguanine provides the terminal moiety of the capped polynucleotide.

Another exemplary cap is mCAP, which is similar to ARCA but has a2′-O-methyl group on guanosine (i.e.,N7,2′-O-dimethyl-guanosine-5′-triphosphate-5′-guanosine, m⁷Gm-ppp-G).

In some embodiments, the cap is a dinucleotide cap analog. As anon-limiting example, the dinucleotide cap analog can be modified atdifferent phosphate positions with a boranophosphate group or aphosphoroselenoate group such as the dinucleotide cap analogs describedin U.S. Pat. No. 8,519,110, the contents of which are hereinincorporated by reference in its entirety.

In another embodiment, the cap is a cap analog is aN7-(4-chlorophenoxyethyl) substituted dinucleotide form of a cap analogknown in the art and/or described herein. Non-limiting examples of aN7-(4-chlorophenoxyethyl) substituted dinucleotide form of a cap analoginclude a N7-(4-chlorophenoxyethyl)-G(5′)ppp(5′)G and aN7-(4-chlorophenoxyethyl)-m^(3′-O)G(5′)ppp(5′)G cap analog (See, e.g.,the various cap analogs and the methods of synthesizing cap analogsdescribed in Kore et al. Bioorganic & Medicinal Chemistry 201321:4570-4574; the contents of which are herein incorporated by referencein its entirety). In another embodiment, a cap analog of the presentinvention is a 4-chloro/bromophenoxyethyl analog.

While cap analogs allow for the concomitant capping of a polynucleotideor a region thereof, in an in vitro transcription reaction, up to 20% oftranscripts can remain uncapped. This, as well as the structuraldifferences of a cap analog from an endogenous 5′-cap structures ofnucleic acids produced by the endogenous, cellular transcriptionmachinery, can lead to reduced translational competency and reducedcellular stability.

Polynucleotides of the invention (e.g., a polynucleotide comprising anucleotide sequence encoding a PCCA or PCCB polypeptide) can also becapped post-manufacture (whether IVT or chemical synthesis), usingenzymes, in order to generate more authentic 5′-cap structures. As usedherein, the phrase “more authentic” refers to a feature that closelymirrors or mimics, either structurally or functionally, an endogenous orwild type feature. That is, a “more authentic” feature is betterrepresentative of an endogenous, wild-type, natural or physiologicalcellular function and/or structure as compared to synthetic features oranalogs, etc., of the prior art, or which outperforms the correspondingendogenous, wild-type, natural or physiological feature in one or morerespects. Non-limiting examples of more authentic 5′cap structures ofthe present invention are those that, among other things, have enhancedbinding of cap binding proteins, increased half-life, reducedsusceptibility to 5′ endonucleases and/or reduced 5′decapping, ascompared to synthetic 5′cap structures known in the art (or to awild-type, natural or physiological 5′cap structure). For example,recombinant Vaccinia Virus Capping Enzyme and recombinant2′-O-methyltransferase enzyme can create a canonical 5′-5′-triphosphatelinkage between the 5′-terminal nucleotide of a polynucleotide and aguanine cap nucleotide wherein the cap guanine contains an N7methylation and the 5′-terminal nucleotide of the mRNA contains a2′-O-methyl. Such a structure is termed the Cap1 structure. This capresults in a higher translational-competency and cellular stability anda reduced activation of cellular pro-inflammatory cytokines, ascompared, e.g., to other 5′cap analog structures known in the art. Capstructures include, but are not limited to, 7mG(5′)ppp(5′)N, pN2p (cap0), 7mG(5′)ppp(5′)NlmpNp (cap 1), and 7mG(5′)-ppp(5′)NlmpN2mp (cap 2).

As a non-limiting example, capping chimeric polynucleotidespost-manufacture can be more efficient as nearly 100% of the chimericpolynucleotides can be capped. This is in contrast to ˜80% when a capanalog is linked to a chimeric polynucleotide in the course of an invitro transcription reaction.

According to the present invention, 5′ terminal caps can includeendogenous caps or cap analogs. According to the present invention, a 5′terminal cap can comprise a guanine analog. Useful guanine analogsinclude, but are not limited to, inosine, N1-methyl-guanosine,2′fluoro-guanosine, 7-deaza-guanosine, 8-oxo-guanosine,2-amino-guanosine, LNA-guanosine, and 2-azido-guanosine.

14. Poly-A Tails

In some embodiments, the polynucleotides of the present disclosure(e.g., a polynucleotide comprising a nucleotide sequence encoding a PCCAor PCCB polypeptide) further comprise a poly-A tail. In furtherembodiments, terminal groups on the poly-A tail can be incorporated forstabilization. In other embodiments, a poly-A tail comprises des-3′hydroxyl tails.

During RNA processing, a long chain of adenine nucleotides (poly-A tail)can be added to a polynucleotide such as an mRNA molecule in order toincrease stability. Immediately after transcription, the 3′ end of thetranscript can be cleaved to free a 3′ hydroxyl. Then poly-A polymeraseadds a chain of adenine nucleotides to the RNA. The process, calledpolyadenylation, adds a poly-A tail that can be between, for example,approximately 80 to approximately 250 residues long, includingapproximately 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190,200, 210, 220, 230, 240 or 250 residues long. In one embodiment, thepoly-A tail is 100 nucleotides in length.

PolyA tails can also be added after the construct is exported from thenucleus.

According to the present invention, terminal groups on the poly A tailcan be incorporated for stabilization. Polynucleotides of the presentinvention can include des-3′ hydroxyl tails. They can also includestructural moieties or 2′-Omethyl modifications as taught by Junjie Li,et al. (Current Biology, Vol. 15, 1501-1507, Aug. 23, 2005, the contentsof which are incorporated herein by reference in its entirety).

The polynucleotides of the present invention can be designed to encodetranscripts with alternative polyA tail structures including histonemRNA. According to Norbury, “Terminal uridylation has also been detectedon human replication-dependent histone mRNAs. The turnover of thesemRNAs is thought to be important for the prevention of potentially toxichistone accumulation following the completion or inhibition ofchromosomal DNA replication. These mRNAs are distinguished by their lackof a 3′ poly(A) tail, the function of which is instead assumed by astable stem-loop structure and its cognate stem-loop binding protein(SLBP); the latter carries out the same functions as those of PABP onpolyadenylated mRNAs” (Norbury, “Cytoplasmic RNA: a case of the tailwagging the dog,” Nature Reviews Molecular Cell Biology; AOP, publishedonline 29 Aug. 2013; doi:10.1038/nrm3645) the contents of which areincorporated herein by reference in its entirety.

Unique poly-A tail lengths provide certain advantages to thepolynucleotides of the present invention. Generally, the length of apoly-A tail, when present, is greater than 30 nucleotides in length. Inanother embodiment, the poly-A tail is greater than 35 nucleotides inlength (e.g., at least or greater than about 35, 40, 45, 50, 55, 60, 70,80, 90, 100, 120, 140, 160, 180, 200, 250, 300, 350, 400, 450, 500, 600,700, 800, 900, 1,000, 1,100, 1,200, 1,300, 1,400, 1,500, 1,600, 1,700,1,800, 1,900, 2,000, 2,500, and 3,000 nucleotides).

In some embodiments, the polynucleotide or region thereof includes fromabout 30 to about 3,000 nucleotides (e.g., from 30 to 50, from 30 to100, from 30 to 250, from 30 to 500, from 30 to 750, from 30 to 1,000,from 30 to 1,500, from 30 to 2,000, from 30 to 2,500, from 50 to 100,from 50 to 250, from 50 to 500, from 50 to 750, from 50 to 1,000, from50 to 1,500, from 50 to 2,000, from 50 to 2,500, from 50 to 3,000, from100 to 500, from 100 to 750, from 100 to 1,000, from 100 to 1,500, from100 to 2,000, from 100 to 2,500, from 100 to 3,000, from 500 to 750,from 500 to 1,000, from 500 to 1,500, from 500 to 2,000, from 500 to2,500, from 500 to 3,000, from 1,000 to 1,500, from 1,000 to 2,000, from1,000 to 2,500, from 1,000 to 3,000, from 1,500 to 2,000, from 1,500 to2,500, from 1,500 to 3,000, from 2,000 to 3,000, from 2,000 to 2,500,and from 2,500 to 3,000).

In some embodiments, the poly-A tail is designed relative to the lengthof the overall polynucleotide or the length of a particular region ofthe polynucleotide. This design can be based on the length of a codingregion, the length of a particular feature or region or based on thelength of the ultimate product expressed from the polynucleotides.

In this context, the poly-A tail can be 10, 20, 30, 40, 50, 60, 70, 80,90, or 100% greater in length than the polynucleotide or featurethereof. The poly-A tail can also be designed as a fraction of thepolynucleotides to which it belongs. In this context, the poly-A tailcan be 10, 20, 30, 40, 50, 60, 70, 80, or 90% or more of the totallength of the construct, a construct region or the total length of theconstruct minus the poly-A tail. Further, engineered binding sites andconjugation of polynucleotides for Poly-A binding protein can enhanceexpression.

Additionally, multiple distinct polynucleotides can be linked togethervia the PABP (Poly-A binding protein) through the 3′-end using modifiednucleotides at the 3′-terminus of the poly-A tail. Transfectionexperiments can be conducted in relevant cell lines at and proteinproduction can be assayed by ELISA at 12 hr, 24 hr, 48 hr, 72 hr and day7 post-transfection.

In some embodiments, the polynucleotides of the present invention aredesigned to include a polyA-G Quartet region. The G-quartet is a cyclichydrogen bonded array of four guanine nucleotides that can be formed byG-rich sequences in both DNA and RNA. In this embodiment, the G-quartetis incorporated at the end of the poly-A tail. The resultantpolynucleotide is assayed for stability, protein production and otherparameters including half-life at various time points. It has beendiscovered that the polyA-G quartet results in protein production froman mRNA equivalent to at least 75% of that seen using a poly-A tail of120 nucleotides alone.

15. Start Codon Region

The invention also includes a polynucleotide that comprises both a startcodon region and the polynucleotide described herein (e.g., apolynucleotide comprising a nucleotide sequence encoding a PCCA or PCCBpolypeptide). In some embodiments, the polynucleotides of the presentinvention can have regions that are analogous to or function like astart codon region.

In some embodiments, the translation of a polynucleotide can initiate ona codon that is not the start codon AUG. Translation of thepolynucleotide can initiate on an alternative start codon such as, butnot limited to, ACG, AGG, AAG, CTG/CUG, GTG/GUG, ATA/AUA, ATT/AUU,TTG/UUG (see Touriol et al. Biology of the Cell 95 (2003) 169-178 andMatsuda and Mauro PLoS ONE, 2010 5:11; the contents of each of which areherein incorporated by reference in its entirety).

As a non-limiting example, the translation of a polynucleotide begins onthe alternative start codon ACG. As another non-limiting example,polynucleotide translation begins on the alternative start codon CTG orCUG. As yet another non-limiting example, the translation of apolynucleotide begins on the alternative start codon GTG or GUG.

Nucleotides flanking a codon that initiates translation such as, but notlimited to, a start codon or an alternative start codon, are known toaffect the translation efficiency, the length and/or the structure ofthe polynucleotide. (See, e.g., Matsuda and Mauro PLoS ONE, 2010 5:11;the contents of which are herein incorporated by reference in itsentirety). Masking any of the nucleotides flanking a codon thatinitiates translation can be used to alter the position of translationinitiation, translation efficiency, length and/or structure of apolynucleotide.

In some embodiments, a masking agent can be used near the start codon oralternative start codon in order to mask or hide the codon to reduce theprobability of translation initiation at the masked start codon oralternative start codon. Non-limiting examples of masking agents includeantisense locked nucleic acids (LNA) polynucleotides and exon-junctioncomplexes (EJCs) (See, e.g., Matsuda and Mauro describing masking agentsLNA polynucleotides and EJCs (PLoS ONE, 2010 5:11); the contents ofwhich are herein incorporated by reference in its entirety).

In another embodiment, a masking agent can be used to mask a start codonof a polynucleotide in order to increase the likelihood that translationwill initiate on an alternative start codon. In some embodiments, amasking agent can be used to mask a first start codon or alternativestart codon in order to increase the chance that translation willinitiate on a start codon or alternative start codon downstream to themasked start codon or alternative start codon.

In some embodiments, a start codon or alternative start codon can belocated within a perfect complement for a miRNA binding site. Theperfect complement of a miRNA binding site can help control thetranslation, length and/or structure of the polynucleotide similar to amasking agent. As a non-limiting example, the start codon or alternativestart codon can be located in the middle of a perfect complement for amiRNA binding site. The start codon or alternative start codon can belocated after the first nucleotide, second nucleotide, third nucleotide,fourth nucleotide, fifth nucleotide, sixth nucleotide, seventhnucleotide, eighth nucleotide, ninth nucleotide, tenth nucleotide,eleventh nucleotide, twelfth nucleotide, thirteenth nucleotide,fourteenth nucleotide, fifteenth nucleotide, sixteenth nucleotide,seventeenth nucleotide, eighteenth nucleotide, nineteenth nucleotide,twentieth nucleotide or twenty-first nucleotide.

In another embodiment, the start codon of a polynucleotide can beremoved from the polynucleotide sequence in order to have thetranslation of the polynucleotide begin on a codon that is not the startcodon. Translation of the polynucleotide can begin on the codonfollowing the removed start codon or on a downstream start codon or analternative start codon. In a non-limiting example, the start codon ATGor AUG is removed as the first 3 nucleotides of the polynucleotidesequence in order to have translation initiate on a downstream startcodon or alternative start codon. The polynucleotide sequence where thestart codon was removed can further comprise at least one masking agentfor the downstream start codon and/or alternative start codons in orderto control or attempt to control the initiation of translation, thelength of the polynucleotide and/or the structure of the polynucleotide.

16. Stop Codon Region

The invention also includes a polynucleotide that comprises both a stopcodon region and the polynucleotide described herein (e.g., apolynucleotide comprising a nucleotide sequence encoding a PCCA or PCCBpolypeptide). In some embodiments, the polynucleotides of the presentinvention can include at least two stop codons before the 3′untranslated region (UTR). The stop codon can be selected from TGA, TAAand TAG in the case of DNA, or from UGA, UAA and UAG in the case of RNA.In some embodiments, the polynucleotides of the present inventioninclude the stop codon TGA in the case or DNA, or the stop codon UGA inthe case of RNA, and one additional stop codon. In a further embodimentthe addition stop codon can be TAA or UAA. In another embodiment, thepolynucleotides of the present invention include three consecutive stopcodons, four stop codons, or more.

17. Polynucleotide Comprising an mRNA Encoding a PCCA or PCCBPolypeptide

In certain embodiments, a polynucleotide of the present disclosure, forexample a polynucleotide comprising an mRNA nucleotide sequence encodinga PCCA or PCCB polypeptide, comprises from 5′ to 3′ end:

-   -   (i) a 5′ cap provided above;    -   (ii) a 5′ UTR, such as the sequences provided above;    -   (iii) an open reading frame encoding a PCCA or PCCB polypeptide,        e.g., a sequence optimized nucleic acid sequence encoding a PCCA        or PCCB disclosed herein;    -   (iv) at least one stop codon;    -   (v) a 3′ UTR, such as the sequences provided above; and    -   (vi) a poly-A tail provided above.

In some embodiments, the polynucleotide further comprises a miRNAbinding site, e.g., a miRNA binding site that binds to miRNA-142. Insome embodiments, the 5′ UTR comprises the miRNA binding site. In someembodiments, the 3′ UTR comprises the miRNA binding site.

In some embodiments, a polynucleotide of the present disclosurecomprises a nucleotide sequence encoding a polypeptide sequence at least70%, at least 80%, at least 81%, at least 82%, at least 83%, at least84%, at least 85%, at least 86%, at least 87%, at least 88%, at least89%, at least 90%, at least 91%, at least 92%, at least 93%, at least94%, at least 95%, at least 96%, at least 97%, at least 98%, at least99%, or 100% identical to the protein sequence of a wild type human PCCA(SEQ ID NO:1) or wild type human PCCB (SEQ ID NO:15).

In some embodiments, a polynucleotide of the present disclosure, forexample a polynucleotide comprising an mRNA nucleotide sequence encodinga polypeptide, comprises (1) a 5′ cap provided above, for example, CAP1,(2) a 5′ UTR, (3) a nucleotide sequence ORF selected from the groupconsisting of SEQ ID NOs: 2, 5-14, 16-27, 196, 197, and 198, (3) a stopcodon, (4) a 3′UTR, and (5) a poly-A tail provided above, for example, apoly-A tail of about 100 residues.

Exemplary PCCA nucleotide constructs are described below:

SEQ ID NO: 28 consists from 5′ to 3′ end: 5′ UTR of SEQ ID NO: 3, PCCAnucleotide ORF of SEQ ID NO: 2, and 3′ UTR of SEQ ID NO: 4.

SEQ ID NO: 29 consists from 5′ to 3′ end: 5′ UTR of SEQ ID NO: 3, PCCAnucleotide ORF of SEQ ID NO: 5, and 3′ UTR of SEQ ID NO: 4.

SEQ ID NO: 30 consists from 5′ to 3′ end: 5′ UTR of SEQ ID NO: 3, PCCAnucleotide ORF of SEQ ID NO: 6, and 3′ UTR of SEQ ID NO: 4.

SEQ ID NO: 31 consists from 5′ to 3′ end: 5′ UTR of SEQ ID NO: 3, PCCAnucleotide ORF of SEQ ID NO: 7, and 3′ UTR of SEQ ID NO: 4.

SEQ ID NO: 32 consists from 5′ to 3′ end: 5′ UTR of SEQ ID NO: 3, PCCAnucleotide ORF of SEQ ID NO: 8, and 3′ UTR of SEQ ID NO: 4.

SEQ ID NO: 33 consists from 5′ to 3′ end: 5′ UTR of SEQ ID NO: 3, PCCAnucleotide ORF of SEQ ID NO: 9, and 3′ UTR of SEQ ID NO: 4.

SEQ ID NO: 34 consists from 5′ to 3′ end: 5′ UTR of SEQ ID NO: 3, PCCAnucleotide ORF of SEQ ID NO: 10, and 3′ UTR of SEQ ID NO: 4.

SEQ ID NO: 35 consists from 5′ to 3′ end: 5′ UTR of SEQ ID NO: 3, PCCAnucleotide ORF of SEQ ID NO: 11, and 3′ UTR of SEQ ID NO: 4.

SEQ ID NO: 36 consists from 5′ to 3′ end: 5′ UTR of SEQ ID NO: 3, PCCAnucleotide ORF of SEQ ID NO: 12, and 3′ UTR of SEQ ID NO: 4.

SEQ ID NO: 37 consists from 5′ to 3′ end: 5′ UTR of SEQ ID NO: 3, PCCAnucleotide ORF of SEQ ID NO: 13, and 3′ UTR of SEQ ID NO: 4.

SEQ ID NO: 38 consists from 5′ to 3′ end: 5′ UTR of SEQ ID NO: 3, PCCAnucleotide ORF of SEQ ID NO: 14, and 3′ UTR of SEQ ID NO: 150.

SEQ ID NO: 63 consists from 5′ to 3′ end: 5′ UTR of SEQ ID NO: 3, PCCAnucleotide ORF of SEQ ID NO: 11, and 3′ UTR of SEQ ID NO: 178.

SEQ ID NO: 65 consists from 5′ to 3′ end: 5′ UTR of SEQ ID NO: 3, PCCAnucleotide ORF of SEQ ID NO: 11, and 3′ UTR of SEQ ID NO:112.

SEQ ID NO:203 consists from 5′ to 3′ end: 5′ UTR of SEQ ID NO: 199, PCCAnucleotide ORF of SEQ ID NO:11, and 3′ UTR of SEQ ID NO:178.

Exemplary PCCB nucleotide constructs are described below:

SEQ ID NO: 39 consists from 5′ to 3′ end: 5′ UTR of SEQ ID NO: 3, PCCBnucleotide ORF of SEQ ID NO: 16, and 3′ UTR of SEQ ID NO: 4.

SEQ ID NO: 40 consists from 5′ to 3′ end: 5′ UTR of SEQ ID NO: 3, PCCBnucleotide ORF of SEQ ID NO: 17, and 3′ UTR of SEQ ID NO: 4.

SEQ ID NO: 41 consists from 5′ to 3′ end: 5′ UTR of SEQ ID NO: 3, PCCBnucleotide ORF of SEQ ID NO: 18, and 3′ UTR of SEQ ID NO: 4.

SEQ ID NO: 42 consists from 5′ to 3′ end: 5′ UTR of SEQ ID NO: 3, PCCBnucleotide ORF of SEQ ID NO: 19, and 3′ UTR of SEQ ID NO: 4.

SEQ ID NO: 43 consists from 5′ to 3′ end: 5′ UTR of SEQ ID NO: 3, PCCBnucleotide ORF of SEQ ID NO: 20, and 3′ UTR of SEQ ID NO: 4.

SEQ ID NO: 44 consists from 5′ to 3′ end: 5′ UTR of SEQ ID NO: 3, PCCBnucleotide ORF of SEQ ID NO: 21, and 3′ UTR of SEQ ID NO: 4.

SEQ ID NO: 45 consists from 5′ to 3′ end: 5′ UTR of SEQ ID NO: 3, PCCBnucleotide ORF of SEQ ID NO: 22, and 3′ UTR of SEQ ID NO: 4.

SEQ ID NO: 46 consists from 5′ to 3′ end: 5′ UTR of SEQ ID NO: 3, PCCBnucleotide ORF of SEQ ID NO: 23, and 3′ UTR of SEQ ID NO: 4.

SEQ ID NO: 47 consists from 5′ to 3′ end: 5′ UTR of SEQ ID NO: 3, PCCBnucleotide ORF of SEQ ID NO: 24, and 3′ UTR of SEQ ID NO: 4.

SEQ ID NO: 48 consists from 5′ to 3′ end: 5′ UTR of SEQ ID NO: 3, PCCBnucleotide ORF of SEQ ID NO: 25, and 3′ UTR of SEQ ID NO: 4.

SEQ ID NO: 49 consists from 5′ to 3′ end: 5′ UTR of SEQ ID NO: 3, PCCBnucleotide ORF of SEQ ID NO: 26, and 3′ UTR of SEQ ID NO: 150.

SEQ ID NO: 50 consists from 5′ to 3′ end: 5′ UTR of SEQ ID NO: 3, PCCBnucleotide ORF of SEQ ID NO: 27, and 3′ UTR of SEQ ID NO: 150.

SEQ ID NO: 66 consists from 5′ to 3′ end: 5′ UTR of SEQ ID NO: 3, PCCBnucleotide ORF of SEQ ID NO: 23, and 3′ UTR of SEQ ID NO: 178.

SEQ ID NO: 67 consists from 5′ to 3′ end: 5′ UTR of SEQ ID NO: 64, PCCBnucleotide ORF of SEQ ID NO: 23, and 3′ UTR of SEQ ID NO:112.

SEQ ID NO:200 consists from 5′ to 3′ end: 5′ UTR of SEQ ID NO: 199, PCCBnucleotide ORF of SEQ ID NO:196, and 3′ UTR of SEQ ID NO:178.

SEQ ID NO:201 consists from 5′ to 3′ end: 5′ UTR of SEQ ID NO: 199, PCCBnucleotide ORF of SEQ ID NO:197, and 3′ UTR of SEQ ID NO:178.

SEQ ID NO:202 consists from 5′ to 3′ end: 5′ UTR of SEQ ID NO: 199, PCCBnucleotide ORF of SEQ ID NO:198, and 3′ UTR of SEQ ID NO: 178.

SEQ ID NO:204 consists from 5′ to 3′ end: 5′ UTR of SEQ ID NO: 199, PCCBnucleotide ORF of SEQ ID NO:23, and 3′ UTR of SEQ ID NO:178.

SEQ ID NO:205 consists from 5′ to 3′ end: 5′ UTR of SEQ ID NO:199, PCCBnucleotide ORF of SEQ ID NO:25, and 3′ UTR of SEQ ID NO:178.

In certain embodiments, in constructs with SEQ ID NOs.:28-50, 63, 65-67,and 200-205, all uracils therein are replaced by N1-methylpseudouracil.In certain embodiments, in constructs with SEQ ID NOs.: 28-50, 63,65-67, and 200-205, all uracils therein are replaced by 5-methoxyuracil.

In some embodiments, a polynucleotide of the present disclosure, forexample a polynucleotide comprising an mRNA nucleotide sequence encodinga PCCA or PCCB polypeptide, comprises (1) a 5′ cap provided above, forexample, CAP1, (2) a nucleotide sequence selected from the groupconsisting of SEQ ID NO: 28-50, 63, 65-67, and 200-205, and (3) a poly-Atail provided above, for example, a poly A tail of ˜100 residues.

TABLE 5 Modified mRNA constructs including ORFs encoding human PCCA orPCCB (each of constructs #1 to #33 comprises a Cap1 5′ terminal cap anda 3′ terminal PolyA region) 5′ UTR PCCA/PCCB ORF 3′ UTR PCCA/PCCB mRNASEQ Name SEQ SEQ construct ID NO (Chemistry) ID NO ID NO:  #1 (SEQ IDNO: 28) 3 PCCA 11 (G5) 2 4  #2 (SEQ ID NO: 29) 3 PCCA 12 (G5) 5 4  #3(SEQ ID NO: 30) 3 PCCA 13 (G5) 6 4  #4 (SEQ ID NO: 31) 3 PCCA 14 (G5) 74  #5 (SEQ ID NO: 32) 3 PCCA 15 (G5) 8 4  #6 (SEQ ID NO: 33) 3 PCCA 16(G5) 9 4  #7 (SEQ ID NO: 34) 3 PCCA 17 (G5) 10 4  #8 (SEQ ID NO: 35) 3PCCA 18 (G5) 11 4  #9 (SEQ ID NO: 36) 3 PCCA 19 (G5) 12 4 #10 (SEQ IDNO: 37) 3 PCCA 20 (G5) 13 4 #11 (SEQ ID NO: 38) 3 PCCA 01-014.2 14 150(G5) #12 (SEQ ID NO: 39) 3 PCCB 11 (G5) 16 4 #13 (SEQ ID NO: 40) 3 PCCB12 (G5) 17 4 #14 (SEQ ID NO: 41) 3 PCCB 13 (G5) 18 4 #15 (SEQ ID NO: 42)3 PCCB 14 (G5) 19 4 #16 (SEQ ID NO: 43) 3 PCCB 15 (G5) 20 4 #17 (SEQ IDNO: 44) 3 PCCB 16 (G5) 21 4 #18 (SEQ ID NO: 45) 3 PCCB 17 (G5) 22 4 #19(SEQ ID NO: 46) 3 PCCB 18 (G5) 23 4 #20 (SEQ ID NO: 47) 3 PCCB 19 (G5)24 4 #21 (SEQ ID NO: 48) 3 PCCB 20 (G5) 25 4 #22 (SEQ ID NO: 49) 3 PCCB01-014 26 150 (G5) #23 (SEQ ID NO: 63) 3 PCCA 21 (G5) 11 178 #24 (SEQ IDNO: 65) 3 PCCA 22 (G5) 11 112 #25 (SEQ ID NO: 66) 3 PCCB 21 (G5) 23 178#26 (SEQ ID NO: 67) 64 PCCB 22 (G5) 23 112 #27 (SEQ ID NO: 50) 3 PCCB 14(G5) 27 150 #28 (SEQ ID NO: 200) 199 SE_PCCB_026 196 178 (G5) #29 (SEQID NO:201) 199 SE_PCCB_027 197 178 (G5) #30 (SEQ ID NO: 202) 199SE_PCCB_028 198 178 (G5) #31 (SEQ ID NO: 203) 199 SE_PCCA_018 11 178(G5) #32 (SEQ ID NO: 204) 199 SE_PCCB_018 23 178 (G5) #33 (SEQ ID NO:205) 199 SE_PCCB_020 25 178

18. Methods of Making Polynucleotides

The present disclosure also provides methods for making a polynucleotideof the invention (e.g., a polynucleotide comprising a nucleotidesequence encoding a PCCA or PCCB polypeptide) or a complement thereof.

In some aspects, a polynucleotide (e.g., a RNA, e.g., an mRNA) disclosedherein, and encoding a PCCA or PCCB polypeptide, can be constructedusing in vitro transcription (IVT). In other aspects, a polynucleotide(e.g., a RNA, e.g., an mRNA) disclosed herein, and encoding a PCCA orPCCB polypeptide, can be constructed by chemical synthesis using anoligonucleotide synthesizer.

In other aspects, a polynucleotide (e.g., a RNA, e.g., an mRNA)disclosed herein, and encoding a PCCA or PCCB polypeptide is made byusing a host cell. In certain aspects, a polynucleotide (e.g., a RNA,e.g., an mRNA) disclosed herein, and encoding a PCCA or PCCB polypeptideis made by one or more combination of the IVT, chemical synthesis, hostcell expression, or any other methods known in the art.

Naturally occurring nucleosides, non-naturally occurring nucleosides, orcombinations thereof, can totally or partially naturally replaceoccurring nucleosides present in the candidate nucleotide sequence andcan be incorporated into a sequence-optimized nucleotide sequence (e.g.,a RNA, e.g., an mRNA) encoding a PCCA or PCCB polypeptide. The resultantpolynucleotides, e.g., mRNAs, can then be examined for their ability toproduce protein and/or produce a therapeutic outcome.

a. In Vitro Transcription/Enzymatic Synthesis

The polynucleotides of the present invention disclosed herein (e.g., apolynucleotide comprising a nucleotide sequence encoding a PCCA or PCCBpolypeptide) can be transcribed using an in vitro transcription (IVT)system. The system typically comprises a transcription buffer,nucleotide triphosphates (NTPs), an RNase inhibitor and a polymerase.The NTPs can be selected from, but are not limited to, those describedherein including natural and unnatural (modified) NTPs. The polymerasecan be selected from, but is not limited to, T7 RNA polymerase, T3 RNApolymerase and mutant polymerases such as, but not limited to,polymerases able to incorporate polynucleotides disclosed herein. SeeU.S. Publ. No. US20130259923, which is herein incorporated by referencein its entirety.

Any number of RNA polymerases or variants can be used in the synthesisof the polynucleotides of the present invention. RNA polymerases can bemodified by inserting or deleting amino acids of the RNA polymerasesequence. As a non-limiting example, the RNA polymerase can be modifiedto exhibit an increased ability to incorporate a 2′-modified nucleotidetriphosphate compared to an unmodified RNA polymerase (see InternationalPublication WO2008078180 and U.S. Pat. No. 8,101,385; hereinincorporated by reference in their entireties).

Variants can be obtained by evolving an RNA polymerase, optimizing theRNA polymerase amino acid and/or nucleic acid sequence and/or by usingother methods known in the art. As a non-limiting example, T7 RNApolymerase variants can be evolved using the continuous directedevolution system set out by Esvelt et al. (Nature 472:499-503 (2011);herein incorporated by reference in its entirety) where clones of T7 RNApolymerase can encode at least one mutation such as, but not limited to,lysine at position 93 substituted for threonine (K93T), 14M, A7T, E63V,V64D, A65E, D66Y, T76N, C125R, S128R, A136T, N165S, G175R, H176L, Y178H,F182L, L196F, G198V, D208Y, E222K, S228A, Q239R, T243N, G259D, M2671,G280C, H300R, D351A, A354S, E356D, L360P, A383V, Y385C, D388Y, S397R,M401T, N410S, K450R, P451T, G452V, E484A, H523L, H524N, G542V, E565K,K577E, K577M, N601S, S684Y, L6991, K713E, N748D, Q754R, E775K, A827V,D851N or L864F. As another non-limiting example, T7 RNA polymerasevariants can encode at least mutation as described in U.S. Pub. Nos.20100120024 and 20070117112; herein incorporated by reference in theirentireties. Variants of RNA polymerase can also include, but are notlimited to, substitutional variants, conservative amino acidsubstitution, insertional variants, and/or deletional variants.

In one aspect, the polynucleotide can be designed to be recognized bythe wild type or variant RNA polymerases. In doing so, thepolynucleotide can be modified to contain sites or regions of sequencechanges from the wild type or parent chimeric polynucleotide.

Polynucleotide or nucleic acid synthesis reactions can be carried out byenzymatic methods utilizing polymerases. Polymerases catalyze thecreation of phosphodiester bonds between nucleotides in a polynucleotideor nucleic acid chain. Currently known DNA polymerases can be dividedinto different families based on amino acid sequence comparison andcrystal structure analysis. DNA polymerase I (pol I) or A polymerasefamily, including the Klenow fragments of E. coli, Bacillus DNApolymerase I, Thermus aquaticus (Taq) DNA polymerases, and the T7 RNAand DNA polymerases, is among the best studied of these families.Another large family is DNA polymerase a (pol u) or B polymerase family,including all eukaryotic replicating DNA polymerases and polymerasesfrom phages T4 and RB69. Although they employ similar catalyticmechanism, these families of polymerases differ in substratespecificity, substrate analog-incorporating efficiency, degree and ratefor primer extension, mode of DNA synthesis, exonuclease activity, andsensitivity against inhibitors.

DNA polymerases are also selected based on the optimum reactionconditions they require, such as reaction temperature, pH, and templateand primer concentrations. Sometimes a combination of more than one DNApolymerases is employed to achieve the desired DNA fragment size andsynthesis efficiency. For example, Cheng et al. increase pH, addglycerol and dimethyl sulfoxide, decrease denaturation times, increaseextension times, and utilize a secondary thermostable DNA polymerasethat possesses a 3′ to 5′ exonuclease activity to effectively amplifylong targets from cloned inserts and human genomic DNA. (Cheng et al.,PNAS 91:5695-5699 (1994), the contents of which are incorporated hereinby reference in their entirety). RNA polymerases from bacteriophage T3,T7, and SP6 have been widely used to prepare RNAs for biochemical andbiophysical studies. RNA polymerases, capping enzymes, and poly-Apolymerases are disclosed in the co-pending International PublicationNo. WO2014/028429, the contents of which are incorporated herein byreference in their entirety.

In one aspect, the RNA polymerase which can be used in the synthesis ofthe polynucleotides of the present invention is a Syn5 RNA polymerase.(see Zhu et al. Nucleic Acids Research 2013, doi:10.1093/nar/gktl 193,which is herein incorporated by reference in its entirety). The Syn5 RNApolymerase was recently characterized from marine cyanophage Syn5 by Zhuet al. where they also identified the promoter sequence (see Zhu et al.Nucleic Acids Research 2013, the contents of which is hereinincorporated by reference in its entirety). Zhu et al. found that Syn5RNA polymerase catalyzed RNA synthesis over a wider range oftemperatures and salinity as compared to T7 RNA polymerase.Additionally, the requirement for the initiating nucleotide at thepromoter was found to be less stringent for Syn5 RNA polymerase ascompared to the T7 RNA polymerase making Syn5 RNA polymerase promisingfor RNA synthesis.

In one aspect, a Syn5 RNA polymerase can be used in the synthesis of thepolynucleotides described herein. As a non-limiting example, a Syn5 RNApolymerase can be used in the synthesis of the polynucleotide requiringa precise 3′-terminus.

In one aspect, a Syn5 promoter can be used in the synthesis of thepolynucleotides. As a non-limiting example, the Syn5 promoter can be5′-ATTGGGCACCCGTAAGGG-3′ (SEQ ID NO: 185 as described by Zhu et al.(Nucleic Acids Research 2013).

In one aspect, a Syn5 RNA polymerase can be used in the synthesis ofpolynucleotides comprising at least one chemical modification describedherein and/or known in the art (see e.g., the incorporation ofpseudo-UTP and 5Me-CTP described in Zhu et al. Nucleic Acids Research2013).

In one aspect, the polynucleotides described herein can be synthesizedusing a Syn5 RNA polymerase which has been purified using modified andimproved purification procedure described by Zhu et al. (Nucleic AcidsResearch 2013).

Various tools in genetic engineering are based on the enzymaticamplification of a target gene which acts as a template. For the studyof sequences of individual genes or specific regions of interest andother research needs, it is necessary to generate multiple copies of atarget gene from a small sample of polynucleotides or nucleic acids.Such methods can be applied in the manufacture of the polynucleotides ofthe invention. For example, polymerase chain reaction (PCR), stranddisplacement amplification (SDA),nucleic acid sequence-basedamplification (NASBA), also called transcription mediated amplification(TMA), and/or rolling-circle amplification (RCA) can be utilized in themanufacture of one or more regions of the polynucleotides of the presentinvention. Assembling polynucleotides or nucleic acids by a ligase isalso widely used.

b. Chemical Synthesis

Standard methods can be applied to synthesize an isolated polynucleotidesequence encoding an isolated polypeptide of interest, such as apolynucleotide of the invention (e.g., a polynucleotide comprising anucleotide sequence encoding a PCCA or PCCB polypeptide). For example, asingle DNA or RNA oligomer containing a codon-optimized nucleotidesequence coding for the particular isolated polypeptide can besynthesized. In other aspects, several small oligonucleotides coding forportions of the desired polypeptide can be synthesized and then ligated.In some aspects, the individual oligonucleotides typically contain 5′ or3′ overhangs for complementary assembly.

A polynucleotide disclosed herein (e.g., a RNA, e.g., an mRNA) can bechemically synthesized using chemical synthesis methods and potentialnucleobase substitutions known in the art. See, for example,International Publication Nos. WO2014093924, WO2013052523; WO2013039857,WO2012135805, WO2013151671; U.S. Publ. No. US20130115272; or U.S. Pat.Nos. 8,999,380 or 8,710,200, all of which are herein incorporated byreference in their entireties.

c. Purification of Polynucleotides Encoding PCCA or PCCB

Purification of the polynucleotides described herein (e.g., apolynucleotide comprising a nucleotide sequence encoding a PCCA or PCCBpolypeptide) can include, but is not limited to, polynucleotideclean-up, quality assurance and quality control. Clean-up can beperformed by methods known in the arts such as, but not limited to,AGENCOURT® beads (Beckman Coulter Genomics, Danvers, Mass.), poly-Tbeads, LNA™ oligo-T capture probes (EXIQON® Inc., Vedbaek, Denmark) orHPLC based purification methods such as, but not limited to, stronganion exchange HPLC, weak anion exchange HPLC, reverse phase HPLC(RP-HPLC), and hydrophobic interaction HPLC (HIC-HPLC).

The term “purified” when used in relation to a polynucleotide such as a“purified polynucleotide” refers to one that is separated from at leastone contaminant. As used herein, a “contaminant” is any substance thatmakes another unfit, impure or inferior. Thus, a purified polynucleotide(e.g., DNA and RNA) is present in a form or setting different from thatin which it is found in nature, or a form or setting different from thatwhich existed prior to subjecting it to a treatment or purificationmethod.

In some embodiments, purification of a polynucleotide of the invention(e.g., a polynucleotide comprising a nucleotide sequence encoding a PCCAor PCCB polypeptide) removes impurities that can reduce or remove anunwanted immune response, e.g., reducing cytokine activity.

In some embodiments, the polynucleotide of the invention (e.g., apolynucleotide comprising a nucleotide sequence encoding a PCCA or PCCBpolypeptide) is purified prior to administration using columnchromatography (e.g., strong anion exchange HPLC, weak anion exchangeHPLC, reverse phase HPLC (RP-HPLC), and hydrophobic interaction HPLC(HIC-HPLC), or (LCMS)).

In some embodiments, the polynucleotide of the invention (e.g., apolynucleotide comprising a nucleotide sequence a PCCA or PCCBpolypeptide) purified using column chromatography (e.g., strong anionexchange HPLC, weak anion exchange HPLC, reverse phase HPLC (RP-HPLC,hydrophobic interaction HPLC (HIC-HPLC), or (LCMS)) presents increasedexpression of the encoded PCCA or PCCB protein compared to theexpression level obtained with the same polynucleotide of the presentdisclosure purified by a different purification method.

In some embodiments, a column chromatography (e.g., strong anionexchange HPLC, weak anion exchange HPLC, reverse phase HPLC (RP-HPLC),hydrophobic interaction HPLC (HIC-HPLC), or (LCMS)) purifiedpolynucleotide comprises a nucleotide sequence encoding a PCCA or PCCBpolypeptide comprising one or more of the point mutations known in theart.

In some embodiments, the use of RP-HPLC purified polynucleotideincreases PCCA or PCCB protein expression levels in cells whenintroduced into those cells, e.g., by 10-100%, i.e., at least about 10%,at least about 20%, at least about 25%, at least about 30%, at leastabout 35%, at least about 40%, at least about 45%, at least about 50%,at least about 55%, at least about 60%, at least about 65%, at leastabout 70%, at least about 75%, at least about 80%, at least about 90%,at least about 95%, or at least about 100% with respect to theexpression levels of PCCA or PCCB protein in the cells before theRP-HPLC purified polynucleotide was introduced in the cells, or after anon-RP-HPLC purified polynucleotide was introduced in the cells.

In some embodiments, the use of RP-HPLC purified polynucleotideincreases functional PCCA or PCCB protein expression levels in cellswhen introduced into those cells, e.g., by 10-100%, i.e., at least about10%, at least about 20%, at least about 25%, at least about 30%, atleast about 35%, at least about 40%, at least about 45%, at least about50%, at least about 55%, at least about 60%, at least about 65%, atleast about 70%, at least about 75%, at least about 80%, at least about90%, at least about 95%, or at least about 100% with respect to thefunctional expression levels of PCCA or PCCB protein in the cells beforethe RP-HPLC purified polynucleotide was introduced in the cells, orafter a non-RP-HPLC purified polynucleotide was introduced in the cells.

In some embodiments, the use of RP-HPLC purified polynucleotideincreases detectable PCCA or PCCB activity in cells when introduced intothose cells, e.g., by 10-100%, i.e., at least about 10%, at least about20%, at least about 25%, at least about 30%, at least about 35%, atleast about 40%, at least about 45%, at least about 50%, at least about55%, at least about 60%, at least about 65%, at least about 70%, atleast about 75%, at least about 80%, at least about 90%, at least about95%, or at least about 100% with respect to the activity levels offunctional PCCA or PCCB in the cells before the RP-HPLC purifiedpolynucleotide was introduced in the cells, or after a non-RP-HPLCpurified polynucleotide was introduced in the cells.

In some embodiments, the purified polynucleotide is at least about 80%pure, at least about 85% pure, at least about 90% pure, at least about95% pure, at least about 96% pure, at least about 97% pure, at leastabout 98% pure, at least about 99% pure, or about 100% pure.

A quality assurance and/or quality control check can be conducted usingmethods such as, but not limited to, gel electrophoresis, UV absorbance,or analytical HPLC. In another embodiment, the polynucleotide can besequenced by methods including, but not limited toreverse-transcriptase-PCR.

d. Quantification of Expressed Polynucleotides Encoding PCCA or PCCB

In some embodiments, the polynucleotides of the present invention (e.g.,a polynucleotide comprising a nucleotide sequence encoding a PCCA orPCCB polypeptide), their expression products, as well as degradationproducts and metabolites can be quantified according to methods known inthe art.

In some embodiments, the polynucleotides of the present invention can bequantified in exosomes or when derived from one or more bodily fluid. Asused herein “bodily fluids” include peripheral blood, serum, plasma,ascites, urine, cerebrospinal fluid (CSF), sputum, saliva, bone marrow,synovial fluid, aqueous humor, amniotic fluid, cerumen, breast milk,broncheoalveolar lavage fluid, semen, prostatic fluid, cowper's fluid orpre-ejaculatory fluid, sweat, fecal matter, hair, tears, cyst fluid,pleural and peritoneal fluid, pericardial fluid, lymph, chyme, chyle,bile, interstitial fluid, menses, pus, sebum, vomit, vaginal secretions,mucosal secretion, stool water, pancreatic juice, lavage fluids fromsinus cavities, bronchopulmonary aspirates, blastocyl cavity fluid, andumbilical cord blood. Alternatively, exosomes can be retrieved from anorgan selected from the group consisting of lung, heart, pancreas,stomach, intestine, bladder, kidney, ovary, testis, skin, colon, breast,prostate, brain, esophagus, liver, and placenta.

In the exosome quantification method, a sample of not more than 2 mL isobtained from the human subject and the exosomes isolated by sizeexclusion chromatography, density gradient centrifugation, differentialcentrifugation, nanomembrane ultrafiltration, immunoabsorbent capture,affinity purification, microfluidic separation, or combinations thereof.In the analysis, the level or concentration of a polynucleotide can bean expression level, presence, absence, truncation or alteration of theadministered construct. It is advantageous to correlate the level withone or more clinical phenotypes or with an assay for a human diseasebiomarker.

The assay can be performed using construct specific probes, cytometry,qRT-PCR, real-time PCR, PCR, flow cytometry, electrophoresis, massspectrometry, or combinations thereof while the exosomes can be isolatedusing immunohistochemical methods such as enzyme linked immunosorbentassay (ELISA) methods. Exosomes can also be isolated by size exclusionchromatography, density gradient centrifugation, differentialcentrifugation, nanomembrane ultrafiltration, immunoabsorbent capture,affinity purification, microfluidic separation, or combinations thereof.

These methods afford the investigator the ability to monitor, in realtime, the level of polynucleotides remaining or delivered. This ispossible because the polynucleotides of the present invention differfrom the endogenous forms due to the structural or chemicalmodifications.

In some embodiments, the polynucleotide can be quantified using methodssuch as, but not limited to, ultraviolet visible spectroscopy (UV/Vis).A non-limiting example of a UV/Vis spectrometer is a NANODROP®spectrometer (ThermoFisher, Waltham, Mass.). The quantifiedpolynucleotide can be analyzed in order to determine if thepolynucleotide can be of proper size, check that no degradation of thepolynucleotide has occurred. Degradation of the polynucleotide can bechecked by methods such as, but not limited to, agarose gelelectrophoresis, HPLC based purification methods such as, but notlimited to, strong anion exchange HPLC, weak anion exchange HPLC,reverse phase HPLC (RP-HPLC), and hydrophobic interaction HPLC(HIC-HPLC), liquid chromatography-mass spectrometry (LCMS), capillaryelectrophoresis (CE) and capillary gel electrophoresis (CGE).

19. Pharmaceutical Compositions and Formulations

The present invention provides pharmaceutical compositions andformulations that comprise any of the polynucleotides described above.In some embodiments, the composition or formulation further comprises adelivery agent.

In some embodiments, the composition or formulation can contain apolynucleotide comprising a sequence optimized nucleic acid sequencedisclosed herein which encodes a PCCA or PCCB polypeptide. In someembodiments, the composition or formulation can contain a polynucleotide(e.g., a RNA, e.g., an mRNA) comprising a polynucleotide (e.g., an ORF)having significant sequence identity to a sequence optimized nucleicacid sequence disclosed herein which encodes a PCCA or PCCB polypeptide.In some embodiments, the polynucleotide further comprises a miRNAbinding site, e.g., a miRNA binding site that binds miR-126, miR-142,miR-144, miR-146, miR-150, miR-155, miR-16, miR-21, miR-223, miR-24,miR-27 and miR-26a.

Pharmaceutical compositions or formulation can optionally comprise oneor more additional active substances, e.g., therapeutically and/orprophylactically active substances. Pharmaceutical compositions orformulation of the present invention can be sterile and/or pyrogen-free.General considerations in the formulation and/or manufacture ofpharmaceutical agents can be found, for example, in Remington: TheScience and Practice of Pharmacy 21St ed., Lippincott Williams &Wilkins, 2005 (incorporated herein by reference in its entirety). Insome embodiments, compositions are administered to humans, humanpatients or subjects. For the purposes of the present disclosure, thephrase “active ingredient” generally refers to polynucleotides to bedelivered as described herein.

Formulations and pharmaceutical compositions described herein can beprepared by any method known or hereafter developed in the art ofpharmacology. In general, such preparatory methods include the step ofassociating the active ingredient with an excipient and/or one or moreother accessory ingredients, and then, if necessary and/or desirable,dividing, shaping and/or packaging the product into a desired single- ormulti-dose unit.

A pharmaceutical composition or formulation in accordance with thepresent disclosure can be prepared, packaged, and/or sold in bulk, as asingle unit dose, and/or as a plurality of single unit doses. As usedherein, a “unit dose” refers to a discrete amount of the pharmaceuticalcomposition comprising a predetermined amount of the active ingredient.The amount of the active ingredient is generally equal to the dosage ofthe active ingredient that would be administered to a human subjectand/or a convenient fraction of such a dosage such as, for example,one-half or one-third of such a dosage.

Relative amounts of the active ingredient, the pharmaceuticallyacceptable excipient, and/or any additional ingredients in apharmaceutical composition in accordance with the present disclosure canvary, depending upon the identity, size, and/or condition of the humansubject being treated and further depending upon the route by which thecomposition is to be administered.

In some embodiments, the compositions and formulations described hereincan contain at least one polynucleotide of the invention. As anon-limiting example, the composition or formulation can contain 1, 2,3, 4 or 5 polynucleotides of the invention. In some embodiments, thecompositions or formulations described herein can comprise more than onetype of polynucleotide. In some embodiments, the composition orformulation can comprise a polynucleotide in linear and circular form.In another embodiment, the composition or formulation can comprise acircular polynucleotide and an in vitro transcribed (IVT)polynucleotide. In yet another embodiment, the composition orformulation can comprise an IVT polynucleotide, a chimericpolynucleotide and a circular polynucleotide.

Although the descriptions of pharmaceutical compositions andformulations provided herein are principally directed to pharmaceuticalcompositions and formulations that are suitable for administration tohumans, it will be understood by the skilled artisan that suchcompositions are generally suitable for administration to any otheranimal, e.g., to non-human animals, e.g. non-human mammals.

The present invention provides pharmaceutical formulations that comprisea polynucleotide described herein (e.g., a polynucleotide comprising anucleotide sequence encoding a PCCA or PCCB polypeptide). Thepolynucleotides described herein can be formulated using one or moreexcipients to: (1) increase stability; (2) increase cell transfection;(3) permit the sustained or delayed release (e.g., from a depotformulation of the polynucleotide); (4) alter the biodistribution (e.g.,target the polynucleotide to specific tissues or cell types); (5)increase the translation of encoded protein in vivo; and/or (6) alterthe release profile of encoded protein in vivo. In some embodiments, thepharmaceutical formulation further comprises a delivery agentcomprising, e.g., a compound having the Formula (I), e.g., any ofCompounds 1-232, e.g., Compound II; a compound having the Formula (III),(IV), (V), or (VI), e.g., any of Compounds 233-342, e.g., Compound VI;or a compound having the Formula (VIII), e.g., any of Compounds 419-428,e.g., Compound I, or any combination thereof. In some embodiments, thedelivery agent comprises Compound II, DSPC, Cholesterol, and Compound Ior PEG-DMG, e.g., with a mole ratio of about 50:10:38.5:1.5. In someembodiments, the delivery agent comprises Compound II, DSPC,Cholesterol, and Compound I or PEG-DMG, e.g., with a mole ratio of about47.5:10.5:39.0:3.0. In some embodiments, the delivery agent comprisesCompound VI, DSPC, Cholesterol, and Compound I or PEG-DMG, e.g., with amole ratio of about 50:10:38.5:1.5. In some embodiments, the deliveryagent comprises Compound VI, DSPC, Cholesterol, and Compound I orPEG-DMG, e.g., with a mole ratio of about 47.5:10.5:39.0:3.0.

A pharmaceutically acceptable excipient, as used herein, includes, butare not limited to, any and all solvents, dispersion media, or otherliquid vehicles, dispersion or suspension aids, diluents, granulatingand/or dispersing agents, surface active agents, isotonic agents,thickening or emulsifying agents, preservatives, binders, lubricants oroil, coloring, sweetening or flavoring agents, stabilizers,antioxidants, antimicrobial or antifungal agents, osmolality adjustingagents, pH adjusting agents, buffers, chelants, cyoprotectants, and/orbulking agents, as suited to the particular dosage form desired. Variousexcipients for formulating pharmaceutical compositions and techniquesfor preparing the composition are known in the art (see Remington: TheScience and Practice of Pharmacy, 21st Edition, A. R. Gennaro(Lippincott, Williams & Wilkins, Baltimore, Md., 2006; incorporatedherein by reference in its entirety).

Exemplary diluents include, but are not limited to, calcium or sodiumcarbonate, calcium phosphate, calcium hydrogen phosphate, sodiumphosphate, lactose, sucrose, cellulose, microcrystalline cellulose,kaolin, mannitol, sorbitol, etc., and/or combinations thereof.

Exemplary granulating and/or dispersing agents include, but are notlimited to, starches, pregelatinized starches, or microcrystallinestarch, alginic acid, guar gum, agar, poly(vinyl-pyrrolidone),(providone), cross-linked poly(vinyl-pyrrolidone) (crospovidone),cellulose, methylcellulose, carboxymethyl cellulose, cross-linked sodiumcarboxymethyl cellulose (croscarmellose), magnesium aluminum silicate(VEEGUM®), sodium lauryl sulfate, etc., and/or combinations thereof.

Exemplary surface active agents and/or emulsifiers include, but are notlimited to, natural emulsifiers (e.g., acacia, agar, alginic acid,sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin,gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin),sorbitan fatty acid esters (e.g., polyoxyethylene sorbitan monooleate[TWEEN®80], sorbitan monopalmitate [SPAN®40], glyceryl monooleate,polyoxyethylene esters, polyethylene glycol fatty acid esters (e.g.,CREMOPHOR®), polyoxyethylene ethers (e.g., polyoxyethylene lauryl ether[BRIJ®30]), PLUORINC®F 68, POLOXAMER®188, etc. and/or combinationsthereof.

Exemplary binding agents include, but are not limited to, starch,gelatin, sugars (e.g., sucrose, glucose, dextrose, dextrin, molasses,lactose, lactitol, mannitol), amino acids (e.g., glycine), natural andsynthetic gums (e.g., acacia, sodium alginate), ethylcellulose,hydroxyethylcellulose, hydroxypropyl methylcellulose, etc., andcombinations thereof.

Oxidation is a potential degradation pathway for mRNA, especially forliquid mRNA formulations. In order to prevent oxidation, antioxidantscan be added to the formulations. Exemplary antioxidants include, butare not limited to, alpha tocopherol, ascorbic acid, ascorbyl palmitate,benzyl alcohol, butylated hydroxyanisole, m-cresol, methionine,butylated hydroxytoluene, monothioglycerol, sodium or potassiummetabisulfite, propionic acid, propyl gallate, sodium ascorbate, etc.,and combinations thereof.

Exemplary chelating agents include, but are not limited to,ethylenediaminetetraacetic acid (EDTA), citric acid monohydrate,disodium edetate, fumaric acid, malic acid, phosphoric acid, sodiumedetate, tartaric acid, trisodium edetate, etc., and combinationsthereof.

Exemplary antimicrobial or antifungal agents include, but are notlimited to, benzalkonium chloride, benzethonium chloride, methylparaben, ethyl paraben, propyl paraben, butyl paraben, benzoic acid,hydroxybenzoic acid, potassium or sodium benzoate, potassium or sodiumsorbate, sodium propionate, sorbic acid, etc., and combinations thereof.

Exemplary preservatives include, but are not limited to, vitamin A,vitamin C, vitamin E, beta-carotene, citric acid, ascorbic acid,butylated hydroxyanisol, ethylenediamine, sodium lauryl sulfate (SLS),sodium lauryl ether sulfate (SLES), etc., and combinations thereof.

In some embodiments, the pH of polynucleotide solutions is maintainedbetween pH 5 and pH 8 to improve stability. Exemplary buffers to controlpH can include, but are not limited to sodium phosphate, sodium citrate,sodium succinate, histidine (or histidine-HCl), sodium malate, sodiumcarbonate, etc., and/or combinations thereof.

Exemplary lubricating agents include, but are not limited to, magnesiumstearate, calcium stearate, stearic acid, silica, talc, malt,hydrogenated vegetable oils, polyethylene glycol, sodium benzoate,sodium or magnesium lauryl sulfate, etc., and combinations thereof.

The pharmaceutical composition or formulation described here can containa cryoprotectant to stabilize a polynucleotide described herein duringfreezing. Exemplary cryoprotectants include, but are not limited tomannitol, sucrose, trehalose, lactose, glycerol, dextrose, etc., andcombinations thereof.

The pharmaceutical composition or formulation described here can containa bulking agent in lyophilized polynucleotide formulations to yield a“pharmaceutically elegant” cake, stabilize the lyophilizedpolynucleotides during long term (e.g., 36 month) storage. Exemplarybulking agents of the present invention can include, but are not limitedto sucrose, trehalose, mannitol, glycine, lactose, raffinose, andcombinations thereof.

In some embodiments, the pharmaceutical composition or formulationfurther comprises a delivery agent. The delivery agent of the presentdisclosure can include, without limitation, liposomes, lipidnanoparticles, lipidoids, polymers, lipoplexes, microvesicles, exosomes,peptides, proteins, cells transfected with polynucleotides,hyaluronidase, nanoparticle mimics, nanotubes, conjugates, andcombinations thereof.

20. Delivery Agents

a. Lipid Compound

The present disclosure provides pharmaceutical compositions withadvantageous properties. The lipid compositions described herein may beadvantageously used in lipid nanoparticle compositions for the deliveryof therapeutic and/or prophylactic agents, e.g., mRNAs, to mammaliancells or organs. For example, the lipids described herein have little orno immunogenicity. For example, the lipid compounds disclosed hereinhave a lower immunogenicity as compared to a reference lipid (e.g., MC3,KC2, or DLinDMA). For example, a formulation comprising a lipiddisclosed herein and a therapeutic or prophylactic agent, e.g., mRNA,has an increased therapeutic index as compared to a correspondingformulation which comprises a reference lipid (e.g., MC3, KC2, orDLinDMA) and the same therapeutic or prophylactic agent.

In certain embodiments, the present application provides pharmaceuticalcompositions comprising:

-   -   (a) a polynucleotide comprising a nucleotide sequence encoding a        PCCA or PCCB polypeptide; and    -   (b) a delivery agent.

Lipid Nanoparticle Formulations

In some embodiments, nucleic acids of the invention (e.g. PCCA or PCCBmRNA) are formulated in a lipid nanoparticle (LNP). Lipid nanoparticlestypically comprise ionizable cationic lipid, non-cationic lipid, steroland PEG lipid components along with the nucleic acid cargo of interest.The lipid nanoparticles of the invention can be generated usingcomponents, compositions, and methods as are generally known in the art,see for example PCT/US2016/052352; PCT/US2016/068300; PCT/US2017/037551;PCT/US2015/027400; PCT/US2016/047406; PCT/US2016000129;PCT/US2016/014280; PCT/US2016/014280; PCT/US2017/038426;PCT/US2014/027077; PCT/US2014/055394; PCT/US2016/52117;PCT/US2012/069610; PCT/US2017/027492; PCT/US2016/059575 andPCT/US2016/069491 all of which are incorporated by reference herein intheir entirety.

Nucleic acids of the present disclosure (e.g. PCCA or PCCB mRNA) aretypically formulated in lipid nanoparticle. In some embodiments, thelipid nanoparticle comprises at least one ionizable cationic lipid, atleast one non-cationic lipid, at least one sterol, and/or at least onepolyethylene glycol (PEG)-modified lipid.

In some embodiments, the lipid nanoparticle comprises a molar ratio of20-60% ionizable cationic lipid. For example, the lipid nanoparticle maycomprise a molar ratio of 20-50%, 20-40%, 20-30%, 30-60%, 30-50%,30-40%, 40-60%, 40-50%, or 50-60% ionizable cationic lipid. In someembodiments, the lipid nanoparticle comprises a molar ratio of 20%, 30%,40%, 50, or 60% ionizable cationic lipid.

In some embodiments, the lipid nanoparticle comprises a molar ratio of5-25% non-cationic lipid. For example, the lipid nanoparticle maycomprise a molar ratio of 5-20%, 5-15%, 5-10%, 10-25%, 10-20%, 10-25%,15-25%, 15-20%, or 20-25% non-cationic lipid. In some embodiments, thelipid nanoparticle comprises a molar ratio of 5%, 10%, 15%, 20%, or 25%non-cationic lipid.

In some embodiments, the lipid nanoparticle comprises a molar ratio of25-55% sterol. For example, the lipid nanoparticle may comprise a molarratio of 25-50%, 25-45%, 25-40%, 25-35%, 25-30%, 30-55%, 30-50%, 30-45%,30-40%, 30-35%, 35-55%, 35-50%, 35-45%, 35-40%, 40-55%, 40-50%, 40-45%,45-55%, 45-50%, or 50-55% sterol. In some embodiments, the lipidnanoparticle comprises a molar ratio of 25%, 30%, 35%, 40%, 45%, 50%, or55% sterol.

In some embodiments, the lipid nanoparticle comprises a molar ratio of0.5-15% PEG-modified lipid. For example, the lipid nanoparticle maycomprise a molar ratio of 0.5-10%, 0.5-5%, 1-15%, 1-10%, 1-5%, 2-15%,2-10%, 2-5%, 5-15%, 5-10%, or 10-15%. In some embodiments, the lipidnanoparticle comprises a molar ratio of 0.5%, 1%, 2%, 3%, 4%, 5%, 6%,7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, or 15% PEG-modified lipid.

In some embodiments, the lipid nanoparticle comprises a molar ratio of20-60% ionizable cationic lipid, 5-25% non-cationic lipid, 25-55%sterol, and 0.5-15% PEG-modified lipid.

Ionizable Lipids

In some aspects, the ionizable lipids of the present disclosure may beone or more of compounds of Formula (I):

or their N-oxides, or salts or isomers thereof, wherein:R₁ is selected from the group consisting of C₅₋₃₀ alkyl, C₅₋₂₀ alkenyl,—R*YR″, —YR″, and —R″M′R′;R₂ and R₃ are independently selected from the group consisting of H,C₁₋₁₄ alkyl, C₂₋₁₄ alkenyl, —R*YR″, —YR″, and —R*OR″, or R2 and R3,together with the atom to which they are attached, form a heterocycle orcarbocycle;R₄ is selected from the group consisting of hydrogen, a C₃₋₆ carbocycle,—(CH₂)_(n)Q, —(CH₂)_(n)CHQR, —CHQR, —CQ(R)₂, and unsubstituted C₁₋₆alkyl, where Q is selected from a carbocycle, heterocycle, —OR,—O(CH₂)_(n)N(R)₂, —C(O)OR, —OC(O)R, —CX₃, —CX₂H, —CXH₂, —CN, —N(R)₂,—C(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R, —N(R)C(O)N(R)₂, —N(R)C(S)N(R)₂,—N(R)R₈, —N(R)S(O)₂R₈, —O(CH₂)_(n)OR, —N(R)C(═NR₉)N(R)₂,—N(R)C(═CHR₉)N(R)₂, —OC(O)N(R)₂, —N(R)C(O)OR, —N(OR)C(O)R, —N(OR)S(O)₂R,—N(OR)C(O)OR, —N(OR)C(O)N(R)₂, —N(OR)C(S)N(R)₂, —N(OR)C(═NR₉)N(R)₂,—N(OR)C(═CHR₉)N(R)₂, —C(═NR₉)N(R)₂, —C(═NR₉)R, —C(O)N(R)OR, and—C(R)N(R)₂C(O)OR, and each n is independently selected from 1, 2, 3, 4,and 5;each R5 is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;each R6 is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;M and M′ are independently selectedfrom —C(O)O—, —OC(O)—, —OC(O)-M″-C(O)O—, —C(O)N(R′)—, —N(R′)C(O)—,—C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)₂—,—S—S—, an aryl group, and a heteroaryl group, in which M″ is a bond,C₁₋₁₃ alkyl or C₂₋₁₃ alkenyl;R₇ is selected from the group consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl,and H;R₈ is selected from the group consisting of C₃₋₆ carbocycle andheterocycle;R₉ is selected from the group consisting of H, CN, NO₂, C₁₋₆ alkyl, —OR,—S(O)₂R, —S(O)₂N(R)₂, C₂₋₆ alkenyl, C₃₋₆ carbocycle and heterocycle;each R is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;each R′ is independently selected from the group consisting of C₁₋₁₈alkyl, C₂₋₁₈ alkenyl, —R*YR″, —YR″, and H;each R″ is independently selected from the group consisting of C₃₋₁₅alkyl and C₃₋₁₅ alkenyl;each R* is independently selected from the group consisting of C₁₋₁₂alkyl and C₂₋₁₂ alkenyl;each Y is independently a C₃₋₆ carbocycle;each X is independently selected from the group consisting of F, Cl, Br,and I; andm is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13; and wherein whenR4 is —(CH₂)_(n)Q, —(CH₂)_(n)CHQR, —CHQR, or —CQ(R)₂, then (i) Q is not—N(R)₂ when n is 1, 2, 3, 4 or 5, or (ii) Q is not 5, 6, or 7-memberedheterocycloalkyl when n is 1 or 2.

In certain embodiments, a subset of compounds of Formula (I) includesthose of Formula (IA):

or its N-oxide, or a salt or isomer thereof, wherein 1 is selected from1, 2, 3, 4, and 5; m is selected from 5, 6, 7, 8, and 9; M₁ is a bond orM′; R₄ is hydrogen, unsubstituted C₁₋₃ alkyl, or —(CH₂)_(n)Q, in which Qis OH, —NHC(S)N(R)₂, —NHC(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R, —N(R)R₈,—NHC(═NR₉)N(R)₂, —NHC(═CHR₉)N(R)₂, —OC(O)N(R)₂, —N(R)C(O)OR, heteroarylor heterocycloalkyl; M and M′ are independently selected from —C(O)O—,—OC(O)—, —OC(O)-M″-C(O)O—, —C(O)N(R′)—, —P(O)(OR′)O—, —S—S—, an arylgroup, and a heteroaryl group, and R₂ and R₃ are independently selectedfrom the group consisting of H, C₁₋₁₄ alkyl, and C₂₋₁₄ alkenyl. Forexample, m is 5, 7, or 9. For example, Q is OH, —NHC(S)N(R)₂, or—NHC(O)N(R)₂. For example, Q is —N(R)C(O)R, or —N(R)S(O)₂R.

In certain embodiments, a subset of compounds of Formula (I) includesthose of Formula (IB):

or its N-oxide, or a salt or isomer thereof in which all variables areas defined herein. For example, m is selected from 5, 6, 7, 8, and 9; R₄is hydrogen, unsubstituted C₁₋₃ alkyl, or —(CH₂)_(n)Q, in which Q is OH,—NHC(S)N(R)₂, —NHC(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R, —N(R)R₈,—NHC(═NR₉)N(R)₂, —NHC(═CHR₉)N(R)₂, —OC(O)N(R)₂, —N(R)C(O)OR, heteroarylor heterocycloalkyl; M and M′ are independently selected from —C(O)O—,—OC(O)—, —OC(O)-M″-C(O)O—, —C(O)N(R′)—, —P(O)(OR′)O—, —S—S—, an arylgroup, and a heteroaryl group; and R₂ and R₃ are independently selectedfrom the group consisting of H, C₁₋₁₄ alkyl, and C₂₋₁₄ alkenyl. Forexample, m is 5, 7, or 9. For example, Q is OH, —NHC(S)N(R)₂, or—NHC(O)N(R)₂. For example, Q is —N(R)C(O)R, or —N(R)S(O)₂R.

In certain embodiments, a subset of compounds of Formula (I) includesthose of Formula (II):

or its N-oxide, or a salt or isomer thereof, wherein 1 is selected from1, 2, 3, 4, and 5; M₁ is a bond or M′; R₄ is hydrogen, unsubstitutedC₁₋₃ alkyl, or —(CH₂)_(n)Q, in which n is 2, 3, or 4, and Q is OH,—NHC(S)N(R)₂, —NHC(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R, —N(R)R₈,—NHC(═NR₉)N(R)₂, —NHC(═CHR₉)N(R)₂, —OC(O)N(R)₂, —N(R)C(O)OR, heteroarylor heterocycloalkyl; M and M′ are independently selected from —C(O)O—,—OC(O)—, —OC(O)-M″-C(O)O—, —C(O)N(R′)—, —P(O)(OR′)O—, —S—S—, an arylgroup, and a heteroaryl group; and R₂ and R₃ are independently selectedfrom the group consisting of H, C₁₋₁₄ alkyl, and C₂₋₁₄ alkenyl.

In one embodiment, the compounds of Formula (I) are of Formula (IIa),

or their N-oxides, or salts or isomers thereof, wherein R₄ is asdescribed herein.

In another embodiment, the compounds of Formula (I) are of Formula(IIb),

or their N-oxides, or salts or isomers thereof, wherein R₄ is asdescribed herein.

In another embodiment, the compounds of Formula (I) are of Formula (IIc)or (IIe):

or their N-oxides, or salts or isomers thereof, wherein R₄ is asdescribed herein.

In another embodiment, the compounds of Formula (I) are of Formula(IIf):

or their N-oxides, or salts or isomers thereof, wherein M is —C(O)O— or—OC(O)—, M″ is C₁₋₆ alkyl or C₂₋₆ alkenyl, R₂ and R₃ are independentlyselected from the group consisting of C₅₋₁₄ alkyl and C₅₋₁₄ alkenyl, andn is selected from 2, 3, and 4.

In a further embodiment, the compounds of Formula (I) are of Formula(IId),

or their N-oxides, or salts or isomers thereof, wherein n is 2, 3, or 4;and m, R′, R″, and R₂ through R₆ are as described herein. For example,each of R₂ and R₃ may be independently selected from the groupconsisting of C₅₋₁₄ alkyl and C₅₋₁₄ alkenyl.

In a further embodiment, the compounds of Formula (I) are of Formula(IIg),

or their N-oxides, or salts or isomers thereof, wherein 1 is selectedfrom 1, 2, 3, 4, and 5; m is selected from 5, 6, 7, 8, and 9; M₁ is abond or M′; M and M′ are independently selected from —C(O)O—, —OC(O)—,—OC(O)-M″-C(O)O—, —C(O)N(R′)—, —P(O)(OR′)O—, —S—S—, an aryl group, and aheteroaryl group; and R₂ and R₃ are independently selected from thegroup consisting of H, C₁₋₁₄ alkyl, and C₂₋₁₄ alkenyl. For example, M″is C₁₋₆ alkyl (e.g., C₁₋₄ alkyl) or C₂₋₆ alkenyl (e.g. C₂₋₄ alkenyl).For example, R₂ and R₃ are independently selected from the groupconsisting of C₅₋₁₄ alkyl and C₅₋₁₄ alkenyl.

In some embodiments, the ionizable lipids are one or more of thecompounds described in U.S. Application Nos. 62/220,091, 62/252,316,62/253,433, 62/266,460, 62/333,557, 62/382,740, 62/393,940, 62/471,937,62/471,949, 62/475,140, and 62/475,166, and PCT Application No.PCT/US2016/052352.

In some embodiments, the ionizable lipids are selected from Compounds1-280 described in U.S. Application No. 62/475,166.

In some embodiments, the ionizable lipid is

or a salt thereof.

In some embodiments, the ionizable lipid is

or a salt thereof.

In some embodiments, the ionizable lipid is

or a salt thereof.

In some embodiments, the ionizable lipid is

or a salt thereof.

The central amine moiety of a lipid according to Formula (I), (IA),(IB), (II), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), or (IIg) may beprotonated at a physiological pH. Thus, a lipid may have a positive orpartial positive charge at physiological pH. Such lipids may be referredto as cationic or ionizable (amino)lipids. Lipids may also bezwitterionic, i.e., neutral molecules having both a positive and anegative charge.

In some aspects, the ionizable lipids of the present disclosure may beone or more of compounds of formula (III),

or salts or isomers thereof, wherein

W is

ring A is

t is 1 or 2;

A₁ and A₂ are each independently selected from CH or N;

Z is CH₂ or absent wherein when Z is CH₂, the dashed lines (1) and (2)each represent a single bond; and when Z is absent, the dashed lines (1)and (2) are both absent;

R₁, R₂, R₃, R₄, and R₅ are independently selected from the groupconsisting of C₅₋₂₀ alkyl, C₅₋₂₀ alkenyl, —R″MR′, —R*YR″, —YR″, and—R*OR″;

R_(X1) and R_(X2) are each independently H or C₁₋₃ alkyl;

each M is independently selected from the group consisting of —C(O)O—,—OC(O)—, —OC(O)O—, —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—,—SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)₂—, —C(O)S—, —SC(O)—, an arylgroup, and a heteroaryl group;

M* is C₁-C₆ alkyl,

W¹ and W² are each independently selected from the group consisting of—O— and —N(R₆)—;

each R₆ is independently selected from the group consisting of H andC₁₋₅ alkyl;

X¹, X², and X³ are independently selected from the group consisting of abond, —CH₂—, —(CH₂)₂—, —CHR—, —CHY—, —C(O)—, —C(O)O—, —OC(O)—,—(CH₂)_(n)—C(O)—, —C(O)—(CH₂)_(n)—, —(CH₂)_(n)—C(O)O—,—OC(O)—(CH₂)_(n)—, —(CH₂)_(n)—OC(O)—, —C(O)O—(CH₂)_(n)—, —CH(OH)—,—C(S)—, and —CH(SH)—;

each Y is independently a C₃₋₆ carbocycle;

each R* is independently selected from the group consisting of C₁₋₁₂alkyl and C₂₋₁₂ alkenyl;

each R is independently selected from the group consisting of C₁₋₃ alkyland a C₃₋₆ carbocycle;

each R′ is independently selected from the group consisting of C₁₋₁₂alkyl, C₂₋₁₂ alkenyl, and H;

each R″ is independently selected from the group consisting of C₃₋₁₂alkyl, C₃₋₁₂ alkenyl and —R*MR′; and

n is an integer from 1-6;

when ring A is

then

i) at least one of X¹, X², and X³ is not —CH₂—; and/or

ii) at least one of R₁, R₂, R₃, R₄, and R₅ is —R″MR′.

In some embodiments, the compound is of any of formulae (IIIa1)-(IIIa8):

In some embodiments, the ionizable lipids are one or more of thecompounds described in U.S. Application Nos. 62/271,146, 62/338,474,62/413,345, and 62/519,826, and PCT Application No. PCT/US2016/068300.

In some embodiments, the ionizable lipids are selected from Compounds1-156 described in U.S. Application No. 62/519,826.

In some embodiments, the ionizable lipids are selected from Compounds1-16, 42-66, 68-76, and 78-156 described in U.S. Application No.62/519,826.

In some embodiments, the ionizable lipid is

or a salt thereof.

In some embodiments, the ionizable lipid is (Compound VII), or a saltthereof.

The central amine moiety of a lipid according to Formula (III), (IIIa1),(IIIa2), (IIIa3), (IIIa4), (IIIa5), (IIIa6), (IIIa7), or (IIIa8) may beprotonated at a physiological pH. Thus, a lipid may have a positive orpartial positive charge at physiological pH. Such lipids may be referredto as cationic or ionizable (amino)lipids. Lipids may also bezwitterionic, i.e., neutral molecules having both a positive and anegative charge.

Phospholipids

The lipid composition of the lipid nanoparticle composition disclosedherein can comprise one or more phospholipids, for example, one or moresaturated or (poly)unsaturated phospholipids or a combination thereof.In general, phospholipids comprise a phospholipid moiety and one or morefatty acid moieties.

A phospholipid moiety can be selected, for example, from thenon-limiting group consisting of phosphatidyl choline, phosphatidylethanolamine, phosphatidyl glycerol, phosphatidyl serine, phosphatidicacid, 2-lysophosphatidyl choline, and a sphingomyelin.

A fatty acid moiety can be selected, for example, from the non-limitinggroup consisting of lauric acid, myristic acid, myristoleic acid,palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleicacid, alpha-linolenic acid, erucic acid, phytanoic acid, arachidic acid,arachidonic acid, eicosapentaenoic acid, behenic acid, docosapentaenoicacid, and docosahexaenoic acid.

Particular phospholipids can facilitate fusion to a membrane. Forexample, a cationic phospholipid can interact with one or morenegatively charged phospholipids of a membrane (e.g., a cellular orintracellular membrane). Fusion of a phospholipid to a membrane canallow one or more elements (e.g., a therapeutic agent) of alipid-containing composition (e.g., LNPs) to pass through the membranepermitting, e.g., delivery of the one or more elements to a targettissue.

Non-natural phospholipid species including natural species withmodifications and substitutions including branching, oxidation,cyclization, and alkynes are also contemplated. For example, aphospholipid can be functionalized with or cross-linked to one or morealkynes (e.g., an alkenyl group in which one or more double bonds isreplaced with a triple bond). Under appropriate reaction conditions, analkyne group can undergo a copper-catalyzed cycloaddition upon exposureto an azide. Such reactions can be useful in functionalizing a lipidbilayer of a nanoparticle composition to facilitate membrane permeationor cellular recognition or in conjugating a nanoparticle composition toa useful component such as a targeting or imaging moiety (e.g., a dye).

Phospholipids include, but are not limited to, glycerophospholipids suchas phosphatidylcholines, phosphatidylethanolamines, phosphatidylserines,phosphatidylinositols, phosphatidy glycerols, and phosphatidic acids.Phospholipids also include phosphosphingolipid, such as sphingomyelin.

In some embodiments, a phospholipid of the invention comprises1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC),1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE),1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC),1,2-dimyristoyl-sn-gly cero-phosphocholine (DMPC),1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC),1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC),1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC),1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC),1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 Diether PC),1-oleoyl-2 cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine(OChemsPC), 1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC),1,2-dilinolenoyl-sn-glycero-3-phosphocholine,1,2-diarachidonoyl-sn-glycero-3-phosphocholine,1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine,1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME 16.0 PE),1,2-distearoyl-sn-glycero-3-phosphoethanolamine,1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine,1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine,1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine,1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine,1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG),sphingomyelin, and mixtures thereof.

In certain embodiments, a phospholipid useful or potentially useful inthe present invention is an analog or variant of DSPC. In certainembodiments, a phospholipid useful or potentially useful in the presentinvention is a compound of Formula (IV):

or a salt thereof, wherein:

each R¹ is independently optionally substituted alkyl; or optionally twoR¹ are joined together with the intervening atoms to form optionallysubstituted monocyclic carbocyclyl or optionally substituted monocyclicheterocyclyl; or optionally three R¹ are joined together with theintervening atoms to form optionally substituted bicyclic carbocyclyl oroptionally substitute bicyclic heterocyclyl;

n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

A is of the formula:

each instance of L² is independently a bond or optionally substitutedC₁₋₆ alkylene, wherein one methylene unit of the optionally substitutedC₁₋₆ alkylene is optionally replaced with O, N(R^(N)), S, C(O),C(O)N(R^(N)), NR^(N)C(O), C(O)O, OC(O), OC(O)O, OC(O)N(R^(N)),—NR^(N)C(O)O, or NR^(N)C(O)N(R^(N));

each instance of R² is independently optionally substituted C₁₋₃₀ alkyl,optionally substituted C₁₋₃₀ alkenyl, or optionally substituted C₁₋₃₀alkynyl; optionally wherein one or more methylene units of R₂ areindependently replaced with optionally substituted carbocyclylene,optionally substituted heterocyclylene, optionally substituted arylene,optionally substituted heteroarylene, N(R^(N)), O, S, C(O),C(O)N(R^(N)), NR^(N)C(O), —NR^(N)C(O)N(R^(N)), C(O)O, OC(O), OC(O)O,OC(O)N(R^(N)), NR^(N)C(O)O, C(O)S, SC(O), —C(═NR^(N)),C(═NR^(N))N(R^(N)), NR^(N)C(═NR^(N)), NR^(N)C(═NR^(N))N(R^(N)), C(S),C(S)N(R^(N)), NR^(N)C(S), NR^(N)C(S)N(R^(N)), S(O), OS(O), S(O)O,OS(O)O, OS(O)₂, S(O)₂O, OS(O)₂O, N(R^(N))S(O), —S(O)N(R^(N)),N(R^(N))S(O)N(R^(N)), OS(O)N(R^(N)), N(R^(N))S(O)O, S(O)₂,N(R^(N))S(O)₂, S(O)₂N(R^(N)), N(R^(N))S(O)₂N(R^(N)), OS(O)₂N(R^(N)), orN(R^(N))S(O)₂O;

each instance of R^(N) is independently hydrogen, optionally substitutedalkyl, or a nitrogen protecting group;

Ring B is optionally substituted carbocyclyl, optionally substitutedheterocyclyl, optionally substituted aryl, or optionally substitutedheteroaryl; and

p is 1 or 2;

provided that the compound is not of the formula:

wherein each instance of R₂ is independently unsubstituted alkyl,unsubstituted alkenyl, or unsubstituted alkynyl.

In some embodiments, the phospholipids may be one or more of thephospholipids described in U.S. Application No. 62/520,530.

i) Phospholipid Head Modifications

In certain embodiments, a phospholipid useful or potentially useful inthe present invention comprises a modified phospholipid head (e.g., amodified choline group). In certain embodiments, a phospholipid with amodified head is DSPC, or analog thereof, with a modified quaternaryamine. For example, in embodiments of Formula (IV), at least one of R¹is not methyl. In certain embodiments, at least one of R¹ is nothydrogen or methyl. In certain embodiments, the compound of Formula (IV)is of one of the following formulae:

or a salt thereof, wherein:

each t is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

each u is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and

each v is independently 1, 2, or 3.

In certain embodiments, a compound of Formula (IV) is of Formula (IV-a):

or a salt thereof.

In certain embodiments, a phospholipid useful or potentially useful inthe present invention comprises a cyclic moiety in place of theglyceride moiety. In certain embodiments, a phospholipid useful in thepresent invention is DSPC, or analog thereof, with a cyclic moiety inplace of the glyceride moiety. In certain embodiments, the compound ofFormula (IV) is of Formula (IV-b):

or a salt thereof.

(ii) Phospholipid Tail Modifications

In certain embodiments, a phospholipid useful or potentially useful inthe present invention comprises a modified tail. In certain embodiments,a phospholipid useful or potentially useful in the present invention isDSPC, or analog thereof, with a modified tail. As described herein, a“modified tail” may be a tail with shorter or longer aliphatic chains,aliphatic chains with branching introduced, aliphatic chains withsubstituents introduced, aliphatic chains wherein one or more methylenesare replaced by cyclic or heteroatom groups, or any combination thereof.For example, in certain embodiments, the compound of (IV) is of Formula(IV-a), or a salt thereof, wherein at least one instance of R² is eachinstance of R² is optionally substituted C₁₋₃₀ alkyl, wherein one ormore methylene units of R² are independently replaced with optionallysubstituted carbocyclylene, optionally substituted heterocyclylene,optionally substituted arylene, optionally substituted heteroarylene,N(R^(N)), O, S, C(O), —C(O)N(R^(N)), NR^(N)C(O), NR^(N)C(O)N(R^(N)),C(O)O, OC(O), OC(O)O, OC(O)N(R^(N)), —NR^(N)C(O)O, C(O)S, SC(O),C(═NR^(N)), C(═NR^(N))N(R^(N)), NR^(N)C(═NR^(N)),—NR^(N)C(═NR^(N))N(R^(N)), C(S), C(S)N(R^(N)), NR^(N)C(S),NR^(N)C(S)N(R^(N)), S(O), OS(O), —S(O)O, OS(O)O, OS(O)₂, S(O)₂O,OS(O)₂O, N(R^(N))S(O), S(O)N(R^(N)), —N(R^(N))S(O)N(R^(N)),OS(O)N(R^(N)), N(R^(N))S(O)O, S(O)₂, N(R^(N))S(O)₂, S(O)₂N(R^(N)),—N(R^(N))S(O)₂N(R^(N)), OS(O)₂N(R^(N)), or N(R^(N))S(O)₂O.

In certain embodiments, the compound of Formula (IV) is of Formula(IV-c):

or a salt thereof, wherein:

each x is independently an integer between 0-30, inclusive; and

each instance is G is independently selected from the group consistingof optionally substituted carbocyclylene, optionally substitutedheterocyclylene, optionally substituted arylene, optionally substitutedheteroarylene, N(R^(N)), O, S, C(O), C(O)N(R^(N)), NR^(N)C(O),—NR^(N)C(O)N(R^(N)), C(O)O, OC(O), OC(O)O, OC(O)N(R^(N)), NR^(N)C(O)O,C(O)S, SC(O), —C(═NR^(N)), C(═NR^(N))N(R^(N)), NR^(N)C(═NR^(N)),NR^(N)C(═NR^(N))N(R^(N)), C(S), C(S)N(R^(N)), NR^(N)C(S),NR^(N)C(S)N(R^(N)), S(O), OS(O), S(O)O, OS(O)O, OS(O)₂, S(O)₂O, OS(O)₂O,N(R^(N))S(O), —S(O)N(R^(N)), N(R^(N))S(O)N(R^(N)), OS(O)N(R^(N)),N(R^(N))S(O)O, S(O)₂, N(R^(N))S(O)₂, S(O)₂N(R^(N)),N(R^(N))S(O)₂N(R^(N)), OS(O)₂N(R^(N)), or N(R^(N))S(O)₂O. Eachpossibility represents a separate embodiment of the present invention.

In certain embodiments, a phospholipid useful or potentially useful inthe present invention comprises a modified phosphocholine moiety,wherein the alkyl chain linking the quaternary amine to the phosphorylgroup is not ethylene (e.g., n is not 2). Therefore, in certainembodiments, a phospholipid useful or potentially useful in the presentinvention is a compound of Formula (IV), wherein n is 1, 3, 4, 5, 6, 7,8, 9, or 10. For example, in certain embodiments, a compound of Formula(IV) is of one of the following formulae:

or a salt thereof.

Alternative Lipids

In certain embodiments, a phospholipid useful or potentially useful inthe present invention comprises a modified phosphocholine moiety,wherein the alkyl chain linking the quaternary amine to the phosphorylgroup is not ethylene (e.g., n is not 2). Therefore, in certainembodiments, a phospholipid useful.

In certain embodiments, an alternative lipid is used in place of aphospholipid of the present disclosure.

In certain embodiments, an alternative lipid of the invention is oleicacid.

In certain embodiments, the alternative lipid is one of the following:

Structural Lipids

The lipid composition of a pharmaceutical composition disclosed hereincan comprise one or more structural lipids. As used herein, the term“structural lipid” refers to sterols and also to lipids containingsterol moieties.

Incorporation of structural lipids in the lipid nanoparticle may helpmitigate aggregation of other lipids in the particle. Structural lipidscan be selected from the group including but not limited to,cholesterol, fecosterol, sitosterol, ergosterol, campesterol,stigmasterol, brassicasterol, tomatidine, tomatine, ursolic acid,alpha-tocopherol, hopanoids, phytosterols, steroids, and mixturesthereof. In some embodiments, the structural lipid is a sterol. Asdefined herein, “sterols” are a subgroup of steroids consisting ofsteroid alcohols. In certain embodiments, the structural lipid is asteroid. In certain embodiments, the structural lipid is cholesterol. Incertain embodiments, the structural lipid is an analog of cholesterol.In certain embodiments, the structural lipid is alpha-tocopherol.

In some embodiments, the structural lipids may be one or more of thestructural lipids described in U.S. Application No. 62/520,530.

Polyethylene Glycol (PEG)-Lipids

The lipid composition of a pharmaceutical composition disclosed hereincan comprise one or more a polyethylene glycol (PEG) lipid.

As used herein, the term “PEG-lipid” refers to polyethylene glycol(PEG)-modified lipids. Non-limiting examples of PEG-lipids includePEG-modified phosphatidylethanolamine and phosphatidic acid,PEG-ceramide conjugates (e.g., PEG-CerC14 or PEG-CerC20), PEG-modifieddialkylamines and PEG-modified 1,2-diacyloxypropan-3-amines. Such lipidsare also referred to as PEGylated lipids. For example, a PEG lipid canbe PEG-c-DOMG, PEG-DMG, PEG-DLPE, PEG-DMPE, PEG-DPPC, or a PEG-DSPElipid.

In some embodiments, the PEG-lipid includes, but not limited to1,2-dimyristoyl-sn-glycerol methoxypolyethylene glycol (PEG-DMG),1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethyleneglycol)] (PEG-DSPE), PEG-disteryl glycerol (PEG-DSG), PEG-dipalmetoleyl,PEG-dioleyl, PEG-distearyl, PEG-diacylglycamide (PEG-DAG),PEG-dipalmitoyl phosphatidylethanolamine (PEG-DPPE), orPEG-1,2-dimyristyloxlpropyl-3-amine (PEG-c-DMA).

In one embodiment, the PEG-lipid is selected from the group consistingof a PEG-modified phosphatidylethanolamine, a PEG-modified phosphatidicacid, a PEG-modified ceramide, a PEG-modified dialkylamine, aPEG-modified diacylglycerol, a PEG-modified dialkylglycerol, andmixtures thereof.

In some embodiments, the lipid moiety of the PEG-lipids includes thosehaving lengths of from about C₁₄ to about C₂₂, preferably from about C₁₄to about C₁₆. In some embodiments, a PEG moiety, for example anmPEG-NH₂, has a size of about 1000, 2000, 5000, 10,000, 15,000 or 20,000daltons. In one embodiment, the PEG-lipid is PEG₂k-DMG.

In one embodiment, the lipid nanoparticles described herein can comprisea PEG lipid which is a non-diffusible PEG. Non-limiting examples ofnon-diffusible PEGs include PEG-DSG and PEG-DSPE.

PEG-lipids are known in the art, such as those described in U.S. Pat.No. 8,158,601 and International Publ. No. WO 2015/130584 A2, which areincorporated herein by reference in their entirety.

In general, some of the other lipid components (e.g., PEG lipids) ofvarious formulae, described herein may be synthesized as describedInternational Patent Application No. PCT/US2016/000129, filed Dec. 10,2016, entitled “Compositions and Methods for Delivery of TherapeuticAgents,” which is incorporated by reference in its entirety.

The lipid component of a lipid nanoparticle composition may include oneor more molecules comprising polyethylene glycol, such as PEG orPEG-modified lipids. Such species may be alternately referred to asPEGylated lipids. A PEG lipid is a lipid modified with polyethyleneglycol. A PEG lipid may be selected from the non-limiting groupincluding PEG-modified phosphatidylethanolamines, PEG-modifiedphosphatidic acids, PEG-modified ceramides, PEG-modified dialkylamines,PEG-modified diacylglycerols, PEG-modified dialkylglycerols, andmixtures thereof. For example, a PEG lipid may be PEG-c-DOMG, PEG-DMG,PEG-DLPE, PEG-DMPE, PEG-DPPC, or a PEG-DSPE lipid.

In some embodiments the PEG-modified lipids are a modified form of PEGDMG. PEG-DMG has the following structure:

In one embodiment, PEG lipids useful in the present invention can bePEGylated lipids described in International Publication No.WO2012099755, the contents of which is herein incorporated by referencein its entirety. Any of these exemplary PEG lipids described herein maybe modified to comprise a hydroxyl group on the PEG chain. In certainembodiments, the PEG lipid is a PEG-OH lipid. As generally definedherein, a “PEG-OH lipid” (also referred to herein as “hydroxy-PEGylatedlipid”) is a PEGylated lipid having one or more hydroxyl (—OH) groups onthe lipid. In certain embodiments, the PEG-OH lipid includes one or morehydroxyl groups on the PEG chain. In certain embodiments, a PEG-OH orhydroxy-PEGylated lipid comprises an —OH group at the terminus of thePEG chain. Each possibility represents a separate embodiment of thepresent invention.

In certain embodiments, a PEG lipid useful in the present invention is acompound of Formula (V). Provided herein are compounds of Formula (V):

or salts thereof, wherein:

R³ is —OR^(O);

R^(O) is hydrogen, optionally substituted alkyl, or an oxygen protectinggroup;

r is an integer between 1 and 100, inclusive;

L¹ is optionally substituted C₁₋₁₀ alkylene, wherein at least onemethylene of the optionally substituted C₁₋₁₀ alkylene is independentlyreplaced with optionally substituted carbocyclylene, optionallysubstituted heterocyclylene, optionally substituted arylene, optionallysubstituted heteroarylene, O, N(R^(N)), S, C(O), C(O)N(R^(N)),NR^(N)C(O), C(O)O, —OC(O), OC(O)O, OC(O)N(R^(N)), NR^(N)C(O)O, orNR^(N)C(O)N(R^(N));

D is a moiety obtained by click chemistry or a moiety cleavable underphysiological conditions;

m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

A is of the formula:

each instance of L² is independently a bond or optionally substitutedC₁₋₆ alkylene, wherein one methylene unit of the optionally substitutedC₁₋₆ alkylene is optionally replaced with O, N(R^(N)), S, C(O),C(O)N(R^(N)), NR^(N)C(O), C(O)O, OC(O), OC(O)O, OC(O)N(R^(N)),—NR^(N)C(O)O, or NR^(N)C(O)N(R^(N));

each instance of R² is independently optionally substituted C₁₋₃₀ alkyl,optionally substituted C₁₋₃₀ alkenyl, or optionally substituted C₁₋₃₀alkynyl; optionally wherein one or more methylene units of R₂ areindependently replaced with optionally substituted carbocyclylene,optionally substituted heterocyclylene, optionally substituted arylene,optionally substituted heteroarylene, N(R^(N)), O, S, C(O),C(O)N(R^(N)), NR^(N)C(O), —NR^(N)C(O)N(R^(N)), C(O)O, OC(O), OC(O)O,OC(O)N(R^(N)), NR^(N)C(O)O, C(O)S, SC(O), —C(═NR^(N)),C(═NR^(N))N(R^(N)), NR^(N)C(═NR^(N)), NR^(N)C(═NR^(N))N(R^(N)), C(S),C(S)N(R^(N)), NR^(N)C(S), NR^(N)C(S)N(R^(N)), S(O), OS(O), S(O)O,OS(O)O, OS(O)₂, S(O)₂O, OS(O)₂O, N(R^(N))S(O), —S(O)N(R^(N)),N(R^(N))S(O)N(R^(N)), OS(O)N(R^(N)), N(R^(N))S(O)O, S(O)₂,N(R^(N))S(O)₂, S(O)₂N(R^(N)), N(R^(N))S(O)₂N(R^(N)), OS(O)₂N(R^(N)), orN(R^(N))S(O)₂O;

each instance of R^(N) is independently hydrogen, optionally substitutedalkyl, or a nitrogen protecting group;

Ring B is optionally substituted carbocyclyl, optionally substitutedheterocyclyl, optionally substituted aryl, or optionally substitutedheteroaryl; and

p is 1 or 2.

In certain embodiments, the compound of Formula (V) is a PEG-OH lipid(i.e., R³ is —OR^(O), and R^(O) is hydrogen). In certain embodiments,the compound of Formula (V) is of Formula (V-OH):

or a salt thereof.

In certain embodiments, a PEG lipid useful in the present invention is aPEGylated fatty acid. In certain embodiments, a PEG lipid useful in thepresent invention is a compound of Formula (VI). Provided herein arecompounds of Formula (VI):

or a salts thereof, wherein:

R³ is —OR^(O);

R^(O) is hydrogen, optionally substituted alkyl or an oxygen protectinggroup;

r is an integer between 1 and 100, inclusive;

R⁵ is optionally substituted C₁₀₋₄₀ alkyl, optionally substituted C₁₀₋₄₀alkenyl, or optionally substituted C₁₀₋₄₀ alkynyl; and optionally one ormore methylene groups of R⁵ are replaced with optionally substitutedcarbocyclylene, optionally substituted heterocyclylene, optionallysubstituted arylene, optionally substituted heteroarylene, N(R^(N)), O,S, C(O), —C(O)N(R^(N)), NR^(N)C(O), NR^(N)C(O)N(R^(N)), C(O)O, OC(O),OC(O)O, OC(O)N(R^(N)), —NR^(N)C(O)O, C(O)S, SC(O), C(═NR^(N)),C(═NR^(N))N(R^(N)), NR^(N)C(═NR^(N)), NR^(N)C(═NR^(N))N(R^(N)), C(S),C(S)N(R^(N)), NR^(N)C(S), NR^(N)C(S)N(R^(N)), S(O), OS(O), S(O)O,OS(O)O, OS(O)₂, —S(O)₂O, OS(O)₂O, N(R^(N))S(O), S(O)N(R^(N)),N(R^(N))S(O)N(R^(N)), OS(O)N(R^(N)), N(R^(N))S(O)O, S(O)₂,N(R^(N))S(O)₂, S(O)₂N(R^(N)), N(R^(N))S(O)₂N(R^(N)), OS(O)₂N(R^(N)), orN(R^(N))S(O)₂O; and

each instance of R^(N) is independently hydrogen, optionally substitutedalkyl, or a nitrogen protecting group.

In certain embodiments, the compound of Formula (VI) is of Formula(VI-OH):

or a salt thereof. In some embodiments, r is 45.

In yet other embodiments the compound of Formula (VI) is:

or a salt thereof.

In one embodiment, the compound of Formula (VI) is

In some aspects, the lipid composition of the pharmaceuticalcompositions disclosed herein does not comprise a PEG-lipid.

In some embodiments, the PEG-lipids may be one or more of the PEG lipidsdescribed in U.S. Application No. 62/520,530.

In some embodiments, a PEG lipid of the invention comprises aPEG-modified phosphatidylethanolamine, a PEG-modified phosphatidic acid,a PEG-modified ceramide, a PEG-modified dialkylamine, a PEG-modifieddiacylglycerol, a PEG-modified dialkylglycerol, and mixtures thereof. Insome embodiments, the PEG-modified lipid is PEG-DMG, PEG-c-DOMG (alsoreferred to as PEG-DOMG), PEG-DSG and/or PEG-DPG.

In some embodiments, a LNP of the invention comprises an ionizablecationic lipid of any of Formula I, II or III, a phospholipid comprisingDSPC, a structural lipid, and a PEG lipid comprising PEG-DMG.

In some embodiments, a LNP of the invention comprises an ionizablecationic lipid of any of Formula I, II or III, a phospholipid comprisingDSPC, a structural lipid, and a PEG lipid comprising a compound havingFormula VI.

In some embodiments, a LNP of the invention comprises an ionizablecationic lipid of Formula I, II or III, a phospholipid comprising acompound having Formula IV, a structural lipid, and the PEG lipidcomprising a compound having Formula V or VI.

In some embodiments, a LNP of the invention comprises an ionizablecationic lipid of Formula I, II or III, a phospholipid comprising acompound having Formula IV, a structural lipid, and the PEG lipidcomprising a compound having Formula V or VI.

In some embodiments, a LNP of the invention comprises an ionizablecationic lipid of Formula I, II or III, a phospholipid having FormulaIV, a structural lipid, and a PEG lipid comprising a compound havingFormula VI.

In some embodiments, a LNP of the invention comprises an ionizablecationic lipid of

and a PEG lipid comprising Formula VI.

In some embodiments, a LNP of the invention comprises an ionizablecationic lipid of

and an alternative lipid comprising oleic acid.

In some embodiments, a LNP of the invention comprises an ionizablecationic lipid of

an alternative lipid comprising oleic acid, a structural lipidcomprising cholesterol, and a PEG lipid comprising a compound havingFormula VI.

In some embodiments, a LNP of the invention comprises an ionizablecationic lipid of

a phospholipid comprising DOPE, a structural lipid comprisingcholesterol, and a PEG lipid comprising a compound having Formula VI.

In some embodiments, a LNP of the invention comprises an ionizablecationic lipid of a phospholipid comprising DOPE, a structural lipidcomprising cholesterol, and a PEG lipid comprising a compound havingFormula VII.

In some embodiments, a LNP of the invention comprises an N:P ratio offrom about 2:1 to about 30:1.

In some embodiments, a LNP of the invention comprises an N:P ratio ofabout 6:1.

In some embodiments, a LNP of the invention comprises an N:P ratio ofabout 3:1.

In some embodiments, a LNP of the invention comprises a wt/wt ratio ofthe ionizable cationic lipid component to the RNA of from about 10:1 toabout 100:1.

In some embodiments, a LNP of the invention comprises a wt/wt ratio ofthe ionizable cationic lipid component to the RNA of about 20:1.

In some embodiments, a LNP of the invention comprises a wt/wt ratio ofthe ionizable cationic lipid component to the RNA of about 10:1.

In some embodiments, a LNP of the invention has a mean diameter fromabout 50 nm to about 150 nm.

In some embodiments, a LNP of the invention has a mean diameter fromabout 70 nm to about 120 nm.

As used herein, the term “alkyl”, “alkyl group”, or “alkylene” means alinear or branched, saturated hydrocarbon including one or more carbonatoms (e.g., one, two, three, four, five, six, seven, eight, nine, ten,eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen,eighteen, nineteen, twenty, or more carbon atoms), which is optionallysubstituted. The notation “C₁₋₁₄ alkyl” means an optionally substitutedlinear or branched, saturated hydrocarbon including 1 14 carbon atoms.Unless otherwise specified, an alkyl group described herein refers toboth unsubstituted and substituted alkyl groups.

As used herein, the term “alkenyl”, “alkenyl group”, or “alkenylene”means a linear or branched hydrocarbon including two or more carbonatoms (e.g., two, three, four, five, six, seven, eight, nine, ten,eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen,eighteen, nineteen, twenty, or more carbon atoms) and at least onedouble bond, which is optionally substituted. The notation “C₂₋₁₄alkenyl” means an optionally substituted linear or branched hydrocarbonincluding 2 14 carbon atoms and at least one carbon-carbon double bond.An alkenyl group may include one, two, three, four, or morecarbon-carbon double bonds. For example, C18 alkenyl may include one ormore double bonds. A C18 alkenyl group including two double bonds may bea linoleyl group. Unless otherwise specified, an alkenyl group describedherein refers to both unsubstituted and substituted alkenyl groups.

As used herein, the term “alkynyl”, “alkynyl group”, or “alkynylene”means a linear or branched hydrocarbon including two or more carbonatoms (e.g., two, three, four, five, six, seven, eight, nine, ten,eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen,eighteen, nineteen, twenty, or more carbon atoms) and at least onecarbon-carbon triple bond, which is optionally substituted. The notation“C₂₋₁₄ alkynyl” means an optionally substituted linear or branchedhydrocarbon including 2 14 carbon atoms and at least one carbon-carbontriple bond. An alkynyl group may include one, two, three, four, or morecarbon-carbon triple bonds. For example, C18 alkynyl may include one ormore carbon-carbon triple bonds. Unless otherwise specified, an alkynylgroup described herein refers to both unsubstituted and substitutedalkynyl groups.

As used herein, the term “carbocycle” or “carbocyclic group” means anoptionally substituted mono- or multi-cyclic system including one ormore rings of carbon atoms. Rings may be three, four, five, six, seven,eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen,seventeen, eighteen, nineteen, or twenty membered rings. The notation“C3-6 carbocycle” means a carbocycle including a single ring having 3-6carbon atoms. Carbocycles may include one or more carbon-carbon doubleor triple bonds and may be non-aromatic or aromatic (e.g., cycloalkyl oraryl groups). Examples of carbocycles include cyclopropyl, cyclopentyl,cyclohexyl, phenyl, naphthyl, and 1,2 dihydronaphthyl groups. The term“cycloalkyl” as used herein means a non-aromatic carbocycle and may ormay not include any double or triple bond. Unless otherwise specified,carbocycles described herein refers to both unsubstituted andsubstituted carbocycle groups, i.e., optionally substituted carbocycles.

As used herein, the term “heterocycle” or “heterocyclic group” means anoptionally substituted mono- or multi-cyclic system including one ormore rings, where at least one ring includes at least one heteroatom.Heteroatoms may be, for example, nitrogen, oxygen, or sulfur atoms.Rings may be three, four, five, six, seven, eight, nine, ten, eleven,twelve, thirteen, or fourteen membered rings. Heterocycles may includeone or more double or triple bonds and may be non-aromatic or aromatic(e.g., heterocycloalkyl or heteroaryl groups). Examples of heterocyclesinclude imidazolyl, imidazolidinyl, oxazolyl, oxazolidinyl, thiazolyl,thiazolidinyl, pyrazolidinyl, pyrazolyl, isoxazolidinyl, isoxazolyl,isothiazolidinyl, isothiazolyl, morpholinyl, pyrrolyl, pyrrolidinyl,furyl, tetrahydrofuryl, thiophenyl, pyridinyl, piperidinyl, quinolyl,and isoquinolyl groups. The term “heterocycloalkyl” as used herein meansa non-aromatic heterocycle and may or may not include any double ortriple bond. Unless otherwise specified, heterocycles described hereinrefers to both unsubstituted and substituted heterocycle groups, i.e.,optionally substituted heterocycles.

As used herein, the term “heteroalkyl”, “heteroalkenyl”, or“heteroalkynyl”, refers respectively to an alkyl, alkenyl, alkynylgroup, as defined herein, which further comprises one or more (e.g., 1,2, 3, or 4) heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, silicon,phosphorus) wherein the one or more heteroatoms is inserted betweenadjacent carbon atoms within the parent carbon chain and/or one or moreheteroatoms is inserted between a carbon atom and the parent molecule,i.e., between the point of attachment. Unless otherwise specified,heteroalkyls, heteroalkenyls, or heteroalkynyls described herein refersto both unsubstituted and substituted heteroalkyls, heteroalkenyls, orheteroalkynyls, i.e., optionally substituted heteroalkyls,heteroalkenyls, or heteroalkynyls.

As used herein, a “biodegradable group” is a group that may facilitatefaster metabolism of a lipid in a mammalian entity. A biodegradablegroup may be selected from the group consisting of, but is not limitedto, —C(O)O—, —OC(O)—, —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—,—SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)2-, an aryl group, and aheteroaryl group. As used herein, an “aryl group” is an optionallysubstituted carbocyclic group including one or more aromatic rings.Examples of aryl groups include phenyl and naphthyl groups. As usedherein, a “heteroaryl group” is an optionally substituted heterocyclicgroup including one or more aromatic rings. Examples of heteroarylgroups include pyrrolyl, furyl, thiophenyl, imidazolyl, oxazolyl, andthiazolyl. Both aryl and heteroaryl groups may be optionallysubstituted. For example, M and M′ can be selected from the non-limitinggroup consisting of optionally substituted phenyl, oxazole, andthiazole. In the formulas herein, M and M′ can be independently selectedfrom the list of biodegradable groups above. Unless otherwise specified,aryl or heteroaryl groups described herein refers to both unsubstitutedand substituted groups, i.e., optionally substituted aryl or heteroarylgroups.

Alkyl, alkenyl, and cyclyl (e.g., carbocyclyl and heterocyclyl) groupsmay be optionally substituted unless otherwise specified. Optionalsubstituents may be selected from the group consisting of, but are notlimited to, a halogen atom (e.g., a chloride, bromide, fluoride, oriodide group), a carboxylic acid (e.g., C(O)OH), an alcohol (e.g., ahydroxyl, OH), an ester (e.g., C(O)OR OC(O)R), an aldehyde (e.g.,C(O)H), a carbonyl (e.g., C(O)R, alternatively represented by C═O), anacyl halide (e.g., C(O)X, in which X is a halide selected from bromide,fluoride, chloride, and iodide), a carbonate (e.g., OC(O)OR), an alkoxy(e.g., OR), an acetal (e.g., C(OR)2R″″, in which each OR are alkoxygroups that can be the same or different and R″″ is an alkyl or alkenylgroup), a phosphate (e.g., P(O)43-), a thiol (e.g., SH), a sulfoxide(e.g., S(O)R), a sulfinic acid (e.g., S(O)OH), a sulfonic acid (e.g.,S(O)2OH), a thial (e.g., C(S)H), a sulfate (e.g., S(O)42-), a sulfonyl(e.g., S(O)2), an amide (e.g., C(O)NR2, or N(R)C(O)R), an azido (e.g.,N3), a nitro (e.g., NO2), a cyano (e.g., CN), an isocyano (e.g., NC), anacyloxy (e.g., OC(O)R), an amino (e.g., NR2, NRH, or NH2), a carbamoyl(e.g., OC(O)NR2, OC(O)NRH, or OC(O)NH2), a sulfonamide (e.g., S(O)2NR2,S(O)2NRH, S(O)2NH2, N(R)S(O)2R, N(H)S(O)2R, N(R)S(O)2H, or N(H)S(O)2H),an alkyl group, an alkenyl group, and a cyclyl (e.g., carbocyclyl orheterocyclyl) group. In any of the preceding, R is an alkyl or alkenylgroup, as defined herein. In some embodiments, the substituent groupsthemselves may be further substituted with, for example, one, two,three, four, five, or six substituents as defined herein. For example, aC1 6 alkyl group may be further substituted with one, two, three, four,five, or six substituents as described herein.

Compounds of the disclosure that contain nitrogens can be converted toN-oxides by treatment with an oxidizing agent (e.g.,3-chloroperoxybenzoic acid (mCPBA) and/or hydrogen peroxides) to affordother compounds of the disclosure. Thus, all shown and claimednitrogen-containing compounds are considered, when allowed by valencyand structure, to include both the compound as shown and its N-oxidederivative (which can be designated as N□O or N+—O—). Furthermore, inother instances, the nitrogens in the compounds of the disclosure can beconverted to N-hydroxy or N-alkoxy compounds. For example, N-hydroxycompounds can be prepared by oxidation of the parent amine by anoxidizing agent such as m CPBA. All shown and claimednitrogen-containing compounds are also considered, when allowed byvalency and structure, to cover both the compound as shown and itsN-hydroxy (i.e., N—OH) and N-alkoxy (i.e., N—OR, wherein R issubstituted or unsubstituted C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkynyl,3-14-membered carbocycle or 3-14-membered heterocycle) derivatives.

(vi) Other Lipid Composition Components

The lipid composition of a pharmaceutical composition disclosed hereincan include one or more components in addition to those described above.For example, the lipid composition can include one or more permeabilityenhancer molecules, carbohydrates, polymers, surface altering agents(e.g., surfactants), or other components. For example, a permeabilityenhancer molecule can be a molecule described by U.S. Patent ApplicationPublication No. 2005/0222064. Carbohydrates can include simple sugars(e.g., glucose) and polysaccharides (e.g., glycogen and derivatives andanalogs thereof).

A polymer can be included in and/or used to encapsulate or partiallyencapsulate a pharmaceutical composition disclosed herein (e.g., apharmaceutical composition in lipid nanoparticle form). A polymer can bebiodegradable and/or biocompatible. A polymer can be selected from, butis not limited to, polyamines, polyethers, polyamides, polyesters,polycarbamates, polyureas, polycarbonates, polystyrenes, polyimides,polysulfones, polyurethanes, polyacetylenes, polyethylenes,polyethyleneimines, polyisocyanates, polyacrylates, polymethacrylates,polyacrylonitriles, and polyarylates.

The ratio between the lipid composition and the polynucleotide range canbe from about 10:1 to about 60:1 (wt/wt).

In some embodiments, the ratio between the lipid composition and thepolynucleotide can be about 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1,17:1, 18:1, 19:1, 20:1, 21:1, 22:1, 23:1, 24:1, 25:1, 26:1, 27:1, 28:1,29:1, 30:1, 31:1, 32:1, 33:1, 34:1, 35:1, 36:1, 37:1, 38:1, 39:1, 40:1,41:1, 42:1, 43:1, 44:1, 45:1, 46:1, 47:1, 48:1, 49:1, 50:1, 51:1, 52:1,53:1, 54:1, 55:1, 56:1, 57:1, 58:1, 59:1 or 60:1 (wt/wt). In someembodiments, the wt/wt ratio of the lipid composition to thepolynucleotide encoding a therapeutic agent is about 20:1 or about 15:1.

In some embodiments, the pharmaceutical composition disclosed herein cancontain more than one polypeptides. For example, a pharmaceuticalcomposition disclosed herein can contain two or more polynucleotides(e.g., RNA, e.g., mRNA).

In one embodiment, the lipid nanoparticles described herein can comprisepolynucleotides (e.g., mRNA) in a lipid:polynucleotide weight ratio of5:1, 10:1, 15:1, 20:1, 25:1, 30:1, 35:1, 40:1, 45:1, 50:1, 55:1, 60:1 or70:1, or a range or any of these ratios such as, but not limited to, 5:1to about 10:1, from about 5:1 to about 15:1, from about 5:1 to about20:1, from about 5:1 to about 25:1, from about 5:1 to about 30:1, fromabout 5:1 to about 35:1, from about 5:1 to about 40:1, from about 5:1 toabout 45:1, from about 5:1 to about 50:1, from about 5:1 to about 55:1,from about 5:1 to about 60:1, from about 5:1 to about 70:1, from about10:1 to about 15:1, from about 10:1 to about 20:1, from about 10:1 toabout 25:1, from about 10:1 to about 30:1, from about 10:1 to about35:1, from about 10:1 to about 40:1, from about 10:1 to about 45:1, fromabout 10:1 to about 50:1, from about 10:1 to about 55:1, from about 10:1to about 60:1, from about 10:1 to about 70:1, from about 15:1 to about20:1, from about 15:1 to about 25:1,from about 15:1 to about 30:1, fromabout 15:1 to about 35:1, from about 15:1 to about 40:1, from about 15:1to about 45:1, from about 15:1 to about 50:1, from about 15:1 to about55:1, from about 15:1 to about 60:1 or from about 15:1 to about 70:1.

In one embodiment, the lipid nanoparticles described herein can comprisethe polynucleotide in a concentration from approximately 0.1 mg/ml to 2mg/ml such as, but not limited to, 0.1 mg/ml, 0.2 mg/ml, 0.3 mg/ml, 0.4mg/ml, 0.5 mg/ml, 0.6 mg/ml, 0.7 mg/ml, 0.8 mg/ml, 0.9 mg/ml, 1.0 mg/ml,1.1 mg/ml, 1.2 mg/ml, 1.3 mg/ml, 1.4 mg/ml, 1.5 mg/ml, 1.6 mg/ml, 1.7mg/ml, 1.8 mg/ml, 1.9 mg/ml, 2.0 mg/ml or greater than 2.0 mg/ml.

(vii) Nanoparticle Compositions

In some embodiments, the pharmaceutical compositions disclosed hereinare formulated as lipid nanoparticles (LNP). Accordingly, the presentdisclosure also provides nanoparticle compositions comprising (i) alipid composition comprising a delivery agent such as compound asdescribed herein, and (ii) a polynucleotide encoding a PCCA or PCCBpolypeptide. In such nanoparticle composition, the lipid compositiondisclosed herein can encapsulate the polynucleotide encoding a PCCA orPCCB polypeptide.

Nanoparticle compositions are typically sized on the order ofmicrometers or smaller and can include a lipid bilayer. Nanoparticlecompositions encompass lipid nanoparticles (LNPs), liposomes (e.g.,lipid vesicles), and lipoplexes. For example, a nanoparticle compositioncan be a liposome having a lipid bilayer with a diameter of 500 nm orless.

Nanoparticle compositions include, for example, lipid nanoparticles(LNPs), liposomes, and lipoplexes. In some embodiments, nanoparticlecompositions are vesicles including one or more lipid bilayers. Incertain embodiments, a nanoparticle composition includes two or moreconcentric bilayers separated by aqueous compartments. Lipid bilayerscan be functionalized and/or crosslinked to one another. Lipid bilayerscan include one or more ligands, proteins, or channels.

In one embodiment, a lipid nanoparticle comprises an ionizable lipid, astructural lipid, a phospholipid, and mRNA. In some embodiments, the LNPcomprises an ionizable lipid, a PEG-modified lipid, a sterol and astructural lipid. In some embodiments, the LNP has a molar ratio ofabout 20-60% ionizable lipid:about 5-25% structural lipid:about 25-55%sterol; and about 0.5-15% PEG-modified lipid.

In some embodiments, the LNP has a polydispersity value of less than0.4. In some embodiments, the LNP has a net neutral charge at a neutralpH. In some embodiments, the LNP has a mean diameter of 50-150 nm. Insome embodiments, the LNP has a mean diameter of 80-100 nm.

As generally defined herein, the term “lipid” refers to a small moleculethat has hydrophobic or amphiphilic properties. Lipids may be naturallyoccurring or synthetic. Examples of classes of lipids include, but arenot limited to, fats, waxes, sterol-containing metabolites, vitamins,fatty acids, glycerolipids, glycerophospholipids, sphingolipids,saccharolipids, and polyketides, and prenol lipids. In some instances,the amphiphilic properties of some lipids leads them to form liposomes,vesicles, or membranes in aqueous media.

In some embodiments, a lipid nanoparticle (LNP) may comprise anionizable lipid. As used herein, the term “ionizable lipid” has itsordinary meaning in the art and may refer to a lipid comprising one ormore charged moieties. In some embodiments, an ionizable lipid may bepositively charged or negatively charged. An ionizable lipid may bepositively charged, in which case it can be referred to as “cationiclipid”. In certain embodiments, an ionizable lipid molecule may comprisean amine group, and can be referred to as an ionizable amino lipid. Asused herein, a “charged moiety” is a chemical moiety that carries aformal electronic charge, e.g., monovalent (+1, or −1), divalent (+2, or−2), trivalent (+3, or −3), etc. The charged moiety may be anionic(i.e., negatively charged) or cationic (i.e., positively charged).Examples of positively-charged moieties include amine groups (e.g.,primary, secondary, and/or tertiary amines), ammonium groups, pyridiniumgroup, guanidine groups, and imidizolium groups. In a particularembodiment, the charged moieties comprise amine groups. Examples ofnegatively-charged groups or precursors thereof, include carboxylategroups, sulfonate groups, sulfate groups, phosphonate groups, phosphategroups, hydroxyl groups, and the like. The charge of the charged moietymay vary, in some cases, with the environmental conditions, for example,changes in pH may alter the charge of the moiety, and/or cause themoiety to become charged or uncharged. In general, the charge density ofthe molecule may be selected as desired.

It should be understood that the terms “charged” or “charged moiety”does not refer to a “partial negative charge” or “partial positivecharge” on a molecule. The terms “partial negative charge” and “partialpositive charge” are given its ordinary meaning in the art. A “partialnegative charge” may result when a functional group comprises a bondthat becomes polarized such that electron density is pulled toward oneatom of the bond, creating a partial negative charge on the atom. Thoseof ordinary skill in the art will, in general, recognize bonds that canbecome polarized in this way.

In some embodiments, the ionizable lipid is an ionizable amino lipid,sometimes referred to in the art as an “ionizable cationic lipid”. Inone embodiment, the ionizable amino lipid may have a positively chargedhydrophilic head and a hydrophobic tail that are connected via a linkerstructure.

In addition to these, an ionizable lipid may also be a lipid including acyclic amine group.

In one embodiment, the ionizable lipid may be selected from, but notlimited to, a ionizable lipid described in International PublicationNos. WO2013086354 and WO2013116126; the contents of each of which areherein incorporated by reference in their entirety.

In yet another embodiment, the ionizable lipid may be selected from, butnot limited to, formula CLI-CLXXXXII of U.S. Pat. No. 7,404,969; each ofwhich is herein incorporated by reference in their entirety.

In one embodiment, the lipid may be a cleavable lipid such as thosedescribed in International Publication No. WO2012170889, hereinincorporated by reference in its entirety. In one embodiment, the lipidmay be synthesized by methods known in the art and/or as described inInternational Publication Nos. WO2013086354; the contents of each ofwhich are herein incorporated by reference in their entirety.

Nanoparticle compositions can be characterized by a variety of methods.For example, microscopy (e.g., transmission electron microscopy orscanning electron microscopy) can be used to examine the morphology andsize distribution of a nanoparticle composition. Dynamic lightscattering or potentiometry (e.g., potentiometric titrations) can beused to measure zeta potentials. Dynamic light scattering can also beutilized to determine particle sizes. Instruments such as the ZetasizerNano ZS (Malvern Instruments Ltd, Malvern, Worcestershire, UK) can alsobe used to measure multiple characteristics of a nanoparticlecomposition, such as particle size, polydispersity index, and zetapotential.

The size of the nanoparticles can help counter biological reactions suchas, but not limited to, inflammation, or can increase the biologicaleffect of the polynucleotide.

As used herein, “size” or “mean size” in the context of nanoparticlecompositions refers to the mean diameter of a nanoparticle composition.

In one embodiment, the polynucleotide encoding a PCCA or PCCBpolypeptide are formulated in lipid nanoparticles having a diameter fromabout 10 to about 100 nm such as, but not limited to, about 10 to about20 nm, about 10 to about 30 nm, about 10 to about 40 nm, about 10 toabout 50 nm, about 10 to about 60 nm, about 10 to about 70 nm, about 10to about 80 nm, about 10 to about 90 nm, about 20 to about 30 nm, about20 to about 40 nm, about 20 to about 50 nm, about 20 to about 60 nm,about 20 to about 70 nm, about 20 to about 80 nm, about 20 to about 90nm, about 20 to about 100 nm, about 30 to about 40 nm, about 30 to about50 nm, about 30 to about 60 nm, about 30 to about 70 nm, about 30 toabout 80 nm, about 30 to about 90 nm, about 30 to about 100 nm, about 40to about 50 nm, about 40 to about 60 nm, about 40 to about 70 nm, about40 to about 80 nm, about 40 to about 90 nm, about 40 to about 100 nm,about 50 to about 60 nm, about 50 to about 70 nm, about 50 to about 80nm, about 50 to about 90 nm, about 50 to about 100 nm, about 60 to about70 nm, about 60 to about 80 nm, about 60 to about 90 nm, about 60 toabout 100 nm, about 70 to about 80 nm, about 70 to about 90 nm, about 70to about 100 nm, about 80 to about 90 nm, about 80 to about 100 nmand/or about 90 to about 100 nm.

In one embodiment, the nanoparticles have a diameter from about 10 to500 nm. In one embodiment, the nanoparticle has a diameter greater than100 nm, greater than 150 nm, greater than 200 nm, greater than 250 nm,greater than 300 nm, greater than 350 nm, greater than 400 nm, greaterthan 450 nm, greater than 500 nm, greater than 550 nm, greater than 600nm, greater than 650 nm, greater than 700 nm, greater than 750 nm,greater than 800 nm, greater than 850 nm, greater than 900 nm, greaterthan 950 nm or greater than 1000 nm.

In some embodiments, the largest dimension of a nanoparticle compositionis 1 μm or shorter (e.g., 1 μm, 900 nm, 800 nm, 700 nm, 600 nm, 500 nm,400 nm, 300 nm, 200 nm, 175 nm, 150 nm, 125 nm, 100 nm, 75 nm, 50 nm, orshorter).

A nanoparticle composition can be relatively homogenous. Apolydispersity index can be used to indicate the homogeneity of ananoparticle composition, e.g., the particle size distribution of thenanoparticle composition. A small (e.g., less than 0.3) polydispersityindex generally indicates a narrow particle size distribution. Ananoparticle composition can have a polydispersity index from about 0 toabout 0.25, such as 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08,0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.20,0.21, 0.22, 0.23, 0.24, or 0.25. In some embodiments, the polydispersityindex of a nanoparticle composition disclosed herein can be from about0.10 to about 0.20.

The zeta potential of a nanoparticle composition can be used to indicatethe electrokinetic potential of the composition. For example, the zetapotential can describe the surface charge of a nanoparticle composition.Nanoparticle compositions with relatively low charges, positive ornegative, are generally desirable, as more highly charged species caninteract undesirably with cells, tissues, and other elements in thebody. In some embodiments, the zeta potential of a nanoparticlecomposition disclosed herein can be from about −10 mV to about +20 mV,from about −10 mV to about +15 mV, from about 10 mV to about +10 mV,from about −10 mV to about +5 mV, from about −10 mV to about 0 mV, fromabout −10 mV to about −5 mV, from about −5 mV to about +20 mV, fromabout −5 mV to about +15 mV, from about −5 mV to about +10 mV, fromabout −5 mV to about +5 mV, from about −5 mV to about 0 mV, from about 0mV to about +20 mV, from about 0 mV to about +15 mV, from about 0 mV toabout +10 mV, from about 0 mV to about +5 mV, from about +5 mV to about+20 mV, from about +5 mV to about +15 mV, or from about +5 mV to about+10 mV.

In some embodiments, the zeta potential of the lipid nanoparticles canbe from about 0 mV to about 100 mV, from about 0 mV to about 90 mV, fromabout 0 mV to about 80 mV, from about 0 mV to about 70 mV, from about 0mV to about 60 mV, from about 0 mV to about 50 mV, from about 0 mV toabout 40 mV, from about 0 mV to about 30 mV, from about 0 mV to about 20mV, from about 0 mV to about 10 mV, from about 10 mV to about 100 mV,from about 10 mV to about 90 mV, from about 10 mV to about 80 mV, fromabout 10 mV to about 70 mV, from about 10 mV to about 60 mV, from about10 mV to about 50 mV, from about 10 mV to about 40 mV, from about 10 mVto about 30 mV, from about 10 mV to about 20 mV, from about 20 mV toabout 100 mV, from about 20 mV to about 90 mV, from about 20 mV to about80 mV, from about 20 mV to about 70 mV, from about 20 mV to about 60 mV,from about 20 mV to about 50 mV, from about 20 mV to about 40 mV, fromabout 20 mV to about 30 mV, from about 30 mV to about 100 mV, from about30 mV to about 90 mV, from about 30 mV to about 80 mV, from about 30 mVto about 70 mV, from about 30 mV to about 60 mV, from about 30 mV toabout 50 mV, from about 30 mV to about 40 mV, from about 40 mV to about100 mV, from about 40 mV to about 90 mV, from about 40 mV to about 80mV, from about 40 mV to about 70 mV, from about 40 mV to about 60 mV,and from about 40 mV to about 50 mV. In some embodiments, the zetapotential of the lipid nanoparticles can be from about 10 mV to about 50mV, from about 15 mV to about 45 mV, from about 20 mV to about 40 mV,and from about 25 mV to about 35 mV. In some embodiments, the zetapotential of the lipid nanoparticles can be about 10 mV, about 20 mV,about 30 mV, about 40 mV, about 50 mV, about 60 mV, about 70 mV, about80 mV, about 90 mV, and about 100 mV.

The term “encapsulation efficiency” of a polynucleotide describes theamount of the polynucleotide that is encapsulated by or otherwiseassociated with a nanoparticle composition after preparation, relativeto the initial amount provided. As used herein, “encapsulation” canrefer to complete, substantial, or partial enclosure, confinement,surrounding, or encasement.

Encapsulation efficiency is desirably high (e.g., close to 100%). Theencapsulation efficiency can be measured, for example, by comparing theamount of the polynucleotide in a solution containing the nanoparticlecomposition before and after breaking up the nanoparticle compositionwith one or more organic solvents or detergents.

Fluorescence can be used to measure the amount of free polynucleotide ina solution. For the nanoparticle compositions described herein, theencapsulation efficiency of a polynucleotide can be at least 50%, forexample 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%,95%, 96%, 97%, 98%, 99%, or 100%. In some embodiments, the encapsulationefficiency can be at least 80%. In certain embodiments, theencapsulation efficiency can be at least 90%.

The amount of a polynucleotide present in a pharmaceutical compositiondisclosed herein can depend on multiple factors such as the size of thepolynucleotide, desired target and/or application, or other propertiesof the nanoparticle composition as well as on the properties of thepolynucleotide.

For example, the amount of an mRNA useful in a nanoparticle compositioncan depend on the size (expressed as length, or molecular mass),sequence, and other characteristics of the mRNA. The relative amounts ofa polynucleotide in a nanoparticle composition can also vary.

The relative amounts of the lipid composition and the polynucleotidepresent in a lipid nanoparticle composition of the present disclosurecan be optimized according to considerations of efficacy andtolerability. For compositions including an mRNA as a polynucleotide,the N:P ratio can serve as a useful metric.

As the N:P ratio of a nanoparticle composition controls both expressionand tolerability, nanoparticle compositions with low N:P ratios andstrong expression are desirable. N:P ratios vary according to the ratioof lipids to RNA in a nanoparticle composition.

In general, a lower N:P ratio is preferred. The one or more RNA, lipids,and amounts thereof can be selected to provide an N:P ratio from about2:1 to about 30:1, such as 2:1,3:1,4:1,5:1, 6:1,7:1, 8:1,9:1, 10:1,12:1, 14:1,16:1,18:1,20:1,22:1,24:1,26:1, 28:1, or 30:1. In certainembodiments, the N:P ratio can be from about 2:1 to about 8:1. In otherembodiments, the N:P ratio is from about 5:1 to about 8:1. In certainembodiments, the N:P ratio is between 5:1 and 6:1. In one specificaspect, the N:P ratio is about is about 5.67:1.

In addition to providing nanoparticle compositions, the presentdisclosure also provides methods of producing lipid nanoparticlescomprising encapsulating a polynucleotide. Such method comprises usingany of the pharmaceutical compositions disclosed herein and producinglipid nanoparticles in accordance with methods of production of lipidnanoparticles known in the art. See, e.g., Wang et al. (2015) “Deliveryof oligonucleotides with lipid nanoparticles” Adv. Drug Deliv. Rev.87:68-80; Silva et al. (2015) “Delivery Systems for Biopharmaceuticals.Part I: Nanoparticles and Microparticles” Curr. Pharm. Technol. 16:940-954; Naseri et al. (2015) “Solid Lipid Nanoparticles andNanostructured Lipid Carriers: Structure, Preparation and Application”Adv. Pharm. Bull. 5:305-13; Silva et al. (2015) “Lipid nanoparticles forthe delivery of biopharmaceuticals” Curr. Pharm. Biotechnol. 16:291-302,and references cited therein.

21. Other Delivery Agents

a. Liposomes, Lipoplexes, and Lipid Nanoparticles

In some embodiments, the compositions or formulations of the presentdisclosure comprise a delivery agent, e.g., a liposome, a lioplexes, alipid nanoparticle, or any combination thereof. The polynucleotidesdescribed herein (e.g., a polynucleotide comprising a nucleotidesequence encoding a PCCA or PCCB polypeptide) can be formulated usingone or more liposomes, lipoplexes, or lipid nanoparticles. Liposomes,lipoplexes, or lipid nanoparticles can be used to improve the efficacyof the polynucleotides directed protein production as these formulationscan increase cell transfection by the polynucleotide; and/or increasethe translation of encoded protein. The liposomes, lipoplexes, or lipidnanoparticles can also be used to increase the stability of thepolynucleotides.

Liposomes are artificially-prepared vesicles that can primarily becomposed of a lipid bilayer and can be used as a delivery vehicle forthe administration of pharmaceutical formulations. Liposomes can be ofdifferent sizes. A multilamellar vesicle (MLV) can be hundreds ofnanometers in diameter, and can contain a series of concentric bilayersseparated by narrow aqueous compartments. A small unicellular vesicle(SUV) can be smaller than 50 nm in diameter, and a large unilamellarvesicle (LUV) can be between 50 and 500 nm in diameter. Liposome designcan include, but is not limited to, opsonins or ligands to improve theattachment of liposomes to unhealthy tissue or to activate events suchas, but not limited to, endocytosis. Liposomes can contain a low or ahigh pH value in order to improve the delivery of the pharmaceuticalformulations.

The formation of liposomes can depend on the pharmaceutical formulationentrapped and the liposomal ingredients, the nature of the medium inwhich the lipid vesicles are dispersed, the effective concentration ofthe entrapped substance and its potential toxicity, any additionalprocesses involved during the application and/or delivery of thevesicles, the optimal size, polydispersity and the shelf-life of thevesicles for the intended application, and the batch-to-batchreproducibility and scale up production of safe and efficient liposomalproducts, etc.

As a non-limiting example, liposomes such as synthetic membrane vesiclescan be prepared by the methods, apparatus and devices described in U.S.Pub. Nos. US20130177638, US20130177637, US20130177636, US20130177635,US20130177634, US20130177633, US20130183375, US20130183373, andUS20130183372. In some embodiments, the polynucleotides described hereincan be encapsulated by the liposome and/or it can be contained in anaqueous core that can then be encapsulated by the liposome as describedin, e.g., Intl. Pub. Nos. WO2012031046, WO2012031043, WO2012030901,WO2012006378, and WO2013086526; and U.S. Pub. Nos. US20130189351,US20130195969 and US20130202684. Each of the references in hereinincorporated by reference in its entirety.

In some embodiments, the polynucleotides described herein can beformulated in a cationic oil-in-water emulsion where the emulsionparticle comprises an oil core and a cationic lipid that can interactwith the polynucleotide anchoring the molecule to the emulsion particle.In some embodiments, the polynucleotides described herein can beformulated in a water-in-oil emulsion comprising a continuoushydrophobic phase in which the hydrophilic phase is dispersed. Exemplaryemulsions can be made by the methods described in Intl. Pub. Nos.WO2012006380 and WO201087791, each of which is herein incorporated byreference in its entirety.

In some embodiments, the polynucleotides described herein can beformulated in a lipid-polycation complex. The formation of thelipid-polycation complex can be accomplished by methods as described in,e.g., U.S. Pub. No. US20120178702. As a non-limiting example, thepolycation can include a cationic peptide or a polypeptide such as, butnot limited to, polylysine, polyornithine and/or polyarginine and thecationic peptides described in Intl. Pub. No. WO2012013326 or U.S. Pub.No. US20130142818. Each of the references is herein incorporated byreference in its entirety.

In some embodiments, the polynucleotides described herein can beformulated in a lipid nanoparticle (LNP) such as those described inIntl. Pub. Nos. WO2013123523, WO2012170930, WO2011127255 andWO2008103276; and U.S. Pub. No. US20130171646, each of which is hereinincorporated by reference in its entirety.

Lipid nanoparticle formulations typically comprise one or more lipids.In some embodiments, the lipid is an ionizable lipid (e.g., an ionizableamino lipid), sometimes referred to in the art as an “ionizable cationiclipid”. In some embodiments, lipid nanoparticle formulations furthercomprise other components, including a phospholipid, a structural lipid,and a molecule capable of reducing particle aggregation, for example aPEG or PEG-modified lipid.

Exemplary ionizable lipids include, but not limited to, any one ofCompounds 1-342 disclosed herein, DLin-MC3-DMA (MC3), DLin-DMA, DLenDMA,DLin-D-DMA, DLin-K-DMA, DLin-M-C2-DMA, DLin-K-DMA, DLin-KC2-DMA,DLin-KC3-DMA, DLin-KC4-DMA, DLin-C2K-DMA, DLin-MP-DMA, DODMA, 98N12-5,C12-200, DLin-C-DAP, DLin-DAC, DLinDAP, DLinAP, DLin-EG-DMA,DLin-2-DMAP, KL10, KL22, KL25, Octyl-CLinDMA, Octyl-CLinDMA (2R),Octyl-CLinDMA (2S), and any combination thereof. Other exemplaryionizable lipids include,(13Z,16Z)-N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine (L608),(20Z,23Z)-N,N-dimethylnonacosa-20,23-dien-10-amine,(17Z,20Z)-N,N-dimemylhexacosa-17,20-dien-9-amine,(16Z,19Z)-N5N-dimethylpentacosa-16,19-dien-8-amine,(13Z,16Z)-N,N-dimethyldocosa-13,16-dien-5-amine,(12Z,15Z)-N,N-dimethylhenicosa-12,15-dien-4-amine,(14Z,17Z)-N,N-dimethyltricosa-14,17-dien-6-amine,(15Z,18Z)-N,N-dimethyltetracosa-15,18-dien-7-amine,(18Z,21Z)-N,N-dimethylheptacosa-18,21-dien-10-amine,(15Z,18Z)-N,N-dimethyltetracosa-15,18-dien-5-amine,(14Z,17Z)-N,N-dimethyltricosa-14,17-dien-4-amine,(19Z,22Z)-N,N-dimeihyloctacosa-19,22-dien-9-amine,(18Z,21Z)-N,N-dimethylheptacosa-18,21-dien-8-amine,(17Z,20Z)-N,N-dimethylhexacosa-17,20-dien-7-amine,(16Z,19Z)-N,N-dimethylpentacosa-16,19-dien-6-amine,(22Z,25Z)-N,N-dimethylhentriaconta-22,25-dien-10-amine,(21Z,24Z)-N,N-dimethyltriaconta-21,24-dien-9-amine,(18Z)-N,N-dimetylheptacos-18-en-10-amine,(17Z)-N,N-dimethylhexacos-17-en-9-amine,(19Z,22Z)-N,N-dimethyloctacosa-19,22-dien-7-amine,N,N-dimethylheptacosan-10-amine,(20Z,23Z)-N-ethyl-N-methylnonacosa-20,23-dien-10-amine,1-[(11Z,14Z)-1-nonylicosa-11,14-dien-1-yl]pyrrolidine,(20Z)-N,N-dimethylheptacos-20-en-10-amine, (15Z)-N,N-dimethyleptacos-15-en-10-amine, (14Z)-N,N-dimethylnonacos-14-en-10-amine,(17Z)-N,N-dimethylnonacos-17-en-10-amine,(24Z)-N,N-dimethyltritriacont-24-en-10-amine,(20Z)-N,N-dimethylnonacos-20-en-10-amine,(22Z)-N,N-dimethylhentriacont-22-en-10-amine,(16Z)-N,N-dimethylpentacos-16-en-8-amine,(12Z,15Z)-N,N-dimethyl-2-nonylhenicosa-12,15-dien-1-amine,N,N-dimethyl-1-[(1S,2R)-2-octylcyclopropyl] eptadecan-8-amine,1-[(1S,2R)-2-hexylcyclopropyl]-N,N-dimethylnonadecan-10-amine,N,N-dimethyl-1-[(1S,2R)-2-octylcyclopropyl]nonadecan-10-amine,N,N-dimethyl-21-[(1S,2R)-2-octylcyclopropyl]henicosan-10-amine,N,N-dimethyl-1-[(1S,2S)-2-{[(1R,2R)-2-pentylcyclopropyl]methyl}cyclopropyl]nonadecan-10-amine,N,N-dimethyl-1-[(1S,2R)-2-octylcyclopropyl]hexadecan-8-amine,N,N-dimethyl-[(1R,2S)-2-undecylcyclopropyl]tetradecan-5-amine,N,N-dimethyl-3-{7-[(1S,2R)-2-octylcyclopropyl]heptyl}dodecan-1-amine,1-[(1R,2S)-2-heptylcyclopropyl]-N,N-dimethyloctadecan-9-amine,1-[(1S,2R)-2-decylcyclopropyl]-N,N-dimethylpentadecan-6-amine,N,N-dimethyl-1-[(1S,2R)-2-octylcyclopropyl]pentadecan-8-amine,R-N,N-dimethyl-1-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-3-(octyloxy)propan-2-amine,S-N,N-dimethyl-1-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-3-(octyloxy)propan-2-amine,1-{2-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-1-[(octyloxy)methyl]ethyl}pyrrolidine,(2S)-N,N-dimethyl-1-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-3-[(5Z)-oct-5-en-1-yloxy]propan-2-amine,1-{2-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-1-[(octyloxy)methyl]ethyl}azetidine,(2S)-1-(hexyloxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-2-amine,(2S)-1-(heptyloxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-2-amine,N,N-dimethyl-1-(nonyloxy)-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-2-amine,N,N-dimethyl-1-[(9Z)-octadec-9-en-1-yloxy]-3-(octyloxy)propan-2-amine;(2S)-N,N-dimethyl-1-[(6Z,9Z,12Z)-octadeca-6,9,12-trien-1-yloxy]-3-(octyloxy)propan-2-amine,(2S)-1-[(11Z,14Z)-icosa-11,14-dien-1-yloxy]-N,N-dimethyl-3-(pentyloxy)propan-2-amine,(2S)-1-(hexyloxy)-3-[(11Z,14Z)-icosa-11,14-dien-1-yloxy]-N,N-dimethylpropan-2-amine,1-[(11Z,14Z)-icosa-11,14-dien-1-yloxy]-N,N-dimethyl-3-(octyloxy)propan-2-amine,1-[(13Z,16Z)-docosa-13,16-dien-1-yloxy]-N,N-dimethyl-3-(octyloxy)propan-2-amine,(2S)-1-[(13Z,16Z)-docosa-13,16-dien-1-yloxy]-3-(hexyloxy)-N,N-dimethylpropan-2-amine,(2S)-1-[(13Z)-docos-13-en-1-yloxy]-3-(hexyloxy)-N,N-dimethylpropan-2-amine,1-[(13Z)-docos-13-en-1-yloxy]-N,N-dimethyl-3-(octyloxy)propan-2-amine,1-[(9Z)-hexadec-9-en-1-yloxy]-N,N-dimethyl-3-(octyloxy)propan-2-amine,(2R)-N,N-dimethyl-H(1-metoyloctyl)oxy]-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-2-amine,(2R)-1-[(3,7-dimethyloctyl)oxy]-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-2-amine,N,N-dimethyl-1-(octyloxy)-3-({8-[(1S,2S)-2-{[(1R,2R)-2-pentylcyclopropyl]methyl}cyclopropyl]octyl}oxy)propan-2-amine,N,N-dimethyl-1-{[8-(2-oclylcyclopropyl)octyl]oxy}-3-(octyloxy)propan-2-amine,and (11E,20Z,23Z)-N,N-dimethylnonacosa-11,20,2-trien-10-amine, and anycombination thereof.

Phospholipids include, but are not limited to, glycerophospholipids suchas phosphatidylcholines, phosphatidylethanolamines, phosphatidylserines,phosphatidylinositols, phosphatidy glycerols, and phosphatidic acids.Phospholipids also include phosphosphingolipid, such as sphingomyelin.In some embodiments, the phospholipids are DLPC, DMPC, DOPC, DPPC, DSPC,DUPC, 18:0 Diether PC, DLnPC, DAPC, DHAPC, DOPE, 4ME 16:0 PE, DSPE,DLPE,DLnPE, DAPE, DHAPE, DOPG, and any combination thereof. In someembodiments, the phospholipids are MPPC, MSPC, PMPC, PSPC, SMPC, SPPC,DHAPE, DOPG, and any combination thereof. In some embodiments, theamount of phospholipids (e.g., DSPC) in the lipid composition rangesfrom about 1 mol % to about 20 mol %.

The structural lipids include sterols and lipids containing sterolmoieties. In some embodiments, the structural lipids includecholesterol, fecosterol, sitosterol, ergosterol, campesterol,stigmasterol, brassicasterol, tomatidine, tomatine, ursolic acid,alpha-tocopherol, and mixtures thereof. In some embodiments, thestructural lipid is cholesterol. In some embodiments, the amount of thestructural lipids (e.g., cholesterol) in the lipid composition rangesfrom about 20 mol % to about 60 mol %.

The PEG-modified lipids include PEG-modified phosphatidylethanolamineand phosphatidic acid, PEG-ceramide conjugates (e.g., PEG-CerC14 orPEG-CerC20), PEG-modified dialkylamines and PEG-modified1,2-diacyloxypropan-3-amines. Such lipids are also referred to asPEGylated lipids. For example, a PEG lipid can be PEG-c-DOMG, PEG-DMG,PEG-DLPE, PEG DMPE, PEG-DPPC, or a PEG-DSPE lipid. In some embodiments,the PEG-lipid are 1,2-dimyristoyl-sn-glycerol methoxypolyethylene glycol(PEG-DMG),1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethyleneglycol)] (PEG-DSPE), PEG-disteryl glycerol (PEG-DSG), PEG-dipalmetoleyl,PEG-dioleyl, PEG-distearyl, PEG-diacylglycamide (PEG-DAG),PEG-dipalmitoyl phosphatidylethanolamine (PEG-DPPE), orPEG-1,2-dimyristyloxlpropyl-3-amine (PEG-c-DMA). In some embodiments,the PEG moiety has a size of about 1000, 2000, 5000, 10,000, 15,000 or20,000 daltons. In some embodiments, the amount of PEG-lipid in thelipid composition ranges from about 0 mol % to about 5 mol %.

In some embodiments, the LNP formulations described herein canadditionally comprise a permeability enhancer molecule. Non-limitingpermeability enhancer molecules are described in U.S. Pub. No.US20050222064, herein incorporated by reference in its entirety.

The LNP formulations can further contain a phosphate conjugate. Thephosphate conjugate can increase in vivo circulation times and/orincrease the targeted delivery of the nanoparticle. Phosphate conjugatescan be made by the methods described in, e.g., Intl. Pub. No.WO2013033438 or U.S. Pub. No. US20130196948. The LNP formulation canalso contain a polymer conjugate (e.g., a water soluble conjugate) asdescribed in, e.g., U.S. Pub. Nos. US20130059360, US20130196948, andUS20130072709. Each of the references is herein incorporated byreference in its entirety.

The LNP formulations can comprise a conjugate to enhance the delivery ofnanoparticles of the present invention in a human subject. Further, theconjugate can inhibit phagocytic clearance of the nanoparticles in ahuman subject. In some embodiments, the conjugate can be a “self”peptide designed from the human membrane protein CD47 (e.g., the “self”particles described by Rodriguez et al, Science 2013 339, 971-975,herein incorporated by reference in its entirety). As shown by Rodriguezet al. the self peptides delayed macrophage-mediated clearance ofnanoparticles which enhanced delivery of the nanoparticles.

The LNP formulations can comprise a carbohydrate carrier. As anon-limiting example, the carbohydrate carrier can include, but is notlimited to, an anhydride-modified phytoglycogen or glycogen-typematerial, phytoglycogen octenyl succinate, phytoglycogen beta-dextrin,anhydride-modified phytoglycogen beta-dextrin (e.g., Intl. Pub. No.WO2012109121, herein incorporated by reference in its entirety).

The LNP formulations can be coated with a surfactant or polymer toimprove the delivery of the particle. In some embodiments, the LNP canbe coated with a hydrophilic coating such as, but not limited to, PEGcoatings and/or coatings that have a neutral surface charge as describedin U.S. Pub. No. US20130183244, herein incorporated by reference in itsentirety.

The LNP formulations can be engineered to alter the surface propertiesof particles so that the lipid nanoparticles can penetrate the mucosalbarrier as described in U.S. Pat. No. 8,241,670 or Intl. Pub. No.WO2013110028, each of which is herein incorporated by reference in itsentirety.

The LNP engineered to penetrate mucus can comprise a polymeric material(i.e., a polymeric core) and/or a polymer-vitamin conjugate and/or atri-block co-polymer. The polymeric material can include, but is notlimited to, polyamines, polyethers, polyamides, polyesters,polycarbamates, polyureas, polycarbonates, poly(styrenes), polyimides,polysulfones, polyurethanes, polyacetylenes, polyethylenes,polyethyeneimines, polyisocyanates, polyacrylates, polymethacrylates,polyacrylonitriles, and polyarylates.

LNP engineered to penetrate mucus can also include surface alteringagents such as, but not limited to, polynucleotides, anionic proteins(e.g., bovine serum albumin), surfactants (e.g., cationic surfactantssuch as for example dimethyldioctadecyl-ammonium bromide), sugars orsugar derivatives (e.g., cyclodextrin), nucleic acids, polymers (e.g.,heparin, polyethylene glycol and poloxamer), mucolytic agents (e.g.,N-acetylcysteine, mugwort, bromelain, papain, clerodendrum,acetylcysteine, bromhexine, carbocisteine, eprazinone, mesna, ambroxol,sobrerol, domiodol, letosteine, stepronin, tiopronin, gelsolin, thymosinβ4 domase alfa, neltenexine, erdosteine) and various DNases includingrhDNase.

In some embodiments, the mucus penetrating LNP can be a hypotonicformulation comprising a mucosal penetration enhancing coating. Theformulation can be hypotonic for the epithelium to which it is beingdelivered. Non-limiting examples of hypotonic formulations can be foundin, e.g., Intl. Pub. No. WO2013110028, herein incorporated by referencein its entirety.

In some embodiments, the polynucleotide described herein is formulatedas a lipoplex, such as, without limitation, the ATUPLEX™ system, theDACC system, the DBTC system and other siRNA-lipoplex technology fromSilence Therapeutics (London, United Kingdom), STEMFECT™ from STEMGENT®(Cambridge, Mass.), and polyethylenimine (PEI) or protamine-basedtargeted and non-targeted delivery of nucleic acids (Aleku et al. CancerRes. 2008 68:9788-9798; Strumberg et al. Int J Clin Pharmacol Ther 201250:76-78; Santel et al., Gene Ther 2006 13:1222-1234; Santel et al.,Gene Ther 2006 13:1360-1370; Gutbier et al., Pulm Pharmacol. Ther. 201023:334-344; Kaufmann et al. Microvasc Res 2010 80:286-293Weide et al. JImmunother. 2009 32:498-507; Weide et al. J Immunother. 2008 31:180-188;Pascolo Expert Opin. Biol. Ther. 4:1285-1294; Fotin-Mleczek et al., 2011J. Immunother. 34:1-15; Song et al., Nature Biotechnol. 2005,23:709-717; Peer et al., Proc Natl Acad Sci USA. 2007 6; 104:4095-4100;deFougerolles Hum Gene Ther. 2008 19:125-132; all of which areincorporated herein by reference in its entirety).

In some embodiments, the polynucleotides described herein are formulatedas a solid lipid nanoparticle (SLN), which can be spherical with anaverage diameter between 10 to 1000 nm. SLN possess a solid lipid corematrix that can solubilize lipophilic molecules and can be stabilizedwith surfactants and/or emulsifiers. Exemplary SLN can be those asdescribed in Intl. Pub. No. WO2013105101, herein incorporated byreference in its entirety.

In some embodiments, the polynucleotides described herein can beformulated for controlled release and/or targeted delivery. As usedherein, “controlled release” refers to a pharmaceutical composition orcompound release profile that conforms to a particular pattern ofrelease to effect a therapeutic outcome. In one embodiment, thepolynucleotides can be encapsulated into a delivery agent describedherein and/or known in the art for controlled release and/or targeteddelivery. As used herein, the term “encapsulate” means to enclose,surround or encase. As it relates to the formulation of the compounds ofthe invention, encapsulation can be substantial, complete or partial.The term “substantially encapsulated” means that at least greater than50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99, or greater than 99% of thepharmaceutical composition or compound of the invention can be enclosed,surrounded or encased within the delivery agent. “Partiallyencapsulation” means that less than 10, 10, 20, 30, 40 50 or less of thepharmaceutical composition or compound of the invention can be enclosed,surrounded or encased within the delivery agent.

Advantageously, encapsulation can be determined by measuring the escapeor the activity of the pharmaceutical composition or compound of theinvention using fluorescence and/or electron micrograph. For example, atleast 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99,99.9, or greater than 99% of the pharmaceutical composition or compoundof the invention are encapsulated in the delivery agent.

In some embodiments, the polynucleotides described herein can beencapsulated in a therapeutic nanoparticle, referred to herein as“therapeutic nanoparticle polynucleotides.” Therapeutic nanoparticlescan be formulated by methods described in, e.g., Intl. Pub. Nos.WO2010005740, WO2010030763, WO2010005721, WO2010005723, andWO2012054923; and U.S. Pub. Nos. US20110262491, US20100104645,US20100087337, US20100068285, US20110274759, US20100068286,US20120288541, US20120140790, US20130123351 and US20130230567; and U.S.Pat. Nos. 8,206,747, 8,293,276, 8,318,208 and 8,318,211, each of whichis herein incorporated by reference in its entirety.

In some embodiments, the therapeutic nanoparticle polynucleotide can beformulated for sustained release. As used herein, “sustained release”refers to a pharmaceutical composition or compound that conforms to arelease rate over a specific period of time. The period of time caninclude, but is not limited to, hours, days, weeks, months and years. Asa non-limiting example, the sustained release nanoparticle of thepolynucleotides described herein can be formulated as disclosed in Intl.Pub. No. WO2010075072 and U.S. Pub. Nos. US20100216804, US20110217377,US20120201859 and US20130150295, each of which is herein incorporated byreference in their entirety.

In some embodiments, the therapeutic nanoparticle polynucleotide can beformulated to be target specific, such as those described in Intl. Pub.Nos. WO2008121949, WO2010005726, WO2010005725, WO2011084521 andWO2011084518; and U.S. Pub. Nos. US20100069426, US20120004293 andUS20100104655, each of which is herein incorporated by reference in itsentirety.

The LNPs can be prepared using microfluidic mixers or micromixers.Exemplary microfluidic mixers can include, but are not limited to, aslit interdigital micromixer including, but not limited to thosemanufactured by Microinnova (Allerheiligen bei Wildon, Austria) and/or astaggered herringbone micromixer (SHM) (see Zhigaltsev et al.,“Bottom-up design and synthesis of limit size lipid nanoparticle systemswith aqueous and triglyceride cores using millisecond microfluidicmixing,” Langmuir 28:3633-40 (2012); Belliveau et al., “Microfluidicsynthesis of highly potent limit-size lipid nanoparticles for in vivodelivery of siRNA,” Molecular Therapy-Nucleic Acids. 1:e37 (2012); Chenet al., “Rapid discovery of potent siRNA-containing lipid nanoparticlesenabled by controlled microfluidic formulation,” J. Am. Chem. Soc.134(16):6948-51 (2012); each of which is herein incorporated byreference in its entirety). Exemplary micromixers include SlitInterdigital Microstructured Mixer (SIMM-V2) or a Standard SlitInterdigital Micro Mixer (SSIMM) or Caterpillar (CPMM) or Impinging-jet(IJMM,) from the Institut für Mikrotechnik Mainz GmbH, Mainz Germany. Insome embodiments, methods of making LNP using SHM further comprisemixing at least two input streams wherein mixing occurs bymicrostructure-induced chaotic advection (MICA). According to thismethod, fluid streams flow through channels present in a herringbonepattern causing rotational flow and folding the fluids around eachother. This method can also comprise a surface for fluid mixing whereinthe surface changes orientations during fluid cycling. Methods ofgenerating LNPs using SHM include those disclosed in U.S. Pub. Nos.US20040262223 and US20120276209, each of which is incorporated herein byreference in their entirety.

In some embodiments, the polynucleotides described herein can beformulated in lipid nanoparticles using microfluidic technology (seeWhitesides, George M., “The Origins and the Future of Microfluidics,”Nature 442: 368-373 (2006); and Abraham et al., “Chaotic Mixer forMicrochannels,” Science 295: 647-651 (2002); each of which is hereinincorporated by reference in its entirety). In some embodiments, thepolynucleotides can be formulated in lipid nanoparticles using amicromixer chip such as, but not limited to, those from HarvardApparatus (Holliston, Mass.) or Dolomite Microfluidics (Royston, UK). Amicromixer chip can be used for rapid mixing of two or more fluidstreams with a split and recombine mechanism.

In some embodiments, the polynucleotides described herein can beformulated in lipid nanoparticles having a diameter from about 1 nm toabout 100 nm such as, but not limited to, about 1 nm to about 20 nm,from about 1 nm to about 30 nm, from about 1 nm to about 40 nm, fromabout 1 nm to about 50 nm, from about 1 nm to about 60 nm, from about 1nm to about 70 nm, from about 1 nm to about 80 nm, from about 1 nm toabout 90 nm, from about 5 nm to about from 100 nm, from about 5 nm toabout 10 nm, about 5 nm to about 20 nm, from about 5 nm to about 30 nm,from about 5 nm to about 40 nm, from about 5 nm to about 50 nm, fromabout 5 nm to about 60 nm, from about 5 nm to about 70 nm, from about 5nm to about 80 nm, from about 5 nm to about 90 nm, about 10 to about 20nm, about 10 to about 30 nm, about 10 to about 40 nm, about 10 to about50 nm, about 10 to about 60 nm, about 10 to about 70 nm, about 10 toabout 80 nm, about 10 to about 90 nm, about 20 to about 30 nm, about 20to about 40 nm, about 20 to about 50 nm, about 20 to about 60 nm, about20 to about 70 nm, about 20 to about 80 nm, about 20 to about 90 nm,about 20 to about 100 nm, about 30 to about 40 nm, about 30 to about 50nm, about 30 to about 60 nm, about 30 to about 70 nm, about 30 to about80 nm, about 30 to about 90 nm, about 30 to about 100 nm, about 40 toabout 50 nm, about 40 to about 60 nm, about 40 to about 70 nm, about 40to about 80 nm, about 40 to about 90 nm, about 40 to about 100 nm, about50 to about 60 nm, about 50 to about 70 nm about 50 to about 80 nm,about 50 to about 90 nm, about 50 to about 100 nm, about 60 to about 70nm, about 60 to about 80 nm, about 60 to about 90 nm, about 60 to about100 nm, about 70 to about 80 nm, about 70 to about 90 nm, about 70 toabout 100 nm, about 80 to about 90 nm, about 80 to about 100 nm and/orabout 90 to about 100 nm.

In some embodiments, the lipid nanoparticles can have a diameter fromabout 10 to 500 nm. In one embodiment, the lipid nanoparticle can have adiameter greater than 100 nm, greater than 150 nm, greater than 200 nm,greater than 250 nm, greater than 300 nm, greater than 350 nm, greaterthan 400 nm, greater than 450 nm, greater than 500 nm, greater than 550nm, greater than 600 nm, greater than 650 nm, greater than 700 nm,greater than 750 nm, greater than 800 nm, greater than 850 nm, greaterthan 900 nm, greater than 950 nm or greater than 1000 nm.

In some embodiments, the polynucleotides can be delivered using smallerLNPs. Such particles can comprise a diameter from below 0.1 μm up to 100nm such as, but not limited to, less than 0.1 μm, less than 1.0 μm, lessthan 5 μm, less than 10 μm, less than 15 um, less than 20 um, less than25 um, less than 30 um, less than 35 um, less than 40 um, less than 50um, less than 55 um, less than 60 um, less than 65 um, less than 70 um,less than 75 um, less than 80 um, less than 85 um, less than 90 um, lessthan 95 um, less than 100 um, less than 125 um, less than 150 um, lessthan 175 um, less than 200 um, less than 225 um, less than 250 um, lessthan 275 um, less than 300 um, less than 325 um, less than 350 um, lessthan 375 um, less than 400 um, less than 425 um, less than 450 um, lessthan 475 um, less than 500 um, less than 525 um, less than 550 um, lessthan 575 um, less than 600 um, less than 625 um, less than 650 um, lessthan 675 um, less than 700 um, less than 725 um, less than 750 um, lessthan 775 um, less than 800 um, less than 825 um, less than 850 um, lessthan 875 um, less than 900 um, less than 925 um, less than 950 um, orless than 975 um.

The nanoparticles and microparticles described herein can begeometrically engineered to modulate macrophage and/or the immuneresponse. The geometrically engineered particles can have varied shapes,sizes and/or surface charges to incorporate the polynucleotidesdescribed herein for targeted delivery such as, but not limited to,pulmonary delivery (see, e.g., Intl. Pub. No. WO2013082111, hereinincorporated by reference in its entirety). Other physical features thegeometrically engineering particles can include, but are not limited to,fenestrations, angled arms, asymmetry and surface roughness, charge thatcan alter the interactions with cells and tissues.

In some embodiment, the nanoparticles described herein are stealthnanoparticles or target-specific stealth nanoparticles such as, but notlimited to, those described in U.S. Pub. No. US20130172406, hereinincorporated by reference in its entirety. The stealth ortarget-specific stealth nanoparticles can comprise a polymeric matrix,which can comprise two or more polymers such as, but not limited to,polyethylenes, polycarbonates, polyanhydrides, polyhydroxyacids,polypropylfumerates, polycaprolactones, polyamides, polyacetals,polyethers, polyesters, poly(orthoesters), polycyanoacrylates, polyvinylalcohols, polyurethanes, polyphosphazenes, polyacrylates,polymethacrylates, polycyanoacrylates, polyureas, polystyrenes,polyamines, polyesters, polyanhydrides, polyethers, polyurethanes,polymethacrylates, polyacrylates, polycyanoacrylates, or combinationsthereof.

b. Lipidoids

In some embodiments, the compositions or formulations of the presentdisclosure comprise a delivery agent, e.g., a lipidoid. Thepolynucleotides described herein (e.g., a polynucleotide comprising anucleotide sequence encoding a PCCA or PCCB polypeptide) can beformulated with lipidoids. Complexes, micelles, liposomes or particlescan be prepared containing these lipidoids and therefore to achieve aneffective delivery of the polynucleotide, as judged by the production ofan encoded protein, following the injection of a lipidoid formulationvia localized and/or systemic routes of administration. Lipidoidcomplexes of polynucleotides can be administered by various meansincluding, but not limited to, intravenous, intramuscular, orsubcutaneous routes.

The synthesis of lipidoids is described in literature (see Mahon et al.,Bioconjug. Chem. 2010 21:1448-1454; Schroeder et al., J Intern Med. 2010267:9-21; Akinc et al., Nat Biotechnol. 2008 26:561-569; Love et al.,Proc Natl Acad Sci USA. 2010 107:1864-1869; Siegwart et al., Proc NatlAcad Sci USA. 2011 108:12996-3001; all of which are incorporated hereinin their entireties).

Formulations with the different lipidoids, including, but not limited topenta[3-(1-laurylaminopropionyl)]-triethylenetetramine hydrochloride(TETA-5LAP; also known as 98N12-5, see Murugaiah et al., AnalyticalBiochemistry, 401:61 (2010)), C12-200 (including derivatives andvariants), and MD1, can be tested for in vivo activity. The lipidoid“98N12-5” is disclosed by Akinc et al., Mol Ther. 2009 17:872-879. Thelipidoid “C12-200” is disclosed by Love et al., Proc Natl Acad Sci USA.2010 107:1864-1869 and Liu and Huang, Molecular Therapy. 2010 669-670.Each of the references is herein incorporated by reference in itsentirety.

In one embodiment, the polynucleotides described herein can beformulated in an aminoalcohol lipidoid. Aminoalcohol lipidoids can beprepared by the methods described in U.S. Pat. No. 8,450,298 (hereinincorporated by reference in its entirety).

The lipidoid formulations can include particles comprising either 3 or 4or more components in addition to polynucleotides. Lipidoids andpolynucleotide formulations comprising lipidoids are described in Intl.Pub. No. WO 2015051214 (herein incorporated by reference in itsentirety.

c. Hyaluronidase

In some embodiments, the polynucleotides described herein (e.g., apolynucleotide comprising a nucleotide sequence encoding a PCCA or PCCBpolypeptide) and hyaluronidase for injection (e.g., intramuscular orsubcutaneous injection). Hyaluronidase catalyzes the hydrolysis ofhyaluronan, which is a constituent of the interstitial barrier.Hyaluronidase lowers the viscosity of hyaluronan, thereby increasestissue permeability (Frost, Expert Opin. Drug Deliv. (2007) 4:427-440).Alternatively, the hyaluronidase can be used to increase the number ofcells exposed to the polynucleotides administered intramuscularly, orsubcutaneously.

d. Nanoparticle Mimics

In some embodiments, the polynucleotides described herein (e.g., apolynucleotide comprising a nucleotide sequence encoding a PCCA or PCCBpolypeptide) is encapsulated within and/or absorbed to a nanoparticlemimic. A nanoparticle mimic can mimic the delivery function organisms orparticles such as, but not limited to, pathogens, viruses, bacteria,fungus, parasites, prions and cells. As a non-limiting example, thepolynucleotides described herein can be encapsulated in a non-vironparticle that can mimic the delivery function of a virus (see e.g.,Intl. Pub. No. WO2012006376 and U.S. Pub. Nos. US20130171241 andUS20130195968, each of which is herein incorporated by reference in itsentirety).

e. Self-Assembled Nanoparticles, or Self-Assembled Macromolecules

In some embodiments, the compositions or formulations of the presentdisclosure comprise the polynucleotides described herein (e.g., apolynucleotide comprising a nucleotide sequence encoding a PCCA or PCCBpolypeptide) in self-assembled nanoparticles, or amphiphilicmacromolecules (AMs) for delivery. AMs comprise biocompatibleamphiphilic polymers that have an alkylated sugar backbone covalentlylinked to poly(ethylene glycol). In aqueous solution, the AMsself-assemble to form micelles. Nucleic acid self-assemblednanoparticles are described in Intl. Appl. No. PCT/US2014/027077, andAMs and methods of forming AMs are described in U.S. Pub. No.US20130217753, each of which is herein incorporated by reference in itsentirety.

f. Cations and Anions

In some embodiments, the compositions or formulations of the presentdisclosure comprise the polynucleotides described herein (e.g., apolynucleotide comprising a nucleotide sequence encoding a PCCA or PCCBpolypeptide) and a cation or anion, such as Zn2+, Ca2+, Cu2+, Mg2+ andcombinations thereof. Exemplary formulations can include polymers and apolynucleotide complexed with a metal cation as described in, e.g., U.S.Pat. Nos. 6,265,389 and 6,555,525, each of which is herein incorporatedby reference in its entirety. In some embodiments, cationicnanoparticles can contain a combination of divalent and monovalentcations. The delivery of polynucleotides in cationic nanoparticles or inone or more depot comprising cationic nanoparticles can improvepolynucleotide bioavailability by acting as a long-acting depot and/orreducing the rate of degradation by nucleases.

g. Amino Acid Lipids

In some embodiments, the compositions or formulations of the presentdisclosure comprise the polynucleotides described herein (e.g., apolynucleotide comprising a nucleotide sequence encoding a PCCA or PCCBpolypeptide) that is formulation with an amino acid lipid. Amino acidlipids are lipophilic compounds comprising an amino acid residue and oneor more lipophilic tails. Non-limiting examples of amino acid lipids andmethods of making amino acid lipids are described in U.S. Pat. No.8,501,824. The amino acid lipid formulations can deliver apolynucleotide in releasable form that comprises an amino acid lipidthat binds and releases the polynucleotides. As a non-limiting example,the release of the polynucleotides described herein can be provided byan acid-labile linker as described in, e.g., U.S. Pat. Nos. 7,098,032,6,897,196, 6,426,086, 7,138,382, 5,563,250, and 5,505,931, each of whichis herein incorporated by reference in its entirety.

h. Interpolyelectrolyte Complexes

In some embodiments, the compositions or formulations of the presentdisclosure comprise the polynucleotides described herein (e.g., apolynucleotide comprising a nucleotide sequence encoding a PCCA or PCCBpolypeptide) in an interpolyelectrolyte complex. Interpolyelectrolytecomplexes are formed when charge-dynamic polymers are complexed with oneor more anionic molecules. Non-limiting examples of charge-dynamicpolymers and interpolyelectrolyte complexes and methods of makinginterpolyelectrolyte complexes are described in U.S. Pat. No. 8,524,368,herein incorporated by reference in its entirety.

i. Crystalline Polymeric Systems

In some embodiments, the compositions or formulations of the presentdisclosure comprise the polynucleotides described herein (e.g., apolynucleotide comprising a nucleotide sequence encoding a PCCA or PCCBpolypeptide) in crystalline polymeric systems. Crystalline polymericsystems are polymers with crystalline moieties and/or terminal unitscomprising crystalline moieties. Exemplary polymers are described inU.S. Pat. No. 8,524,259 (herein incorporated by reference in itsentirety).

j. Polymers, Biodegradable Nanoparticles, and Core-Shell Nanoparticles

In some embodiments, the compositions or formulations of the presentdisclosure comprise the polynucleotides described herein (e.g., apolynucleotide comprising a nucleotide sequence encoding a PCCA or PCCBpolypeptide) and a natural and/or synthetic polymer. The polymersinclude, but not limited to, polyethenes, polyethylene glycol (PEG),poly(l-lysine)(PLL), PEG grafted to PLL, cationic lipopolymer,biodegradable cationic lipopolymer, polyethyleneimine (PEI),cross-linked branched poly(alkylene imines), a polyamine derivative, amodified poloxamer, elastic biodegradable polymer, biodegradablecopolymer, biodegradable polyester copolymer, biodegradable polyestercopolymer, multiblock copolymers, poly[a-(4-aminobutyl)-L-glycolic acid)(PAGA), biodegradable cross-linked cationic multi-block copolymers,polycarbonates, polyanhydrides, polyhydroxyacids, polypropylfumerates,polycaprolactones, polyamides, polyacetals, polyethers, polyesters,poly(orthoesters), polycyanoacrylates, polyvinyl alcohols,polyurethanes, polyphosphazenes, polyureas, polystyrenes, polyamines,polylysine, poly(ethylene imine), poly(serine ester),poly(L-lactide-co-L-lysine), poly(4-hydroxy-L-proline ester),amine-containing polymers, dextran polymers, dextran polymer derivativesor combinations thereof.

Exemplary polymers include, DYNAMIC POLYCONJUGATE® (Arrowhead ResearchCorp., Pasadena, Calif.) formulations from MIRUS® Bio (Madison, Wis.)and Roche Madison (Madison, Wis.), PHASERX™ polymer formulations suchas, without limitation, SMARTT POLYMER TECHNOLOGY™ (PHASERX®, Seattle,Wash.), DMRI/DOPE, poloxamer, VAXFECTIN® adjuvant from Vical (San Diego,Calif.), chitosan, cyclodextrin from Calando Pharmaceuticals (Pasadena,Calif.), dendrimers and poly(lactic-co-glycolic acid) (PLGA) polymers.RONDEL™ (RNAi/Oligonucleotide Nanoparticle Delivery) polymers (ArrowheadResearch Corporation, Pasadena, Calif.) and pH responsive co-blockpolymers such as PHASERX® (Seattle, Wash.).

The polymer formulations allow a sustained or delayed release of thepolynucleotide (e.g., following intramuscular or subcutaneousinjection). The altered release profile for the polynucleotide canresult in, for example, translation of an encoded protein over anextended period of time. The polymer formulation can also be used toincrease the stability of the polynucleotide. Sustained releaseformulations can include, but are not limited to, PLGA microspheres,ethylene vinyl acetate (EVAc), poloxamer, GELSITE® (Nanotherapeutics,Inc. Alachua, Fla.), HYLENEX® (Halozyme Therapeutics, San Diego Calif.),surgical sealants such as fibrinogen polymers (Ethicon Inc. Cornelia,Ga.), TISSELL® (Baxter International, Inc. Deerfield, Ill.), PEG-basedsealants, and COSEAL® (Baxter International, Inc. Deerfield, Ill.).

As a non-limiting example modified mRNA can be formulated in PLGAmicrospheres by preparing the PLGA microspheres with tunable releaserates (e.g., days and weeks) and encapsulating the modified mRNA in thePLGA microspheres while maintaining the integrity of the modified mRNAduring the encapsulation process. EVAc are non-biodegradable,biocompatible polymers that are used extensively in pre-clinicalsustained release implant applications (e.g., extended release productsOcusert a pilocarpine ophthalmic insert for glaucoma or progestasert asustained release progesterone intrauterine device; transdermal deliverysystems Testoderm, Duragesic and Selegiline; catheters). Poloxamer F-407NF is a hydrophilic, non-ionic surfactant triblock copolymer ofpolyoxyethylene-polyoxypropylene-polyoxyethylene having a low viscosityat temperatures less than 5° C. and forms a solid gel at temperaturesgreater than 15° C.

As a non-limiting example, the polynucleotides described herein can beformulated with the polymeric compound of PEG grafted with PLL asdescribed in U.S. Pat. No. 6,177,274. As another non-limiting example,the polynucleotides described herein can be formulated with a blockcopolymer such as a PLGA-PEG block copolymer (see e.g., U.S. Pub. No.US20120004293 and U.S. Pat. Nos. 8,236,330 and 8,246,968), or aPLGA-PEG-PLGA block copolymer (see e.g., U.S. Pat. No. 6,004,573). Eachof the references is herein incorporated by reference in its entirety.

In some embodiments, the polynucleotides described herein can beformulated with at least one amine-containing polymer such as, but notlimited to polylysine, polyethylene imine, poly(amidoamine) dendrimers,poly(amine-co-esters) or combinations thereof. Exemplary polyaminepolymers and their use as delivery agents are described in, e.g., U.S.Pat. Nos. 8,460,696, 8,236,280, each of which is herein incorporated byreference in its entirety.

In some embodiments, the polynucleotides described herein can beformulated in a biodegradable cationic lipopolymer, a biodegradablepolymer, or a biodegradable copolymer, a biodegradable polyestercopolymer, a biodegradable polyester polymer, a linear biodegradablecopolymer, PAGA, a biodegradable cross-linked cationic multi-blockcopolymer or combinations thereof as described in, e.g., U.S. Pat. Nos.6,696,038, 6,517,869, 6,267,987, 6,217,912, 6,652,886, 8,057,821, and8,444,992; U.S. Pub. Nos. US20030073619, US20040142474, US20100004315,US2012009145 and US20130195920; and Intl Pub. Nos. WO2006063249 andWO2013086322, each of which is herein incorporated by reference in itsentirety.

In some embodiments, the polynucleotides described herein can beformulated in or with at least one cyclodextrin polymer as described inU.S. Pub. No. US20130184453. In some embodiments, the polynucleotidesdescribed herein can be formulated in or with at least one crosslinkedcation-binding polymers as described in Intl. Pub. Nos. WO2013106072,WO2013106073 and WO2013106086. In some embodiments, the polynucleotidesdescribed herein can be formulated in or with at least PEGylated albuminpolymer as described in U.S. Pub. No. US20130231287. Each of thereferences is herein incorporated by reference in its entirety.

In some embodiments, the polynucleotides disclosed herein can beformulated as a nanoparticle using a combination of polymers, lipids,and/or other biodegradable agents, such as, but not limited to, calciumphosphate. Components can be combined in a core-shell, hybrid, and/orlayer-by-layer architecture, to allow for fine-tuning of thenanoparticle for delivery (Wang et al., Nat Mater. 2006 5:791-796;Fuller et al., Biomaterials. 2008 29:1526-1532; DeKoker et al., Adv DrugDeliv Rev. 2011 63:748-761; Endres et al., Biomaterials. 201132:7721-7731; Su et al., Mol Pharm. 2011 Jun. 6; 8(3):774-87; hereinincorporated by reference in their entireties). As a non-limitingexample, the nanoparticle can comprise a plurality of polymers such as,but not limited to hydrophilic-hydrophobic polymers (e.g., PEG-PLGA),hydrophobic polymers (e.g., PEG) and/or hydrophilic polymers (Intl. Pub.No. WO20120225129, herein incorporated by reference in its entirety).

The use of core-shell nanoparticles has additionally focused on ahigh-throughput approach to synthesize cationic cross-linked nanogelcores and various shells (Siegwart et al., Proc Natl Acad Sci USA. 2011108:12996-13001; herein incorporated by reference in its entirety). Thecomplexation, delivery, and internalization of the polymericnanoparticles can be precisely controlled by altering the chemicalcomposition in both the core and shell components of the nanoparticle.For example, the core-shell nanoparticles can efficiently deliver siRNAto mouse hepatocytes after they covalently attach cholesterol to thenanoparticle.

In some embodiments, a hollow lipid core comprising a middle PLGA layerand an outer neutral lipid layer containing PEG can be used to deliveryof the polynucleotides as described herein. In some embodiments, thelipid nanoparticles can comprise a core of the polynucleotides disclosedherein and a polymer shell, which is used to protect the polynucleotidesin the core. The polymer shell can be any of the polymers describedherein and are known in the art. The polymer shell can be used toprotect the polynucleotides in the core.

Core-shell nanoparticles for use with the polynucleotides describedherein are described in U.S. Pat. No. 8,313,777 or Intl. Pub. No.WO2013124867, each of which is herein incorporated by reference in theirentirety.

k. Peptides and Proteins

In some embodiments, the compositions or formulations of the presentdisclosure comprise the polynucleotides described herein (e.g., apolynucleotide comprising a nucleotide sequence encoding a PCCA or PCCBpolypeptide) that is formulated with peptides and/or proteins toincrease transfection of cells by the polynucleotide, and/or to alterthe biodistribution of the polynucleotide (e.g., by targeting specifictissues or cell types), and/or increase the translation of encodedprotein (e.g., Intl. Pub. Nos. WO2012110636 and WO2013123298. In someembodiments, the peptides can be those described in U.S. Pub. Nos.US20130129726, US20130137644 and US20130164219. Each of the referencesis herein incorporated by reference in its entirety.

I. Conjugates

In some embodiments, the compositions or formulations of the presentdisclosure comprise the polynucleotides described herein (e.g., apolynucleotide comprising a nucleotide sequence encoding a PCCA or PCCBpolypeptide) that is covalently linked to a carrier or targeting group,or including two encoding regions that together produce a fusion protein(e.g., bearing a targeting group and therapeutic protein or peptide) asa conjugate. The conjugate can be a peptide that selectively directs thenanoparticle to neurons in a tissue or organism, or assists in crossingthe blood-brain barrier.

The conjugates include a naturally occurring substance, such as aprotein (e.g., human serum albumin (HSA), low-density lipoprotein (LDL),high-density lipoprotein (HDL), or globulin); an carbohydrate (e.g., adextran, pullulan, chitin, chitosan, inulin, cyclodextrin or hyaluronicacid); or a lipid. The ligand can also be a recombinant or syntheticmolecule, such as a synthetic polymer, e.g., a synthetic polyamino acid,an oligonucleotide (e.g., an aptamer). Examples of polyamino acidsinclude polyamino acid is a polylysine (PLL), poly L-aspartic acid, polyL-glutamic acid, styrene-maleic acid anhydride copolymer,poly(L-lactide-co-glycolied) copolymer, divinyl ether-maleic anhydridecopolymer, N-(2-hydroxypropyl)methacrylamide copolymer (HMPA),polyethylene glycol (PEG), polyvinyl alcohol (PVA), polyurethane,poly(2-ethylacryllic acid), N-isopropylacrylamide polymers, orpolyphosphazine. Example of polyamines include: polyethylenimine,polylysine (PLL), spermine, spermidine, polyamine,pseudopeptide-polyamine, peptidomimetic polyamine, dendrimer polyamine,arginine, amidine, protamine, cationic lipid, cationic porphyrin,quaternary salt of a polyamine, or an alpha helical peptide.

In some embodiments, the conjugate can function as a carrier for thepolynucleotide disclosed herein. The conjugate can comprise a cationicpolymer such as, but not limited to, polyamine, polylysine, polyalkylenimine, and polyethylenimine that can be grafted to withpoly(ethylene glycol). Exemplary conjugates and their preparations aredescribed in U.S. Pat. No. 6,586,524 and U.S. Pub. No. US20130211249,each of which herein is incorporated by reference in its entirety.

The conjugates can also include targeting groups, e.g., a cell or tissuetargeting agent, e.g., a lectin, glycoprotein, lipid or protein, e.g.,an antibody, that binds to a specified cell type such as a kidney cell.A targeting group can be a thyrotropin, melanotropin, lectin,glycoprotein, surfactant protein A, Mucin carbohydrate, multivalentlactose, multivalent galactose, N-acetyl-galactosamine,N-acetyl-glucosamine multivalent mannose, multivalent fucose,glycosylated polyaminoacids, multivalent galactose, transferrin,bisphosphonate, polyglutamate, polyaspartate, a lipid, cholesterol, asteroid, bile acid, folate, vitamin B12, biotin, an RGD peptide, an RGDpeptide mimetic or an aptamer.

Targeting groups can be proteins, e.g., glycoproteins, or peptides,e.g., molecules having a specific affinity for a co-ligand, orantibodies e.g., an antibody, that binds to a specified cell type suchas an endothelial cell or bone cell. Targeting groups can also includehormones and hormone receptors. They can also include non-peptidicspecies, such as lipids, lectins, carbohydrates, vitamins, cofactors,multivalent lactose, multivalent galactose, N-acetyl-galactosamine,N-acetyl-glucosamine multivalent mannose, multivalent frucose, oraptamers. The ligand can be, for example, a lipopolysaccharide, or anactivator of p38 MAP kinase.

The targeting group can be any ligand that is capable of targeting aspecific receptor. Examples include, without limitation, folate, GalNAc,galactose, mannose, mannose-6P, apatamers, integrin receptor ligands,chemokine receptor ligands, transferrin, biotin, serotonin receptorligands, PSMA, endothelin, GCPII, somatostatin, LDL, and HDL ligands. Inparticular embodiments, the targeting group is an aptamer. The aptamercan be unmodified or have any combination of modifications disclosedherein. As a non-limiting example, the targeting group can be aglutathione receptor (GR)-binding conjugate for targeted delivery acrossthe blood-central nervous system barrier as described in, e.g., U.S.Pub. No. US2013021661012 (herein incorporated by reference in itsentirety).

In some embodiments, the conjugate can be a synergisticbiomolecule-polymer conjugate, which comprises a long-actingcontinuous-release system to provide a greater therapeutic efficacy. Thesynergistic biomolecule-polymer conjugate can be those described in U.S.Pub. No. US20130195799. In some embodiments, the conjugate can be anaptamer conjugate as described in Intl. Pat. Pub. No. WO2012040524. Insome embodiments, the conjugate can be an amine containing polymerconjugate as described in U.S. Pat. No. 8,507,653. Each of thereferences is herein incorporated by reference in its entirety. In someembodiments, the polynucleotides can be conjugated to SMARTT POLYMERTECHNOLOGY® (PHASERX®, Inc. Seattle, Wash.).

In some embodiments, the polynucleotides described herein are covalentlyconjugated to a cell penetrating polypeptide, which can also include asignal sequence or a targeting sequence. The conjugates can be designedto have increased stability, and/or increased cell transfection; and/oraltered the biodistribution (e.g., targeted to specific tissues or celltypes).

In some embodiments, the polynucleotides described herein can beconjugated to an agent to enhance delivery. In some embodiments, theagent can be a monomer or polymer such as a targeting monomer or apolymer having targeting blocks as described in Intl. Pub. No.WO2011062965. In some embodiments, the agent can be a transport agentcovalently coupled to a polynucleotide as described in, e.g., U.S. Pat.Nos. 6,835.393 and 7,374,778. In some embodiments, the agent can be amembrane barrier transport enhancing agent such as those described inU.S. Pat. Nos. 7,737,108 and 8,003,129. Each of the references is hereinincorporated by reference in its entirety.

22. Accelerated Blood Clearance

The disclosure provides compounds, compositions and methods of usethereof for reducing the effect of ABC on a repeatedly administeredactive agent such as a biologically active agent. As will be readilyapparent, reducing or eliminating altogether the effect of ABC on anadministered active agent effectively increases its half-life and thusits efficacy.

In some embodiments the term reducing ABC refers to any reduction in ABCin comparison to a positive reference control ABC inducing LNP such asan MC3 LNP. ABC inducing LNPs cause a reduction in circulating levels ofan active agent upon a second or subsequent administration within agiven time frame. Thus a reduction in ABC refers to less clearance ofcirculating agent upon a second or subsequent dose of agent, relative toa standard LNP. The reduction may be, for instance, at least 10%, 15%,20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%,90%, 95%, 98%, or 100%. In some embodiments the reduction is 10-100%,10-50%, 20-100%, 20-50%, 30-100%, 30-50%, 40%-100%, 40-80%, 50-90%, or50-100%. Alternatively the reduction in ABC may be characterized as atleast a detectable level of circulating agent following a second orsubsequent administration or at least a 2 fold, 3 fold, 4 fold, 5 foldincrease in circulating agent relative to circulating agent followingadministration of a standard LNP. In some embodiments the reduction is a2-100 fold, 2-50 fold, 3-100 fold, 3-50 fold, 3-20 fold, 4-100 fold,4-50 fold, 4-40 fold, 4-30 fold, 4-25 fold, 4-20 fold, 4-15 fold, 4-10fold, 4-5 fold, 5-100 fold, 5-50 fold, 5-40 fold, 5-30 fold, 5-25 fold,5-20 fold, 5-15 fold, 5-10 fold, 6-100 fold, 6-50 fold, 6-40 fold, 6-30fold, 6-25 fold, 6-20 fold, 6-15 fold, 6-10 fold, 8-100 fold, 8-50 fold,8-40 fold, 8-30 fold, 8-25 fold, 8-20 fold, 8-15 fold, 8-10 fold, 10-100fold, 10-50 fold, 10-40 fold, 10-30 fold, 10-25 fold, 10-20 fold, 10-15fold, 20-100 fold, 20-50 fold, 20-40 fold, 20-30 fold, or 20-25 fold.

The disclosure provides lipid-comprising compounds and compositions thatare less susceptible to clearance and thus have a longer half-life invivo. This is particularly the case where the compositions are intendedfor repeated including chronic administration, and even moreparticularly where such repeated administration occurs within days orweeks.

Significantly, these compositions are less susceptible or altogethercircumvent the observed phenomenon of accelerated blood clearance (ABC).ABC is a phenomenon in which certain exogenously administered agents arerapidly cleared from the blood upon second and subsequentadministrations. This phenomenon has been observed, in part, for avariety of lipid-containing compositions including but not limited tolipidated agents, liposomes or other lipid-based delivery vehicles, andlipid-encapsulated agents. Heretofore, the basis of ABC has been poorlyunderstood and in some cases attributed to a humoral immune response andaccordingly strategies for limiting its impact in vivo particularly in aclinical setting have remained elusive.

This disclosure provides compounds and compositions that are lesssusceptible, if at all susceptible, to ABC. In some important aspects,such compounds and compositions are lipid-comprising compounds orcompositions. The lipid-containing compounds or compositions of thisdisclosure, surprisingly, do not experience ABC upon second andsubsequent administration in vivo. This resistance to ABC renders thesecompounds and compositions particularly suitable for repeated use invivo, including for repeated use within short periods of time, includingdays or 1-2 weeks. This enhanced stability and/or half-life is due, inpart, to the inability of these compositions to activate B1a and/or B1bcells and/or conventional B cells, pDCs and/or platelets.

This disclosure therefore provides an elucidation of the mechanismunderlying accelerated blood clearance (ABC). It has been found, inaccordance with this disclosure and the inventions provided herein, thatthe ABC phenomenon at least as it relates to lipids and lipidnanoparticles is mediated, at least in part an innate immune responseinvolving B1a and/or Bib cells, pDC and/or platelets. B1a cells arenormally responsible for secreting natural antibody, in the form ofcirculating IgM. This IgM is poly-reactive, meaning that it is able tobind to a variety of antigens, albeit with a relatively low affinity foreach.

It has been found in accordance with the invention that some lipidatedagents or lipid-comprising formulations such as lipid nanoparticlesadministered in vivo trigger and are subject to ABC. It has now beenfound in accordance with the invention that upon administration of afirst dose of the LNP, one or more cells involved in generating aninnate immune response (referred to herein as sensors) bind such agent,are activated, and then initiate a cascade of immune factors (referredto herein as effectors) that promote ABC and toxicity. For instance, B1aand B1b cells may bind to LNP, become activated (alone or in thepresence of other sensors such as pDC and/or effectors such as IL6) andsecrete natural IgM that binds to the LNP. Pre-existing natural IgM inthe human subject may also recognize and bind to the LNP, therebytriggering complement fixation. After administration of the first dose,the production of natural IgM begins within 1-2 hours of administrationof the LNP. Typically, by about 2-3 weeks the natural IgM is clearedfrom the system due to the natural half-life of IgM. Natural IgG isproduced beginning around 96 hours after administration of the LNP. Theagent, when administered in a naïve setting, can exert its biologicaleffects relatively unencumbered by the natural IgM producedpost-activation of the B1a cells or Bib cells or natural IgG. Thenatural IgM and natural IgG are non-specific and thus are distinct fromanti-PEG IgM and anti-PEG IgG.

Although Applicant is not bound by mechanism, it is proposed that LNPstrigger ABC and/or toxicity through the following mechanisms. It isbelieved that when an LNP is administered to a human subject the LNP israpidly transported through the blood to the spleen. The LNPs mayencounter immune cells in the blood and/or the spleen. A rapid innateimmune response is triggered in response to the presence of the LNPwithin the blood and/or spleen. Applicant has shown herein that withinhours of administration of an LNP several immune sensors have reacted tothe presence of the LNP. These sensors include but are not limited toimmune cells involved in generating an immune response, such as B cells,pDC, and platelets. The sensors may be present in the spleen, such as inthe marginal zone of the spleen and/or in the blood. The LNP mayphysically interact with one or more sensors, which may interact withother sensors. In such a case the LNP is directly or indirectlyinteracting with the sensors. The sensors may interact directly with oneanother in response to recognition of the LNP. For instance, manysensors are located in the spleen and can easily interact with oneanother. Alternatively, one or more of the sensors may interact with LNPin the blood and become activated. The activated sensor may theninteract directly with other sensors or indirectly (e.g., through thestimulation or production of a messenger such as a cytokine e.g., IL6).

In some embodiments the LNP may interact directly with and activate eachof the following sensors: pDC, B1a cells, B1b cells, and platelets.These cells may then interact directly or indirectly with one another toinitiate the production of effectors which ultimately lead to the ABCand/or toxicity associated with repeated doses of LNP. For instance,Applicant has shown that LNP administration leads to pDC activation,platelet aggregation and activation and B cell activation. In responseto LNP platelets also aggregate and are activated and aggregate with Bcells. pDC cells are activated. LNP has been found to interact with thesurface of platelets and B cells relatively quickly. Blocking theactivation of any one or combination of these sensors in response to LNPis useful for dampening the immune response that would ordinarily occur.This dampening of the immune response results in the avoidance of ABCand/or toxicity.

The sensors once activated produce effectors. An effector, as usedherein, is an immune molecule produced by an immune cell, such as a Bcell. Effectors include but are not limited to immunoglobulin such asnatural IgM and natural IgG and cytokines such as IL6. B1a and B1b cellsstimulate the production of natural IgMs within 2-6 hours followingadministration of an LNP. Natural IgG can be detected within 96 hours.IL6 levels are increased within several hours. The natural IgM and IgGcirculate in the body for several days to several weeks. During thistime the circulating effectors can interact with newly administeredLNPs, triggering those LNPs for clearance by the body. For instance, aneffector may recognize and bind to an LNP. The Fc region of the effectormay be recognized by and trigger uptake of the decorated LNP bymacrophage. The macrophage are then transported to the spleen. Theproduction of effectors by immune sensors is a transient response thatcorrelates with the timing observed for ABC.

If the administered dose is the second or subsequent administered dose,and if such second or subsequent dose is administered before thepreviously induced natural IgM and/or IgG is cleared from the system(e.g., before the 2-3 window time period), then such second orsubsequent dose is targeted by the circulating natural IgM and/ornatural IgG or Fc which trigger alternative complement pathwayactivation and is itself rapidly cleared. When LNP are administeredafter the effectors have cleared from the body or are reduced in number,ABC is not observed.

Thus, it is useful according to aspects of the invention to inhibit theinteraction between LNP and one or more sensors, to inhibit theactivation of one or more sensors by LNP (direct or indirect), toinhibit the production of one or more effectors, and/or to inhibit theactivity of one or more effectors. In some embodiments the LNP isdesigned to limit or block interaction of the LNP with a sensor. Forinstance the LNP may have an altered PC and/or PEG to preventinteractions with sensors. Alternatively or additionally an agent thatinhibits immune responses induced by LNPs may be used to achieve any oneor more of these effects.

It has also been determined that conventional B cells are alsoimplicated in ABC. Specifically, upon first administration of an agent,conventional B cells, referred to herein as CD19(+), bind to and reactagainst the agent. Unlike B1a and Bib cells though, conventional B cellsare able to mount first an IgM response (beginning around 96 hours afteradministration of the LNPs) followed by an IgG response (beginningaround 14 days after administration of the LNPs) concomitant with amemory response. Thus conventional B cells react against theadministered agent and contribute to IgM (and eventually IgG) thatmediates ABC. The IgM and IgG are typically anti-PEG IgM and anti-PEGIgG.

It is contemplated that in some instances, the majority of the ABCresponse is mediated through B1a cells and B1a-mediated immuneresponses. It is further contemplated that in some instances, the ABCresponse is mediated by both IgM and IgG, with both conventional B cellsand B1a cells mediating such effects. In yet still other instances, theABC response is mediated by natural IgM molecules, some of which arecapable of binding to natural IgM, which may be produced by activatedB1a cells. The natural IgMs may bind to one or more components of theLNPs, e.g., binding to a phospholipid component of the LNPs (such asbinding to the PC moiety of the phospholipid) and/or binding to aPEG-lipid component of the LNPs (such as binding to PEG-DMG, inparticular, binding to the PEG moiety of PEG-DMG). Since B1a expressesCD36, to which phosphatidylcholine is a ligand, it is contemplated thatthe CD36 receptor may mediate the activation of B1a cells and thusproduction of natural IgM. In yet still other instances, the ABCresponse is mediated primarily by conventional B cells.

It has been found in accordance with the invention that the ABCphenomenon can be reduced or abrogated, at least in part, through theuse of compounds and compositions (such as agents, delivery vehicles,and formulations) that do not activate B1a cells. Compounds andcompositions that do not activate B1a cells may be referred to herein asB1a inert compounds and compositions. It has been further found inaccordance with the invention that the ABC phenomenon can be reduced orabrogated, at least in part, through the use of compounds andcompositions that do not activate conventional B cells. Compounds andcompositions that do not activate conventional B cells may in someembodiments be referred to herein as CD19-inert compounds andcompositions. Thus, in some embodiments provided herein, the compoundsand compositions do not activate B1a cells and they do not activateconventional B cells. Compounds and compositions that do not activateB1a cells and conventional B cells may in some embodiments be referredto herein as B1a/CD19-inert compounds and compositions.

These underlying mechanisms were not heretofore understood, and the roleof B1a and B1b cells and their interplay with conventional B cells inthis phenomenon was also not appreciated.

Accordingly, this disclosure provides compounds and compositions that donot promote ABC. These may be further characterized as not capable ofactivating B1a and/or B1b cells, platelets and/or pDC, and optionallyconventional B cells also. These compounds (e.g., agents, includingbiologically active agents such as prophylactic agents, therapeuticagents and diagnostic agents, delivery vehicles, including liposomes,lipid nanoparticles, and other lipid-based encapsulating structures,etc.) and compositions (e.g., formulations, etc.) are particularlydesirable for applications requiring repeated administration, and inparticular repeated administrations that occur within with short periodsof time (e.g., within 1-2 weeks). This is the case, for example, if theagent is a nucleic acid based therapeutic that is provided to a humansubject at regular, closely-spaced intervals. The findings providedherein may be applied to these and other agents that are similarlyadministered and/or that are subject to ABC.

Of particular interest are lipid-comprising compounds, lipid-comprisingparticles, and lipid-comprising compositions as these are known to besusceptible to ABC. Such lipid-comprising compounds particles, andcompositions have been used extensively as biologically active agents oras delivery vehicles for such agents. Thus, the ability to improve theirefficacy of such agents, whether by reducing the effect of ABC on theagent itself or on its delivery vehicle, is beneficial for a widevariety of active agents.

Also provided herein are compositions that do not stimulate or boost anacute phase response (ARP) associated with repeat dose administration ofone or more biologically active agents.

The composition, in some instances, may not bind to IgM, including butnot limited to natural IgM.

The composition, in some instances, may not bind to an acute phaseprotein such as but not limited to C-reactive protein.

The composition, in some instances, may not trigger a CD5(+) mediatedimmune response. As used herein, a CD5(+) mediated immune response is animmune response that is mediated by B1a and/or Bib cells. Such aresponse may include an ABC response, an acute phase response, inductionof natural IgM and/or IgG, and the like.

The composition, in some instances, may not trigger a CD19(+) mediatedimmune response. As used herein, a CD19(+) mediated immune response isan immune response that is mediated by conventional CD19(+), CD5(−) Bcells. Such a response may include induction of IgM, induction of IgG,induction of memory B cells, an ABC response, an anti-drug antibody(ADA) response including an anti-protein response where the protein maybe encapsulated within an LNP, and the like.

B1a cells are a subset of B cells involved in innate immunity. Thesecells are the source of circulating IgM, referred to as natural antibodyor natural serum antibody. Natural IgM antibodies are characterized ashaving weak affinity for a number of antigens, and therefore they arereferred to as “poly-specific” or “poly-reactive”, indicating theirability to bind to more than one antigen. B1a cells are not able toproduce IgG. Additionally, they do not develop into memory cells andthus do not contribute to an adaptive immune response. However, they areable to secrete IgM upon activation. The secreted IgM is typicallycleared within about 2-3 weeks, at which point the immune system isrendered relatively naïve to the previously administered antigen. If thesame antigen is presented after this time period (e.g., at about 3 weeksafter the initial exposure), the antigen is not rapidly cleared.However, significantly, if the antigen is presented within that timeperiod (e.g., within 2 weeks, including within 1 week, or within days),then the antigen is rapidly cleared. This delay between consecutivedoses has rendered certain lipid-containing therapeutic or diagnosticagents unsuitable for use.

In humans, B1a cells are CD19(+), CD20(+), CD27(+), CD43(+), CD70(−) andCD5(+). In mice, B1a cells are CD19(+), CD5(+), and CD45 B cell isoformB220(+). It is the expression of CD5 which typically distinguishes B1acells from other convention B cells. B1a cells may express high levelsof CD5, and on this basis may be distinguished from other B-1 cells suchas B-1b cells which express low or undetectable levels of CD5. CD5 is apan-T cell surface glycoprotein. B1a cells also express CD36, also knownas fatty acid translocase. CD36 is a member of the class B scavengerreceptor family. CD36 can bind many ligands, including oxidized lowdensity lipoproteins, native lipoproteins, oxidized phospholipids, andlong-chain fatty acids.

B1b cells are another subset of B cells involved in innate immunity.These cells are another source of circulating natural IgM. Severalantigens, including PS, are capable of inducing T cell independentimmunity through Bib activation. CD27 is typically upregulated on Bibcells in response to antigen activation. Similar to B1a cells, the B1bcells are typically located in specific body locations such as thespleen and peritoneal cavity and are in very low abundance in the blood.The B1b secreted natural IgM is typically cleared within about 2-3weeks, at which point the immune system is rendered relatively naïve tothe previously administered antigen. If the same antigen is presentedafter this time period (e.g., at about 3 weeks after the initialexposure), the antigen is not rapidly cleared. However, significantly,if the antigen is presented within that time period (e.g., within 2weeks, including within 1 week, or within days), then the antigen israpidly cleared. This delay between consecutive doses has renderedcertain lipid-containing therapeutic or diagnostic agents unsuitable foruse.

In some embodiments it is desirable to block B1a and/or Bib cellactivation. One strategy for blocking B1a and/or B1b cell activationinvolves determining which components of a lipid nanoparticle promote Bcell activation and neutralizing those components. It has beendiscovered herein that at least PEG and phosphatidylcholine (PC)contribute to B1a and Bib cell interaction with other cells and/oractivation. PEG may play a role in promoting aggregation between B1cells and platelets, which may lead to activation. PC (a helper lipid inLNPs) is also involved in activating the B1 cells, likely throughinteraction with the CD36 receptor on the B cell surface. Numerousparticles have PEG-lipid alternatives, PEG-less, and/or PC replacementlipids (e.g. oleic acid or analogs thereof) have been designed andtested. Applicant has established that replacement of one or more ofthese components within an LNP that otherwise would promote ABC uponrepeat administration, is useful in preventing ABC by reducing theproduction of natural IgM and/or B cell activation. Thus, the inventionencompasses LNPs that have reduced ABC as a result of a design whicheliminates the inclusion of B cell triggers.

Another strategy for blocking B1a and/or B1b cell activation involvesusing an agent that inhibits immune responses induced by LNPs. Thesetypes of agents are discussed in more detail below. In some embodimentsthese agents block the interaction between B1a/B1b cells and the LNP orplatelets or pDC. For instance, the agent may be an antibody or otherbinding agent that physically blocks the interaction. An example of thisis an antibody that binds to CD36 or CD6. The agent may also be acompound that prevents or disables the B1a/B1b cell from signaling onceactivated or prior to activation. For instance, it is possible to blockone or more components in the B1a/B1b signaling cascade the results fromB cell interaction with LNP or other immune cells. In other embodimentsthe agent may act one or more effectors produced by the B1a/B1b cellsfollowing activation. These effectors include for instance, natural IgMand cytokines.

It has been demonstrated according to aspects of the invention that whenactivation of pDC cells is blocked, B cell activation in response to LNPis decreased. Thus, in order to avoid ABC and/or toxicity, it may bedesirable to prevent pDC activation. Similar to the strategies discussedabove, pDC cell activation may be blocked by agents that interfere withthe interaction between pDC and LNP and/or B cells/platelets.Alternatively, agents that act on the pDC to block its ability to getactivated or on its effectors can be used together with the LNP to avoidABC.

Platelets may also play an important role in ABC and toxicity. Veryquickly after a first dose of LNP is administered to a human subjectplatelets associate with the LNP, aggregate and are activated. In someembodiments it is desirable to block platelet aggregation and/oractivation. One strategy for blocking platelet aggregation and/oractivation involves determining which components of a lipid nanoparticlepromote platelet aggregation and/or activation and neutralizing thosecomponents. It has been discovered herein that at least PEG contributeto platelet aggregation, activation and/or interaction with other cells.Numerous particles have PEG-lipid alternatives and PEG-less have beendesigned and tested. Applicant has established that replacement of oneor more of these components within an LNP that otherwise would promoteABC upon repeat administration, is useful in preventing ABC by reducingthe production of natural IgM and/or platelet aggregation. Thus, theinvention encompasses LNPs that have reduced ABC as a result of a designwhich eliminates the inclusion of platelet triggers. Alternativelyagents that act on the platelets to block its activity once it isactivated or on its effectors can be used together with the LNP to avoidABC.

(i) Measuring ABC Activity and Related Activities

Various compounds and compositions provided herein, including LNPs, donot promote ABC activity upon administration in vivo. These LNPs may becharacterized and/or identified through any of a number of assays, suchas but not limited to those described below, as well as any of theassays disclosed in the Examples section, include the methods subsectionof the Examples.

In some embodiments the methods involve administering an LNP withoutproducing an immune response that promotes ABC. An immune response thatpromotes ABC involves activation of one or more sensors, such as B1cells, pDC, or platelets, and one or more effectors, such as naturalIgM, natural IgG or cytokines such as IL6. Thus administration of an LNPwithout producing an immune response that promotes ABC, at a minimuminvolves administration of an LNP without significant activation of oneor more sensors and significant production of one or more effectors.Significant used in this context refers to an amount that would lead tothe physiological consequence of accelerated blood clearance of all orpart of a second dose with respect to the level of blood clearanceexpected for a second dose of an ABC triggering LNP. For instance, theimmune response should be dampened such that the ABC observed after thesecond dose is lower than would have been expected for an ABC triggeringLNP.

(ii) B1a or B1b Activation Assay

Certain compositions provided in this disclosure do not activate Bcells, such as B1a or Bib cells (CD19+CD5+) and/or conventional B cells(CD19+CD5−). Activation of B1a cells, B1b cells, or conventional B cellsmay be determined in a number of ways, some of which are provided below.B cell population may be provided as fractionated B cell populations orunfractionated populations of splenocytes or peripheral bloodmononuclear cells (PBMC). If the latter, the cell population may beincubated with the LNP of choice for a period of time, and thenharvested for further analysis. Alternatively, the supernatant may beharvested and analyzed.

(iii) Upregulation of Activation Marker Cell Surface Expression

Activation of B1a cells, B1b cells, or conventional B cells may bedemonstrated as increased expression of B cell activation markersincluding late activation markers such as CD86. In an exemplarynon-limiting assay, unfractionated B cells are provided as a splenocytepopulation or as a PBMC population, incubated with an LNP of choice fora particular period of time, and then stained for a standard B cellmarker such as CD19 and for an activation marker such as CD86, andanalyzed using for example flow cytometry. A suitable negative controlinvolves incubating the same population with medium, and then performingthe same staining and visualization steps. An increase in CD86expression in the test population compared to the negative controlindicates B cell activation.

(iv) Pro-Inflammatory Cytokine Release

B cell activation may also be assessed by cytokine release assay. Forexample, activation may be assessed through the production and/orsecretion of cytokines such as IL-6 and/or TNF-alpha upon exposure withLNPs of interest.

Such assays may be performed using routine cytokine secretion assayswell known in the art. An increase in cytokine secretion is indicativeof B cell activation.

(v) LNP Binding/Association to and/or Uptake by B Cells

LNP association or binding to B cells may also be used to assess an LNPof interest and to further characterize such LNP. Association/bindingand/or uptake/internalization may be assessed using a detectablylabeled, such as fluorescently labeled, LNP and tracking the location ofsuch LNP in or on B cells following various periods of incubation.

The invention further contemplates that the compositions provided hereinmay be capable of evading recognition or detection and optionallybinding by downstream mediators of ABC such as circulating IgM and/oracute phase response mediators such as acute phase proteins (e.g.,C-reactive protein (CRP).

(vi) Methods of Use for Reducing ABC

Also provided herein are methods for delivering LNPs, which mayencapsulate an agent such as a therapeutic agent, to a human subjectwithout promoting ABC.

In some embodiments, the method comprises administering any of the LNPsdescribed herein, which do not promote ABC, for example, do not induceproduction of natural IgM binding to the LNPs, do not activate B1aand/or Bib cells. As used herein, an LNP that “does not promote ABC”refers to an LNP that induces no immune responses that would lead tosubstantial ABC or a substantially low level of immune responses that isnot sufficient to lead to substantial ABC. An LNP that does not inducethe production of natural IgMs binding to the LNP refers to LNPs thatinduce either no natural IgM binding to the LNPs or a substantially lowlevel of the natural IgM molecules, which is insufficient to lead tosubstantial ABC. An LNP that does not activate B1a and/or B1b cellsrefer to LNPs that induce no response of B1a and/or B1b cells to producenatural IgM binding to the LNPs or a substantially low level of B1aand/or B1b responses, which is insufficient to lead to substantial ABC.

In some embodiments the terms do not activate and do not induceproduction are a relative reduction to a reference value or condition.In some embodiments the reference value or condition is the amount ofactivation or induction of production of a molecule such as IgM by astandard LNP such as an MC3 LNP. In some embodiments the relativereduction is a reduction of at least 30%, for example at least 30%, 35%,40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%,94%, 95%, 96%, 97%, 98%, 99%, or 100%. In other embodiments the terms donot activate cells such as B cells and do not induce production of aprotein such as IgM may refer to an undetectable amount of the activecells or the specific protein.

(vii) Platelet Effects and Toxicity

The invention is further premised in part on the elucidation of themechanism underlying dose-limiting toxicity associated with LNPadministration. Such toxicity may involve coagulopathy, disseminatedintravascular coagulation (DIC, also referred to as consumptivecoagulopathy), whether acute or chronic, and/or vascular thrombosis. Insome instances, the dose-limiting toxicity associated with LNPs is acutephase response (APR) or complement activation-related pseudoallergy(CARPA).

As used herein, coagulopathy refers to increased coagulation (bloodclotting) in vivo. The findings reported in this disclosure areconsistent with such increased coagulation and significantly provideinsight on the underlying mechanism. Coagulation is a process thatinvolves a number of different factors and cell types, and heretoforethe relationship between and interaction of LNPs and platelets has notbeen understood in this regard. This disclosure provides evidence ofsuch interaction and also provides compounds and compositions that aremodified to have reduced platelet effect, including reduced plateletassociation, reduced platelet aggregation, and/or reduced plateletaggregation. The ability to modulate, including preferablydown-modulate, such platelet effects can reduce the incidence and/orseverity of coagulopathy post-LNP administration. This in turn willreduce toxicity relating to such LNP, thereby allowing higher doses ofLNPs and importantly their cargo to be administered to patients in needthereof.

CARPA is a class of acute immune toxicity manifested in hypersensitivityreactions (HSRs), which may be triggered by nanomedicines andbiologicals. Unlike allergic reactions, CARPA typically does not involveIgE but arises as a consequence of activation of the complement system,which is part of the innate immune system that enhances the body'sabilities to clear pathogens. One or more of the following pathways, theclassical complement pathway (CP), the alternative pathway (AP), and thelectin pathway (LP), may be involved in CARPA. Szebeni, MolecularImmunology, 61:163-173 (2014).

The classical pathway is triggered by activation of the C1-complex,which contains. C1q, C1r, C1s, or C1qr2s2. Activation of the C1-complexoccurs when C1q binds to IgM or IgG complexed with antigens, or when C1qbinds directly to the surface of the pathogen. Such binding leads toconformational changes in the C1q molecule, which leads to theactivation of C1r, which in turn, cleave C1s. The C1r2s2 component nowsplits C4 and then C2, producing C4a, C4b, C2a, and C2b. C4b and C2bbind to form the classical pathway C3-convertase (C4b2b complex), whichpromotes cleavage of C3 into C3a and C3b. C3b then binds the C3convertase to from the C5 convertase (C4b2b3b complex). The alternativepathway is continuously activated as a result of spontaneous C3hydrolysis. Factor P (properdin) is a positive regulator of thealternative pathway. Oligomerization of properdin stabilizes the C3convertase, which can then cleave much more C3. The C3 molecules canbind to surfaces and recruit more B, D, and P activity, leading toamplification of the complement activation.

Acute phase response (APR) is a complex systemic innate immune responsesfor preventing infection and clearing potential pathogens. Numerousproteins are involved in APR and C-reactive protein is awell-characterized one.

It has been found, in accordance with the invention, that certain LNPare able to associate physically with platelets almost immediately afteradministration in vivo, while other LNP do not associate with plateletsat all or only at background levels. Significantly, those LNPs thatassociate with platelets also apparently stabilize the plateletaggregates that are formed thereafter. Physical contact of the plateletswith certain LNPs correlates with the ability of such platelets toremain aggregated or to form aggregates continuously for an extendedperiod of time after administration. Such aggregates comprise activatedplatelets and also innate immune cells such as macrophages and B cells.

23. Methods of Use

The polynucleotides, pharmaceutical compositions and formulationsdescribed herein are used in the preparation, manufacture andtherapeutic use of to treat and/or prevent PCC-related diseases,disorders or conditions. In some embodiments, the polynucleotides,compositions and formulations of the invention are used to treat and/orprevent metabolic acidosis (e.g., acidosis of the blood and tissues),hyperammonemia, and/or hyperglycinemia. In some embodiments, thepolynucleotides, compositions and formulations of the invention are usedto treat and/or prevent the accumulation of propionyl-CoA and/ormetabolites of branched-chain amino acid catabolism, e.g., accumulationin the tissue (e.g., liver), whole blood (e.g., in dried blood spots),plasma, serum, RBCs, urine, and/or other fluids.

In some embodiments, the polynucleotides, pharmaceutical compositionsand formulations of the invention are used in methods for reducing thelevels of propionic acid in a human subject in need thereof. Forinstance, one aspect of the invention provides a method of alleviatingthe symptoms of propionic acidemia in a human subject comprising theadministration of a composition or formulation comprising apolynucleotide encoding PCCA and/or PCCA to that human subject (e.g., anmRNA encoding a PCCA polypeptide) and/or a PCCB polypeptide. In someembodiments, the invention provides a method of alleviating the symptomsof propionic acidemia in a human subject comprising theco-administration of a composition or formulation comprising apolynucleotide encoding PCCA and a composition or formulation comprisinga polynucleotide encoding PCCB to that human subject

In some embodiments, the polynucleotides, pharmaceutical compositionsand formulations of the invention are used to reduce the level ofpropionic acid, the method comprising administering to the human subjectan effective amount of a polynucleotide encoding a PCCA polypeptideand/or PCCB polypeptide. In some embodiments, the administration of thepolynucleotide, pharmaceutical composition or formulation of theinvention results in reduction in the level of propionic acid to lessthan 1,200 μM (e.g., 100, 125, 150, 175, 200, 225, 250, 275, 300, 325,350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, 625, 650, 675,700, 725, 750, 775, 800, 825, 850, 875, 900, 925, 950, 975, 1000, 1025,1050, 1075, 1100, 1125, 1150, 1175 μM), within a short period of time(e.g., within about 6 hours, within about 8 hours, within about 12hours, within about 16 hours, within about 20 hours, or within about 24hours) after administration of the polynucleotide, pharmaceuticalcomposition or formulation of the invention.

In some embodiments, the administration of the polynucleotide,pharmaceutical composition or formulation of the invention results inreduction in the level of propionic acid over the course of at least 12hours, at least 1 day, at least 5 days, at least 10 days, at least 12days, at least 14 days, at least 16 days, at least 18 days, at least 20days, at least 21 days, at least 22 days, at least 24 days, at least 26days, at least 28 days, at least 30 days, at least 32 days, at least 35days, at least 40 days, at least 45 days, at least 50 days, or at least60 days. In some embodiments, the administration of the polynucleotide,pharmaceutical composition or formulation of the invention results inreduction in the level of propionic acid over the course of between 1day and 30 days, between 15 days and 45 days, or between 30 days and 60days.

In some embodiments, the administration of an effective amount of apolynucleotide, pharmaceutical composition or formulation of theinvention reduces the levels of at least one biomarker of PA, e.g.,propionyl-L-carnitine (C3), 2-methylcitric acid (2-MC),3-hydroxypropionic acid, (30HPA), propionylglycine, glycine, lactateand/or ammonia. In some embodiments, the administration of an effectiveamount of a polynucleotide, pharmaceutical composition or formulation ofthe invention reduces the levels of propionyl-L-camitine (C3),2-methylcitric acid (2-MC), 3-hydroxypropionic acid, (30HPA),propionylglycine, glycine, lactate and/or ammonia in the tissue (e.g.,liver), whole blood (e.g., in dried blood spots), plasma, serum, RBCs,urine, and/or other fluids. In one embodiment, the administration of aneffective amount of a polynucleotide, pharmaceutical composition orformulation of the invention reduces the levels of ammonia in a tissueof the human subject and further reduces the level of at least oneadditional biomarker.

In some embodiments, the administration of the polynucleotide,pharmaceutical composition or formulation of the invention results inreduction in the level of one or more biomarkers of PA (e.g., at leastone biomarker of PA in addition to ammonia), within a short period oftime (e.g., within about 6 hours, within about 8 hours, within about 12hours, within about 16 hours, within about 20 hours, or within about 24hours) after administration of the polynucleotide, pharmaceuticalcomposition or formulation of the invention. In some embodiments, theadministration of the polynucleotide, pharmaceutical composition orformulation of the invention results in reduction in the level of one ormore biomarkers of PA over the course of at least 12 hours, at least 1day, at least 5 days, at least 10 days, at least 12 days, at least 14days, at least 16 days, at least 18 days, at least 20 days, at least 21days, at least 22 days, at least 24 days, at least 26 days, at least 28days, at least 30 days, at least 32 days, at least 35 days, at least 40days, at least 45 days, at least 50 days, or at least 60 days. In someembodiments, the administration of the polynucleotide, pharmaceuticalcomposition or formulation of the invention results in reduction in thelevel of one or more biomarkers of PA over the course of between 1 dayand 30 days, between 15 days and 45 days, or between 30 and 60 days.

In some embodiments, the administration of the polynucleotide,pharmaceutical composition or formulation of the invention results inreduction in the level of ammonia. In some embodiments, theadministration of the polynucleotide, pharmaceutical composition orformulation of the invention results in reduction in the level ofammonia in a human subject having PA, e.g., reduction in plasma ammonialevels to normal or about normal levels of ammonia. In some embodiments,the effects of co-administering PCCA and PCCB mRNAs on plasma ammonialevels can be compared to the effects on ammonia levels that result fromadministering Carbaglu® to a human subject, e.g., a mammal such as ahuman. Carbaglu® is a drug approved by the European Medicines Agency(EMA)- to treat hyperammonemia due to PA. The polynucleotides describedherein can have several advantages over Carbaglu®. For example,Carbaglu® has a relatively short half-life of approximately 5-6 hours,so patients must take 2-4 doses of Carbaglu daily for the drug to beeffective. By contrast, in some cases the polynucleotides describedherein (mRNA-expressed human PCCA and PCCB) have a liver residence timeof 21 days or more following administration of mRNAs in some mammals, sopatients could be dosed less frequently with these polynucleotidesrelative to Carbaglu®. In addition, Carbaglu® only has an impact onammonia levels by activating ureagenesis, whereas mRNAs encoding PCCAand PCCB restore functional PCC enzyme and propionate metabolism in theliver, and thus should have an impact on other disease-associatedmetabolites in addition to ammonia.

Replacement therapy is a potential treatment for PA. Thus, in certainaspects of the invention, the polynucleotides, e.g., mRNA, disclosedherein comprise one or more sequences encoding a PCCA and/or PCCBpolypeptide that is suitable for use in gene replacement therapy for PA.In some embodiments, the present disclosure treats a lack of PCCA and/orPCCB or PCC activity, or decreased or abnormal PCC activity in a humansubject by providing at least one polynucleotide, e.g., mRNA, thatencodes a PCCA polypeptide and/or a PCCB polypeptide to the humansubject. In some embodiments, the polynucleotide is sequence-optimized.In some embodiments, the at least one polynucleotide (e.g., an mRNA)comprises a nucleic acid sequence (e.g., an ORF) encoding a PCCApolypeptide and/or PCCB polypeptide, wherein the at least one nucleicacid is sequence-optimized, e.g., by modifying its G/C, uridine, orthymidine content, and/or the at least one polynucleotide comprises atleast one chemically modified nucleoside. In some embodiments, the atleast one polynucleotide comprises a miRNA binding site, e.g., a miRNAbinding site that binds miRNA-142 and/or a miRNA binding site that bindsmiRNA-126.

In some embodiments, the administration of a composition or formulationcomprising at least one polynucleotide, pharmaceutical composition orformulation of the invention to a human subject results in a decrease inpropionic acid in blood/plasma to a level at least 10%, at least 15%, atleast 20%, at least 25%, at least 30%, at least 35%, at least 40%, atleast 45%, at least 50%, at least 55%, at least 60%, at least 65%, atleast 70%, at least 75%, at least 80%, at least 85%, at least 90%, atleast 95%, or to 100% lower than the level observed prior to theadministration of the composition or formulation.

In some embodiments, the administration of the at least onepolynucleotide, pharmaceutical composition or formulation of theinvention results in expression of PCCA and/or PCCB in cells of thehuman subject. In some embodiments, administering the at least onepolynucleotide, pharmaceutical composition or formulation of theinvention results in an increase of PCCA and/or PCCB expression and/orenzymatic activity in the human subject. For example, in someembodiments, the polynucleotides of the present invention are used inmethods of administering a composition or formulation comprising atleast one mRNA encoding a PCCA and/or PCCB polypeptide to a humansubject, wherein the method results in an increase of PCCA and/or PCCBexpression and/or enzymatic activity in at least some cells of a humansubject.

In some embodiments, the administration of a composition or formulationcomprising at least one mRNA encoding a PCCA and/or PCCB polypeptide toa human subject results in an increase of PCCA and/or PCCB expressionand/or PCC enzymatic activity (e.g., as measured by reduction in atleast one biomarker of disease, such as at least one biomarker inaddition to ammonia levels) in cells subject to a level at least 2%, atleast 5%, at least 10%, at least 15%, at least 20%, at least 25%, atleast 30%, at least 35%, at least 40%, at least 45%, at least 50%, atleast 55%, at least 60%, at least 65%, at least 70%, at least 75%, atleast 80%, at least 85%, at least 90%, at least 95%, or to 100% or moreof the expression and/or activity level expected in a normal humansubject, e.g., a human not suffering from PA. In one embodiment, suchadministration results in an increase in PCCA and/or PCCB expressionand/or PCC enzymatic activity as soon as 1-2 days post administrationand which lasts as long as 3-4 weeks after a single intravenous dose. Inanother embodiment, repeat dosing results in sustained PCCA and/or PCCBexpression and/or PCC enzymatic activity. In yet another embodiment,such administration results in expression of PCCA and/or PCCB in thehuman subject's liver cells, e.g., in mitochondria.

In some embodiments, the administration of the polynucleotide,pharmaceutical composition or formulation of the invention results inexpression of PCCA and/or PCCB protein in at least some of the cells ofa human subject that persists for a period of time sufficient to allowsignificant propionic acid metabolism to occur.

In some embodiments, the expression of the encoded polypeptide isincreased. In some embodiments, the at least one polynucleotideincreases PCCA and/or PCCB expression and/or PCC enzymatic activitylevels in cells when introduced into those cells, e.g., by at least 2%,at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, atleast 30%, at least 35%, at least 40%, at least 45%, at least 50%, atleast 55%, at least 60%, at least 65%, at least 70%, at least 75%, atleast 80%, at least 85%, at least 90%, at least 95%, or to 100% withrespect to the PCCA and/or PCCB expression and/or PCC enzymatic activitylevel in the cells before the at least one polypeptide is introduced inthe cells.

In some embodiments, the method or use comprises administering at leastone polynucleotide, e.g., mRNA, comprising at least one nucleotidesequence having sequence similarity to a polynucleotide selected fromthe group of SEQ ID NOs: 2, 5-14, 16-27, 196, 197, and 198 or a at leastone polynucleotide selected from the group of SEQ ID NOs: 28-50, 63,65-67, and 200-205, wherein the at least one polynucleotide encodes aPCCA and/or PCCB polypeptide.

Other aspects of the present disclosure relate to transplantation ofcells containing polynucleotides to a mammalian subject. Administrationof cells to human subjects is known to those of ordinary skill in theart, and includes, but is not limited to, local implantation (e.g.,topical or subcutaneous administration), organ delivery or systemicinjection (e.g., intravenous injection or inhalation), and theformulation of cells in pharmaceutically acceptable carriers.

In some embodiments, the polynucleotides (e.g., mRNA), pharmaceuticalcompositions and formulations used in the methods of the inventioncomprise a uracil-modified sequence encoding a PCCA and/or PCCBpolypeptide disclosed herein and a miRNA binding site disclosed herein,e.g., a miRNA binding site that binds to miR-142 and/or a miRNA bindingsite that binds to miR-126. In some embodiments, the uracil-modifiedsequence encoding a PCCA and/or PCCB polypeptide comprises at least onechemically modified nucleobase, e.g., N1-methylpseudouracil or5-methoxyuracil. In some embodiments, at least 95% of a type ofnucleobase (e.g., uracil) in a uracil-modified sequence encoding a PCCAand/or PCCB polypeptide of the invention are modified nucleobases. Insome embodiments, at least 95% of uracil in a uracil-modified sequenceencoding a PCCA and/or PCCB polypeptide is 1-N-methylpseudouridine or5-methoxyuridine. In some embodiments, the polynucleotide (e.g., a RNA,e.g., a mRNA) disclosed herein is formulated with a delivery agentcomprising, e.g., a compound having the Formula (I), e.g., any ofCompounds 1-232, e.g., Compound II; a compound having the Formula (III),(IV), (V), or (VI), e.g., any of Compounds 233-342, e.g., Compound VI;or a compound having the Formula (VIII), e.g., any of Compounds 419-428,e.g., Compound I, or any combination thereof. In some embodiments, thedelivery agent comprises Compound II, DSPC, Cholesterol, and Compound Ior PEG-DMG, e.g., with a mole ratio of about 47.5:10.5:39.0:3.0 or about50:10:38.5:1.5. In some embodiments, the delivery agent comprisesCompound VI, DSPC, Cholesterol, and Compound I or PEG-DMG, e.g., with amole ratio in the range of about 30 to about 60 mol % Compound II or VI(or related suitable amino lipid) (e.g., 30-40, 40-45, 45-50, 50-55 or55-60 mol % Compound II or VI (or related suitable amino lipid)), about5 to about 20 mol % phospholipid (or related suitable phospholipid or“helper lipid”) (e.g., 5-10, 10-15, or 15-20 mol % phospholipid (orrelated suitable phospholipid or “helper lipid”)), about 20 to about 50mol % cholesterol (or related sterol or “non-cationic” lipid) (e.g.,about 20-30, 30-35, 35-40, 40-45, or 45-50 mol % cholesterol (or relatedsterol or “non-cationic” lipid)) and about 0.05 to about 10 mol % PEGlipid (or other suitable PEG lipid) (e.g., 0.05-1, 1-2, 2-3, 3-4, 4-5,5-7, or 7-10 mol % PEG lipid (or other suitable PEG lipid)). Anexemplary delivery agent can comprise mole ratios of, for example,47.5:10.5:39.0:3.0 or 50:10:38.5:1.5. In certain instances, an exemplarydelivery agent can comprise mole ratios of, for example,47.5:10.5:39.0:3; 47.5:10:39.5:3; 47.5:11:39.5:2; 47.5:10.5:39.5:2.5;47.5:11:39:2.5; 48.5:10:38.5:3; 48.5:10.5:39:2; 48.5:10.5:38.5:2.5;48.5:10.5:39.5:1.5; 48.5:10.5:38.0:3; 47:10.5:39.5:3; 47:10:40.5:2.5;47:11:40:2; 47:10.5:39.5:3; 48:10.5:38.5:3; 48:10:39.5:2.5; 48:11:39:2;or 48:10.5:38.5:3. In some embodiments, the delivery agent comprisesCompound II or VI, DSPC, Cholesterol, and Compound I or PEG-DMG, e.g.,with a mole ratio of about 47.5:10.5:39.0:3.0. In some embodiments, thedelivery agent comprises Compound II or VI, DSPC, Cholesterol, andCompound I or PEG-DMG, e.g., with a mole ratio of about47.5:10.5:39.0:3.0 or about 50:10:38.5:1.5.

The skilled artisan will appreciate that the therapeutic effectivenessof a drug or a treatment of the instant invention can be characterizedor determined by measuring the level of expression of an encoded protein(e.g., enzyme) in a sample or in samples taken from a subject (e.g.,from a preclinical test subject (rodent, primate, etc.) or from aclinical subject (human). Likewise, the therapeutic effectiveness of adrug or a treatment of the instant invention can be characterized ordetermined by measuring the level of activity of an encoded protein(e.g., enzyme) in a sample or in samples taken from a subject (e.g.,from a preclinical test subject (rodent, primate, etc.) or from aclinical subject (human). Furthermore, the therapeutic effectiveness ofa drug or a treatment of the instant invention can be characterized ordetermined by measuring the level of an appropriate biomarker insample(s) taken from a subject. Levels of protein and/or biomarkers canbe determined post-administration with a single dose of an mRNAtherapeutic of the invention or can be determined and/or monitored atseveral time points following administration with a single dose or canbe determined and/or monitored throughout a course of treatment, e.g., amulti-dose treatment.

PA is associated with an impaired ability to catalyze the carboxylationof propionyl-CoA to methylmalonyl-CoA. Accordingly, PA patients commonlyshow high levels of propionic acid in their blood.

PA is an autosomal recessive inborn metabolic disorder characterized bythe inability to catalyze the carboxylation of propionyl-CoA tomethylmalonyl-CoA. Accordingly, PA patients can be asymptomatic carriersof the disorder or suffer from the various symptoms associated with thedisease. PA patients commonly show high levels of propionic acid intheir whole blood, plasma, serum, urine, and/or tissue (e.g., liver).Unless otherwise specified, the methods of treating PA patients or humansubjects disclosed herein include treatment of both asymptomaticcarriers and those individuals with abnormal levels of biomarkers.

PCCA or PCCB Protein Expression Levels

Certain aspects of the invention feature measurement, determinationand/or monitoring of the expression level or levels of propionyl-CoAcarboxylase alpha (PCCA) protein and/or propionyl-CoA carboxylase beta(PCCB) in a subject, for example, in an animal (e.g., rodents, primates,and the like) or in a human subject. Animals include normal, healthy orwild type animals, as well as animal models for use in understanding PAand treatments thereof. Exemplary animal models include rodent models,for example, PCCA deficient mice (null or hypomorphic) also referred toas PCCA mice.

PCCA or PCCB protein expression levels can be measured or determined byany art-recognized method for determining protein levels in biologicalsamples, e.g., from blood samples or a needle biopsy. The term “level”or “level of a protein” as used herein, preferably means the weight,mass or concentration of the protein within a sample or a human subject.It will be understood by the skilled artisan that in certain embodimentsthe sample may be subjected, e.g., to any of the following:purification, precipitation, separation, e.g. centrifugation and/orHPLC, and subsequently subjected to determining the level of theprotein, e.g., using mass and/or spectrometric analysis. In exemplaryembodiments, enzyme-linked immunosorbent assay (ELISA) can be used todetermine protein expression levels. In other exemplary embodiments,protein purification, separation and LC-MS can be used as a means fordetermining the level of a protein according to the invention. In someembodiments, an mRNA therapy of the invention (e.g., a singleintravenous dose) results in increased PCCA and/or PCCB proteinexpression levels in the liver tissue of the human subject (e.g.,2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold,20-fold, 30-fold, 40-fold, 50-fold increase and/or increased to at least50%, at least 60%, at least 70%, at least 75%, 80%, at least 85%, atleast 90%, at least 95%, or at least 100% of normal levels) for at least6 hours, at least 12 hours, at least 24 hours, at least 36 hours, atleast 48 hours, at least 60 hours, at least 72 hours, at least 84 hours,at least 96 hours, at least 108 hours, at least 122 hours, at least 1week, at least 2 weeks, at least 3 weeks, at least 4 weeks afteradministration of a single dose of the mRNA therapy. In someembodiments, an mRNA therapy of the invention (e.g., a singleintravenous dose) results in decreased propionic acid expression levelsin the blood, plasma, serum or liver tissue of the human subject (e.g.,less than 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375,400, 425, 450, 475, 500, 525, 550, 575, 600, 625, 650, 675, 700, 725,750, 775, 800, 825, 850, 875, 900, 925, 950, 975, 1000, 1025, 1050,1075, 1100, 1125, 1150, 1175 or 1,200 μM) for at least 6 hours, at least12 hours, at least 24 hours, at least 36 hours, at least 48 hours, atleast 60 hours, at least 72 hours, at least 84 hours, at least 96 hours,at least 108 hours, at least 122 hours, at least 1 week, at least 2weeks, at least 3 weeks, at least 4 weeks after administration of asingle dose of the mRNA therapy.

PCC Protein Activity

In PA patients, PCC enzymatic activity is reduced compared to a normalphysiological activity level. Further aspects of the invention featuremeasurement, determination and/or monitoring of the activity level(s)(i.e., enzymatic activity level(s)) of PCCA or PCCB protein in asubject, for example, in an animal (e.g., rodent, primate, and the like)or in a human subject. Activity levels can be measured or determined byany art-recognized method for determining enzymatic activity levels inbiological samples. The term “activity level” or “enzymatic activitylevel” as used herein, preferably means the activity of the enzyme pervolume, mass or weight of sample or total protein within a sample. Inexemplary embodiments, the “activity level” or “enzymatic activitylevel” is described in terms of units per milliliter of fluid (e.g.,bodily fluid, e.g., serum, plasma, urine and the like) or is describedin terms of units per weight of tissue or per weight of protein (e.g.,total protein) within a sample. Units (“U”) of enzyme activity can bedescribed in terms of weight or mass of substrate hydrolyzed per unittime. In certain embodiments of the invention feature PCC activitydescribed in terms of U/ml plasma or U/mg protein (tissue), where units(“U”) are described in terms of nmol substrate hydrolyzed per hour (ornmol/hr).

In certain embodiments, an mRNA therapy of the invention features apharmaceutical composition comprising a dose of mRNA effective to resultin at least 5 U/mg, at least 10 U/mg, at least 20 U/mg, at least 30U/mg, at least 40 U/mg, at least 50 U/mg, at least 60 U/mg, at least 70U/mg, at least 80 U/mg, at least 90 U/mg, at least 100 U/mg, or at least150 U/mg of PCCA or PCCB activity in tissue (e.g., liver) between 6 and12 hours, or between 12 and 24, between 24 and 48, or between 48 and 72hours post administration (e.g., at 48 or at 72 hours postadministration).

In exemplary embodiments, an mRNA therapy of the invention features apharmaceutical composition comprising a single intravenous dose of mRNAthat results in the above-described levels of activity. In anotherembodiment, an mRNA therapy of the invention features a pharmaceuticalcomposition which can be administered in multiple single unitintravenous doses of mRNA that maintain the above-described levels ofactivity.

PA Biomarkers

Further aspects of the invention feature determining the level (orlevels) of a biomarker determined in a sample as compared to a level(e.g., a reference level) of the same or another biomarker in anothersample, e.g., from the same patient, from another patient, from acontrol and/or from the same or different time points, and/or aphysiologic level, and/or an elevated level, and/or a supraphysiologiclevel, and/or a level of a control. The skilled artisan will be familiarwith physiologic levels of biomarkers, for example, levels in normal orwildtype animals, normal or healthy subjects, and the like, inparticular, the level or levels characteristic of subjects who arehealthy and/or normal functioning. As used herein, the phrase “elevatedlevel” means amounts greater than normally found in a normal or wildtypepreclinical animal or in a normal or healthy subject, e.g. a humansubject. As used herein, the term “supraphysiologic” means amountsgreater than normally found in a normal or wildtype preclinical animalor in a normal or healthy subject, e.g. a human subject, optionallyproducing a significantly enhanced physiologic response. As used herein,the term “comparing” or “compared to” preferably means the mathematicalcomparison of the two or more values, e.g., of the levels of thebiomarker(s). It will thus be readily apparent to the skilled artisanwhether one of the values is higher, lower or identical to another valueor group of values if at least two of such values are compared with eachother. Comparing or comparison to can be in the context, for example, ofcomparing to a control value, e.g., as compared to a reference blood(e.g., dried blood spot), serum, plasma, urine and/or tissue (e.g.,liver) propionyl-L-carnitine (C3), 2-methylcitric acid (2-MC),3-hydroxypropionic acid, (30HPA), propionylglycine, glycine, lactate orammonia level, in said subject prior to administration (e.g., in aperson suffering from PA) or in a normal or healthy subject.

As used herein, a “control” is preferably a sample from a human subjectwherein the PA status of said human subject is known. In one embodiment,a control is a sample of a healthy patient. In another embodiment, thecontrol is a sample from at least one human subject having a known PAstatus, for example, a severe, mild, or healthy PA status, e.g. acontrol patient. In another embodiment, the control is a sample from ahuman subject not being treated for PA. In a still further embodiment,the control is a sample from a single human subject or a pool of samplesfrom different human subjects and/or samples taken from the humansubject(s) at different time points.

The term “level” or “level of a biomarker” as used herein, preferablymeans the mass, weight or concentration of a biomarker of the inventionwithin a sample or a human subject. It will be understood by the skilledartisan that in certain embodiments the sample may be subjected to,e.g., one or more of the following: substance purification,precipitation, separation, e.g. centrifugation and/or HPLC andsubsequently subjected to determining the level of the biomarker, e.g.using mass spectrometric analysis. In certain embodiments, LC-MS can beused as a means for determining the level of a biomarker according tothe invention.

The term “determining the level” of a biomarker as used herein can meanmethods which include quantifying an amount of at least one substance ina sample from a human subject, for example, in a bodily fluid from thehuman subject (e.g., blood, serum, plasma, urine, lymph, etc.) or in atissue of the human subject (e.g., liver, etc.).

The term “reference level” as used herein can refer to levels (e.g., ofa biomarker) in a human subject prior to administration of an mRNAtherapy of the invention (e.g., in a person suffering from PA) or in anormal or healthy human subject.

As used herein, the term “normal subject” or “healthy subject” refers toa human subject not suffering from symptoms associated with PA.Moreover, a human subject will be considered to be normal (or healthy)if it has no mutation of the functional portions or domains of the PCCAand PCCB genes and/or no mutation of the PCCA and PCCB genes resultingin a reduction of or deficiency of the enzyme PCC or the activitythereof, resulting in symptoms associated with PA. Said mutations willbe detected if a sample from the subject is subjected to a genetictesting for such PCCA and/or PCCB mutations. In certain embodiments ofthe present invention, a sample from a healthy subject is used as acontrol sample, or the known or standardized value for the level ofbiomarker from samples of healthy or normal subjects is used as acontrol.

In some embodiments, comparing the level of the biomarker in a samplefrom a human subject in need of treatment for PA or in a human subjectbeing treated for PA to a control level of the biomarker comprisescomparing the level of the biomarker in the sample from the subject (inneed of treatment or being treated for PA) to a baseline or referencelevel, wherein if a level of the biomarker in the sample from thesubject (in need of treatment or being treated for PA) is elevated,increased or higher compared to the baseline or reference level, this isindicative that the subject is suffering from PA and/or is in need oftreatment; and/or wherein if a level of the biomarker in the sample fromthe subject (in need of treatment or being treated for PA) is decreasedor lower compared to the baseline level this is indicative that thesubject is not suffering from, is successfully being treated for PA, oris not in need of treatment for PA. The stronger the reduction (e.g., atleast 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, atleast 6-fold, at least 7-fold, at least 8-fold, at least 10-fold, atleast 20-fold, at least-30 fold, at least 40-fold, at least 50-foldreduction and/or at least 10%, at least 20%, at least 30% at least 40%,at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, orat least 100% reduction) of the level of a biomarker, within a certaintime period, e.g., within 6 hours, within 12 hours, 24 hours, 36 hours,48 hours, 60 hours, or 72 hours, and/or for a certain duration of time,e.g., 48 hours, 72 hours, 96 hours, 120 hours, 144 hours, 1 week, 2weeks, 3 weeks, 4 weeks, 1 month, 2 months, 3 months, 4 months, 5months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12months, 18 months, 24 months, etc. the more successful is a therapy,such as for example an mRNA therapy of the invention (e.g., a singledose or a multiple regimen).

A reduction of at least about 20%, at least about 30%, at least about40%, at least about 50%, at least about 60%, at least about 70%, atleast about 80%, at least about 90%, at least 100% or more of the levelof biomarker, in particular, in bodily fluid (e.g., whole blood, plasma,serum, urine, e.g., urinary sediment) or in tissue(s) in a human subject(e.g., liver), within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more days followingadministration is indicative of a dose suitable for successful treatmentPA, wherein reduction as used herein, preferably means that the level ofbiomarker determined at the end of a specified time period (e.g.,post-administration, for example, of a single intravenous dose) iscompared to the level of the same biomarker determined at the beginningof said time period (e.g., pre-administration of said dose). Exemplarytime periods include 12, 24, 48, 72, 96, 120 or 144 hours, 5 days, 8days, 10 days, 12 days, 14 days, 16 days, 18 days, 20 days, 21 days, 22days, 23 days, 25 days, 30 days, 32 days, 35 days, 40 days, 45 days, 50days, 55 days, or 60 days post administration, in particular 24, 48, 72or 96 hours post administration.

A sustained reduction in substrate levels (e.g., biomarkers) isparticularly indicative of mRNA therapeutic dosing and/or administrationregimens successful for treatment of PA. Such sustained reduction can bereferred to herein as “duration” of effect. In exemplary embodiments, areduction of at least about 20%, at least about 30%, at least about 40%,at least about 50%, at least about 60%, at least about 65%, at leastabout 70%, at least about 75%, at least about 80%, at least about 85%,at least about 90%, or at least about 95% at least about 96%, at leastabout 97%, at least about 98%, at least about 99%, at least about 100%or more of the level of biomarker, in particular, in a bodily fluid(e.g., whole blood, plasma, serum, urine, e.g., urinary sediment) or intissue(s) in a human subject (e.g., liver), within 1, 2, 3, 4, 5, 6, 7,8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,30, 35, 40, 45, 50, 55,60 or more days following administration isindicative of a successful therapeutic approach. In exemplaryembodiments, sustained reduction in substrate (e.g., biomarker) levelsin one or more samples (e.g., fluids and/or tissues) is preferred. Forexample, mRNA therapies resulting in sustained reduction in a biomarker,optionally in combination with sustained reduction of said biomarker inat least one tissue, preferably two, three, four, five or more tissues,is indicative of successful treatment.

In some embodiments, a single dose of an mRNA therapy of the inventionis about 0.2 to about 0.8 mpk, about 0.3 to about 0.7 mpk, about 0.4 toabout 0.8 mpk, or about 0.5 mpk. In another embodiment, a single dose ofan mRNA therapy of the invention is less than 1.5 mpk, less than 1.25mpk, less than 1 mpk, or less than 0.75 mpk. In some embodiments, asingle dose of an mRNA therapy described herein is between 0.1 mpk to2.5 mpk, e.g., 0.5 mpk to 2.0 mpk, 0.75 mpk to 2.0 mpk, 0.8 mpk to 2.0mpk, 0.9 mpk to 2.0 mpk, 1 mpk to 1.75 mpk, 1.0 mpk to 1.5 mpk, 1.1 mpkto 1.5 mpk, or 1.2 mpk to 1.4 mpk.

24. Compositions and Formulations for Use

Certain aspects of the invention are directed to compositions orformulations comprising any of the polynucleotides disclosed above.

In some embodiments, the composition or formulation comprises:

-   -   (i) a polynucleotide (e.g., a RNA, e.g., an mRNA) comprising a        sequence-optimized nucleotide sequence (e.g., an ORF) encoding a        PCCA or PCCB polypeptide (e.g., the wild-type sequence,        functional fragment, or variant thereof), wherein the        polynucleotide comprises at least one chemically modified        nucleobase, e.g., N1-methylpseudouracil or 5-methoxyuracil        (e.g., wherein at least about 25%, at least about 30%, at least        about 40%, at least about 50%, at least about 60%, at least        about 70%, at least about 80%, at least about 90%, at least        about 95%, at least about 99%, or 100% of the uracils are        N1-methylpseudouracils or 5-methoxyuracils), and wherein the        polynucleotide further comprises a miRNA binding site, e.g., a        miRNA binding site that binds to miR-142 (e.g., a miR-142-3p or        miR-142-5p binding site) and/or a miRNA binding site that binds        to miR-126 (e.g., a miR-126-3p or miR-126-5p binding site); and    -   (ii) a delivery agent comprising, e.g., a compound having the        Formula (I), e.g., any of Compounds 1-232, e.g., Compound II; a        compound having the Formula (III), (IV), (V), or (VI), e.g., any        of Compounds 233-342, e.g., Compound VI; or a compound having        the Formula (VIII), e.g., any of Compounds 419-428, e.g.,        Compound I, or any combination thereof. In some embodiments, the        delivery agent is a lipid nanoparticle comprising Compound II,        Compound VI, a salt or a stereoisomer thereof, or any        combination thereof. In some embodiments, the delivery agent        comprises Compound II, DSPC, Cholesterol, and Compound I or        PEG-DMG, e.g., with a mole ratio of about 50:10:38.5:1.5. In        some embodiments, the delivery agent comprises Compound II,        DSPC, Cholesterol, and Compound I or PEG-DMG, e.g., with a mole        ratio of about 47.5:10.5:39.0:3.0. In some embodiments, the        delivery agent comprises Compound VI, DSPC, Cholesterol, and        Compound I or PEG-DMG, e.g., with a mole ratio of about        50:10:38.5:1.5. In some embodiments, the delivery agent        comprises Compound VI, DSPC, Cholesterol, and Compound I or        PEG-DMG, e.g., with a mole ratio of about 47.5:10.5:39.0:3.0.

In some embodiments, the uracil or thymine content of the ORF relativeto the theoretical minimum uracil or thymine content of a nucleotidesequence encoding the PCCA or PCCB polypeptide (% U_(TM) or % T_(TM)),is between about 100% and about 150%.

In some embodiments, the polynucleotides, compositions or formulationsabove are used to treat and/or prevent PCCA- or PCCB-related diseases,disorders or conditions, e.g., PA.

25. Forms of Administration

The polynucleotides, pharmaceutical compositions and formulations of theinvention described above can be administered by any route that resultsin a therapeutically effective outcome. These include, but are notlimited to enteral (into the intestine), gastroenteral, epidural (intothe dura matter), oral (by way of the mouth), transdermal, peridural,intracerebral (into the cerebrum), intracerebroventricular (into thecerebral ventricles), epicutaneous (application onto the skin),intradermal, (into the skin itself), subcutaneous (under the skin),nasal administration (through the nose), intravenous (into a vein),intravenous bolus, intravenous drip, intraarterial (into an artery),intramuscular (into a muscle), intracardiac (into the heart),intraosseous infusion (into the bone marrow), intrathecal (into thespinal canal), intraperitoneal, (infusion or injection into theperitoneum), intravesical infusion, intravitreal, (through the eye),intracavernous injection (into a pathologic cavity) intracavitary (intothe base of the penis), intravaginal administration, intrauterine,extra-amniotic administration, transdermal (diffusion through the intactskin for systemic distribution), transmucosal (diffusion through amucous membrane), transvaginal, insufflation (snorting), sublingual,sublabial, enema, eye drops (onto the conjunctiva), in ear drops,auricular (in or by way of the ear), buccal (directed toward the cheek),conjunctival, cutaneous, dental (to a tooth or teeth), electro-osmosis,endocervical, endosinusial, endotracheal, extracorporeal, hemodialysis,infiltration, interstitial, intra-abdominal, intra-amniotic,intra-articular, intrabiliary, intrabronchial, intrabursal,intracartilaginous (within a cartilage), intracaudal (within the caudaequine), intracisternal (within the cistema magna cerebellomedularis),intracorneal (within the cornea), dental intracornal, intracoronary(within the coronary arteries), intracorporus cavernosum (within thedilatable spaces of the corporus cavernosa of the penis), intradiscal(within a disc), intraductal (within a duct of a gland), intraduodenal(within the duodenum), intradural (within or beneath the dura),intraepidermal (to the epidermis), intraesophageal (to the esophagus),intragastric (within the stomach), intragingival (within the gingivae),intraileal (within the distal portion of the small intestine),intralesional (within or introduced directly to a localized lesion),intraluminal (within a lumen of a tube), intralymphatic (within thelymph), intramedullary (within the marrow cavity of a bone),intrameningeal (within the meninges), intraocular (within the eye),intraovarian (within the ovary), intrapericardial (within thepericardium), intrapleural (within the pleura), intraprostatic (withinthe prostate gland), intrapulmonary (within the lungs or its bronchi),intrasinal (within the nasal or periorbital sinuses), intraspinal(within the vertebral column), intrasynovial (within the synovial cavityof a joint), intratendinous (within a tendon), intratesticular (withinthe testicle), intrathecal (within the cerebrospinal fluid at any levelof the cerebrospinal axis), intrathoracic (within the thorax),intratubular (within the tubules of an organ), intratympanic (within theaurus media), intravascular (within a vessel or vessels),intraventricular (within a ventricle), iontophoresis (by means ofelectric current where ions of soluble salts migrate into the tissues ofthe body), irrigation (to bathe or flush open wounds or body cavities),laryngeal (directly upon the larynx), nasogastric (through the nose andinto the stomach), occlusive dressing technique (topical routeadministration that is then covered by a dressing that occludes thearea), ophthalmic (to the external eye), oropharyngeal (directly to themouth and pharynx), parenteral, percutaneous, periarticular, peridural,perineural, periodontal, rectal, respiratory (within the respiratorytract by inhaling orally or nasally for local or systemic effect),retrobulbar (behind the pons or behind the eyeball), intramyocardial(entering the myocardium), soft tissue, subarachnoid, subconjunctival,submucosal, topical, transplacental (through or across the placenta),transtracheal (through the wall of the trachea), transtympanic (acrossor through the tympanic cavity), ureteral (to the ureter), urethral (tothe urethra), vaginal, caudal block, diagnostic, nerve block, biliaryperfusion, cardiac perfusion, photopheresis or spinal. In specificembodiments, compositions can be administered in a way that allows themcross the blood-brain barrier, vascular barrier, or other epithelialbarrier. In some embodiments, a formulation for a route ofadministration can include at least one inactive ingredient.

The polynucleotides of the present invention (e.g., a polynucleotidecomprising a nucleotide sequence encoding a—polypeptide or a functionalfragment or variant thereof) can be delivered to a cell naked. As usedherein in, “naked” refers to delivering polynucleotides free from agentsthat promote transfection. The naked polynucleotides can be delivered tothe cell using routes of administration known in the art and describedherein.

The polynucleotides of the present invention (e.g., a polynucleotidecomprising a nucleotide sequence encoding a PCCA or PCCB polypeptide ora functional fragment or variant thereof) can be formulated, using themethods described herein. The formulations can contain polynucleotidesthat can be modified and/or unmodified. The formulations can furtherinclude, but are not limited to, cell penetration agents, apharmaceutically acceptable carrier, a delivery agent, a bioerodible orbiocompatible polymer, a solvent, and a sustained-release deliverydepot. The formulated polynucleotides can be delivered to the cell usingroutes of administration known in the art and described herein.

A pharmaceutical composition for parenteral administration can compriseat least one inactive ingredient. Any or none of the inactiveingredients used can have been approved by the US Food and DrugAdministration (FDA). A non-exhaustive list of inactive ingredients foruse in pharmaceutical compositions for parenteral administrationincludes hydrochloric acid, mannitol, nitrogen, sodium acetate, sodiumchloride and sodium hydroxide.

Injectable preparations, for example, sterile injectable aqueous oroleaginous suspensions can be formulated according to the known artusing suitable dispersing agents, wetting agents, and/or suspendingagents. Sterile injectable preparations can be sterile injectablesolutions, suspensions, and/or emulsions in nontoxic parenterallyacceptable diluents and/or solvents, for example, as a solution in1,3-butanediol. Among the acceptable vehicles and solvents that can beemployed are water, Ringer's solution, U.S.P., and isotonic sodiumchloride solution. Sterile, fixed oils are conventionally employed as asolvent or suspending medium. For this purpose, any bland fixed oil canbe employed including synthetic mono- or diglycerides. Fatty acids suchas oleic acid can be used in the preparation of injectables. The sterileformulation can also comprise adjuvants such as local anesthetics,preservatives and buffering agents.

Injectable formulations can be sterilized, for example, by filtrationthrough a bacterial-retaining filter, and/or by incorporatingsterilizing agents in the form of sterile solid compositions that can bedissolved or dispersed in sterile water or other sterile injectablemedium prior to use.

Injectable formulations can be for direct injection into a region of atissue, organ and/or human subject. As a non-limiting example, a tissue,organ and/or human subject can be directly injected a formulation byintramyocardial injection into the ischemic region. (See, e.g., Zangi etal. Nature Biotechnology 2013; the contents of which are hereinincorporated by reference in its entirety).

In order to prolong the effect of an active ingredient, it is oftendesirable to slow the absorption of the active ingredient fromsubcutaneous or intramuscular injection. This can be accomplished by theuse of a liquid suspension of crystalline or amorphous material withpoor water solubility. The rate of absorption of the drug then dependsupon its rate of dissolution which, in turn, can depend upon crystalsize and crystalline form. Alternatively, delayed absorption of aparenterally administered drug form is accomplished by dissolving orsuspending the drug in an oil vehicle. Injectable depot forms are madeby forming microencapsule matrices of the drug in biodegradable polymerssuch as polylactide-polyglycolide. Depending upon the ratio of drug topolymer and the nature of the particular polymer employed, the rate ofdrug release can be controlled. Examples of other biodegradable polymersinclude poly(orthoesters) and poly(anhydrides). Depot injectableformulations are prepared by entrapping the drug in liposomes ormicroemulsions that are compatible with body tissues.

26. Kits and Devices

a. Kits

The invention provides a variety of kits for conveniently and/oreffectively using the claimed nucleotides of the present invention.Typically, kits will comprise sufficient amounts and/or numbers ofcomponents to allow a user to perform multiple treatments of a humansubject(s) and/or to perform multiple experiments.

In one aspect, the present invention provides kits comprising themolecules (polynucleotides) of the invention.

Said kits can be for protein production, comprising a firstpolynucleotides comprising a translatable region. The kit can furthercomprise packaging and instructions and/or a delivery agent to form aformulation composition. The delivery agent can comprise a saline, abuffered solution, a lipidoid or any delivery agent disclosed herein.

In some embodiments, the buffer solution can include sodium chloride,calcium chloride, phosphate and/or EDTA. In another embodiment, thebuffer solution can include, but is not limited to, saline, saline with2 mM calcium, 5% sucrose, 5% sucrose with 2 mM calcium, 5% Mannitol, 5%Mannitol with 2 mM calcium, Ringer's lactate, sodium chloride, sodiumchloride with 2 mM calcium and mannose (See, e.g., U.S. Pub. No.20120258046; herein incorporated by reference in its entirety). In afurther embodiment, the buffer solutions can be precipitated or it canbe lyophilized. The amount of each component can be varied to enableconsistent, reproducible higher concentration saline or simple bufferformulations. The components can also be varied in order to increase thestability of modified RNA in the buffer solution over a period of timeand/or under a variety of conditions. In one aspect, the presentinvention provides kits for protein production, comprising: apolynucleotide comprising a translatable region, provided in an amounteffective to produce a desired amount of a protein encoded by thetranslatable region when introduced into a target cell; a secondpolynucleotide comprising an inhibitory nucleic acid, provided in anamount effective to substantially inhibit the innate immune response ofthe cell; and packaging and instructions.

In one aspect, the present invention provides kits for proteinproduction, comprising a polynucleotide comprising a translatableregion, wherein the polynucleotide exhibits reduced degradation by acellular nuclease, and packaging and instructions.

In one aspect, the present invention provides kits for proteinproduction, comprising a polynucleotide comprising a translatableregion, wherein the polynucleotide exhibits reduced degradation by acellular nuclease, and a mammalian cell suitable for translation of thetranslatable region of the first nucleic acid.

b. Devices

The present invention provides for devices that can incorporatepolynucleotides that encode polypeptides of interest. These devicescontain in a stable formulation the reagents to synthesize apolynucleotide in a formulation available to be immediately delivered toa subject in need thereof, such as a human patient

Devices for administration can be employed to deliver thepolynucleotides of the present invention according to single, multi- orsplit-dosing regimens taught herein. Such devices are taught in, forexample, International Application Publ. No. WO2013151666, the contentsof which are incorporated herein by reference in their entirety.

Method and devices known in the art for multi-administration to cells,organs and tissues are contemplated for use in conjunction with themethods and compositions disclosed herein as embodiments of the presentinvention. These include, for example, those methods and devices havingmultiple needles, hybrid devices employing for example lumens orcatheters as well as devices utilizing heat, electric current orradiation driven mechanisms.

According to the present invention, these multi-administration devicescan be utilized to deliver the single, multi- or split dosescontemplated herein. Such devices are taught for example in,International Application Publ. No. WO2013151666, the contents of whichare incorporated herein by reference in their entirety.

In some embodiments, the polynucleotide is administered subcutaneouslyor intramuscularly via at least 3 needles to three different, optionallyadjacent, sites simultaneously, or within a 60 minutes period (e.g.,administration to 4, 5, 6, 7, 8, 9, or 10 sites simultaneously or withina 60 minute period).

c. Methods and Devices Utilizing Catheters and/or Lumens

Methods and devices using catheters and lumens can be employed toadminister the polynucleotides of the present invention on a single,multi- or split dosing schedule. Such methods and devices are describedin International Application Publication No. WO2013151666, the contentsof which are incorporated herein by reference in their entirety.

d. Methods and Devices Utilizing Electrical Current

Methods and devices utilizing electric current can be employed todeliver the polynucleotides of the present invention according to thesingle, multi- or split dosing regimens taught herein. Such methods anddevices are described in International Application Publication No.WO2013151666, the contents of which are incorporated herein by referencein their entirety.

27. Definitions

In order that the present disclosure can be more readily understood,certain terms are first defined. As used in this application, except asotherwise expressly provided herein, each of the following terms shallhave the meaning set forth below. Additional definitions are set forththroughout the application.

The invention includes embodiments in which exactly one member of thegroup is present in, employed in, or otherwise relevant to a givenproduct or process. The invention includes embodiments in which morethan one, or all of the group members are present in, employed in, orotherwise relevant to a given product or process.

In this specification and the appended claims, the singular forms “a”,“an” and “the” include plural referents unless the context clearlydictates otherwise. The terms “a” (or “an”), as well as the terms “oneor more,” and “at least one” can be used interchangeably herein. Incertain aspects, the term “a” or “an” means “single.” In other aspects,the term “a” or “an” includes “two or more” or “multiple.”

Furthermore, “and/or” where used herein is to be taken as specificdisclosure of each of the two specified features or components with orwithout the other. Thus, the term “and/or” as used in a phrase such as“A and/or B” herein is intended to include “A and B,” “A or B,” “A”(alone), and “B” (alone). Likewise, the term “and/or” as used in aphrase such as “A, B, and/or C” is intended to encompass each of thefollowing aspects: A, B, and C; A, B, or C; A or C; A or B; B or C; Aand C; A and B; B and C; A (alone); B (alone); and C (alone).

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this disclosure is related. For example, the ConciseDictionary of Biomedicine and Molecular Biology, Juo, Pei-Show, 2nd ed.,2002, CRC Press; The Dictionary of Cell and Molecular Biology, 3rd ed.,1999, Academic Press; and the Oxford Dictionary Of Biochemistry AndMolecular Biology, Revised, 2000, Oxford University Press, provide oneof skill with a general dictionary of many of the terms used in thisdisclosure.

Wherever aspects are described herein with the language “comprising,”otherwise analogous aspects described in terms of “consisting of” and/or“consisting essentially of” are also provided.

Units, prefixes, and symbols are denoted in their Systeme Internationalde Unites (SI) accepted form. Numeric ranges are inclusive of thenumbers defining the range. Where a range of values is recited, it is tobe understood that each intervening integer value, and each fractionthereof, between the recited upper and lower limits of that range isalso specifically disclosed, along with each subrange between suchvalues. The upper and lower limits of any range can independently beincluded in or excluded from the range, and each range where either,neither or both limits are included is also encompassed within theinvention. Where a value is explicitly recited, it is to be understoodthat values which are about the same quantity or amount as the recitedvalue are also within the scope of the invention. Where a combination isdisclosed, each subcombination of the elements of that combination isalso specifically disclosed and is within the scope of the invention.Conversely, where different elements or groups of elements areindividually disclosed, combinations thereof are also disclosed. Whereany element of an invention is disclosed as having a plurality ofalternatives, examples of that invention in which each alternative isexcluded singly or in any combination with the other alternatives arealso hereby disclosed; more than one element of an invention can havesuch exclusions, and all combinations of elements having such exclusionsare hereby disclosed.

Nucleotides are referred to by their commonly accepted single-lettercodes. Unless otherwise indicated, nucleic acids are written left toright in 5′ to 3′ orientation. Nucleobases are referred to herein bytheir commonly known one-letter symbols recommended by the IUPAC-IUBBiochemical Nomenclature Commission. Accordingly, A represents adenine,C represents cytosine, G represents guanine, T represents thymine, Urepresents uracil.

Amino acids are referred to herein by either their commonly known threeletter symbols or by the one-letter symbols recommended by the IUPAC-IUBBiochemical Nomenclature Commission. Unless otherwise indicated, aminoacid sequences are written left to right in amino to carboxyorientation.

About: The term “about” as used in connection with a numerical valuethroughout the specification and the claims denotes an interval ofaccuracy, familiar and acceptable to a person skilled in the art, suchinterval of accuracy is ±10%.

Where ranges are given, endpoints are included. Furthermore, unlessotherwise indicated or otherwise evident from the context andunderstanding of one of ordinary skill in the art, values that areexpressed as ranges can assume any specific value or subrange within thestated ranges in different embodiments of the invention, to the tenth ofthe unit of the lower limit of the range, unless the context clearlydictates otherwise.

Administered in combination: As used herein, the term “administered incombination” or “combined administration” means that two or more agentsare administered to a human subject at the same time or within aninterval such that there can be an overlap of an effect of each agent onthe patient. In some embodiments, they are administered within about 60,30, 15, 10, 5, or 1 minute of one another. In some embodiments, theadministrations of the agents are spaced sufficiently closely togethersuch that a combinatorial (e.g., a synergistic) effect is achieved.

Amino acid substitution: The term “amino acid substitution” refers toreplacing an amino acid residue present in a parent or referencesequence (e.g., a wild type PCCA or PCCB sequence) with another aminoacid residue. An amino acid can be substituted in a parent or referencesequence (e.g., a wild type PCCA or PCCB polypeptide sequence), forexample, via chemical peptide synthesis or through recombinant methodsknown in the art. Accordingly, a reference to a “substitution atposition X” refers to the substitution of an amino acid present atposition X with an alternative amino acid residue. In some aspects,substitution patterns can be described according to the schema AnY,wherein A is the single letter code corresponding to the amino acidnaturally or originally present at position n, and Y is the substitutingamino acid residue. In other aspects, substitution patterns can bedescribed according to the schema An(YZ), wherein A is the single lettercode corresponding to the amino acid residue substituting the amino acidnaturally or originally present at position X, and Y and Z arealternative substituting amino acid residue.

In the context of the present disclosure, substitutions (even when theyreferred to as amino acid substitution) are conducted at the nucleicacid level, i.e., substituting an amino acid residue with an alternativeamino acid residue is conducted by substituting the codon encoding thefirst amino acid with a codon encoding the second amino acid.

Animal: As used herein, the term “animal” refers to any member of theanimal kingdom. In some embodiments, “animal” refers to humans at anystage of development. In some embodiments, “animal” refers to non-humananimals at any stage of development. In certain embodiments, thenon-human animal is a mammal (e.g., a rodent, a mouse, a rat, a rabbit,a monkey, a dog, a cat, a sheep, cattle, a primate, or a pig). In someembodiments, animals include, but are not limited to, mammals, birds,reptiles, amphibians, fish, and worms. In some embodiments, the animalis a transgenic animal, genetically-engineered animal, or a clone.

Approximately: As used herein, the term “approximately,” as applied toone or more values of interest, refers to a value that is similar to astated reference value. In certain embodiments, the term “approximately”refers to a range of values that fall within 25%, 20%, 19%, 18%, 17%,16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%,or less in either direction (greater than or less than) of the statedreference value unless otherwise stated or otherwise evident from thecontext (except where such number would exceed 100% of a possiblevalue).

Associated with: As used herein with respect to a disease, the term“associated with” means that the symptom, measurement, characteristic,or status in question is linked to the diagnosis, development, presence,or progression of that disease. As association can, but need not, becausatively linked to the disease. For example, symptoms, sequelae, orany effects causing a decrease in the quality of life of a patient of PAare considered associated with PA and in some embodiments of the presentinvention can be treated, ameliorated, or prevented by administering thepolynucleotides of the present invention to a human subject in needthereof.

When used with respect to two or more moieties, the terms “associatedwith,” “conjugated,” “linked,” “attached,” and “tethered,” when usedwith respect to two or more moieties, means that the moieties arephysically associated or connected with one another, either directly orvia one or more additional moieties that serves as a linking agent, toform a structure that is sufficiently stable so that the moieties remainphysically associated under the conditions in which the structure isused, e.g., physiological conditions. An “association” need not bestrictly through direct covalent chemical bonding. It can also suggestionic or hydrogen bonding or a hybridization based connectivitysufficiently stable such that the “associated” entities remainphysically associated.

Bifunctional: As used herein, the term “bifunctional” refers to anysubstance, molecule or moiety that is capable of or maintains at leasttwo functions. The functions can affect the same outcome or a differentoutcome. The structure that produces the function can be the same ordifferent. For example, bifunctional modified RNAs of the presentinvention can encode a PCCA or PCCB peptide (a first function) whilethose nucleosides that comprise the encoding RNA are, in and ofthemselves, capable of extending the half-life of the RNA (secondfunction). In this example, delivery of the bifunctional modified RNA toa human subject suffering from a protein deficiency would produce notonly a peptide or protein molecule that can ameliorate or treat adisease or conditions, but would also maintain a population modified RNApresent in the human subject for a prolonged period of time. In otheraspects, a bifunction modified mRNA can be a chimeric or quimericmolecule comprising, for example, an RNA encoding a PCCA or PCCB peptide(a first function) and a second protein either fused to first protein orco-expressed with the first protein.

Biocompatible: As used herein, the term “biocompatible” means compatiblewith living cells, tissues, organs or systems posing little to no riskof injury, toxicity or rejection by the immune system.

Biodegradable: As used herein, the term “biodegradable” means capable ofbeing broken down into innocuous products by the action of livingthings.

Biologically active: As used herein, the phrase “biologically active”refers to a characteristic of any substance that has activity in abiological system and/or organism. For instance, a substance that, whenadministered to an organism, has a biological effect on that organism,is considered to be biologically active. In particular embodiments, apolynucleotide of the present invention can be considered biologicallyactive if even a portion of the polynucleotide is biologically active ormimics an activity considered biologically relevant.

Chimera: As used herein, “chimera” is an entity having two or moreincongruous or heterogeneous parts or regions. For example, a chimericmolecule can comprise a first part comprising a PCCA or PCCBpolypeptide, and a second part (e.g., genetically fused to the firstpart) comprising a second therapeutic protein (e.g., a protein with adistinct enzymatic activity, an antigen binding moiety, or a moietycapable of extending the plasma half life of PCCA or PCCB, for example,an Fc region of an antibody).

Sequence Optimization: The term “sequence optimization” refers to aprocess or series of processes by which nucleobases in a referencenucleic acid sequence are replaced with alternative nucleobases,resulting in a nucleic acid sequence with improved properties, e.g.,improved protein expression or decreased immunogenicity.

In general, the goal in sequence optimization is to produce a synonymousnucleotide sequence than encodes the same polypeptide sequence encodedby the reference nucleotide sequence. Thus, there are no amino acidsubstitutions (as a result of codon optimization) in the polypeptideencoded by the codon optimized nucleotide sequence with respect to thepolypeptide encoded by the reference nucleotide sequence.

Codon substitution: The terms “codon substitution” or “codonreplacement” in the context of sequence optimization refer to replacinga codon present in a reference nucleic acid sequence with another codon.A codon can be substituted in a reference nucleic acid sequence, forexample, via chemical peptide synthesis or through recombinant methodsknown in the art. Accordingly, references to a “substitution” or“replacement” at a certain location in a nucleic acid sequence (e.g., anmRNA) or within a certain region or subsequence of a nucleic acidsequence (e.g., an mRNA) refer to the substitution of a codon at suchlocation or region with an alternative codon.

As used herein, the terms “coding region” and “region encoding” andgrammatical variants thereof, refer to an Open Reading Frame (ORF) in apolynucleotide that upon expression yields a polypeptide or protein.

Compound: As used herein, the term “compound,” is meant to include allstereoisomers and isotopes of the structure depicted. As used herein,the term “stereoisomer” means any geometric isomer (e.g., cis- andtrans-isomer), enantiomer, or diastereomer of a compound. The presentdisclosure encompasses any and all stereoisomers of the compoundsdescribed herein, including stereomerically pure forms (e.g.,geometrically pure, enantiomerically pure, or diastereomerically pure)and enantiomeric and stereoisomeric mixtures, e.g., racemates.Enantiomeric and stereomeric mixtures of compounds and means ofresolving them into their component enantiomers or stereoisomers arewell-known. “Isotopes” refers to atoms having the same atomic number butdifferent mass numbers resulting from a different number of neutrons inthe nuclei. For example, isotopes of hydrogen include tritium anddeuterium. Further, a compound, salt, or complex of the presentdisclosure can be prepared in combination with solvent or watermolecules to form solvates and hydrates by routine methods.

Contacting: As used herein, the term “contacting” means establishing aphysical connection between two or more entities. For example,contacting a mammalian cell with a nanoparticle composition means thatthe mammalian cell and a nanoparticle are made to share a physicalconnection. Methods of contacting cells with external entities both invivo and ex vivo are well known in the biological arts. For example,contacting a nanoparticle composition and a mammalian cell disposedwithin a mammal can be performed by varied routes of administration(e.g., intravenous, intramuscular, intradermal, and subcutaneous) andcan involve varied amounts of nanoparticle compositions. Moreover, morethan one mammalian cell can be contacted by a nanoparticle composition.

Conservative amino acid substitution: A “conservative amino acidsubstitution” is one in which the amino acid residue in a proteinsequence is replaced with an amino acid residue having a similar sidechain. Families of amino acid residues having similar side chains havebeen defined in the art, including basic side chains (e.g., lysine,arginine, or histidine), acidic side chains (e.g., aspartic acid orglutamic acid), uncharged polar side chains (e.g., glycine, asparagine,glutamine, serine, threonine, tyrosine, or cysteine), nonpolar sidechains (e.g., alanine, valine, leucine, isoleucine, proline,phenylalanine, methionine, or tryptophan), beta-branched side chains(e.g., threonine, valine, isoleucine) and aromatic side chains (e.g.,tyrosine, phenylalanine, tryptophan, or histidine). Thus, if an aminoacid in a polypeptide is replaced with another amino acid from the sameside chain family, the amino acid substitution is considered to beconservative. In another aspect, a string of amino acids can beconservatively replaced with a structurally similar string that differsin order and/or composition of side chain family members.

Non-conservative amino acid substitution: Non-conservative amino acidsubstitutions include those in which (i) a residue having anelectropositive side chain (e.g., Arg, His or Lys) is substituted for,or by, an electronegative residue (e.g., Glu or Asp), (ii) a hydrophilicresidue (e.g., Ser or Thr) is substituted for, or by, a hydrophobicresidue (e.g., Ala, Leu, Ile, Phe or Val), (iii) a cysteine or prolineis substituted for, or by, any other residue, or (iv) a residue having abulky hydrophobic or aromatic side chain (e.g., Val, His, Ile or Trp) issubstituted for, or by, one having a smaller side chain (e.g., Ala orSer) or no side chain (e.g., Gly).

Other amino acid substitutions can be readily identified by workers ofordinary skill. For example, for the amino acid alanine, a substitutioncan be taken from any one of D-alanine, glycine, beta-alanine,L-cysteine and D-cysteine. For lysine, a replacement can be any one ofD-lysine, arginine, D-arginine, homo-arginine, methionine, D-methionine,ornithine, or D-ornithine. Generally, substitutions in functionallyimportant regions that can be expected to induce changes in theproperties of isolated polypeptides are those in which (i) a polarresidue, e.g., serine or threonine, is substituted for (or by) ahydrophobic residue, e.g., leucine, isoleucine, phenylalanine, oralanine; (ii) a cysteine residue is substituted for (or by) any otherresidue; (iii) a residue having an electropositive side chain, e.g.,lysine, arginine or histidine, is substituted for (or by) a residuehaving an electronegative side chain, e.g., glutamic acid or asparticacid; or (iv) a residue having a bulky side chain, e.g., phenylalanine,is substituted for (or by) one not having such a side chain, e.g.,glycine. The likelihood that one of the foregoing non-conservativesubstitutions can alter functional properties of the protein is alsocorrelated to the position of the substitution with respect tofunctionally important regions of the protein: some non-conservativesubstitutions can accordingly have little or no effect on biologicalproperties.

Conserved: As used herein, the term “conserved” refers to nucleotides oramino acid residues of a polynucleotide sequence or polypeptidesequence, respectively, that are those that occur unaltered in the sameposition of two or more sequences being compared. Nucleotides or aminoacids that are relatively conserved are those that are conserved amongstmore related sequences than nucleotides or amino acids appearingelsewhere in the sequences.

In some embodiments, two or more sequences are said to be “completelyconserved” if they are 100% identical to one another. In someembodiments, two or more sequences are said to be “highly conserved” ifthey are at least 70% identical, at least 80% identical, at least 90%identical, or at least 95% identical to one another. In someembodiments, two or more sequences are said to be “highly conserved” ifthey are about 70% identical, about 80% identical, about 90% identical,about 95%, about 98%, or about 99% identical to one another. In someembodiments, two or more sequences are said to be “conserved” if theyare at least 30% identical, at least 40% identical, at least 50%identical, at least 60% identical, at least 70% identical, at least 80%identical, at least 90% identical, or at least 95% identical to oneanother. In some embodiments, two or more sequences are said to be“conserved” if they are about 30% identical, about 40% identical, about50% identical, about 60% identical, about 70% identical, about 80%identical, about 90% identical, about 95% identical, about 98%identical, or about 99% identical to one another. Conservation ofsequence can apply to the entire length of an polynucleotide orpolypeptide or can apply to a portion, region or feature thereof.

Controlled Release: As used herein, the term “controlled release” refersto a pharmaceutical composition or compound release profile thatconforms to a particular pattern of release to effect a therapeuticoutcome.

Cyclic or Cyclized: As used herein, the term “cyclic” refers to thepresence of a continuous loop. Cyclic molecules need not be circular,only joined to form an unbroken chain of subunits. Cyclic molecules suchas the engineered RNA or mRNA of the present invention can be singleunits or multimers or comprise one or more components of a complex orhigher order structure.

Cytotoxic: As used herein, “cytotoxic” refers to killing or causinginjurious, toxic, or deadly effect on a cell (e.g., a mammalian cell(e.g., a human cell)), bacterium, virus, fungus, protozoan, parasite,prion, or a combination thereof.

Delivering: As used herein, the term “delivering” means providing anentity to a destination. For example, delivering a polynucleotide to ahuman subject can involve administering a nanoparticle compositionincluding the polynucleotide to the human subject (e.g., by anintravenous, intramuscular, intradermal, or subcutaneous route).Administration of a nanoparticle composition to a mammal or mammaliancell can involve contacting one or more cells with the nanoparticlecomposition.

Delivery Agent: As used herein, “delivery agent” refers to any substancethat facilitates, at least in part, the in vivo, in vitro, or ex vivodelivery of a polynucleotide to targeted cells.

Destabilized: As used herein, the term “destable,” “destabilize,” or“destabilizing region” means a region or molecule that is less stablethan a starting, wild-type or native form of the same region ormolecule.

Diastereomer: As used herein, the term “diastereomer,” meansstereoisomers that are not mirror images of one another and arenon-superimposable on one another.

Digest: As used herein, the term “digest” means to break apart intosmaller pieces or components. When referring to polypeptides orproteins, digestion results in the production of peptides.

Distal: As used herein, the term “distal” means situated away from thecenter or away from a point or region of interest.

Domain: As used herein, when referring to polypeptides, the term“domain” refers to a motif of a polypeptide having one or moreidentifiable structural or functional characteristics or properties(e.g., binding capacity, serving as a site for protein-proteininteractions).

Dosing regimen: As used herein, a “dosing regimen” or a “dosing regimen”is a schedule of administration or physician determined regimen oftreatment, prophylaxis, or palliative care.

Effective Amount: As used herein, the term “effective amount” of anagent is that amount sufficient to effect beneficial or desired results,for example, clinical results, and, as such, an “effective amount”depends upon the context in which it is being applied. For example, inthe context of administering an agent that treats a protein deficiency(e.g., a PCC deficiency), an effective amount of an agent is, forexample, an amount of mRNA expressing sufficient PCCA and/or PCCB toameliorate, reduce, eliminate, or prevent the symptoms associated withthe PCC deficiency, as compared to the severity of the symptom observedwithout administration of the agent. The term “effective amount” can beused interchangeably with “effective dose,” “therapeutically effectiveamount,” or “therapeutically effective dose.”

Enantiomer: As used herein, the term “enantiomer” means each individualoptically active form of a compound of the invention, having an opticalpurity or enantiomeric excess (as determined by methods standard in theart) of at least 80% (i.e., at least 90% of one enantiomer and at most10% of the other enantiomer), at least 90%, or at least 98%.

Encapsulate: As used herein, the term “encapsulate” means to enclose,surround or encase.

Encapsulation Efficiency: As used herein, “encapsulation efficiency”refers to the amount of a polynucleotide that becomes part of ananoparticle composition, relative to the initial total amount ofpolynucleotide used in the preparation of a nanoparticle composition.For example, if 97 mg of polynucleotide are encapsulated in ananoparticle composition out of a total 100 mg of polynucleotideinitially provided to the composition, the encapsulation efficiency canbe given as 97%. As used herein, “encapsulation” can refer to complete,substantial, or partial enclosure, confinement, surrounding, orencasement.

Encodedprotein cleavage signal: As used herein, “encoded proteincleavage signal” refers to the nucleotide sequence that encodes aprotein cleavage signal.

Engineered: As used herein, embodiments of the invention are“engineered” when they are designed to have a feature or property,whether structural or chemical, that varies from a starting point, wildtype or native molecule.

Enhanced Delivery: As used herein, the term “enhanced delivery” meansdelivery of more (e.g., at least 1.5 fold more, at least 2-fold more, atleast 3-fold more, at least 4-fold more, at least 5-fold more, at least6-fold more, at least 7-fold more, at least 8-fold more, at least 9-foldmore, at least 10-fold more) of a polynucleotide by a nanoparticle to atarget tissue of interest (e.g., mammalian liver) compared to the levelof delivery of a polynucleotide by a control nanoparticle to a targettissue of interest (e.g., MC3, KC2, or DLinDMA). The level of deliveryof a nanoparticle to a particular tissue can be measured by comparingthe amount of protein produced in a tissue to the weight of said tissue,comparing the amount of polynucleotide in a tissue to the weight of saidtissue, comparing the amount of protein produced in a tissue to theamount of total protein in said tissue, or comparing the amount ofpolynucleotide in a tissue to the amount of total polynucleotide in saidtissue. It will be understood that the enhanced delivery of ananoparticle to a target tissue need not be determined in a humansubject being treated, it can be determined in a surrogate such as ananimal model (e.g., a rat model).

Exosome: As used herein, “exosome” is a vesicle secreted by mammaliancells or a complex involved in RNA degradation.

Expression: As used herein, “expression” of a nucleic acid sequencerefers to one or more of the following events: (1) production of an mRNAtemplate from a DNA sequence (e.g., by transcription); (2) processing ofan mRNA transcript (e.g., by splicing, editing, 5′ cap formation, and/or3′ end processing); (3) translation of an mRNA into a polypeptide orprotein; and (4) post-translational modification of a polypeptide orprotein.

Ex Vivo: As used herein, the term “ex vivo” refers to events that occuroutside of an organism (e.g., animal, plant, or microbe or cell ortissue thereof). Ex vivo events can take place in an environmentminimally altered from a natural (e.g., in vivo) environment.

Feature: As used herein, a “feature” refers to a characteristic, aproperty, or a distinctive element. When referring to polypeptides,“features” are defined as distinct amino acid sequence-based componentsof a molecule. Features of the polypeptides encoded by thepolynucleotides of the present invention include surface manifestations,local conformational shape, folds, loops, half-loops, domains,half-domains, sites, termini or any combination thereof.

Formulation: As used herein, a “formulation” includes at least apolynucleotide and one or more of a carrier, an excipient, and adelivery agent.

Fragment: A “fragment,” as used herein, refers to a portion. Forexample, fragments of proteins can comprise polypeptides obtained bydigesting full-length protein isolated from cultured cells. In someembodiments, a fragment is a subsequences of a full length protein(e.g., PCCA or PCCB) wherein N-terminal, and/or C-terminal, and/orinternal subsequences have been deleted. In some preferred aspects ofthe present invention, the fragments of a protein of the presentinvention are functional fragments.

Functional: As used herein, a “functional” biological molecule is abiological molecule in a form in which it exhibits a property and/oractivity by which it is characterized. Thus, a functional fragment of apolynucleotide of the present invention is a polynucleotide capable ofexpressing a functional PCCA or PCCB fragment. As used herein, afunctional fragment of PCCA or PCCB refers to a fragment of wild typePCCA or PCCB (i.e., a fragment of any of its naturally occurringisoforms), or a mutant or variant thereof, wherein the fragment retainsa least about 10%, at least about 15%, at least about 20%, at leastabout 25%, at least about 30%, at least about 35%, at least about 40%,at least about 45%, at least about 50%, at least about 55%, at leastabout 60%, at least about 65%, at least about 70%, at least about 75%,at least about 80%, at least about 85%, at least about 90%, or at leastabout 95% of the biological activity of the corresponding full lengthprotein.

PCC Associated Disease: As use herein the terms “PCC-associated disease”or “PCC-associated disorder” refer to diseases or disorders,respectively, which result from aberrant PCC activity (e.g., decreasedactivity or increased activity). As a non-limiting example, PA is a PCCassociated disease.

The terms “PCC enzymatic activity” and “PCC activity,” are usedinterchangeably in the present disclosure and refer to PCC's ability tocatalyze the carboxylation of propionyl-CoA to methylmalonyl-CoA.Accordingly, a fragment or variant retaining or having PCC enzymaticactivity or PC activity refers to a fragment or variant that hasmeasurable enzymatic activity in catalyzing the carboxylation ofpropionyl-CoA to methylmalonyl-CoA.

Helper Lipid: As used herein, the term “helper lipid” refers to acompound or molecule that includes a lipidic moiety (for insertion intoa lipid layer, e.g., lipid bilayer) and a polar moiety (for interactionwith physiologic solution at the surface of the lipid layer). Typicallythe helper lipid is a phospholipid. A function of the helper lipid is to“complement” the amino lipid and increase the fusogenicity of thebilayer and/or to help facilitate endosomal escape, e.g., of nucleicacid delivered to cells. Helper lipids are also believed to be a keystructural component to the surface of the LNP.

Homology: As used herein, the term “homology” refers to the overallrelatedness between polymeric molecules, e.g. between nucleic acidmolecules (e.g. DNA molecules and/or RNA molecules) and/or betweenpolypeptide molecules. Generally, the term “homology” implies anevolutionary relationship between two molecules. Thus, two moleculesthat are homologous will have a common evolutionary ancestor. In thecontext of the present invention, the term homology encompasses both toidentity and similarity.

In some embodiments, polymeric molecules are considered to be“homologous” to one another if at least 25%, 30%, 35%, 40%, 45%, 50%,55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% of the monomers inthe molecule are identical (exactly the same monomer) or are similar(conservative substitutions). The term “homologous” necessarily refersto a comparison between at least two sequences (polynucleotide orpolypeptide sequences).

Identity: As used herein, the term “identity” refers to the overallmonomer conservation between polymeric molecules, e.g., betweenpolynucleotide molecules (e.g. DNA molecules and/or RNA molecules)and/or between polypeptide molecules. Calculation of the percentidentity of two polynucleotide sequences, for example, can be performedby aligning the two sequences for optimal comparison purposes (e.g.,gaps can be introduced in one or both of a first and a second nucleicacid sequences for optimal alignment and non-identical sequences can bedisregarded for comparison purposes). In certain embodiments, the lengthof a sequence aligned for comparison purposes is at least 30%, at least40%, at least 50%, at least 60%, at least 70%, at least 80%, at least90%, at least 95%, or 100% of the length of the reference sequence. Thenucleotides at corresponding nucleotide positions are then compared.When a position in the first sequence is occupied by the same nucleotideas the corresponding position in the second sequence, then the moleculesare identical at that position. The percent identity between the twosequences is a function of the number of identical positions shared bythe sequences, taking into account the number of gaps, and the length ofeach gap, which needs to be introduced for optimal alignment of the twosequences. The comparison of sequences and determination of percentidentity between two sequences can be accomplished using a mathematicalalgorithm. When comparing DNA and RNA, thymine (T) and uracil (U) can beconsidered equivalent.

Suitable software programs are available from various sources, and foralignment of both protein and nucleotide sequences. One suitable programto determine percent sequence identity is bl2seq, part of the BLASTsuite of program available from the U.S. government's National Centerfor Biotechnology Information BLAST web site (blast.ncbi.nlm.nih.gov).Bl2seq performs a comparison between two sequences using either theBLASTN or BLASTP algorithm. BLASTN is used to compare nucleic acidsequences, while BLASTP is used to compare amino acid sequences. Othersuitable programs are, e.g., Needle, Stretcher, Water, or Matcher, partof the EMBOSS suite of bioinformatics programs and also available fromthe European Bioinformatics Institute (EBI) at www.ebi.ac.uk/Tools/psa.

Sequence alignments can be conducted using methods known in the art suchas MAFFT, Clustal (ClustalW, Clustal X or Clustal Omega), MUSCLE, etc.

Different regions within a single polynucleotide or polypeptide targetsequence that aligns with a polynucleotide or polypeptide referencesequence can each have their own percent sequence identity. It is notedthat the percent sequence identity value is rounded to the nearesttenth. For example, 80.11, 80.12, 80.13, and 80.14 are rounded down to80.1, while 80.15, 80.16, 80.17, 80.18, and 80.19 are rounded up to80.2. It also is noted that the length value will always be an integer.

In certain aspects, the percentage identity “% ID” of a first amino acidsequence (or nucleic acid sequence) to a second amino acid sequence (ornucleic acid sequence) is calculated as % ID=100×(Y/Z), where Y is thenumber of amino acid residues (or nucleobases) scored as identicalmatches in the alignment of the first and second sequences (as alignedby visual inspection or a particular sequence alignment program) and Zis the total number of residues in the second sequence. If the length ofa first sequence is longer than the second sequence, the percentidentity of the first sequence to the second sequence will be higherthan the percent identity of the second sequence to the first sequence.

One skilled in the art will appreciate that the generation of a sequencealignment for the calculation of a percent sequence identity is notlimited to binary sequence-sequence comparisons exclusively driven byprimary sequence data. It will also be appreciated that sequencealignments can be generated by integrating sequence data with data fromheterogeneous sources such as structural data (e.g., crystallographicprotein structures), functional data (e.g., location of mutations), orphylogenetic data. A suitable program that integrates heterogeneous datato generate a multiple sequence alignment is T-Coffee, available atwww.tcoffee.org, and alternatively available, e.g., from the EBI. Itwill also be appreciated that the final alignment used to calculatepercent sequence identity can be curated either automatically ormanually.

Immune response: The term “immune response” refers to the action of, forexample, lymphocytes, antigen presenting cells, phagocytic cells,granulocytes, and soluble macromolecules produced by the above cells orthe liver (including antibodies, cytokines, and complement) that resultsin selective damage to, destruction of, or elimination from the humanbody of invading pathogens, cells or tissues infected with pathogens,cancerous cells, or, in cases of autoimmunity or pathologicalinflammation, normal human cells or tissues. In some cases, theadministration of a nanoparticle comprising a lipid component and anencapsulated therapeutic agent can trigger an immune response, which canbe caused by (i) the encapsulated therapeutic agent (e.g., an mRNA),(ii) the expression product of such encapsulated therapeutic agent(e.g., a polypeptide encoded by the mRNA), (iii) the lipid component ofthe nanoparticle, or (iv) a combination thereof.

Inflammatory response: “Inflammatory response” refers to immuneresponses involving specific and non-specific defense systems. Aspecific defense system reaction is a specific immune system reaction toan antigen. Examples of specific defense system reactions includeantibody responses. A non-specific defense system reaction is aninflammatory response mediated by leukocytes generally incapable ofimmunological memory, e.g., macrophages, eosinophils and neutrophils. Insome aspects, an immune response includes the secretion of inflammatorycytokines, resulting in elevated inflammatory cytokine levels.

Inflammatory cytokines: The term “inflammatory cytokine” refers tocytokines that are elevated in an inflammatory response. Examples ofinflammatory cytokines include interleukin-6 (IL-6), CXCL1 (chemokine(C—X—C motif) ligand 1; also known as GROα, interferon-γ (IFNγ), tumornecrosis factor α (TNFα), interferon γ-induced protein 10 (IP-10), orgranulocyte-colony stimulating factor (G-CSF). The term inflammatorycytokines includes also other cytokines associated with inflammatoryresponses known in the art, e.g., interleukin-1 (IL-1), interleukin-8(IL-8), interleukin-12 (IL-12), interleukin-13 (Il-13), interferon α(IFN-α), etc.

In Vitro: As used herein, the term “in vitro” refers to events thatoccur in an artificial environment, e.g., in a test tube or reactionvessel, in cell culture, in a Petri dish, etc., rather than within anorganism (e.g., animal, plant, or microbe).

In Vivo: As used herein, the term “in vivo” refers to events that occurwithin an organism (e.g., animal, plant, or microbe or cell or tissuethereof).

Insertional and deletional variants: “Insertional variants” whenreferring to polypeptides are those with one or more amino acidsinserted immediately adjacent to an amino acid at a particular positionin a native or starting sequence. “Immediately adjacent” to an aminoacid means connected to either the alpha-carboxy or alpha-aminofunctional group of the amino acid. “Deletional variants” when referringto polypeptides are those with one or more amino acids in the native orstarting amino acid sequence removed. Ordinarily, deletional variantswill have one or more amino acids deleted in a particular region of themolecule.

Intact: As used herein, in the context of a polypeptide, the term“intact” means retaining an amino acid corresponding to the wild typeprotein, e.g., not mutating or substituting the wild type amino acid.Conversely, in the context of a nucleic acid, the term “intact” meansretaining a nucleobase corresponding to the wild type nucleic acid,e.g., not mutating or substituting the wild type nucleobase.

Ionizable amino lipid: The term “ionizable amino lipid” includes thoselipids having one, two, three, or more fatty acid or fatty alkyl chainsand a pH-titratable amino head group (e.g., an alkylamino ordialkylamino head group). An ionizable amino lipid is typicallyprotonated (i.e., positively charged) at a pH below the pKa of the aminohead group and is substantially not charged at a pH above the pKa. Suchionizable amino lipids include, but are not limited to DLin-MC3-DMA(MC3) and (13Z,165Z)-N,N-dimethyl-3-nonydocosa-13-16-dien-1-amine(L608).

Isolated: As used herein, the term “isolated” refers to a substance orentity that has been separated from at least some of the components withwhich it was associated (whether in nature or in an experimentalsetting). Isolated substances (e.g., polynucleotides or polypeptides)can have varying levels of purity in reference to the substances fromwhich they have been isolated. Isolated substances and/or entities canbe separated from at least about 10%, about 20%, about 30%, about 40%,about 50%, about 60%, about 70%, about 80%, about 90%, or more of theother components with which they were initially associated. In someembodiments, isolated substances are more than about 80%, about 85%,about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about96%, about 97%, about 98%, about 99%, or more than about 99% pure. Asused herein, a substance is “pure” if it is substantially free of othercomponents.

Substantially isolated: By “substantially isolated” is meant that thecompound is substantially separated from the environment in which it wasformed or detected. Partial separation can include, for example, acomposition enriched in the compound of the present disclosure.Substantial separation can include compositions containing at leastabout 50%, at least about 60%, at least about 70%, at least about 80%,at least about 90%, at least about 95%, at least about 97%, or at leastabout 99% by weight of the compound of the present disclosure, or saltthereof.

A polynucleotide, vector, polypeptide, cell, or any compositiondisclosed herein which is “isolated” is a polynucleotide, vector,polypeptide, cell, or composition which is in a form not found innature. Isolated polynucleotides, vectors, polypeptides, or compositionsinclude those which have been purified to a degree that they are nolonger in a form in which they are found in nature. In some aspects, apolynucleotide, vector, polypeptide, or composition which is isolated issubstantially pure.

Isomer: As used herein, the term “isomer” means any tautomer,stereoisomer, enantiomer, or diastereomer of any compound of theinvention. It is recognized that the compounds of the invention can haveone or more chiral centers and/or double bonds and, therefore, exist asstereoisomers, such as double-bond isomers (i.e., geometric E/Z isomers)or diastereomers (e.g., enantiomers (i.e., (+) or (−)) or cis/transisomers). According to the invention, the chemical structures depictedherein, and therefore the compounds of the invention, encompass all ofthe corresponding stereoisomers, that is, both the stereomerically pureform (e.g., geometrically pure, enantiomerically pure, ordiastereomerically pure) and enantiomeric and stereoisomeric mixtures,e.g., racemates. Enantiomeric and stereoisomeric mixtures of compoundsof the invention can typically be resolved into their componentenantiomers or stereoisomers by well-known methods, such as chiral-phasegas chromatography, chiral-phase high performance liquid chromatography,crystallizing the compound as a chiral salt complex, or crystallizingthe compound in a chiral solvent. Enantiomers and stereoisomers can alsobe obtained from stereomerically or enantiomerically pure intermediates,reagents, and catalysts by well-known asymmetric synthetic methods.

Linker: As used herein, a “linker” refers to a group of atoms, e.g.,10-1,000 atoms, and can be comprised of the atoms or groups such as, butnot limited to, carbon, amino, alkylamino, oxygen, sulfur, sulfoxide,sulfonyl, carbonyl, and imine. The linker can be attached to a modifiednucleoside or nucleotide on the nucleobase or sugar moiety at a firstend, and to a payload, e.g., a detectable or therapeutic agent, at asecond end. The linker can be of sufficient length as to not interferewith incorporation into a nucleic acid sequence. The linker can be usedfor any useful purpose, such as to form polynucleotide multimers (e.g.,through linkage of two or more chimeric polynucleotides molecules or IVTpolynucleotides) or polynucleotides conjugates, as well as to administera payload, as described herein. Examples of chemical groups that can beincorporated into the linker include, but are not limited to, alkyl,alkenyl, alkynyl, amido, amino, ether, thioether, ester, alkylene,heteroalkylene, aryl, or heterocyclyl, each of which can be optionallysubstituted, as described herein. Examples of linkers include, but arenot limited to, unsaturated alkanes, polyethylene glycols (e.g.,ethylene or propylene glycol monomeric units, e.g., diethylene glycol,dipropylene glycol, triethylene glycol, tripropylene glycol,tetraethylene glycol, or tetraethylene glycol), and dextran polymers andderivatives thereof., Other examples include, but are not limited to,cleavable moieties within the linker, such as, for example, a disulfidebond (—S—S—) or an azo bond (—N═N—), which can be cleaved using areducing agent or photolysis. Non-limiting examples of a selectivelycleavable bond include an amido bond can be cleaved for example by theuse of tris(2-carboxyethyl)phosphine (TCEP), or other reducing agents,and/or photolysis, as well as an ester bond can be cleaved for exampleby acidic or basic hydrolysis.

Methods of Administration: As used herein, “methods of administration”can include intravenous, intramuscular, intradermal, subcutaneous, orother methods of delivering a composition to a subject. A method ofadministration can be selected to target delivery (e.g., to specificallydeliver) to a specific region or system of a body.

Modified: As used herein “modified” refers to a changed state orstructure of a molecule of the invention. Molecules can be modified inmany ways including chemically, structurally, and functionally. In someembodiments, the mRNA molecules of the present invention are modified bythe introduction of non-natural nucleosides and/or nucleotides, e.g., asit relates to the natural ribonucleotides A, U, G, and C. Noncanonicalnucleotides such as the cap structures are not considered “modified”although they differ from the chemical structure of the A, C, G, Uribonucleotides.

Mucus: As used herein, “mucus” refers to the natural substance that isviscous and comprises mucin glycoproteins.

Nanoparticle Composition: As used herein, a “nanoparticle composition”is a composition comprising one or more lipids. Nanoparticlecompositions are typically sized on the order of micrometers or smallerand can include a lipid bilayer. Nanoparticle compositions encompasslipid nanoparticles (LNPs), liposomes (e.g., lipid vesicles), andlipoplexes. For example, a nanoparticle composition can be a liposomehaving a lipid bilayer with a diameter of 500 nm or less.

Naturally occurring: As used herein, “naturally occurring” meansexisting in nature without artificial aid.

Non-human vertebrate: As used herein, a “non-human vertebrate” includesall vertebrates except Homo sapiens, including wild and domesticatedspecies. Examples of non-human vertebrates include, but are not limitedto, mammals, such as alpaca, banteng, bison, camel, cat, cattle, deer,dog, donkey, gayal, goat, guinea pig, horse, llama, mule, pig, rabbit,reindeer, sheep water buffalo, and yak.

Nucleic acid sequence: The terms “nucleic acid sequence,” “nucleotidesequence,” or “polynucleotide sequence” are used interchangeably andrefer to a contiguous nucleic acid sequence. The sequence can be eithersingle stranded or double stranded DNA or RNA, e.g., an mRNA.

The term “nucleic acid,” in its broadest sense, includes any compoundand/or substance that comprises a polymer of nucleotides. These polymersare often referred to as polynucleotides. Exemplary nucleic acids orpolynucleotides of the invention include, but are not limited to,ribonucleic acids (RNAs), deoxyribonucleic acids (DNAs), threose nucleicacids (TNAs), glycol nucleic acids (GNAs), peptide nucleic acids (PNAs),locked nucleic acids (LNAs, including LNA having a β-D-riboconfiguration, α-LNA having an α-L-ribo configuration (a diastereomer ofLNA), 2′-amino-LNA having a 2′-amino functionalization, and2′-amino-α-LNA having a 2′-amino functionalization), ethylene nucleicacids (ENA), cyclohexenyl nucleic acids (CeNA) or hybrids orcombinations thereof.

The phrase “nucleotide sequence encoding” refers to the nucleic acid(e.g., an mRNA or DNA molecule) coding sequence which encodes apolypeptide. The coding sequence can further include initiation andtermination signals operably linked to regulatory elements including apromoter and polyadenylation signal capable of directing expression inthe cells of an individual or mammal to which the nucleic acid isadministered. The coding sequence can further include sequences thatencode signal peptides.

Off-target: As used herein, “off target” refers to any unintended effecton any one or more target, gene, or cellular transcript.

Open reading frame: As used herein, “open reading frame” or “ORF” refersto a sequence which does not contain a stop codon in a given readingframe.

Operably linked: As used herein, the phrase “operably linked” refers toa functional connection between two or more molecules, constructs,transcripts, entities, moieties or the like.

Optionally substituted: Herein a phrase of the form “optionallysubstituted X” (e.g., optionally substituted alkyl) is intended to beequivalent to “X, wherein X is optionally substituted” (e.g., “alkyl,wherein said alkyl is optionally substituted”). It is not intended tomean that the feature “X” (e.g., alkyl) per se is optional.

Part: As used herein, a “part” or “region” of a polynucleotide isdefined as any portion of the polynucleotide that is less than theentire length of the polynucleotide.

Patient: As used herein, “patient” refers to a subject who can seek orbe in need of treatment, requires treatment, is receiving treatment,will receive treatment, or a subject who is under care by a trainedprofessional for a particular disease or condition. In some embodiments,the treatment is needed, required, or received to prevent or decreasethe risk of developing acute disease, i.e., it is a prophylactictreatment.

Pharmaceutically acceptable: The phrase “pharmaceutically acceptable” isemployed herein to refer to those compounds, materials, compositions,and/or dosage forms that are, within the scope of sound medicaljudgment, suitable for use in contact with the tissues of human beingsand animals without excessive toxicity, irritation, allergic response,or other problem or complication, commensurate with a reasonablebenefit/risk ratio.

Pharmaceutically acceptable excipients: The phrase “pharmaceuticallyacceptable excipient,” as used herein, refers any ingredient other thanthe compounds described herein (for example, a vehicle capable ofsuspending or dissolving the active compound) and having the propertiesof being substantially nontoxic and non-inflammatory in a patient.Excipients can include, for example: antiadherents, antioxidants,binders, coatings, compression aids, disintegrants, dyes (colors),emollients, emulsifiers, fillers (diluents), film formers or coatings,flavors, fragrances, glidants (flow enhancers), lubricants,preservatives, printing inks, sorbents, suspensing or dispersing agents,sweeteners, and waters of hydration. Exemplary excipients include, butare not limited to: butylated hydroxytoluene (BHT), calcium carbonate,calcium phosphate (dibasic), calcium stearate, croscarmellose,crosslinked polyvinyl pyrrolidone, citric acid, crospovidone, cysteine,ethylcellulose, gelatin, hydroxypropyl cellulose, hydroxypropylmethylcellulose, lactose, magnesium stearate, maltitol, mannitol,methionine, methylcellulose, methyl paraben, microcrystalline cellulose,polyethylene glycol, polyvinyl pyrrolidone, povidone, pregelatinizedstarch, propyl paraben, retinyl palmitate, shellac, silicon dioxide,sodium carboxymethyl cellulose, sodium citrate, sodium starch glycolate,sorbitol, starch (corn), stearic acid, sucrose, talc, titanium dioxide,vitamin A, vitamin E, vitamin C, and xylitol.

Pharmaceutically acceptable salts: The present disclosure also includespharmaceutically acceptable salts of the compounds described herein. Asused herein, “pharmaceutically acceptable salts” refers to derivativesof the disclosed compounds wherein the parent compound is modified byconverting an existing acid or base moiety to its salt form (e.g., byreacting the free base group with a suitable organic acid). Examples ofpharmaceutically acceptable salts include, but are not limited to,mineral or organic acid salts of basic residues such as amines; alkalior organic salts of acidic residues such as carboxylic acids; and thelike. Representative acid addition salts include acetate, acetic acid,adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzenesulfonic acid, benzoate, bisulfate, borate, butyrate, camphorate,camphorsulfonate, citrate, cyclopentanepropionate, digluconate,dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate,glycerophosphate, hemisulfate, heptonate, hexanoate, hydrobromide,hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate,lactate, laurate, lauryl sulfate, malate, maleate, malonate,methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate,oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate,phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate,tartrate, thiocyanate, toluenesulfonate, undecanoate, valerate salts,and the like. Representative alkali or alkaline earth metal saltsinclude sodium, lithium, potassium, calcium, magnesium, and the like, aswell as nontoxic ammonium, quaternary ammonium, and amine cations,including, but not limited to ammonium, tetramethylammonium,tetraethylammonium, methylamine, dimethylamine, trimethylamine,triethylamine, ethylamine, and the like. The pharmaceutically acceptablesalts of the present disclosure include the conventional non-toxic saltsof the parent compound formed, for example, from non-toxic inorganic ororganic acids. The pharmaceutically acceptable salts of the presentdisclosure can be synthesized from the parent compound that contains abasic or acidic moiety by conventional chemical methods. Generally, suchsalts can be prepared by reacting the free acid or base forms of thesecompounds with a stoichiometric amount of the appropriate base or acidin water or in an organic solvent, or in a mixture of the two;generally, nonaqueous media like ether, ethyl acetate, ethanol,isopropanol, or acetonitrile are used. Lists of suitable salts are foundin Remington's Pharmaceutical Sciences, 17^(th) ed., Mack PublishingCompany, Easton, Pa., 1985, p. 1418, Pharmaceutical Salts: Properties,Selection, and Use, P. H. Stahl and C.G. Wermuth (eds.), Wiley-VCH,2008, and Berge et al., Journal of Pharmaceutical Science, 66, 1-19(1977), each of which is incorporated herein by reference in itsentirety.

Pharmaceutically acceptable solvate: The term “pharmaceuticallyacceptable solvate,” as used herein, means a compound of the inventionwherein molecules of a suitable solvent are incorporated in the crystallattice. A suitable solvent is physiologically tolerable at the dosageadministered. For example, solvates can be prepared by crystallization,recrystallization, or precipitation from a solution that includesorganic solvents, water, or a mixture thereof. Examples of suitablesolvents are ethanol, water (for example, mono-, di-, and tri-hydrates),N-methylpyrrolidinone (NMP), dimethyl sulfoxide (DMSO),N,N′-dimethylformamide (DMF), N,N′-dimethylacetamide (DMAC),1,3-dimethyl-2-imidazolidinone (DMEU),1,3-dimethyl-3,4,5,6-tetrahydro-2-(1H)-pyrimidinone (DMPU), acetonitrile(ACN), propylene glycol, ethyl acetate, benzyl alcohol, 2-pyrrolidone,benzyl benzoate, and the like. When water is the solvent, the solvate isreferred to as a “hydrate.”

Pharmacokinetic: As used herein, “pharmacokinetic” refers to any one ormore properties of a molecule or compound as it relates to thedetermination of the fate of substances administered to a livingorganism. Pharmacokinetics is divided into several areas including theextent and rate of absorption, distribution, metabolism and excretion.This is commonly referred to as ADME where: (A) Absorption is theprocess of a substance entering the blood circulation; (D) Distributionis the dispersion or dissemination of substances throughout the fluidsand tissues of the body; (M) Metabolism (or Biotransformation) is theirreversible transformation of parent compounds into daughtermetabolites; and (E) Excretion (or Elimination) refers to theelimination of the substances from the body. In rare cases, some drugsirreversibly accumulate in body tissue.

Physicochemical: As used herein, “physicochemical” means of or relatingto a physical and/or chemical property.

Polynucleotide: The term “polynucleotide” as used herein refers topolymers of nucleotides of any length, including ribonucleotides,deoxyribonucleotides, analogs thereof, or mixtures thereof. This termrefers to the primary structure of the molecule. Thus, the term includestriple-, double- and single-stranded deoxyribonucleic acid (“DNA”), aswell as triple-, double- and single-stranded ribonucleic acid (“RNA”).It also includes modified, for example by alkylation, and/or by capping,and unmodified forms of the polynucleotide. More particularly, the term“polynucleotide” includes polydeoxyribonucleotides (containing2-deoxy-D-ribose), polyribonucleotides (containing D-ribose), includingtRNA, rRNA, hRNA, siRNA and mRNA, whether spliced or unspliced, anyother type of polynucleotide which is an N- or C-glycoside of a purineor pyrimidine base, and other polymers containing normucleotidicbackbones, for example, polyamide (e.g., peptide nucleic acids “PNAs”)and polymorpholino polymers, and other synthetic sequence-specificnucleic acid polymers providing that the polymers contain nucleobases ina configuration which allows for base pairing and base stacking, such asis found in DNA and RNA. In particular aspects, the polynucleotidecomprises an mRNA. In other aspect, the mRNA is a synthetic mRNA. Insome aspects, the synthetic mRNA comprises at least one unnaturalnucleobase. In some aspects, all nucleobases of a certain class havebeen replaced with unnatural nucleobases (e.g., all uridines in apolynucleotide disclosed herein can be replaced with an unnaturalnucleobase, e.g., 5-methoxyuridine). In some aspects, the polynucleotide(e.g., a synthetic RNA or a synthetic DNA) comprises only naturalnucleobases, i.e., A (adenosine), G (guanosine), C (cytidine), and T(thymidine) in the case of a synthetic DNA, or A, C, G, and U (uridine)in the case of a synthetic RNA.

The skilled artisan will appreciate that the T bases in the codon mapsdisclosed herein are present in DNA, whereas the T bases would bereplaced by U bases in corresponding RNAs. For example, acodon-nucleotide sequence disclosed herein in DNA form, e.g., a vectoror an in-vitro translation (IVT) template, would have its T basestranscribed as U based in its corresponding transcribed mRNA. In thisrespect, both codon-optimized DNA sequences (comprising T) and theircorresponding mRNA sequences (comprising U) are consideredcodon-optimized nucleotide sequence of the present invention. A skilledartisan would also understand that equivalent codon-maps can begenerated by replaced one or more bases with non-natural bases. Thus,e.g., a TTC codon (DNA map) would correspond to a UUC codon (RNA map),which in turn would correspond to a ΨΨC codon (RNA map in which U hasbeen replaced with pseudouridine).

Standard A-T and G-C base pairs form under conditions which allow theformation of hydrogen bonds between the N3-H and C4-oxy of thymidine andthe N1 and C6-NH2, respectively, of adenosine and between the C2-oxy, N3and C4-NH2, of cytidine and the C2-NH2, N′—H and C6-oxy, respectively,of guanosine. Thus, for example, guanosine(2-amino-6-oxy-9-O-D-ribofuranosyl-purine) can be modified to formisoguanosine (2-oxy-6-amino-9-O-D-ribofuranosyl-purine). Suchmodification results in a nucleoside base which will no longereffectively form a standard base pair with cytosine. However,modification of cytosine (1-O-D-ribofuranosyl-2-oxy-4-amino-pyrimidine)to form isocytosine (1-P-D-ribofuranosyl-2-amino-4-oxy-pyrimidine-)results in a modified nucleotide which will not effectively base pairwith guanosine but will form a base pair with isoguanosine (U.S. Pat.No. 5,681,702 to Collins et al.). Isocytosine is available from SigmaChemical Co. (St. Louis, Mo.); isocytidine can be prepared by the methoddescribed by Switzer et al. (1993) Biochemistry 32:10489-10496 andreferences cited therein; 2′-deoxy-5-methyl-isocytidine can be preparedby the method of Tor et al., 1993, J. Am. Chem. Soc. 115:4461-4467 andreferences cited therein; and isoguanine nucleotides can be preparedusing the method described by Switzer et al., 1993, supra, and Mantschet al., 1993, Biochem. 14:5593-5601, or by the method described in U.S.Pat. No. 5,780,610 to Collins et al. Other nonnatural base pairs can besynthesized by the method described in Piccirilli et al., 1990, Nature343:33-37, for the synthesis of 2,6-diaminopyrimidine and its complement(1-methylpyrazolo-[4,3]pyrimidine-5,7-(4H,6H)-dione. Other such modifiednucleotide units which form unique base pairs are known, such as thosedescribed in Leach et al. (1992) J. Am. Chem. Soc. 114:3675-3683 andSwitzer et al., supra.

Polypeptide: The terms “polypeptide,” “peptide,” and “protein” are usedinterchangeably herein to refer to polymers of amino acids of anylength. The polymer can comprise modified amino acids. The terms alsoencompass an amino acid polymer that has been modified naturally or byintervention; for example, disulfide bond formation, glycosylation,lipidation, acetylation, phosphorylation, or any other manipulation ormodification, such as conjugation with a labeling component. Alsoincluded within the definition are, for example, polypeptides containingone or more analogs of an amino acid (including, for example, unnaturalamino acids such as homocysteine, omithine, p-acetylphenylalanine,D-amino acids, and creatine), as well as other modifications known inthe art.

The term, as used herein, refers to proteins, polypeptides, and peptidesof any size, structure, or function. Polypeptides include encodedpolynucleotide products, naturally occurring polypeptides, syntheticpolypeptides, homologs, orthologs, paralogs, fragments and otherequivalents, variants, and analogs of the foregoing. A polypeptide canbe a monomer or can be a multi-molecular complex such as a dimer, trimeror tetramer. They can also comprise single chain or multichainpolypeptides. Most commonly disulfide linkages are found in multichainpolypeptides. The term polypeptide can also apply to amino acid polymersin which one or more amino acid residues are an artificial chemicalanalogue of a corresponding naturally occurring amino acid. In someembodiments, a “peptide” can be less than or equal to 50 amino acidslong, e.g., about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 amino acidslong.

Polypeptide variant: As used herein, the term “polypeptide variant”refers to molecules that differ in their amino acid sequence from anative or reference sequence. The amino acid sequence variants canpossess substitutions, deletions, and/or insertions at certain positionswithin the amino acid sequence, as compared to a native or referencesequence. Ordinarily, variants will possess at least about 50% identity,at least about 60% identity, at least about 70% identity, at least about80% identity, at least about 90% identity, at least about 95% identity,at least about 99% identity to a native or reference sequence. In someembodiments, they will be at least about 80%, or at least about 90%identical to a native or reference sequence.

Polypeptide per unit drug (PUD): As used herein, a PUD or product perunit drug, is defined as a subdivided portion of total daily dose,usually 1 mg, pg, kg, etc., of a product (such as a polypeptide) asmeasured in body fluid or tissue, usually defined in concentration suchas pmol/mL, mmol/mL, etc. divided by the measure in the body fluid.

Preventing: As used herein, the term “preventing” refers to partially orcompletely delaying onset of an infection, disease, disorder and/orcondition; partially or completely delaying onset of one or moresymptoms, features, or clinical manifestations of a particularinfection, disease, disorder, and/or condition; partially or completelydelaying onset of one or more symptoms, features, or manifestations of aparticular infection, disease, disorder, and/or condition; partially orcompletely delaying progression from an infection, a particular disease,disorder and/or condition; and/or decreasing the risk of developingpathology associated with the infection, the disease, disorder, and/orcondition.

Proliferate: As used herein, the term “proliferate” means to grow,expand or increase or cause to grow, expand or increase rapidly.“Proliferative” means having the ability to proliferate.“Anti-proliferative” means having properties counter to or inapposite toproliferative properties.

Prophylactic: As used herein, “prophylactic” refers to a therapeutic orcourse of action used to prevent the spread of disease.

Prophylaxis: As used herein, a “prophylaxis” refers to a measure takento maintain health and prevent the spread of disease. An “immuneprophylaxis” refers to a measure to produce active or passive immunityto prevent the spread of disease.

Protein cleavage site: As used herein, “protein cleavage site” refers toa site where controlled cleavage of the amino acid chain can beaccomplished by chemical, enzymatic or photochemical means.

Protein cleavage signal: As used herein “protein cleavage signal” refersto at least one amino acid that flags or marks a polypeptide forcleavage.

Protein of interest: As used herein, the terms “proteins of interest” or“desired proteins” include those provided herein and fragments, mutants,variants, and alterations thereof.

Proximal: As used herein, the term “proximal” means situated nearer tothe center or to a point or region of interest.

Pseudouridine: As used herein, pseudouridine (ψ) refers to theC-glycoside isomer of the nucleoside uridine. A “pseudouridine analog”is any modification, variant, isoform or derivative of pseudouridine.For example, pseudouridine analogs include but are not limited to1-carboxymethyl-pseudouridine, 1-propynyl-pseudouridine,1-taurinomethyl-pseudouridine, 1-taurinomethyl-4-thio-pseudouridine,1-methylpseudouridine (m¹ψ) (also known as N1-methyl-pseudouridine),1-methyl-4-thio-pseudouridine (m¹s⁴ψ), 4-thio-1-methyl-pseudouridine,3-methyl-pseudouridine (m³ψ), 2-thio-1-methyl-pseudouridine,1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-1-deaza-pseudouridine,dihydropseudouridine, 2-thio-dihydropseudouridine, 2-methoxyuridine,2-methoxy-4-thio-uridine, 4-methoxy-pseudouridine,4-methoxy-2-thio-pseudouridine,1-methyl-3-(3-amino-3-carboxypropyl)pseudouridine (acp³ψ), and2′-O-methyl-pseudouridine (ψm).

Purified: As used herein, “purify,” “purified,” “purification” means tomake substantially pure or clear from unwanted components, materialdefilement, admixture or imperfection.

Reference Nucleic Acid Sequence: The term “reference nucleic acidsequence” or “reference nucleic acid” or “reference nucleotide sequence”or “reference sequence” refers to a starting nucleic acid sequence(e.g., a RNA, e.g., an mRNA sequence) that can be sequence optimized. Insome embodiments, the reference nucleic acid sequence is a wild typenucleic acid sequence, a fragment or a variant thereof. In someembodiments, the reference nucleic acid sequence is a previouslysequence optimized nucleic acid sequence.

Salts: In some aspects, the pharmaceutical composition for deliverydisclosed herein and comprises salts of some of their lipidconstituents. The term “salt” includes any anionic and cationic complex.Non-limiting examples of anions include inorganic and organic anions,e.g., fluoride, chloride, bromide, iodide, oxalate (e.g., hemioxalate),phosphate, phosphonate, hydrogen phosphate, dihydrogen phosphate, oxide,carbonate, bicarbonate, nitrate, nitrite, nitride, bisulfite, sulfide,sulfite, bisulfate, sulfate, thiosulfate, hydrogen sulfate, borate,formate, acetate, benzoate, citrate, tartrate, lactate, acrylate,polyacrylate, fumarate, maleate, itaconate, glycolate, gluconate,malate, mandelate, tiglate, ascorbate, salicylate, polymethacrylate,perchlorate, chlorate, chlorite, hypochlorite, bromate, hypobromite,iodate, an alkylsulfonate, an arylsulfonate, arsenate, arsenite,chromate, dichromate, cyanide, cyanate, thiocyanate, hydroxide,peroxide, permanganate, and mixtures thereof.

Sample: As used herein, the term “sample” or “biological sample” refersto a subset of its tissues, cells or component parts (e.g., body fluids,including but not limited to blood, mucus, lymphatic fluid, synovialfluid, cerebrospinal fluid, saliva, amniotic fluid, amniotic cord blood,urine, vaginal fluid and semen). A sample further can include ahomogenate, lysate or extract prepared from a whole organism or a subsetof its tissues, cells or component parts, or a fraction or portionthereof, including but not limited to, for example, plasma, serum,spinal fluid, lymph fluid, the external sections of the skin,respiratory, intestinal, and genitourinary tracts, tears, saliva, milk,blood cells, tumors, organs. A sample further refers to a medium, suchas a nutrient broth or gel, which can contain cellular components, suchas proteins or nucleic acid molecule.

Signal Sequence: As used herein, the phrases “signal sequence,” “signalpeptide,” and “transit peptide” are used interchangeably and refer to asequence that can direct the transport or localization of a protein to acertain organelle, cell compartment, or extracellular export. The termencompasses both the signal sequence polypeptide and the nucleic acidsequence encoding the signal sequence. Thus, references to a signalsequence in the context of a nucleic acid refer in fact to the nucleicacid sequence encoding the signal sequence polypeptide.

Signal transduction pathway: A “signal transduction pathway” refers tothe biochemical relationship between a variety of signal transductionmolecules that play a role in the transmission of a signal from oneportion of a cell to another portion of a cell. As used herein, thephrase “cell surface receptor” includes, for example, molecules andcomplexes of molecules capable of receiving a signal and thetransmission of such a signal across the plasma membrane of a cell.

Similarity: As used herein, the term “similarity” refers to the overallrelatedness between polymeric molecules, e.g. between polynucleotidemolecules (e.g. DNA molecules and/or RNA molecules) and/or betweenpolypeptide molecules. Calculation of percent similarity of polymericmolecules to one another can be performed in the same manner as acalculation of percent identity, except that calculation of percentsimilarity takes into account conservative substitutions as isunderstood in the art.

Single unit dose: As used herein, a “single unit dose” is a dose of anytherapeutic administered in one dose/at one time/single route/singlepoint of contact, i.e., single administration event.

Split dose: As used herein, a “split dose” is the division of singleunit dose or total daily dose into two or more doses.

Specific delivery: As used herein, the term “specific delivery,”“specifically deliver,” or “specifically delivering” means delivery ofmore (e.g., at least 1.5 fold more, at least 2-fold more, at least3-fold more, at least 4-fold more, at least 5-fold more, at least 6-foldmore, at least 7-fold more, at least 8-fold more, at least 9-fold more,at least 10-fold more) of a polynucleotide by a nanoparticle to a targettissue of interest (e.g., mammalian liver) compared to an off-targettissue (e.g., mammalian spleen). The level of delivery of a nanoparticleto a particular tissue can be measured by comparing the amount ofprotein produced in a tissue to the weight of said tissue, comparing theamount of polynucleotide in a tissue to the weight of said tissue,comparing the amount of protein produced in a tissue to the amount oftotal protein in said tissue, or comparing the amount of polynucleotidein a tissue to the amount of total polynucleotide in said tissue. Forexample, for renovascular targeting, a polynucleotide is specificallyprovided to a mammalian kidney as compared to the liver and spleen if1.5, 2-fold, 3-fold, 5-fold, 10-fold, 15 fold, or 20 fold morepolynucleotide per 1 g of tissue is delivered to a kidney compared tothat delivered to the liver or spleen following systemic administrationof the polynucleotide. It will be understood that the ability of ananoparticle to specifically deliver to a target tissue need not bedetermined in a subject being treated, it can be determined in asurrogate such as an animal model (e.g., a rat model).

Stable: As used herein “stable” refers to a compound that issufficiently robust to survive isolation to a useful degree of purityfrom a reaction mixture, and in some cases capable of formulation intoan efficacious therapeutic agent.

Stabilized: As used herein, the term “stabilize,” “stabilized,”“stabilized region” means to make or become stable.

Stereoisomer: As used herein, the term “stereoisomer” refers to allpossible different isomeric as well as conformational forms that acompound can possess (e.g., a compound of any formula described herein),in particular all possible stereochemically and conformationallyisomeric forms, all diastereomers, enantiomers and/or conformers of thebasic molecular structure. Some compounds of the present invention canexist in different tautomeric forms, all of the latter being includedwithin the scope of the present invention.

Subject: By “subject” or “individual” or “animal” or “patient” or“mammal,” is meant any subject, particularly a mammalian subject, forwhom diagnosis, prognosis, or therapy is desired. Mammalian subjectsinclude, but are not limited to, humans, domestic animals, farm animals,zoo animals, sport animals, pet animals such as dogs, cats, guinea pigs,rabbits, rats, mice, horses, cattle, cows; primates such as apes,monkeys, orangutans, and chimpanzees; canids such as dogs and wolves;felids such as cats, lions, and tigers; equids such as horses, donkeys,and zebras; bears, food animals such as cows, pigs, and sheep; ungulatessuch as deer and giraffes; rodents such as mice, rats, hamsters andguinea pigs; and so on. In certain embodiments, the mammal is a humansubject. In other embodiments, a subject is a human patient. In aparticular embodiment, a subject is a human patient in need oftreatment.

Substantially: As used herein, the term “substantially” refers to thequalitative condition of exhibiting total or near-total extent or degreeof a characteristic or property of interest. One of ordinary skill inthe biological arts will understand that biological and chemicalcharacteristics rarely, if ever, go to completion and/or proceed tocompleteness or achieve or avoid an absolute result. The term“substantially” is therefore used herein to capture the potential lackof completeness inherent in many biological and chemicalcharacteristics.

Substantially equal: As used herein as it relates to time differencesbetween doses, the term means plus/minus 2%.

Substantially simultaneous: As used herein and as it relates toplurality of doses, the term means within 2 seconds.

Suffering from: An individual who is “suffering from” a disease,disorder, and/or condition has been diagnosed with or displays one ormore symptoms of the disease, disorder, and/or condition.

Susceptible to: An individual who is “susceptible to” a disease,disorder, and/or condition has not been diagnosed with and/or cannotexhibit symptoms of the disease, disorder, and/or condition but harborsa propensity to develop a disease or its symptoms. In some embodiments,an individual who is susceptible to a disease, disorder, and/orcondition (for example, PA) can be characterized by one or more of thefollowing: (1) a genetic mutation associated with development of thedisease, disorder, and/or condition; (2) a genetic polymorphismassociated with development of the disease, disorder, and/or condition;(3) increased and/or decreased expression and/or activity of a proteinand/or nucleic acid associated with the disease, disorder, and/orcondition; (4) habits and/or lifestyles associated with development ofthe disease, disorder, and/or condition; (5) a family history of thedisease, disorder, and/or condition; and (6) exposure to and/orinfection with a microbe associated with development of the disease,disorder, and/or condition. In some embodiments, an individual who issusceptible to a disease, disorder, and/or condition will develop thedisease, disorder, and/or condition. In some embodiments, an individualwho is susceptible to a disease, disorder, and/or condition will notdevelop the disease, disorder, and/or condition.

Sustained release: As used herein, the term “sustained release” refersto a pharmaceutical composition or compound release profile thatconforms to a release rate over a specific period of time.

Synthetic: The term “synthetic” means produced, prepared, and/ormanufactured by the hand of man. Synthesis of polynucleotides or othermolecules of the present invention can be chemical or enzymatic.

Targeted Cells: As used herein, “targeted cells” refers to any one ormore cells of interest. The cells can be found in vitro, in vivo, insitu or in the tissue or organ of an organism. The organism can be ananimal, for example a mammal, a human, a subject or a patient.

Target tissue: As used herein “target tissue” refers to any one or moretissue types of interest in which the delivery of a polynucleotide wouldresult in a desired biological and/or pharmacological effect. Examplesof target tissues of interest include specific tissues, organs, andsystems or groups thereof. In particular applications, a target tissuecan be a liver, a kidney, a lung, a spleen, or a vascular endothelium invessels (e.g., intra-coronary or intra-femoral). An “off-target tissue”refers to any one or more tissue types in which the expression of theencoded protein does not result in a desired biological and/orpharmacological effect.

The presence of a therapeutic agent in an off-target issue can be theresult of:

(i) leakage of a polynucleotide from the administration site toperipheral tissue or distant off-target tissue via diffusion or throughthe bloodstream (e.g., a polynucleotide intended to express apolypeptide in a certain tissue would reach the off-target tissue andthe polypeptide would be expressed in the off-target tissue); or

(ii) leakage of an polypeptide after administration of a polynucleotideencoding such polypeptide to peripheral tissue or distant off-targettissue via diffusion or through the bloodstream (e.g., a polynucleotidewould expressed a polypeptide in the target tissue, and the polypeptidewould diffuse to peripheral tissue).

Targeting sequence: As used herein, the phrase “targeting sequence”refers to a sequence that can direct the transport or localization of aprotein or polypeptide.

Terminus: As used herein the terms “termini” or “terminus,” whenreferring to polypeptides, refers to an extremity of a peptide orpolypeptide. Such extremity is not limited only to the first or finalsite of the peptide or polypeptide but can include additional aminoacids in the terminal regions. The polypeptide based molecules of theinvention can be characterized as having both an N-terminus (terminatedby an amino acid with a free amino group (NH₂)) and a C-terminus(terminated by an amino acid with a free carboxyl group (COOH)).Proteins of the invention are in some cases made up of multiplepolypeptide chains brought together by disulfide bonds or bynon-covalent forces (multimers, oligomers). These sorts of proteins willhave multiple N- and C-termini. Alternatively, the termini of thepolypeptides can be modified such that they begin or end, as the casecan be, with a non-polypeptide based moiety such as an organicconjugate.

Therapeutic Agent: The term “therapeutic agent” refers to an agent that,when administered to a subject, has a therapeutic, diagnostic, and/orprophylactic effect and/or elicits a desired biological and/orpharmacological effect. For example, in some embodiments, an mRNAencoding a PCCA or PCCB polypeptide can be a therapeutic agent.

Therapeutically effective amount: As used herein, the term“therapeutically effective amount” means an amount of an agent to bedelivered (e.g., nucleic acid, drug, therapeutic agent, diagnosticagent, prophylactic agent, etc.) that is sufficient, when administeredto a subject suffering from or susceptible to an infection, disease,disorder, and/or condition, to treat, improve symptoms of, diagnose,prevent, and/or delay the onset of the infection, disease, disorder,and/or condition.

Therapeutically effective outcome: As used herein, the term“therapeutically effective outcome” means an outcome that is sufficientin a subject suffering from or susceptible to an infection, disease,disorder, and/or condition, to treat, improve symptoms of, diagnose,prevent, and/or delay the onset of the infection, disease, disorder,and/or condition.

Total daily dose: As used herein, a “total daily dose” is an amountgiven or prescribed in 24 hr. period. The total daily dose can beadministered as a single unit dose or a split dose.

Transcription factor: As used herein, the term “transcription factor”refers to a DNA-binding protein that regulates transcription of DNA intoRNA, for example, by activation or repression of transcription. Sometranscription factors effect regulation of transcription alone, whileothers act in concert with other proteins. Some transcription factor canboth activate and repress transcription under certain conditions. Ingeneral, transcription factors bind a specific target sequence orsequences highly similar to a specific consensus sequence in aregulatory region of a target gene. Transcription factors can regulatetranscription of a target gene alone or in a complex with othermolecules.

Transcription: As used herein, the term “transcription” refers tomethods to produce mRNA (e.g., an mRNA sequence or template) from DNA(e.g., a DNA template or sequence)

Transfection: As used herein, “transfection” refers to the introductionof a polynucleotide (e.g., exogenous nucleic acids) into a cell whereina polypeptide encoded by the polynucleotide is expressed (e.g., mRNA) orthe polypeptide modulates a cellular function (e.g., siRNA, miRNA). Asused herein, “expression” of a nucleic acid sequence refers totranslation of a polynucleotide (e.g., an mRNA) into a polypeptide orprotein and/or post-translational modification of a polypeptide orprotein. Methods of transfection include, but are not limited to,chemical methods, physical treatments and cationic lipids or mixtures.

Treating, treatment, therapy: As used herein, the term “treating” or“treatment” or “therapy” refers to partially or completely alleviating,ameliorating, improving, relieving, delaying onset of, inhibitingprogression of, reducing severity of, and/or reducing incidence of oneor more symptoms or features of a disease, e.g., metabolic acidosis(e.g., acidosis of the blood and tissues), hyperammonemia,hyperglycinemia, PA. For example, “treating” PA can refer to diminishingsymptoms associate with the disease, prolong the lifespan (increase thesurvival rate) of patients, reducing the severity of the disease,preventing or delaying the onset of the disease, etc. Treatment can beadministered to a subject who does not exhibit signs of a disease,disorder, and/or condition and/or to a subject who exhibits only earlysigns of a disease, disorder, and/or condition for the purpose ofdecreasing the risk of developing pathology associated with the disease,disorder, and/or condition.

Unmodified: As used herein, “unmodified” refers to any substance,compound or molecule prior to being changed in some way. Unmodified can,but does not always, refer to the wild type or native form of abiomolecule. Molecules can undergo a series of modifications wherebyeach modified molecule can serve as the “unmodified” starting moleculefor a subsequent modification.

Uracil: Uracil is one of the four nucleobases in the nucleic acid ofRNA, and it is represented by the letter U. Uracil can be attached to aribose ring, or more specifically, a ribofuranose via a p-N₁-glycosidicbond to yield the nucleoside uridine. The nucleoside uridine is alsocommonly abbreviated according to the one letter code of its nucleobase,i.e., U. Thus, in the context of the present disclosure, when a monomerin a polynucleotide sequence is U, such U is designated interchangeablyas a “uracil” or a “uridine.”

Uridine Content: The terms “uridine content” or “uracil content” areinterchangeable and refer to the amount of uracil or uridine present ina certain nucleic acid sequence. Uridine content or uracil content canbe expressed as an absolute value (total number of uridine or uracil inthe sequence) or relative (uridine or uracil percentage respect to thetotal number of nucleobases in the nucleic acid sequence).

Uridine-Modified Sequence: The terms “uridine-modified sequence” refersto a sequence optimized nucleic acid (e.g., a synthetic mRNA sequence)with a different overall or local uridine content (higher or loweruridine content) or with different uridine patterns (e.g., gradientdistribution or clustering) with respect to the uridine content and/oruridine patterns of a candidate nucleic acid sequence. In the content ofthe present disclosure, the terms “uridine-modified sequence” and“uracil-modified sequence” are considered equivalent andinterchangeable.

A “high uridine codon” is defined as a codon comprising two or threeuridines, a “low uridine codon” is defined as a codon comprising oneuridine, and a “no uridine codon” is a codon without any uridines. Insome embodiments, a uridine-modified sequence comprises substitutions ofhigh uridine codons with low uridine codons, substitutions of highuridine codons with no uridine codons, substitutions of low uridinecodons with high uridine codons, substitutions of low uridine codonswith no uridine codons, substitution of no uridine codons with lowuridine codons, substitutions of no uridine codons with high uridinecodons, and combinations thereof. In some embodiments, a high uridinecodon can be replaced with another high uridine codon. In someembodiments, a low uridine codon can be replaced with another lowuridine codon. In some embodiments, a no uridine codon can be replacedwith another no uridine codon. A uridine-modified sequence can beuridine enriched or uridine rarefied.

Uridine Enriched: As used herein, the terms “uridine enriched” andgrammatical variants refer to the increase in uridine content (expressedin absolute value or as a percentage value) in an sequence optimizednucleic acid (e.g., a synthetic mRNA sequence) with respect to theuridine content of the corresponding candidate nucleic acid sequence.Uridine enrichment can be implemented by substituting codons in thecandidate nucleic acid sequence with synonymous codons containing lessuridine nucleobases. Uridine enrichment can be global (i.e., relative tothe entire length of a candidate nucleic acid sequence) or local (i.e.,relative to a subsequence or region of a candidate nucleic acidsequence).

Uridine Rarefied: As used herein, the terms “uridine rarefied” andgrammatical variants refer to a decrease in uridine content (expressedin absolute value or as a percentage value) in an sequence optimizednucleic acid (e.g., a synthetic mRNA sequence) with respect to theuridine content of the corresponding candidate nucleic acid sequence.Uridine rarefication can be implemented by substituting codons in thecandidate nucleic acid sequence with synonymous codons containing lessuridine nucleobases. Uridine rarefication can be global (i.e., relativeto the entire length of a candidate nucleic acid sequence) or local(i.e., relative to a subsequence or region of a candidate nucleic acidsequence).

Variant: The term variant as used in present disclosure refers to bothnatural variants (e.g., polymorphisms, isoforms, etc) and artificialvariants in which at least one amino acid residue in a native orstarting sequence (e.g., a wild type sequence) has been removed and adifferent amino acid inserted in its place at the same position. Thesevariants can de described as “substitutional variants.” Thesubstitutions can be single, where only one amino acid in the moleculehas been substituted, or they can be multiple, where two or more aminoacids have been substituted in the same molecule. If amino acids areinserted or deleted, the resulting variant would be an “insertionalvariant” or a “deletional variant” respectively.

Initiation Codon: As used herein, the term “initiation codon”, usedinterchangeably with the term “start codon”, refers to the first codonof an open reading frame that is translated by the ribosome and iscomprised of a triplet of linked adenine-uracil-guanine nucleobases. Theinitiation codon is depicted by the first letter codes of adenine (A),uracil (U), and guanine (G) and is often written simply as “AUG”.Although natural mRNAs may use codons other than AUG as the initiationcodon, which are referred to herein as “alternative initiation codons”,the initiation codons of polynucleotides described herein use the AUGcodon. During the process of translation initiation, the sequencecomprising the initiation codon is recognized via complementarybase-pairing to the anticodon of an initiator tRNA (Met-tRNA_(i) ^(Met))bound by the ribosome. Open reading frames may contain more than one AUGinitiation codon, which are referred to herein as “alternate initiationcodons”.

The initiation codon plays a critical role in translation initiation.The initiation codon is the first codon of an open reading frame that istranslated by the ribosome. Typically, the initiation codon comprisesthe nucleotide triplet AUG, however, in some instances translationinitiation can occur at other codons comprised of distinct nucleotides.The initiation of translation in eukaryotes is a multistep biochemicalprocess that involves numerous protein-protein, protein-RNA, and RNA-RNAinteractions between messenger RNA molecules (mRNAs), the 40S ribosomalsubunit, other components of the translation machinery (e.g., eukaryoticinitiation factors; eIFs). The current model of mRNA translationinitiation postulates that the pre-initiation complex (alternatively“43S pre-initiation complex”; abbreviated as “PIC”) translocates fromthe site of recruitment on the mRNA (typically the 5′ cap) to theinitiation codon by scanning nucleotides in a 5′ to 3′ direction untilthe first AUG codon that resides within a specific translation-promotivenucleotide context (the Kozak sequence) is encountered (Kozak (1989) JCell Biol 108:229-241). Scanning by the PIC ends upon complementarybase-pairing between nucleotides comprising the anticodon of theinitiator Met-tRNA_(i) ^(Met) transfer RNA and nucleotides comprisingthe initiation codon of the mRNA. Productive base-pairing between theAUG codon and the Met-tRNA_(i) ^(Met) anticodon elicits a series ofstructural and biochemical events that culminate in the joining of thelarge 60S ribosomal subunit to the PIC to form an active ribosome thatis competent for translation elongation.

Kozak Sequence: The term “Kozak sequence” (also referred to as “Kozakconsensus sequence”) refers to a translation initiation enhancer elementto enhance expression of a gene or open reading frame, and which ineukaryotes, is located in the 5′ UTR. The Kozak consensus sequence wasoriginally defined as the sequence GCCRCC, where R=a purine, followingan analysis of the effects of single mutations surrounding theinitiation codon (AUG) on translation of the preproinsulin gene (Kozak(1986) Cell 44:283-292). Polynucleotides disclosed herein comprise aKozak consensus sequence, or a derivative or modification thereof(Examples of translational enhancer compositions and methods of usethereof, see U.S. Pat. No. 5,807,707 to Andrews et al., incorporatedherein by reference in its entirety; U.S. Pat. No. 5,723,332 toChernajovsky, incorporated herein by reference in its entirety; U.S.Pat. No. 5,891,665 to Wilson, incorporated herein by reference in itsentirety.)

Modified: As used herein “modified” or “modification” refers to achanged state or a change in composition or structure of apolynucleotide (e.g., mRNA). Polynucleotides may be modified in variousways including chemically, structurally, and/or functionally. Forexample, polynucleotides may be structurally modified by theincorporation of one or more RNA elements, wherein the RNA elementcomprises a sequence and/or an RNA secondary structure(s) that providesone or more functions (e.g., translational regulatory activity).Accordingly, polynucleotides of the disclosure may be comprised of oneor more modifications (e.g., may include one or more chemical,structural, or functional modifications, including any combinationthereof).

Nucleobase: As used herein, the term “nucleobase” (alternatively“nucleotide base” or “nitrogenous base”) refers to a purine orpyrimidine heterocyclic compound found in nucleic acids, including anyderivatives or analogs of the naturally occurring purines andpyrimidines that confer improved properties (e.g., binding affinity,nuclease resistance, chemical stability) to a nucleic acid or a portionor segment thereof. Adenine, cytosine, guanine, thymine, and uracil arethe nucleobases predominately found in natural nucleic acids. Othernatural, non-natural, and/or synthetic nucleobases, as known in the artand/or described herein, can be incorporated into nucleic acids.

Nucleoside Nucleotide: As used herein, the term “nucleoside” refers to acompound containing a sugar molecule (e.g., a ribose in RNA or adeoxyribose in DNA), or derivative or analog thereof, covalently linkedto a nucleobase (e.g., a purine or pyrimidine), or a derivative oranalog thereof (also referred to herein as “nucleobase”), but lacking aninternucleoside linking group (e.g., a phosphate group). As used herein,the term “nucleotide” refers to a nucleoside covalently bonded to aninternucleoside linking group (e.g., a phosphate group), or anyderivative, analog, or modification thereof that confers improvedchemical and/or functional properties (e.g., binding affinity, nucleaseresistance, chemical stability) to a nucleic acid or a portion orsegment thereof.

Nucleic acid: As used herein, the term “nucleic acid” is used in itsbroadest sense and encompasses any compound and/or substance thatincludes a polymer of nucleotides, or derivatives or analogs thereof.These polymers are often referred to as “polynucleotides”. Accordingly,as used herein the terms “nucleic acid” and “polynucleotide” areequivalent and are used interchangeably. Exemplary nucleic acids orpolynucleotides of the disclosure include, but are not limited to,ribonucleic acids (RNAs), deoxyribonucleic acids (DNAs), DNA-RNAhybrids, RNAi-inducing agents, RNAi agents, siRNAs, shRNAs, mRNAs,modified mRNAs, miRNAs, antisense RNAs, ribozymes, catalytic DNA, RNAsthat induce triple helix formation, threose nucleic acids (TNAs), glycolnucleic acids (GNAs), peptide nucleic acids (PNAs), locked nucleic acids(LNAs, including LNA having a β-D-ribo configuration, α-LNA having anα-L-ribo configuration (a diastereomer of LNA), 2′-amino-LNA having a2-amino functionalization, and 2′-amino-α-LNA having a 2-aminofunctionalization) or hybrids thereof.

Nucleic Acid Structure: As used herein, the term “nucleic acidstructure” (used interchangeably with “polynucleotide structure”) refersto the arrangement or organization of atoms, chemical constituents,elements, motifs, and/or sequence of linked nucleotides, or derivativesor analogs thereof, that comprise a nucleic acid (e.g., an mRNA). Theterm also refers to the two-dimensional or three-dimensional state of anucleic acid. Accordingly, the term “RNA structure” refers to thearrangement or organization of atoms, chemical constituents, elements,motifs, and/or sequence of linked nucleotides, or derivatives or analogsthereof, comprising an RNA molecule (e.g., an mRNA) and/or refers to atwo-dimensional and/or three dimensional state of an RNA molecule.Nucleic acid structure can be further demarcated into fourorganizational categories referred to herein as “molecular structure”,“primary structure”, “secondary structure”, and “tertiary structure”based on increasing organizational complexity.

Open Reading Frame: As used herein, the term “open reading frame”,abbreviated as “ORF”, refers to a segment or region of an mRNA moleculethat encodes a polypeptide. The ORF comprises a continuous stretch ofnon-overlapping, in-frame codons, beginning with the initiation codonand ending with a stop codon, and is translated by the ribosome.

Pre-Initiation Complex (PIC): As used herein, the term “pre-initiationcomplex” (alternatively “43S pre-initiation complex”; abbreviated as“PIC”) refers to a ribonucleoprotein complex comprising a 40S ribosomalsubunit, eukaryotic initiation factors (eIF1, eIF1A, eIF3, eIF5), andthe eIF2-GTP-Met-tRNA_(i) ^(Met) ternary complex, that is intrinsicallycapable of attachment to the 5′ cap of an mRNA molecule and, afterattachment, of performing ribosome scanning of the 5′ UTR.

RNA element: As used herein, the term “RNA element” refers to a portion,fragment, or segment of an RNA molecule that provides a biologicalfunction and/or has biological activity (e.g., translational regulatoryactivity). Modification of a polynucleotide by the incorporation of oneor more RNA elements, such as those described herein, provides one ormore desirable functional properties to the modified polynucleotide. RNAelements, as described herein, can be naturally-occurring, non-naturallyoccurring, synthetic, engineered, or any combination thereof. Forexample, naturally-occurring RNA elements that provide a regulatoryactivity include elements found throughout the transcriptomes ofviruses, prokaryotic and eukaryotic organisms (e.g., humans). RNAelements in particular eukaryotic mRNAs and translated viral RNAs havebeen shown to be involved in mediating many functions in cells.Exemplary natural RNA elements include, but are not limited to,translation initiation elements (e.g., internal ribosome entry site(IRES), see Kieft et al., (2001) RNA 7(2):194-206), translation enhancerelements (e.g., the APP mRNA translation enhancer element, see Rogers etal., (1999) J Biol Chem 274(10):6421-6431), mRNA stability elements(e.g., AU-rich elements (AREs), see Garneau et al., (2007) Nat Rev MolCell Biol 8(2):113-126), translational repression element (see e.g.,Blumer et al., (2002) Mech Dev 110(1-2):97-112), protein-binding RNAelements (e.g., iron-responsive element, see Selezneva et al., (2013) JMol Biol 425(18):3301-3310), cytoplasmic polyadenylation elements(Villalba et al., (2011) Curr Opin Genet Dev 21(4):452-457), andcatalytic RNA elements (e.g., ribozymes, see Scott et al., (2009)Biochim Biophys Acta 1789(9-10):634-641).

Residence time: As used herein, the term “residence time” refers to thetime of occupancy of a pre-initiation complex (PIC) or a ribosome at adiscrete position or location along an mRNA molecule.

Translational Regulatory Activity: As used herein, the term“translational regulatory activity” (used interchangeably with“translational regulatory function”) refers to a biological function,mechanism, or process that modulates (e.g., regulates, influences,controls, varies) the activity of the translational apparatus, includingthe activity of the PIC and/or ribosome. In some aspects, the desiredtranslation regulatory activity promotes and/or enhances thetranslational fidelity of mRNA translation. In some aspects, the desiredtranslational regulatory activity reduces and/or inhibits leakyscanning.

28. Equivalents and Scope

Those skilled in the art will recognize, or be able to ascertain usingno more than routine experimentation, many equivalents to the specificembodiments in accordance with the invention described herein. The scopeof the present invention is not intended to be limited to the aboveDescription, but rather is as set forth in the appended claims.

In the claims, articles such as “a,” “an,” and “the” can mean one ormore than one unless indicated to the contrary or otherwise evident fromthe context. Claims or descriptions that include “or” between one ormore members of a group are considered satisfied if one, more than one,or all of the group members are present in, employed in, or otherwiserelevant to a given product or process unless indicated to the contraryor otherwise evident from the context. The invention includesembodiments in which exactly one member of the group is present in,employed in, or otherwise relevant to a given product or process. Theinvention includes embodiments in which more than one, or all of thegroup members are present in, employed in, or otherwise relevant to agiven product or process.

It is also noted that the term “comprising” is intended to be open andpermits but does not require the inclusion of additional elements orsteps. When the term “comprising” is used herein, the term “consistingof” is thus also encompassed and disclosed.

Where ranges are given, endpoints are included. Furthermore, it is to beunderstood that unless otherwise indicated or otherwise evident from thecontext and understanding of one of ordinary skill in the art, valuesthat are expressed as ranges can assume any specific value or subrangewithin the stated ranges in different embodiments of the invention, tothe tenth of the unit of the lower limit of the range, unless thecontext clearly dictates otherwise.

In addition, it is to be understood that any particular embodiment ofthe present invention that falls within the prior art can be explicitlyexcluded from any one or more of the claims. Since such embodiments aredeemed to be known to one of ordinary skill in the art, they can beexcluded even if the exclusion is not set forth explicitly herein. Anyparticular embodiment of the compositions of the invention (e.g., anynucleic acid or protein encoded thereby; any method of production; anymethod of use; etc.) can be excluded from any one or more claims, forany reason, whether or not related to the existence of prior art.

All cited sources, for example, references, publications, databases,database entries, and art cited herein, are incorporated into thisapplication by reference, even if not expressly stated in the citation.In case of conflicting statements of a cited source and the instantapplication, the statement in the instant application shall control.

Section and table headings are not intended to be limiting.

Construct Sequences

By “G5” is meant that all uracils (U) in the mRNA are replaced byN1-methylpseudouracils.

mRNA ORF Sequence ORF Sequence 5′ UTR 3′ UTR Construct Name (Amino Acid)(Nucleotide) Sequence Sequence Sequence SEQ ID NO:  1   2   3   4  28PCCA_11 MAGFWVGTAPLVAA AUGGCCGGAUUCUG GGGAAA UGAUAA SEQ ID (hPCCA;GRRGRWPPQQLMLS GGUCGGCACAGCCC UAAGAG UAGGCU NO: 28 G5) AALRTLKHVLYYSRCUCUUGUGGCCGCA AGAAAA GGAGCC consists Cap: C1 QCLMVSRNLGSVGYGGGAGGCGCGGCCG GAAGAG UCGGUG from 5′ to PolyA tail: DPNEKTFDKILVANRCUGGCCACCACAGC UAAGAA GCCUAG 3′ end: 5′ 100 nt GEIACRVIRTCKKMGAGCUGAUGCUGUCU GAAAUA CUUCUU UTR of IKTVAIHSDVDASSV GCCGCCCUGCGGACUAAGAG GCCCCU SEQ ID HVKMADEAVCVGPA CCUGAAGCACGUGC CCACC UGGGCC NO: 3,PTSKSYLNMDAIMEA UGUACUAUAGCAGA UCCCCC ORF IKKTRAQAVHPGYGF CAGUGUCUGAUGGUCAGCCC Sequence LSENKEFARCLAAED GUCCAGAAACCUCG CUCCUC of SEQ IDVVFIGPDTHAIQAMG GAAGCGUGGGCUAC CCCUUC NO: 2, and DKIESKLLAKKAEVNGACCCCAACGAGAA CUGCAC 3′ UTR of TIPGFDGVVKDAEEA GACCUUCGACAAGA CCGUACSEQ ID VRIAREIGYPVMIKAS UCCUGGUCGCCAAC CCCCUC NO: 4 AGGGGKGMRIAWDDCGCGGCGAGAUCGC CAUAAA EETRDGFRLSSQEAA UUGCCGGGUGAUCA GUAGGASSFGDDRLLIEKFIDN GGACCUGUAAGAAG AACACU PRHIEIQVLGDKHGN AUGGGCAUCAAGACACAGUG ALWLNERECSIQRRN CGUGGCCAUCCACA GUCUUU QKVVEEAPSIFLDAEGCGACGUAGACGCC GAAUAA TRRAMGEQAVALAR AGCAGCGUGCACGU AGUCUGAVKYSSAGTVEFLVD CAAGAUGGCCGACG AGUGGG SKKNFYFLEMNTRLQ AAGCGGUGUGCGUGCGGC VEHPVTECITGLDLV GGGCCCGCCCCUAC QEMIRVAKGYPLRH AUCCAAGUCCUAUCKQADIRINGWAVECR UUAACAUGGACGCC VYAEDPYKSFGLPSI AUCAUGGAGGCCAUGRLSQYQEPLHLPGV CAAGAAGACUAGAG RVDSGIQPGSDISIYY CCCAAGCCGUUCAUDPMISKLITYGSDRTE CCGGGGUACGGAUU ALKRMADALDNYVI UCUGUCCGAGAACARGVTHNIALLREVIIN AAGAGUUCGCUAGG SRFVKGDISTKFLSDV UGCCUCGCCGCCGAYPDGFKGHMLTKSE AGACGUUGUCUUCA KNQLLAIASSLFVAF UUGGUCCAGACACCQLRAQHFQENSRMP CACGCCAUCCAGGC VIKPDIANWELSVKL UAUGGGCGAUAAGAIIDKVHTVVASNNGS UCGAGAGCAAGCUG VFSVEVDGSKLNVTS CUGGCUAAGAAGGCTWNLASPLLSVSVDG AGAGGUGAACACCA TQRTVQCLSREAGGN UCCCCGGAUUCGACMSIQFLGTVYKVNIL GGAGUGGUCAAAGA TRLAAELNKFMLEK CGCGGAGGAGGCCGVTEDTSSVLRSPMPG UGAGGAUCGCGAGA VVVAVSVKPGDAVA GAGAUCGGAUACCCEGQEICVIEAMKMQN GGUGAUGAUCAAGG SMTAGKTGTVKSVH CCUCAGCAGGCGGCCQAGDTVGEGDLLV GGCGGAAAGGGAAU ELE GAGAAUUGCCUGGG ACGACGAGGAAACCCGCGACGGCUUCCG GCUCAGCUCCCAGG AAGCAGCUUCUAGC UUUGGCGACGAUCGGCUGCUGAUUGAGA AAUUCAUCGAUAAC CCCAGACACAUAGA GAUCCAGGUGCUGGGUGACAAGCACGGC AACGCCCUGUGGCU GAACGAGAGAGAGU GCUCCAUUCAGAGGAGGAACCAGAAGGU GGUUGAGGAGGCGC CUAGCAUCUUCCUG GACGCUGAAACAAGGAGAGCCAUGGGUG AGCAGGCCGUGGCC CUGGCUCGCGCCGU UAAGUAUAGCAGCGCCGGCACCGUCGAG UUCCUGGUGGACUC CAAGAAGAACUUCU AUUUCCUGGAGAUGAACACCCGCCUGCA GGUGGAGCACCCCG UCACUGAGUGUAUU ACCGGCCUCGACCUGGUCCAGGAGAUGA UCAGAGUCGCCAAG GGGUAUCCCCUGCG GCACAAGCAGGCAGACAUCCGCAUCAAC GGCUGGGCCGUGGA GUGCAGAGUGUACG CCGAGGACCCCUACAAGAGCUUCGGCCU GCCAAGCAUCGGCA GACUGUCUCAGUAC CAAGAACCCCUGCACCUGCCCGGCGUGA GAGUAGACAGCGGC AUUCAGCCUGGAAG CGACAUUAGCAUCUACUACGACCCUAUG AUCAGCAAGCUCAU CACCUACGGUUCUG ACCGGACCGAGGCCCUGAAACGGAUGGC UGACGCCCUGGACA ACUACGUGAUCCGG GGCGUGACUCACAACAUCGCCCUCCUGA GGGAAGUCAUCAUC AACAGCCGAUUCGU GAAGGGAGACAUCUCCACCAAGUUCCUG AGCGACGUGUACCC UGACGGCUUCAAAG GCCACAUGCUGACCAAGAGCGAGAAGAA CCAGCUCCUGGCCA UCGCCAGUAGCCUG UUCGUGGCCUUCCAGCUGAGGGCCCAGC ACUUUCAGGAGAAC AGCAGGAUGCCAGU GAUUAAGCCUGACAUCGCCAACUGGGAG CUGUCAGUCAAGCU GCACGAUAAGGUGC ACACAGUGGUGGCCAGCAAUAACGGCUC CGUGUUCAGCGUCG AGGUGGACGGCUCC AAACUGAACGUCACCAGCACCUGGAAUC UGGCCUCACCCUUA CUGAGCGUGUCUGU GGACGGCACCCAGAGAACCGUGCAGUGU UUGUCUAGGGAGGC AGGCGGCAACAUGU CCAUCCAGUUUCUGGGAACAGUGUACAA AGUGAAUAUCCUGA CCAGACUGGCCGCU GAGCUGAACAAGUUCAUGCUUGAGAAGG UGACCGAGGAUACU AGCUCCGUUCUGAG AUCCCCUAUGCCCGGUGUGGUCGUGGCA GUGAGCGUGAAGCC UGGUGACGCGGUGG CAGAGGGUCAGGAGAUCUGUGUCAUUGA GGCUAUGAAGAUGC AGAAUAGCAUGACA GCCGGUAAGACCGGGACGGUUAAAUCCG UUCACUGCCAGGCU GGCGACACCGUGGG CGAGGGCGAUCUGUUAGUGGAGCUUGAG SEQ ID NO:  1   5   3   4  29 PCCA_12 MAGFWVGTAPLVAAAUGGCGGGCUUUUG GGGAAA UGAUAA SEQ ID (hPCCA; GRRGRWPPQQLMLSGGUGGGCACCGCCC UAAGAG UAGGCU NO: 29 G5) AALRTLKHVLYYSR CACUGGUCGCUGCCAGAAAA GGAGCC consists Cap: C1 QCLMVSRNLGSVGY GGCAGGAGAGGACG GAAGAGUCGGUG from 5′ to PolyA tail: DPNEKTFDKILVANR GUGGCCACCCCAGC UAAGAAGCCUAG 3′ end: 5′ 100 nt GEIACRVIRTCKKMG AGCUCAUGCUGAGC GAAAUA CUUCUUUTR of IKTVAIHSDVDASSV GCCGCACUCAGAAC UAAGAG GCCCCU SEQ IDHVKMADEAVCVGPA CCUGAAGCACGUGC CCACC UGGGCC NO: 3, PTSKSYLNMDAIMEAUGUACUACUCGCGA UCCCCC ORF IKKTRAQAVHPGYGF CAGUGCCUUAUGGU CAGCCC SequenceLSENKEFARCLAAED GUCUAGGAACCUGG CUCCUC of SEQ ID VVFIGPDTHAIQAMGGCUCUGUCGGCUAC CCCUUC NO: 5, and DKIESKLLAKKAEVN GAUCCGAACGAGAA CUGCAC3′ UTR of TIPGFDGVVKDAEEA GACCUUCGACAAGA CCGUAC SEQ ID VRIAREIGYPVMIKASUCCUGGUCGCCAAC CCCCUC NO: 4 AGGGGKGMRIAWDD AGGGGCGAAAUCGC CAUAAAEETRDGFRLSSQEAA CUGUAGAGUCAUAA GUAGGA SSFGDDRLLIEKFIDN GGACCUGUAAGAAGAACACU PRHIEIQVLGDKHGN AUGGGCAUCAAGAC ACAGUG ALWLNERECSIQRRNCGUGGCUAUCCACA GUCUUU QKVVEEAPSIFLDAE GCGACGUGGACGCU GAAUAATRRAMGEQAVALAR AGCUCCGUACACGU AGUCUG AVKYSSAGTVEFLVD GAAGAUGGCCGACGAGUGGG SKKNFYFLEMNTRLQ AGGCAGUGUGCGUG CGGC VEHPVTECITGLDLVGGUCCGGCUCCCAC QEMIRVAKGYPLRH CUCCAAGUCCUACC KQADIRINGWAVECRUGAACAUGGACGCC VYAEDPYKSFGLPSI AUCAUGGAAGCCAU GRLSQYQEPLHLPGVCAAGAAGACUAGAG RVDSGIQPGSDISIYY CCCAGGCCGUGCAC DPMISKLITYGSDRTECCAGGCUACGGGUU ALKRMADALDNYVI UCUCUCCGAGAAUA RGVTHNIALLREVIINAAGAGUUCGCCAGG SRFVKGDISTKFLSDV UGCCUGGCUGCCGA YPDGFKGHMLTKSEGGACGUGGUGUUUA KNQLLAIASSLFVAF UCGGACCCGAUACU QLRAQHFQENSRMPCACGCCAUCCAGGC VIKPDIANWELSVKL CAUGGGCGACAAGA HDKVHTVVASNNGSUAGAGUCUAAGCUG VFSVEVDGSKLNVTS UUGGCCAAGAAAGC TWNLASPLLSVSVDGUGAGGUGAACACCA TQRTVQCLSREAGGN UCCCCGGCUUCGAC MSIQFLGTVYKVNILGGUGUGGUUAAGG TRLAAELNKFMLEK ACGCCGAGGAAGCU VTEDTSSVLRSPMPGGUGCGCAUCGCCAG VVVAVSVKPGDAVA GGAAAUCGGCUACC EGQEICVIEAMKMQNCCGUGAUGAUCAAG SMTAGKTGTVKSVH GCAAGUGCAGGAGG CQAGDTVGEGDLLVAGGCGGCAAAGGGA ELE UGAGAAUCGCCUGG GACGACGAAGAAAC UAGAGACGGUUUCCGGCUGUCUUCCCAG GAGGCUGCAUCAUC UUUUGGAGACGAUC GGUUGCUGAUUGAGAAGUUUAUUGACAA CCCGCGGCACAUCG AGAUCCAGGUGCUC GGUGACAAGCACGGCAACGCCCUCUGGC UCAACGAAAGAGAG UGCAGCAUUCAGCG CCGGAACCAGAAAGUGGUGGAGGAGGCU CCCAGUAUUUUCCU GGACGCCGAAACCC GGAGAGCCAUGGGAGAGCAGGCUGUGGC UCUCGCUAGGGCGG UGAAGUACAGCUCC GCCGGCACAGUCGAGUUCCUGGUGGACU CCAAGAAGAACUUC UACUUCCUGGAGAU GAACACAAGACUGCAGGUGGAGCAUCCC GUUACCGAGUGUAU AACCGGCCUGGAUC UGGUCCAGGAGAUGAUCAGAGUCGCCAA GGGAUAUCCCCUUA GGCAUAAACAGGCC GACAUCAGGAUCAACGGCUGGGCCGUCG AGUGCCGGGUGUAC GCUGAGGACCCUUA UAAGAGCUUCGGCUUACCAUCCAUUGGC AGACUGUCCCAGUA CCAGGAACCUCUGC ACUUGCCCGGAGUGAGAGUCGACAGCGG CAUCCAGCCCGGCA GCGACAUCUCCAUC UACUACGACCCCAUGAUAUCAAAGCUGA UCACCUACGGCUCG GAUAGAACAGAGGC UCUGAAGAGGAUGGCUGACGCCCUGGAC AACUACGUGAUCCG GGGUGUGACACACA ACAUUGCCCUGCUGAGGGAGGUGAUCAU CAAUAGCCGGUUUG UGAAGGGUGAUAU UUCCACCAAGUUCCUGUCUGACGUGUAU CCGGACGGAUUCAA GGGCCACAUGCUGA CAAAGUCCGAGAAGAAUCAGCUGCUGGC CAUAGCUUCUUCAC UGUUCGUGGCCUUU CAGCUGAGAGCUCAGCACUUCCAGGAGA ACUCAAGAAUGCCC GUGAUCAAGCCUGA UAUCGCCAAUUGGGAGCUGAGCGUGAAG CUGCACGACAAGGU ACACACAGUGGUGG CCAGCAACAACGGCAGCGUGUUUUCCGU GGAGGUAGACGGAA GCAAACUGAACGUG ACAUCUACCUGGAAUCUGGCCUCUCCUC UGCUGAGUGUUAGC GUCGACGGCACGCA GAGAACUGUGCAGUGCCUGAGCCGGGAG GCGGGCGGAAACAU GUCAAUCCAGUUUC UCGGCACUGUCUACAAGGUCAACAUCCU GACCAGACUGGCUG CUGAGCUGAAUAAA UUCAUGCUCGAGAAGGUGACCGAGGACA CAAGCUCGGUGCUC AGAAGCCCAAUGCC CGGCGUGGUGGUCGCCGUCAGCGUCAAG CCCGGCGACGCUGU GGCCGAAGGCCAGG AAAUCUGCGUCAUCGAGGCGAUGAAGAU GCAGAAUUCAAUGA CUGCCGGGAAGACC GGCACCGUCAAGAGCGUGCAUUGCCAGG CAGGGGACACCGUG GGCGAAGGGGACCU UCUGGUGGAGCUCG AG SEQ IDNO:  1   6   3   4  30 PCCA_13 MAGFWVGTAPLVAA AUGGCCGGCUUCUG GGGAAAUGAUAA SEQ ID (hPCCA; GRRGRWPPQQLMLS GGUGGGCACCGCAC UAAGAG UAGGCU NO: 30G5) AALRTLKHVLYYSR CCCUCGUGGCCGCC AGAAAA GGAGCC consists Cap: C1QCLMVSRNLGSVGY GGCAGAAGAGGCAG GAAGAG UCGGUG from 5′ to PolyA tail:DPNEKTFDKILVANR GUGGCCUCCCCAGC UAAGAA GCCUAG 3′ end: 5′ 100 ntGEIACRVIRTCKKMG AGCUGAUGCUGAGC GAAAUA CUUCUU UTR of IKTVAIHSDVDASSVGCCGCCCUGCGGAC UAAGAG GCCCCU SEQ ID HVKMADEAVCVGPA CCUGAAGCACGUGC CCACCUGGGCC NO: 3, PTSKSYLNMDAIMEA UGUACUACAGCCGG UCCCCC ORF IKKTRAQAVHPGYGFCAGUGCCUGAUGGU CAGCCC Sequence LSENKEFARCLAAED GAGCCGGAACCUGG CUCCUCof SEQ ID VVFIGPDTHAIQAMG GCAGCGUGGGCUAC CCCUUC NO: 6, andDKIESKLLAKKAEVN GACCCCAACGAGAA CUGCAC 3′ UTR of TIPGFDGVVKDAEEAGACCUUCGACAAGA CCGUAC SEQ ID VRIAREIGYPVMIKAS UUUUGGUGGCAAAC CCCCUCNO: 4 AGGGGKGMRIAWDD CGGGGCGAGAUCGC CAUAAA EETRDGFRLSSQEAACUGCCGGGUGAUCC GUAGGA SSFGDDRLLIEKFIDN GGACCUGCAAGAAG AACACUPRHIEIQVLGDKHGN AUGGGCAUCAAGAC ACAGUG ALWLNERECSIQRRN CGUGGCCAUCCACAGUCUUU QKVVEEAPSIFLDAE GCGACGUGGACGCC GAAUAA TRRAMGEQAVALARAGCAGCGUGCACGU AGUCUG AVKYSSAGTVEFLVD GAAGAUGGCCGACG AGUGGGSKKNFYFLEMNTRLQ AGGCCGUGUGCGUC CGGC VEHPVTECITGLDLV GGCCCCGCCCCUACQEMIRVAKGYPLRH CAGCAAGAGCUACC KQADIRINGWAVECR UGAACAUGGACGCGVYAEDPYKSFGLPSI AUCAUGGAGGCCAU GRLSQYQEPLHLPGV CAAGAAGACCCGGGRVDSGIQPGSDISIYY CCCAGGCCGUGCAC DPMISKLITYGSDRTE CCCGGCUACGGCUUALKRMADALDNYVI CCUGAGCGAGAACA RGVTHNIALLREVIIN AGGAGUUCGCCCGGSRFVKGDISTKFLSDV UGCCUGGCCGCAGA YPDGFKGHMLTKSE GGACGUGGUGUUCAKNQLLAIASSLFVAF UCGGCCCCGACACC QLRAQHFQENSRMP CACGCCAUCCAGGCVIKPDIANWELSVKL CAUGGGCGACAAGA HDKVHTVVASNNGS UCGAGAGCAAGCUGVFSVEVDGSKLNVTS CUGGCCAAGAAGGC TWNLASPLLSVSVDG CGAGGUGAACACCATQRTVQCLSREAGGN UCCCCGGCUUCGAC MSIQFLGTVYKVNIL GGCGUGGUGAAGGATRLAAELNKFMLEK CGCCGAGGAAGCUG VTEDTSSVLRSPMPG UGCGGAUCGCCCGGVVVAVSVKPGDAVA GAGAUCGGCUACCC EGQEICVIEAMKMQN CGUGAUGAUCAAGGSMTAGKTGTVKSVH CCAGCGCCGGAGGC CQAGDTVGEGDLLV GGAGGCAAGGGCAU ELEGAGAAUCGCUUGGG ACGACGAGGAGACA AGAGACGGCUUUCG GCUGAGCAGCCAGGAGGCAGCGAGCAGC UUCGGCGACGACCG GCUGCUGAUCGAGA AGUUCAUCGACAACCCUCGGCACAUCGA GAUCCAGGUGCUGG GAGACAAGCACGGC AACGCCCUGUGGCUGAACGAGCGGGAGU GCAGCAUCCAGCGG CGGAACCAGAAGGU GGUGGAGGAGGCCCCUAGCAUCUUCCUG GACGCUGAAACCAG GAGAGCCAUGGGAG AGCAGGCCGUUGCCCUGGCCCGGGCCGU GAAGUACUCUAGCG CUGGCACCGUGGAG UUCCUGGUUGACUCUAAGAAGAACUUCU AUUUUCUGGAGAUG AACACCCGGCUGCA GGUGGAGCACCCCGUCACCGAGUGCAUC ACCGGCCUGGACCU GGUGCAGGAGAUGA UCCGCGUGGCUAAGGGCUACCCUCUGCG GCACAAGCAGGCUG ACAUCCGGAUCAAC GGCUGGGCCGUAGAGUGCCGUGUCUACG CCGAGGACCCCUAC AAGUCCUUCGGCCU GCCAUCCAUCGGCAGGCUGUCCCAGUAC CAGGAGCCCCUGCA CCUGCCCGGCGUGC GAGUGGAUAGCGGCAUUCAGCCCGGCAG CGACAUCAGCAUCU ACUACGACCCUAUG AUCUCCAAGCUAAUCACCUACGGCAGCG AUCGGACCGAGGCC CUGAAGAGAAUGGC UGACGCCCUGGACAACUACGUGAUCAGA GGCGUGACCCACAA CAUCGCCCUGCUGC GGGAGGUGAUCAUCAACAGCCGGUUCGU GAAGGGCGAUAUCA GCACCAAGUUUCUG UCCGACGUUUACCCCGACGGCUUCAAGG GCCACAUGCUGACC AAGAGCGAGAAGAA CCAGCUGCUCGCCAUCGCAAGCUCCCUG UUCGUGGCCUUCCA GCUGCGAGCACAGC ACUUCCAGGAGAAUAGUAGAAUGCCCGU GAUCAAGCCCGACA UCGCCAACUGGGAG CUGAGCGUGAAGCUGCACGACAAGGUGC ACACCGUUGUGGCU AGCAACAACGGUUC UGUGUUCAGCGUGGAGGUGGACGGUAGC AAACUGAACGUGAC CAGCACCUGGAACC UCGCCUCACCACUGCUCAGCGUGAGCGU GGACGGAACCCAGC GGACCGUGCAGUGC CUCAGCCGGGAAGCCGGCGGCAACAUGA GCAUUCAGUUUCUC GGCACUGUGUACAA GGUGAAUAUCCUGACCAGGCUGGCCGCU GAGCUGAACAAGUU CAUGCUGGAGAAGG UGACAGAGGACACUAGCAGCGUUCUGCG GAGCCCCAUGCCAG GGGUGGUGGUCGCC GUUAGCGUCAAGCCUGGCGACGCUGUGG CCGAGGGCCAGGAG AUCUGCGUGAUCGA GGCCAUGAAGAUGCAGAACAGCAUGACC GCCGGCAAGACUGG CACAGUGAAGUCAG UGCACUGCCAGGCCGGCGACACCGUGGG CGAGGGCGACCUGC UGGUGGAGCUGGAG SEQ ID NO:  1   7   3   4 31 PCCA_14 MAGFWVGTAPLVAA AUGGCCGGCUUCUG GGGAAA UGAUAA SEQ ID (hPCCA;GRRGRWPPQQLMLS GGUGGGCACCGCAC UAAGAG UAGGCU NO: 31 G5) AALRTLKHVLYYSRCCCUGGUGGCUGCU AGAAAA GGAGCC consists Cap: C1 QCLMVSRNLGSVGYGGGAGACGGGGACG GAAGAG UCGGUG from 5′ to PolyA tail: DPNEKTFDKILVANRGUGGCCUCCUCAGC UAAGAA GCCUAG 3′ end: 5′ 100 nt GEIACRVIRTCKKMGAGCUGAUGCUGAGC GAAAUA CUUCUU UTR of IKTVAIHSDVDASSV GCCGCCCUGCGGACUAAGAG GCCCCU SEQ ID HVKMADEAVCVGPA CCUGAAGCACGUGC CCACC UGGGCC NO: 3,PTSKSYLNMDAIMEA UGUACUACAGCCGG UCCCCC ORF IKKTRAQAVHPGYGF CAGUGCCUGAUGGUCAGCCC Sequence LSENKEFARCLAAED GAGCCGGAACCUGG CUCCUC of SEQ IDVFIGPDTHAIQAMG GCAGCGUGGGCUAC CCCUUC NO: 7, and DKIESKLLAKKAEVNGACCCCAACGAGAA CUGCAC 3′ UTR of TIPGFDGVVKDAEEA GACCUUCGACAAGA CCGUACSEQ ID VRIAREIGYPVMIKAS UCCUGGUCGCCAAC CCCCUC NO: 4 AGGGGKGMRIAWDDCGGGGCGAGAUCGC CAUAAA EETRDGFRLSSQEAA CUGCCGGGUGAUCC GUAGGASSFGDDRLLIEKFIDN GGACCUGCAAGAAG AACACU PRHIEIQVLGDKHGN AUGGGCAUCAAGACACAGUG ALWLNERECSIQRRN CGUGGCCAUCCACA GUCUUU QKVVEEAPSIFLDAEGCGACGUGGACGCC GAAUAA TRRAMGEQAVALAR AGCAGCGUGCACGU AGUCUGAVKYSSAGTVEFLVD GAAGAUGGCCGACG AGUGGG SKKNFYFLEMNTRLQ AGGCCGUGUGCGUGCGGC VEHPVTECITGLDLV GGCCCUGCGCCUAC QEMIRVAKGYPLRH CAGCAAGAGCUACCKQADIRINGWAVECR UGAACAUGGACGCU VYAEDPYKSFGLPSI AUCAUGGAGGCCAUGRLSQYQEPLHLPGV CAAGAAGACCCGGG RVDSGIQPGSDISIYY CCCAGGCCGUGCACDPMISKLITYGSDRTE CCCGGCUACGGCUU ALKRMADALDNYVI CCUGAGCGAGAACARGVTHNIALLREVIIN AGGAGUUCGCCCGG SRFVKGDISTKFLSDV UGCCUGGCAGCAGAYPDGFKGHMLTKSE GGACGUGGUGUUCA KNQLLAIASSLFVAF UCGGCCCCGACACCQLRAQHFQENSRMP CACGCCAUCCAGGC VIKPDIANWELSVKL CAUGGGAGACAAGAHDKVHTVVASNNGS UUGAGAGCAAGCUG VFSVEVDGSKLNVTS CUGGCCAAGAAGGCTWNLASPLLSVSVDG CGAGGUGAACACCA TQRTVQCLSREAGGN UCCCCGGCUUCGACMSIQFLGTVYKVNIL GGCGUGGUGAAGGA TRLAAELNKFMLEK CGCCGAAGAGGCCGVTEDTSSVLRSPMPG UCCGGAUCGCCCGG VVVAVSVKPGDAVA GAGAUCGGCUACCCEGQEICVIEAMKMQN CGUGAUGAUCAAGG SMTAGKTGTVKSVH CCUCCGCCGGUGGACQAGDTVGEGDLLV GGCGGCAAGGGCAU ELE GAGGAUCGCUUGGG ACGACGAGGAGACUAGAGACGGCUUUCG GCUGAGCAGCCAGG AGGCAGCCAGCUCA UUCGGCGACGACCGGCUGCUGAUCGAGA AGUUCAUCGACAAU CCACGGCACAUCGA GAUCCAGGUGCUGGGCGAUAAACACGGC AACGCCCUGUGGCU GAACGAGCGGGAGU GCAGCAUCCAGCGGCGGAACCAGAAGGU GGUGGAGGAGGCUC CUAGCAUCUUCCUU GACGCCGAGACACGCAGAGCUAUGGGCG AGCAGGCUGUGGCC CUGGCCCGGGCCGU GAAGUACUCCAGUGCUGGCACCGUGGAG UUCCUCGUGGACAG CAAGAAGAACUUCU ACUUCCUCGAGAUGAACACCCGGCUGCA GGUGGAGCACCCCG UCACCGAGUGCAUC ACCGGCCUGGACCUGGUGCAGGAGAUGA UCCGUGUGGCUAAG GGCUACCCUCUGCG GCACAAACAGGCCGACAUCCGGAUCAAC GGCUGGGCCGUCGA GUGCAGGGUGUACG CCGAGGACCCCUACAAGAGCUUCGGGCU GCCUAGCAUUGGCA GGCUCAGCCAGUAC CAGGAGCCCCUGCACCUGCCCGGCGUGA GGGUCGACUCUGGC AUACAGCCCGGCAG CGACAUCAGCAUCUAUUACGAUCCCAUG AUCAGCAAACUGAU CACCUACGGUAGCG ACCGGACCGAGGCUCUGAAGAGAAUGGC CGACGCCCUGGACA ACUACGUGAUACGG GGCGUGACCCACAACAUCGCCCUGCUGC GGGAGGUGAUCAUC AACAGCCGGUUCGU GAAGGGCGAUAUCUCUACCAAGUUCCUG UCCGACGUGUACCC CGACGGGUUUAAGG GCCACAUGCUGACCAAGAGUGAGAAGA ACCAACUGCUUGCC AUCGCAAGCAGCCU GUUCGUGGCCUUCCAGCUGCGAGCCCAG CACUUCCAGGAGAA CUCCCGGAUGCCCG UGAUCAAGCCCGACAUCGCCAACUGGGA GCUGAGCGUGAAGC UGCACGACAAGGUG CACACCGUGGUUGCCAGCAACAACGGCU CAGUGUUCAGCGUG GAGGUGGACGGCUC UAAGCUCAACGUGACCAGCACCUGGAAU CUGGCCAGCCCGCU GCUGUCUGUCAGCG UCGACGGCACCCAGCGGACCGUGCAGUG UCUGAGCCGGGAGG CCGGCGGUAACAUG AGCAUUCAGUUCCUGGGCACUGUGUACA AAGUGAACAUCCUG ACCCGCCUGGCUGC AGAGCUGAACAAGUUCAUGCUGGAGAAG GUGACCGAAGACAC AUCAAGCGUGCUGC GGAGCCCCAUGCCUGGCGUCGUGGUAGC CGUGUCCGUGAAGC CCGGCGACGCGGUU GCCGAGGGCCAGGAGAUCUGCGUGAUCG AGGCCAUGAAGAUG CAGAACAGCAUGAC CGCCGGCAAGACGGGAACCGUUAAGUCC GUCCACUGCCAGGC UGGCGAUACUGUGG GCGAGGGCGACCUGCUGGUGGAGCUGGA G SEQ ID NO:  1   8   3   4  32 PCCA_15 MAGFWVGTAPLVAAAUGGCCGGCUUCUG GGGAAA UGAUAA SEQ ID (hPCCA; GRRGRWPPQQLMLSGGUGGGCACCGCCC UAAGAG UAGGCU NO: 32 G5) AALRTLKHVLYYSR CACUGGUGGCUGCGAGAAAA GGAGCC consists Cap: C1 QCLMVSRNLGSVGY GGCAGGAGGGGCAG GAAGAGUCGGUG from 5′ to PolyA tail: DPNEKTFDKILVANR GUGGCCUCCUCAGC UAAGAAGCCUAG 3′ end: 5′ 100 nt GEIACRVIRTCKKMG AGCUGAUGCUGAGC GAAAUA CUUCUUUTR of IKTVAIHSDVDASSV GCCGCCCUCCGCAC UAAGAG GCCCCU SEQ IDHVKMADEAVCVGPA CCUCAAGCACGUCC CCACC UGGGCC NO: 3, PTSKSYLNMDAIMEAUCUACUACUCCCGC UCCCCC ORF IKKTRAQAVHPGYGF CAGUGCCUCAUGGU CAGCCC SequenceLSENKEFARCLAAED GUCCCGCAACCUCG CUCCUC of SEQ ID VVFIGPDTHAIQAMGGCUCCGUCGGCUAC CCCUUC NO: 8, and DKIESKLLAKKAEVN GACCCCAACGAGAA CUGCAC3′ UTR of TIPGFDGVVKDAEEA GACCUUCGACAAGA CCGUAC SEQ ID VRIAREIGYPVMIKASUCCUCGUCGCCAAC CCCCUC NO: 4 AGGGGKGMRIAWDD CGCGGCGAGAUCGC CAUAAAEETRDGFRLSSQEAA CUGCCGCGUCAUCC GUAGGA SSFGDDRLLIEKFIDN GCACCUGCAAGAAGAACACU PRHIEIQVLGDKHGN AUGGGCAUCAAGAC ACAGUG ALWLNERECSIQRRNCGUCGCCAUCCACU GUCUUU QKVVEEAPSIFLDAE CCGACGUCGACGCC GAAUAATRRAMGEQAVALAR UCCUCCGUCCACGU AGUCUG AVKYSSAGTVEFLVD CAAGAUGGCCGACGAGUGGG SKKNFYFLEMNTRLQ AGGCCGUCUGCGUU CGGC VEHPVTECITGLDLVGGACCCGCCCCUAC QEMIRVAKGYPLRH CUCCAAGUCCUACC KQADIRINGWAVECRUCAACAUGGACGCC VYAEDPYKSFGLPSI AUCAUGGAGGCCAU GRLSQYQEPLHLPGVCAAGAAGACCCGCG RVDSGIQPGSDISIYY CCCAGGCCGUCCAC DPMISKLITYGSDRTECCCGGCUACGGCUU ALKRMADALDNYVI CCUCUCCGAGAACA RGVTHNIALLREVIINAGGAGUUCGCCAGA SRFVKGDISTKFLSDV UGCCUGGCUGCCGA YPDGFKGHMLTKSEGGACGUCGUCUUCA KNQLLAIASSLFVAF UCGGCCCUGACACC QLRAQHFQENSRMPCACGCUAUCCAGGC VIKPDIANWELSVKL CAUGGGCGACAAGA HDKVHTVVASNNGSUAGAGUCCAAGCUC VFSVEVDGSKLNVTS CUCGCCAAGAAGGC TWNLASPLLSVSVDGCGAGGUCAACACCA TQRTVQCLSREAGGN UCCCCGGCUUCGAC MSIQFLGTVYKVNILGGCGUCGUCAAGGA TRLAAELNKFMLEK CGCGGAAGAGGCCG VTEDTSSVLRSPMPGUUCGCAUCGCCCGG VVVAVSVKPGDAVA GAAAUCGGCUACCC EGQEICVIEAMKMQNCGUCAUGAUCAAGG SMTAGKTGTVKSVH CCUCCGCCGGUGGA CQAGDTVGEGDLLVGGCGGCAAGGGCAU ELE GAGGAUUGCCUGGG ACGACGAGGAAACG AGAGACGGUUUCCGCCUCUCCUCCCAGG AAGCCGCAAGCUCA UUCGGCGACGAUAG ACUGCUGAUCGAGAAGUUCAUCGACAAU CCUCGCCACAUCGA GAUCCAGGUCCUCG GCGACAAACACGGCAACGCCCUCUGGCU CAACGAGCGCGAGU GCUCCAUCCAGCGC CGCAACCAGAAGGUCGUCGAGGAGGCAC CCUCCAUCUUCCUC GACGCCGAAACCAG GCGCGCCAUGGGUGAGCAGGCCGUGGCC CUGGCCCGAGCCGU CAAGUACAGCUCCG CUGGGACCGUCGAGUUUCUGGUUGACUC CAAGAAGAACUUCU ACUUCCUGGAGAUG AACACCCGCCUCCAGGUCGAGCAUCCUG UGACCGAGUGCAUC ACCGGCCUCGACCU CGUCCAGGAGAUGAUCCGAGUGGCCAAG GGAUACCCGCUCCG CCACAAGCAGGCUG ACAUCCGCAUCAACGGCUGGGCGGUUGA GUGUAGGGUGUACG CUGAAGACCCCUAC AAGUCUUUCGGCCUGCCCAGCAUCGGCA GACUGUCCCAGUAC CAGGAGCCCCUCCA CCUCCCCGGCGUGAGGGUGGACUCUGGC AUCCAGCCCGGCUC CGACAUCUCCAUCU AUUACGAUCCUAUGAUCUCAAAGCUGAU CACCUACGGUUCCG AUCGCACCGAGGCU CUGAAGCGCAUGGCUGACGCCCUCGACA ACUACGUAAUCAGA GGCGUCACCCACAA CAUCGCCCUCCUGAGAGAGGUCAUCAUC AACUCCCGCUUCGU GAAGGGUGAUAUCU CUACCAAGUUUCUGAGCGACGUGUACCC UGACGGGUUCAAGG GCCACAUGCUCACC AAGUCCGAGAAGAACCAGCUGCUGGCCA UAGCCAGCAGCCUC UUCGUCGCCUUCCA GCUGAGAGCCCAGCACUUCCAAGAGAAU UCUCGUAUGCCCGU CAUCAAGCCCGACA UCGCCAACUGGGAGCUCUCCGUCAAGCU CCACGACAAGGUCC ACACCGUGGUUGCA UCCAACAACGGCAGCGUGUUCUCCGUCG AGGUCGACGGAAGC AAGCUGAACGUCAC CUCUACCUGGAACCUCGCCUCUCCCCUU CUGUCUGUGAGCGU GGACGGCACCCAGC GCACCGUGCAGUGCCUGUCCCGCGAGGC UGGCGGCAACAUGU CCAUUCAAUUCCUG GGCACUGUGUACAAGGUGAACAUCCUGA CACGGCUCGCAGCC GAACUCAACAAGUU CAUGCUCGAGAAGGUGACCGAAGACACC AGCUCCGUGCUCCG CAGCCCUAUGCCCG GGGUGGUCGUGGCCGUGUCCGUCAAACC CGGCGACGCUGUGG CGGAGGGACAGGAG AUCUGCGUCAUCGAGGCCAUGAAGAUGC AGAACUCCAUGACG GCGGGGAAGACCGG AACAGUCAAGAGCGUGCAUUGCCAAGCC GGCGAUACCGUCGG CGAGGGCGACUUGC UGGUGGAGCUCGAG SEQ ID NO: 1   9   3   4  33 PCCA 16 MAGFWVGTAPLVAA AUGGCCGGCUUCUG GGGAAA UGAUAASEQ ID (hPCCA_; GRRGRWPPQQLMLS GGUGGGCACCGCGC UAAGAG UAGGCU NO: 33 G5)AALRTLKHVLYYSR CCCUGGUGGCCGCC AGAAAA GGAGCC consists Cap: C1QCLMVSRNLGSVGY GGCCGGCGGGGCCG GAAGAG UCGGUG from 5′ to PolyA tail:DPNEKTFDKILVANR GUGGCCACCCCAGC UAAGAA GCCUAG 3′ end: 5′ 100 ntGEIACRVIRTCKKMG AGCUGAUGCUGAGC GAAAUA CUUCUU UTR of IKTVAIHSDVDASSVGCCGCCCUGCGGAC UAAGAG GCCCCU SEQ ID HVKMADEAVCVGPA CCUGAAGCACGUGC CCACCUGGGCC NO: 3, PTSKSYLNMDAIMEA UGUACUACAGCCGG UCCCCC ORF IKKTRAQAVHPGYGFCAGUGCCUGAUGGU CAGCCC Sequence LSENKEFARCLAAED GAGCCGGAACCUGG CUCCUCof SEQ ID VVFIGPDTHAIQAMG GCAGCGUGGGCUAC CCCUUC NO: 9, andDKIESKLLAKKAEVN GACCCCAACGAGAA CUGCAC 3′ UTR of TIPGFDGVVKDAEEAGACCUUCGACAAGA CCGUAC SEQ ID VRIAREIGYPVMIKAS UCCUGGUGGCCAAC CCCCUCNO: 4 AGGGGKGMRIAWDD CGGGGCGAGAUCGC CAUAAA EETRDGFRLSSQEAACUGCCGGGUGAUCC GUAGGA SSFGDDRLLIEKFIDN GGACCUGCAAGAAG AACACUPRHIEIQVLGDKHGN AUGGGCAUCAAGAC ACAGUG ALWLNERECSIQRRN CGUGGCCAUCCACAGUCUUU QKVVEEAPSIFLDAE GCGACGUGGACGCC GAAUAA TRRAMGEQAVALARAGCAGCGUGCACGU AGUCUG AVKYSSAGTVEFLVD GAAGAUGGCCGACG AGUGGGSKKNFYFLEMNTRLQ AGGCCGUGUGCGUG CGGC VEHPVTECITGLDLV GGCCCCGCGCCCACQEMIRVAKGYPLRH CAGCAAGAGCUACC KQADIRINGWAVECR UGAACAUGGACGCCVYAEDPYKSFGLPSI AUCAUGGAGGCCAU GRLSQYQEPLHLPGV CAAGAAGACCCGGGRVDSGIQPGSDISIYY CCCAGGCCGUGCAC DPMISKLITYGSDRTE CCCGGCUACGGCUUALKRMADALDNYVI CCUGAGCGAGAACA RGVTHNIALLREVIIN AGGAGUUCGCCCGGSRFVKGDISTKFLSDV UGCCUGGCCGCCGA YPDGFKGHMLTKSE GGACGUGGUGUUCAKNQLLAIASSLFVAF UCGGCCCCGACACC QLRAQHFQENSRMP CACGCCAUCCAGGCVIKPDIANWELSVKL CAUGGGCGACAAGA HDKVHTVVASNNGS UCGAGAGCAAGCUGVFSVEVDGSKLNVTS CUGGCCAAGAAGGC TWNLASPLLSVSVDG CGAGGUGAACACCATQRTVQCLSREAGGN UCCCCGGCUUCGAC MSIQFLGTVYKVNIL GGCGUGGUGAAGGATRLAAELNKFMLEK CGCCGAGGAGGCCG VTEDTSSVLRSPMPG UGCGGAUCGCCCGGVVVAVSVKPGDAVA GAGAUCGGCUACCC EGQEICVIEAMKMQN CGUGAUGAUCAAGGSMTAGKTGTVKSVH CCAGCGCCGGCGGC CQAGDTVGEGDLLV GGCGGCAAGGGCAU ELEGCGGAUCGCCUGGG ACGACGAGGAGACC CGGGACGGCUUCCG GCUGAGCAGCCAGGAGGCCGCCAGCAGC UUCGGCGACGACCG GCUGCUGAUCGAGA AGUUCAUCGACAACCCACGGCACAUCGA GAUCCAGGUGCUGG GCGACAAGCACGGC AACGCCCUGUGGCUGAACGAGCGGGAGU GCAGCAUCCAGCGG CGGAACCAGAAGGU GGUGGAGGAGGCGCCCAGCAUCUUCCUG GACGCCGAGACCCG GCGGGCCAUGGGCG AGCAGGCCGUGGCCCUGGCCCGGGCCGU GAAGUACAGCAGCG CCGGCACCGUGGAG UUCCUGGUGGACAGCAAGAAGAACUUCU ACUUCCUGGAGAUG AACACCCGGCUGCA GGUGGAGCACCCCGUGACCGAGUGCAUC ACCGGCCUGGACCU GGUGCAGGAGAUGA UCCGGGUGGCCAAGGGCUACCCGCUGCG GCACAAGCAGGCCG ACAUCCGGAUCAAC GGCUGGGCCGUGGAGUGCCGGGUGUACG CCGAGGACCCCUAC AAGAGCUUCGGCCU GCCCAGCAUCGGCCGGCUGAGCCAGUAC CAGGAGCCCCUGCA CCUGCCCGGCGUGC GGGUGGACAGCGGCAUCCAGCCCGGCAG CGACAUCAGCAUCU ACUACGACCCCAUG AUCAGCAAGCUGAUCACCUACGGCAGCG ACCGGACCGAGGCC CUGAAGCGGAUGGC CGACGCCCUGGACAACUACGUGAUCCGG GGCGUGACCCACAA CAUCGCCCUGCUGC GGGAGGUGAUCAUCAACAGCCGGUUCGU GAAGGGCGACAUCA GCACCAAGUUCCUG AGCGACGUGUACCCCGACGGCUUCAAGG GCCACAUGCUGACC AAGAGCGAGAAGAA CCAGCUGCUGGCCAUCGCCAGCAGCCUG UUCGUGGCCUUCCA GCUGCGGGCCCAGC ACUUCCAGGAGAACAGCCGGAUGCCCGU GAUCAAGCCCGACA UCGCCAACUGGGAG CUGAGCGUGAAGCUGCACGACAAGGUGC ACACCGUGGUGGCC AGCAACAACGGCAG CGUGUUCAGCGUGGAGGUGGACGGCAGC AAGCUGAACGUGAC CAGCACCUGGAACC UGGCCAGCCCUCUGCUGAGCGUGAGCGU GGACGGCACCCAGC GGACCGUGCAGUGC CUGAGCCGGGAGGCCGGCGGCAACAUGA GCAUCCAGUUCCUG GGCACCGUGUACAA GGUGAACAUCCUGACCCGGCUGGCCGCC GAGCUGAACAAGUU CAUGCUGGAGAAGG UGACCGAGGACACCAGCAGCGUGCUGCG GAGCCCCAUGCCCG GCGUGGUGGUGGCC GUGAGCGUGAAGCCCGGCGACGCCGUGG CCGAGGGCCAGGAG AUCUGCGUGAUCGA GGCCAUGAAGAUGCAGAACAGCAUGACC GCCGGCAAGACCGG CACCGUGAAGAGCG UGCACUGCCAGGCCGGCGACACCGUGGG CGAGGGCGACCUGC UGGUGGAGCUGGAG SEQ ID NO:  1  10   3   4 34 PCCA_17 MAGFWVGTAPLVAA AUGGCCGGCUUCUG GGGAAA UGAUAA SEQ ID (hPCCA_;GRRGRWPPQQLMLS GGUCGGCACCGCCC UAAGAG UAGGCU NO: 34 G5) AALRTLKHVLYYSRCACUCGUGGCAGCC AGAAAA GGAGCC consists Cap: C1 QCLMVSRNLGSVGYGGCAGAAGAGGCCG GAAGAG UCGGUG from 5′ to PolyA tail: DPNEKTFDKILVANRGUGGCCUCCCCAGC UAAGAA GCCUAG 3′ end: 5′ 100 nt GEIACRVIRTCKKMGAGCUGAUGCUGAGC GAAAUA CUUCUU UTR of IKTVAIHSDVDASSV GCCGCCCUGAGAACUAAGAG GCCCCU SEQ ID HVKMADEAVCVGPA CCUGAAGCACGUGC CCACC UGGGCC NO: 3,PTSKSYLNMDAIMEA UGUACUACAGCAGA UCCCCC ORF IKKTRAQAVHPGYGF CAGUGCCUGAUGGUCAGCCC Sequence LSENKEFARCLAAED GAGCAGAAAUCUGG CUCCUC of SEQ IDVVFIGPDTHAIQAMG GAUCUGUCGGGUAC CCCUUC NO: 10, DKIESKLLAKKAEVNGACCCCAACGAGAA CUGCAC and 3′ TIPGFDGVVKDAEEA GACCUUCGACAAGA CCGUACUTR of VRIAREIGYPVMIKAS UCCUGGUGGCCAAC CCCCUC SEQ ID AGGGGKGMRIAWDDAGAGGCGAGAUCGC CAUAAA NO: 4 EETRDGFRLSSQEAA CUGCAGAGUGAUCA GUAGGASSFGDDRLLIEKFIDN GAACCUGCAAGAAG AACACU PRHIEIQVLGDKHGN AUGGGCAUCAAGACACAGUG ALWLNERECSIQRRN CGUGGCCAUCCACA GUCUUU QKVVEEAPSIFLDAEGCGACGUGGACGCG GAAUAA TRRAMGEQAVALAR UCCAGCGUGCACGU AGUCUGAVKYSSAGTVEFLVD GAAGAUGGCCGACG AGUGGG SKKNFYFLEMNTRLQ AGGCCGUGUGCGUACGGC VEHPVTECITGLDLV GGCCCCGCUCCCAC QEMIRVAKGYPLRH CAGCAAGAGCUACCKQADIRINGWAVECR UGAACAUGGACGCC VYAEDPYKSFGLPSI AUCAUGGAGGCCAUGRLSQYQEPLHLPGV CAAGAAGACCAGAG RVDSGIQPGSDISIYY CCCAGGCUGUGCAUDPMISKLITYGSDRTE CCCGGCUACGGCUU ALKRMADALDNYVI CCUGAGCGAGAACARGVTHNIALLREVIIN AGGAGUUCGCCAGG SRFVKGDISTKFLSDV UGUCUGGCUGCCGAYPDGFKGHMLTKSE AGACGUCGUGUUCA KNQLLAIASSLFVAF UCGGCCCCGACACCQLRAQHFQENSRMP CACGCGAUCCAGGC VIKPDIANWELSVKL CAUGGGUGAUAAGAHDKVHTVVASNNGS UCGAGAGCAAACUG VFSVEVDGSKLNVTS CUGGCCAAGAAGGCTWNLASPLLSVSVDG CGAGGUGAACACCA TQRTVQCLSREAGGN UCCCCGGCUUCGACMSIQFLGTVYKVNIL GGCGUGGUGAAAGA TRLAAELNKFMLEK CGCCGAGGAGGCAGVTEDTSSVLRSPMPG UGAGAAUCGCCAGA VVVAVSVKPGDAVA GAGAUCGGCUACCCEGQEICVIEAMKMQN CGUGAUGAUCAAGG SMTAGKTGTVKSVH CCAGCGCAGGUGGCCQAGDTVGEGDLLV GGAGGCAAGGGCAU ELE GAGGAUUGCCUGGG ACGACGAAGAGACGAGGGACGGGUUCCG ACUGAGCAGCCAGG AGGCCGCCAGCUCC UUCGGCGACGACAGACUGCUGAUCGAGA AGUUCAUCGACAAC CCCAGACACAUCGA GAUACAGGUGCUCGGAGACAAGCACGGC AACGCCCUGUGGCU GAACGAGAGAGAGU GCAGCAUCCAGAGAAGAAACCAGAAGGU GGUGGAGGAGGCCC CAUCAAUCUUCCUC GACGCCGAAACCAGACGGGCCAUGGGAG AGCAAGCCGUGGCA CUGGCUAGGGCCGU GAAGUACAGCUCCGCCGGAACCGUGGAG UUUCUGGUCGACUC CAAGAAGAACUUCU ACUUCCUGGAGAUGAAUACCCGUCUGCA GGUGGAGCACCCCG UGACCGAGUGCAUC ACCGGUCUGGACCUGGUGCAGGAGAUGA UCAGAGUGGCCAAG GGCUACCCUCUGAG ACACAAGCAGGCCGACAUCAGAAUCAAC GGCUGGGCCGUGGA GUGCAGAGUGUACG CCGAGGACCCCUACAAGAGCUUCGGCCU GCCCAGCAUCGGCA GACUGAGCCAGUAC CAGGAGCCCCUGCACCUGCCCGGCGUGA GAGUGGACAGCGGC AUCCAGCCCGGCUC UGACAUCUCCAUAUACUACGACCCCAUG AUCAGCAAGCUCAU CACCUACGGCAGCG ACAGAACCGAGGCCCUGAAGAGAAUGGC CGACGCCCUGGACA ACUACGUGAUCAGA GGCGUGACCCACAACAUCGCCCUGCUGA GAGAGGUGAUCAUC AACAGCAGAUUCGU GAAGGGCGACAUCAGCACCAAGUUCCUG AGCGACGUGUACCC CGACGGCUUCAAGG GCCACAUGCUGACCAAGAGCGAGAAGAA CCAGCUUCUGGCAA UCGCCUCCAGCCUG UUCGUGGCCUUCCAGCUGAGAGCCCAGC ACUUCCAGGAGAAC AGCAGAAUGCCCGU GAUCAAGCCCGACAUCGCCAACUGGGAG CUGAGCGUGAAGCU GCACGACAAGGUCC AUACGGUGGUCGCCAGCAACAACGGCAG CGUGUUCAGCGUGG AGGUGGACGGCAGC AAGCUGAACGUGACCAGCACCUGGAACC UCGCCUCACCCCUC CUGAGCGUCAGCGU CGACGGCACCCAGAGAACCGUGCAGUGU CUGAGCAGAGAGGC AGGCGGCAACAUGA GCAUCCAGUUCCUGGGCACCGUGUACAA GGUGAACAUCCUGA CCAGACUGGCCGCC GAGCUGAACAAGUUCAUGCUGGAGAAGG UGACCGAGGACACC AGCAGCGUGCUGAG AAGCCCCAUGCCCGGAGUGGUGGUGGCC GUGAGCGUGAAACC GGGUGACGCAGUGG CCGAGGGCCAGGAGAUCUGCGUGAUCGA GGCCAUGAAGAUGC AGAACAGCAUGACG GCCGGAAAGACCGGCACCGUGAAGUCCG UGCACUGCCAAGCC GGCGAUACCGUGGG CGAGGGCGACCUCCUCGUCGAGCUGGAG SEQ ID NO:  1  11   3   4  35 PCCA_18 MAGFWVGTAPLVAAAUGGCCGGCUUCUG GGGAAA UGAUAA SEQ ID (hPCCA_; GRRGRWPPQQLMLSGGUCGGCACAGCCC UAAGAG UAGGCU NO: 35 G5) AALRTLKHVLYYSR CUCUGGUGGCAGCCAGAAAA GGAGCC consists Cap: C1 QCLMVSRNLGSVGY GGCAGAAGAGGACG GAAGAGUCGGUG from 5′ to PolyA tail: DPNEKTFDKILVANR GUGGCCUCCCCAGC UAAGAAGCCUAG 3′ end: 5′ 100 nt GEIACRVIRTCKKMG AACUGAUGCUGAGC GAAAUA CUUCUUUTR of IKTVAIHSDVDASSV GCCGCCCUGAGAAC UAAGAG GCCCCU SEQ IDHVKMADEAVCVGPA CCUGAAGCACGUGC CCACC UGGGCC NO: 3, PTSKSYLNMDAIMEAUGUACUACAGCAGA UCCCCC ORF IKKTRAQAVHPGYGF CAGUGCCUGAUGGU CAGCCC SequenceLSENKEFARCLAAED GAGCAGAAAUCUGG CUCCUC of SEQ ID VVFIGPDTHAIQAMGGCAGCGUGGGGUAC CCCUUC NO: 11, DKIESKLLAKKAEVN GAUCCCAACGAGAA CUGCACand 3′ TIPGFDGVVKDAEEA GACCUUCGAUAAGA CCGUAC UTR of VRIAREIGYPVMIKASUUCUGGUCGCGAAU CCCCUC SEQ ID AGGGGKGMRIAWDD AGAGGCGAGAUCGC CAUAAA NO: 4EETRDGFRLSSQEAA CUGCAGGGUGAUCA GUAGGA SSFGDDRLLIEKFIDN GAACCUGCAAGAAGAACACU PRHIEIQVLGDKHGN AUGGGCAUCAAGAC ACAGUG ALWLNERECSIQRRNCGUGGCCAUCCAUU GUCUUU QKVVEEAPSIFLDAE CGGACGUCGACGCG GAAUAATRRAMGEQAVALAR AGCAGCGUUCACGU AGUCUG AVKYSSAGTVEFLVD GAAGAUGGCAGACGAGUGGG SKKNFYFLEMNTRLQ AGGCCGUGUGCGUG CGGC VEHPVTECITGLDLVGGACCCGCCCCGAC QEMIRVAKGYPLRH CAGCAAGAGCUACC KQADIRINGWAVECRUGAACAUGGACGCC VYAEDPYKSFGLPSI AUCAUGGAGGCCAU GRLSQYQEPLHLPGVCAAGAAGACCCGCG RVDSGIQPGSDISIYY CUCAAGCCGUGCAC DPMISKLITYGSDRTECCGGGCUACGGCUU ALKRMADALDNYVI UCUGAGCGAGAACA RGVTHNIALLREVIINAGGAAUUCGCCAGG SRFVKGDISTKFLSDV UGUCUCGCCGCCGA YPDGFKGHMLTKSEGGACGUAGUCUUCA KNQLLAIASSLFVAF UCGGCCCUGAUACG QLRAQHFQENSRMPCACGCGAUCCAGGC VIKPDIANWELSVKL CAUGGGCGACAAGA HDKVHTVVASNNGSUCGAGAGCAAACUG VFSVEVDGSKLNVTS CUGGCCAAGAAAGC TWNLASPLLSVSVDGAGAAGUCAACACCA TQRTVQCLSREAGGN UCCCCGGCUUCGAC MSIQFLGTVYKVNILGGCGUGGUGAAGGA TRLAAELNKFMLEK CGCCGAAGAGGCUG VTEDTSSVLRSPMPGUCCGCAUCGCCAGA VVVAVSVKPGDAVA GAGAUCGGCUACCC EGQEICVIEAMKMQNUGUGAUGAUAAAG SMTAGKTGTVKSVH GCUAGCGCUGGAGG CQAGDTVGEGDLLVUGGCGGAAAGGGCA ELE UGAGAAUCGCCUGG GACGACGAGGAGAC UAGAGACGGCUUCAGACUGUCCUCCCAG GAGGCCGCCAGCUC CUUCGGAGACGACA GACUGCUGAUCGAGAAGUUCAUCGACAA CCCCAGACACAUCG AAAUCCAGGUGCUC GGUGACAAGCACGGGAACGCCCUGUGGC UGAACGAGAGAGAG UGCAGCAUCCAGAG AAGAAACCAGAAGGUGGUGGAGGAGGCG CCGAGCAUCUUUCU GGACGCGGAGACAA GGAGAGCGAUGGGCGAACAGGCCGUCGC CCUAGCAAGAGCCG UGAAGUACUCCAGU GCCGGAACCGUCGAGUUUCUUGUCGACA GCAAGAAGAAUUUC UACUUCCUGGAGAU GAACACCAGGCUGCAGGUGGAGCAUCCC GUGACAGAGUGCAU CACUGGACUGGAUC UGGUGCAGGAGAUGAUCAGGGUGGCCAA GGGCUAUCCCCUGA GACACAAGCAGGCC GACAUCAGAAUCAACGGCUGGGCCGUGG AGUGCAGAGUGUAC GCCGAGGACCCCUA CAAGAGCUUCGGCCUGCCCAGCAUCGGC AGACUGAGCCAGUA CCAGGAGCCCCUGC ACCUGCCCGGCGUGAGAGUGGACAGCGG CAUCCAACCGGGGA GCGAUAUCAGCAUC UACUACGACCCCAUGAUCAGCAAGCUGA UAACCUACGGCAGC GACAGAACCGAGGC CCUGAAGAGAAUGGCCGACGCCCUGGAC AACUACGUGAUCAG AGGCGUGACCCACA ACAUCGCCCUGCUGAGAGAGGUGAUCAU CAACUCGAGGUUCG UGAAAGGCGACAUC AGCACCAAGUUCCUGAGCGACGUGUAUC CCGACGGAUUCAAA GGUCACAUGCUGAC CAAGAGCGAGAAGAACCAGCUGCUGGCC AUCGCCUCAUCCCU GUUCGUGGCCUUCC AGCUGAGAGCCCAGCACUUCCAGGAGAA CAGCAGAAUGCCCG UGAUCAAGCCCGAC AUCGCCAACUGGGAGCUGAGCGUGAAGC UGCACGACAAGGUG CACACUGUCGUUGC CAGCAACAACGGCUCCGUGUUCAGCGUA GAGGUGGACGGAUC UAAGCUGAACGUGA CCUCCACCUGGAACCUGGCAAGCCCUCU CCUGUCAGUGAGCG UGGACGGCACCCAG AGAACCGUGCAGUGUCUGUCCCGCGAGG CCGGCGGAAACAUG AGCAUCCAGUUCCU GGGCACCGUGUACAAGGUGAACAUCCUG ACCAGACUGGCCGC CGAGCUGAACAAGU UCAUGCUGGAGAAAGUGACGGAGGAUAC CAGCUCCGUGCUGA GAAGCCCCAUGCCC GGAGUGGUGGUGGCCGUUUCCGUGAAAC CUGGUGACGCCGUG GCCGAGGGGCAAGA GAUCUGCGUGAUCGAGGCCAUGAAGAUG CAGAAUUCCAUGAC CGCCGGAAAGACCG GCACCGUCAAAUCAGUGCACUGCCAGGC GGGCGACACAGUGG GUGAGGGCGACCUG CUGGUGGAGCUGGA G SEQ ID NO: 1  12   3   4  36 PCCA_19 MAGFWVGTAPLVAA AUGGCCGGGUUCUG GGGAAA UGAUAASEQ ID (hPCCA_; GRRGRWPPQQLMLS GGUGGGGACCGCCC UAAGAG UAGGCU NO: 36 G5)AALRTLKHVLYYSR CACUCGUGGCCGCC AGAAAA GGAGCC consists Cap: C1QCLMVSRNLGSVGY GGGAGGAGAGGGA GAAGAG UCGGUG from 5′ to PolyA tail:DPNEKTFDKILVANR GGUGGCCACCGCAA UAAGAA GCCUAG 3′ end: 5′ 100 ntGEIACRVIRTCKKMG CAACUAAUGCUAAG GAAAUA CUUCUU UTR of IKTVAIHSDVDASSVCGCCGCCCUACGGA UAAGAG GCCCCU SEQ ID HVKMADEAVCVGPA CCCUAAAGCACGUA CCACCUGGGCC NO: 3, PTSKSYLNMDAIMEA CUAUACUACAGCAG UCCCCC ORF IKKTRAQAVHPGYGFGCAGUGCCUAAUGG CAGCCC Sequence LSENKEFARCLAAED UGAGCAGGAACCUA CUCCUCof SEQ ID VVFIGPDTHAIQAMG GGGAGCGUGGGGUA CCCUUC NO: 12, DKIESKLLAKKAEVNCGAUCCAAACGAGA CUGCAC and 3′ TIPGFDGVVKDAEEA AGACCUUCGAUAAG CCGUACUTR of VRIAREIGYPVMIKAS AUACUAGUGGCCAA CCCCUC SEQ ID AGGGGKGMRIAWDDUAGAGGGGAGAUCG CAUAAA NO: 4 EETRDGFRLSSQEAA CCUGCAGAGUGAUA GUAGGASSFGDDRLLIEKFIDN AGGACCUGCAAGAA AACACU PRHIEIQVLGDKHGN GAUGGGGAUCAAGAACAGUG ALWLNERECSIQRRN CCGUGGCCAUACAC GUCUUU QKVVEEAPSIFLDAEAGCGACGUGGACGC GAAUAA TRRAMGEQAVALAR CAGCAGCGUGCACG AGUCUGAVKYSSAGTVEFLVD UGAAGAUGGCCGAC AGUGGG SKKNFYFLEMNTRLQ GAGGCCGUGUGUGUCGGC VEHPVTECITGLDLV GGGGCCAGCCCCAA QEMIRVAKGYPLRH CCAGCAAGAGCUACKQADIRINGWAVECR CUAAACAUGGACGC VYAEDPYKSFGLPSI GAUAAUGGAGGCAAGRLSQYQEPLHLPGV UCAAGAAGACCAGA RVDSGIQPGSDISIYY GCGCAAGCCGUGCADPMISKLITYGSDRTE CCCUGGGUACGGGU ALKRMADALDNYVI UCCUAUCCGAGAACRGVTHNIALLREVIIN AAGGAGUUCGCCAG SRFVKGDISTKFLSDV GUGCCUAGCCGCGGYPDGFKGHMLTKSE AGGACGUGGUUUUC KNQLLAIASSLFVAF AUAGGGCCAGAUACQLRAQHFQENSRMP GCACGCCAUCCAAG VIKPDIANWELSVKL CCAUGGGAGAUAAGHDKVHTVVASNNGS AUCGAGAGCAAGCU VFSVEVDGSKLNVTS ACUAGCCAAGAAGGTWNLASPLLSVSVDG CCGAGGUGAACACC TQRTVQCLSREAGGN AUACCAGGGUUCGAMSIQFLGTVYKVNIL CGGGGUGGUGAAGG TRLAAELNKFMLEK ACGCCGAGGAGGCCVTEDTSSVLRSPMPG GUGAGGAUUGCCAG VVVAVSVKPGDAVA GGAGAUAGGGUACCEGQEICVIEAMKMQN CAGUGAUGAUAAAG SMTAGKTGTVKSVH GCCUCUGCCGGUGGCQAGDTVGEGDLLV AGGAGGGAAGGGG ELE AUGCGGAUAGCCUG GGACGACGAGGAGACGAGGGACGGCUUC AGGCUAAGCAGCCA AGAGGCCGCCUCUA GCUUCGGGGACGAUAGGCUACUAAUAGA GAAGUUCAUAGAUA ACCCAAGGCACAUA GAGAUACAAGUACUAGGGGAUAAACACG GUAACGCCCUGUGG CUCAACGAGAGAGA GUGCAGCAUACAAAGGAGGAACCAGAAG GUGGUUGAGGAGGC GCCAAGCAUCUUCC UAGACGCCGAGACACGGAGGGCGAUGGG AGAACAGGCCGUGG CCCUAGCCAGGGCC GUUAAGUACUCAAGCGCAGGGACCGUGG AGUUCCUAGUGGAU AGCAAGAAGAACUU CUACUUCCUCGAGAUGAAUACCAGGCUA CAAGUGGAGCACCC AGUAACCGAGUGCA UCACGGGGCUCGAUCUAGUGCAAGAGAU GAUAAGGGUGGCCA AGGGGUAUCCACUA AGGCACAAGCAAGCGGAUAUAAGGAUA AACGGGUGGGCCGU UGAGUGCAGGGUGU ACGCCGAGGAUCCCUACAAGUCCUUCGG GCUACCAAGCAUAG GGAGGCUAUCUCAA UACCAAGAGCCACUACACCUACCAGGGG UGAGGGUUGAUAGC GGGAUCCAACCAGG GUCUGAUAUAAGCAUCUACUACGAUCCC AUGAUAUCUAAGCU AAUAACCUACGGGA GCGACAGGACGGAGGCCCUAAAGAGGAU GGCGGACGCCCUAG AUAACUACGUGAUA CGCGGGGUGACCCACAACAUUGCCCUAC UAAGGGAGGUGAUC AUAAAUUCUAGGUU CGUGAAGGGAGAUAUAUCAACGAAGUUU CUAAGCGACGUUUA CCCAGACGGGUUCA AGGGGCACAUGCUAACCAAGAGCGAGAA GAAUCAACUGCUCG CCAUCGCCUCAUCA CUAUUCGUGGCCUUCCAACUAAGGGCCC AACACUUCCAAGAG AAUAGCCGGAUGCC UGUGAUAAAGCCAGAUAUAGCCAAUUGG GAACUAAGCGUGAA GCUCCACGAUAAGG UGCACACCGUGGUGGCCAGCAACAACGG AUCUGUGUUCAGCG UGGAGGUGGACGGU AGCAAGCUCAACGUGACCAGCACCUGGA AUCUAGCCAGCCCA CUACUGAGCGUCAG CGUUGACGGGACCCAAAGGACCGUGCAG UGCUUGAGCAGGGA GGCCGGAGGGAAUA UGUCCAUUCAAUUCCUAGGGACGGUCUA CAAGGUAAACAUAC UAACCCGACUAGCC GCCGAGCUCAACAAGUUCAUGCUAGAGA AGGUGACCGAGGAU ACGUCUAGCGUGCU ACGUAGCCCAAUGCCAGGAGUGGUAGUU GCCGUGUCAGUGAA GCCAGGGGACGCCG UAGCCGAGGGACAAGAGAUCUGCGUGAU CGAGGCCAUGAAGA UGCAGAAUAGCAUG ACCGCAGGGAAGACGGGGACGGUGAAGU CUGUUCACUGCCAA GCCGGGGAUACCGU AGGGGAGGGAGAUCUACUCGUGGAGCUA GAG SEQ ID NO:  1  13   3   4  37 PCCA_20 MAGFWVGTAPLVAAAUGGCCGGCUUCUG GGGAAA UGAUAA SEQ ID (hPCCA_; GRRGRWPPQQLMLSGGUGGGCACCGCGC UAAGAG UAGGCU NO: 37 G5) AALRTLKHVLYYSR CCCUGGUGGCCGCCAGAAAA GGAGCC consists QCLMVSRNLGSVGY GGCAGAAGAGGCAG GAAGAG UCGGUGfrom 5′ to DPNEKTFDKILVANR GUGGCCGCCCCAGC UAAGAA GCCUAG 3′ end: 5′GEIACRVIRTCKKMG AGCUGAUGCUGAGC GAAAUA CUUCUU UTR of IKTVAIHSDVDASSVGCCGCCCUGAGAAC UAAGAG GCCCCU SEQ ID HVKMADEAVCVGPA CCUGAAGCACGUGC CCACCUGGGCC NO: 3, PTSKSYLNMDAIMEA UGUACUACAGCAGA UCCCCC ORF IKKTRAQAVHPGYGFCAGUGCCUGAUGGU CAGCCC Sequence LSENKEFARCLAAED GAGCAGAAACCUGG CUCCUCof SEQ ID VVFIGPDTHAIQAMG GCAGCGUGGGCUAC CCCUUC NO: 13, DKIESKLLAKKAEVNGACCCCAACGAGAA CUGCAC and 3′ TIPGFDGVVKDAEEA GACCUUCGACAAGA CCGUACUTR of VRIAREIGYPVMIKAS UCCUGGUGGCCAAC CCCCUC SEQ ID AGGGGKGMRIAWDDAGAGGCGAGAUCGC CAUAAA NO: 4 EETRDGFRLSSQEAA CUGCAGAGUGAUCA GUAGGASSFGDDRLLIEKFIDN GAACCUGCAAGAAG AACACU PRHIEIQVLGDKHGN AUGGGCAUCAAGACACAGUG ALWLNERECSIQRRN CGUGGCCAUCCACA GUCUUU QKVVEEAPSIFLDAEGCGACGUGGACGCC GAAUAA TRRAMGEQAVALAR AGCAGCGUGCACGU AGUCUGAVKYSSAGTVEFLVD GAAGAUGGCCGACG AGUGGG SKKNFYFLEMNTRLQ AGGCCGUGUGCGUGCGGC VEHPVTECITGLDLV GGCCCCGCGCCCAC QEMIRVAKGYPLRH CAGCAAGAGCUACCKQADIRINGWAVECR UGAACAUGGACGCC VYAEDPYKSFGLPSI AUCAUGGAGGCCAUGRLSQYQEPLHLPGV CAAGAAGACCAGAG RVDSGIQPGSDISIYY CCCAGGCCGUGCACDPMISKLITYGSDRTE CCCGGCUACGGCUU ALKRMADALDNYVI CCUGAGCGAGAACARGVTHNIALLREVIIN AGGAGUUCGCCAGG SRFVKGDISTKFLSDV UGCCUGGCCGCCGAYPDGFKGHMLTKSE GGACGUGGUGUUCA KNQLLAIASSLFVAF UCGGCCCCGACACCQLRAQHFQENSRMP CACGCCAUCCAGGC VIKPDIANWELSVKL CAUGGGCGACAAGAHDKVHTVVASNNGS UCGAGAGCAAGCUG VFSVEVDGSKLNVTS CUGGCCAAGAAGGCTWNLASPLLSVSVDG CGAGGUGAACACCA TQRTVQCLSREAGGN UCCCCGGCUUCGACMSIQFLGTVYKVNIL GGCGUGGUGAAGGA TRLAAELNKFMLEK CGCCGAGGAGGCCGVTEDTSSVLRSPMPG UGAGAAUCGCCAGA VVVAVSVKPGDAVA GAGAUCGGCUACCCEGQEICVIEAMKMQN CGUGAUGAUCAAGG SMTAGKTGTVKSVH CCAGCGCCGGCGGCCQAGDTVGEGDLLV GGCGGCAAGGGCAU ELE GAGAAUCGCCUGGG ACGACGAGGAGACCAGAGACGGCUUCAG ACUGAGCAGCCAGG AGGCCGCCAGCAGC UUCGGCGACGACAGACUGCUGAUCGAGA AGUUCAUCGACAAC CCCAGACACAUCGA GAUCCAGGUGCUGGGCGACAAGCACGGC AACGCCCUGUGGCU GAACGAGAGAGAGU GCAGCAUCCAGAGAAGAAACCAGAAGGU GGUGGAGGAGGCGC CCAGCAUCUUCCUG GACGCCGAGACCAGAAGAGCCAUGGGCG AGCAGGCCGUGGCC CUGGCCAGAGCCGU GAAGUACAGCAGCGCCGGCACCGUGGAG UUCCUGGUGGACAG CAAGAAGAACUUCU ACUUCCUGGAGAUGAACACCAGACUGCA GGUGGAGCACCCCG UGACCGAGUGCAUC ACCGGCCUGGACCUGGUGCAGGAGAUGA UCAGAGUGGCCAAG GGCUACCCACUGAG ACACAAGCAGGCCGACAUCAGAAUCAAC GGCUGGGCCGUGGA GUGCAGAGUGUACG CCGAGGACCCCUACAAGAGCUUCGGCCU GCCCAGCAUCGGCA GACUGAGCCAGUAC CAAGAACCGUUACAUCUACCUGGUGUCC GAGUGGACAGCGGC AUCCAGCCCGGCAG CGACAUCAGCAUCUACUACGACCCCAUG AUCAGCAAGCUGAU CACCUACGGCAGCG ACAGAACCGAGGCCCUGAAGAGAAUGGC CGACGCCCUGGACA ACUACGUGAUCAGA GGCGUGACCCACAACAUCGCCCUGCUGA GAGAGGUGAUCAUC AACAGCAGAUUCGU GAAGGGCGACAUCAGCACCAAGUUCCUG AGCGACGUGUACCC CGACGGCUUCAAGG GCCACAUGCUGACCAAGAGCGAGAAGAA CCAGCUGCUGGCCA UCGCCAGCAGCCUG UUCGUGGCCUUCCAGCUGAGAGCCCAGC ACUUCCAGGAGAAC AGCAGAAUGCCCGU GAUCAAGCCCGACAUCGCCAACUGGGAG CUGAGCGUGAAGCU GCACGACAAGGUGC ACACCGUGGUGGCCAGCAACAACGGCAG CGUGUUCAGCGUGG AGGUGGACGGCAGC AAGCUGAACGUGACCAGCACCUGGAACC UGGCCAGCCCACUG CUGAGCGUGAGCGU GGACGGCACCCAGAGAACCGUGCAGUGC CUGAGCAGAGAGGC CGGCGGCAACAUGA GCAUCCAGUUCCUGGGCACCGUGUACAA GGUGAACAUCCUGA CCAGACUGGCCGCC GAGCUGAACAAGUUCAUGCUGGAGAAGG UGACCGAGGACACC AGCAGCGUGCUGAG AAGCCCCAUGCCCGGCGUGGUGGUGGCC GUGAGCGUGAAGCC CGGCGACGCCGUGG CCGAGGGCCAGGAGAUCUGCGUGAUCGA GGCCAUGAAGAUGC AGAACAGCAUGACC GCCGGCAAGACCGGCACCGUGAAGAGCG UGCACUGCCAGGCC GGCGACACCGUGGG CGAGGGCGACCUGCUGGUGGAGCUGGAG SEQ ID NO:  1  14   3 150  38 PCCA_-014 MAGFWVGTAPLVAAAUGGCAGGCUUCUG GGGAAA UGAUAA SEQ ID (hPCCA_; GRRGRWPPQQLMLSGGUUGGCACUGCCC UAAGAG UAGGCU NO: 38 G5) AALRTLKHVLYYSR CACUCGUGGCCGCCAGAAAA GGAGCC consists Cap: C1 QCLMVSRNLGSVGY GGCAGAAGGGGAAG GAAGAGUCGGUG from 5′ to PolyA tail: DPNEKTFDKILVANR GUGGCCUCCCCAGC UAAGAAGCCAUG 3′ end: 5′ 100 nt GEIACRVIRTCKKMG AGCUCAUGCUGUCC GAAAUA CUUCUUUTR of IKTVAIHSDVDASSV GCCGCUCUGCGAAC UAAGAG GCCCCU SEQ IDHVKMADEAVCVGPA CCUGAAGCACGUGC CCACC UGGGCC NO: 3, PTSKSYLNMDAIMEAUGUAUUAUAGCAGG UCCCCC ORF IKKTRAQAVHPGYGF CAGUGCCUCAUGGU CAGCCC SequenceLSENKEFARCLAAED UUCCCGGAACCUGG CUCCUC of SEQ ID VVFIGPDTHAIQAMGGGAGCGUGGGCUAU CCCUUC NO: 14, DKIESKLLAKKAEVN GACCCUAAUGAGAA CUGCACand 3′ TIPGFDGVVKDAEEA GACUUUCGACAAGA CCGUAC UTR of VRIAREIGYPVMIKASUCCUGGUCGCUAAC CCCCGU SEQ ID AGGGGKGMRIAWDD AGAGGCGAGAUCGC GGUCUUNO: 150 EETRDGFRLSSQEAA CUGCAGGGUGAUCA UGAAUA SSFGDDRLLIEKFIDNGAACAUGCAAGAAG AAGUCU PRHIEIQVLGDKHGN AUGGGCAUCAAGAC GAGUGGALWLNERECSIQRRN CGUCGCGAUCCAUA GCGGC QKVVEEAPSIFLDAE GCGACGUGGAUGCCTRRAMGEQAVALAR AGCAGCGUUCACGU AVKYSSAGTVEFLVD CAAGAUGGCCGACGSKKNFYFLEMNTRLQ AGGCUGUGUGCGUC VEHPVTECITGLDLV GGCCCCGCCCCAACQEMIRVAKGYPLRH UUCCAAGAGCUAUC KQADIRINGWAVECR UGAACAUGGACGCCVYAEDPYKSFGLPSI AUAAUGGAGGCUAU GRLSQYQEPLHLPGV CAAGAAGACCAGAGRVDSGIQPGSDISIYY CCCAGGCAGUUCAU DPMISKLITYGSDRTE CCCGGCUACGGAUUALKRMADALDNYVI CCUGAGCGAGAACA RGVTHNIALLREVIIN AGGAGUUCGCUAGASRFVKGDISTKFLSDV UGUCUGGCCGCCGA YPDGFKGHMLTKSE AGACGUGGUUUUCAKNQLLAIASSLFVAF UCGGUCCAGACACC QLRAQHFQENSRMP CAUGCCAUCCAAGCVIKPDIANWELSVKL CAUGGGCGAUAAGA HDKVHTVVASNNGS UCGAGAGCAAGCUCVFSVEVDGSKLNVTS CUGGCCAAGAAGGC TWNLASPLLSVSVDG CGAGGUGAACACCATQRTVQCLSREAGGN UCCCCGGCUUCGAU MSIQFLGTVYKVNIL GGCGUGGUGAAGGATRLAAELNKFMLEK CGCGGAGGAGGCAG VTEDTSSVLRSPMPG UGCGCAUUGCCAGGVVVAVSVKPGDAVA GAGAUCGGCUACCC EGQEICVIEAMKMQN CGUGAUGAUCAAGGSMTAGKTGTVKSVH CUUCCGCAGGGGGA CQAGDTVGEGDLLV GGCGGCAAAGGCAU ELEGCGGAUUGCCUGGG AUGAUGAAGAAACC AGAGAUGGCUUCAG ACUGUCAAGCCAGGAGGCCGCCAGCAGC UUCGGCGACGACAG ACUGCUGAUCGAGA AGUUUAUAGAUAACCCCCGACACAUAGA AAUCCAGGUGCUGG GAGACAAGCACGGC AACGCUCUGUGGCUGAACGAGCGGGAAU GCAGUAUCCAGAGG AGAAACCAGAAGGU GGUUGAGGAGGCCCCCUCAAUCUUCCUG GAUGCCGAGACAAG ACGCGCCAUGGGUG AGCAGGCUGUAGCCCUCGCCCGUGCCGU GAAGUAUAGCAGCG CCGGGACAGUGGAG UUCUUGGUCGACUCCAAGAAGAAUUUCU AUUUUCUGGAGAUG AACACUCGGCUCCA AGUAGAGCACCCCGUGACUGAGUGCAUU ACAGGCCUUGAUCU GGUGCAGGAGAUGA UUAGGGUUGCCAAGGGCUACCCUCUGCG CCACAAGCAGGCCG ACAUCAGGAUCAAU GGCUGGGCUGUCGAGUGUAGGGUGUACG CAGAGGACCCGUAC AAGAGCUUCGGCCU UCCCUCUAUUGGCAGGCUGAGCCAGUAC CAGGAGCCUCUGCA CCUACCCGGCGUUC GCGUGGACAGCGGUAUCCAACCAGGCUC UGAUAUCAGCAUUU AUUACGACCCAAUG AUCUCAAAGCUGAUCACAUACGGCAGCG ACAGAACCGAGGCC CUGAAGCGAAUGGC CGACGCCCUGGACAACUACGUGAUCCGG GGCGUCACACAUAA CAUUGCCCUGCUGA GAGAGGUGAUCAUUAAUUCUCGGUUCGU CAAAGGCGACAUCA GCACUAAGUUUCUG AGCGACGUGUACCCCGACGGGUUUAAAG GCCACAUGCUGACA AAGAGCGAGAAGAA CCAGUUGCUGGCCAUCGCCUCUAGCCUG UUCGUAGCCUUCCA GCUGCGAGCACAGC ACUUCCAGGAGAAUAGCAGAAUGCCAGU GAUCAAGCCCGACA UCGCUAACUGGGAG CUGAGCGUGAAGCUCCAUGAUAAGGUCC ACACAGUUGUGGCC AGCAACAACGGCUC AGUGUUCAGCGUGGAGGUAGACGGCUCC AAGCUGAACGUGAC CAGCACUUGGAAUC UGGCCAGCCCCCUGCUGAGCGUGUCCGU GGACGGCACCCAGA GAACCGUGCAGUGC CUGAGCAGGGAGGCCGGGGGCAACAUGU CCAUCCAGUUUCUG GGGACCGUCUAUAA GGUUAACAUCCUGACUAGACUGGCGGCU GAGCUUAACAAGUU UAUGUUAGAGAAA GUGACCGAGGAUACAAGCAGCGUGCUGC GUAGCCCCAUGCCU GGCGUGGUCGUGGC CGUGAGCGUCAAGCCAGGCGAUGCAGUG GCUGAGGGCCAGGA GAUUUGUGUGAUA GAGGCCAUGAAGAUGCAGAACUCUAUGA CCGCCGGAAAGACU GGCACCGUGAAGUC UGUCCAUUGUCAGGCCGGAGACACCGUG GGGGAAGGAGACCU GCUCGUCGAGCUGG AG SEQ ID NO:  1  11   3178  63 PCCA_21 MAGFWVGTAPLVAA AUGGCCGGCUUCUG UGAUAA SEQ ID (hPCCA_;GRRGRWPPQQLMLS GGUCGGCACAGCCC GGGAAA UAGUCC NO: 63 G5) AALRTLKHVLYYSRCUCUGGUGGCAGCC UAAGAG AUAAAG consists Cap: C1 QCLMVSRNLGSVGYGGCAGAAGAGGACG AGAAAA UAGGAA from 5′ to PolyA tail: DPNEKTFDKILVANRGUGGCCUCCCCAGC GAAGAG ACACUA 3′ end: 5′ 100 nt GEIACRVIRTCKKMGAACUGAUGCUGAGC UAAGAA CAGCUG UTR of IKTVAIHSDVDASSV GCCGCCCUGAGAACGAAAUA GAGCCU SEQ ID HVKMADEAVCVGPA CCUGAAGCACGUGC UAAGAG CGGUGG NO: 3,PTSKSYLNMDAIMEA UGUACUACAGCAGA CCACC CCUAGC ORF IKKTRAQAVHPGYGFCAGUGCCUGAUGGU UUCUUG Sequence LSENKEFARCLAAED GAGCAGAAAUCUGG CCCCUUof SEQ ID VVFIGPDTHAIQAMG GCAGCGUGGGGUAC GGGCCU NO: 11, DKIESKLLAKKAEVNGAUCCCAACGAGAA CCAUAA and 3′ TIPGFDGVVKDAEEA GACCUUCGAUAAGA AGUAGGUTR of VRIAREIGYPVMIKAS UUCUGGUCGCGAAU AAACAC SEQ ID AGGGGKGMRIAWDDAGAGGCGAGAUCGC UACAUC NO: 178 EETRDGFRLSSQEAA CUGCAGGGUGAUCA CCCCCASSFGDDRLLIEKFIDN GAACCUGCAAGAAG GCCCCU PRHIEIQVLGDKHGN AUGGGCAUCAAGACCCUCCC ALWLNERECSIQRRN CGUGGCCAUCCAUU CUUCCU QKVVEEAPSIFLDAECGGACGUCGACGCG GCACCC TRRAMGEQAVALAR AGCAGCGUUCACGU GUACCCAVKYSSAGTVEFLVD GAAGAUGGCAGACG CCUCCA SKKNFYFLEMNTRLQ AGGCCGUGUGCGUGUAAAGU VEHPVTECITGLDLV GGACCCGCCCCGAC AGGAAA QEMIRVAKGYPLRHCAGCAAGAGCUACC CACUAC KQADIRINGWAVECR UGAACAUGGACGCC AGUGGUVYAEDPYKSFGLPSI AUCAUGGAGGCCAU CUUUGA GRLSQYQEPLHLPGV CAAGAAGACCCGCGAUAAAG RVDSGIQPGSDISIYY CUCAAGCCGUGCAC UCUGAG DPMISKLITYGSDRTECCGGGCUACGGCUU UGGGCG ALKRMADALDNYVI UCUGAGCGAGAACA GC RGVTHNIALLREVIINAGGAAUUCGCCAGG SRFVKGDISTKFLSDV UGUCUCGCCGCCGA YPDGFKGHMLTKSEGGACGUAGUCUUCA KNQLLAIASSLFVAF UCGGCCCUGAUACG QLRAQHFQENSRMPCACGCGAUCCAGGC VIKPDIANWELSVKL CAUGGGCGACAAGA HDKVHTVVASNNGSUCGAGAGCAAACUG VFSVEVDGSKLNVTS CUGGCCAAGAAAGC TWNLASPLLSVSVDGAGAAGUCAACACCA TQRTVQCLSREAGGN UCCCCGGCUUCGAC MSIQFLGTVYKVNILGGCGUGGUGAAGGA TRLAAELNKFMLEK CGCCGAAGAGGCUG VTEDTSSVLRSPMPGUCCGCAUCGCCAGA VVVAVSVKPGDAVA GAGAUCGGCUACCC EGQEICVIEAMKMQNUGUGAUGAUAAAG SMTAGKTGTVKSVH GCUAGCGCUGGAGG CQAGDTVGEGDLLVUGGCGGAAAGGGCA ELE UGAGAAUCGCCUGG GACGACGAGGAGAC UAGAGACGGCUUCAGACUGUCCUCCCAG GAGGCCGCCAGCUC CUUCGGAGACGACA GACUGCUGAUCGAGAAGUUCAUCGACAA CCCCAGACACAUCG AAAUCCAGGUGCUC GGUGACAAGCACGGGAACGCCCUGUGGC UGAACGAGAGAGAG UGCAGCAUCCAGAG AAGAAACCAGAAGGUGGUGGAGGAGGCG CCGAGCAUCUUUCU GGACGCGGAGACAA GGAGAGCGAUGGGCGAACAGGCCGUCGC CCUAGCAAGAGCCG UGAAGUACUCCAGU GCCGGAACCGUCGAGUUUCUUGUCGACA GCAAGAAGAAUUUC UACUUCCUGGAGAU GAACACCAGGCUGCAGGUGGAGCAUCCC GUGACAGAGUGCAU CACUGGACUGGAUC UGGUGCAGGAGAUGAUCAGGGUGGCCAA GGGCUAUCCCCUGA GACACAAGCAGGCC GACAUCAGAAUCAACGGCUGGGCCGUGG AGUGCAGAGUGUAC GCCGAGGACCCCUA CAAGAGCUUCGGCCUGCCCAGCAUCGGC AGACUGAGCCAGUA CCAGGAGCCCCUGC ACCUGCCCGGCGUGAGAGUGGACAGCGG CAUCCAACCGGGGA GCGAUAUCAGCAUC UACUACGACCCCAUGAUCAGCAAGCUGA UAACCUACGGCAGC GACAGAACCGAGGC CCUGAAGAGAAUGGCCGACGCCCUGGAC AACUACGUGAUCAG AGGCGUGACCCACA ACAUCGCCCUGCUGAGAGAGGUGAUCAU CAACUCGAGGUUCG UGAAAGGCGACAUC AGCACCAAGUUCCUGAGCGACGUGUAUC CCGACGGAUUCAAA GGUCACAUGCUGAC CAAGAGCGAGAAGAACCAGCUGCUGGCC AUCGCCUCAUCCCU GUUCGUGGCCUUCC AGCUGAGAGCCCAGCACUUCCAGGAGAA CAGCAGAAUGCCCG UGAUCAAGCCCGAC AUCGCCAACUGGGAGCUGAGCGUGAAGC UGCACGACAAGGUG CACACUGUCGUUGC CAGCAACAACGGCUCCGUGUUCAGCGUA GAGGUGGACGGAUC UAAGCUGAACGUGA CCUCCACCUGGAACCUGGCAAGCCCUCU CCUGUCAGUGAGCG UGGACGGCACCCAG AGAACCGUGCAGUGUCUGUCCCGCGAGG CCGGCGGAAACAUG AGCAUCCAGUUCCU GGGCACCGUGUACAAGGUGAACAUCCUG ACCAGACUGGCCGC CGAGCUGAACAAGU UCAUGCUGGAGAAAGUGACGGAGGAUAC CAGCUCCGUGCUGA GAAGCCCCAUGCCC GGAGUGGUGGUGGCCGUUUCCGUGAAAC CUGGUGACGCCGUG GCCGAGGGGCAAGA GAUCUGCGUGAUCGAGGCCAUGAAGAUG CAGAAUUCCAUGAC CGCCGGAAAGACCG GCACCGUCAAAUCAGUGCACUGCCAGGC GGGCGACACAGUGG GUGAGGGCGACCUG CUGGUGGAGCUGGA G SEQ ID NO: 1  11   3 112  65 PCCA_22 MAGFWVGTAPLVAA AUGGCCGGCUUCUG GGGAAA UGAUAASEQ ID (hPCCA; GRRGRWPPQQLMLS GGUCGGCACAGCCC UAAGAG UAGUCC NO: 65 G5)AALRTLKHVLYYSR CUCUGGUGGCAGCC AGAAAA AUAAAG consists Cap: C1QCLMVSRNLGSVGY GGCAGAAGAGGACG GAAGAG UAGGAA from 5′ to PolyA tail:DPNEKTIFDKILVANR GUGGCCUCCCCAGC UAAGAA ACACUA 3′ end: 5′ 100 ntGEIACRVIRTCKKMG AACUGAUGCUGAGC GAAAUA CAGCUG UTR of IKTVAIHSDVDASSVGCCGCCCUGAGAAC UAAGAG GAGCCU SEQ ID HVKMADEAVCVGPA CCUGAAGCACGUGC CCACCCGGUGG NO: 3, PTSKSYLNMDAIMEA UGUACUACAGCAGA CCUAGC ORF IKKTRAQAVHPGYGFCAGUGCCUGAUGGU UUCUUG Sequence LSENKEFARCLAAED GAGCAGAAAUCUGG CCCCUUof SEQ ID VVFIGPDTHAIQAMG GCAGCGUGGGGUAC GGGCCU NO: 11, DKIESKLLAKKAEVNGAUCCCAACGAGAA CCCCCC and 3′ TIPGFDGVVKDAEEA GACCUUCGAUAAGA AGCCCCUTR of VRIAREIGYPVMIKAS UUCUGGUCGCGAAU UCCUCC SEQ ID AGGGGKGMRIAWDDAGAGGCGAGAUCGC CCUUCC NO: 112 EETRDGFRLSSQEAA CUGCAGGGUGAUCA UGCACCSSFGDDRLLIEKFIDN GAACCUGCAAGAAG CGUACC PRHIEIQVLGDKHGN AUGGGCAUCAAGACCCCCGC ALWLNERECSIQRRN CGUGGCCAUCCAUU AUUAUU QKVVEEAPSIFLDAECGGACGUCGACGCG ACUCAC TRRAMGEQAVALAR AGCAGCGUUCACGU GGUACGAVKYSSAGTVEFLVD GAAGAUGGCAGACG AGUGGU SKKNFYFLEMNTRLQ AGGCCGUGUGCGUGCUUUGA VEHPVTECITGLDLV GGACCCGCCCCGAC AUAAAG QEMIRVAKGYPLRHCAGCAAGAGCUACC UCUGAG KQADIRINGWAVECR UGAACAUGGACGCC UGGGCGVYAEDPYKSFGLPSI AUCAUGGAGGCCAU GC GRLSQYQEPLHLPGV CAAGAAGACCCGCGRVDSGIQPGSDISIYY CUCAAGCCGUGCAC DPMISKLITYGSDRTE CCGGGCUACGGCUUALKRMADALDNYVI UCUGAGCGAGAACA RGVTHNIALLREVIIN AGGAAUUCGCCAGGSRFVKGDISTKFLSDV UGUCUCGCCGCCGA YPDGFKGHMLTKSE GGACGUAGUCUUCAKNQLLAIASSLFVAF UCGGCCCUGAUACG QLRAQHFQENSRMP CACGCGAUCCAGGCVIKPDIANWELSVKL CAUGGGCGACAAGA HDKVHTVVASNNGS UCGAGAGCAAACUGVFSVEVDGSKLNVTS CUGGCCAAGAAAGC TWNLASPLLSVSVDG AGAAGUCAACACCATQRTVQCLSREAGGN UCCCCGGCUUCGAC MSIQFLGTVYKVNIL GGCGUGGUGAAGGATRLAAELNKFMLEK CGCCGAAGAGGCUG VTEDTSSVLRSPMPG UCCGCAUCGCCAGAVVVAVSVKPGDAVA GAGAUCGGCUACCC EGQEICVIEAMKMQN UGUGAUGAUAAAGSMTAGKTGTVKSVH GCUAGCGCUGGAGG CQAGDTVGEGDLLV UGGCGGAAAGGGCA ELEUGAGAAUCGCCUGG GACGACGAGGAGAC UAGAGACGGCUUCA GACUGUCCUCCCAGGAGGCCGCCAGCUC CUUCGGAGACGACA GACUGCUGAUCGAG AAGUUCAUCGACAACCCCAGACACAUCG AAAUCCAGGUGCUC GGUGACAAGCACGG GAACGCCCUGUGGCUGAACGAGAGAGAG UGCAGCAUCCAGAG AAGAAACCAGAAGG UGGUGGAGGAGGCGCCGAGCAUCUUUCU GGACGCGGAGACAA GGAGAGCGAUGGGC GAACAGGCCGUCGCCCUAGCAAGAGCCG UGAAGUACUCCAGU GCCGGAACCGUCGA GUUUCUUGUCGACAGCAAGAAGAAUUUC UACUUCCUGGAGAU GAACACCAGGCUGC AGGUGGAGCAUCCCGUGACAGAGUGCAU CACUGGACUGGAUC UGGUGCAGGAGAUG AUCAGGGUGGCCAAGGGCUAUCCCCUGA GACACAAGCAGGCC GACAUCAGAAUCAA CGGCUGGGCCGUGGAGUGCAGAGUGUAC GCCGAGGACCCCUA CAAGAGCUUCGGCC UGCCCAGCAUCGGCAGACUGAGCCAGUA CCAGGAGCCCCUGC ACCUGCCCGGCGUG AGAGUGGACAGCGGCAUCCAACCGGGGA GCGAUAUCAGCAUC UACUACGACCCCAU GAUCAGCAAGCUGAUAACCUACGGCAGC GACAGAACCGAGGC CCUGAAGAGAAUGG CCGACGCCCUGGACAACUACGUGAUCAG AGGCGUGACCCACA ACAUCGCCCUGCUG AGAGAGGUGAUCAUCAACUCGAGGUUCG UGAAAGGCGACAUC AGCACCAAGUUCCU GAGCGACGUGUAUCCCGACGGAUUCAAA GGUCACAUGCUGAC CAAGAGCGAGAAGA ACCAGCUGCUGGCCAUCGCCUCAUCCCU GUUCGUGGCCUUCC AGCUGAGAGCCCAG CACUUCCAGGAGAACAGCAGAAUGCCCG UGAUCAAGCCCGAC AUCGCCAACUGGGA GCUGAGCGUGAAGCUGCACGACAAGGUG CACACUGUCGUUGC CAGCAACAACGGCU CCGUGUUCAGCGUAGAGGUGGACGGAUC UAAGCUGAACGUGA CCUCCACCUGGAAC CUGGCAAGCCCUCUCCUGUCAGUGAGCG UGGACGGCACCCAG AGAACCGUGCAGUG UCUGUCCCGCGAGGCCGGCGGAAACAUG AGCAUCCAGUUCCU GGGCACCGUGUACA AGGUGAACAUCCUGACCAGACUGGCCGC CGAGCUGAACAAGU UCAUGCUGGAGAAA GUGACGGAGGAUACCAGCUCCGUGCUGA GAAGCCCCAUGCCC GGAGUGGUGGUGGC CGUUUCCGUGAAACCUGGUGACGCCGUG GCCGAGGGGCAAGA GAUCUGCGUGAUCG AGGCCAUGAAGAUGCAGAAUUCCAUGAC CGCCGGAAAGACCG GCACCGUCAAAUCA GUGCACUGCCAGGCGGGCGACACAGUGG GUGAGGGCGACCUG CUGGUGGAGCUGGA G SEQ ID NO: 15  16   3   4 39 PCCB_11 MAAALRVAAVGARL AUGGCCGCCGCCCU GGGAAA UGAUAA SEQ ID (hPCCB;SVLASGLRAAVRSLC UAGGGUCGCAGCCG UAAGAG UAGGCU NO: 39 G5) SQATSVNERIENKRRUGGGCGCUAGACUG AGAAAA GGAGCC consists Cap: C1 TALLGGGQRRIDAQHUCAGUGCUGGCCAG GAAGAG UCGGUG from 5′ to PolyA tail: KRGKLTARERISLLLCGGCCUAAGAGCCG UAAGAA GCCUAG 3′ end: 5′ 100 nt DPGSFVESDMFVEHRCCGUUAGGAGCCUG GAAAUA CUUCUU UTR of CADFGMAADKNKFP UGCAGCCAGGCUAC UAAGAGGCCCCU SEQ ID GDSVVTGRGRINGRL UAGCGUGAACGAGA CCACC UGGGCC NO: 3 ,VYVFSQDFTVFGGSL GAAUAGAGAACAAA UCCCCC ORF SGAHAQKICKIMDQA CGCCGUACAGCUCUCAGCCC Sequence ITVGAPVIGLNDSGG GCUAGGAGGAGGCC CUCCUC of SEQ IDARIQEGVESLAGYAD AGAGACGUAUCGAC CCCUUC NO: 16, IFLRNVTASGVIPQISLGCCCAGCACAAGCG CUGCAC and 3′ IMGPCAGGAVYSPAL GGGCAAGCUGACCG CCGUACUTR of TDFTFMVKDTSYLFI CCCGGGAGCGCAUC CCCCUC SEQ ID TGPDVVKSVTNEDVTAGCCUCCUGCUUGA CAUAAA NO: 4 QEELGGAKTHTTMS CCCCGGCAGCUUUG GUAGGAGVAHRAFENDVDAL UUGAGUCGGACAUG AACACU CNLRDFFNYLPLSSQ UUCGUGGAGCACCGACAGUG DPAPVRECHDPSDRL GUGCGCUGACUUCG GUCUUU VPELDTIVPLESTKAYGCAUGGCUGCCGAC GAAUAA NMVDIIHSVVDEREF AAGAACAAGUUCCC AGUCUGFEIMPNYAKNIIVGFA CGGCGACUCCGUGG AGUGGG RMNGRTVGIVGNQP UGACAGGAAGGGGACGGC KVASGCLDINSSVKG CGGAUCAACGGCCG ARFVRFCDAFNIPLIT GCUGGUGUACGUGUFVDVPGFLPGTAQEY UCUCUCAGGACUUC GGIIRHGAKLLYAFA ACUGUGUUCGGCGGEATVPKVTVITRKAY CUCCCUUUCUGGCG GGAYDVMSSKHLCG CCCACGCCCAGAAGDTNYAWPTAEIAVM AUCUGUAAGAUUAU GAKGAVEIIFKGHEN GGACCAGGCAAUCAVEAAQAEYIEKFANP CCGUGGGAGCUCCC FPAAVRGFVDDIIQPS GUCAUCGGCCUGAASTRARICCDLDVLAS CGACUCAGGCGGCG KKVQRPWRKHANIP CCCGAAUCCAGGAG LGGCGUGGAGAGCCU GGCCGGGUACGCAG ACAUUUUCCUGAGA AACGUGACCGCUAGCGGCGUUAUCCCAC AGAUCAGCCUGAUC AUGGGACCUUGCGC UGGAGGAGCAGUCUACAGCCCAGCCCUG ACUGAUUUUACCUU CAUGGUGAAAGACA CAAGCUACCUGUUCAUCACUGGGCCGGA CGUAGUUAAGAGUG UGACUAACGAGGAC GUGACCCAGGAGGAGCUGGGCGGAGCCA AGACCCAUACGACU AUGAGCGGUGUGGC GCACCGCGCCUUCGAGAACGACGUGGAC GCCCUGUGCAAUCU GCGCGACUUCUUCA AUUACCUGCCCUUAAGCAGCCAAGAUCC CGCACCCGUGCGGG AGUGCCACGAUCCA AGCGAUAGGCUGGUGCCCGAGCUGGACA CCAUUGUGCCUCUG GAGUCAACUAAGGC UUACAACAUGGUUGACAUCAUCCACAGC GUGGUCGACGAGCG CGAGUUCUUCGAGA UCAUGCCCAACUACGCGAAGAAUAUCAU CGUGGGCUUUGCCC GCAUGAACGGCCGG ACCGUCGGGAUCGUCGGCAAUCAACCUA AGGUCGCCAGCGGU UGCCUGGACAUCAA CAGCUCGGUGAAGGGCGCCAGGUUCGUU AGAUUCUGCGACGC UUUCAACAUCCCUC UGAUCACUUUCGUAGACGUUCCCGGCUU CCUCCCUGGGACCG CACAGGAGUACGGA GGAAUCAUUAGGCACGGCGCCAAGCUGC UCUACGCCUUCGCU GAGGCUACCGUGCC UAAGGUGACCGUGAUCACUAGGAAGGCC UACGGUGGCGCCUA CGACGUCAUGAGCA GCAAGCACCUGUGUGGAGACACAAACUA CGCCUGGCCCACAG CUGAGAUUGCGGUU AUGGGAGCCAAGGGCGCCGUGGAGAUUA UUUUCAAGGGCCAC GAGAACGUGGAGGC CGCCCAGGCCGAGUACAUCGAGAAGUUU GCCAACCCCUUCCC UGCCGCCGUGAGAG GAUUUGUGGACGAUAUUAUCCAGCCCUC CUCCACCAGAGCCA GGAUCUGCUGCGAC CUCGACGUUUUGGCCUCGAAGAAGGUGC AACGGCCCUGGCGC AAACACGCAAACAU CCCGCUG SEQ ID NO: 15  17  3   4  40 PCCB_12 MAAALRVAAVGARL AUGGCCGCCGCCCU GGGAAA UGAUAA SEQ ID(hPCCB; SVLASGLRAAVRSLC GAGGGUGGCCGCAG UAAGAG UAGGCU NO: 40 G5)SQATSVNERIENKRR UCGGCGCACGACUC AGAAAA GGAGCC consists Cap: C1TALLGGGQRRIDAQH UCCGUGCUGGCUAG GAAGAG UCGGUG from 5′ to PolyA tail:KRGKLTARERISLLL CGGCCUGAGAGCCG UAAGAA GCCUAG 3′ end: 5′ 100 ntDPGSFVESDMFVEHR CUGUGCGGAGCCUG GAAAUA CUUCUU UTR of CADFGMAADKNKFPUGCUCUCAGGCUAC UAAGAG GCCCCU SEQ ID GDSVVTGRGRINGRL GUCGGUUAACGAGC CCACCUGGGCC NO: 3, VYVFSQDFTVFGGSL GUAUAGAGAACAAG UCCCCC ORF SGAHAQKICKIMDQACGGCGCACCGCUCU CAGCCC Sequence ITVGAPVIGLNDSGG CCUUGGCGGCGGCC CUCCUCof SEQ ID ARIQEGVESLAGYAD AGAGGAGAAUAGAC CCCUUC NO: 17,IFLRNVTASGVIPQISL GCCCAGCAUAAGCG CUGCAC and 3′ IMGPCAGGAVYSPALUGGAAAGCUGACCG CCGUAC UTR of TDFTFMVKDTSYLFI CCAGAGAGAGAAUA CCCCUCSEQ ID TGPDVVKSVTNEDVT UCCCUUCUCCUGGA CAUAAA NO: 4 QEELGGAKTHTTMSUCCCGGGUCUUUCG GUAGGA GVAHRAFENDVDAL UGGAGAGCGACAUG AACACUCNLRDFFNYLPLSSQ UUCGUCGAACACAG ACAGUG DPAPVRECHDPSDRL GUGCGCCGACUUUGGUCUUU VPELDTIVPLESTKAY GGAUGGCUGCUGAC GAAUAA NMVDIIHSVVDEREFAAGAACAAGUUCCC AGUCUG FEIMPNYAKNIIVGFA UGGAGAUUCAGUAG AGUGGGRMNGRTVGIVGNQP UGACAGGUAGGGGC CGGC KVASGCLDINSSVKG AGGAUCAACGGCAGARFVRFCDAFNIPLIT ACUGGUCUACGUGU FVDVPGFLPGTAQEY UUUCCCAAGAUUUCGGIIRHGAKLLYAFA ACCGUGUUCGGCGG EATVPKVTVITRKAY CAGCCUGAGCGGCGGGAYDVMSSKHLCG CUCACGCACAGAAG DTNYAWPTAEIAVM AUCUGCAAGAUCAUGAKGAVEIIFKGHEN GGAUCAGGCAAUUA VEAAQAEYIEKFANP CAGUGGGCGCCCCUFPAAVRGFVDDIIQPS GUGAUCGGCCUGAA STRARICCDLDVLAS CGACAGUGGCGGCGKKVQRPWRKHANIP CGAGAAUUCAGGAG L GGAGUGGAAUCUCU GGCUGGGUACGCCGACAUUUUCCUGCGA AACGUCACAGCCAG CGGGGUUAUUCCCC AAAUUUCGCUCAUCAUGGGGCCUUGCGC CGGCGGUGCUGUGU ACAGCCCUGCCCUC ACCGACUUCACCUUCAUGGUGAAAGACA CCUCCUAUCUGUUC AUUACAGGACCCGA CGUGGUGAAAUCCGUGACAAACGAGGAC GUGACCCAGGAGGA ACUCGGCGGCGCUA AGACCCACACAACCAUGUCAGGCGUUGC CCACAGAGCGUUCG AGAACGACGUGGAC GCUCUGUGCAACCUGAGAGACUUCUUCA ACUACCUGCCUCUG AGCUCGCAGGACCC AGCUCCCGUGCGGGAGUGUCACGAUCCC AGCGAUCGUCUGGU GCCUGAACUGGACA CAAUCGUUCCACUGGAGUCCACCAAGGC CUAUAAUAUGGUGG ACAUUAUCCACAGC GUGGUGGACGAAAGGGAAUUCUUCGAGA UCAUGCCCAAUUAC GCCAAGAAUAUCAU CGUGGGCUUCGCCAGAAUGAACGGCCGC ACCGUGGGCAUCGU UGGCAAUCAACCUA AGGUGGCCAGCGGCUGCCUCGACAUUAA CAGCAGUGUGAAAG GCGCCAGAUUCGUG CGGUUUUGCGACGCCUUUAAUAUCCCUC UGAUCACCUUCGUG GACGUGCCCGGGUU UCUGCCGGGCACCGCCCAGGAGUACGGA GGGAUCAUUAGACA CGGUGCUAAGCUGC UGUACGCCUUCGCCGAGGCCACAGUGCC CAAGGUUACCGUUA UCACACGCAAAGCC UACGGCGGAGCCUACGACGUGAUGAGCA GCAAACACCUCUGU GGCGACACCAACUA CGCUUGGCCCACAGCCGAGAUUGCCGUG AUGGGCGCCAAGGG CGCUGUGGAGAUCA UUUUCAAAGGCCACGAGAACGUGGAGGC UGCCCAGGCCGAGU AUAUCGAGAAGUUC GCAAACCCCUUCCCAGCAGCAGUGCGGG GCUUCGUCGACGAC AUCAUCCAGCCUUC UAGCACCAGGGCAAGAAUCUGCUGUGAC CUUGACGUGCUCGC CAGUAAGAAGGUCC AGAGGCCGUGGAGAAAGCACGCUAACAU UCCCCUG SEQ ID NO: 15  18   3   4  41 PCCB_13MAAALRVAAVGARL AUGGCCGCCGCCCU GGGAAA UGAUAA SEQ ID (hPCCB;SVLASGLRAAVRSLC GCGGGUUGCAGCCG UAAGAG UAGGCU NO: 41 G5) SQATSVNERIENKRRUGGGCGCCCGGCUG AGAAAA GGAGCC consists Cap: C1 TALLGGGQRRIDAQHAGCGUGUUGGCCUC GAAGAG UCGGUG from 5′ to PolyA tail: KRGKLTARERISLLLAGGGCUGAGAGCCG UAAGAA GCCUAG 3′ end: 5′ 100 nt DPGSFVESDMFVEHRCUGUGCGGAGCCUG GAAAUA CUUCUU UTR of CADFGMAADKNKFP UGCAGCCAGGCCAC UAAGAGGCCCCU SEQ ID GDSVVTGRGRINGRL CAGCGUGAACGAGC CCACC UGGGCC NO: 3,VYVFSQDFTVFGGSL GGAUCGAGAACAAG UCCCCC ORF SGAHAQKICKIMDQA CGGCGGACUGCCCUCAGCCC Sequence ITVGAPVIGLNDSGG GCUGGGCGGCGGGC CUCCUC of SEQ IDARIQEGVESLAGYAD AGAGGAGAAUCGAC CCCUUC NO: 18, IFLRNVTASGVIPQISLGCCCAGCACAAGCG CUGCAC and 3′ IMGPCAGGAVYSPAL GGGCAAGCUGACCG CCGUACUTR of TDFTFMVKDTSYLFI CCCGGGAGAGGAUU CCCCUC SEQ ID TGPDVVKSVTNEDVTAGCCUGCUGCUGGA CAUAAA NO: 4 QEELGGAKTHTTMS CCCCGGCAGCUUCG GUAGGAGVAHRAFENDVDAL UGGAGAGCGACAUG AACACU CNLRDFFNYLPLSSQ UUCGUCGAGCACCGACAGUG DPAPVRECHDPSDRL GUGCGCCGACUUCG GUCUUU VPELDTIVPLESTKAYGCAUGGCAGCUGAC GAAUAA NMVDIIHSVVDEREF AAGAACAAGUUCCC AGUCUGFEIMPNYAKNIIVGFA CGGCGACAGCGUGG AGUGGG RMNGRTVGIVGNQP UGACCGGCCGGGGCCGGC KVASGCLDINSSVKG CGGAUCAACGGCCG ARFVRFCDAFNIPLIT GCUGGUGUACGUGUFVDVPGFLPGTAQEY UCAGCCAGGACUUC GGIIRHGAKLLYAFA ACCGUGUUCGGCGGEATVPKVTVITRKAY CAGCCUGAGCGGCG GGAYDVMSSKHLCG CCCACGCCCAGAAGDTNYAWPTAEIAVM AUCUGCAAGAUCAU GAKGAVEIIFKGHEN GGACCAGGCCAUCAVEAAQAEYIEKFANP CUGUCGGCGCACCC FPAAVRGFVDDIIQPS GUGAUCGGCCUGAASTRARICCDLDVLAS CGACAGCGGCGGCG KKVQRPWRKHANIP CACGUAUCCAGGAG LGGUGUAGAAUCUCU GGCCGGCUACGCCG ACAUCUUCCUGCGG AACGUGACCGCCUCAGGGGUGAUUCCUC AGAUCUCGCUGAUC AUGGGCCCCUGCGC CGGAGGUGCUGUGUACAGCCCCGCCCUG ACCGACUUCACAUU CAUGGUGAAGGACA CCAGCUACCUGUUCAUCACCGGCCCCGA CGUGGUGAAAUCUG UGACCAACGAGGAC GUGACCCAGGAGGAGUUAGGAGGCGCCA AGACCCACACCACC AUGAGUGGCGUGGC CCACCGGGCCUUCGAGAACGACGUGGAC GCCCUGUGCAACCU GCGGGACUUCUUCA ACUACCUGCCCCUGUCAAGUCAGGACCC CGCUCCGGUACGGG AGUGCCACGACCCC AGCGAUAGACUGGUGCCCGAGCUGGACA CCAUCGUGCCCCUG GAGAGCACCAAGGC CUACAACAUGGUGGACAUCAUCCACUCU GUGGUAGACGAGCG GGAGUUCUUCGAGA UCAUGCCCAACUACGCCAAGAACAUCAU CGUGGGCUUUGCUC GCAUGAACGGUCGU ACCGUUGGUAUCGUCGGAAACCAGCCCA AGGUGGCCUCCGGU UGCCUCGAUAUCAA CUCCAGCGUAAAGGGCGCUCGGUUCGUG CGGUUCUGCGACGC CUUCAACAUUCCAC UGAUCACAUUCGUGGACGUGCCCGGCUU CCUGCCCGGCACCG CCCAGGAGUACGGC GGCAUCAUCCGGCACGGAGCAAAGCUGC UGUACGCCUUCGCC GAGGCCACCGUGCC UAAGGUGACCGUGAUCACCCGGAAGGCC UACGGCGGCGCAUA CGACGUGAUGAGCA GCAAGCACCUGUGCGGCGACACAAAUUA CGCUUGGCCCACUG CCGAGAUCGCCGUG AUGGGUGCUAAGGGAGCCGUGGAGAUCA UCUUCAAGGGCCAC GAGAACGUGGAGGC AGCCCAGGCCGAGUACAUCGAGAAGUUC GCCAACCCCUUCCC CGCCGCGGUCCGCG GAUUUGUUGACGAUAUCAUCCAGCCCAG CAGCACCCGGGCCC GAAUCUGCUGCGAC CUAGACGUAUUGGCCUCUAAGAAGGUGC AGCGGCCCUGGCGG AAGCACGCAAACAU CCCACUG SEQ ID NO: 15  19  3   4  42 PCCB_14 MAAALRVAAVGARL AUGGCCGCCGCGCU GGGAAA UGAUAA SEQ ID(hPCBB; SVLASGLRAAVRSLC CAGAGUUGCCGCGG UAAGAG UAGGCU NO: 42 G5)SQATSVNERIENKRR UCGGCGCACGCCUG AGAAAA GGAGCC consists TALLGGGQRRIDAQHAGCGUGCUGGCCAG GAAGAG UCGGUG from 5′ to KRGKLTARERISLLL CGGCCUGCGUGCAGUAAGAA GCCUAG 3′ end: 5′ DPGSFVESDMFVEHR CAGUCCGGAGCCUG GAAAUA CUUCUUUTR of CADFGMAADKNKFP UGCAGCCAGGCCAC UAAGAG GCCCCU SEQ IDGDSVVTGRGRINGRL CAGCGUGAACGAGC CCACC UGGGCC NO: 3, VYVFSQDFTVFGGSLGGAUCGAGAACAAG UCCCCC ORF SGAHAQKICKIMDQA CGGCGGACCGCACU CAGCCC SequenceITVGAPVIGLNDSGG CCUGGGCGGCGGUC CUCCUC of SEQ ID ARIQEGVESLAGYADAACGCAGGAUUGAC CCCUUC NO: 19, IFLRNVTASGVIPQISL GCCCAGCACAAGCG CUGCACand 3′ IMGPCAGGAVYSPAL GGGCAAGCUGACCG CCGUAC UTR of TDFTFMVKDTSYLFICCCGGGAGCGGAUU CCCCUC SEQ ID TGPDVVKSVTNEDVT AGCCUGCUGCUGGA CAUAAA NO: 4QEELGGAKTHTTMS CCCCGGCAGCUUCG GUAGGA GVAHRAFENDVDAL UGGAGAGCGACAUGAACACU CNLRDFFNYLPLSSQ UUUGUCGAACACCG ACAGUG DPAPVRECHDPSDRLGUGCGCCGACUUCG GUCUUU VPELDTIVPLESTKAY GCAUGGCCGCUGAC GAAUAANMVDIIHSVVDEREF AAGAACAAGUUCCC AGUCUG FEIMPNYAKNIIVGFA CGGCGACAGCGUGGAGUGGG RMNGRTVGIVGNQP UGACCGGCCGGGGC CGGC KVASGCLDINSSVKG CGGAUCAACGGCCGARFVRFCDAFNIPLIT GCUGGUGUACGUGU FVDVPGFLPGTAQEY UCAGCCAGGACUUCGGIIRHGAKLLYAFA ACCGUGUUCGGCGG EATVPKVTVITRKAY CAGCCUGAGCGGCGGGAYDVMSSKHLCG CCCACGCCCAGAAG DTNYAWPTAEIAVM AUCUGCAAGAUCAUGAKGAVEIIFKGHEN GGACCAGGCCAUCA VEAAQAEYIEKFANP CCGUGGGUGCUCCGFPAAVRGFVDDIIQPS GUGAUCGGCCUGAA STRARICCDLDVLAS CGACUCAGGAGGUGKKVQRPWRKHANIP CCCGGAUCCAGGAG L GGAGUGGAAUCUCU GGCCGGCUACGCCGACAUCUUCCUGCGG AACGUGACCGCUAG CGGCGUGAUACCUC AAAUUUCUCUGAUCAUGGGACCAUGCGC UGGCGGGGCCGUGU ACAGCCCCGCCCUG ACCGACUUUACGUUCAUGGUGAAGGACA CCAGCUACCUGUUC AUCACCGGCCCCGA CGUGGUCAAGUCCGUGACCAACGAGGAC GUGACCCAGGAGGA ACUCGGUGGGGCCA AGACCCACACCACCAUGUCCGGCGUUGC CCACCGGGCCUUCG AGAACGACGUGGAC GCCCUGUGCAACCUGCGGGACUUCUUCA ACUACCUGCCCCUG UCUUCACAAGAUCC UGCUCCAGUGCGGGAGUGCCACGACCCC AGCGACCGUUUGGU GCCCGAGCUGGACA CCAUCGUGCCCCUGGAGAGCACCAAGGC CUACAACAUGGUGG ACAUCAUCCACUCC GUUGUAGACGAGCGGGAGUUCUUCGAGA UCAUGCCCAACUAC GCCAAGAACAUCAU CGUGGGCUUCGCCCGUAUGAACGGCCGU ACCGUCGGGAUUGU GGGGAACCAGCCCA AGGUUGCUUCUGGGUGCCUAGACAUCAA CUCAAGCGUCAAAG GGGCCCGGUUCGUG CGGUUCUGCGACGCCUUCAACAUUCCCC UGAUCACGUUCGUU GACGUGCCCGGCUU CCUGCCCGGCACCGCCCAGGAGUACGGC GGCAUCAUCCGGCA CGGUGCCAAACUGC UGUACGCCUUCGCCGAGGCCACCGUUCC CAAGGUGACCGUGA UCACCCGGAAAGCU UACGGAGGGGCUUACGACGUGAUGAGCA GCAAGCACCUGUGC GGCGACACAAAUUA CGCUUGGCCUACCGCCGAGAUCGCCGUG AUGGGCGCAAAGGG CGCUGUUGAGAUCA UCUUCAAGGGCCACGAGAACGUGGAGGC UGCUCAGGCCGAGU ACAUCGAGAAGUUC GCCAACCCCUUCCCCGCUGCCGUGCGGG GUUUCGUGGACGAU AUUAUUCAGCCCAG CAGCACCCGGGCCAGAAUCUGCUGCGAC CUGGACGUUUUGGC AUCAAAGAAGGUGC AGCGGCCCUGGCGGAAGCACGCCAAUAU CCCUCUG SEQ ID NO: 15  20   3   4  43 PCCB_15MAAALRVAAVGARL AUGGCCGCCGCCCU GGGAAA UGAUAA SEQ ID (hPCCB;SVLASGLRAAVRSLC UCGGGUUGCAGCGG UAAGAG UAGGCU NO: 43 G5) SQATSVNERIENKRRUCGGUGCUCGGCUG AGAAAA GGAGCC consists Cap: C1 TALLGGGQRRIDAQHAGCGUGCUCGCUUC GAAGAG UCGGUG from 5′ to PolyA tail: KRGKLTARERISLLLCGGUCUUAGGGCUG UAAGAA GCCUAG 3′ end: 5′ 100 nt DPGSFVESDMFVEHRCUGUGCGGAGCCUG GAAAUA CUUCUU UTR of CADFGMAADKNKFP UGCAGCCAGGCCAC UAAGAGGCCCCU SEQ ID GDSVVTGRGRINGRL CUCCGUCAACGAGC CCACC UGGGCC NO: 3VYVFSQDFTVFGGSL GCAUCGAGAACAAG UCCCCC ORF SGAHAQKICKIMDQA CGCCGCACUGCCCUCAGCCC Sequence ITVGAPVIGLNDSGG GCUGGGCGGAGGCC CUCCUC of SEQ IDARIQEGVESLAGYAD AGAGGCGAAUCGAC CCCUUC NO: 20, IFLRNVTASGVIPQISLGCCCAGCACAAGCG CUGCAC and 3′ IMGPCAGGAVYSPAL CGGCAAGCUCACCG CCGUACUTR of TDFTFMVKDTSYLFI CCAGGGAACGGAUC CCCCUC SEQ ID TGPDVVKSVTNEDVTUCCCUCCUCCUCGA CAUAAA NO: 4 QEELGGAKTHTTMS CCCCGGCUCCUUCG GUAGGAGVAHRAFENDVDAL UCGAGUCCGACAUG AACACU CNLRDFFNYLPLSSQ UUCGUAGAACACCGACAGUG DPAPVRECHDPSDRL CUGCGCCGACUUCG GUCUUU VPELDTIVPLESTKAYGCAUGGCCGCAGAC GAAUAA NMVDIIHSVVDEREF AAGAACAAGUUCCC AGUCUGFEIMPNYAKNIIVGFA CGGCGACUCCGUCG AGUGGG RMNGRTVGIVGNQP UCACCGGCCGCGGCCGGC KVASGCLDINSSVKG CGCAUCAACGGCCG ARFVRFCDAFNIPLIT CCUCGUCUACGUCUFVDVPGFLPGTAQEY UCUCCCAGGACUUC GGIIRHGAKLLYAFA ACCGUCUUCGGCGGEATVPKVTVITRKAY CUCCCUCUCCGGCG GGAYDVMSSKHLCG CCCACGCCCAGAAGDTNYAWPTAEIAVM AUCUGCAAGAUCAU GAKGAVEIIFKGHEN GGACCAGGCCAUCAVEAAQAEYIEKFANP CCGUCGGCGCCCCG FPAAVRGFVDDIIQPS GUCAUCGGCCUCAASTRARICCDLDVLAS CGACUCCGGCGGCG KKVQRPWRKHANIP CCCGCAUCCAGGAG LGGAGUCGAAUCCCU CGCCGGCUACGCCG ACAUCUUCCUCCGC AACGUCACCGCCUCCGGCGUCAUCCCGC AGAUCAGCCUUAUC AUGGGCCCCUGCGC CGGUGGUGCUGUCUACAGUCCGGCCCUC ACCGACUUUACGUU CAUGGUCAAGGACA CCUCCUACCUCUUCAUCACUGGCCCCGA CGUCGUCAAGUCCG UCACCAACGAGGAC GUCACCCAGGAGGAGCUGGGAGGCGCCA AGACCCACACCACC AUGUCCGGUGUGGC CCACCGCGCCUUCGAGAACGACGUUGAC GCCCUCUGCAACCU CCGCGACUUCUUCA ACUACCUUCCACUCAGCUCACAGGACCC AGUGCCACGACCCC UCCGACAGGCUGGU UCCCGAGCUCGACACCAUCGUGCCGCUC GAGUCCACCAAGGC CUACAACAUGGUCG ACAUCAUCCAUAGCGUGGUCGACGAGCG CGAGUUCUUCGAGA UCAUGCCCAACUAC GCCAAGAACAUCAUCGUCGGCUUCGCGC GGAUGAACGGCAGG ACCGUCGGUAUAGU CGGCAACCAGCCCAAGGUCGCCAGCGGG UGCCUAGAUAUUAA CUCCUCCGUUAAAG GGGCAAGAUUCGUCCGCUUCUGCGACGC CUUCAACAUCCCCU UGAUUACCUUCGUG GACGUCCCCGGCUUCCUCCCCGGAACAG CCCAGGAGUACGGC GGCAUCAUCCGCCA CGGUGCCAAACUCCUCUACGCCUUCGCC GAGGCCACCGUCCC CAAAGUGACCGUCA UCACCCGAAAGGCCUACGGAGGCGCUUA CGACGUCAUGUCCU CCAAGCACCUCUGC GGCGACACCAAUUACGCUUGGCCUACUG CCGAGAUCGCCGUC AUGGGCGCUAAAGG AGCUGUUGAGAUAAUCUUCAAGGGCCAC GAGAACGUCGAGGC CGCGCAGGCCGAGU ACAUUGAGAAGUUCGCCAACCCCUUCCC CGCAGCCGUCCGCG GUUUCGUGGACGAC AUUAUUCAACCUUCUUCUACCCGUGCCC GUAUCUGCUGCGAC CUGGACGUGCUCGC CUCCAAGAAGGUCCAGCGCCCCUGGCGC AAGCACGCCAAUAU CCCACUC SEQ ID NO: 15  21   3   4  44PCCB_16 MAAALRVAAVGARL AUGGCCGCCGCCCU GGGAAA UGAUAA SEQ ID (hPCCB;SVLASGLRAAVRSLC GCGGGUGGCCGCCG UAAGAG UAGGCU NO: 44 G5) SQATSVNERIENKRRUGGGCGCCCGGCUG AGAAAA GGAGCC consists Cap: C1 TALLGGGQRRIDAQHAGCGUGCUGGCCAG GAAGAG UCGGUG from 5′ to PolyA tail: KRGKLTARERISLLLCGGCCUGCGGGCCG UAAGAA GCCUAG 3′ end: 5′ 100 nt DPGSFVESDMFVEHRCCGUGCGGAGCCUG GAAAUA CUUCUU UTR of CADFGMAADKNKFP UGCAGCCAGGCCAC UAAGAGGCCCCU SEQ ID GDSVVTGRGRINGRL CAGCGUGAACGAGC CCACC UGGGCC NO: 3,VYVFSQDFTVFGGSL GGAUCGAGAACAAG UCCCCC ORF SGAHAQKICKIMDQA CGGCGGACCGCCCUCAGCCC Sequence ITVGAPVIGLNDSGG GCUGGGCGGCGGCC CUCCUC of SEQ IDARIQEGVESLAGYAD AGCGGCGGAUCGAC CCCUUC NO: 21, IFLRNVTASGVIPQISLGCCCAGCACAAGCG CUGCAC and 3′ IMGPCAGGAVYSPAL GGGCAAGCUGACCG CCGUACUTR of TDFTFMVKDTSYLFI CCCGGGAGCGGAUC CCCCUC SEQ ID TGPDVVKSVTNEDVTAGCCUGCUGCUGGA CAUAAA NO: 4 QEELGGAKTHTTMS CCCCGGCAGCUUCG GUAGGAGVAHRAFENDVDAL UGGAGAGCGACAUG AACACU CNLRDFFNYLPLSSQ UUCGUGGAGCACCGACAGUG DPAPVRECHDPSDRL GUGCGCCGACUUCG GUCUUU VPELDTIVPLESTKAYGCAUGGCCGCCGAC GAAUAA NMVDIIHSVVDEREF AAGAACAAGUUCCC AGUCUGFEIMPNYAKNIIVGFA CGGCGACAGCGUGG AGUGGG RMNGRTVGIVGNQP UGACCGGCCGGGGCCGGC KVASGCLDINSSVKG CGGAUCAACGGCCG ARFVRFCDAFNIPLIT GCUGGUGUACGUGUFVDVPGFLPGTAQEY UCAGCCAGGACUUC GGIIRHGAKLLYAFA ACCGUGUUCGGCGGEATVPKVTVITRKAY CAGCCUGAGCGGCG GGAYDVMSSKHLCG CCCACGCCCAGAAGDTNYAWPTAEIAVM AUCUGCAAGAUCAU GAKGAVEIIFKGHEN GGACCAGGCCAUCAVEAAQAEYIEKFANP CCGUGGGCGCGCCC FPAAVRGFVDDIIQPS GUGAUCGGCCUGAASTRARICCDLDVLAS CGACAGCGGCGGCG KKVQRPWRKHANIP CCCGGAUCCAGGAG LGGCGUGGAGAGCCU GGCCGGCUACGCCG ACAUCUUCCUGCGG AACGUGACCGCCAGCGGCGUGAUCCCGC AGAUCAGCCUGAUC AUGGGCCCCUGCGC CGGCGGCGCCGUGUACAGCCCCGCCCUG ACCGACUUCACCUU CAUGGUGAAGGACA CCAGCUACCUGUUCAUCACCGGCCCCGA CGUGGUGAAGAGCG UGACCAACGAGGAC GUGACCCAGGAGGAGCUGGGCGGCGCCA AGACCCACACCACC AUGAGCGGCGUGGC CCACCGGGCCUUCGAGAACGACGUGGAC GCCCUGUGCAACCU GCGGGACUUCUUCA ACUACCUGCCCCUGAGCAGCCAGGACCC CGCGCCCGUGCGGG AGUGCCACGACCCC AGCGACCGGCUGGUGCCCGAGCUGGACA CCAUCGUGCCCCUG GAGAGCACCAAGGC CUACAACAUGGUGGACAUCAUCCACAGC GUGGUGGACGAGCG GGAGUUCUUCGAGA UCAUGCCCAACUACGCCAAGAACAUCAU CGUGGGCUUCGCCC GGAUGAACGGCCGG ACCGUGGGCAUCGUGGGCAACCAGCCCA AGGUGGCCAGCGGC UGCCUGGACAUCAA CAGCAGCGUGAAGGGCGCCCGGUUCGUG CGGUUCUGCGACGC CUUCAACAUCCCAC UGAUCACCUUCGUGGACGUGCCCGGCUU CCUGCCCGGCACCG CCCAGGAGUACGGC GGCAUCAUCCGGCACGGCGCCAAGCUGC UGUACGCCUUCGCC GAGGCCACCGUGCC CAAGGUGACCGUGAUCACCCGGAAGGCC UACGGCGGCGCCUA CGACGUGAUGAGCA GCAAGCACCUGUGCGGCGACACCAACUA CGCCUGGCCCACCG CCGAGAUCGCCGUG AUGGGCGCCAAGGGCGCCGUGGAGAUCA UCUUCAAGGGCCAC GAGAACGUGGAGGC CGCCCAGGCCGAGUACAUCGAGAAGUUC GCCAACCCCUUCCC CGCCGCCGUGCGGG GCUUCGUGGACGACAUCAUCCAGCCCAG CAGCACCCGGGCCC GGAUCUGCUGCGAC CUGGACGUGCUGGCCAGCAAGAAGGUGC AGCGGCCCUGGCGG AAGCACGCCAACAU CCCGCUG SEQ ID NO: 15  22  3   4  45 PCCB_17 MAAALRVAAVGARL AUGGCCGCGGCCCU GGGAAA UGAUAA SEQ ID(hPCCB; SVLASGLRAAVRSLC GCGGGUCGCGGCCG UAAGAG UAGGCU NO: 45 G5)SQATSVNERIENKRR UGGGAGCCAGACUG AGAAAA GGAGCC consists TALLGGGQRRIDAQHUCCGUGCUAGCCUC GAAGAG UCGGUG from 5′ to KRGKLTARERISLLL AGGGCUGCGCGCCGUAAGAA GCCUAG 3′ end: 5′ DPGSFVESDMFVEHR CUGUGAGAAGCCUG GAAAUA CUUCUUUTR of CADFGMAADKNKFP UGCAGCCAGGCCAC UAAGAG GCCCCU SEQ IDGDSVVTGRGRINGRL CAGCGUGAACGAGA CCACC UGGGCC NO: 3, VYVFSQDFTVFGGSLGAAUCGAGAACAAG UCCCCC ORF SGAHAQKICKIMDQA AGAAGAACCGCUCU CAGCCC SequenceITVGAPVIGLNDSGG GCUGGGUGGCGGCC CUCCUC of SEQ ID ARIQEGVESLAGYADAGAGAAGAAUCGAC CCCUUC NO: 22, IFLRNVTASGVIPQISL GCCCAGCACAAGAG CUGCACand 3′ IMGPCAGGAVYSPAL AGGCAAGCUGACCG CCGUAC UTR of TDFTFMVKDTSYLFICCAGAGAGAGAAUC CCCCUC SEQ ID TGPDVVKSVTNEDVT AGCCUGCUGCUGGA CAUAAA NO: 4QEELGGAKTHTTMS CCCCGGCAGCUUCG GUAGGA GVAHRAFENDVDAL UGGAGAGCGACAUGAACACU CNLRDFFNYLPLSSQ UUCGUGGAGCACCG ACAGUG DPAPVRECHDPSDRLCUGCGCCGACUUCG GUCUUU VPELDTIVPLESTKAY GCAUGGCCGCCGAC GAAUAANMVDIIHSVVDEREF AAGAACAAGUUCCC AGUCUG FEIMPNYAKNIIVGFA CGGCGACAGCGUGGAGUGGG RMNGRTVGIVGNQP UGACCGGCAGAGGC CGGC KVASGCLDINSSVKG AGAAUCAACGGCAGARFVRFCDAFNIPLIT ACUGGUGUACGUGU FVDVPGFLPGTAQEY UCAGCCAGGACUUCGGIIRHGAKLLYAFA ACCGUGUUCGGCGG EATVPKVTVITRKAY CUCCCUGAGCGGGGGGAYDVMSSKHLCG CCCACGCCCAGAAG DTNYAWPTAEIAVM AUCUGCAAGAUCAUGAKGAVEIIFKGHEN GGACCAAGCCAUUA VEAAQAEYIEKFANP CCGUGGGCGCUCCUFPAAVRGFVDDIIQPS GUGAUCGGCCUGAA STRARICCDLDVLAS CGACUCCGGCGGCGKKVQRPWRKHANIP CGAGGAUCCAGGAG L GGCGUGGAAAGCCU GGCGGGUUACGCCGACAUCUUCCUGAGA AACGUCACCGCAUC CGGAGUGAUUCCCC AGAUCAGCCUGAUCAUGGGUCCCUGCGC GGGCGGAGCCGUGU ACAGCCCCGCCCUG ACCGACUUCACCUUCAUGGUGAAGGACA CCAGCUACCUGUUC AUCACCGGCCCCGA CGUGGUCAAGAGCGUGACCAACGAGGAC GUGACCCAAGAGGA GCUCGGAGGCGCCA AGACCCACACCACCAUGAGCGGCGUGGC CCACAGAGCCUUCG AGAACGACGUGGAC GCCCUGUGCAACCUGAGAGACUUCUUCA ACUACCUGCCCCUG AGUUCUCAGGAUCC UGCACCCGUGAGAGAGUGCCACGACCCC AGCGACAGACUGGU GCCCGAGCUGGACA CCAUCGUGCCCCUGGAGAGCACCAAGGC CUACAACAUGGUGG ACAUCAUCCACAGC GUUGUGGACGAGAGAGAGUUCUUCGAGA UCAUGCCCAACUAC GCCAAGAACAUCAU CGUGGGCUUCGCCAGAAUGAACGGCAGG ACUGUGGGAAUCGU GGGCAACCAGCCCA AGGUGGCCAGCGGCUGCCUGGACAUCAA CAGCAGCGUGAAGG GCGCCAGAUUCGUG AGAUUCUGCGACGCCUUCAACAUCCCGC UGAUCACAUUCGUG GACGUUCCCGGCUU CCUGCCCGGCACAGCCCAGGAGUACGGC GGCAUCAUCAGACA CGGCGCCAAGCUGC UGUACGCCUUCGCCGAGGCCACCGUGCC CAAGGUGACCGUGA UCACCAGAAAGGCC UACGGCGGAGCUUACGACGUGAUGAGCA GCAAGCACCUGUGC GGUGACACUAACUA CGCCUGGCCGACCGCCGAGAUCGCCGUG AUGGGCGCCAAAGG GGCCGUGGAGAUCA UCUUCAAGGGCCACGAGAACGUGGAGGC CGCCCAGGCCGAGU ACAUCGAGAAGUUC GCCAACCCCUUCCCCGCCGCCGUCAGGG GUUUCGUGGACGAC AUCAUCCAGCCCUC CUCCACCAGAGCCAGAAUCUGCUGCGAC CUGGACGUACUGGC CAGCAAGAAGGUGC AACGUCCCUGGAGAAAGCACGCCAACAU CCCUCUG SEQ ID NO: 15  23   3   4  46 PCCB_18MAAALRVAAVGARL AUGGCCGCAGCCCU GGGAAA UGAUAA SEQ ID (hPCCB;SVLASGLRAAVRSLC CAGAGUGGCUGCCG UAAGAG UAGGCU NO: 46 G5) SQATSVNERIENKRRUGGGAGCCAGACUC AGAAAA GGAGCC consists Cap: C1 TALLGGGQRRIDAQHAGCGUGCUCGCCUC GAAGAG UCGGUG from 5′ to PolyA tail: KRGKLTARERISLLLAGGCCUGCGGGCCG UAAGAA GCCUAG 3′ end: 5′ 100 nt DPGSFVESDMFVEHRCAGUCAGAAGCCUG GAAAUA CUUCUU UTR of CADFGMAADKNKFP UGCAGCCAGGCAAC UAAGAGGCCCCU SEQ ID GDSVVTGRGRINGRL CUCAGUGAACGAGA CCACC UGGGCC NO: 3,VYVFSQDFTVFGGSL GAAUCGAGAACAAG UCCCCC ORF SGAHAQKICKIMDQA AGACGGACCGCCCUCAGCCC Sequence ITVGAPVIGLNDSGG GCUGGGUGGCGGGC CUCCUC of SEQ IDARIQEGVESLAGYAD AAAGAAGAAUUGAC CCCUUC NO: 23, IFLRNVTASGVIPQISLGCCCAGCACAAGAG CUGCAC and 3′ IMGPCAGGAVYSPAL AGGCAAGCUGACCG CCGUACUTR of TDFTFMVKDTSYLFI CCCGCGAGCGCAUC CCCCUC SEQ ID TGPDVVKSVTNEDVTAGCCUGCUGCUGGA CAUAAA NO: 4 QEELGGAKTHTTMS CCCCGGCAGCUUCG GUAGGAGVAHRAFENDVDAL UGGAGAGCGACAUG AACACU CNLRDFFNYLPLSSQ UUCGUGGAGCAUCGACAGUG DPAPVRECHDPSDRL GUGUGCCGACUUCG GUCUUU VPELDTIVPLESTKAYGCAUGGCCGCCGAC GAAUAA NMVDIIHSVVDEREF AAGAACAAGUUCCC AGUCUGFEIMPNYAKNIIVGFA CGGCGACAGCGUGG AGUGGG RMNGRTVGIVGNQP UGACCGGCAGAGGCCGGC KVASGCLDINSSVKG AGAAUCAACGGCAG ARFVRFCDAFNIPLIT ACUGGUGUACGUGUFVDVPGFLPGTAQEY UCUCACAAGACUUU GGIIRHGAKLLYAFA ACCGUCUUCGGAGGEATVPKVTVITRKAY AUCCCUGUCAGGGG GGAYDVMSSKHLCG CUCACGCCCAGAAGDTNYAWPTAEIAVM AUCUGCAAGAUCAU GAKGAVEIIFKGHEN GGACCAGGCCAUCAVEAAQAEYIEKFANP CCGUGGGCGCUCCC FPAAVRGFVDDIIQPS GUGAUCGGCCUGAASTRARICCDLDVLAS CGACAGCGGAGGCG KKVQRPWRKHANIP CCAGGAUCCAAGAG LGGAGUGGAGUCCCU GGCCGGCUACGCCG ACAUCUUCCUGAGA AACGUGACCGCCUCGGGCGUGAUCCCAC AGAUCUCCCUGAUC AUGGGACCCUGCGC CGGCGGGGCCGUCUACAGCCCUGCCCUG ACCGACUUCACCUU CAUGGUGAAGGACA CCAGCUACCUGUUCAUCACCGGCCCCGA CGUGGUCAAGAGCG UGACCAACGAGGAC GUGACCCAGGAGGAGCUCGGCGGAGCCA AGACUCACACAACC AUGUCCGGCGUCGC UCAUAGGGCCUUCGAGAACGACGUGGAC GCCCUGUGCAACCU GAGAGACUUCUUCA ACUACCUGCCAUUGAGCAGCCAGGAUCC CGCCCCUGUGAGAG AGUGCCACGACCCC AGCGACAGACUGGUGCCCGAGCUGGACA CCAUCGUGCCCCUG GAGAGCACCAAGGC CUACAACAUGGUGGACAUCAUCCACAGC GUGGUGGACGAGAG AGAGUUCUUCGAGA UCAUGCCCAACUACGCCAAGAACAUCAU CGUGGGCUUCGCCA GAAUGAACGGCAGA ACCGUGGGCAUUGUGGGCAACCAGCCCA AGGUCGCCAGCGGC UGCCUCGACAUCAA CAGCAGCGUGAAGGGCGCCAGAUUCGUG AGAUUCUGCGACGC CUUCAACAUACCUC UGAUCACCUUUGUGGACGUGCCUGGUUU CCUCCCGGGCACCG CCCAAGAAUACGGU GGCAUCAUCAGACACGGCGCCAAGCUGC UGUACGCCUUCGCC GAGGCCACCGUGCC CAAGGUGACCGUUAUCACCCGCAAAGCC UACGGCGGCGCCUA CGACGUGAUGAGCA GCAAGCACCUGUGUGGCGACACCAAUUA CGCCUGGCCCACCG CCGAGAUCGCCGUC AUGGGCGCGAAAGGAGCCGUGGAGAUCA UCUUCAAGGGCCAC GAGAACGUGGAGGC CGCCCAGGCCGAGUACAUCGAGAAGUUC GCCAACCCCUUCCC UGCCGCCGUGAGGG GCUUCGUCGACGAUAUCAUCCAGCCCAG CUCCACCCGCGCCA GAAUCUGUUGCGAC CUGGACGUGCUGGCCAGCAAGAAGGUGC AAAGACCCUGGAGA AAGCACGCCAACAU CCCGCUG SEQ ID NO: 15  24  3   4  47 PCCB_19 MAAALRVAAVGARL AUGGCCGCCGCCCU GGGAAA UGAUAA SEQ ID(hPCCB; SVLASGLRAAVRSLC AAGGGUUGCCGCAG UAAGAG UAGGCU NO: 47 G5)SQATSVNERIENKRR UUGGUGCCAGGCUA AGAAAA GGAGCC consists Cap: C1TALLGGGQRRIDAQH AGCGUGCUAGCCAG GAAGAG UCGGUG from 5′ to PolyA tail:KRGKLTARERISLLL CGGGCUACGGGCGG UAAGAA GCCUAG 3′ end: 5′ 100 ntDPGSFVESDMFVEHR CGGUAAGGAGCCUG GAAAUA CUUCUU UTR of CADFGMAADKNKFPUGCAGCCAAGCCAC UAAGAG GCCCCU SEQ ID GDSVVTGRGRINGRL CAGCGUGAACGAGA CCACCUGGGCC NO: 3, VYVFSQDFTVFGGSL GGAUAGAGAACAAG UCCCCC ORF SGAHAQKICKIMDQAAGGAGGACCGCCCU CAGCCC Sequence ITVGAPVIGLNDSGG ACUAGGCGGUGGGC CUCCUCof SEQ ID ARIQEGVESLAGYAD AACGCCGGAUCGAC CCCUUC NO: 24,IFLRNVTASGVIPQISL GCCCAACACAAGAG CUGCAC and 3′ IMGPCAGGAVYSPALGGGAAAGCUAACCG CCGUAC UTR of TDFTFMVKDTSYLFI CCAGGGAAAGAAUA CCCCUCSEQ ID TGPDVVKSVTNEDVT AGCCUACUACUAGA CAUAAA NO: 4 QEELGGAKTHTTMSUCCAGGGAGCUUCG GUAGGA GVAHRAFENDVDAL UGGAGAGCGAUAUG AACACUCNLRDFFNYLPLSSQ UUUGUGGAGCACAG ACAGUG DPAPVRECHDPSDRL GUGCGCCGAUUUCGGUCUUU VPELDTIVPLESTKAY GGAUGGCCGCAGAU GAAUAA NMVDIIHSVVDEREFAAGAACAAGUUCCC AGUCUG FEIMPNYAKNIIVGFA AGGGGAUAGCGUGG AGUGGGRMNGRTVGIVGNQP UGACCGGGAGAGGA CGGC KVASGCLDINSSVKG AGGAUAAACGGGAGARFVRFCDAFNIPLIT GCUAGUGUACGUGU FVDVPGFLPGTAQEY UCAGCCAAGAUUUCGGIIRHGAKLLYAFA ACCGUGUUCGGAGG EATVPKVTVITRKAY GAGCCUAAGCGGGGGGAYDVMSSKHLCG CCCACGCCCAGAAG DTNYAWPTAEIAVM AUUUGCAAGAUAAUGAKGAVEIIFKGHEN GGAUCAAGCCAUAA VEAAQAEYIEKFANP CCGUUGGAGCGCCAFPAAVRGFVDDIIQPS GUGAUAGGGCUAAA STRARICCDLDVLAS CGAUAGCGGUGGAGKKVQRPWRKHANIP CCCGGAUCCAAGAG L GGCGUGGAAUCUCU AGCCGGGUACGCCGAUAUAUUCCUAAGG AACGUGACCGCGUC UGGUGUGAUACCAC AAAUUAGUCUCAUAAUGGGGCCUUGCGC AGGAGGGGCUGUGU ACAGCCCAGCCCUA ACCGAUUUCACGUUCAUGGUGAAGGAUA CCAGCUACCUAUUC AUAACCGGGCCAGA CGUGGUAAAGUCCGUGACCAACGAGGAC GUGACCCAAGAGGA AUUAGGAGGAGCCA AGACCCACACCACCAUGUCCGGGGUUGC CCACAGGGCCUUCG AGAACGACGUGGAC GCCCUGUGCAACCUAAGGGAUUUCUUCA ACUACCUACCACUA UCUUCCCAAGAUCC UGCCCCAGUGAGGGAGUGCCACGAUCCA AGCGAUAGACUGGU CCCAGAGCUAGAUA CCAUAGUGCCACUAGAGAGCACCAAGGC CUACAACAUGGUGG AUAUAAUACACUCC GUGGUGGACGAGAGGGAGUUCUUCGAGA UAAUGCCAAACUAC GCCAAGAACAUAAU AGUGGGGUUCGCCAGGAUGAACGGGCGU ACCGUGGGGAUAGU AGGAAACCAACCAA AGGUGGCCUCUGGGUGCCUAGAUAUAAA CAGCUCUGUCAAGG GAGCCCGCUUCGUG AGGUUCUGCGACGCCUUCAACAUACCUC UAAUAACAUUCGUU GACGUGCCAGGGUU CCUACCAGGGACGGCACAAGAGUACGGA GGGAUAAUAAGGCA CGGGGCGAAGCUAC UAUACGCCUUCGCCGAGGCCACCGUGCC UAAGGUGACCGUGA UAACCAGGAAGGCU UACGGAGGGGCCUACGACGUGAUGAGCA GCAAGCACCUGUGC GGGGAUACCAACUA CGCGUGGCCAACCGCCGAGAUAGCCGUG AUGGGUGCAAAGGG UGCUGUGGAGAUAA UAUUCAAGGGGCACGAGAACGUGGAGGC CGCGCAGGCCGAGU ACAUAGAGAAGUUC GCCAACCCAUUCCCAGCAGCGGUACGGG GAUUUGUUGACGAU AUCAUUCAACCAAG CAGCACCCGCGCGAGAAUUUGCUGCGAC UUAGACGUGUUAGC GAGCAAGAAGGUAC AACGGCCCUGGAGGAAGCACGCUAACAU CCCACUA SEQ ID NO: 15  25   3   4  48 PCCB_20MAAALRVAAVGARL AUGGCGGCGGCAUU GGGAAA UGAUAA SEQ ID (hPCCB;SVLASGLRAAVRSLC ACGGGUGGCGGCGG UAAGAG UAGGCU NO: 48 G5) SQATSVNERIENKRRUCGGGGCAAGGCUC AGAAAA GGAGCC consists Cap: C1 TALLGGGQRRIDAQHAGCGUGCUGGCCAG GAAGAG UCGGUG from 5′ to PolyA tail: KRGKLTARERISLLLCGGCCUGAGAGCCG UAAGAA GCCUAG 3′ end: 5′ 100 nt DPGSFVESDMFVEHRCCGUGAGAAGCCUG GAAAUA CUUCUU UTR of CADFGMAADKNKFP UGCAGCCAGGCCAC UAAGAGGCCCCU SEQ ID GDSVVTGRGRINGRL CAGCGUGAACGAGA CCACC UGGGCC NO: 3,VYVFSQDFTVFGGSL GAAUCGAGAACAAG UCCCCC ORF SGAHAQKICKIMDQA AGAAGAACCGCCCUCAGCCC Sequence ITVGAPVIGLNDSGG GCUGGGCGGCGGCC CUCCUC of SEQ IDARIQEGVESLAGYAD AGAGAAGAAUCGAC CCCUUC NO: 25, IFLRNVTASGVIPQISLGCCCAGCACAAGAG CUGCAC and 3′ IMGPCAGGAVYSPAL AGGCAAGCUGACCG CCGUACUTR of TDFTFMVKDTSYLFI CCAGAGAGAGAAUC CCCCUC SEQ ID TGPDVVKSVTNEDVTAGCCUGCUGCUGGA CAUAAA NO: 4 QEELGGAKTHTTMS CCCCGGCAGCUUCG GUAGGAGVAHRAFENDVDAL UGGAGAGCGACAUG AACACU CNLRDFFNYLPLSSQ UUCGUGGAGCACAGACAGUG DPAPVRECHDPSDRL GUGCGCCGACUUCG GUCUUU VPELDTIVPLESTKAYGCAUGGCCGCCGAC GAAUAA NMVDIIHSVVDEREF AAGAACAAGUUCCC AGUCUGFEIMPNYAKNIIVGFA CGGCGACAGCGUGG AGUGGG RMNGRTVGIVGNQP UGACCGGCAGAGGCCGGC KVASGCLDINSSVKG AGAAUCAACGGCAG ARFVRFCDAFNIPLIT ACUGGUGUACGUGUFVDVPGFLPGTAQEY UCAGCCAGGACUUC GGIIRHGAKLLYAFA ACCGUGUUCGGCGGEATVPKVTVITRKAY CAGCCUGAGCGGCG GGAYDVMSSKHLCG CCCACGCCCAGAAGDTNYAWPTAEIAVM AUCUGCAAGAUCAU GAKGAVEIIFKGHEN GGACCAGGCCAUCAVEAAQAEYIEKFANP CCGUGGGCGCGCCC FPAAVRGFVDDIIQPS GUGAUCGGCCUGAASTRARICCDLDVLAS CGACAGCGGCGGCG KKVQRPWRKHANIP CCAGAAUCCAGGAG LGGCGUGGAGAGCCU GGCCGGCUACGCCG ACAUCUUCCUGAGA AACGUGACCGCCAGCGGCGUGAUCCCAC AGAUCAGCCUGAUC AUGGGCCCCUGCGC CGGCGGCGCCGUGUACAGCCCCGCCCUG ACCGACUUCACCUU CAUGGUGAAGGACA CCAGCUACCUGUUCAUCACCGGCCCCGA CGUGGUGAAGAGCG UGACCAACGAGGAC GUGACCCAGGAGGAGCUGGGCGGCGCCA AGACCCACACCACC AUGAGCGGCGUGGC CCACAGAGCCUUCGAGAACGACGUGGAC GCCCUGUGCAACCU GAGAGACUUCUUCA ACUACCUGCCCCUGAGCAGCCAGGACCC CGCGCCCGUGAGAG AGUGCCACGACCCC AGCGACAGACUGGUGCCCGAGCUGGACA CCAUCGUGCCCCUG GAGAGCACCAAGGC CUACAACAUGGUGGACAUCAUCCACAGC GUGGUGGACGAGAG AGAGUUCUUCGAGA UCAUGCCCAACUACGCCAAGAACAUCAU CGUGGGCUUCGCCA GAAUGAACGGCAGA ACCGUGGGCAUCGUGGGCAACCAGCCCA AGGUGGCCAGCGGC UGCCUGGACAUCAA CAGCAGCGUGAAGGGCGCCAGAUUCGUG AGAUUCUGCGACGC CUUCAACAUCCCUC UGAUCACCUUCGUGGACGUGCCCGGCUU CCUGCCCGGCACCG CCCAGGAGUACGGC GGCAUCAUCAGACACGGCGCCAAGCUGC UGUACGCCUUCGCC GAGGCCACCGUGCC CAAGGUGACCGUGAUCACCAGAAAGGCC UACGGCGGCGCCUA CGACGUGAUGAGCA GCAAGCACCUGUGCGGCGACACCAACUA CGCCUGGCCCACCG CCGAGAUCGCCGUG AUGGGCGCCAAGGGCGCCGUGGAGAUCA UCUUCAAGGGCCAC GAGAACGUGGAGGC CGCCCAGGCCGAGUACAUCGAGAAGUUC GCCAACCCCUUCCC CGCCGCCGUGAGAG GCUUCGUGGACGACAUCAUCCAGCCCAG CAGCACCAGAGCCA GAAUCUGCUGCGAC CUGGACGUGCUGGCCAGCAAGAAGGUGC AGAGACCCUGGAGA AAGCACGCCAACAU CCCUCUG SEQ ID NO: 15  23  3 178  66 PCCB_21 MAAALRVAAVGARL AUGGCCGCAGCCCU GGGAAA UGAUAA SEQ ID(hPCCB; SVLASGLRAAVRSLC CAGAGUGGCUGCCG UAAGAG UAGUCC NO: 66 G5)SQATSVNERIENKRR UGGGAGCCAGACUC AGAAAA AUAAAG consists Cap: C1TALLGGGQRRIDAQH AGCGUGCUCGCCUC GAAGAG UAGGAA from 5′ to PolyA tail:KRGKLTARERISLLL AGGCCUGCGGGCCG UAAGAA ACACUA 3′ end: 5′ 100 ntDPGSFVESDMFVEHR CAGUCAGAAGCCUG GAAAUA CAGCUG UTR of CADFGMAADKNKFPUGCAGCCAGGCAAC UAAGAG GAGCCU SEQ ID GDSVVTGRGRINGRL CUCAGUGAACGAGA CCACCCGGUGG NO: 3, VYVFSQDFTVFGGSL GAAUCGAGAACAAG CCUAGC ORF SGAHAQKICKIMDQAAGACGGACCGCCCU UUCUUG Sequence ITVGAPVIGLNDSGG GCUGGGUGGCGGGC CCCCUUof SEQ ID ARIQEGVESLAGYAD AAAGAAGAAUUGAC GGGCCU NO: 23,IFLRNVTASGVIPQISL GCCCAGCACAAGAG CCAUAA and 3′ IMGPCAGGAVYSPALAGGCAAGCUGACCG AGUAGG UTR of TDFTFMVKDTSYLFI CCCGCGAGCGCAUC AAACACSEQ ID TGPDVVKSVTNEDVT AGCCUGCUGCUGGA UACAUC NO: 178 QEELGGAKTHTTMSCCCCGGCAGCUUCG CCCCCA GVAHRAFENDVDAL UGGAGAGCGACAUG GCCCCUCNLRDFFNYLPLSSQ UUCGUGGAGCAUCG CCUCCC DPAPVRECHDPSDRL GUGUGCCGACUUCGCUUCCU VPELDTIVPLESTKAY GCAUGGCCGCCGAC GCACCC NMVDIIHSVVDEREFAAGAACAAGUUCCC GUACCC FEIMPNYAKNIIVGFA CGGCGACAGCGUGG CCUCCARMNGRTVGIVGNQP UGACCGGCAGAGGC UAAAGU KVASGCLDINSSVKG AGAAUCAACGGCAGAGGAAA ARFVRFCDAFNIPLIT ACUGGUGUACGUGU CACUAC FVDVPGFLPGTAQEYUCUCACAAGACUUU AGUGGU GGIIRHGAKLLYAFA ACCGUCUUCGGAGG CUUUGAEATVPKVTVITRKAY AUCCCUGUCAGGGG AUAAAG GGAYDVMSSKHLCG CUCACGCCCAGAAGUCUGAG DTNYAWPTAEIAVM AUCUGCAAGAUCAU UGGGCG GAKGAVEIIFKGHENGGACCAGGCCAUCA GC VEAAQAEYIEKFANP CCGUGGGCGCUCCC FPAAVRGFVDDIIQPSGUGAUCGGCCUGAA STRARICCDLDVLAS CGACAGCGGAGGCG KKVQRPWRKHANIPCCAGGAUCCAAGAG L GGAGUGGAGUCCCU GGCCGGCUACGCCG ACAUCUUCCUGAGAAACGUGACCGCCUC GGGCGUGAUCCCAC AGAUCUCCCUGAUC AUGGGACCCUGCGCCGGCGGGGCCGUCU ACAGCCCUGCCCUG ACCGACUUCACCUU CAUGGUGAAGGACACCAGCUACCUGUUC AUCACCGGCCCCGA CGUGGUCAAGAGCG UGACCAACGAGGACGUGACCCAGGAGGA GCUCGGCGGAGCCA AGACUCACACAACC AUGUCCGGCGUCGCUCAUAGGGCCUUCG AGAACGACGUGGAC GCCCUGUGCAACCU GAGAGACUUCUUCAACUACCUGCCAUUG AGCAGCCAGGAUCC CGCCCCUGUGAGAG AGUGCCACGACCCCAGCGACAGACUGGU GCCCGAGCUGGACA CCAUCGUGCCCCUG GAGAGCACCAAGGCCUACAACAUGGUGG ACAUCAUCCACAGC GUGGUGGACGAGAG AGAGUUCUUCGAGAUCAUGCCCAACUAC GCCAAGAACAUCAU CGUGGGCUUCGCCA GAAUGAACGGCAGAACCGUGGGCAUUGU GGGCAACCAGCCCA AGGUCGCCAGCGGC UGCCUCGACAUCAACAGCAGCGUGAAGG GCGCCAGAUUCGUG AGAUUCUGCGACGC CUUCAACAUACCUCUGAUCACCUUUGUG GACGUGCCUGGUUU CCUCCCGGGCACCG CCCAAGAAUACGGUGGCAUCAUCAGACA CGGCGCCAAGCUGC UGUACGCCUUCGCC GAGGCCACCGUGCCCAAGGUGACCGUUA UCACCCGCAAAGCC UACGGCGGCGCCUA CGACGUGAUGAGCAGCAAGCACCUGUGU GGCGACACCAAUUA CGCCUGGCCCACCG CCGAGAUCGCCGUCAUGGGCGCGAAAGG AGCCGUGGAGAUCA UCUUCAAGGGCCAC GAGAACGUGGAGGCCGCCCAGGCCGAGU ACAUCGAGAAGUUC GCCAACCCCUUCCC UGCCGCCGUGAGGGGCUUCGUCGACGAU AUCAUCCAGCCCAG CUCCACCCGCGCCA GAAUCUGUUGCGACCUGGACGUGCUGGC CAGCAAGAAGGUGC AAAGACCCUGGAGA AAGCACGCCAACAU CCCGCUGSEQ ID NO: 15  23  64 112  67 PCCB_22 MAAALRVAAVGARL AUGGCCGCAGCCCUGGGAAA UGAUAA SEQ ID (hPCCB; SVLASGLRAAVRSLC CAGAGUGGCUGCCG TAAGAGUAGUCC NO: 67 G5) SQATSVNERIENKRR UGGGAGCCAGACUC AGAAAA AUAAAG consistsCap: C1 TALLGGGQRRIDAQH AGCGUGCUCGCCUC GAAGAG UAGGAA from 5′ toPolyA tail: KRGKLTARERISLLL AGGCCUGCGGGCCG TAAGAA ACACUA 3′ end: 5′100 nt DPGSFVESDMFVEHR CAGUCAGAAGCCUG GAAATA CAGCUG UTR ofCADFGMAADKNKFP UGCAGCCAGGCAAC TAAGAG GAGCCU SEQ ID GDSVVTGRGRINGRLCUCAGUGAACGAGA CCACC CGGUGG NO: 64, VYVFSQDFTVFGGSL GAAUCGAGAACAAGCCUAGC ORF SGAHAQKICKIMDQA AGACGGACCGCCCU UUCUUG SequenceITVGAPVIGLNDSGG GCUGGGUGGCGGGC CCCCUU of SEQ ID ARIQEGVESLAGYADAAAGAAGAAUUGAC GGGCCU NO: 23, IFLRNVTASGVIPQISL GCCCAGCACAAGAG CCCCCCand 3′ IMGPCAGGAVYSPAL AGGCAAGCUGACCG AGCCCC UTR of TDFTFMVKDTSYLFICCCGCGAGCGCAUC UCCUCC SEQ ID TGPDVVKSVTNEDVT AGCCUGCUGCUGGA CCUUCCNO: 112 QEELGGAKTHTTMS CCCCGGCAGCUUCG UGCACC GVAHRAFENDVDALUGGAGAGCGACAUG CGUACC CNLRDFFNYLPLSSQ UUCGUGGAGCAUCG CCCCGCDPAPVRECHDPSDRL GUGUGCCGACUUCG AUUAUU VPELDTIVPLESTKAY GCAUGGCCGCCGACACUCAC NMVDIIHSVVDEREF AAGAACAAGUUCCC GGUACG FEIMPNYAKNIIVGFACGGCGACAGCGUGG AGUGGU RMNGRTVGIVGNQP UGACCGGCAGAGGC CUUUGAKVASGCLDINSSVKG AGAAUCAACGGCAG AUAAAG ARFVRFCDAFNIPLIT ACUGGUGUACGUGUUCUGAG FVDVPGFLPGTAQEY UCUCACAAGACUUU UGGGCG GGIIRHGAKLLYAFAACCGUCUUCGGAGG GC EATVPKVTVITRKAY AUCCCUGUCAGGGG GGAYDVMSSKHLCGCUCACGCCCAGAAG DTNYAWPTAEIAVM AUCUGCAAGAUCAU GAKGAVEIIFKGHENGGACCAGGCCAUCA VEAAQAEYIEKFANP CCGUGGGCGCUCCC FPAAVRGFVDDIIQPSGUGAUCGGCCUGAA STRARICCDLDVLAS CGACAGCGGAGGCG KKVQRPWRKHANIPCCAGGAUCCAAGAG L GGAGUGGAGUCCCU GGCCGGCUACGCCG ACAUCUUCCUGAGAAACGUGACCGCCUC GGGCGUGAUCCCAC AGAUCUCCCUGAUC AUGGGACCCUGCGCCGGCGGGGCCGUCU ACAGCCCUGCCCUG ACCGACUUCACCUU CAUGGUGAAGGACACCAGCUACCUGUUC AUCACCGGCCCCGA CGUGGUCAAGAGCG UGACCAACGAGGACGUGACCCAGGAGGA GCUCGGCGGAGCCA AGACUCACACAACC AUGUCCGGCGUCGCUCAUAGGGCCUUCG AGAACGACGUGGAC GCCCUGUGCAACCU GAGAGACUUCUUCAACUACCUGCCAUUG AGCAGCCAGGAUCC CGCCCCUGUGAGAG AGUGCCACGACCCCAGCGACAGACUGGU GCCCGAGCUGGACA CCAUCGUGCCCCUG GAGAGCACCAAGGCCUACAACAUGGUGG ACAUCAUCCACAGC GUGGUGGACGAGAG AGAGUUCUUCGAGAUCAUGCCCAACUAC GCCAAGAACAUCAU CGUGGGCUUCGCCA GAAUGAACGGCAGAACCGUGGGCAUUGU GGGCAACCAGCCCA AGGUCGCCAGCGGC UGCCUCGACAUCAACAGCAGCGUGAAGG GCGCCAGAUUCGUG AGAUUCUGCGACGC CUUCAACAUACCUCUGAUCACCUUUGUG GACGUGCCUGGUUU CCUCCCGGGCACCG CCCAAGAAUACGGUGGCAUCAUCAGACA CGGCGCCAAGCUGC UGUACGCCUUCGCC GAGGCCACCGUGCCCAAGGUGACCGUUA UCACCCGCAAAGCC UACGGCGGCGCCUA CGACGUGAUGAGCAGCAAGCACCUGUGU GGCGACACCAAUUA CGCCUGGCCCACCG CCGAGAUCGCCGUCAUGGGCGCGAAAGG AGCCGUGGAGAUCA UCUUCAAGGGCCAC GAGAACGUGGAGGCCGCCCAGGCCGAGU ACAUCGAGAAGUUC GCCAACCCCUUCCC UGCCGCCGUGAGGGGCUUCGUCGACGAU AUCAUCCAGCCCAG CUCCACCCGCGCCA GAAUCUGUUGCGACCUGGACGUGCUGGC CAGCAAGAAGGUGC AAAGACCCUGGAGA AAGCACGCCAACAU CCCGCUGSEQ ID NO: 15  26   3 150  49 PCCB-014 MAAALRVAAVGARL AUGGCCGCCGCCCUGGGAAA UGAUAA SEQ ID (hPCCB; SVLASGLRAAVRSLC GAGAGUGGCCGCUG UAAGAGUAGGCU NO: 49 G5) SQATSVNERIENKRR UGGGCGCCAGGCUG AGAAAA GGAGCC consistsCap: C1 TALLGGGQRRIDAQH AGCGUGCUCGCUAG GAAGAG UCGGUG from 5′ toPolyA tail: KRGKLTARERISLLL CGGCCUGAGAGCCG UAAGAA GCCAUG 3′ end: 5′100 nt DPGSFVESDMFVEHR CCGUUAGAAGCCUG GAAAUA CUUCUU UTR ofCADFGMAADKNKFP UGCAGCCAGGCCAC UAAGAG GCCCCU SEQ ID GDSVVTGRGRINGRLCUCCGUGAACGAGA CCACC UGGGCC NO: 3, VYVFSQDFTVFGGSL GGAUCGAGAAUAAG UCCCCCORF SGAHAQKICKIMDQA AGACGAACCGCCCU CAGCCC Sequence ITVGAPVIGLNDSGGGCUCGGCGGCGGCC CUCCUC of SEQ ID ARIQEGVESLAGYAD AGAGACGCAUCGAC CCCUUCNO: 26, IFLRNVTASGVIPQISL GCCCAGCACAAGCG CUGCAC and 3′ IMGPCAGGAVYSPALAGGUAAGCUGACAG CCGUAC UTR of TDFTFMVKDTSYLFI CCAGGGAGCGAAUC CCCCGUSEQ ID TGPDVVKSVTNEDVT AGCCUGCUCCUGGA GGUCUU NO: 150 QEELGGAKTHTTMSCCCCGGAAGCUUCG UGAAUA GVAHRAFENDVDAL UGGAAUCCGACAUG AAGUCUCNLRDFFNYLPLSSQ UUCGUUGAGCACAG GAGUGG DPAPVRECHDPSDRL AUGCGCCGACUUCGGCGGC VPELDTIVPLESTKAY GCAUGGCCGCCGAC NMVDIIHSVVDEREF AAGAACAAGUUUCCFEIMPNYAKNIIVGFA AGGGGACUCAGUGG RMNGRTVGIVGNQP UCACCGGAAGAGGCKVASGCLDINSSVKG CGCAUCAACGGCCG ARFVRFCDAFNIPLIT CCUGGUCUACGUGUFVDVPGFLPGTAQEY UCUCACAGGACUUU GGIIRHGAKLLYAFA ACAGUGUUCGGCGGEATVPKVTVITRKAY CAGCCUGUCAGGCG GGAYDVMSSKHLCG CCCAUGCCCAGAAGDTNYAWPTAEIAVM AUCUGCAAGAUCAU GAKGAVEIIFKGHEN GGAUCAGGCCAUCAVEAAQAEYIEKFANP CAGUGGGCGCCCCC FPAAVRGFVDDIIQPS GUGAUCGGUCUGAASTRARICCDLDVLAS CGACUCUGGCGGCG KKVQRPWRKHANIP CCAGAAUUCAAGAG LGGCGUGGAGAGCCU GGCCGGUUACGCCG ACAUUUUCCUGAGG AACGUCACCGCCAGCGGCGUCAUCCCCC AGAUCUCUCUGAUC AUGGGCCCCUGCGC UGGCGGCGCCGUGUACAGCCCCGCCCUG ACCGAUUUCACCUU CAUGGUGAAGGAUA CCAGCUAUCUGUUCAUCACCGGCCCGGA UGUGGUGAAGAGU GUGACCAACGAGGA CGUGACCCAGGAGGAGCUGGGUGGAGCC AAGACUCACACAAC CAUGUCCGGCGUGG CCCAUCGAGCCUUUGAGAACGACGUCGA CGCCCUGUGUAACC UGAGAGACUUCUUC AAUUACCUGCCCCUGAGCUCCCAGGACC CCGCCCCAGUUAGG GAGUGCCACGAUCC CUCCGACCGCCUGGUGCCCGAGCUGGAC ACCAUCGUGCCCCU GGAGAGCACCAAGG CCUACAACAUGGUGGAUAUCAUCCAUAG CGUCGUCGACGAGC GCGAGUUCUUCGAG AUCAUGCCCAACUACGCCAAGAACAUCA UCGUGGGCUUUGCC AGGAUGAACGGCCG CACCGUGGGCAUUGUGGGCAACCAGCCC AAGGUGGCCUCUGG CUGCCUGGACAUCA ACAGCAGCGUGAAGGGUGCUAGGUUCGU GAGGUUCUGCGAUG CCUUUAACAUCCCA CUUAUCACCUUCGUUGAUGUCCCUGGCU UCCUGCCUGGCACC GCCCAGGAGUACGG CGGCAUCAUCAGACAUGGUGCCAAGCUG CUGUACGCCUUCGC CGAGGCCACCGUGC CCAAGGUGACCGUGAUUACCCGGAAAGC CUACGGCGGCGCCU ACGACGUCAUGAGC AGCAAGCACCUGUGCGGCGACACCAACU ACGCCUGGCCCACC GCCGAGAUCGCCGU CAUGGGCGCCAAGGGGGCCGUCGAGAUC AUCUUCAAGGGACA CGAGAACGUGGAGG CCGCUCAGGCCGAGUACAUCGAGAAGUU CGCUAACCCUUUCC CCGCCGCUGUUAGA GGAUUCGUGGAUGACAUCAUCCAGCCAA GCAGCACCCGGGCC AGGAUCUGCUGUGA CCUGGAUGUGCUGGCUAGCAAGAAGGUG CAGAGACCCUGGAG AAAGCACGCCAACA UUCCCCUG SEQ ID NO: 15  27  3 150  50 PCCB-014 MAAALRVAAVGARL AUGGCCGCCGCCCU GGGAAA UGAUAA SEQ ID(hPCCB; SVLASGLRAAVRSLC GAGAGUGGCCGCUG UAAGAG UAGGCU NO: 50 G5)SQATSVNERIENKRR UGGGCGCCAGGCUG AGAAAA GGAGCC consists Cap: C1TALLGGGQRRIDAQH AGCGUGCUCGCUAG GAAGAG UCGGUG from 5′ to PolyA tail:KRGKLTARERISLLL CGGCCUGAGAGCCG UAAGAA GCCAUG 3′ end: 5′ 100 ntDPGSFVESDMFVEHR CCGUUAGAAGCCUG GAAAUA CUUCUU UTR of CADFGMAADKNKFPUGCAGCCAGGCCAC UAAGAG GCCCCU SEQ ID GDSVVTGRGRINGRL CUCCGUGAACGAGA CCACCUGGGCC NO: 3, VYVFSQDFTVFGGSL GGAUCGAGAAUAAG UCCCCC ORF SGAHAQKICKIMDQAAGACGAACCGCCCU CAGCCC Sequence ITVGAPVIGLNDSGG GCUCGGCGGCGGCC CUCCUCof SEQ ID ARIQEGVESLAGYAD AGAGACGCAUCGAC CCCUUC NO: 27,IFLRNVTASGVIPQISL GCCCAGCACAAGCG CUGCAC and 3′ IMGPCAGGAVYSPALAGGUAAGCUGACAG CCGUAC UTR of TDFTFMVKDTSYLFI CCAGGGAGCGAAUC CCCCGUSEQ ID TGPDVVKSVTNEDVT AGCCUGCUCCUGGA GGUCUU NO: 150 QEELGGAKTHTTMSCCCCGGAAGCUUCG UGAAUA GVAHRAFENDVDAL UGGAAUCCGACAUG AAGUCUCNLRDFFNYLPLSSQ UUCGUUGAGCACAG GAGUGG DPAPVRECHDPSDRL AUGCGCCGACUUCGGCGGC VPELDTIVPLESTKAY GCAUGGCCGCCGAC NMVDIIHSVVDEREF AAGAACAAGUUUCCFEIMPNYAKNIIVGFA AGGGGACUCAGUGG RMNGRTVGIVGNQP UCACCGGAAGAGGCKVASGCLDINSSVKG CGCAUCAACGGCCG ARFVRFCDAFNIPLIT CCUGGUCUACGUGUFVDVPGFLPGTAQEY UCUCACAGGACUUU GGIIRHGAKLLYAFA ACAGUGUUCGGCGGEATVPKVTVITRKAY CAGCCUGUCAGGCG GGAYDVMSSKHLCG CCCAUGCCCAGAAGDTNYAWPTAEIAVM AUCUGCAAGAUCAU GAKGAVEIIFKGHEN GGAUCAGGCCAUCAVEAAQAEYIEKFANP CAGUGGGCGCCCCC FPAAVRGFVDDIIQPS GUGAUCGGUCUGAASTRARICCDLDVLAS CGACUCUGGCGGCG KKVQRPWRKHANIP CCAGAAUUCAAGAG LGGCGUGGAGAGCCU GGCCGGUUACGCCG ACAUUUUCCUGAGG AACGUCACCGCCAGCGGCGUCAUCCCCC AGAUCUCUCUGAUC AUGGGCCCCUGCGC UGGCGGCGCCGUGUACAGCCCCGCCCUG ACCGAUUUCACCUU CAUGGUGAAGGAUA CCAGCUAUCUGUUCAUCACCGGCCCGGA UGUGGUGAAGAGU GUGACCAACGAGGA CGUGACCCAGGAGGAGCUGGGUGGAGCC AAGACUCACACAAC CAUGUCCGGCGUGG CCCAUCGAGCCUUUGAGAACGACGUCGA CGCCCUGUGUAACC UGAGAGACUUCUUC AAUUACCUGCCCCUGAGCUCCCAGGACC CCGCCCCAGUUAGG GAGUGCCACGAUCC CUCCGACCGCCUGGUGCCCGAGCUGGAC ACCAUCGUGCCCCU GGAGAGCACCAAGG CCUACAACAUGGUGGAUAUCAUCCAUAG CGUCGUCGACGAGC GCGAGUUCUUCGAG AUCAUGCCCAACUACGCCAAGAACAUCA UCGUGGGCUUUGCC AGGAUGAACGGCCG CACCGUGGGCAUUGUGGGCAACCAGCCC AAGGUGGCCUCUGG CUGCCUGGACAUCA ACAGCAGCGUGAAGGGUGCUAGGUUCGU GAGGUUCUGCGAUG CCUUUAACAUCCCA CUUAUCACCUUCGUUGAUGUCCCUGGCU UCCUGCCUGGCACC GCCCAGGAGUACGG CGGCAUCAUCAGACAUGGUGCCAAGCUG CUGUACGCCUUCGC CGAGGCCACCGUGC CCAAGGUGACCGUGAUUACCCGGAAAGC CUACGGCGGCGCCU ACGACGUCAUGAGC AGCAAGCACCUGUGCGGCGACACCAACU ACGCCUGGCCCACC GCCGAGAUCGCCGU CAUGGGCGCCAAGGGGGCCGUCGAGAUC AUCUUCAAGGGACA CGAGAACGUGGAGG CCGCUCAGGCCGAGUACAUCGAGAAGUU CGCUAACCCUUUCC CCGCCGCUGUUAGA GGAUUCGUGGAUGACAUCAUCCAGCCAA GCAGCACCCGGGCC AGGAUCUGCUGUGA CCUGGAUGUGCUGGCUAGCAAGAAGGUG CAGAGACCCUGGAG AAAGCACGCCAACA UUCCCCUG SEQ ID NO:  1  51  3 150  57 LX- MAGFWVGTAPLVAA AUGGCCGGGUUCUG GGGAAA UGAUAA SEQ IDhPCCA_- GRRGRWPPQQLMLS GGUGGGCACCGCCC UAAGAG UAGGCU NO: 57 01-015.2AALRTLKHVLYYSR CCCUGGUCGCUGCA AGAAAA GGAGCC consists (hPCCA_;QCLMVSRNLGSVGY GGCCGGAGGGGCAG GAAGAG UCGGUG from 5′ to G5; SE#7)DPNEKTFDKILVANR GUGGCCCCCUCAGC UAAGAA GCCAUG 3′ end: 5′ Cap: C1GEIACRVIRTCKKMG AGCUGAUGCUGAGC GAAAUA CUUCUU UTR of PolyA tail:IKTVAIHSDVDASSV GCCGCUCUUCGGAC UAAGAG GCCCCU SEQ ID 100 ntHVKMADEAVCVGPA ACUCAAACACGUGC CCACC UGGGCC NO: 3, PTSKSYLNMDAIMEAUGUACUAUAGCAGA UCCCCC ORF IKKTRAQAVHPGYGF CAGUGCCUGAUGGU CAGCCC SequenceLSENKEFARCLAAED GAGUAGGAACCUCG CUCCUC of SEQ ID VVFIGPDTHAIQAMGGCAGCGUGGGGUAU CCCUUC NO: 51, DKIESKLLAKKAEVN GAUCCCAACGAGAA CUGCACand 3′ TIPGFDGVVKDAEEA GACCUUCGACAAGA CCGUAC UTR of VRIAREIGYPVMIKASUCCUGGUGGCAAAU CCCCGU SEQ ID AGGGGKGMRIAWDD CGGGGCGAGAUCGC GGUCUUNO: 150 EETRDGFRLSSQEAA CUGCAGGGUGAUCA UGAAUA SSFGDDRLLIEKFIDNGAACCUGCAAGAAG AAGUCU PRHIEIQVLGDKHGN AUGGGCAUCAAGAC GAGUGGALWLNERECSIQRRN CGUCGCUAUUCACA GCGGC QKVVEEAPSIFLDAE GCGACGUGGAUGCCTRRAMGEQAVALAR UCAAGCGUGCACGU AVKYSSAGTVEFLVD GAAGAUGGCAGACGSKKNFYFLEMNTRLQ AAGCAGUGUGUGUG VEHPVTECITGLDLV GGCCCCGCCCCUACQEMIRVAKGYPLRH UUCAAAGUCCUACC KQADIRINGWAVECR UUAAUAUGGACGCAVYAEDPYKSFGLPSI AUUAUGGAGGCAAU GRLSQYQEPLHLPGV CAAGAAGACCAGGGRVDSGIQPGSDISIYY CUCAAGCUGUGCAU DPMISKLITYGSDRTE CCAGGAUAUGGCUUALKRMADALDNYVI CCUGUCCGAGAACA RGVTHNIALLREVIIN AGGAGUUCGCCAGASRFVKGDISTKFLSDV UGCCUGGCAGCCGA YPDGFKGHMLTKSE GGAUGUGGUCUUUAKNQLLAIASSLFVAF UCGGCCCUGAUACA QLRAQHFQENSRMP CACGCCAUCCAGGCVIKPDIANWELSVKL UAUGGGGGAUAAG IIDKVHTVVASNNGS AUCGAGAGUAAGCUVFSVEVDGSKLNVTS GCUGGCGAAGAAAG TWNLASPLLSVSVDG CCGAGGUGAACACCTQRTVQCLSREAGGN AUUCCGGGCUUUGA MSIQFLGTVYKVNIL CGGCGUGGUGAAGGTRLAAELNKFMLEK ACGCCGAGGAGGCC VTEDTSSVLRSPMPG GUGCGGAUCGCUAGVVVAVSVKPGDAVA GGAGAUCGGCUACC EGQEICVIEAMKMQN CUGUGAUGAUCAAGSMTAGKTGTVKSVH GCUUCUGCCGGCGG CQAGDTVGEGDLLV AGGCGGAAAGGGCA ELEUGCGUAUUGCUUGG GACGACGAGGAAAC CCGCGACGGCUUUC GGCUGAGCAGCCAGGAAGCCGCCAGUAG CUUUGGCGAUGACC GGCUUCUUAUAGAG AAGUUUAUCGACAACCCCAGACACAUUG AGAUCCAGGUAUUG GGCGAUAAACACGG AAAUGCCCUUUGGCUGAAUGAGAGAGA AUGCUCCAUCCAGA GAAGGAACCAGAAG GUGGUGGAGGAGGCCCCCUCAAUCUUCC UGGACGCCGAGACC CGUAGAGCCAUGGG CGAGCAGGCCGUGGCCCUCGCCAGAGCU GUGAAGUAUUCCUC UGCUGGCACCGUGG AGUUCUUAGUGGAUUCCAAGAAGAACUU CUACUUCCUCGAGA UGAAUACCAGACUC CAGGUGGAGCAUCCCGUCACCGAAUGCA UCACUGGCCUGGAC CUGGUGCAGGAGAU GAUCAGAGUUGCUAAGGGUUACCCACUG CGCCACAAGCAGGC UGACAUCAGGAUCA ACGGGUGGGCAGUGGAGUGCAGAGUGUA UGCUGAGGACCCCU ACAAGAGCUUCGGC CUGCCGAGCAUCGGCCGGCUGAGCCAGU ACCAGGAACCCCUC CACCUGCCUGGCGU ACGGGUGGACAGUGGAAUCCAGCCCGGC AGCGACAUCAGCAU UUAUUACGAUCCCA UGAUCUCGAAGUUGAUCACCUAUGGGUC UGACAGAACCGAGG CCCUGAAGAGAAUG GCCGACGCGCUGGAUAACUACGUGAUUC GGGGAGUGACUCAC AACAUAGCUCUACU GCGUGAGGUCAUCAUCAAUAGCAGAUUC GUAAAGGGCGACAU UAGCACCAAGUUUC UUUCCGACGUGUACCCAGACGGUUUUAA GGGACACAUGCUGA CAAAGUCUGAGAAG AACCAGCUGCUGGCCAUAGCCAGCAGCC UGUUCGUGGCCUUU CAGCUCCGAGCCCA ACACUUCCAGGAGAACAGCAGAAUGCCA GUGAUCAAGCCUGA CAUCGCCAACUGGG AGCUGUCUGUGAAACUGCACGACAAGGU GCAUACCGUCGUGG CCAGCAACAAUGGC UCCGUGUUCUCCGUGGAGGUGGAUGGCU CAAAGCUGAACGUG ACCUCGACAUGGAA CCUCGCCUCUCCCCUGCUGAGUGUGAGC GUGGACGGCACACA GAGAACCGUGCAGU GCCUGAGUAGAGAAGCAGGGGGCAACAU GUCCAUUCAGUUUC UCGGCACCGUGUAC AAGGUCAAUAUUCUCACCAGACUCGCCG CCGAGCUGAACAAG UUCAUGCUUGAGAA GGUGACCGAGGAUACUAGUUCCGUGCUC AGAUCCCCUAUGCC CGGCGUGGUGGUCG CUGUGUCCGUCAAGCCCGGCGACGCCGU GGCCGAGGGACAGG AGAUUUGCGUGAUU GAGGCUAUGAAGAUGCAGAAUAGCAUGA CUGCUGGCAAGACG GGCACAGUGAAGAG CGUGCAUUGCCAGGCAGGCGACACAGUG GGCGAAGGAGACCU GCUGGUCGAGUUAG AG SEQ ID NO:  1  52   3150  58 LX- MAGFWVGTAPLVAA AUGGCAGGCUUCUG GGGAAA UGAUAA SEQ ID hPCCA_-GRRGRWPPQQLMLS GGUUGGCACUGCCC UAAGAG UAGGCU NO: 58 10-002 AALRTLKHVLYYSRCACUCGUGGCCGCC AGAAAA GGAGCC consists (hPPCA; QCLMVSRNLGSVGYGGCAGAAGGGGAAG GAAGAG UCGGUG from 5′ to G5; Pv2- DPNEKTFDKILIANRGGUGGCCUCCCCAGC UAAGAA GCCAUG 3′ end: 5′ SE#1) EIACRVIRTCKKMGIAGCUCAUGCUGUCC GAAAUA CUUCUU UTR of Cap: C1 KTVAIHSDVDASSVHGCCGCUCUGCGAAC UAAGAG GCCCCU SEQ ID PolyA tail: VKMADEAVCVGPAPCCUGAAGCACGUGC CCACC UGGGCC NO: 3, 100 nt TSKSYLNMDAIMEAI UGUAUUAUAGCAGGUCCCCC ORF KKTRAQAVHPGYGF CAGUGCCUCAUGGU CAGCCC Sequence LSENKEFARCLAAEDUUCCCGGAACCUGG CUCCUC of SEQ ID VVFIGPDTHAIQAMG GGAGCGUGGGCUAU CCCUUCNO: 52, DKIESKLLAKKAEVN GACCCUAAUGAGAA CUGCAC and 3′ TIPGFDGVVKDAEEAGACUUUCGACAAGA CCGUAC UTR of VRIAREIGYPVMIKAS UCCUGAUCGCUAAC CCCCGUSEQ ID AGGGGKGMRIAWDD AGAGGCGAGAUCGC GGUCUU NO: 150 EETRDGFRLSSQEAACUGCAGGGUGAUCA UGAAUA SSFGDDRLLIEKFIDN GAACAUGCAAGAAG AAGUCUPRHIEIQVLGDKHGN AUGGGCAUCAAGAC GAGUGG ALWLNERECSIQRRN CGUCGCGAUCCAUAGCGGC QKVVEEAPSIFLDAE GCGACGUGGAUGCC TRRAMGEQAVALAR AGCAGCGUUCACGUAVKYSSAGTVEFLVD CAAGAUGGCCGACG SKKNFYFLEMNTRLQ AGGCUGUGUGCGUCVEHPVTECITGLDLV GGCCCCGCCCCAAC QEMIRVAKGYPLRH UUCCAAGAGCUAUCKQADIRINGWAVECR UGAACAUGGACGCC VYAEDPYKSFGLPSI AUAAUGGAGGCUAUGRLSQYQEPLHLPGV CAAGAAGACCAGAG RVDSGIQPGSDISIYY CCCAGGCAGUUCAUDPMISKLITYGSDRTE CCCGGCUACGGAUU ALKRMEDALDNYVI CCUGAGCGAGAACARGVTHNIALLREVIIN AGGAGUUCGCUAGA SRFVKGDISTKFLSDV UGUCUGGCCGCCGAYPDGFKGHMLTKSE AGACGUGGUUUUCA KNQLLAIASSLFVAF UCGGUCCAGACACCQLRAQHFQENSRVPV CAUGCCAUCCAAGC IKPDIANWELSVKLH CAUGGGCGAUAAGADKVHTVVASNNGSV UCGAGAGCAAGCUC FSVEVDGSKLNVTST CUGGCCAAGAAGGCWNLASPLLSVSVDGT CGAGGUGAACACCA QRTVQCLSREAGGN UCCCCGGCUUCGAUMSIQFLGTVYKVNIL GGCGUGGUGAAGGA TRLAAELNKFMLEK CGCGGAGGAGGCAGVTEDTSSVLRSPMPG UGCGCAUUGCCAGG VVVAVSVKPGDAVA GAGAUCGGCUACCCEGQEICVIEAMKMQN CGUGAUGAUCAAGG SMTAGKTGTVKSVH CUUCCGCAGGGGGACQAGDTVGEGDLLV GGCGGCAAAGGCAU ELE GCGGAUUGCCUGGG AUGAUGAAGAAACCAGAGAUGGCUUCAG ACUGUCAAGCCAGG AGGCCGCCAGCAGC UUCGGCGACGACAGACUGCUGAUCGAGA AGUUUAUAGAUAAC CCCCGACACAUAGA AAUCCAGGUGCUGGGAGACAAGCACGGC AACGCUCUGUGGCU GAACGAGCGGGAAU GCAGUAUCCAGAGGAGAAACCAGAAGGU GGUUGAGGAGGCCC CCUCAAUCUUCCUG GAUGCCGAGACAAGACGCGCCAUGGGUG AGCAGGCUGUAGCC CUCGCCCGUGCCGU GAAGUAUAGCAGCGCCGGGACAGUGGAG UUCUUGGUCGACUC CAAGAAGAAUUUCU AUUUUCUGGAGAUGAACACUCGGCUCCA AGUAGAGCACCCCG UGACUGAGUGCAUU ACAGGCCUUGAUCUGGUGCAGGAGAUGA UUAGGGUUGCCAAG GGCUACCCUCUGCG CCACAAGCAGGCCGACAUCAGGAUCAAU GGCUGGGCUGUCGA GUGUAGGGUGUACG CAGAGGACCCGUACAAGAGCUUCGGCCU UCCCUCUAUUGGCA GGCUGAGCCAGUAC CAGGAGCCUCUGCACCUACCCGGCGUUC GCGUGGACAGCGGU AUCCAACCAGGCUC UGAUAUCAGCAUUUAUUACGACCCAAUG AUCUCAAAGCUGAU CACAUACGGCAGCG ACAGAACCGAGGCCCUGAAGCGAAUGGA GGACGCCCUGGACA ACUACGUGAUCCGG GGCGUCACACAUAACAUUGCCCUGCUGA GAGAGGUGAUCAUU AAUUCUCGGUUCGU CAAAGGCGACAUCAGCACUAAGUUUCUG AGCGACGUGUACCC CGACGGGUUUAAAG GCCACAUGCUGACAAAGAGCGAGAAGAA CCAGUUGCUGGCCA UCGCCUCUAGCCUG UUCGUAGCCUUCCAGCUGCGAGCACAGC ACUUCCAGGAGAAU AGCAGAGUGCCAGU GAUCAAGCCCGACAUCGCUAACUGGGAG CUGAGCGUGAAGCU CCAUGAUAAGGUCC ACACAGUUGUGGCCAGCAACAACGGCUC AGUGUUCAGCGUGG AGGUAGACGGCUCC AAGCUGAACGUGACCAGCACUUGGAAUC UGGCCAGCCCCCUG CUGAGCGUGUCCGU GGACGGCACCCAGAGAACCGUGCAGUGC CUGAGCAGGGAGGC CGGGGGCAACAUGU CCAUCCAGUUUCUGGGGACCGUCUAUAA GGUUAACAUCCUGA CUAGACUGGCGGCU GAGCUUAACAAGUUUAUGUUAGAGAAA GUGACCGAGGAUAC AAGCAGCGUGCUGC GUAGCCCCAUGCCUGGCGUGGUCGUGGC CGUGAGCGUCAAGC CAGGCGAUGCAGUG GCUGAGGGCCAGGAGAUUUGUGUGAUA GAGGCCAUGAAGAU GCAGAACUCUAUGA CCGCCGGAAAGACUGGCACCGUGAAGUC UGUCCAUUGUCAGG CCGGAGACACCGUG GGGGAAGGAGACCUGCUCGUCGAGCUGG AG SEQ ID NO:  1  53   3 150  59 LX- MAGFWVGTAPLVAAAUGGCCGGCUUCUG GGGAAA UGAUAA SEQ ID hPCCA_- GRRGRWPPQQLMLSGGUGGGCACCGCUC UAAGAG UAGGCU NO: 59 01-018 AALRTLKHVLYYSR CAUUGGUGGCCGCCAGAAAA GGAGCC consists (hPCCA_; QCLMVSRNLGSVGY GGCAGACGGGGCCG GAAGAGUCGGUG from 5′ to G5; SE#9) DPNEKTFDKILVANR CUGGCCUCCUCAAC UAAGAA GCCAUG3′ end: 5′ Cap: C1 GEIACRVIRTCKKMG AGCUUAUGUUAUCA GAAAUA CUUCUU UTR ofPolyA tail: IKTVAIHSDVDASSV GCCGCUUUGCGGAC UAAGAG GCCCCU SEQ ID 100 ntHVKMADEAVCVGPA CUUGAAGCACGUGC CCACC UGGGCC NO: 3, PTSKSYLNMDAIMEAUUUACUAUAGCAGG UCCCCC ORF IKKTRAQAVHPGYGF CAGUGCCUCAUGGU CAGCCC SequenceLSENKEFARCLAAED GUCCAGGAAUCUCG CUCCUC of SEQ ID VVFIGPDTHAIQAMGGCAGCGUGGGUUAC CCCUUC NO: 53, DKIESKLLAKKAEVN GAUCCUAACGAGAA CUGCACand 3′ TIPGFDGVVKDAEEA GACCUUCGAUAAGA CCGUAC UTR of VRIAREIGYPVMIKASUCCUGGUAGCAAAC CCCCGU SEQ ID AGGGGKGMRIAWDD CGCGGCGAGAUCGC GGUCUUNO: 150 EETRDGFRLSSQEAA CUGUAGGGUGAUCA UGAAUA SSFGDDRLLIEKFIDNGGACCUGCAAGAAG AAGUCU PRHIEIQVLGDKHGN AUGGGAAUAAAGAC GAGUGGALWLNERECSIQRRN CGUGGCCAUUCACU GCGGC QKVVEEAPSIFLDAE CCGAUGUGGACGCCTRRAMGEQAVALAR AGCAGCGUGCACGU AVKYSSAGTVEFLVD UAAGAUGGCCGACGSKKNFYFLEMNTRLQ AGGCCGUGUGCGUG VEHPVTECITGLDLV GGCCCUGCCCCUACQEMIRVAKGYPLRH UAGCAAGUCUUACC KQADIRINGWAVECR UGAACAUGGACGCCVYAEDPYKSFGLPSI AUCAUGGAGGCCAU GRLSQYQEPLHLPGV CAAGAAGACCAGAGRVDSGIQPGSDISIYY CCCAGGCCGUUCAU DPMISKLITYGSDRTE CCAGGAUACGGCUUALKRMADALDNYVI CCUGAGCGAGAACA RGVTHNIALLREVIIN AGGAAUUCGCCAGGSRFVKGDISTKFLSDV UGCCUGGCGGCCGA YPDGFKGHMLTKSE AGAUGUGGUGUUCAKNQLLAIASSLFVAF UCGGUCCAGACACA QLRAQHFQENSRMP CACGCCAUCCAAGCVIKPDIANWELSVKL CAUGGGCGACAAGA HDKVHTVVASNNGS UCGAGAGCAAGCUGVFSVEVDGSKLNVTS CUGGCUAAGAAGGC TWNLASPLLSVSVDG CGAGGUCAACACAATQRTVQCLSREAGGN UCCCUGGCUUCGAC MSIQFLGTVYKVNIL GGUGUCGUGAAGGATRLAAELNKFMLEK UGCCGAGGAGGCCG VTEDTSSVLRSPMPG UGCGGAUCGCCCGUVVVAVSVKPGDAVA GAGAUUGGCUAUCC EGQEICVIEAMKMQN AGUGAUGAUCAAGGSMTAGKTGTVKSVH CCUCCGCCGGAGGA CQAGDTVGEGDLLV GGCGGCAAGGGCAU ELEGAGAAUCGCGUGGG ACGACGAGGAAACU AGAGACGGAUUCCG CCUGAGCAGUCAGGAGGCCGCUAGCAGC UUCGGCGACGAUAG ACUGCUGAUCGAGA AGUUCAUCGACAACCCAAGACACAUCGA GAUCCAAGUGUUAG GCGAUAAGCACGGC AAUGCCCUCUGGCUGAAUGAGCGGGAGU GCAGCAUUCAGCGG AGAAAUCAGAAGGU GGUGGAGGAGGCUCCAUCCAUUUUCCUC GACGCCGAGACUAG AAGGGCAAUGGGCG AACAAGCUGUUGCCCUGGCAAGAGCCGU GAAGUACUCUAGCG CCGGCACCGUCGAG UUCCUGGUCGACAGCAAGAAGAACUUCU ACUUCCUGGAGAUG AACACAAGACUGCA GGUGGAACACCCUGUCACCGAGUGCAUA ACAGGCCUGGACCU UGUGCAGGAGAUGA UUAGGGUGGCCAAGGGAUACCCUCUGCG CCACAAGCAGGCCG ACAUCCGGAUCAAC GGCUGGGCCGUGGAGUGCCGAGUCUACG CCGAGGAUCCUUAC AAGAGCUUCGGCUU GCCUAGCAUCGGCAGGCUGAGCCAGUAU CAGGAGCCGCUGCA CCUGCCUGGUGUUA GAGUGGACUCAGGAAUCCAGCCGGGCAG CGACAUCAGCAUCU ACUAUGACCCGAUG AUCUCCAAGCUCAUUACCUACGGCUCUG ACAGAACAGAAGCU CUGAAGCGCAUGGC UGACGCCCUGGACAACUACGUGAUCAGA GGCGUGACCCACAA UAUCGCCCUGCUGC GGGAGGUGAUCAUCAAUUCCCGUUUCGU GAAGGGCGAUAUCA GCACAAAGUUCCUU AGCGAUGUCUACCCUGACGGCUUCAAGG GCCACAUGCUGACU AAGAGCGAGAAGAA CCAGCUCCUGGCCAUCGCAUCAAGCCUC UUCGUCGCCUUCCA GCUGCGGGCUCAGC ACUUCCAGGAGAACAGCCGGAUGCCAGU GAUCAAGCCAGACA UCGCCAACUGGGAG CUUUCUGUCAAGCUGCACGACAAGGUGC AUACAGUCGUGGCU UCUAACAAUGGCAG CGUCUUCUCCGUGGAGGUCGACGGAUCA AAGCUGAACGUGAC CAGCACCUGGAAUC UGGCCAGCCCUCUUCUCAGCGUGUCCGU GGACGGAACCCAGA GAACCGUGCAGUGU CUGAGUAGAGAGGCCGGCGGCAACAUGA GCAUACAGUUCCUG GGCACCGUGUACAA GGUCAACAUCCUGACCAGGCUGGCUGCG GAGCUGAACAAGUU CAUGUUGGAGAAGG UGACGGAGGACACCUCUAGCGUGCUGCG AAGCCCUAUGCCGG GUGUCGUAGUGGCU GUGAGCGUGAAGCCAGGCGACGCCGUGG CAGAGGGCCAAGAG AUUUGUGUUAUUG AGGCAAUGAAGAUGCAGAAUAGCAUGAC CGCCGGCAAGACCG GCACUGUGAAGUCC GUUCACUGCCAGGCCGGCGAUACCGUGG GUGAGGGCGACUUG CUCGUGGAGUUGGA A SEQ ID NO:  1  54   3 150 60 LX- MAGFWVGTAPLVAA AUGGCCGGGUUCUG GGGAAA UGAUAA SEQ ID hPCCA_-GRRGRWPPQQLMLS GGUGGGCACCGCCC UAAGAG UAGGCU NO: 60 10-003 AALRTLKHVLYYSRCCCUGGUCGCUGCA AGAAAA GGAGCC consists (hPCCA_; QCLMVSRNLGSVGYGGCCGGAGGGGCAG GAAGAG UCGGUG from 5′ to G5; DPNEKTFDKILIANRGGUGGCCCCCUCAGC UAAGAA GCCAUG 3′ end: 5′ Pv2 SE#4) EIACRVIRTCKKMGIAGCUGAUGCUGAGC GAAAUA CUUCUU UTR of Cap: C1 KTVAIHSDVDASSVHGCCGCUCUUCGGAC UAAGAG GCCCCU SEQ ID PolyA tail: VKMADEAVCVGPAPACUCAAACACGUGC CCACC UGGGCC NO: 3, 100 nt TSKSYLNMDAIMEAI UGUACUAUAGCAGAUCCCCC ORF KKTRAQAVHPGYGF CAGUGCCUGAUGGU CAGCCC Sequence LSENKEFARCLAAEDGAGUAGGAACCUCG CUCCUC of SEQ ID VVFIGPDTHAIQAMG GCAGCGUGGGGUAU CCCUUCNO: 54, DKIESKLLAKKAEVN GAUCCCAACGAGAA CUGCAC and 3′ TIPGFDGVVKDAEEAGACCUUCGACAAGA CCGUAC UTR of VRIAREIGYPVMIKAS UCCUGAUCGCAAAU CCCCGUSEQ ID AGGGGKGMRIAWDD CGGGGCGAGAUCGC GGUCUU NO: 150 EETRDGFRLSSQEAACUGCAGGGUGAUCA UGAAUA SSFGDDRLLIEKFIDN GAACCUGCAAGAAG AAGUCUPRHIEIQVLGDKHGN AUGGGCAUCAAGAC GAGUGG ALWLNERECSIQRRN CGUCGCUAUUCACAGCGGC QKVVEEAPSIFLDAE GCGACGUGGAUGCC TRRAMGEQAVALAR UCAAGCGUGCACGUAVKYSSAGTVEFLVD GAAGAUGGCAGACG SKKNFYFLEMNTRLQ AAGCAGUGUGUGUGVEHPVTECITGLDLV GGCCCCGCCCCUAC QEMIRVAKGYPLRH UUCAAAGUCCUACCKQADIRINGWAVECR UUAAUAUGGACGCA VYAEDPYKSFGLPSI AUUAUGGAGGCAAUGRLSQYQEPLHLPGV CAAGAAGACCAGGG RVDSGIQPGSDISIYY CUCAAGCUGUGCAUDPMISKLITYGSDRTE CCAGGAUAUGGCUU ALKRMEDALDNYVI CCUGUCCGAGAACARGVTHNIALLREVIIN AGGAGUUCGCCAGA SRFVKGDISTKFLSDV UGCCUGGCAGCCGAYPDGFKGHMLTKSE GGAUGUGGUCUUUA KNQLLAIASSLFVAF UCGGCCCUGAUACAQLRAQHFQENSRVPV CACGCCAUCCAGGC IKPDIANWELSVKLH UAUGGGGGAUAAGDKVHTVVASNNGSV AUCGAGAGUAAGCU FSVEVDGSKLNVTST GCUGGCGAAGAAAGWNLASPLLSVSVDGT CCGAGGUGAACACC QRTVQCLSREAGGN AUUCCGGGCUUUGAMSIQFLGTVYKVNIL CGGCGUGGUGAAGG TRLAAELNKFMLEK ACGCCGAGGAGGCCVTEDTSSVLRSPMPG GUGCGGAUCGCUAG VVVAVSVKPGDAVA GGAGAUCGGCUACCEGQEICVIEAMKMQN CUGUGAUGAUCAAG SMTAGKTGTVKSVH GCUUCUGCCGGCGGCQAGDTVGEGDLLV AGGCGGAAAGGGCA ELE UGCGUAUUGCUUGG GACGACGAGGAAACCCGCGACGGCUUUC GGCUGAGCAGCCAG GAAGCCGCCAGUAG CUUUGGCGAUGACCGGCUUCUUAUAGAG AAGUUUAUCGACAA CCCCAGACACAUUG AGAUCCAGGUAUUGGGCGAUAAACACGG AAAUGCCCUUUGGC UGAAUGAGAGAGA AUGCUCCAUCCAGAGAAGGAACCAGAAG GUGGUGGAGGAGGC CCCCUCAAUCUUCC UGGACGCCGAGACCCGUAGAGCCAUGGG CGAGCAGGCCGUGG CCCUCGCCAGAGCU GUGAAGUAUUCCUCUGCUGGCACCGUGG AGUUCUUAGUGGAU UCCAAGAAGAACUU CUACUUCCUCGAGAUGAAUACCAGACUC CAGGUGGAGCAUCC CGUCACCGAAUGCA UCACUGGCCUGGACCUGGUGCAGGAGAU GAUCAGAGUUGCUA AGGGUUACCCACUG CGCCACAAGCAGGCUGACAUCAGGAUCA ACGGGUGGGCAGUG GAGUGCAGAGUGUA UGCUGAGGACCCCUACAAGAGCUUCGGC CUGCCGAGCAUCGG CCGGCUGAGCCAGU ACCAGGAACCCCUCCACCUGCCUGGCGU ACGGGUGGACAGUG GAAUCCAGCCCGGC AGCGACAUCAGCAUUUAUUACGAUCCCA UGAUCUCGAAGUUG AUCACCUAUGGGUC UGACAGAACCGAGGCCCUGAAGAGAAUG GAGGACGCGCUGGA UAACUACGUGAUUC GGGGAGUGACUCACAACAUAGCUCUACU GCGUGAGGUCAUCA UCAAUAGCAGAUUC GUAAAGGGCGACAUUAGCACCAAGUUUC UUUCCGACGUGUAC CCAGACGGUUUUAA GGGACACAUGCUGACAAAGUCUGAGAAG AACCAGCUGCUGGC CAUAGCCAGCAGCC UGUUCGUGGCCUUUCAGCUCCGAGCCCA ACACUUCCAGGAGA ACAGCAGAGUGCCA GUGAUCAAGCCUGACAUCGCCAACUGGG AGCUGUCUGUGAAA CUGCACGACAAGGU GCAUACCGUCGUGGCCAGCAACAAUGGC UCCGUGUUCUCCGU GGAGGUGGAUGGCU CAAAGCUGAACGUGACCUCGACAUGGAA CCUCGCCUCUCCCC UGCUGAGUGUGAGC GUGGACGGCACACAGAGAACCGUGCAGU GCCUGAGUAGAGAA GCAGGGGGCAACAU GUCCAUUCAGUUUCUCGGCACCGUGUAC AAGGUCAAUAUUCU CACCAGACUCGCCG CCGAGCUGAACAAGUUCAUGCUUGAGAA GGUGACCGAGGAUA CUAGUUCCGUGCUC AGAUCCCCUAUGCCCGGCGUGGUGGUCG CUGUGUCCGUCAAG CCCGGCGACGCCGU GGCCGAGGGACAGGAGAUUUGCGUGAUU GAGGCUAUGAAGAU GCAGAAUAGCAUGA CUGCUGGCAAGACGGGCACAGUGAAGAG CGUGCAUUGCCAGG CAGGCGACACAGUG GGCGAAGGAGACCUGCUGGUCGAGUUAG AG SEQ ID NO:  1  55   3 150  61 LX- MAGFWVGTAPLVAAAUGGCCGGCUUCUG GGGAAA UGAUAA SEQ ID hPCCA_- GRRGRWPPQQLMLSGGUUGGCACCGCCC UAAGAG UAGGCU NO: 61 01-017 AALRTLKHVLYYSR CUCUCGUGGCCGCAAGAAAA GGAGCC consists (hPCCA_; QCLMVSRNLGSVGY GGAAGGAGGGGCAG GAAGAGUCGGUG from 5′ to G5; SE#8) DPNEKTFDKILVANR GUGGCCUCCACAGC UAAGAA GCCAUG3′ end: 5′ Cap: C1 GEIACRVIRTCKKMG AGCUUAUGUUGUCC GAAAUA CUUCUU UTR ofPolyA tail: IKTVAIHSDVDASSV GCCGCCCUCAGAAC UAAGAG GCCCCU SEQ ID 100 ntHVKMADEAVCVGPA ACUCAAGCACGUGC CCACC UGGGCC NO: 3, PTSKSYLNMDAIMEAUAUACUACAGCAGA UCCCCC ORF IKKTRAQAVHPGYGF CAGUGCUUGAUGGU CAGCCC SequenceLSENKEFARCLAAED GUCCAGAAAUCUGG CUCCUC of SEQ ID VVFIGPDTHAIQAMGGCAGCGUAGGUUAU CCCUUC NO: 55, DKIESKLLAKKAEVN GACCCUAACGAGAA CUGCACand 3′ TIPGFDGVVKDAEEA GACCUUCGACAAGA CCGUAC UTR of VRIAREIGYPVMIKASUCCUGGUGGCUAAC CCCCGU SEQ ID AGGGGKGMRIAWDD AGGGGAGAAAUCGC GGUCUUNO: 150 EETRDGFRLSSQEAA CUGUAGGGUCAUUA UGAAUA SSFGDDRLLIEKFIDNGAACCUGCAAGAAG AAGUCU PRHIEIQVLGDKHGN AUGGGAAUCAAGAC GAGUGGALWLNERECSIQRRN CGUCGCUAUCCACU GCGGC QKVVEEAPSIFLDAE CUGACGUUGAUGCATRRAMGEQAVALAR AGCAGCGUGCACGU AVKYSSAGTVEFLVD CAAGAUGGCUGAUGSKKNFYFLEMNTRLQ AGGCUGUCUGCGUC VEHPVTECITGLDLV GGUCCUGCUCCAACQEMIRVAKGYPLRH AUCUAAGAGCUACC KQADIRINGWAVECR UGAACAUGGACGCUVYAEDPYKSFGLPSI AUCAUGGAGGCCAU GRLSQYQEPLHLPGV UAAGAAGACAAGGGRVDSGIQPGSDISIYY CCCAGGCCGUGCAC DPMISKLITYGSDRTE CCUGGAUACGGCUUALKRMADALDNYVI CCUCAGCGAGAAUA RGVTHNIALLREVIIN AGGAGUUCGCAAGASRFVKGDISTKFLSDV UGUCUCGCCGCCGA YPDGFKGHMLTKSE GGACGUCGUGUUCAKNQLLAIASSLFVAF UAGGCCCUGACACC QLRAQHFQENSRMP CACGCCAUCCAGGCVIKPDIANWELSVKL AAUGGGCGAUAAGA IIDKVHTVVASNNGS UCGAGUCCAAGCUGVFSVEVDGSKLNVTS UUAGCAAAGAAGGC TWNLASPLLSVSVDG CGAAGUGAACACCATQRTVQCLSREAGGN UUCCUGGCUUCGAU MSIQFLGTVYKVNIL GGCGUCGUGAAGGATRLAAELNKFMLEK CGCUGAGGAGGCAG VTEDTSSVLRSPMPG UGAGAAUCGCCAGAVVVAVSVKPGDAVA GAGAUCGGAUACCC EGQEICVIEAMKMQN UGUGAUGAUCAAGGSMTAGKTGTVKSVH CCUCUGCCGGAGGC CQAGDTVGEGDLLV GGAGGCAAGGGCAU ELEGAGGAUUGCCUGGG AUGACGAAGAGACG CGUGACGGCUUCCG ACUGAGCUCUCAGGAGGCUGCCUCUUCU UUCGGAGACGAUAG GCUGCUGAUCGAGA AGUUCAUCGACAACCCUCGGCACAUCGA GAUCCAGGUGCUCG GUGACAAGCAUGGA AAUGCCCUGUGGCUGAACGAGCGGGAGU GCUCUAUUCAGAGA AGAAACCAGAAGGU GGUGGAGGAGGCCCCUAGCAUCUUCUUA GACGCUGAAACUCG GAGAGCCAUGGGCG AGCAGGCCGUGGCGCUGGCUAGAGCCGU GAAGUACAGCAGUG CAGGCACAGUGGAG UUCCUGGUGGAUAGCAAGAAGAAUUUCU ACUUCCUGGAGAUG AAUACCAGGCUGCA GGUGGAGCACCCGGUGACGGAGUGCAUC ACAGGCCUGGACCU GGUCCAAGAAAUGA UCAGAGUGGCCAAGGGCUACCCUCUGCG GCAUAAGCAGGCUG ACAUCCGGAUUAAC GGAUGGGCCGUAGAGUGCCGUGUUUAUG CCGAGGACCCUUAC AAGAGCUUCGGUUU GCCAAGCAUUGGCCGGCUGUCCCAGUAC CAAGAGCCACUGCA UCUGCCAGGCGUCA GGGUGGACAGCGGCAUCCAGCCAGGCUC UGACAUCAGCAUUU AUUACGACCCGAUG AUCAGCAAGCUGAUCACAUAUGGAUCCG AUAGAACCGAAGCC CUGAAGAGAAUGGC AGAUGCUCUGGACAACUACGUGAUCAGG GGCGUGACCCACAA CAUCGCCCUGCUCA GGGAAGUGAUCAUUAAUAGCCGGUUCGU GAAGGGCGAUAUCA GCACCAAGUUCCUG UCAGACGUUUAUCCAGAUGGCUUCAAGG GACACAUGCUGACA AAGUCCGAGAAGAA UCAGCUCCUGGCCAUUGCCAGCUCUCUC UUCGUGGCCUUCCA GUUGAGAGCGCAGC ACUUCCAGGAGAACAGUCGAAUGCCUGU CAUUAAGCCUGACA UCGCCAAUUGGGAG CUGAGCGUGAAGCUCCACGACAAGGUCC ACACUGUCGUGGCC AGCAACAACGGCUC AGUGUUCAGCGUGGAAGUCGACGGCUCC AAGCUCAAUGUGAC CUCCACUUGGAACC UGGCUUCCCCACUUCUGUCUGUGAGCGU GGACGGCACUCAGC GGACGGUGCAAUGU CUGAGCAGGGAAGCCGGCGGCAAUAUGA GCAUCCAAUUCCUC GGAACCGUGUACAA GGUUAACAUCCUUACGCGACUGGCCGCU GAGCUGAAUAAGUU CAUGCUGGAGAAGG UGACCGAGGACACCUCUAGCGUGCUGCG GAGCCCUAUGCCAG GAGUGGUGGUGGCC GUGUCCGUGAAGCCUGGAGACGCCGUGG CCGAAGGCCAGGAA AUUUGCGUCAUCGA AGCCAUGAAGAUGCAGAACAGCAUGACC GCCGGCAAGACCGG AACGGUUAAGUCUG UCCACUGCCAGGCCGGCGACACCGUGGG AGAGGGUGACCUCC UGGUUGAGCUGGAG SEQ ID NO:  1  56   3 150 62 LX- MAGFWVGTAPLVAA AUGGCCGGCUUCUG GGGAAA UGAUAA SEQ ID hPCCA_-GRRGRWPPQQLMLS GGUGGGCACCGCCC UAAGAG UAGGCU NO: 62 01-019 AALRTLKHVLYYSRCCCUUGUCGCAGCA AGAAAA GGAGCC consists (hPCCA_; QCLMVSRNLGSVGYGGAAGGCGGGGCCG GAAGAG UCGGUG from 5′ to G5; DPNEKTFDKILVANRGUGGCCUCCCCAGC UAAGAA GCCAUG 3′ end: 5′ SE#10) GEIACRVIRTCKKMGAGUUAAUGCUUAGC GAAAUA CUUCUU UTR of Cap: C1 IKTVAIHSDVDASSVGCCGCCCUCCGCAC UAAGAG GCCCCU SEQ ID PolyA tail: HVKMADEAVCVGPACCUCAAGCACGUCC CCACC UGGGCC NO: 3, 100 nt PTSKSYLNMDAIMEA UCUACUACUCCCGCUCCCCC ORF IKKTRAQAVHPGYGF CAGUGCCUCAUGGU CAGCCC SequenceLSENKEFARCLAAED AUCCCGCAACCUCG CUCCUC of SEQ ID VVFIGPDTHAIQAMGGCUCCGUCGGCUAC CCCUUC NO: 56, DKIESKLLAKKAEVN GACCCCAACGAGAA CUGCACand 3′ TIPGFDGVVKDAEEA GACCUUCGACAAGA CCGUAC UTR of VRIAREIGYPVMIKASUCCUCGUCGCCAAC CCCCGU SEQ ID AGGGGKGMRIAWDD CGCGGCGAGAUCGC GGUCUUNO: 150 EETRDGFRLSSQEAA CUGCCGCGUCAUCC UGAAUA SSFGDDRLLIEKFIDNGCACCUGCAAGAAG AAGUCU PRHIEIQVLGDKHGN AUGGGCAUCAAGAC GAGUGGALWLNERECSIQRRN CGUCGCCAUCCACU GCGGC QKVVEEAPSIFLDAE CCGACGUCGACGCCTRRAMGEQAVALAR UCCUCCGUCCACGU AVKYSSAGTVEFLVD CAAGAUGGCCGACGSKKNFYFLEMNTRLQ AGGCCGUCUGCGUC VEHPVTECITGLDLV GGCCCCGCCCCCACQEMIRVAKGYPLRH CUCCAAGUCCUACC KQADIRINGWAVECR UCAACAUGGACGCCVYAEDPYKSFGLPSI AUCAUGGAGGCCAU GRLSQYQEPLHLPGV CAAGAAGACCCGCGRVDSGIQPGSDISIYY CCCAGGCCGUCCAC DPMISKLITYGSDRTE CCCGGCUACGGCUUALKRMADALDNYVI CCUCUCCGAGAACA RGVTHNIALLREVIIN AGGAGUUCGCCCGCSRFVKGDISTKFLSDV UGCCUCGCCGCCGA YPDGFKGHMLTKSE GGACGUCGUCUUCAKNQLLAIASSLFVAF UCGGCCCUGACACC QLRAQHFQENSRMP CACGCAAUUCAGGCVIKPDIANWELSVKL CAUGGGUGACAAGA IIDKVHTVVASNNGS UUGAGUCCAAGCUCVFSVEVDGSKLNVTS CUCGCCAAGAAGGC TWNLASPLLSVSVDG CGAGGUCAACACCATQRTVQCLSREAGGN UCCCCGGCUUCGAC MSIQFLGTVYKVNIL GGCGUCGUCAAGGATRLAAELNKFMLEK UGCUGAAGAGGCAG VTEDTSSVLRSPMPG UCCGCAUCGCCAGAVVVAVSVKPGDAVA GAGAUAGGCUACCC EGQEICVIEAMKMQN CGUCAUGAUCAAGGSMTAGKTGTVKSVH CCUCCGCCGGCGGC CQAGDTVGEGDLLV GGAGGAAAGGGCAU ELEGCGGAUCGCAUGGG ACGACGAGGAAACC CGCGACGGUUUCCG CCUCUCCUCCCAGGAGGCCGCCUCCAGU UUCGGCGACGACAG ACUCUUGAUCGAGA AGUUCAUCGACAACCCCCGCCACAUCGA GAUCCAGGUCCUCG GAGAUAAGCACGGC AACGCCCUCUGGCUCAACGAGCGCGAGU GCUCCAUCCAGCGC CGCAACCAGAAGGU CGUGGAGGAGGCCCCCUCCAUCUUCCUC GACGCAGAAACAAG GCGCGCGAUGGGAG AGCAGGCAGUGGCCCUUGCCAGGGCCGU CAAGUACUCCUCCG CAGGUACCGUCGAG UUCCUCGUGGACUCCAAGAAGAACUUCU ACUUCUUGGAGAUG AACACACGACUGCA GGUCGAGCAUCCUGUAACCGAGUGCAUC ACCGGCCUCGACCU CGUCCAGGAGAUGA UCCGCGUUGCCAAGGGCUACCCUCUCCG CCACAAGCAGGCCG ACAUCCGCAUCAAC GGCUGGGCUGUGGAAUGUCGGGUGUAUG CCGAGGAUCCCUAC AAGUCCUUCGGCCU GCCAUCUAUUGGCAGACUAUCGCAGUAC CAGGAGCCCCUCCA CCUCCCCGGCGUGC GCGUUGACUCUGGCAUCCAGCCCGGCUC CGACAUCAGCAUCU ACUAUGAUCCGAUG AUCAGCAAGCUUAUCACCUAUGGCUCAG ACCGCACCGAGGCG CUGAAGCGCAUGGC UGACGCCCUCGACAACUAUGUUAUCCGG GGCGUCACCCACAA CAUCGCACUCCUAC GGGAGGUCAUCAUCAACUCCCGCUUCGU GAAGGGUGACAUCU CCACCAAGUUCUUG AGUGACGUGUACCCUGACGGCUUCAAGG GCCACAUGCUCACC AAGUCCGAGAAGAA CCAACUGCUGGCUAUCGCCAGCAGUCUC UUCGUCGCCUUCCA GCUGAGGGCCCAGC ACUUCCAAGAGAAUAGCAGGAUGCCCGU CAUCAAGCCCGACA UCGCCAACUGGGAG CUCUCCGUCAAGCUCCACGACAAGGUCC ACACCGUCGUCGCA UCCAACAACGGAUC UGUGUUCUCCGUCGAGGUCGACGGAUCU AAGCUGAACGUCAC AAGCACUUGGAACC UCGCCUCCCCCCUGCUUUCAGUGAGCGU GGACGGCACCCAGC GCACCGUGCAGUGC CUGAGCCGCGAGGCGGGAGGCAACAUGU CGAUACAGUUCCUG GGCACAGUGUACAA GGUGAAUAUCCUGACAAGACUGGCUGCU GAGCUCAACAAGUU CAUGCUCGAGAAGG UCACCGAGGACACUUCUUCGGUGCUCCG CUCCCCCAUGCCUG GAGUGGUUGUGGCC GUGUCAGUAAAGCCAGGCGACGCUGUUG CCGAGGGUCAGGAA AUCUGCGUCAUCGA GGCCAUGAAGAUGCAGAACUCCAUGACG GCCGGCAAGACGGG CACUGUCAAGUCUG UGCAUUGCCAGGCCGGAGACACUGUGGG CGAGGGCGACCUAC UGGUUGAGCUCGAG SEQ ID NO: 15 196 199 178200 SE_PCCB_ MAAALRVAAVGARL AUGGCCGCAGCCCU AGGAAA UGAUAA SEQ ID 026SVLASGLRAAVRSLC CAGAGUGGCUGCCG UAAGAG UAGUCC NO: 200 (hPCCB;SQATSVNERIENKRR UGGGAGCCAGACUC AGAAAA AUAAAG consists G5)TALLGGGQRRIDAQH AGCGUGCUCGCCUC GAAGAG UAGGAA from 5′ to Cap: C1KRGKLTARERISLLL AGGCCUGCGGGCCG UAAGAA ACACUA 3′ end: 5′ PolyA tail:DPGSFVESDMFVEHR CAGUCAGAAGCCUG GAAAUA CAGCUG UTR of 100 ntCADFGMAADKNKFP UGCAGCCAGGCAAC UAAGAG GAGCCU SEQ ID GDSVVTGRGRINGRLCUCAGUGAACGAGA CCACC CGGUGG NO: 199, VYVFSQDFTVFGGSL GAAUCGAGAACAAGCCUAGC ORF SGAHAQKICKIMDQA AGACGGACCGCCCU UUCUUG SequenceITVGAPVIGLNDSGG GCUGGGUGGCGGGC CCCCUU of SEQ ID ARIQEGVESLAGYADAAAGAAGAAUUGAC GGGCCU NO: 196, IFLRNVTASGVIPQISL GCCCAGCACAAGAG CCAUAAand 3′ IMGPCAGGAVYSPAL AGGCAAGCUGACCG AGUAGG UTR of TDFTFMVKDTSYLFICCCGCGAGCGCAUC AAACAC SEQ ID TGPDVVKSVTNEDVT AGCCUGCUGCUGGA UACAUCNO: 178 QEELGGAKTHTTMS CCCCGGCAGCUUCG CCCCCA GVAHRAFENDVDALUGGAGAGCGACAUG GCCCCU CNLRDFFNYLPLSSQ UUCGUGGAGCAUCG CCUCCCDPAPVRECHDPSDRL GUGUGCCGACUUCG CUUCCU VPELDTIVPLESTKAY GCAUGGCCGCCGACGCACCC NMVDIIHSVVDEREF AAGAACAAGUUCCC GUACCC FEIMPNYAKNIIVGFACGGCGACAGCGUGG CCUCCA RMNGRTVGIVGNQP UGACCGGCAGAGGC UAAAGUKVASGCLDINSSVKG AGAAUCAACGGCAG AGGAAA ARFVRFCDAFNIPLIT ACUGGUGUACGUGUCACUAC FVDVPGFLPGTAQEY UCUCACAAGACUUU AGUGGU GGIIRHGAKLLYAFAACCGUCUUCGGAGG CUUUGA EATVPKVTVITRKAY AUCCCUGUCAGGGG AUAAAGGGAYDVMSSKHLCG CUCACGCCCAGAAG UCUGAG DTNYAWPTAEIAVM AUCUGCAAGAUCAUUGGGCG GAKGAVEIIFKGHEN GGACCAGGCCAUCA GC VEAAQAEYIEKFANP CCGUGGGCGCUCCCFPAAVRGFVDDIIQPS GUGAUCGGCCUGAA STRARICCDLDVLAS CGACAGCGGAGGCGKKVQRPWRKHANIP CCAGGAUCCAAGAG L GGAGUGGAGUCCCU GGCCGGCUACGCCGACAUCUUCCUGAGA AACGUGACCGCCUC GGGCGUGAUCCCAC AGAUCUCCCUGAUCAUGGGACCCUGCGC CGGCGGGGCCGUCU ACAGCCCUGCCCUG ACCGACUUCACCUUCAUGGUGAAGGACA CCAGCUACCUGUUC AUCACCGGCCCCGA CGUGGUCAAGAGCGUGACCAACGAGGAC GUGACCCAGGAGGA GCUCGGCGGAGCCA AGACUCACACAACCAUGUCCGGCGUCGC UCAUAGGGCCUUCG AGAACGACGUGGAC GCCCUGUGCAACCUGAGAGACUUCUUCA ACUACCUGCCAUUG AGCAGCCAGGAUCC CGCCCCUGUGAGAGAGUGCCACGACCCC AGCGACAGACUGGU GCCCGAGCUGGACA CCAUCGUGCCCCUGGAGAGCACCAAGGC CUACAACAUGGUGG ACAUCAUCCACAGC GUGGUGGACGAGAGAGAGUUCUUCGAGA UCAUGCCCAACUAC GCCAAGAACAUCAU CGUGGGCUUCGCCAGAAUGAACGGCAGA ACCGUGGGCAUUGU GGGCAACCAGCCCA AGGUCGCCAGCGGCUGCCUCGACAUCAA CAGCAGCGUGAAGG GCGCCAGAUUCGUG AGAUUCUGCGACGCCUUCAACAUACCUC UGAUCACCUUUGUG GACGUGCCUGGUUU CCUCCCGGGCACCGCCCAAGAAUACGGU GGCAUCAUCAGACA CGGCGCCAAGCUGC UGUACGCCUUCGCCGAGGCCACCGUGCC CAAGGUGACCGUUA UCACCCGCAAAGCC UACGGCGGCGCCUACGACGUGAUGAGCA GCAAGCACCUGUGU GGCGACACCAAUUA CGCCUGGCCCACCGCCGAGAUCGCCGUC AUGGGCGCGAAAGG AGCCGUGGAGAUCA UCUUCAAGGGCCACGAGAACGUGGAGGC CGCCCAGGCCGAGU ACAUCGAGAAGUUC GCCAACCCCUUCCCUGCCGCCGUGAGGG GCUUCGUCGACGAU AUCAUCCAGCCCAG CUCCACCCGCGCCAGAAUUUGUUGCGAC CUGGACGUGCUGGC CAGCAAGAAGGUGC AAAGACCCUGGAGAAAGCACGCCAACAU CCCGCUG SEQ ID NO: 15 197 199 178 201 SE_PCCB_MAAALRVAAVGARL AUGGCCGCAGCCCU AGGAAA UGAUAA SEQ ID 027 SVLASGLRAAVRSLCCAGAGUGGCUGCCG UAAGAG UAGUCC NO:201 (hPCCB; SQATSVNERIENKRRUGGGAGCCAGACUC AGAAAA AUAAAG consists G5) TALLGGGQRRIDAQH AGCGUGCUCGCCUCGAAGAG UAGGAA from 5′ to Cap: C1 KRGKLTARERISLLL AGGCCUGCGGGCCG UAAGAAACACUA 3′ end: 5′ PolyA tail: DPGSFVESDMFVEHR CAGUCAGAAGCCUG GAAAUACAGCUG UTR of 100 nt CADFGMAADKNKFP UGCAGCCAGGCAAC UAAGAG GAGCCU SEQ IDGDSVVTGRGRINGRL CUCAGUGAACGAGA CCACC CGGUGG NO: 199, VYVFSQDFTVFGGSLGAAUCGAGAACAAG CCUAGC ORF SGAHAQKICKIMDQA AGACGGACCGCCCU UUCUUG SequenceITVGAPVIGLNDSGG GCUGGGUGGCGGGC CCCCUU of SEQ ID ARIQEGVESLAGYADAAAGAAGAAUUGAC GGGCCU NO:197, IFLRNVTASGVIPQISL GCCCAGCACAAGAG CCAUAAand 3′ IMGPCAGGAVYSPAL AGGCAAGCUGACCG AGUAGG UTR of TDFTFMVKDTSYLFICCCGCGAGCGCAUC AAACAC SEQ ID TGPDVVKSVTNEDVT AGCCUGCUGCUGGA UACAUCNO:178 QEELGGAKTHTTMS CCCCGGCAGCUUCG CCCCCA GVAHRAFENDVDALUGGAGAGCGACAUG GCCCCU CNLRDFFNYLPLSSQ UUCGUGGAGCAUCG CCUCCCDPAPVRECHDPSDRL GUGUGCCGACUUCG CUUCCU VPELDTIVPLESTKAY GCAUGGCCGCCGACGCACCC NMVDIIHSVVDEREF AAGAACAAGUUCCC GUACCC FEIMPNYAKNIIVGFACGGCGACAGCGUGG CCUCCA RMNGRTVGIVGNQP UGACCGGCAGAGGC UAAAGUKVASGCLDINSSVKG AGAAUCAACGGCAG AGGAAA ARFVRFCDAFNIPLIT ACUGGUGUACGUGUCACUAC FVDVPGFLPGTAQEY UCUCACAAGACUUU AGUGGU GGIIRHGAKLLYAFAACCGUCUUCGGAGG CUUUGA EATVPKVTVITRKAY AUCCCUGUCAGGGG AUAAAGGGAYDVMSSKHLCG CUCACGCCCAGAAG UCUGAG DTNYAWPTAEIAVM AUCUGCAAGAUCAUUGGGCG GAKGAVEIIFKGHEN GGACCAGGCCAUCA GC VEAAQAEYIEKFANP CCGUGGGCGCUCCCFPAAVRGFVDDIIQPS GUGAUCGGCCUGAA STRARICCDLDVLAS CGACAGCGGAGGCGKKVQRPWRKHANIP CCAGGAUCCAAGAG L GGAGUGGAGUCCCU GGCCGGCUACGCCGACAUCUUCCUGAGA AACGUGACCGCCUC GGGCGUGAUCCCAC AGAUCUCCCUGAUCAUGGGACCCUGCGC CGGCGGGGCCGUCU ACAGCCCUGCCCUG ACCGACUUCACCUUCAUGGUGAAGGACA CCAGCUACCUGUUC AUCACCGGCCCCGA CGUGGUCAAGAGCGUGACCAACGAGGAC GUGACCCAGGAGGA GCUCGGCGGAGCCA AGACUCACACAACCAUGUCCGGCGUCGC UCAUAGGGCCUUCG AGAACGACGUGGAC GCCCUGUGCAACCUGAGAGACUUCUUCA ACUACCUGCCAUUG AGCAGCCAGGAUCC CGCCCCUGUGAGAGAGUGCCACGACCCC AGCGACAGACUGGU GCCCGAGCUGGACA CCAUCGUGCCCCUGGAGAGCACCAAGGC CUACAACAUGGUGG ACAUCAUCCACAGC GUGGUGGACGAGAGAGAGUUCUUCGAGA UCAUGCCCAACUAC GCCAAGAACAUCAU CGUGGGCUUCGCCAGAAUGAACGGCAGA ACCGUGGGCAUUGU GGGCAACCAGCCCA AGGUCGCCAGCGGCUGCCUCGACAUCAA CAGCAGCGUGAAGG GCGCCAGAUUCGUG AGAUUCUGCGACGCCUUCAACAUACCUC UGAUCACCUUUGUG GACGUGCCUGGUUU CCUCCCGGGCACCGCCCAAGAAUACGGU GGCAUCAUCAGACA CGGCGCCAAGCUGC UGUACGCCUUCGCCGAGGCCACCGUGCC CAAGGUGACCGUUA UCACCCGCAAAGCC UACGGCGGCGCCUACGACGUGAUGAGCA GCAAGCACCUGUGU GGCGACACCAAUUA CGCCUGGCCCACCGCCGAGAUCGCCGUC AUGGGCGCGAAAGG AGCCGUGGAGAUCA UCUUCAAGGGCCACGAGAACGUGGAGGC CGCCCAGGCCGAGU ACAUCGAGAAGUUC GCCAACCCCUUCCCUGCCGCCGUGAGGG GCUUCGUCGACGAU AUCAUCCAGCCCAG CUCCACCCGCGCCAGAAUCUGCUGCGAC CUGGACGUGCUGGC CAGCAAGAAGGUGC AAAGACCCUGGAGAAAGCACGCCAACAU CCCGCUG SEQ ID NO: 15 198 199 178 202 SE_PCCB_MAAALRVAAVGARL AUGGCCGCAGCCCU AGGAAA UGAUAA SEQ ID 028 SVLASGLRAAVRSLCCAGAGUGGCUGCCG UAAGAG UAGUCC NO: 202 (hPCCB; SQATSVNERIENKRRUGGGAGCCAGACUC AGAAAA AUAAAG consists G5) TALLGGGQRRIDAQH AGCGUGCUCGCCUCGAAGAG UAGGAA from 5′ to Cap: C1 KRGKLTARERISLLL AGGCCUGCGGGCCG UAAGAAACACUA 3′ end: 5′ PolyA tail: DPGSFVESDMFVEHR CAGUCAGAAGCCUG GAAAUACAGCUG UTR of 100 nt CADFGMAADKNKFP UGCAGCCAGGCAAC UAAGAG GAGCCU SEQ IDGDSVVTGRGRINGRL CUCAGUGAACGAGA CCACC CGGUGG NO: 199, VYVFSQDFTVFGGSLGAAUCGAGAACAAG CCUAGC ORF SGAHAQKICKIMDQA AGACGGACCGCCCU UUCUUG SequenceITVGAPVIGLNDSGG GCUGGGUGGCGGGC CCCCUU of SEQ ID ARIQEGVESLAGYADAAAGAAGAAUUGAC GGGCCU NO: 198, IFLRNVTASGVIPQISL GCCCAGCACAAGAG CCAUAAand 3′ IMGPCAGGAVYSPAL AGGCAAGCUGACCG AGUAGG UTR of TDFTFMVKDTSYLFICCCGCGAGCGCAUC AAACAC SEQ ID TGPDVVKSVTNEDVT AGCCUGCUGCUGGA UACAUCNO: 178 QEELGGAKTHTTMS CCCCGGCAGCUUCG CCCCCA GVAHRAFENDVDALUGGAGAGCGACAUG GCCCCU CNLRDFFNYLPLSSQ UUCGUGGAGCAUCG CCUCCCDPAPVRECHDPSDRL GUGUGCCGACUUCG CUUCCU VPELDTIVPLESTKAY GCAUGGCCGCCGACGCACCC NMVDIIHSVVDEREF AAGAACAAGUUCCC GUACCC FEIMPNYAKNIIVGFACGGCGACAGCGUGG CCUCCA RMNGRTVGIVGNQP UGACCGGCAGAGGC UAAAGUKVASGCLDINSSVKG AGAAUCAACGGCAG AGGAAA ARFVRFCDAFNIPLIT ACUGGUGUACGUGUCACUAC FVDVPGFLPGTAQEY UCUCACAAGACUUU AGUGGU GGIIRHGAKLLYAFAACCGUCUUCGGAGG CUUUGA EATVPKVTVITRKAY AUCCCUGUCAGGGG AUAAAGGGAYDVMSSKHLCG CUCACGCCCAGAAG UCUGAG DTNYAWPTAEIAVM AUCUGCAAGAUCAUUGGGCG GAKGAVEIIFKGHEN GGACCAGGCCAUCA GC VEAAQAEYIEKFANP CCGUGGGCGCUCCCFPAAVRGFVDDIIQPS GUGAUCGGCCUGAA STRARICCDLDVLAS CGACAGCGGAGGCGKKVQRPWRKHANIP CCAGGAUCCAAGAG L GGAGUGGAGUCCCU GGCCGGCUACGCCGACAUCUUCCUGAGA AACGUGACCGCCUC GGGCGUGAUCCCAC AGAUCUCCCUGAUCAUGGGACCCUGCGC CGGCGGGGCCGUCU ACAGCCCUGCCCUG ACCGACUUCACCUUCAUGGUGAAGGACA CCAGCUACCUGUUC AUCACCGGCCCCGA CGUGGUCAAGAGCGUGACCAACGAGGAC GUGACCCAGGAGGA GCUCGGCGGAGCCA AGACUCACACAACCAUGUCCGGCGUCGC UCAUAGGGCCUUCG AGAACGACGUGGAC GCCCUGUGCAACCUGAGAGACUUCUUCA ACUACCUGCCAUUG AGCAGCCAGGAUCC CGCCCCUGUGAGAGAGUGCCACGACCCC AGCGACAGACUGGU GCCCGAGCUGGACA CCAUCGUGCCCCUGGAGAGCACCAAGGC CUACAACAUGGUGG ACAUCAUCCACAGC GUGGUGGACGAGAGAGAGUUCUUCGAGA UCAUGCCCAACUAC GCCAAGAACAUCAU CGUGGGCUUCGCCAGAAUGAACGGCAGA ACCGUGGGCAUUGU GGGCAACCAGCCCA AGGUCGCCAGCGGCUGCCUCGACAUCAA CAGCAGCGUGAAGG GCGCCAGAUUCGUG AGAUUCUGCGACGCCUUCAACAUACCUC UGAUCACCUUUGUG GACGUGCCUGGUUU CCUCCCGGGCACCGCCCAAGAAUACGGU GGCAUCAUCAGACA CGGCGCCAAGCUGC UGUACGCCUUCGCCGAGGCCACCGUGCC CAAGGUGACCGUUA UCACCCGCAAAGCC UACGGCGGCGCCUACGACGUGAUGAGCA GCAAGCACCUGUGU GGCGACACCAAUUA CGCCUGGCCCACCGCCGAGAUCGCCGUC AUGGGCGCGAAAGG AGCCGUGGAGAUCA UCUUCAAGGGCCACGAGAACGUGGAGGC CGCCCAGGCCGAGU ACAUCGAGAAGUUC GCCAACCCCUUCCCUGCCGCCGUGAGGG GCUUCGUCGACGAU AUCAUCCAGCCCAG CUCCACCCGCGCCAGGAUUUGCUGCGAC CUGGACGUGCUGGC CAGCAAGAAGGUGC AAAGACCCUGGAGAAAGCACGCCAACAU CCCGCUG SEQ ID NO:  1  11 199 178 203 SE_PCCA_MAGFWVGTAPLVAA AUGGCCGGCUUCUG AGGAAA UGAUAA SEQ ID 018_ GRRGRWPPQQLMLSGGUCGGCACAGCCC UAAGAG UAGUCC NO: 203 3xmiR142_ AALRTLKHVLYYSRCUCUGGUGGCAGCC AGAAAA AUAAAG consists AGG QCLMVSRNLGSVGY GGCAGAAGAGGACGGAAGAG UAGGAA from 5′ to (hPCCA_; DPNEKTFDKILVANR GUGGCCUCCCCAGC UAAGAAACACUA 3′ end: 5′ G5) GEIACRVIRTCKKMG AACUGAUGCUGAGC GAAAUA CAGCUGUTR of Cap: C1 IKTVAIHSDVDASSV GCCGCCCUGAGAAC UAAGAG GAGCCU SEQ IDPolyA tail: HVKMADEAVCVGPA CCUGAAGCACGUGC CCACC CGGUGG NO: 199, 100 ntPTSKSYLNMDAIMEA UGUACUACAGCAGA CCUAGC ORF IKKTRAQAVHPGYGF CAGUGCCUGAUGGUUUCUUG Sequence LSENKEFARCLAAED GAGCAGAAAUCUGG CCCCUU of SEQ IDVVFIGPDTHAIQAMG GCAGCGUGGGGUAC GGGCCU NO: 11, DKIESKLLAKKAEVNGAUCCCAACGAGAA CCAUAA and 3′ TIPGFDGVVKDAEEA GACCUUCGAUAAGA AGUAGGUTR of VRIAREIGYPVMIKAS UUCUGGUCGCGAAU AAACAC SEQ ID AGGGGKGMRIAWDDAGAGGCGAGAUCGC UACAUC NO: 178 EETRDGFRLSSQEAA CUGCAGGGUGAUCA CCCCCASSFGDDRLLIEKFIDN GAACCUGCAAGAAG GCCCCU PRHIEIQVLGDKHGN AUGGGCAUCAAGACCCUCCC ALWLNERECSIQRRN CGUGGCCAUCCAUU CUUCCU QKVVEEAPSIFLDAECGGACGUCGACGCG GCACCC TRRAMGEQAVALAR AGCAGCGUUCACGU GUACCCAVKYSSAGTVEFLVD GAAGAUGGCAGACG CCUCCA SKKNFYFLEMNTRLQ AGGCCGUGUGCGUGUAAAGU VEHPVTECITGLDLV GGACCCGCCCCGAC AGGAAA QEMIRVAKGYPLRHCAGCAAGAGCUACC CACUAC KQADIRINGWAVECR UGAACAUGGACGCC AGUGGUVYAEDPYKSFGLPSI AUCAUGGAGGCCAU CUUUGA GRLSQYQEPLHLPGV CAAGAAGACCCGCGAUAAAG RVDSGIQPGSDISIYY CUCAAGCCGUGCAC UCUGAG DPMISKLITYGSDRTECCGGGCUACGGCUU UGGGCG ALKRMADALDNYVI UCUGAGCGAGAACA GC RGVTHNIALLREVIINAGGAAUUCGCCAGG SRFVKGDISTKFLSDV UGUCUCGCCGCCGA YPDGFKGHMLTKSEGGACGUAGUCUUCA KNQLLAIASSLFVAF UCGGCCCUGAUACG QLRAQHFQENSRMPCACGCGAUCCAGGC VIKPDIANWELSVKL CAUGGGCGACAAGA HDKVHTVVASNNGSUCGAGAGCAAACUG VFSVEVDGSKLNVTS CUGGCCAAGAAAGC TWNLASPLLSVSVDGAGAAGUCAACACCA TQRTVQCLSREAGGN UCCCCGGCUUCGAC MSIQFLGTVYKVNILGGCGUGGUGAAGGA TRLAAELNKFMLEK CGCCGAAGAGGCUG VTEDTSSVLRSPMPGUCCGCAUCGCCAGA VVVAVSVKPGDAVA GAGAUCGGCUACCC EGQEICVIEAMKMQNUGUGAUGAUAAAG SMTAGKTGTVKSVH GCUAGCGCUGGAGG CQAGDTVGEGDLLVUGGCGGAAAGGGCA ELE UGAGAAUCGCCUGG GACGACGAGGAGAC UAGAGACGGCUUCAGACUGUCCUCCCAG GAGGCCGCCAGCUC CUUCGGAGACGACA GACUGCUGAUCGAGAAGUUCAUCGACAA CCCCAGACACAUCG AAAUCCAGGUGCUC GGUGACAAGCACGGGAACGCCCUGUGGC UGAACGAGAGAGAG UGCAGCAUCCAGAG AAGAAACCAGAAGGUGGUGGAGGAGGCG CCGAGCAUCUUUCU GGACGCGGAGACAA GGAGAGCGAUGGGCGAACAGGCCGUCGC CCUAGCAAGAGCCG UGAAGUACUCCAGU GCCGGAACCGUCGAGUUUCUUGUCGACA GCAAGAAGAAUUUC UACUUCCUGGAGAU GAACACCAGGCUGCAGGUGGAGCAUCCC GUGACAGAGUGCAU CACUGGACUGGAUC UGGUGCAGGAGAUGAUCAGGGUGGCCAA GGGCUAUCCCCUGA GACACAAGCAGGCC GACAUCAGAAUCAACGGCUGGGCCGUGG AGUGCAGAGUGUAC GCCGAGGACCCCUA CAAGAGCUUCGGCCUGCCCAGCAUCGGC AGACUGAGCCAGUA CCAGGAGCCCCUGC ACCUGCCCGGCGUGAGAGUGGACAGCGG CAUCCAACCGGGGA GCGAUAUCAGCAUC UACUACGACCCCAUGAUCAGCAAGCUGA UAACCUACGGCAGC GACAGAACCGAGGC CCUGAAGAGAAUGGCCGACGCCCUGGAC AACUACGUGAUCAG AGGCGUGACCCACA ACAUCGCCCUGCUGAGAGAGGUGAUCAU CAACUCGAGGUUCG UGAAAGGCGACAUC AGCACCAAGUUCCUGAGCGACGUGUAUC CCGACGGAUUCAAA GGUCACAUGCUGAC CAAGAGCGAGAAGAACCAGCUGCUGGCC AUCGCCUCAUCCCU GUUCGUGGCCUUCC AGCUGAGAGCCCAGCACUUCCAGGAGAA CAGCAGAAUGCCCG UGAUCAAGCCCGAC AUCGCCAACUGGGAGCUGAGCGUGAAGC UGCACGACAAGGUG CACACUGUCGUUGC CAGCAACAACGGCUCCGUGUUCAGCGUA GAGGUGGACGGAUC UAAGCUGAACGUGA CCUCCACCUGGAACCUGGCAAGCCCUCU CCUGUCAGUGAGCG UGGACGGCACCCAG AGAACCGUGCAGUGUCUGUCCCGCGAGG CCGGCGGAAACAUG AGCAUCCAGUUCCU GGGCACCGUGUACAAGGUGAACAUCCUG ACCAGACUGGCCGC CGAGCUGAACAAGU UCAUGCUGGAGAAAGUGACGGAGGAUAC CAGCUCCGUGCUGA GAAGCCCCAUGCCC GGAGUGGUGGUGGCCGUUUCCGUGAAAC CUGGUGACGCCGUG GCCGAGGGGCAAGA GAUCUGCGUGAUCGAGGCCAUGAAGAUG CAGAAUUCCAUGAC CGCCGGAAAGACCG GCACCGUCAAAUCAGUGCACUGCCAGGC GGGCGACACAGUGG GUGAGGGCGACCUG CUGGUGGAGCUGGA G SEQ ID NO:15  23 199 178 204 SE_PCCB_ MAAALRVAAVGARL AUGGCCGCAGCCCU AGGAAA UGAUAASEQ ID 018_ SVLASGLRAAVRSLC CAGAGUGGCUGCCG UAAGAG UAGUCC NO: 2043xmiR142_ SQATSVNERIENKRR UGGGAGCCAGACUC AGAAAA AUAAAG consists AGGTALLGGGQRRIDAQH AGCGUGCUCGCCUC GAAGAG UAGGAA from 5′ to (hPCCB;KRGKLTARERISLLL AGGCCUGCGGGCCG UAAGAA ACACUA 3′ end: 5′ G5)DPGSFVESDMFVEHR CAGUCAGAAGCCUG GAAAUA CAGCUG UTR of Cap: C1CADFGMAADKNKFP UGCAGCCAGGCAAC UAAGAG GAGCCU SEQ ID PolyA tail:GDSVVTGRGRINGRL CUCAGUGAACGAGA CCACC CGGUGG NO: 199, 100 ntVYVFSQDFTVFGGSL GAAUCGAGAACAAG CCUAGC ORF SGAHAQKICKIMDQA AGACGGACCGCCCUUUCUUG Sequence ITVGAPVIGLNDSGG GCUGGGUGGCGGGC CCCCUU of SEQ IDARIQEGVESLAGYAD AAAGAAGAAUUGAC GGGCCU NO: 23, IFLRNVTASGVIPQISLGCCCAGCACAAGAG CCAUAA and 3′ IMGPCAGGAVYSPAL AGGCAAGCUGACCG AGUAGGUTR of TDFTFMVKDTSYLFI CCCGCGAGCGCAUC AAACAC SEQ ID TGPDVVKSVTNEDVTAGCCUGCUGCUGGA UACAUC NO: 178 QEELGGAKTHTTMS CCCCGGCAGCUUCG CCCCCAGVAHRAFENDVDAL UGGAGAGCGACAUG GCCCCU CNLRDFFNYLPLSSQ UUCGUGGAGCAUCGCCUCCC DPAPVRECHDPSDRL GUGUGCCGACUUCG CUUCCU VPELDTIVPLESTKAYGCAUGGCCGCCGAC GCACCC NMVDIIHSVVDEREF AAGAACAAGUUCCC GUACCCFEIMPNYAKNIIVGFA CGGCGACAGCGUGG CCUCCA RMNGRTVGIVGNQP UGACCGGCAGAGGCUAAAGU KVASGCLDINSSVKG AGAAUCAACGGCAG AGGAAA ARFVRFCDAFNIPLITACUGGUGUACGUGU CACUAC FVDVPGFLPGTAQEY UCUCACAAGACUUU AGUGGUGGIIRHGAKLLYAFA ACCGUCUUCGGAGG CUUUGA EATVPKVTVITRKAY AUCCCUGUCAGGGGAUAAAG GGAYDVMSSKHLCG CUCACGCCCAGAAG UCUGAG DTNYAWPTAEIAVMAUCUGCAAGAUCAU UGGGCG GAKGAVEIIFKGHEN GGACCAGGCCAUCA GC VEAAQAEYIEKFANPCCGUGGGCGCUCCC FPAAVRGFVDDIIQPS GUGAUCGGCCUGAA STRARICCDLDVLASCGACAGCGGAGGCG KKVQRPWRKHANIP CCAGGAUCCAAGAG L GGAGUGGAGUCCCUGGCCGGCUACGCCG ACAUCUUCCUGAGA AACGUGACCGCCUC GGGCGUGAUCCCACAGAUCUCCCUGAUC AUGGGACCCUGCGC CGGCGGGGCCGUCU ACAGCCCUGCCCUGACCGACUUCACCUU CAUGGUGAAGGACA CCAGCUACCUGUUC AUCACCGGCCCCGACGUGGUCAAGAGCG UGACCAACGAGGAC GUGACCCAGGAGGA GCUCGGCGGAGCCAAGACUCACACAACC AUGUCCGGCGUCGC UCAUAGGGCCUUCG AGAACGACGUGGACGCCCUGUGCAACCU GAGAGACUUCUUCA ACUACCUGCCAUUG AGCAGCCAGGAUCCCGCCCCUGUGAGAG AGUGCCACGACCCC AGCGACAGACUGGU GCCCGAGCUGGACACCAUCGUGCCCCUG GAGAGCACCAAGGC CUACAACAUGGUGG ACAUCAUCCACAGCGUGGUGGACGAGAG AGAGUUCUUCGAGA UCAUGCCCAACUAC GCCAAGAACAUCAUCGUGGGCUUCGCCA GAAUGAACGGCAGA ACCGUGGGCAUUGU GGGCAACCAGCCCAAGGUCGCCAGCGGC UGCCUCGACAUCAA CAGCAGCGUGAAGG GCGCCAGAUUCGUGAGAUUCUGCGACGC CUUCAACAUACCUC UGAUCACCUUUGUG GACGUGCCUGGUUUCCUCCCGGGCACCG CCCAAGAAUACGGU GGCAUCAUCAGACA CGGCGCCAAGCUGCUGUACGCCUUCGCC GAGGCCACCGUGCC CAAGGUGACCGUUA UCACCCGCAAAGCCUACGGCGGCGCCUA CGACGUGAUGAGCA GCAAGCACCUGUGU GGCGACACCAAUUACGCCUGGCCCACCG CCGAGAUCGCCGUC AUGGGCGCGAAAGG AGCCGUGGAGAUCAUCUUCAAGGGCCAC GAGAACGUGGAGGC CGCCCAGGCCGAGU ACAUCGAGAAGUUCGCCAACCCCUUCCC UGCCGCCGUGAGGG GCUUCGUCGACGAU AUCAUCCAGCCCAGCUCCACCCGCGCCA GAAUCUGUUGCGAC CUGGACGUGCUGGC CAGCAAGAAGGUGCAAAGACCCUGGAGA AAGCACGCCAACAU CCCGCUG SEQ ID NO: 15  25 199 178 205SE_PCCB_ MAAALRVAAVGARL AUGGCGGCGGCAUU AGGAAA UGAUAA SEQ ID 020_SVLASGLRAAVRSLC ACGGGUGGCGGCGG UAAGAG UAGUCC NO: 205 3xmiR142_SQATSVNERIENKRR UCGGGGCAAGGCUC AGAAAA AUAAAG consists AGGTALLGGGQRRIDAQH AGCGUGCUGGCCAG GAAGAG UAGGAA from 5′ to (hPCCB;KRGKLTARERISLLL CGGCCUGAGAGCCG UAAGAA ACACUA 3′ end: 5′ G5)DPGSFVESDMFVEHR CCGUGAGAAGCCUG GAAAUA CAGCUG UTR of Cap: C1CADFGMAADKNKFP UGCAGCCAGGCCAC UAAGAG GAGCCU SEQ ID PolyA tail:GDSVVTGRGRINGRL CAGCGUGAACGAGA CCACC CGGUGG NO: 199, 100 ntVYVFSQDFTVFGGSL GAAUCGAGAACAAG CCUAGC ORF SGAHAQKICKIMDQA AGAAGAACCGCCCUUUCUUG Sequence ITVGAPVIGLNDSGG GCUGGGCGGCGGCC CCCCUU of SEQ IDARIQEGVESLAGYAD AGAGAAGAAUCGAC GGGCCU NO: 25, IFLRNVTASGVIPQISLGCCCAGCACAAGAG CCAUAA and 3′ IMGPCAGGAVYSPAL AGGCAAGCUGACCG AGUAGGUTR of TDFTFMVKDTSYLFI CCAGAGAGAGAAUC AAACAC SEQ ID TGPDVVKSVTNEDVTAGCCUGCUGCUGGA UACAUC NO: 178 QEELGGAKTHTTMS CCCCGGCAGCUUCG CCCCCAGVAHRAFENDVDAL UGGAGAGCGACAUG GCCCCU CNLRDFFNYLPLSSQ UUCGUGGAGCACAGCCUCCC DPAPVRECHDPSDRL GUGCGCCGACUUCG CUUCCU VPELDTIVPLESTKAYGCAUGGCCGCCGAC GCACCC NMVDIIHSVVDEREF AAGAACAAGUUCCC GUACCCFEIMPNYAKNIIVGFA CGGCGACAGCGUGG CCUCCA RMNGRTVGIVGNQP UGACCGGCAGAGGCUAAAGU KVASGCLDINSSVKG AGAAUCAACGGCAG AGGAAA ARFVRFCDAFNIPLITACUGGUGUACGUGU CACUAC FVDVPGFLPGTAQEY UCAGCCAGGACUUC AGUGGUGGIIRHGAKLLYAFA ACCGUGUUCGGCGG CUUUGA EATVPKVTVITRKAY CAGCCUGAGCGGCGAUAAAG GGAYDVMSSKHLCG CCCACGCCCAGAAG UCUGAG DTNYAWPTAEIAVMAUCUGCAAGAUCAU UGGGCG GAKGAVEIIFKGHEN GGACCAGGCCAUCA GC VEAAQAEYIEKFANPCCGUGGGCGCGCCC FPAAVRGFVDDIIQPS GUGAUCGGCCUGAA STRARICCDLDVLASCGACAGCGGCGGCG KKVQRPWRKHANIP CCAGAAUCCAGGAG L GGCGUGGAGAGCCUGGCCGGCUACGCCG ACAUCUUCCUGAGA AACGUGACCGCCAG CGGCGUGAUCCCACAGAUCAGCCUGAUC AUGGGCCCCUGCGC CGGCGGCGCCGUGU ACAGCCCCGCCCUGACCGACUUCACCUU CAUGGUGAAGGACA CCAGCUACCUGUUC AUCACCGGCCCCGACGUGGUGAAGAGCG UGACCAACGAGGAC GUGACCCAGGAGGA GCUGGGCGGCGCCAAGACCCACACCACC AUGAGCGGCGUGGC CCACAGAGCCUUCG AGAACGACGUGGACGCCCUGUGCAACCU GAGAGACUUCUUCA ACUACCUGCCCCUG AGCAGCCAGGACCCCGCGCCCGUGAGAG AGUGCCACGACCCC AGCGACAGACUGGU GCCCGAGCUGGACACCAUCGUGCCCCUG GAGAGCACCAAGGC CUACAACAUGGUGG ACAUCAUCCACAGCGUGGUGGACGAGAG AGAGUUCUUCGAGA UCAUGCCCAACUAC GCCAAGAACAUCAUCGUGGGCUUCGCCA GAAUGAACGGCAGA ACCGUGGGCAUCGU GGGCAACCAGCCCAAGGUGGCCAGCGGC UGCCUGGACAUCAA CAGCAGCGUGAAGG GCGCCAGAUUCGUGAGAUUCUGCGACGC CUUCAACAUCCCUC UGAUCACCUUCGUG GACGUGCCCGGCUUCCUGCCCGGCACCG CCCAGGAGUACGGC GGCAUCAUCAGACA CGGCGCCAAGCUGCUGUACGCCUUCGCC GAGGCCACCGUGCC CAAGGUGACCGUGA UCACCAGAAAGGCCUACGGCGGCGCCUA CGACGUGAUGAGCA GCAAGCACCUGUGC GGCGACACCAACUACGCCUGGCCCACCG CCGAGAUCGCCGUG AUGGGCGCCAAGGG CGCCGUGGAGAUCAUCUUCAAGGGCCAC GAGAACGUGGAGGC CGCCCAGGCCGAGU ACAUCGAGAAGUUCGCCAACCCCUUCCC CGCCGCCGUGAGAG GCUUCGUGGACGAC AUCAUCCAGCCCAGCAGCACCAGAGCCA GAAUCUGCUGCGAC CUGGACGUGCUGGC CAGCAAGAAGGUGCAGAGACCCUGGAGA AAGCACGCCAACAU CCCUCUG

EXAMPLES Example 1: Chimeric Polynucleotide Synthesis

A. Triphosphate Route

Two regions or parts of a chimeric polynucleotide can be joined orligated using triphosphate chemistry. According to this method, a firstregion or part of 100 nucleotides or less can be chemically synthesizedwith a 5′ monophosphate and terminal 3′desOH or blocked OH. If theregion is longer than 80 nucleotides, it can be synthesized as twostrands for ligation.

If the first region or part is synthesized as a non-positionallymodified region or part using in vitro transcription (IVT), conversionthe 5′monophosphate with subsequent capping of the 3′ terminus canfollow. Monophosphate protecting groups can be selected from any ofthose known in the art.

The second region or part of the chimeric polynucleotide can besynthesized using either chemical synthesis or IVT methods. IVT methodscan include an RNA polymerase that can utilize a primer with a modifiedcap. Alternatively, a cap of up to 80 nucleotides can be chemicallysynthesized and coupled to the IVT region or part.

It is noted that for ligation methods, ligation with DNA T4 ligase,followed by treatment with DNAse should readily avoid concatenation.

The entire chimeric polynucleotide need not be manufactured with aphosphate-sugar backbone. If one of the regions or parts encodes apolypeptide, then such region or part can comprise a phosphate-sugarbackbone.

Ligation can then be performed using any known click chemistry,orthoclick chemistry, solulink, or other bioconjugate chemistries knownto those in the art.

B. Synthetic route

The chimeric polynucleotide can be made using a series of startingsegments. Such segments include:

(a) Capped and protected 5′ segment comprising a normal 3′OH (SEG. 1)

(b) 5′ triphosphate segment which can include the coding region of apolypeptide and comprising a normal 3′OH (SEG. 2)

(c) 5′ monophosphate segment for the 3′ end of the chimericpolynucleotide (e.g., the tail) comprising cordycepin or no 3′OH (SEG.3)

After synthesis (chemical or IVT), segment 3 (SEG. 3) can be treatedwith cordycepin and then with pyrophosphatase to create the5′monophosphate.

Segment 2 (SEG. 2) can then be ligated to SEG. 3 using RNA ligase. Theligated polynucleotide can then be purified and treated withpyrophosphatase to cleave the diphosphate. The treated SEG.2-SEG. 3construct is then purified and SEG. 1 is ligated to the 5′ terminus. Afurther purification step of the chimeric polynucleotide can beperformed.

Where the chimeric polynucleotide encodes a polypeptide, the ligated orjoined segments can be represented as: 5′ UTR (SEG. 1), open readingframe or ORF (SEG. 2) and 3′ UTR+PolyA (SEG. 3).

The yields of each step can be as much as 90-95%.

Example 2: PCR for cDNA Production

PCR procedures for the preparation of cDNA can be performed using 2xKAPA HIFI™ HotStart ReadyMix by Kapa Biosystems (Woburn, Mass.). Thissystem includes 2×KAPA ReadyMix12.5 μl; Forward Primer (10 μM) 0.75 μl;Reverse Primer (10 μM) 0.75 μl; Template cDNA-100 ng; and dH₂0 dilutedto 25.0 μl. The PCR reaction conditions can be: at 95° C. for 5 min. and25 cycles of 98° C. for 20 sec, then 58° C. for 15 sec, then 72° C. for45 sec, then 72° C. for 5 min. then 4° C. to termination.

The reverse primer of the instant invention can incorporate a poly-T120for a poly-A120 in the mRNA. Other reverse primers with longer orshorter poly(T) tracts can be used to adjust the length of the poly(A)tail in the polynucleotide mRNA.

The reaction can be cleaned up using Invitrogen's PURELINK™ PCR MicroKit (Carlsbad, Calif.) per manufacturer's instructions (up to 5 μg).Larger reactions will require a cleanup using a product with a largercapacity. Following the cleanup, the cDNA can be quantified using theNANODROP™ and analyzed by agarose gel electrophoresis to confirm thecDNA is the expected size. The cDNA can then be submitted for sequencinganalysis before proceeding to the in vitro transcription reaction.

Example 3: In Vitro Transcription (IVT)

The in vitro transcription reactions can generate polynucleotidescontaining uniformly modified polynucleotides. Such uniformly modifiedpolynucleotides can comprise a region or part of the polynucleotides ofthe invention. The input nucleotide triphosphate (NTP) mix can be madeusing natural and un-natural NTPs.

A typical in vitro transcription reaction can include the following:

-   -   1 Template cDNA—1.0 μg    -   2 10× transcription buffer (400 mM Tris-HCl pH 8.0, 190 mM        MgCl₂, 50 mM DTT, 10 mM Spermidine)—2.0 μl    -   3 Custom NTPs (25 mM each)—7.2 μl    -   4 RNase Inhibitor—20 U    -   5 T7 RNA polymerase—3000 U    -   6 dH₂0—Up to 20.0 μl. and    -   7 Incubation at 37° C. for 3 hr-5 hrs.

The crude IVT mix can be stored at 4° C. overnight for cleanup the nextday. 1 U of RNase-free DNase can then be used to digest the originaltemplate. After 15 minutes of incubation at 37° C., the mRNA can bepurified using Ambion's MEGACLEAR™ Kit (Austin, Tex.) following themanufacturer's instructions. This kit can purify up to 500 μg of RNA.Following the cleanup, the RNA can be quantified using the NanoDrop andanalyzed by agarose gel electrophoresis to confirm the RNA is the propersize and that no degradation of the RNA has occurred.

Example 4: Enzymatic Capping

Capping of a polynucleotide can be performed with a mixture includes:IVT RNA 60 μg-180 μg and dH₂0 up to 72 μl. The mixture can be incubatedat 65° C. for 5 minutes to denature RNA, and then can be transferredimmediately to ice.

The protocol can then involve the mixing of 10× Capping Buffer (0.5 MTris-HCl (pH 8.0), 60 mM KCl, 12.5 mM MgCl₂) (10.0 μl); 20 mM GTP (5.0μl); 20 mM S-Adenosyl Methionine (2.5 μl); RNase Inhibitor (100 U);2′-O-Methyltransferase (400U); Vaccinia capping enzyme (Guanylyltransferase) (40 U); dH₂0 (Up to 28 μl); and incubation at 37° C. for 30minutes for 60 μg RNA or up to 2 hours for 180 μg of RNA.

The polynucleotide can then be purified using Ambion's MEGACLEAR™ Kit(Austin, Tex.) following the manufacturer's instructions. Following thecleanup, the RNA can be quantified using the NANODROP™ (ThermoFisher,Waltham, Mass.) and analyzed by agarose gel electrophoresis to confirmthe RNA is the proper size and that no degradation of the RNA hasoccurred. The RNA product can also be sequenced by running areverse-transcription-PCR to generate the cDNA for sequencing.

Example 5: PolyA Tailing Reaction

Without a poly-T in the cDNA, a poly-A tailing reaction must beperformed before cleaning the final product. This can be done by mixingCapped IVT RNA (100 μl); RNase Inhibitor (20 U); 1Ox Tailing Buffer (0.5M Tris-HCl (pH 8.0), 2.5 M NaCl, 100 mM MgCl₂) (12.0 μl); 20 mM ATP (6.0μl); Poly-A Polymerase (20 U); dH₂0 up to 123.5 μl and incubating at 37°C. for 30 min. If the poly-A tail is already in the transcript, then thetailing reaction can be skipped and proceed directly to cleanup withAmbion's MEGACLEAR™ kit (Austin, Tex.) (up to 500 μg). Poly-A Polymeraseis, in some cases, a recombinant enzyme expressed in yeast.

It should be understood that the processivity or integrity of the polyAtailing reaction does not always result in an exact size polyA tail.Hence polyA tails of approximately between 40-200 nucleotides, e.g.,about 40, 50, 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100,101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 150-165, 155, 156,157, 158, 159, 160, 161, 162, 163, 164 or 165 are within the scope ofthe invention.

Example 6: Natural 5′ Caps and 5′ Cap Analogues

5′-capping of polynucleotides can be completed concomitantly during thein vitro-transcription reaction using the following chemical RNA capanalogs to generate the 5′-guanosine cap structure according tomanufacturer protocols: 3′-O-Me-m7G(5′)ppp(5′) G [the ARCA cap];G(5′)ppp(5′)A; G(5′)ppp(5′)G; m7G(5′)ppp(5′)A; m7G(5′)ppp(5′)G (NewEngland BioLabs, Ipswich, Mass.). 5′-capping of modified RNA can becompleted post-transcriptionally using a Vaccinia Virus Capping Enzymeto generate the “Cap 0” structure: m7G(5′)ppp(5′)G (New England BioLabs,Ipswich, Mass.). Cap 1 structure can be generated using both VacciniaVirus Capping Enzyme and a 2′-O methyl-transferase to generate:m7G(5′)ppp(5′)G-2′-O-methyl. Cap 2 structure can be generated from theCap 1 structure followed by the 2′-O-methylation of the5′-antepenultimate nucleotide using a 2′-O methyl-transferase. Cap 3structure can be generated from the Cap 2 structure followed by the2′-O-methylation of the 5′-preantepenultimate nucleotide using a 2′-Omethyl-transferase. Enzymes can be derived from a recombinant source.

When transfected into mammalian cells, the modified mRNAs can have astability of between 12-18 hours or more than 18 hours, e.g., 24, 36,48, 60, 72 or greater than 72 hours.

Example 7: Capping Assays

A. Protein Expression Assay

Polynucleotides encoding a polypeptide, containing any of the capstaught herein, can be transfected into cells at equal concentrations.After 6, 12, 24 and 36 hours post-transfection, the amount of proteinsecreted into the culture medium can be assayed by ELISA. Syntheticpolynucleotides that secrete higher levels of protein into the mediumwould correspond to a synthetic polynucleotide with a highertranslationally-competent Cap structure.

B. Purity Analysis Synthesis

Polynucleotides encoding a polypeptide, containing any of the capstaught herein, can be compared for purity using denaturing Agarose-Ureagel electrophoresis or HPLC analysis. Polynucleotides with a single,consolidated band by electrophoresis correspond to the higher purityproduct compared to polynucleotides with multiple bands or streakingbands. Synthetic polynucleotides with a single HPLC peak would alsocorrespond to a higher purity product. The capping reaction with ahigher efficiency would provide a more pure polynucleotide population.

C. Cytokine Analysis

Polynucleotides encoding a polypeptide, containing any of the capstaught herein, can be transfected into cells at multiple concentrations.After 6, 12, 24 and 36 hours post-transfection the amount ofpro-inflammatory cytokines such as TNF-alpha and IFN-beta secreted intothe culture medium can be assayed by ELISA. Polynucleotides resulting inthe secretion of higher levels of pro-inflammatory cytokines into themedium would correspond to polynucleotides containing animmune-activating cap structure.

D. Capping Reaction Efficiency

Polynucleotides encoding a polypeptide, containing any of the capstaught herein, can be analyzed for capping reaction efficiency by LC-MSafter nuclease treatment. Nuclease treatment of capped polynucleotideswould yield a mixture of free nucleotides and the capped5′-5-triphosphate cap structure detectable by LC-MS. The amount ofcapped product on the LC-MS spectra can be expressed as a percent oftotal polynucleotide from the reaction and would correspond to cappingreaction efficiency. The cap structure with higher capping reactionefficiency would have a higher amount of capped product by LC-MS.

Example 8: Agarose Gel Electrophoresis of Modified RNA or RT PCRProducts

Individual polynucleotides (200-400 ng in a 20 μl volume) or reversetranscribed PCR products (200-400 ng) can be loaded into a well on anon-denaturing 1.2% Agarose E-Gel (Invitrogen, Carlsbad, Calif.) and runfor 12-15 minutes according to the manufacturer protocol.

Example 9: Nanodrop Modified RNA Quantification and UV Spectral Data

Modified polynucleotides in TE buffer (1 μl) can be used for Nanodrop UVabsorbance readings to quantitate the yield of each polynucleotide froma chemical synthesis or in vitro transcription reaction.

Example 10: Formulation of Modified mRNA Using Lipidoids

Polynucleotides can be formulated for in vitro experiments by mixing thepolynucleotides with the lipidoid at a set ratio prior to addition tocells. In vivo formulation can require the addition of extra ingredientsto facilitate circulation throughout the body. To test the ability ofthese lipidoids to form particles suitable for in vivo work, a standardformulation process used for siRNA-lipidoid formulations can be used asa starting point. After formation of the particle, polynucleotide can beadded and allowed to integrate with the complex. The encapsulationefficiency can be determined using a standard dye exclusion assays.

Example 11: Method of Screening for Protein Expression

A. Electrospray Ionization

A biological sample that can contain proteins encoded by apolynucleotide administered to the subject can be prepared and analyzedaccording to the manufacturer protocol for electrospray ionization (ESI)using 1, 2, 3 or 4 mass analyzers. A biologic sample can also beanalyzed using a tandem ESI mass spectrometry system.

Patterns of protein fragments, or whole proteins, can be compared toknown controls for a given protein and identity can be determined bycomparison.

B. Matrix-Assisted Laser Desorption/Ionization

A biological sample that can contain proteins encoded by one or morepolynucleotides administered to the subject can be prepared and analyzedaccording to the manufacturer protocol for matrix-assisted laserdesorption/ionization (MALDI).

Patterns of protein fragments, or whole proteins, can be compared toknown controls for a given protein and identity can be determined bycomparison.

C. Liquid Chromatography-Mass spectrometry-Mass spectrometry

A biological sample, which can contain proteins encoded by one or morepolynucleotides, can be treated with a trypsin enzyme to digest theproteins contained within. The resulting peptides can be analyzed byliquid chromatography-mass spectrometry-mass spectrometry (LC/MS/MS).The peptides can be fragmented in the mass spectrometer to yielddiagnostic patterns that can be matched to protein sequence databasesvia computer algorithms. The digested sample can be diluted to achieve 1ng or less starting material for a given protein. Biological samplescontaining a simple buffer background (e.g., water or volatile salts)are amenable to direct in-solution digest; more complex backgrounds(e.g., detergent, non-volatile salts, glycerol) require an additionalclean-up step to facilitate the sample analysis.

Patterns of protein fragments, or whole proteins, can be compared toknown controls for a given protein and identity can be determined bycomparison.

Example 12: Synthesis of mRNA Encoding PCCA and PCCB

Sequence optimized polynucleotides encoding PCCA polypeptides, i.e., SEQID NOs: 1, or PCCB polypeptides, i.e., SEQ ID NOs: 15, were synthesizedand characterized as described in Examples 1 to 11. mRNA's encodinghuman PCCA isoform 1 and human PCCB isoform 1 were prepared for theExamples described below, and were synthesized and characterized asdescribed in Examples 1 to 11.

An mRNA encoding human PCCA can be constructed, e.g., by using the ORFsequences provided in SEQ ID NOs: 2 and 5-14. An mRNA encoding humanPCCB can be constructed, e.g., by using the ORF sequences provided inSEQ ID NO: 16-27, 196, 197, and 198. The mRNA sequence includes both 5′and 3′ UTR regions flanking the ORF sequence (nucleotide). In anexemplary construct, the 5′ UTR and 3′ UTR sequences are SEQ ID NO: 3and SEQ ID NO: 4, respectively (see Sequence Listing).

5′UTR: (SEQ ID NO: 3) GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACC3′UTR: (SEQ ID NO: 4) UGAUAAUAGGCUGGAGCCUCGGUGGCCUAGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCUCCAUAAAGUAGGAAACACUACAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC

In another exemplary construct, the 5′ UTR and 3′ UTR sequences are asfollows:

5′UTR: (SEQ ID NO: 88)UCAAGCUUUUGGACCCUCGUACAGAAGCUAAUACGACUCACUAUAGGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACC 3′UTR: (SEQ ID NO: 150)UGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCGUGGUCUUUGAA UAAAGUCUGAGUGGGCGGC

In another exemplary construct, the 5′ UTR and 3′ UTR sequences are asfollows:

5′ UTR: (SEQ ID NO: 3) GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACC3′UTR: (SEQ ID NO: 178) UGAUAAUAGUCCAUAAAGUAGGAAACACUACAGCUGGAGCCUCGGUGGCCUAGCUUCUUGCCCCUUGGGCCUCCAUAAAGUAGGAAACACUACAUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCUCCAUAAAGUAGGAAACACUACAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC

In another exemplary construct, the 5′ UTR and 3′ UTR sequences are asfollows:

5′ UTR: (SEQ ID NO: 64) GGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAATATAAGAGCCACC3′UTR: (SEQ ID NO: 112) UGAUAAUAGUCCAUAAAGUAGGAAACACUACAGCUGGAGCCUCGGUGGCCUAGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCGCAUUAUUACUCACGGUACGAGUGGUCUU UGAAUAAAGUCUGAGUGGGCGGC

In another exemplary construct, the 5′ UTR and 3′ UTR sequences are asfollows:

5′UTR: (SEQ ID NO: 3) GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACC3′UTR: (SEQ ID NO: 112)UGAUAAUAGUCCAUAAAGUAGGAAACACUACAGCUGGAGCCUCGGUGGCCUAGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCGCAUUAUUACUCACGGUACGAGUGGUCUUUGAAUAAAG UCUGAGUGGGCGGC

In another exemplary construct, the 5′ UTR and 3′ UTR sequences are asfollows:

5′UTR: (SEQ ID NO: 199) AGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACC3′UTR: (SEQ ID NO: 4) UGAUAAUAGGCUGGAGCCUCGGUGGCCUAGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCUCCAUAAAGUAGGAAACACUACAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC

In another exemplary construct, the 5′ UTR and 3′ UTR sequences are asfollows:

5′UTR: (SEQ ID NO: 199) AGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACC3′UTR: (SEQ ID NO: 178)UGAUAAUAGUCCAUAAAGUAGGAAACACUACAGCUGGAGCCUCGGUGGCCUAGCUUCUUGCCCCUUGGGCCUCCAUAAAGUAGGAAACACUACAUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCUCCAUAAAGUAGGAAACACUACAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC

In another exemplary construct, the 5′ UTR and 3′ UTR sequences are asfollows:

5′UTR: (SEQ ID NO: 199) AGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACC3′UTR: (SEQ ID NO: 112)UGAUAAUAGUCCAUAAAGUAGGAAACACUACAGCUGGAGCCUCGGUGGCCUAGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCGCAUUAUUACUCACGGUACGAGUGGUCUUUGAAUAAAG UCUGAGUGGGCGGC

The PCCA and PCCB mRNA sequences were prepared as modified mRNA.Specifically, during in vitro translation, modified mRNA can begenerated using N1-methyl-pseudouridine-5′-Triphosphate or 5-methoxy-UTPto ensure that the mRNAs contain 100% N1-methyl-pseudouridine or5-methoxy-uridine instead of uridine. Further, PCCA/PCCB-mRNA can besynthesized with a primer that introduces a polyA-tail, and a Cap 1structure is generated on both mRNAs using Vaccinia Virus Capping Enzymeand a 2′-O methyl-transferase to generate: m7G(5′)ppp(5′)G-2′-O-methyl.

Example 13: Detecting Endogenous PCCA/PCCB Expression In Vitro

PCCA and PCCB expression is characterized in a variety of cell linesderived from both mice and human sources. Cell are cultured in standardconditions and cell extracts are obtained by placing the cells in lysisbuffer. For comparison purposes, appropriate controls are also prepared.To analyze PCCA and PCCB expression, lysate samples are prepared fromthe tested cells and mixed with lithium dodecyl sulfate sample loadingbuffer and subjected to standard Western blot analysis. For detection ofPCCA, the antibody used is a commercial anti-PCCA antibody. A commercialanti-PCCB antibody is used for detection of PCCB. For detection of aload control, the antibody used is anti-citrate synthase (rabbitpolyclonal; ab96600; Abcam). To examine the localization of endogenousPCCA or PCCB, immunofluorescence analysis is performed on cells. PCCAexpression is detected using a commercial anti-PCCA antibody, while PCCBexpression is detected using a commercial PCCB antibody. The location ofspecific organelles can be detected with existing commercial products.For example, mitochondria can be detected using Mitotracker, and thenucleus can be stained with DAPI. Image analysis is performed on a ZeissELYRA imaging system.

Endogenous PCCA expression in vehicle control-transfected cells can beused as a comparator group to determine changes in PCCA expressionresulting from transfection with mRNAs comprising nucleic acids encodingPCCA. Likewise, endogenous PCCB expression in vehiclecontrol-transfected cells can be used as a comparator group to determinechanges in PCCB expression resulting from transfection with mRNAscomprising nucleic acids encoding PCCB.

Example 14: In Vitro Expression of PCCA/PCCB in Cells

To measure in vitro expression of human PCCA and PCCB in a mouse orhuman liver cell line, Hepa1-6 cells (ATCC® HB-8064™), PCCA-deficientHep3B cells, PCCB-deficient Hep3B cells, or patient fibroblasts areused. Cells are seeded on 6-well plates (BD Biosciences, San Jose, USA)one day prior to transfection. mRNA formulations comprising wild type orsequence optimized human PCCA and PCCB, or a GFP control, aretransfected using 1 or 2 μg mRNA and 3 or 6 μL Lipofectamin MessagerMaxin 100 μL OPTI-MEM per well and incubated.

After 24 and 48 hours, the cells in each well are lysed using aconsistent amount of lysis buffer. Appropriate controls are used,including actin (detected using anti-B-actin mouse monoclonal antibody#3700; Cell Signaling Technology). Protein concentrations of each aredetermined using a BCA assay according to manufacturer's instructions.To analyze PCCA and PCCB expression, equal loads of each lysate (i.e. 40μg) are prepared in a loading buffer and subjected to standard Westernblot analysis. For detection of PCCA, PCCB and control, commercialantibodies are used according to the manufacturer's instructions.

Example 15: In Vitro PCC Activity in Cells

An in vitro PCC activity assay is performed to determine whether PCCA orPCCB exogenously-expressed after introduction of mRNA comprising a PCCAor PCCB sequence is active.

A. Expression Assay

Hepa 1-6 cells, PCCA-deficient or PCCB-deficient patient fibroblastscells are transfected with mRNA formulations comprising human PCCA orPCCB, or a GFP control. Cells are transfected withLipofectamin-MessagerMax and lysed as described in Example 14 above.Appropriate controls are also prepared.

B. Activity Assay

To assess whether exogenous PCCA and PCCB can form functional PCCcomplex, an in vitro activity assay was performed using transfected Hepa1-6 cells, PCCA-deficient or PCCB-deficient patient fibroblasts lysatesas the source of enzymatic activity. To begin, lysate is mixed with PCCsubstrates, ATP, propionyl CoA, and 14C radioisotope labeled sodiumbicarbonate. The reaction mixture was incubated at 37C for 15 min in aThermo-mixer. The reaction was stopped by 5% TCA and vortexing. Thereaction tubes were then centrifuged at 13,000 g for 5 min, and thesupernatant was collected for quantification of radioisotope labeledenzymatic products methylmalonyl-CoA resulting from the activity of PCCprotein complex using Microbeta2 scintillation counter according to themanufacturers' recommendations.

Example 16: Human PCCA and PCCB Mutant and Chimeric Constructs

A polynucleotide of the present invention can comprise at least a firstregion of linked nucleotides encoding human PCCA or PCCB, which can beconstructed, expressed, and characterized according to the examplesabove. Similarly, the polynucleotide sequence can contain one or moremutations that results in the expression of a PCCA or PCCB withincreased or decreased activity. Furthermore, the polynucleotidesequence encoding PCCA or PCCB can be part of a construct encoding achimeric fusion protein.

Example 17: Production of Nanoparticle Compositions

A. Production of Nanoparticle Compositions

Nanoparticles can be made with mixing processes such as microfluidicsand T-junction mixing of two fluid streams, one of which contains thepolynucleotide and the other has the lipid components.

Lipid compositions are prepared by combining an ionizable amino lipiddisclosed herein, e.g., a lipid according to Formula (I) such asCompound II or a lipid according to Formula (III) such as Compound VI, aphospholipid (such as DOPE or DSPC, obtainable from Avanti Polar Lipids,Alabaster, Ala.), a PEG lipid (such as 1,2-dimyristoyl-sn-glycerolmethoxypolyethylene glycol, also known as PEG-DMG, obtainable fromAvanti Polar Lipids, Alabaster, Ala.), and a structural lipid (such ascholesterol, obtainable from Sigma-Aldrich, Taufkirchen, Germany, or acorticosteroid (such as prednisolone, dexamethasone, prednisone, andhydrocortisone), or a combination thereof) at concentrations of about 50mM in ethanol. Solutions should be refrigerated for storage at, forexample, −20° C. Lipids are combined to yield desired molar ratios anddiluted with water and ethanol to a final lipid concentration of betweenabout 5.5 mM and about 25 mM.

Nanoparticle compositions including a polynucleotide and a lipidcomposition are prepared by combining the lipid solution with a solutionincluding the a polynucleotide at lipid composition to polynucleotidewt:wt ratios between about 5:1 and about 50:1. The lipid solution israpidly injected using a NanoAssemblr microfluidic based system at flowrates between about 10 ml/min and about 18 ml/min into thepolynucleotide solution to produce a suspension with a water to ethanolratio between about 1:1 and about 4:1.

For nanoparticle compositions including an RNA, solutions of the RNA atconcentrations of 0.1 mg/ml in deionized water are diluted in 50 mMsodium citrate buffer at a pH between 3 and 4 to form a stock solution.

Nanoparticle compositions can be processed by dialysis to remove ethanoland achieve buffer exchange. Formulations are dialyzed twice againstphosphate buffered saline (PBS), pH 7.4, at volumes 200 times that ofthe primary product using Slide-A-Lyzer cassettes (Thermo FisherScientific Inc., Rockford, Ill.) with a molecular weight cutoff of 10kD. The first dialysis is carried out at room temperature for 3 hours.The formulations are then dialyzed overnight at 4° C. The resultingnanoparticle suspension is filtered through 0.2 μm sterile filters(Sarstedt, N0mbrecht, Germany) into glass vials and sealed with crimpclosures. Nanoparticle composition solutions of 0.01 mg/ml to 0.10 mg/mlare generally obtained.

The method described above induces nano-precipitation and particleformation. Alternative processes including, but not limited to,T-junction and direct injection, can be used to achieve the samenano-precipitation.

B. Characterization of Nanoparticle Compositions

A Zetasizer Nano ZS (Malvern Instruments Ltd, Malvern, Worcestershire,UK) can be used to determine the particle size, the polydispersity index(PDI) and the zeta potential of the nanoparticle compositions in 1×PBSin determining particle size and 15 mM PBS in determining zetapotential.

Ultraviolet-visible spectroscopy can be used to determine theconcentration of a polynucleotide (e.g., RNA) in nanoparticlecompositions. 100 μL of the diluted formulation in 1×PBS is added to 900μL of a 4:1 (v/v) mixture of methanol and chloroform. After mixing, theabsorbance spectrum of the solution is recorded, for example, between230 nm and 330 nm on a DU 800 spectrophotometer (Beckman Coulter,Beckman Coulter, Inc., Brea, Calif.). The concentration ofpolynucleotide in the nanoparticle composition can be calculated basedon the extinction coefficient of the polynucleotide used in thecomposition and on the difference between the absorbance at a wavelengthof, for example, 260 nm and the baseline value at a wavelength of, forexample, 330 nm.

For nanoparticle compositions including an RNA, a QUANT-IT™ RIBOGREEN®RNA assay (Invitrogen Corporation Carlsbad, Calif.) can be used toevaluate the encapsulation of an RNA by the nanoparticle composition.The samples are diluted to a concentration of approximately 5 μg/mL in aTE buffer solution (10 mM Tris-HCl, 1 mM EDTA, pH 7.5). 50 μL of thediluted samples are transferred to a polystyrene 96 well plate andeither 50 μL of TE buffer or 50 μL of a 2% Triton X-100 solution isadded to the wells. The plate is incubated at a temperature of 37° C.for 15 minutes. The RIBOGREEN® reagent is diluted 1:100 in TE buffer,and 100 μL of this solution is added to each well. The fluorescenceintensity can be measured using a fluorescence plate reader (WallacVictor 1420 Multilabel Counter; Perkin Elmer, Waltham, Mass.) at anexcitation wavelength of, for example, about 480 nm and an emissionwavelength of, for example, about 520 nm. The fluorescence values of thereagent blank are subtracted from that of each of the samples and thepercentage of free RNA is determined by dividing the fluorescenceintensity of the intact sample (without addition of Triton X-100) by thefluorescence value of the disrupted sample (caused by the addition ofTriton X-100).

Exemplary formulations of the nanoparticle compositions are presented inthe Table 6 below. The term “Compound” refers to an ionizable lipid suchas MC3, Compound II, or Compound VI. “Phospholipid” can be DSPC or DOPE.“PEG-lipid” can be PEG-DMG or Compound I.

TABLE 6 Exemplary Formulations of Nanoparticles Composition (mol %)Components 40:20:38.5:1.5 Compound:Phospholipid:Chol:PEG-lipid45:15:38.5:1.5 Compound:Phospholipid:Chol:PEG-lipid 50:10:38.5:1.5Compound:Phospholipid:Chol:PEG-lipid 55:5:38.5:1.5Compound:Phospholipid:Chol:PEG-lipid 60:5:33.5:1.5Compound:Phospholipid:Chol:PEG-lipid 45:20:33.5:1.5Compound:Phospholipid:Chol:PEG-lipid 50:20:28.5:1.5Compound:Phospholipid:Chol:PEG-lipid 55:20:23.5:1.5Compound:Phospholipid:Chol:PEG-lipid 60:20:18.5:1.5Compound:Phospholipid:Chol:PEG-lipid 40:15:43.5:1.5Compound:Phospholipid:Chol:PEG-lipid 50:15:33.5:1.5Compound:Phospholipid:Chol:PEG-lipid 55:15:28.5:1.5Compound:Phospholipid:Chol:PEG-lipid 60:15:23.5:1.5Compound:Phospholipid:Chol:PEG-lipid 40:10:48.5:1.5Compound:Phospholipid:Chol:PEG-lipid 45:10:43.5:1.5Compound:Phospholipid:Chol:PEG-lipid 55:10:33.5:1.5Compound:Phospholipid:Chol:PEG-lipid 60:10:28.5:1.5Compound:Phospholipid:Chol:PEG-lipid 40:5:53.5:1.5Compound:Phospholipid:Chol:PEG-lipid 45:5:48.5:1.5Compound:Phospholipid:Chol:PEG-lipid 50:5:43.5:1.5Compound:Phospholipid:Chol:PEG-lipid 40:20:40:0Compound:Phospholipid:Chol:PEG-lipid 45:20:35:0Compound:Phospholipid:Chol:PEG-lipid 50:20:30:0Compound:Phospholipid:Chol:PEG-lipid 55:20:25:0Compound:Phospholipid:Chol:PEG-lipid 60:20:20:0Compound:Phospholipid:Chol:PEG-lipid 40:15:45:0Compound:Phospholipid:Chol:PEG-lipid 45:15:40:0Compound:Phospholipid:Chol:PEG-lipid 50:15:35:0Compound:Phospholipid:Chol:PEG-lipid 55:15:30:0Compound:Phospholipid:Chol:PEG-lipid 60:15:25:0Compound:Phospholipid:Chol:PEG-lipid 40:10:50:0Compound:Phospholipid:Chol:PEG-lipid 45:10:45:0Compound:Phospholipid:Chol:PEG-lipid 50:10:40:0Compound:Phospholipid:Chol:PEG-lipid 55:10:35:0Compound:Phospholipid:Chol:PEG-lipid 60:10:30:0Compound:Phospholipid:Chol:PEG-lipid

Example 18: In Vivo PCCA Expression and PCC Activity in an Animal Model

To assess the ability of PCCA-containing mRNAs to facilitate PCCAexpression in vivo, mRNA encoding human PCCA is introduced into ananimal model of Propionic Acidemia (PA).

A genetic mouse model of PA is the Pcca^(−/−) (A138T) hypomorphic mouse(Guenzel et al., Mol. Ther., 1316-1323, 2013). Pcca^(−/−) knockout micelacking PCCA protein exhibit substantial increases in C3 andmethylcitric acid, and die within 36 hours of birth (Miyazaki et al., J.Biol. Chem., 35995-35999, 2001). Because these null mutant animals dieshortly after birth, they are difficult to use for testing intravenousinjection therapies. By contrast, Pcca^(−/−) (A138T) mice have beenengineered to express a mutant human PCCA that was identified previouslyin human PA patients with mild-to-moderate symptoms. The mutant PCCAprotein has an A138T substitution that causes protein instability andreduces protein levels relative to wild type protein. Pcca^(−/−) (A138T)mice have approximately 2-5% of wild type PCC activity (about 2% ofwild-type PCC activity in liver), exhibit delayed growth throughoutneonatal development, are smaller than their littermates, and haveelevated disease-associated metabolites (PA biomarkers), includingpropionyl-L-camitine (C3; produced by the addition of carnitine topropionyl-CoA) normalized to acetylcarnitine (C2), 2-methylcitric acid(2MC; a toxin produced by the combination of propionyl-CoaA andoxaloacetate), and 3-hydroxypropionic acid (3-HP), consistent withbiochemical presentation in human patients. Pcca^(−/−) (A138T) mice alsoexhibit elevated plasma ammonia levels, similar to PA presentation inhumans, where hyperammonia is common and mild-to-moderate ammoniaelevations may present chronically or during acute metabolicdecompensations in patients. Pcca^(−/−) (A138T) mice also have increasedheart mass, similar to PA patients who can have delayed growth andcardiomyopathy. However, the small amount of PCC enzyme activity inthese mice allows them to survive to adulthood (they exhibit onlymarginally decreased survival over 3 months following birth). FemalePcca^(−/−) (A138T) mice have consistently higher biomarker levels thanmale mutant mice, although the reason for this remains unclear.Pcca^(−/−) (A138T) hypomorphic mice are injected intravenously with0.1-2 mg/kg of either control mRNA (GFP or Luciferase) or human PCCAmRNA. The mRNA is formulated in lipid nanoparticles (CompoundII/PEG-DMG) for delivery into the mice. Mice are sacrificed after 24 or48 hrs and PCCA protein levels in liver lysates are determined byWestern Blot and liquid chromatography-mass spectrometry-massspectrometry (LC/MS/MS). PCC enzymatic activity is determined usingMicroBeta2, as described in Example 15. Citrate synthase expression isexamined for use as a protein loading control. Treatment with mRNAencoding PCCA is expected to reliably induce expression of PCCA andactivity of PCC. Blood levels ofpropionyl-L-carnitine/acetyl-L-carnitine (C3/C2), 2-methylcitirc acid(2-MC), 3-hydroxypropionic acid (3-HP), and ammonia are measured as PAmarkers.

Example 19: Assessing Duration of Biochemical Response Due toAdministration of PCCA mRNA in Pcca^(−/−) (A138T) Hypomorphic Mice

The levels of PA markers C3/C2 and 2-MC in dried blood spots (DBS)collected from Pcca^(−/−) (A138T) hypomorphic mice was measured −4 (4days before administration), 2, 7, 10, 14, 21, and 24 days following twodoses of intravenous injection of 1-methyl-pseudouridine modified mRNAencoding human PCCA or wild type human PCCA mRNA at 1 mg/kg. Themodified PCCA mRNA constructs used for injections are represented by SEQID NOs: 38 and 57-59. The mRNA was formulated in lipid nanoparticles(MC3) for delivery into the mice. PBS or control mRNA encoding GFP wasalso injected into Pcca^(−/−) (A138T) hypomorphic mice. The mRNAencoding human PCCA was IV injected at 1 mg/kg a second time 22 daysafter the first injection. At day 24, blood was drawn and tissue washarvested. C3/C2 and 2-MC blood levels were measured for each time pointusing LC-MS/MS.

A significant decrease in blood C3/C2 and 2-MC levels in Pcca^(−/−)(A138T) hypomorphic mice was observed over the course of the entire 21days after single IV injection of mRNA encoding human PCCA relative tohypomorphic mice that received an IV injection of eGFP control mRNA. Asshown in FIG. 1A, C3/C2 levels decreased in hypomorphic miceadministered human PCCA mRNA, while C3/C2 levels in hypomorphic miceadministered control mRNA remained elevated. Up to a 70% reduction inC3/C2 levels in DBS was observed at around day 2. FIG. 1B shows that2-MC levels decreased in hypomorphic mice that had been administeredmRNA encoding PCCA. An up to 60% reduction in 2-MC levels in DBS wasobserved at about day 2.

Example 20: In Vivo Ammonia Reduction in an Animal Model

Levels of ammonia, a disease-associated metabolite that accumulates inPA patients due to secondary inhibition of ureagenesis, particularlyduring acute metabolic decompensations, was measured in plasma fromPcca^(−/−) (A138T) hypomorphic mice 21 days after a single IV injectionof 1-methyl-pseudouridine modified mRNA encoding human PCCA at 1 mg/kgor control mRNA encoding GFP. The modified PCCA constructs used forinjections are represented by SEQ ID NOs:38 and 57-62. The mRNA wasformulated in lipid nanoparticles (MC3) for delivery into the mice.Ammonia levels were measured using a clinical analyzer (see Pesh-Imam etal, Clin. Chem., 1978, 24(11):2044-2046, herein incorporated byreference in its entirety). The lower limit of quantification (LLOQ) was23.4 μmol/L for ammonia assays. Plasma samples with hemolysis wereremoved from the analysis. As shown in FIG. 2A, several of the PCCA mRNAconstructs reduced ammonia levels to within the range of wild-typeammonia levels at 21 days after a single IV administration relative tocontrol mRNA or PBS alone.

The levels of ammonia in the plasma of Pcca^(−/−) (A138T) hypomorphicmice were also measured 21 days (3 weeks) and 28 days (4 weeks) after asingle IV injection of 1-methyl-pseudouridine modified mRNAs encodinghuman PCCA and PCCB (PCCA_18, SEQ ID NO:35; and PCCB_18, SEQ ID NO:46,respectively) at 1 mg/kg or control mRNA encoding luciferase(n=4-5/group) The results were compared to ammonia levels in wild-typeFVB mice. As shown in FIG. 2B, ammonia levels decreased approximately2-fold in mice injected with a single dose of mRNAs encoding PCCA andPCCB at 21 days (3 weeks) and 28 days (4 weeks) post-injection relativeto controls. These results suggest that injection of PCCA and PCCB mRNAsresult in a PD response in Pcca^(−/−) (A138T) hypomorphic mice due tothe production of functional PCC enzyme to correct the underlyingmetabolic defect.

The effects of co-administering PCCA and PCCB mRNAs on plasma ammonialevels are compared to the effects on ammonia levels that result fromadministering carglumic acid to mice. Pcca^(−/−) (A138T) hypomorphicmice are injected with 1-methyl-pseudouridine modified mRNAs encodinghuman PCCA and PCCB (or control mRNA encoding Luciferase), or areadministered carglumic acid. Ammonia levels in the mice injected withmRNAs and the mice administered carglumic acid are then monitored andcompared.

Example 21: PCCB Mutant Animal Model

A mouse model is used that is hypomorphic for PCCB gene expression.Hypomorphic pccb mutant mice are expected to exhibit symptoms ofpropionic academia, show increases in C3, 3HP and 2-methylcitric acid.Modified mRNA encoding human PCCB and/or PCCA is intravenously injectedinto this mutant mouse model to test PCCB and PCCA expression and PCCactivity. The levels of PA biomarkers (2-MC, C3/C2, and 3-HP) are alsotested in hypomorphic pccb mice.

Wild-type CD-1 mice are injected with 5×10¹¹ units per mouse of eitherrAAV2/8-shRNA1-EF1a-ZsGreen-ShRNA2 (sequences provided below) orrAAV2/8-EF1a-ZsGreen empty control virus. Three different cohorts ofmice are sacrificed at 1, 2, and 3 weeks post-dosing to examine the PCCAand PCCB mRNA levels by q-PCR or bDNA assay, PCCA and PCCB proteinlevels by capillary electrophoresis (CE) and LC-MS/MS, and PCC activityin liver. This is to determine how long it takes for the shRNA to takeeffect, and how much reduction in PCCB is achieved. PCCA mRNA and/orprotein levels might be affected after PCCB is knocked down as areduction of PCC complex formation may de-stabilize PCCA as well.

siRNA: UUUAAUUAGCUCAUAAUUC shRNA1:agatctGAATTATGAGCTAATTAAAtacctgacccataTTTAATTAGCTC ATAATTCTTTTTggtaccshRNA2: ctcgagaagaaggtatattgctgttgacagtgagcgACGAATTATGAGCTAATTAAAtagtgaagcttcagatgtaTTTAATTAGCTCATAATTCGCtgcctactgcctcggacttcaaggggtcagtcagaattc

Example 22: In Vivo Dosing in Wild-Type Mice Administered mRNA EncodingHuman PCCA

To determine the dose of PCCA mRNA that could effectively increase PCCactivity in vivo, a single IV tail vein injection of either 0.5 mg/kg or2 mg/kg of 1-methyl-pseudouridine modified mRNA encoding human PCCA(PCCA-014; SEQ ID NO:38) was administered to wild-type CD-1 mice. ThemRNA was formulated in lipid nanoparticles (Compound II/PEG-DMG) fordelivery into mice. PCC activity was assessed 24 hours, 48 hours, 72hours, or 96 hours after mRNA administration using a Microbeta2scintillation counter, as described in Example 15, on mitochondrialfractions isolated from liver lysates collected from the mouse. 5 μg ofmitochondrial matrix protein was loaded to the PCC reaction. Controlmice were administered PBS or a luciferase construct. FIG. 3 shows thata single 0.5 mg/kg dose of PCCA mRNA produced higher PCC activity than asingle 2 mg/kg dose of PCCA mRNA at 24 hours and 48 hours followingadministration. PCC activity increased over time, and reached itsmaximum level at 72 hours following mRNA administration.

Example 23: PCC Activity and PCCA Protein Expression in Wild-Type MiceAdministered a Single Dose of mRNA Encoding Human PCCA

To test the ability of 1-methyl-pseudouridine modified mRNA constructsto express PCCA and increase PCC activity in vivo, a single 0.5 mg/kgdose of each construct (PCCA_11 to PCCA_20 and PCCA-014, represented bySEQ ID NOs: 28-38, respectively) was IV administered to wild-type FVBmice via tail vein injection. The mRNA was formulated in lipidnanoparticles (Compound II/PEG-DMG) for delivery into mice. PCCAexpression was determined by capillary electrophoresis on mitochondrialfractions isolated from liver lysates collected from the mouse. PCCactivity was assessed 72 hours after mRNA administration using aMicrobeta2 scintillation counter, as described in Example 15, on mouseliver mitochondrial fractions. 5 μg of mitochondrial matrix protein wasloaded to the PCC reaction. Control mice were administered a luciferaseconstruct or left untreated. FIG. 4 shows that the PCCA mRNA constructsincreased PCC activity 72 hours after a single administration relativeto controls. FIG. 5 shows that mRNA encoding PCCA can increase theexpression of PCCA after a single administration in mice. Some of themRNA constructs that increased PCC activity at higher levels (see FIG.4) produced greater PCCA expression levels in vivo (see FIG. 5),including the PCCA_16, PCCA_18, and PCCA_20 constructs. PCCA_18 wasselected to use in subsequent in vivo studies.

Example 24: In Vitro PCC Activity and PCCA/PCCB Expression inPCCA-Deficient Patient Fibroblasts Transfected with mRNA Encoding HumanPCCA

PCC activity was measured in GM371 PCCA-deficient patient fibroblasts 24hours or 48 hours after transfection with 1 μg or 2 μg of1-methyl-pseudouridine modified mRNA encoding human PCCA (PCCA-014; SEQID NO: 38), or a GFP control. PCC activity was assessed as described inExample 15. 30 μg of protein was loaded to the PCC reaction. FIG. 6shows that PCCA mRNA increased PCC activity in PCCA-deficient patientfibroblasts.

GM371 PCCA-deficient patient fibroblasts (Coriell Institute) weretransfected with 1 μg of 1-methyl-pseudouridine modified mRNA constructsencoding PCCA (PCCA_11 to PCCA_20 and PCCA-014, represented by SEQ IDNOs: 28-38, respectively), or a GFP control. PCC activity was tested asdescribed in Example 15, in the cells harvested approximately 40 hoursafter transfection. About 25 μg of protein was loaded to the PCCreaction. FIG. 7A shows that PCC activity increased upon transfectionwith any of the PCCA mRNA constructs. FIG. 7B provides the PCC activitylevels for each of the PCCA mRNA constructs relative to the GFP control.

PCCA and PCCB expression levels were tested in the GM371 PCCA-deficientpatient fibroblasts transfected with the different mRNA constructsencoding PCCA, or a GFP control using capillary electrophoresis, asdescribed in Examples 14 and 15. Since the PCCB protein requires PCCAfor stability, PCCB is also deficient in PCCA-deficient fibroblasts.FIG. 8A shows that mRNA encoding PCCA can increase the expression ofPCCA in patient-derived fibroblasts. Some of the mRNA constructs thatincreased PCC complex activity at higher levels (see FIGS. 7A and 7B)produced greater PCCA expression levels in cells. FIG. 8B shows PCCBexpression levels were increased in patient-derived fibroblaststransfected with PCCA mRNA relative to control.

Example 25: In Vitro PCC Activity and PCCA/PCCB Expression inPCCB-Deficient Patient Fibroblasts Transfected with mRNA Encoding HumanPCCB

PCC activity was measured in GM1298 PCCB-deficient patient fibroblasts(Coriell Institute) 24 hours or 48 hours after transfection with 1 μg, 2μg or 3 μg of 1-methyl-pseudouridine modified mRNA encoding human PCCB(PCCB-014; SEQ ID NO: 49), or a GFP control. PCC activity was assessedas described in Example 15. 30 μg of protein was loaded to the PCCreaction. FIG. 9 shows that PCCB mRNA increased PCC activity inPCCB-deficient patient fibroblasts.

GM1298 PCCB-deficient patient fibroblasts were transfected with 1 μg of1-methyl-pseudouridine modified mRNA constructs encoding human PCCB(PCCB_11 to PCCB_20 and PCCB-014, represented by SEQ ID NOs: 39-49,respectively), or a GFP control. PCC activity was tested as described inExample 15, in the cells harvested approximately 24 hours aftertransfection. About 30 μg of protein was loaded to the PCC reaction.FIG. 10 shows that PCC activity increased upon transfection with any ofthe PCCB mRNA constructs.

PCCB and PCCA expression levels were tested in the GM1298 PCCB-deficientpatient fibroblasts transfected with the different mRNA constructsencoding human PCCB, or a GFP control using capillary electrophoresis,as described in Examples 14 and 15. PCCA does not usually require PCCBfor its stability, thus PCCB-deficient fibroblasts exhibit endogenousPCCA expression levels. FIG. 11A shows that mRNA encoding human PCCB canincrease the expression of PCCB in patient-derived fibroblasts. FIG. 11Bshows PCCA expression levels in patient-derived fibroblasts transfectedwith PCCB mRNA. FIG. 11C shows the capillary electrophoresis imagesshowing PCCA and PCCB expression levels. PCCB_18 was selected for use insubsequent in vivo studies based on the results shown in FIG. 10 andFIG. 11A.

Example 26: PCCA:PCCB Molar Ratio Titration in PCCA-Deficient PatientFibroblasts Transfected with mRNAs Encoding Human PCCA and Human PCCB

PCC activity was measured in GM371 PCCA-deficient patient fibroblasts 24hours or 40 hours after transfection with 1-methyl-pseudouridinemodified mRNAs encoding human PCCA (PCCA-014; SEQ ID NO: 38) and humanPCCB (PCCB-014; SEQ ID NO: 49) at different molar ratios of PCCA:PCCBmRNA (A:B ratio). Transfection with a GFP mRNA was used as a control.Total mRNA in each ratio group was equalized to 1 μg of PCCA mRNA (molaramount). PCC activity was assessed as described in Example 15.Approximately 25 μg of protein was loaded to the PCC reaction. FIG. 12Ashows that a PCCA:PCCB molar ratio of 1:1 (A:B ratio of 1:1) increasedPCC activity the greatest in PCCA-deficient patient fibroblasts at both24 and 40 hours after transfection.

PCCA and PCCB expression levels are also assayed in GM371 PCCA-deficientpatient fibroblasts and/or PCCA KO Hep3B cells 24 hours and 48 hoursafter transfection with 1-methyl-pseudouridine modified mRNAs encodinghuman PCCA and human PCCB at different molar ratios of PCCA:PCCB mRNA(A:B ratio), or a GFP control, using capillary electrophoresis, asdescribed in Examples 14 and 15. Transfecting cells with different molarratios of PCCA:PCCB, including a 1:1 molar ratio of PCCA:PCCB, resultsin expression of both PCCA and PCCB.

Example 27: PCCA:PCCB Molar Ratio Titration in PCCB-Deficient PatientFibroblasts Transfected with mRNAs Encoding Human PCCA and Human PCCB

PCC activity was measured in GM1298 PCCB-deficient patient fibroblasts24 hours after transfection with 1-methyl-pseudouridine modified mRNAsencoding human PCCA (PCCA-014; SEQ ID NO: 38) and human PCCB (PCCB-014;SEQ ID NO: 49) at different molar ratios of PCCA:PCCB mRNA (A:B ratio).Transfection with a GFP mRNA was used as a control. Total mRNA in eachratio group was equalized to 1 μg of PCCA mRNA (molar amount), or 2 μgof PCCA mRNA (molar amount). PCC activity was assessed as described inExample 15. Approximately 26 μg of protein was loaded to the PCCreaction. FIG. 12B shows that a PCCA:PCCB molar ratio of 1:1 (A:B ratioof 1:1) increased PCC activity the greatest in PCCB-deficient patientfibroblasts at 24 after transfection.

Example 28: In Vitro PCC Activity in PCCA- and PCCB-Deficient PatientFibroblasts Transfected with mRNAs Encoding Human PCCA and PCCB

PCC activity was measured in human fibroblasts (3-4×10⁵/well, n=2 percondition) isolated from a PCCA-deficient PA patient (GM371PCCA-deficient patient fibroblasts, Coriell Institute) and aPCCB-deficient PA patient (GM1298 PCCB-deficient patient fibroblasts,Coriell Institute) 24 hours after transfection (with lipofectamine) with0.5 or 1 μg of 1-methyl-pseudouridine modified mRNA encoding human PCCA(PCCA_18; SEQ ID NO:35) alone, mRNA encoding human PCCB (PCCB_18; SEQ IDNO:46) alone, or mRNAs encoding human PCCA (PCCA_18; SEQ ID NO:35) andPCCB (PCCB_18; SEQ ID NO:46) at a molar ratio of 1:1. Control cells weretransfected with 1 μg of mRNA encoding GFP. PCC activity was measured inthe transfected cell lysates using a radiometric activity assay asdescribed in Example 15. Briefly, lysate was mixed with PCC substrates,ATP, propionyl CoA, and ¹⁴C radioisotope labeled sodium bicarbonate. Thereaction mixture was incubated at 37° C. for 15 minutes, followed by theaddition of 5% TCA to stop the reaction, and was then centrifuged at13,000 g for 5 minutes. Supernatant was collected for quantification ofradioisotope labeled enzymatic products methylmalonyl-CoA usingMicrobeta2 scintillation counter. FIG. 13A shows that co-transfection ofmRNAs encoding PCCA and PCCB at a molar ratio of 1:1 increased PCCenzyme activity at higher levels (5-25 fold higher) compared to thetransfection of mRNA encoding PCCA or PCCB alone in both PCCA- andPCCB-deficient fibroblasts. These data suggest increased production offunctional PCC enzyme due to transfection of both PCCA and PCCB mRNAs,compared to transfection of PCCA mRNA alone and PCCB mRNA alone in bothsubtypes (PCCA-deficient and PCCB-deficient).

PCC activity was also measured in human fibroblasts (3-4×10⁵/well, n=2per condition isolated from a PCCA-deficient PA patient (GM371PCCA-deficient patient fibroblasts) and a PCCB-deficient PA patient(GM1298 PCCB-deficient patient fibroblasts) 24 hours after transfection(with lipofectamine) with 0.03125-2 μg of 1-methyl-pseudouridinemodified mRNAs encoding human PCCA (PCCA_18; SEQ ID NO:35) and humanPCCB (PCCB_18; SEQ ID NO:46) at a molar ratio of 1:1, or a GFP controlmRNA. FIG. 13B shows a dose-dependent effect, wherein transfection withlarger amounts of PCCA and PCCB mRNAs induced greater PCC activitylevels in both PCCA- and PCCB-deficient fibroblasts. Transfection ofcells with 2 μg of mRNAs led to the greatest PCC activity levels whichstarted to plateau, but transfection with 0.5-1 μg of mRNAs wassufficient to induce PCC activity levels that are greater than the PCCactivity levels in normal human fibroblasts. Transfection of PCCA andPCCB mRNAs across a range of concentrations resulted in similar PCCactivity in patient fibroblasts obtained from both subtypes(PCCA-deficient and PCCB-deficient).

Example 29: PCCA:PCCB Molar Ratio Titration in Hepa1-6 Cells Transfectedwith mRNAs Encoding Human PCCA and Human PCCB

PCC activity was measured in Hepa1-6 liver cells (ATCC® HB-8064™) 24hours or 40 hours after transfection with 1-methyl-pseudouridinemodified mRNAs encoding human PCCA (PCCA-014; SEQ ID NO: 38) and humanPCCB (PCCB-014; SEQ ID NO: 49) at different molar ratios of PCCA:PCCBmRNA (A:B ratio). Transfection with a GFP mRNA was used as a control.Total mRNA in each ratio group was equalized to 1 μg of PCCA mRNA (molaramount). In some cases, total mRNA in each ratio group was equalized to2 μg of PCCA mRNA (“double dose”). PCC activity was assessed asdescribed in Example 15. Approximately 25 μg of protein was loaded tothe PCC reaction. FIG. 14 shows that a PCCA:PCCB molar ratio of 1:1 (A:Bratio of 1:1) increased PCC activity the greatest in Hepa1-6 liver cellsat both 24 and 40 hours after transfection.

PCCA and PCCB expression levels are also assayed in Hepa1-6 and/or Hep3B(ATCC® HB-8064™) liver cells 24 hours and 48 hours after transfectionwith 1-methyl-pseudouridine modified mRNAs encoding human PCCA and humanPCCB at different molar ratios of PCCA:PCCB mRNA (A:B ratio), or a GFPcontrol, using capillary electrophoresis, as described in Examples 14and 15. Transfecting cells with different molar ratios of PCCA:PCCB,including a 1:1 molar ratio of PCCA:PCCB, results in expression oroverexpression of both PCCA and PCCB.

Example 30: In Vitro PCC Activity and PCCA/PCCB Expression in Hepa1-6Cells Transfected with mRNA Encoding Human PCCA

PCC activity was measured in Hepa1-6 cells 24 hours, 48 hours or 72hours after transfection with 1 μg, 2 μg, 3 μg, or 4 μg of1-methyl-pseudouridine modified mRNA encoding human PCCA (PCCA-014; SEQID NO: 38), or a GFP control. PCC activity was assessed as described inExample 15. 30 μg of protein was loaded to the PCC reaction. FIG. 15shows that PCCA mRNA alone did not significantly increased PCC activityin Hepa1-6 liver cells under most of the conditions tested.

Hepa1-6 cells were transfected with 2 μg of 1-methyl-pseudouridinemodified mRNA constructs encoding PCCA (PCCA_11 to PCCA_20 and PCCB-014,represented by SEQ ID NOs: 28-38, respectively), or a GFP control. PCCactivity was tested as described in Example 15, in the cellsapproximately 48 hours after transfection. About 25 μg of protein wasloaded to the PCC reaction. FIG. 16A shows that PCC activity increasedmildly upon transfection with the PCCA mRNA constructs. FIG. 16Bprovides the PCC activity levels for each of the PCCA mRNA constructsrelative to the GFP control.

PCCA and PCCB expression levels were tested in the Hepa1-6 transfectedwith the different mRNA constructs encoding human PCCA, or a GFP controlusing capillary electrophoresis, as described in Examples 14 and 15.FIG. 17A shows that mRNA encoding human PCCA can increase the expressionof PCCA in Hepa1-6 cells. FIG. 17B shows PCCB expression levels inHepa1-6 cells transfected with PCCA mRNA.

Example 31: In Vitro PCC Activity and PCCA/PCCB Expression in Hepa1-6Cells Transfected with mRNA Encoding Human PCCB

PCC activity was measured in Hepa1-6 cells 24 hours after transfectionwith 1 μg or 3 μg of 1-methyl-pseudouridine modified mRNA encoding humanPCCB (PCCB-014; SEQ ID NO: 49), or a GFP control. In addition, 0.5 μg ofmRNA encoding human PCCA (PCCA-014; SEQ ID NO: 38) and 0.5 μg of mRNAencoding PCCB (PCCB-014; SEQ ID NO: 49) were transfected into cells. PCCactivity was assessed as described in Example 15. 30 μg of protein wasloaded to the PCC reaction. FIG. 18 shows that there was no significantincrease in PCC activity when PCCB mRNA was transfected alone, but PCCactivity was markedly increased when PCCA and PCCB were transfectedtogether.

Hepa1-6 cells were transfected with 1 μg, 3 μg, 4 μg, or 6 μg of1-methyl-pseudouridine modified mRNA constructs encoding PCCB (PCCB-014;SEQ ID NO: 49), or a GFP control. PCC activity was tested as describedin Example 15, at 24 hours or 48 hours after transfection. About 30 μgof protein was loaded to the PCC reaction. FIG. 19 shows PCC activityupon transfection with PCCB mRNA.

Example 32: In Vivo Dose Dependent PCC Activity Due to Administration ofPCCA and PCCB mRNAs in Pcca^(−/−) (A138T) Hypomorphic Mice

To determine whether the co-administration of PCCA and PCCB mRNAs canincrease PCC activity in a dose dependent manner, 0.25 mg/kg, 0.5 mg/kgor 1 mg/kg of 1-methyl-pseudouridine modified PCCA and PCCB mRNAsencoding human PCCA (PCCA_18; SEQ ID NO:35) and human PCCB (PCCB_18; SEQID NO: 46) at a molar ratio of 1:1 were administered to male Pcca^(−/−)(A138T) hypomorphic mice via a single IV bolus tail vein injection. ThemRNAs were formulated in lipid nanoparticles (Compound II/PEG-DMG) fordelivery into mice (n=4/group). As controls, 1 mg/kg of mRNA encodingluciferase was injected into Pcca^(−/−) (A138T) hypomorphic mice orwild-type FVB mice (n=4) by single IV tail vein injection. Mice werebled 3 days prior to mRNA administration. Mice were sacrificed andhepatic PCC activity was assessed 2 days after IV injection using aMicrobeta2 scintillation counter, as described in Example 15, onmitochondrial fractions isolated from liver lysates collected from themouse. Protein expression of PCCA and PCCB in mitochondrial fractionsisolated from livers of Pcca^(−/−) (A138T) and WT mice was assessedusing capillary electrophoresis and normalized to citrate synthaseprotein levels.

FIG. 20A shows a dose dependent effect associated with a singleco-administration of PCCA and PCCB mRNAs in hypomorphic mice, such thathigher doses of mRNAs result in greater hepatic PCC activity, comparedto mice injected with control mRNA. Administration of 0.25 mg/kg of PCCAand PCCB mRNAs resulted in the lowest PCC activity and administration of1 mg/kg of PCCA and PCCB mRNAs resulted in the highest PCC activity.Specifically, hepatic PCC enzyme activity was 22%, 44% and 76% of liverPCC activity levels observed in luciferase mRNA-administered wild-typemice at dose levels of 0.25, 0.5 and 1 mg/kg, respectively, two daysafter a single IV administration of PCCA and PCCB mRNAs in hypomorphicPcca^(−/−) (A138T) mice. FIGS. 20B and 20C show that hepatic PCCA andPCCB proteins levels assessed by capillary electrophoresis increased ina dose-dependent manner, respectively, 2 days after the human PCCA andPCCB mRNAs were administered in a single injection to Pcca^(−/−) (A138T)mice.

To assess whether co-administration of PCCA and PCCB mRNAs has a dosedependent effect on 2-MC levels and C3/C2 levels, PA biomarkers, 0.25mg/kg, 0.5 mg/kg or 1 mg/kg of 1-methyl-pseudouridine modified PCCA andPCCB mRNAs encoding human PCCA (PCCA_18; SEQ ID NO:35) and human PCCB(PCCB_18; SEQ ID NO:46) at a 1:1 molar ratio, or 1 mg/kg of mRNAencoding luciferase as a control, were administered to Pcca^(−/−)(A138T) hypomorphic mice (n=4/group) via a single IV tail veininjection. The mice were pre-bled 3 days prior to administration ofPCCA/PCCB mRNAs to determine baseline 2-MC and C3/C2 levels. The mRNAswere formulated in lipid nanoparticles (Compound II/PEG-DMG) fordelivery into mice. The levels of 2-MC in plasma was measured 2 daysafter IV injection using LC-MS/MS, and compared to the 2-MC levels inpre-bleed plasma samples. The amount of C3 in dried blood spot (DBS)normalized to C2 ratio concentrations was also measured 2 days after IVinjection by methanol extraction, enrichment via a cation exchangecolumn and LC-MS analysis. The lower limit of quantification (LLOQ) was0.5 μM for 2MC and 12 nM for C3 and C2 carnitines. P-values wereobtained from paired-tests to compare means from pre-treatment vs.post-treatment metabolite concentrations.

FIG. 20D shows that the co-administration of PCCA and PCCB mRNAsresulted in a dose dependent reduction of 2-MC plasma levels inhypomorphic mice, such that 1 mg/kg of PCCA and PCCB mRNAs reduces 2-MClevels the most. Plasma 2-MC decreased 42%, 65%, and 76% on average 2days after a single injection of 0.25, 0.5, and 1 mg/kg of PCCA and PCCBmRNAs, respectively, to Pcca^(−/−) (A138T) hypomorphic mice, compared topre-treatment levels of 2-MC. FIG. 20E shows that C3/C2 carnitine ratioconcentrations were similarly decreased by 37%, 39%, and 55% on average2 days after a single injection of 0.25, 0.5, and 1 mg/kg of PCCA andPCCB mRNAs, respectively, compared to pre-treatment levels at these doselevels. By contrast, Pcca^(−/−) (A138T) mice injected with 1 mg/kg ofluciferase mRNA exhibited elevated plasma 2-MC concentrations and DBSC3/C2 camitine ratio concentrations. Thus, a dose-dependent metaboliccorrection was observed, consistent with the observed hepatic activityof PCC (see FIG. 20A).

The results of these experiments showed that administration of mRNAsencoding human PCCA and PCCB can restore functional hepatic PCC enzyme.

Example 33: Repeat Dose Study Assessing Biochemical Response Due toCo-Administration of PCCA and PCCB mRNAs in Pcca^(−/−) (A138T)Hypomorphic Mice Over Six Months

A 6-month repeat dose study was performed to evaluate whether repeat IVadministration of PCCA and PCCB mRNAs could improve the biochemicalabnormalities, growth, and heart mass symptoms of PA. Pcca^(−/−) (A138T)hypomorphic mice (females) were injected with 0.5 mg/kg or 1 mg/kg of1-methyl-pseudouridine modified PCCA and PCCB mRNAs encoding human PCCA(PCCA_18; SEQ ID NO:35) and human PCCB (PCCB_18; SEQ ID NO:46), or with1 mg/kg of mRNA encoding luciferase as a control. Mice were given sixdoses of mRNAs by IV tail vein injection as follows: a first dose at day0, a second dose at day 49, a third dose at day 77, a fourth dose at day107, a fifth dose at day 135, and a sixth dose at day 163. Mice werepre-bled four days before the first dose, and sacrificed for testing 48hours after the final sixth dose was administered. The mRNAs wereformulated in lipid nanoparticles (Compound II/PEG-DMG) for deliveryinto mice. The levels of PA biomarkers C3/C2 carnitine ratio, 2-MC, and3-HP were measured in blood drawn from the mice over the course of 165days using LC-MS/MS (n=6/group). The lower limit of quantification(LLOQ) was 0.5 μM for 2-MC and C3 and C2 carnitines, and 25 μM for 3-HP.For 3HP, values below LLOQ were reported as 25 μM; many of the PCCA andPCCB mRNA-treated mice were <LLOQ for plasma 3HP. Wild-type levels werebelow LLOQ for 2MC and 3HP, and 0.06±0.02 for C3/C2 carnitine ratiobased on n=6 WT FVB mice. Table 7 provides an overview of the studydesign.

TABLE 7 Study Design of 6-Month Repeat Dose Pharmacology Study inPCCa^(-/-) (A138T) mice Dose Sacrifice Group Mouse Model Treatment ROADose Level Schedule N Time Point 1 Pcca^(-/-) (A138T) Luciferase mRNA IVbolus 1 mg/kg Day 1*, 6 6 months (2 2 (female) hPCCA + hPCCB 0.5 mg/kgWeeks 8, 6 days after mRNAs 12, 16, 20, the 6^(th) 3 hPCCA + hPCCB 1mg/kg 24 injection) mRNAs 6 4 WT(female) N/A N/A N/A N/A 6 N/A *Adaptivedesign to assess the duration of biochemical response (plasma 2MC, C3/C2carnitine ratios and 3HP levels) due to human PCCA+ PCCB mRNA after asingle dose. The second dose was administered after plasma biomarkerlevels rebounded to basal pre-treatment levels. The subsequent dosinginterval in the study was selected based on the duration of biochemicalresponse observed after the first dose. Bleeding schedule for Pcca^(-/-)(A138T) mice: 3 days before, 6 hours and 2, 7, 10, 14, 21, 28, 35, 42,49 ays after the first injection, 1, 2, 3, 4 weeks after each injectionof second through fifth doses, and 2 days after the sixth injection.

A rapid and significant decrease (>50%) in plasma C3/C2, 2-MC, and 3-HPlevels in Pcca^(−/−) (A138T) hypomorphic mice was observed as early as 6hours after the first IV injection of the mRNAs encoding PCCA and PCCBrelative to hypomorphic mice that received an IV injection of luciferasecontrol mRNA, demonstrating a rapid metabolic correction in mice (seeFIGS. 21A-C). These results were consistent with the results of apharmacokinetic/pharmacodynamics study (see Example 34). A decrease inthe biomarkers was sustained for about 2-3 weeks following injection,before biomarker concentrations began to rebound. Based on this durationof biochemical response, the dosing interval was determined to bemonthly (i.e., dose administration every 4 weeks) for the remainder ofthe study.

As shown in FIG. 21A, C3/C2 plasma levels decreased in hypomorphic miceadministered 0.5 mg/kg or 1.0 mg/kg of human PCCA and PCCB mRNAs, whileC3/C2 levels in hypomorphic mice administered control mRNA remainedelevated. There was a significant and sustained reduction in C3/C2 aftereach administered dose of mRNAs encoding human PCCA and PCCB. Incontrast, mice injected with the luciferase control mRNA did not exhibita C3/C2 metabolic response. FIG. 21B shows that there was a significantand sustained decrease in 2-MC plasma levels in Pcca^(−/−) (A138T)hypomorphic mice that had been repeatedly administered mRNAs encodinghuman PCCA and PCCB. Administration of 0.5 mg/kg of PCCA and PCCB mRNAsresulted in about a 50% reduction in 2-MC levels (in μM). 2-MC levelsstarted to rebound at approximately 20 days following the first dose ofmRNAs, although the levels were still significantly lower than controlthrough 49 days. 2-MC levels significantly decreased again following thesecond dose of mRNAs administered on day 49, and after each of thesubsequent third, fourth, fifth, and sixth doses. FIG. 21C shows asignificant and sustained reduction in 3-HP plasma levels, relative tocontrol, after each administered dose of mRNAs encoding PCCA and PCCB,similar to what was observed for the 2-MC and C3/C2 biomarkers.

Thus, the results showed that a single dose of mRNAs encoding human PCCAand PCCB exhibited a long duration of action in Pcca^(−/−) (A138T)hypomorphic mice, eliciting a biochemical response that lasted about 1month. In addition, the results showed that repeat dosing of mRNAsencoding human PCCA and PCCB resulted in sustained efficacy.Co-administration of mRNAs encoding human PCCA and PCCB had a longduration of action since significant reductions in PA biomarkers (C3/C2,2-MC, 3-HP) were observed over the course of 165 days in response torepeat doses of mRNAs compared to control mRNA (all p<0.001). A similarbiomarker response across all three biomarkers was observed in the 0.5mg/kg and 1 mg/kg dose level groups. This shows that mRNAs encoding forhuman PCCA and PCCB reconstitute an active and stable intracellular PCCcomplex in liver that results in a significant decrease indisease-associated biomarkers (i.e., 2-MC, C3/C2 and 3-HP lowered in adose dependent manner) with a long duration of effect (i.e., biochemicalresponse) in a mouse model for PA, and can be dosed repeatedly withsustained pharmacology.

Additional pharmacology endpoints were assessed at the end of the6-month study to help determine the clinical outcome and safety profileof repeat dosing of mRNAs encoding human PCCA and PCCB. Mice weresacrificed 2 days following the last (sixth) dose of PCCA and PCCB mRNAs(n=6/group). Plasma ammonia levels were determined, as described inExample 20, and compared to ammonia levels in control mice. The LLOQ ofplasma ammonia was 23.4 μmol/L. Body weight gain was also calculated asthe body weight at the end of the study (6-month time point) minus thebody weight at the beginning of the study (day 1). The heart weight ofinjected mice was also measured and compared to the heart weight ofPcca^(−/−) (A138T) hypomorphic mice and wild-type mice. Heart weight wasdetermined as a ratio to body weight since the body weights of mice candiffer.

FIG. 22A shows that a dose-dependent decrease in plasma ammonia wasobserved in Pcca^(−/−) (A138T) mice administered human PCCA and PCCBmRNAs at the end of the study. Mice that were administered 1 mg/kg ofthe PCCA and PCCB mRNAs exhibited near wild-type levels of ammonia. Theshaded bar for wild-type mice in FIG. 22A is the minimum and maximumammonia level in n=6 wild-type age-matched female mice. FIG. 22B showsthat Pcca^(−/−) (A138T) mice injected with human PCCA and PCCB mRNAs(0.5 or 1 mg/kg) generally exhibited greater body weight gain at the endof the study compared to control mice administered 1 mg/kg of theluciferase mRNA. FIG. 22C shows that Pcca^(−/−) (A138T) hypomorphic micethat were administered 1 mg/kg of mRNAs encoding human PCCA and PCCBexhibited a dose-dependent decrease in heart mass normalized to bodyweight compared to mice that were administered the control mRNA. Micethat received repeat administration of 1 mg/kg of the PCCA and PCCBmRNAs have significantly lower heart weights normalized to body weightcompared to control mRNA-injected mice. The shaded bar for wild-typemice in FIG. 22C is the minimum and maximum heart weight/body weight inn=6 wild-type age-matched female mice. P-value obtained from Dunnett'spost-hoc multiple comparison test following a one-way ANOVA.Cardiomyopathy is frequently found in PA patients, and these findingssuggest an amelioration of enlarged hearts in Pcca^(−/−) (A138T) micedue to treatment with mRNAs encoding human PCCA and PCCB.

Clinical chemistry parameters were also assessed at the end of the6-month study in the mRNA-injected Pcca^(−/−) (A138T) mice and inuntreated age-matched wild-type mice. Plasma levels of ALT and AST werefirst measured by in-house clinical analyzer. Remaining plasma was usedto measure GGT, triglycerides, cholesterol, bile acids and albuminmeasurement by clinical analyzer. Plasma from mice was collected withEDTA. Pcca^(−/−) (A138T) mice injected with control mRNA had liverenzyme concentrations within normal range, similar to most PA patients.Table 8 provides the results of these measurements. Data is shown asmean±SD. One-way ANOVA analysis was performed, followed by Dunnett'smultiple comparison tests to perform pairwise comparisons between allgroups. An outlier in the untreated wild-type group was removed fromstatistical analyses for ALT and AST. ** p<0.01 vs. control mRNA, ***p<0.001 vs. control mRNA.

TABLE 8 Serum chemistry parameters from 6-month repeat dose study inPccca^(−/−)(A138T) mice and untreated wild-type mice Control mRNA,hPCCA + hPCCB hPCCA + hPCCB 1 mg/kg mRNA, 0.5 mg/kg mRNA, 1 mg/kg (n = 6Pcca^(−/−) (n = 6 Pcca^(−/−) (n = 5-6 Pcca^(−/−) Untreated WT (A138T)mice) (A138T) mice) (A138T) mice) (n = 4-6 WT mice) ALT (U/L) 133.83 ±42.23    51.00 ± 18.75***   43.50 ± 15.98***  117.83 ± 129.35** AST(U/L) 115.17 ± 24.49  76.83 ± 19.18 79.33 ± 24.22 140.83 ± 95.50  GGT(U/L) 0 ± 0 0 ± 0 0 ± 0 0 ± 0 Triglycerides 181.30 ± 130.03 145.00 ±29.04  172.80 ± 33.06  347.25 ± 54.44  (mg/dL) Cholesterol 141.20 ±15.24  125.70 ± 14.71  135.00 ± 18.97  182.75 ± 80.39  (mg/dL) BileAcids 5.18 ± 0.68 5.97 ± 3.50 5.26 ± 3.90 6.33 ± 2.53 (umol/L) Albumin(g/dL) 2.83 ± 0.22 3.03 ± 0.23 3.12 ± 0.09 2.90 ± 0.22

Plasma ALT levels were significantly lower in the Pcca^(−/−) (A138T)mice that were injected with human PCCA and PCCB mRNAs (both at the 0.5mg/kg and 1 mg/kg doses) and in untreated wild-type mice compared toPcca^(−/−) (A138T) mice injected with control mRNA. The plasma ALTlevels in the mice injected with the mRNAs encoding PCCA and PCCB weresimilar to levels reported in 8-week old wild-type (FVB) female mice(seehttp://jackson.jax.org/rs/444-BUH-304/images/physiological_data_001800.pdf),and were not significantly different from the plasma ALT levels in theage-matched untreated wild-type mice from the study. All other serumchemistry parameters (AST, GGT, triglycerides, cholesterol, bile acids,and albumin) were not statistically different between groups, althoughthere was a trend towards lower AST in Pcca^(−/−) (A138T) miceadministered PCCA and PCCB mRNAs compared to the mice administeredcontrol mRNA. All clinical chemistry parameters were within the normalrange observed in wild-type mice and thus these data suggest thatadministering human PCCA and PCCB mRNAs was well-tolerated in Pcca^(−/−)(A138T) mice after the 6-month repeat dose study.

Example 34: Assessing Duration of Biochemical Response Due toCo-Administration of PCCA and PCCB mRNAs in Pcca^(−/−) (A138T)Hypomorphic Mice

A study was conducted to characterize the pharmacokinetics (PK) ofmRNA-encoded human PCCA and PCCB proteins and PCC enzyme activity inliver and the pharmacodynamic (PD) response. Pcca^(−/−) (A138T)hypomorphic mice (mixed genders) were injected with a single dose of 1mg/kg of 1-methyl-pseudouridine modified PCCA and PCCB mRNAs encodinghuman PCCA (PCCA_18; SEQ ID NO:35) and human PCCB (PCCB_18; SEQ IDNO:46), or with 1 mg/kg of mRNA encoding luciferase as a control, by IVtail vein injection. Previous studies showed no difference in hepaticPCCA and PCCB protein levels and PCC enzyme activity in Pcca^(−/−)(A138T) mice administered luciferase mRNA in LNPs compared to PBS (datanot shown). The mRNAs were formulated in lipid nanoparticles (CompoundII/PEG-DMG) for delivery into mice. Mice were sacrificed at 6 hours, 24hours, 48 hours, 7 days, 14 days, 21 days or 28 days following a singleinjection of mRNAs (n=3-4 mice per time point). For each time point,hepatic PCC activity was measured using a Microbeta2 scintillationcounter, as described in Example 15, on mitochondrial fraction isolatedfrom liver lysates. Plasma PA biomarkers (2-MC, C3/C2 ratio, 3-HP, andammonia) were also measured. Plasma levels of 2-MC, C3/C2 carnitineratio, and 3-HP were measured using LC-MS/MS at each time point. Thelower limit of quantification (LLOQ) was 0.5 μM for 2-MC and C3 and C2carnitines, and 25 μM for 3-HP. Absolute quantification of human PCCAand PCCB proteins was also measured by LC-MS/MS. Homogenized mouselivers were spiked with isotopically labeled signature peptides (naturalC and N atoms on lysine were replaced by 13C and 15N isotopes; ThermoScientific Pierce) specific for human wild-type PCCA (AQAVHPGYGFLSENK,which does not recognize the human PCCA A138T mutant) and PCCB(TVGIVGNQPK) as an internal standard. Mice administered the controlluciferase mRNA were used to assess the baseline PCCA and PCCB proteinlevels and PCC enzyme activity in liver.

FIG. 23A shows that PCCA protein levels were substantially increased asearly as 6 hours (the first time point) after injection of PCCA and PCCBmRNAs, and peaked at 48 hours (Tmax), relative to PCCA protein levels incontrol mice injected with control mRNA (i.e., the baseline level whichis below LLOQ). PCCA protein levels decreased to within control levelsby 28 days following injection. PCCB protein levels exhibited a similarprotein expression pattern and an approximate 1:1 molar ratio ofPCCA/PCCB over the course of 28 days. PCCA and PCCB proteinconcentrations (pmol/mg tissue) were similar across the time course.LLOQ for PCCA and PCCB was 26 and 16 ng/mg tissue, respectively). AllPCCA and PCCB protein values from luciferase mRNA-injected mice werebelow the LLOQ at all time points. FIG. 23B shows that hepatic PCCactivity levels were higher in Pcca^(−/−) (A138T) hypomorphic mice at 6hours, 24 hours, 48 hours, 7 days, 14 days and 21 days followinginjection of PCCA and PCCB mRNAs relative to luciferase controls. PCCactivity increased above background levels as early as 6 hours (thefirst time point) and peaked at 48-hours post-injection, reaching nearwild-type levels (86.1% of wild-type levels), and fell within controlmRNA levels (i.e., baseline) at 28 days post-injection. The kinetics ofPCC enzyme activity in liver was consistent with the kinetics of thePCCA and PCCB proteins, and demonstrates restoration of functional PCCenzyme activity in a mouse model of PA. It is expected that PCC activitylevels will not increase in the heart and brain tissue of mice injectedwith PCCA and PCCB mRNAs compared to controls.

FIG. 23C shows that plasma levels of 2-MC were reduced in micesacrificed at 1, 2, 7, 14, 21, and 28 days after a single injection ofmRNAs encoding PCCA and PCCB, showing that the combination of PCCA andPCCB mRNAs had a long duration of action in reducing 2-MC levels over atleast 4 weeks. Indeed, there was a greater than 50% reduction in 2-MClevels in mice injected with PCCA and PCCB mRNAs compared to controlmice at 28 days. FIG. 23D shows that plasma levels of C3/C2 were reducedat 6 hours, and 1, 2, 7, 14, and 21 days after a single injection ofmRNAs encoding PCCA and PCCB, showing that the combination of PCCA andPCCB mRNAs had a long duration of action in reducing C3/C2 levels overat least 3 weeks. The C3/C2 ratio level was reduced by more than 50% asearly as 6 hours after injection, indicating a rapid metaboliccorrection, but was similar to control levels at 28 days followinginjection. FIG. 23E shows 3-HP levels were much reduced over the courseof 28 days following injection of PCCA and PCCB mRNAs. 3-HP levels werereduced by greater than 50% by 6 hours and at 28 days after injectionrelative to control. Thus, all plasma primary disease biomarkers(metabolites that accumulate in PA due to the metabolic block) that wereexamined were substantially lower in Pcca^(−/−) (A138T) mice that wereadministered a single dose of PCCA and PCCB mRNAs relative to control.In addition, plasma ammonia, a secondary PA disease biomarker (whichaccumulates due to secondary inhibition of ureagenesis) was alsosignificantly reduced in Pcca^(−/−) (A138T) mice administered a singledose of PCCA and PCCB mRNAs relative to controls (see Example 20).Reduction of all of these PA biomarkers demonstrate a pharmacodynamicsresponse in mice treated with PCCA and PCCB mRNAs due to the productionof functional PCC enzyme, which corrects the underlying metabolic defectof PA.

2-MC levels were also measured in key disease-associated tissues (liver,heart, and brain) of mice at each time point (6 hours, 1 day, 2 days, 7days, 14 days, 21 days, and 28 days) following mRNA injection usingLC-MS/MS. Tissue samples (in milligrams) were homogenized in 4 volumes(in microliters) of water: acetonitrile (80:20, v/v) and tissue 2MCconcentrations were quantified by LC-MS/MS. The LLOQ of 2MC in alltissues was 2.5 μM. Values below the LLOQ were reported as 2.5 μM (i.e.the LLOQ). P-values were obtained from Sidak's multiple comparison testto compare PCCA and PCCB mRNAs vs. control mRNA groups at each timepoint following a two-way ANOVA. *p<0.05, **p<0.01.

FIG. 23F shows that 2-MC levels were also reduced for at least 28 daysin the livers of Pcca^(−/−) (A138T) hypomorphic mice following a singleinjection of PCCA and PCCB mRNAs, relative to luciferase control mRNA.Indeed, 2-MC concentrations were substantially lower (>85%) 1 to 21 daysafter injection; the reduction in liver 2-MC concentrations wasstatistically significant at all time point except for the 6-hour,2-day, and 28-day time points. FIG. 23G shows that 2-MC levels were alsoreduced in the hearts of Pcca^(−/−) (A138T) hypomorphic mice injectedwith PCCA and PCCB mRNAs, ranging from 27-58% lower on average intreated vs. control mice. FIG. 23H shows that brain 2-MC concentrationswere 6-38% lower on average in mice administered PCCA and PCCB mRNAscompared to controls, but these differences were not statisticallysignificant. C3/C2 and 3-HP levels will also be measured in the livers,hearts, and brains of Pcca^(−/−) (A138T) hypomorphic mice followinginjection of PCCA and PCCB mRNA.

PCCA and PCCB protein expression levels are also measured in the tissues(liver and spleen) of Pcca−/− (A138T) hypomorphic mice that areadministered 1 mg/kg of 1-methyl-pseudouridine modified PCCA and PCCBmRNAs encoding human PCCA (PCCA_18; SEQ ID NO: 35) and human PCCB(PCCB_18; SEQ ID NO: 46) at a 1:1 molar ratio, or with 1 mg/kg of mRNAencoding luciferase as a control, by a single IV tail vein injection.Protein levels are assessed by LC-MS/MS at 6 hours, 24 hours, 48 hours,7 days, 14 days, 21 days and 28 days following injection.

Modified human PCCA and PCCB mRNA levels are also measured in the plasmaand tissues (liver and spleen) of Pcca−/− (A138T) hypomorphic mice thatare administered 1 mg/kg of 1-methyl-pseudouridine modified PCCA andPCCB mRNAs encoding human PCCA (PCCA_18; SEQ ID NO: 35) and human PCCB(PCCB_18; SEQ ID NO: 46) at a 1:1 molar ratio, or with 1 mg/kg of mRNAencoding luciferase as a control, by a single IV tail vein injection.The levels of mRNA encoding modified human PCCA and PCCB is assayed at 6hours, 24 hours, 48 hours, and 7 days following injection of mice usinga bDNA (as described in Cell Reports, 2017, 21:3548-58, which is hereinincorporated by reference in its entirety) or qPCR assay. It is expectedthat modified human PCCA and PCCB mRNA levels will be detectable in theplasma and the tissues (liver, spleen) of mice post-injection.

Example 35: In Vivo Formation of PCC Dodecamer

The PCC holoenzyme is an alpha(6)beta(6) dodecamer with a molecularweight of approximately 800 kDa in humans. To determine if1-methyl-pseudouridine modified PCCA and PCCB mRNAs encoding human PCCA(PCCA_18; SEQ ID NO: 35) and human PCCB (PCCB_18; SEQ ID NO: 46) canexpress PCCA and PCCB proteins that form a PCC dodecamer of theappropriate molecular weight, Pcca^(−/−) (A138T) hypomorphic mice areinjected with a single 1 mg/kg dose of mRNAs encoding human PCCA andPCCB via tail vein injection. Mitochondrial fractions of liver lysatesare isolated from mice 2 days after injections, and proteins areseparated by size exclusion chromatography using Superose 6 column (GEHealthcare) with a 500 ul loop. Fractions are then pooled and theprotein concentrated. PCCA and PCCB expression and the enrichment of PCCcomplex in pooled fractions is assessed using capillary electrophoresisas described in Example 13 and PCC activity is assessed as described inExample 15. PCC complex formation can also be assessed by bluenative-polyacrylamide gel followed by western blotting (as described inJiang et al., J. Biol. Chem., 2005, 280(30):27719-27, which is hereinincorporated by reference in its entirety). It is expected that theco-injection of PCCA and PCCB mRNAs will result in the formation of PCCcomplexes at a molecular weight of approximately 800 kDa inmitochondria, indicating that mRNA expressed human PCCA and PCCB canform dodecamers in mice.

Example 36: Assessing Cardiomyopathy in Pcca^(−/−) (A138T) HypomorphicMice

Cardiomyopathy is observed in human patients with propionic academia,and Pcca^(−/−) (A138T) hypomorphic mice have enlarged hearts relative towild-type mice (Guenzel et al., Mol. Ther., 1316-1323, 2013, hereinincorporated by reference in its entirety; see, also, Example 33, FIG.22C). Heart weight is assessed in Pcca^(−/−) (A138T) hypomorphic mice(compared to age- and gender-matched wild-type mice) to determine ifthese hypomorphic mice have cardiomyopathy. If increased heart weight(normalized to body weight) and cardiac hypertrophy is detected, thenPcca^(−/−) (A138T) hypomorphic mice will be administered multiple doses(e.g., at 0.5 mg/kg or 1 mg/kg) of 1-methyl-pseudouridine modified PCCAand PCCB mRNAs encoding human PCCA and human PCCB, or mRNA encodingluciferase as a control, over a period of time, as described in Example31, to determine if cardiomyopathy can be improved by administering PCCAand PCCB mRNAs.

Indeed, FIG. 22C of Example 33 shows that the hearts of Pcca^(−/−)(A138T) hypomorphic mice are enlarged relative to wild-type mice, andrepeat injection of mRNAs encoding PCCA and PCCB over about 165 days candecrease heart size in these mice.

Example 37: Assessing Liver Histology and Mitochondrial Function inPcca^(−/−) (A138T) Hypomorphic Mice

Liver histology is determined in Pcca^(−/−) (A138T) hypomorphic mice(compared to age-matched wild-type mice) by hematoxylin and eosin (H&E)staining. If liver pathology is detected, then Pcca^(−/−) (A138T)hypomorphic mice will be administered multiple doses of1-methyl-pseudouridine modified PCCA and PCCB mRNAs encoding human PCCAand human PCCB, or mRNA encoding luciferase as a control, over a periodof time to determine if liver pathology can be improved by administeringPCCA and PCCB mRNAs. It is expected that the livers of Pcca^(−/−)(A138T) hypomorphic mice will not be significantly different than thelivers of wild-type mice because ALT/AST levels were observed to not besignificantly different in these mice (data not shown).

Mitochondrial dysfunction has also been reported in Pcca^(−/−) (A138T)hypomorphic mice (Gallego-Villar et al., Free Radical Biology andMedicine, 96:1-12, 2016). Liver mitochondrial function is assessed inPcca^(−/−) (A138T) hypomorphic mice and compared to liver mitochondrialfunction in wild-type mice by XFe 96 Extracellular Flux Analyzer(Seahorse Bioscience). Pcca^(−/−) (A138T) hypomorphic mice are thenadministered multiple doses of 1-methyl-pseudouridine modified PCCA andPCCB mRNAs encoding human PCCA and human PCCB, or mRNA encodingluciferase as a control, over a period of time, as described in Example31, to determine if mitochondrial function can be improved byadministering PCCA and PCCB mRNAs.

Example 38: Localization of PCCA/PCCB in PCCA-Deficient PatientFibroblasts Transfected with mRNA Encoding Human PCCA/PCCB

The subcellular co-localization of PCCA and PCCB proteins was examinedin GM371 PCCA-deficient patient fibroblasts (9,000 cells/well on a96-well plate) 24 hours after transfection with a total of 25 ng of1-methyl-pseudouridine modified mRNAs encoding human PCCA (PCCA_18; SEQID NO: 35) and PCCB (PCCB_18; SEQ ID NO: 46), or a luciferase control.Commercial anti-PCCA monoclonal antibody (Santa Cruz #sc-393527) andanti-PCCB polyclonal antibody (Novus #NBP1-85886) were used to detectmRNA-expressed PCCA and PCCB using immunofluorescence microscopy.Mitotracker Red was used to confirm the identity of mitochondria andDAPI was used to stain nuclei. Image analysis was performed on a ZeissELYRA imaging system. As shown in FIG. 24A, PCCA and PCCB translatedfrom the administered mRNAs co-localized with mitochondria inPCCA-deficient patient fibroblasts, showing that the mRNA-encodedproteins localized to the proper subcellular portions of the cells.These results also suggested that mRNA-expressed PCCA and PCCB formcomplexes in cells. There was no PAAC or PCCB staining in negativecontrol cells that were transfected with mRNA encoding luciferase. FIG.24B shows that there was marked luciferase expression in PCCA-deficientpatient fibroblasts transfected with the luciferase mRNA.

Example 39: Pharmacology Study Using Different Lipid Nanoparticles

A one-month pharmacology study was conducted to evaluate the effects offormulating human PCCA (SE_PCCA_018; SEQ ID NO:203) and PCCB mRNAs(SE_PCCB_018; SEQ ID NO:204) in two different lipid nanoparticles(LNPs). The mRNAs were formulated at a molar ratio of 1:1 in eitherCompound II/PEG-DMG or Compound II/Compound I, and injectedintravenously into Pcca^(−/−) (A138T) mice (n=6/group) in 2 0.5 mg/kgdoses at day 0 and day 28. Control mice were injected with tris-sucrosebuffer at day 0 and day 28. Plasma was collected prior to injections andon days 2, 8, 14, 21 and 28 days after the first IV dose, and 2 daysafter the second IV dose. Plasma 2-MC, C3/C2 carnitine ratio and 3-HPconcentrations were quantified by LC-MS/MS at each time point. HepaticPCC activity was measured at sacrifice 2 days after the second dose.Data shown as mean±SD. The LLOQ was 0.5 μM for plasma 2-MC, C3 and C2carnitines. The LLOQ for 3-HP was 25 or 50 μM for samples with nodilution or with 1:2 dilution. For 3-HP, values below the LLOQ werereported as 25 or 50 μM (i.e. the LLOQ) for samples with no dilution orwith 1:2 dilution, respectively. Wild-type biomarker levels were belowthe LLOQ for plasma 2MC and 3HP, and 0.04±0.005 for plasma C3/C2carnitine ratio based on n=6 wild-type mice.

FIGS. 25A-C show that pharmacodynamics (PD) responses, defined byreductions in primary disease biomarkers (2-MC, C3/C2, 3-HP), weresimilar in Pcca^(−/−) (A138T) mice that were administered human PCCA andPCCB mRNAs formulated in both LNPs (Compound II/PEG-DMG and CompoundII/Compound I). The area under the effect curve (AUE) was slightly lowerfor the Compound II/Compound I formulation compared to the CompoundII/PEG-DMG formulation. In contrast, consistent with previousexperiments, no metabolic response was observed for mice administeredbuffer solution (tris-sucrose). Consistent with the lower AUE observedin the Compound II/Compound I LNP group, hepatic PCC activity wasslightly lower in mice that received mRNAs formulated in CompoundII/Compound I compared to PCC activity in mice that received PCCA andPCCB mRNAs formulated in Compound II/PEG-DMG (FIG. 25D). The duration ofbiochemical response across all biomarkers was approximately 4 weeks.These data demonstrate that PCCA and PCCB mRNAs formulated in eitherCompound II/PEG-DMG or Compound II/Compound I resulted in similarpharmacology results in Pcca^(−/−) (A138T) mice.

It is to be appreciated that the Detailed Description section, and notthe Summary and Abstract sections, is intended to be used to interpretthe claims. The Summary and Abstract sections can set forth one or morebut not all exemplary embodiments of the present invention ascontemplated by the inventor(s), and thus, are not intended to limit thepresent invention and the appended claims in any way.

The present invention has been described above with the aid offunctional building blocks illustrating the implementation of specifiedfunctions and relationships thereof. The boundaries of these functionalbuilding blocks have been arbitrarily defined herein for the convenienceof the description. Alternate boundaries can be defined so long as thespecified functions and relationships thereof are appropriatelyperformed.

The foregoing description of the specific embodiments will so fullyreveal the general nature of the invention that others can, by applyingknowledge within the skill of the art, readily modify and/or adapt forvarious applications such specific embodiments, without undueexperimentation, without departing from the general concept of thepresent invention. Therefore, such adaptations and modifications areintended to be within the meaning and range of equivalents of thedisclosed embodiments, based on the teaching and guidance presentedherein. It is to be understood that the phraseology or terminologyherein is for the purpose of description and not of limitation, suchthat the terminology or phraseology of the present specification is tobe interpreted by the skilled artisan in light of the teachings andguidance.

The breadth and scope of the present invention should not be limited byany of the above-described exemplary embodiments, but should be definedonly in accordance with the following claims and their equivalents.

All publications, patent applications, patents, and other referencesmentioned herein are incorporated by reference in their entirety. Incase of conflict, the present specification, including definitions, willcontrol.

1. A pharmaceutical composition comprising a delivery agent comprising alipid nanoparticle comprising a compound of Formula (I):

or an N-oxide, salt, or isomer thereof, wherein: R₁ is selected from thegroup consisting of C₅₋₃₀ alkyl, C₅₋₂₀ alkenyl, —R*YR″, —YR″, and—R″M′R′; R₂ and R₃ are independently selected from the group consistingof H, C₁₋₁₄ alkyl, C₂₋₁₄ alkenyl, —R*YR″, —YR″, and —R*OR″, or R₂ andR₃, together with the atom to which they are attached, form aheterocycle or carbocycle; R₄ is selected from the group consisting ofhydrogen, a C₃₋₆ carbocycle, —(CH₂)_(n)Q, —(CH₂)_(n)CHQR, —CHQR,—CQ(R)₂, and unsubstituted C₁₋₆ alkyl, where Q is selected from acarbocycle, heterocycle, —OR, —O(CH₂)_(n)N(R)₂, —C(O)OR, —OC(O)R, —CX₃,—CX₂H, —CXH₂, —CN, —N(R)₂, —C(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R,—N(R)C(O)N(R)₂, —N(R)C(S)N(R)₂, —N(R)R₈, —N(R)S(O)₂R₈, —O(CH₂)_(n)OR,—N(R)C(═NR₉)N(R)₂, —N(R)C(═CHR₉)N(R)₂, —OC(O)N(R)₂, —N(R)C(O)OR,—N(OR)C(O)R, —N(OR)S(O)₂R, —N(OR)C(O)OR, —N(OR)C(O)N(R)₂,—N(OR)C(S)N(R)₂, —N(OR)C(═NR₉)N(R)₂, —N(OR)C(═CHR₉)N(R)₂, —C(═NR₉)N(R)₂,—C(═NR₉)R, —C(O)N(R)OR, and —C(R)N(R)₂C(O)OR, and each n isindependently selected from 1, 2, 3, 4, and 5; each R₅ is independentlyselected from the group consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl, and H;each R₆ is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H; M and M′ are independently selected from—C(O)O—, —OC(O)—, —OC(O)-M″-C(O)O—, —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—,—C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)₂—, —S—S—, anaryl group, and a heteroaryl group, in which M″ is a bond, C₁₋₁₃ alkylor C₂₋₁₃ alkenyl; R₇ is selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H; R₈ is selected from the group consisting ofC₃₋₆ carbocycle and heterocycle; R₉ is selected from the groupconsisting of H, CN, NO₂, C₁₋₆ alkyl, —OR, —S(O)₂R, —S(O)₂N(R)₂, C₂₋₆alkenyl, C₃₋₆ carbocycle and heterocycle; each R is independentlyselected from the group consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl, and H;each R′ is independently selected from the group consisting of C₁₋₁₈alkyl, C₂₋₁₈ alkenyl, —R*YR″, —YR″, and H; each R″ is independentlyselected from the group consisting of C₃₋₁₅ alkyl and C₃₋₁₅ alkenyl;each R* is independently selected from the group consisting of C₁₋₁₂alkyl and C₂₋₁₂ alkenyl; each Y is independently a C₃₋₆ carbocycle; eachX is independently selected from the group consisting of F, Cl, Br, andI; m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13; and whereinwhen R₄ is —(CH₂)_(n)Q, —(CH₂)_(n)CHQR, —CHQR, or —CQ(R)₂, then (i) Q isnot —N(R)₂ when n is 1, 2, 3, 4 or 5, or (ii) Q is not 5, 6, or7-membered heterocycloalkyl when n is 1 or 2, wherein the pharmaceuticalcomposition comprises an mRNA comprising an open reading frame (ORF)encoding a propionyl-CoA carboxylase alpha (PCCA) polypeptide, andwherein the pharmaceutical composition when administered as a singleintravenous dose to a human subject in need thereof is sufficient to:(i) increase the level of PCC activity in liver tissue to within atleast 2%, at least 5%, at least 10%, at least 20%, at least 30%, atleast 40%, at least 50%, at least 60%, at least 70%, at least 80%, atleast 90%, or at least 100% of normal PCC activity level for at least 12hours, at least 24 hours, at least 48 hours, at least 72 hours, at least96 hours, at least 120 hours, at least 1 week, at least 2 weeks, atleast 3 weeks, or at least 4 weeks post-administration; (ii) increasethe level of PCC activity in liver tissue at least 1.5-fold, at least2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least10-fold, at least 20-fold, or at least 50-fold compared to the subject'sbaseline PCC activity level or a reference PCC activity level in a humansubject having propionic academia (PA) for at least 12 hours, at least24 hours, at least 48 hours, at least 72 hours, at least 96 hours, atleast 120 hours, at least 1 week, at least 2 weeks, at least 3 weeks, orat least 4 weeks post-administration; (iii) reduce plasma, serum, wholeblood, and/or liver levels of propionic acid at least 30%, at least 40%,at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, orat least 100% compared to the subject's baseline plasma, serum, wholeblood and/or liver propionic acid level or a reference plasma, serum,whole blood and/or liver propionic acid level in a human subject havingpropionic acidemia (PA) for at least 12 hours, at least 24 hours, atleast 48 hours, at least 72 hours, at least 96 hours, at least 120hours, at least 1 week, at least 2 weeks, at least 3 weeks, or at least4 weeks post-administration; (iv) reduce plasma, serum, whole blood,and/or urine levels of propionyl-L-carnitine (C3), 2-methylcitric acid(2-MC), 3-hydroxypropionic acid, (30HPA), and/or ammonia at least 30%,at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, atleast 90%, or at least 100% compared to the subject's baseline plasma,serum, or urine level or a reference plasma, serum, or urine C3, 2-MC,3OHPA, and/or ammonia level in a human subject having PA for at least 12hours, at least 24 hours, at least 48 hours, at least 72 hours, at least96 hours, at least 120 hours, at least 1 week, at least 2 weeks, atleast 3 weeks, or at least 4 weeks post-administration; (v) reduceplasma, serum, whole blood and/or liver levels of propionic acid atleast 1.5-fold, at least 2-fold, at least 5-fold, at least 10-fold, atleast 20-fold, or at least 50-fold as compared to the subject's baselineplasma, serum, whole blood and/or liver propionic acid level or areference plasma, serum, whole blood and/or liver propionic acid levelin a patient with PA for at least 12 hours, at least 24 hours, at least48 hours, at least 72 hours, at least 96 hours, at least 120 hours, atleast 1 week, at least 2 weeks, at least 3 weeks, or at least 4 weekspost-administration; and/or (vi) reduce plasma, serum, and/or urinelevel of C3, 2-MC, 30HPA, and/or ammonia at least 1.5-fold, at least2-fold at least 5-fold, at least 10-fold, at least 20-fold or at least50-fold as compared to the subject's baseline plasma, serum, and/orurine C3, 2-MC, 3OHPA, and/or ammonia level or a reference plasma,serum, and/or urine C3, 2-MC, 30HPA, and/or ammonia level in a patientwith PA for at least 12 hours, at least 24 hours, at least 48 hours, atleast 72 hours, at least 96 hours, at least 120 hours, at least 1 week,at least 2 weeks, at least 3 weeks, or at least 4 weekspost-administration.
 2. A pharmaceutical composition comprising adelivery agent comprising a lipid nanoparticle comprising a compound ofFormula (I):

or an N-oxide, salt, or isomer thereof, wherein: R₁ is selected from thegroup consisting of C₅₋₃₀ alkyl, C₅₋₂₀ alkenyl, —R*YR″, —YR″, and—R″M′R′; R₂ and R₃ are independently selected from the group consistingof H, C₁₋₁₄ alkyl, C₂₋₁₄ alkenyl, —R*YR″, —YR″, and —R*OR″, or R₂ andR₃, together with the atom to which they are attached, form aheterocycle or carbocycle; R₄ is selected from the group consisting ofhydrogen, a C₃₋₆ carbocycle, —(CH₂)_(n)Q, —(CH₂)_(n)CHQR, —CHQR,—CQ(R)₂, and unsubstituted C₁₋₆ alkyl, where Q is selected from acarbocycle, heterocycle, —OR, —O(CH₂)_(n)N(R)₂, —C(O)OR, —OC(O)R, —CX₃,—CX₂H, —CXH₂, —CN, —N(R)₂, —C(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R,—N(R)C(O)N(R)₂, —N(R)C(S)N(R)₂, —N(R)R₈, —N(R)S(O)₂R₈, —O(CH₂)_(n)OR,—N(R)C(═NR₉)N(R)₂, —N(R)C(═CHR₉)N(R)₂, —OC(O)N(R)₂, —N(R)C(O)OR,—N(OR)C(O)R, —N(OR)S(O)₂R, —N(OR)C(O)OR, —N(OR)C(O)N(R)₂,—N(OR)C(S)N(R)₂, —N(OR)C(═NR₉)N(R)₂, —N(OR)C(═CHR₉)N(R)₂, —C(═NR₉)N(R)₂,—C(═NR₉)R, —C(O)N(R)OR, and —C(R)N(R)₂C(O)OR, and each n isindependently selected from 1, 2, 3, 4, and 5; each R₅ is independentlyselected from the group consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl, and H;each R₆ is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H; M and M′ are independently selected from—C(O)O—, —OC(O)—, —OC(O)-M″-C(O)O—, —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—,—C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)₂—, —S—S—, anaryl group, and a heteroaryl group, in which M″ is a bond, C₁₋₁₃ alkylor C₂₋₁₃ alkenyl; R₇ is selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H; R₈ is selected from the group consisting ofC₃₋₆ carbocycle and heterocycle; R₉ is selected from the groupconsisting of H, CN, NO₂, C₁₋₆ alkyl, —OR, —S(O)₂R, —S(O)₂N(R)₂, C₂₋₆alkenyl, C₃₋₆ carbocycle and heterocycle; each R is independentlyselected from the group consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl, and H;each R′ is independently selected from the group consisting of C₁₋₁₈alkyl, C₂₋₁₈ alkenyl, —R*YR″, —YR″, and H; each R″ is independentlyselected from the group consisting of C₃₋₁₅ alkyl and C₃₋₁₅ alkenyl;each R* is independently selected from the group consisting of C₁₋₁₂alkyl and C₂₋₁₂ alkenyl; each Y is independently a C₃₋₆ carbocycle; eachX is independently selected from the group consisting of F, Cl, Br, andI; m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13; and whereinwhen R₄ is —(CH₂)_(n)Q, —(CH₂)_(n)CHQR, —CHQR, or —CQ(R)₂, then (i) Q isnot —N(R)₂ when n is 1, 2, 3, 4 or 5, or (ii) Q is not 5, 6, or7-membered heterocycloalkyl when n is 1 or 2, wherein the pharmaceuticalcomposition comprises an mRNA comprising an open reading frame (ORF)encoding a propionyl-CoA carboxylase beta (PCCB) polypeptide, andwherein the pharmaceutical composition when administered as a singleintravenous dose to a human subject in need thereof is sufficient to:(i) increase the level of PCC activity in liver tissue to within atleast 2%, at least 5%, at least 10%, at least 20%, at least 30%, atleast 40%, at least 50%, at least 60%, at least 70%, at least 80%, atleast 90%, or at least 100% of normal PCC activity level for at least 12hours, at least 24 hours, at least 48 hours, at least 72 hours, at least96 hours, at least 120 hours, at least 1 week, at least 2 weeks, atleast 3 weeks, or at least 4 weeks post-administration; (ii) increasethe level of PCC activity in liver tissue at least 1.5-fold, at least2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least10-fold, at least 20-fold, or at least 50-fold compared to the subject'sbaseline PCC activity level or a reference PCC activity level in a humansubject having propionic academia (PA) for at least 12 hours, at least24 hours, at least 48 hours, at least 72 hours, at least 96 hours, atleast 120 hours, at least 1 week, at least 2 weeks, at least 3 weeks, orat least 4 weeks post-administration; (iii) reduce plasma, serum, wholeblood, and/or liver levels of propionic acid at least 30%, at least 40%,at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, orat least 100% compared to the subject's baseline plasma, serum, wholeblood and/or liver propionic acid level or a reference plasma, serum,whole blood and/or liver propionic acid level in a human subject havingPA for at least 12 hours, at least 24 hours, at least 48 hours, at least72 hours, at least 96 hours, at least 120 hours, at least 1 week, atleast 2 weeks, at least 3 weeks, or at least 4 weekspost-administration; (iv) reduce plasma, serum, whole blood, and/orurine levels of propionyl-L-carnitine (C3), 2-methylcitric acid (2-MC),3-hydroxypropionic acid, (30HPA), and/or ammonia at least 30%, at least40%, at least 50%, at least 60%, at least 70%, at least 80%, at least90%, or at least 100% compared to the subject's baseline plasma, serum,or urine level or a reference plasma, serum, or urine C3, 2-MC, 3OHPA,and/or ammonia level in a human subject having PA for at least 12 hours,at least 24 hours, at least 48 hours, at least 72 hours, at least 96hours, at least 120 hours, at least 1 week, at least 2 weeks, at least 3weeks, or at least 4 weeks post-administration; (v) reduce plasma,serum, whole blood and/or liver levels of propionic acid at least1.5-fold, at least 2-fold, at least 5-fold, at least 10-fold, at least20-fold, or at least 50-fold as compared to the subject's baselineplasma, serum, whole blood and/or liver propionic acid level or areference plasma, serum, whole blood and/or liver propionic acid levelin a patient with PA for at least 12 hours, at least 24 hours, at least48 hours, at least 72 hours, at least 96 hours, at least 120 hours, atleast 1 week, at least 2 weeks, at least 3 weeks, or at least 4 weekspost-administration; and/or (vi) reduce plasma, serum, and/or urinelevel of C3, 2-MC, 30HPA, and/or ammonia at least 1.5-fold, at least2-fold at least 5-fold, at least 10-fold, at least 20-fold or at least50-fold as compared to the subject's baseline plasma, serum, and/orurine C3, 2-MC, 3OHPA, and/or ammonia level or a reference plasma,serum, and/or urine C3, 2-MC, 30HPA, and/or ammonia level in a patientwith PA for at least 12 hours, at least 24 hours, at least 48 hours, atleast 72 hours, at least 96 hours, at least 120 hours, at least 1 week,at least 2 weeks, at least 3 weeks, or at least 4 weekspost-administration.
 3. A pharmaceutical composition comprising adelivery agent comprising a lipid nanoparticle comprising a compound ofFormula (I):

or an N-oxide, salt, or isomer thereof, wherein: R₁ is selected from thegroup consisting of C₅₋₃₀ alkyl, C₅₋₂₀ alkenyl, —R*YR″, —YR″, and—R″M′R′; R₂ and R₃ are independently selected from the group consistingof H, C₁₋₁₄ alkyl, C₂₋₁₄ alkenyl, —R*YR″, —YR″, and —R*OR″, or R₂ andR₃, together with the atom to which they are attached, form aheterocycle or carbocycle; R₄ is selected from the group consisting ofhydrogen, a C₃₋₆ carbocycle, —(CH₂)_(n)Q, —(CH₂)_(n)CHQR, —CHQR,—CQ(R)₂, and unsubstituted C₁₋₆ alkyl, where Q is selected from acarbocycle, heterocycle, —OR, —O(CH₂)_(n)N(R)₂, —C(O)OR, —OC(O)R, —CX₃,—CX₂H, —CXH₂, —CN, —N(R)₂, —C(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R,—N(R)C(O)N(R)₂, —N(R)C(S)N(R)₂, —N(R)R₈, —N(R)S(O)₂R₈, —O(CH₂)_(n)OR,—N(R)C(═NR₉)N(R)₂, —N(R)C(═CHR₉)N(R)₂, —OC(O)N(R)₂, —N(R)C(O)OR,—N(OR)C(O)R, —N(OR)S(O)₂R, —N(OR)C(O)OR, —N(OR)C(O)N(R)₂,—N(OR)C(S)N(R)₂, —N(OR)C(═NR₉)N(R)₂, —N(OR)C(═CHR₉)N(R)₂, —C(═NR₉)N(R)₂,—C(═NR₉)R, —C(O)N(R)OR, and —C(R)N(R)₂C(O)OR, and each n isindependently selected from 1, 2, 3, 4, and 5; each R₅ is independentlyselected from the group consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl, and H;each R₆ is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H; M and M′ are independently selected from—C(O)O—, —OC(O)—, —OC(O)-M″-C(O)O—, —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—,—C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)₂—, —S—S—, anaryl group, and a heteroaryl group, in which M″ is a bond, C₁₋₁₃ alkylor C₂₋₁₃ alkenyl; R₇ is selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H; R₈ is selected from the group consisting ofC₃₋₆ carbocycle and heterocycle; R₉ is selected from the groupconsisting of H, CN, NO₂, C₁₋₆ alkyl, —OR, —S(O)₂R, —S(O)₂N(R)₂, C₂₋₆alkenyl, C₃₋₆ carbocycle and heterocycle; each R is independentlyselected from the group consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl, and H;each R′ is independently selected from the group consisting of C₁₋₁₈alkyl, C₂₋₁₈ alkenyl, —R*YR″, —YR″, and H; each R″ is independentlyselected from the group consisting of C₃₋₁₅ alkyl and C₃₋₁₅ alkenyl;each R* is independently selected from the group consisting of C₁₋₁₂alkyl and C₂₋₁₂ alkenyl; each Y is independently a C₃₋₆ carbocycle; eachX is independently selected from the group consisting of F, Cl, Br, andI; m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13; and whereinwhen R₄ is —(CH₂)_(n)Q, —(CH₂)_(n)CHQR, —CHQR, or —CQ(R)₂, then (i) Q isnot —N(R)₂ when n is 1, 2, 3, 4 or 5, or (ii) Q is not 5, 6, or7-membered heterocycloalkyl when n is 1 or 2, wherein the pharmaceuticalcomposition comprises an mRNA comprising an open reading frame (ORF)encoding a propionyl-CoA carboxylase alpha (PCCA) polypeptide and anmRNA comprising an open reading frame (ORF) encoding a propionyl-CoAcarboxylase beta (PCCB) polypeptide, and wherein the pharmaceuticalcomposition when administered as a single intravenous dose to a humansubject in need thereof is sufficient to: (i) increase the level of PCCactivity in liver tissue to within at least 2%, at least 5%, at least10%, at least 20%, at least 30%, at least 40%, at least 50%, at least60%, at least 70%, at least 80%, at least 90%, or at least 100% ofnormal PCC activity level for at least 12 hours, at least 24 hours, atleast 48 hours, at least 72 hours, at least 96 hours, at least 120hours, at least 1 week, at least 2 weeks, at least 3 weeks, or at least4 weeks post-administration; (ii) increase the level of PCC activity inliver tissue at least 1.5-fold, at least 2-fold, at least 3-fold, atleast 4-fold, at least 5-fold, at least 10-fold, at least 20-fold, or atleast 50-fold compared to the subject's baseline PCC activity level or areference PCC activity level in a human subject having propionicacademia (PA) for at least 12 hours, at least 24 hours, at least 48hours, at least 72 hours, at least 96 hours, at least 120 hours, atleast 1 week, at least 2 weeks, at least 3 weeks, or at least 4 weekspost-administration; (iii) reduce plasma, serum, whole blood, and/orliver levels of propionic acid at least 30%, at least 40%, at least 50%,at least 60%, at least 70%, at least 80%, at least 90%, or at least 100%compared to the subject's baseline plasma, serum, whole blood and/orliver propionic acid level or a reference plasma, serum, whole bloodand/or liver propionic acid level in a human subject having PA for atleast 12 hours, at least 24 hours, at least 48 hours, at least 72 hours,at least 96 hours, at least 120 hours, at least 1 week, at least 2weeks, at least 3 weeks, or at least 4 weeks post-administration; (iv)reduce plasma, serum, whole blood, and/or urine levels ofpropionyl-L-carnitine (C3), 2-methylcitric acid (2-MC),3-hydroxypropionic acid, (30HPA), and/or ammonia at least 30%, at least40%, at least 50%, at least 60%, at least 70%, at least 80%, at least90%, or at least 100% compared to the subject's baseline plasma, serum,or urine level or a reference plasma, serum, or urine C3, 2-MC, 3OHPA,and/or ammonia level in a human subject having PA for at least 12 hours,at least 24 hours, at least 48 hours, at least 72 hours, at least 96hours, at least 120 hours, at least 1 week, at least 2 weeks, at least 3weeks, or at least 4 weeks post-administration; (v) reduce plasma,serum, whole blood and/or liver levels of propionic acid at least1.5-fold, at least 2-fold, at least 5-fold, at least 10-fold, at least20-fold, or at least 50-fold as compared to the subject's baselineplasma, serum, whole blood and/or liver propionic acid level or areference plasma, serum, whole blood and/or liver propionic acid levelin a patient with PA for at least 12 hours, at least 24 hours, at least48 hours, at least 72 hours, at least 96 hours, at least 120 hours, atleast 1 week, at least 2 weeks, at least 3 weeks, or at least 4 weekspost-administration; and/or (vi) reduce plasma, serum, and/or urinelevel of C3, 2-MC, 30HPA, and/or ammonia at least 1.5-fold, at least2-fold at least 5-fold, at least 10-fold, at least 20-fold or at least50-fold as compared to the subject's baseline plasma, serum, and/orurine C3, 2-MC, 3OHPA, and/or ammonia level or a reference plasma,serum, and/or urine C3, 2-MC, 30HPA, and/or ammonia level in a patientwith PA for at least 12 hours, at least 24 hours, at least 48 hours, atleast 72 hours, at least 96 hours, at least 120 hours, at least 1 week,at least 2 weeks, at least 3 weeks, or at least 4 weekspost-administration. 4.-26. (canceled)
 27. The pharmaceuticalcomposition of claim 3, wherein the human subject has propionic acidemia(PA).
 28. The pharmaceutical composition of claim 3, wherein the humansubject is on a protein restricted diet.
 29. The pharmaceuticalcomposition of claim 3, wherein the human subject is not on a proteinrestricted diet. 30.-67. (canceled)
 68. A method of expressing apropionyl-CoA carboxylase alpha (PCCA) polypeptide in a human subject inneed thereof, comprising administering to the subject an effectiveamount of the pharmaceutical composition of claim
 1. 69. A method ofexpressing a propionyl-CoA carboxylase beta (PCCB) polypeptide in ahuman subject in need thereof, comprising administering to the subjectan effective amount of the pharmaceutical composition of claim
 2. 70. Amethod of expressing a propionyl-CoA carboxylase alpha (PCCA)polypeptide and a propionyl-CoA carboxylase beta (PCCB) polypeptide in ahuman subject in need thereof, comprising administering to the subjectan effective amount of the pharmaceutical compositions of claim 3.71.-72. (canceled)
 73. A method of treating, preventing, or delaying theonset and/or progression of propionic academia (PA) in a human subjectin need thereof, comprising administering to the subject an effectiveamount of the pharmaceutical composition of claim
 3. 74.-77. (canceled)78. A method of reducing propionic acid blood level in a human subjectin need thereof, comprising administering to the subject an effectiveamount of the pharmaceutical composition of claim
 3. 79.-82. (canceled)83. A method of reducing C3, 2-MC, 30HPA, and/or ammonia plasma, serum,whole blood, and/or liver level in a human subject in need thereof,comprising administering to the subject an effective amount of thepharmaceutical composition of claim
 3. 84.-87. (canceled)
 88. The methodof claim 68, wherein: (i) the propionic acid blood and/or liver level isreduced at least 20%, at least 30%, at least 40%, at least 50%, at least60%, at least 70%, at least 80%, at least 90%, or at least 100% ascompared to the subject's baseline propionic acid blood and/or liverlevel or a reference propionic acid blood and/or liver level in apatient with PA, for at least 24 hours, at least 48 hours, at least 72hours, at least 96 hours, at least 120 hours, 6 days, 1 week, 8 days, 9days, 10 days, 11 days, 12 days, 14 days, 18 days, or 21 days after asingle administration; (ii) the propionic acid plasma, serum, and/orurine level is reduced at least 20%, at least 30%, at least 40%, atleast 30%, at least 40%, at least 50%, at least 60%, at least 70%, atleast 80%, at least 90%, or at least 100% as compared to the subject'sbaseline propionic acid plasma, serum, and/or urine level or a referencepropionic acid plasma, serum, and/or urine level in a patient with PA,for at least 24 hours, at least 48 hours, at least 72 hours, at least 96hours, at least 120 hours, 6 days, 1 week, 8 days, 9 days, 10 days, 11days, 12 days, 14 days, 18 days, or 21 days after a singleadministration; (iii) the propionic acid blood and/or liver level isreduced to at least within 10-fold, at least within 5-fold, at leastwithin 2-fold, or at least within 1.5-fold as compared to a normalpropionic acid blood and/or liver level within at least 24 hours, atleast 48 hours, at least 72 hours, at least 96 hours, at least 120hours, 6 days, 1 week, 8 days, 9 days, 10 days, 11 days, 12 days, 14days, 18 days, or 21 days after a single administration; (iv) thepropionic acid plasma, serum, and/or urine level is reduced to at leastwithin 10-fold, at least within 5-fold, at least within 2-fold, or atleast within 1.5-fold, as compared to a normal propionic acid plasma,serum, and/or urine level, for at least 24 hours, at least 48 hours, atleast 72 hours, at least 96 hours, at least 120 hours, 6 days, 1 week, 8days, 9 days, 10 days, 11 days, 12 days, 14 days, 18 days, or 21 daysafter a single administration; (v) the C3, 2-MC, 30HPA, and/or ammoniaplasma, serum, whole blood, and/or liver level is reduced at least 20%,at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, atleast 80%, at least 90%, or at least 100% as compared to the subject'sbaseline plasma, serum, whole blood and/or liver C3, 2-MC, 30HPA, and/orammonia or a reference C3, 2-MC, 30HPA, and/or ammonia plasma, serum,whole blood, and/or liver level in a patient with PA, for at least 24hours, at least 48 hours, at least 72 hours, at least 96 hours, at least120 hours, 6 days, 1 week, 8 days, 9 days, 10 days, 11 days, 12 days, 14days, 18 days, or 21 days after a single administration; and/or (vi) theC3, 2-MC, 30HPA, and/or ammonia plasma, serum, whole blood, and/or liverlevel is reduced to at least within 10-fold, at least within 5-fold, atleast within 2-fold, or at least within 1.5-fold as compared to a normalC3, 2-MC, 30HPA, and/or ammonia plasma, serum, whole blood, and/or liverlevel within at least 24 hours, at least 48 hours, at least 72 hours, atleast 96 hours, at least 120 hours, 6 days, 1 week, 8 days, 9 days, 10days, 11 days, 12 days, 14 days, 18 days, or 21 days after a singleadministration.
 89. A method of increasing PCC activity in a humansubject in need thereof, comprising administering to the subject aneffective amount of the pharmaceutical composition of claim
 3. 90.-93.(canceled)
 94. The method of claim 68, wherein: (i) the level of PCCactivity in the subject is increased at least 1.5-fold, at least 2-fold,at least 5-fold, at least 10-fold, at least 20-fold, or at least 50-foldas compared to a reference PCC activity level in a subject having PA forat least 24 hours, at least 48 hours, at least 72 hours, at least 96hours, or at least 120 hours after a single administration; and/or (ii)12 hours after a single administration of the pharmaceutical compositionor polynucleotide is administered to the subject, the PCC activity inthe subject is increased at least 20%, at least 30%, at least 40%, atleast 50%, at least 60%, at least 70%, at least 80%, at least 90%, atleast 100%, at least 150%, at least 200%, at least 300%, at least 400%,at least 500%, or at least 600% compared to the subject's baseline PCCactivity.
 95. The method of claim 89, wherein the PCC activity isincreased in the liver or blood of the subject.
 96. The method of claim68, wherein the administration to the subject is about once a week,about once every two weeks, or about once a month.
 97. The method ofclaim 68, wherein the pharmaceutical composition or polynucleotide isadministered intravenously.